UID,Searchword,API,URL,Title,Summary,Article,Title_Sentiment,Title_Positive,Title_Neutral,Title_Negative,Article_Sentiment,Article_Positive,Article_Neutral,Article_Negative,Verified,Language,Topics,Date,Load_Date,Source
12045,Deutsche Boerse,Twitter API,Twitter,"@DavanteGolino @Bluegooose @unusual_whales The adidas AG share is listed on the ""Deutsche BÃ¶rse"" stock exchange inâ€¦ https://t.co/YiUrPYyjBp",nan,"@DavanteGolino @Bluegooose @unusual_whales The adidas AG share is listed on the ""Deutsche BÃ¶rse"" stock exchange inâ€¦ https://t.co/YiUrPYyjBp",neutral,0.05,0.95,0.01,neutral,0.05,0.95,0.01,True,English,"['Deutsche BÃ¶rse"" stock exchange', 'adidas AG share', 'DavanteGolino', 'Bluegooose', 'Deutsche BÃ¶rse"" stock exchange', 'adidas AG share', 'DavanteGolino', 'Bluegooose']",2022-10-25,2022-10-28,Unknown
12046,Deutsche Boerse,Twitter API,Twitter,Congratulations Bieke Depoorter ğŸ‘Depoorter has been shortlisted for next yearâ€™s Deutsche BÃ¶rse Photography Foundaâ€¦ https://t.co/vjlazqHdSr,nan,Congratulations Bieke Depoorter ğŸ‘Depoorter has been shortlisted for next yearâ€™s Deutsche BÃ¶rse Photography Foundaâ€¦ https://t.co/vjlazqHdSr,positive,0.98,0.02,0.0,positive,0.98,0.02,0.0,True,English,"['Deutsche BÃ¶rse Photography Founda', 'next year', 'Bieke Depoorter', 'Congratulations', 'Deutsche BÃ¶rse Photography Founda', 'next year', 'Bieke Depoorter', 'Congratulations']",2022-10-25,2022-10-28,Unknown
12047,Deutsche Boerse,Twitter API,Twitter,Market capitalisation of â‚¬30.80 Billion is not a joke. One of my biggest client has decided to move to #Deutscheâ€¦ https://t.co/0XwXFx9Awl,nan,Market capitalisation of â‚¬30.80 Billion is not a joke. One of my biggest client has decided to move to #Deutscheâ€¦ https://t.co/0XwXFx9Awl,negative,0.0,0.09,0.9,negative,0.0,0.09,0.9,True,English,"['Market capitalisation', 'biggest client', '80 Billion', 'joke', 'Market capitalisation', 'biggest client', '80 Billion', 'joke']",2022-10-25,2022-10-28,Unknown
12048,Deutsche Boerse,Twitter API,Twitter,$DBOEY â†‘upgrade Deutsche Boerse initiated with a Buy at Societe Generale,nan,$DBOEY â†‘upgrade Deutsche Boerse initiated with a Buy at Societe Generale,neutral,0.0,0.99,0.0,neutral,0.0,0.99,0.0,True,English,"['upgrade Deutsche Boerse', 'Societe Generale', 'Buy', 'upgrade Deutsche Boerse', 'Societe Generale', 'Buy']",2022-10-25,2022-10-28,Unknown
12049,Deutsche Boerse,Twitter API,Twitter,CASE STUDY: Learn how Deutsche BÃ¶rseâ€™s threat intelligence team and the head of physical security use Dataminr to pâ€¦ https://t.co/zNoTYQot4O,nan,CASE STUDY: Learn how Deutsche BÃ¶rseâ€™s threat intelligence team and the head of physical security use Dataminr to pâ€¦ https://t.co/zNoTYQot4O,negative,0.0,0.25,0.75,negative,0.0,0.25,0.75,True,English,"['Deutsche BÃ¶rse', 'threat intelligence team', 'CASE STUDY', 'physical security', 'head', 'Dataminr', 'Deutsche BÃ¶rse', 'threat intelligence team', 'CASE STUDY', 'physical security', 'head', 'Dataminr']",2022-10-24,2022-10-28,Unknown
12090,Deutsche Boerse,Twitter API,Twitter,CoinShares launches staked Algorand ETP on Deutsche Boerse Xetra $TTC #TechTrees https://t.co/4sKUJIcJ0b,nan,CoinShares launches staked Algorand ETP on Deutsche Boerse Xetra $TTC #TechTrees https://t.co/4sKUJIcJ0b,neutral,0.0,0.99,0.0,neutral,0.0,0.99,0.0,True,English,"['Deutsche Boerse Xetra', 'Algorand ETP', 'CoinShares', 'TTC', 'TechTrees', 'Deutsche Boerse Xetra', 'Algorand ETP', 'CoinShares', 'TTC', 'TechTrees']",2022-10-26,2022-10-28,Unknown
12183,Euroclear,NewsApi.org,https://finance.yahoo.com/news/verkkokauppa-com-decided-third-installment-044500589.html,Verkkokauppa.com decided on the third installment of the quarterly dividend,Verkkokauppa.com decided on the third installment of the quarterly dividend Verkkokauppa.com Oyj Stock Exchange Release 27 October 2022 at 7:45 am EEST The...,Verkkokauppa.com OyjVerkkokauppa.com decided on the third installment of the quarterly dividendVerkkokauppa.com Oyj Stock Exchange Release 27 October 2022 at 7:45 am EESTThe Board of Directors of Verkkokauppa.com Oyj has decided today  on the basis of the authorization granted by the Annual General Meeting 2022  that a dividend of EUR 0.063 per share (EUR 2 839 581.80 in total) be distributed from retained earnings.The dividend will be paid to a shareholder registered in the companyâ€™s shareholdersâ€™ register maintained by Euroclear Finland Ltd on the record date for the dividend on 31 October 2022. The dividend will be paid on 7 November 2022.Verkkokauppa.comâ€™s Annual General Meeting  held on 24 March 2022  resolved to authorize the Board of Directors to decide at its discretion on the distribution of dividends. Based on the authorization  the total amount of the quarterly dividend distribution shall not exceed EUR 0.186 per share.Following distribution of dividends resolved upon 27 October 2022  the Company does not have any valid authorizations for distribution of funds.Before the Board of Directors implements the resolution regarding the distribution of dividend  it must assess  from the viewpoint of Companyâ€™s financial position  whether the requirements in the Finnish Companies Act for the distribution of dividend are fulfilled.During 2022  Verkkokauppa.com has paid dividends  including this distribution  to its shareholders in the total amount of EUR 11.2 million  i.e. EUR 0.246 per share.For more information  please contact:Mikko ForsellCFO  Verkkokauppa.com Oyjmikko.forsell@verkkokauppa.comTel. +358 10 309 5555Marja MÃ¤kinenHead of Investor Relations and Corporate CommunicationsVerkkokauppa.com OyjMarja.makinen@verkkokauppa.comTel. +358 40 671 2999Distribution:Nasdaq HelsinkiMain mediawww.verkkokauppa.comVerkkokauppa.com empowers its customers to follow their passion by providing a wide product assortment of around 90 000 products. Verkkokauppa.com Oyj serves its retail and corporate customers through its webstore  megastores  kiosk and network of collection points as well as fast deliveries and various services. As Finlandâ€™s most popular and most visited domestic online retailer  its deliveries cover around 75 percent of the Finnish population within the next day. The Company has four megastores: in Oulu  Pirkkala  Raisio  and Helsinki  where its headquarters is also located. Verkkokauppa.com employs more than 750 people and its shares are listed on the Nasdaq Helsinki stock exchange with the ticker VERK.,neutral,0.0,1.0,0.0,negative,0.0,0.12,0.88,True,English,"['Verkkokauppa.com', 'third installment', 'quarterly dividend', 'Oyj Stock Exchange Release', 'Nasdaq Helsinki stock exchange', 'Annual General Meeting', 'wide product assortment', 'domestic online retailer', 'Finnish Companies Act', 'Euroclear Finland Ltd', 'Marja MÃ¤kinen', 'quarterly dividend distribution', 'Finnish population', 'third installment', 'record date', 'valid authorizations', 'financial position', 'Mikko Forsell', 'Investor Relations', 'Corporate Communications', 'Main media', 'collection points', 'various services', 'next day', 'total amount', 'shareholdersâ€™ register', 'corporate customers', 'fast deliveries', 'four megastores', 'Verkkokauppa.com', 'Board', 'Directors', 'basis', 'earnings', 'company', '31 October', '7 November', '24 March', 'discretion', 'dividends', '27 October', 'funds', 'resolution', 'viewpoint', 'requirements', 'information', 'CFO', 'Tel.', 'Head', 'makinen', 'passion', '90,000 products', 'webstore', 'kiosk', 'network', 'popular', '75 percent', 'Oulu', 'Pirkkala', 'Raisio', '750 people', 'shares', 'ticker', 'VERK.', '7:45']",2022-10-27,2022-10-28,finance.yahoo.com
12184,Euroclear,NewsApi.org,https://finance.yahoo.com/news/shell-plc-third-quarter-2022-060200033.html,Shell plc Third Quarter 2022 Interim Dividend,London  October 27  2022 âˆ’ The Board of Shell plc (â€œShellâ€ or the â€œCompanyâ€) today announced an interim dividend in respect of the third quarter of 2022 of...,London  October 27  2022 âˆ’ The Board of Shell plc (â€œShellâ€ or the â€œCompanyâ€) today announced an interim dividend in respect of the third quarter of 2022 of US$ 0.25 per ordinary share.Details relating to the third quarter 2022 interim dividendPer ordinary share Q3 2022 Shell Shares (US$) 0.25Shareholders will be able to elect to receive their dividends in US dollars  euros or pounds sterling.Absent any valid election to the contrary  persons holding their ordinary shares through Euroclear Nederland will receive their dividends in euros.Absent any valid election to the contrary  shareholders (both holding in certificated and uncertificated form (CREST members)) and persons holding their shares through the Shell Corporate Nominee will receive their dividends in pounds sterling.The pound sterling and euro equivalent dividend payments will be announced on December 5  2022.Per ADS Q3 2022 Shell ADSs (US$) 0.5Cash dividends on American Depositary Shares (â€œADSsâ€) will be paid  by default  in US dollars.Each ADS represents two ordinary shares. ADSs are evidenced by an American Depositary Receipt (â€œADRâ€) certificate. In many cases the terms ADR and ADS are used interchangeably.Dividend timetable for the third quarter 2022 interim dividendEvent Date Announcement date October 27  2022 Ex- Dividend Date for ADSs November 9  2022 Ex- Dividend Date for ordinary shares November 10  2022 Record date November 11  2022 Closing of currency election date (see Note below) November 25  2022 Pound sterling and euro equivalents announcement date December 5  2022 Payment date December 19  2022NoteA different currency election date may apply to shareholders holding shares in a securities account with a bank or financial institution ultimately holding through Euroclear Nederland. This may also apply to other shareholders who do not hold their shares either directly on the Register of Members or in the corporate sponsored nominee arrangement. Shareholders can contact their broker  financial intermediary  bank or financial institution for the election deadline that applies.Story continuesTaxation - cash dividendsWith the Companyâ€™s tax residence moved to the UK  dividends paid to shareholders on their ordinary shares will not attract Dutch dividend withholding tax. This means that holders of the former A shares receive their dividends in full as Dutch dividend withholding tax is no longer withheld on these dividends. Holders of the former B shares receive their dividends directly from the Company as these dividends will no longer be paid through the Dividend Access Mechanism.If you are uncertain as to the tax treatment of any dividends you should consult your tax advisor.Dividend Reinvestment Programmes (â€œDRIPâ€)The following organisations operate Dividend Reinvestment Plans (â€œDRIPsâ€) which enable Shellâ€™s shareholders to elect to have their dividend payments used to purchase Shell shares:Equiniti Financial Services Limited (â€œEFSLâ€)  for those holding shares (a) directly on the register as certificate holder or as CREST Member and (b) via the Shell Corporate Nominee;ABN-AMRO NV (â€œABNâ€) for Financial Intermediaries holding shares via Euroclear Nederland;JPMorgan Chase Bank  N.A. (â€œJPMâ€) for holders of ADSs; andOther DRIPs may also be available from the intermediary through which investors hold their shares and ADSs.Such organisations provide their DRIPs fully on their account and not on behalf of Shell.Interested parties should contact DRIP Offerors directly.More information can be found at https://www.shell.com/dripTo be eligible to participate in the DRIPs for the next dividend  shareholders must make a valid dividend reinvestment election before the published date for the close of elections.EnquiriesMedia International: +44 207 934 5550Media Americas: +1 832 337 4355Cautionary NoteThe companies in which Shell plc directly and indirectly owns investments are separate legal entities. In this announcement â€œShellâ€  â€œShell Groupâ€ and â€œGroupâ€ are sometimes used for convenience where references are made to Shell plc and its subsidiaries in general. Likewise  the words â€œweâ€  â€œusâ€ and â€œourâ€ are also used to refer to Shell plc and its subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular entity or entities. â€˜â€˜Subsidiariesâ€™â€™  â€œShell subsidiariesâ€ and â€œShell companiesâ€ as used in this announcement refer to entities over which Shell plc either directly or indirectly has control. Entities and unincorporated arrangements over which Shell has joint control are generally referred to as â€œjoint venturesâ€ and â€œjoint operationsâ€  respectively. â€œJoint venturesâ€ and â€œjoint operationsâ€ are collectively referred to as â€œjoint arrangementsâ€. Entities over which Shell has significant influence but neither control nor joint control are referred to as â€œassociatesâ€. The term â€œShell interestâ€ is used for convenience to indicate the direct and/or indirect ownership interest held by Shell in an entity or unincorporated joint arrangement  after exclusion of all third-party interest.Forward-Looking StatementsThis announcement contains forward-looking statements (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995) concerning the financial condition  results of operations and businesses of Shell. All statements other than statements of historical fact are  or may be deemed to be  forward-looking statements. Forward-looking statements are statements of future expectations that are based on managementâ€™s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results  performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements include  among other things  statements concerning the potential exposure of Shell to market risks and statements expressing managementâ€™s expectations  beliefs  estimates  forecasts  projections and assumptions. These forward-looking statements are identified by their use of terms and phrases such as â€œaimâ€  â€œambitionâ€  â€˜â€˜anticipateâ€™â€™  â€˜â€˜believeâ€™â€™  â€˜â€˜couldâ€™â€™  â€˜â€˜estimateâ€™â€™  â€˜â€˜expectâ€™â€™  â€˜â€˜goalsâ€™â€™  â€˜â€˜intendâ€™â€™  â€˜â€˜mayâ€™â€™  â€œmilestonesâ€  â€˜â€˜objectivesâ€™â€™  â€˜â€˜outlookâ€™â€™  â€˜â€˜planâ€™â€™  â€˜â€˜probablyâ€™â€™  â€˜â€˜projectâ€™â€™  â€˜â€˜risksâ€™â€™  â€œscheduleâ€  â€˜â€˜seekâ€™â€™  â€˜â€˜shouldâ€™â€™  â€˜â€˜targetâ€™â€™  â€˜â€˜willâ€™â€™ and similar terms and phrases. There are a number of factors that could affect the future operations of Shell and could cause those results to differ materially from those expressed in the forward-looking statements included in this announcement  including (without limitation): (a) price fluctuations in crude oil and natural gas; (b) changes in demand for Shellâ€™s products; (c) currency fluctuations; (d) drilling and production results; (e) reserves estimates; (f) loss of market share and industry competition; (g) environmental and physical risks; (h) risks associated with the identification of suitable potential acquisition properties and targets  and successful negotiation and completion of such transactions; (i) the risk of doing business in developing countries and countries subject to international sanctions; (j) legislative  judicial  fiscal and regulatory developments including regulatory measures addressing climate change; (k) economic and financial market conditions in various countries and regions; (l) political risks  including the risks of expropriation and renegotiation of the terms of contracts with governmental entities  delays or advancements in the approval of projects and delays in the reimbursement for shared costs; (m) risks associated with the impact of pandemics  such as the COVID-19 (coronavirus) outbreak; and (n) changes in trading conditions. No assurance is provided that future dividend payments will match or exceed previous dividend payments. All forward-looking statements contained in this announcement are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Additional risk factors that may affect future results are contained in Shell plcâ€™s Form 20-F for the year ended December 31  2021 (available at www.shell.com/investor and www.sec.gov). These risk factors also expressly qualify all forward-looking statements contained in this announcement and should be considered by the reader. Each forward-looking statement speaks only as of the date of this announcement  October 27  2022. Neither Shell plc nor any of its subsidiaries undertake any obligation to publicly update or revise any forward-looking statement as a result of new information  future events or other information. In light of these risks  results could differ materially from those stated  implied or inferred from the forward-looking statements contained in this announcement.Shellâ€™s net carbon footprintAlso  in this announcement we may refer to Shellâ€™s â€œNet Carbon Footprintâ€ or â€œNet Carbon Intensityâ€  which include Shellâ€™s carbon emissions from the production of our energy products  our suppliersâ€™ carbon emissions in supplying energy for that production and our customersâ€™ carbon emissions associated with their use of the energy products we sell. Shell only controls its own emissions. The use of the term Shellâ€™s â€œNet Carbon Footprintâ€ or â€œNet Carbon Intensityâ€ are for convenience only and not intended to suggest these emissions are those of Shell plc or its subsidiaries.Shellâ€™s net-Zero Emissions TargetShellâ€™s operating plan  outlook and budgets are forecasted for a ten-year period and are updated every year. They reflect the current economic environment and what we can reasonably expect to see over the next ten years. Accordingly  they reflect our Scope 1  Scope 2 and Net Carbon Footprint (NCF) targets over the next ten years. However  Shellâ€™s operating plans cannot reflect our 2050 net-zero emissions target and 2035 NCF target  as these targets are currently outside our planning period. In the future  as society moves towards net-zero emissions  we expect Shellâ€™s operating plans to reflect this movement. However  if society is not net zero in 2050  as of today  there would be significant risk that Shell may not meet this target.Forward Looking Non-GAAP measuresThis announcement may contain certain forward-looking non-GAAP measures such as cash capital expenditure and divestments. We are unable to provide a reconciliation of these forward-looking Non-GAAP measures to the most comparable GAAP financial measures because certain information needed to reconcile those Non-GAAP measures to the most comparable GAAP financial measures is dependent on future events some of which are outside the control of Shell  such as oil and gas prices  interest rates and exchange rates. Moreover  estimating such GAAP measures with the required precision necessary to provide a meaningful reconciliation is extremely difficult and could not be accomplished without unreasonable effort. Non-GAAP measures in respect of future periods which cannot be reconciled to the most comparable GAAP financial measure are calculated in a manner which is consistent with the accounting policies applied in Shell plcâ€™s consolidated financial statements.The contents of websites referred to in this announcement do not form part of this announcement.We may have used certain terms  such as resources  in this announcement that the United States Securities and Exchange Commission (SEC) strictly prohibits us from including in our filings with the SEC. Investors are urged to consider closely the disclosure in our Form 20-F  File No 1-32575  available on the SEC website www.sec.gov.LEI number of Shell plc: 21380068P1DRHMJ8KU70Classification: Additional regulated information required to be disclosed under the laws of a Member State,neutral,0.0,1.0,0.0,mixed,0.29,0.22,0.5,True,English,"['Shell plc', 'Third Quarter', 'Interim Dividend', 'Equiniti Financial Services Limited', 'Dutch dividend withholding tax', 'different currency election date', 'third quarter 2022 interim dividend', 'Event Date Announcement date', 'euro equivalents announcement date', 'valid dividend reinvestment election', 'Dividend Reinvestment Programmes', 'Dividend Reinvestment Plans', 'Ex- Dividend Date', 'Dividend Access Mechanism', 'American Depositary Receipt', 'Enquiries Media International', 'indirect ownership interest', 'equivalent dividend payments', 'American Depositary Shares', 'former B shares', 'Per ADS Q3', 'JPMorgan Chase Bank', 'unincorporated joint arrang', 'separate legal entities', 'former A shares', 'two ordinary shares', 'Shell Corporate Nominee', 'valid election', 'Dividend timetable', 'next dividend', 'Record date', 'Payment date', 'election deadline', 'tax residence', 'tax treatment', 'tax advisor', 'N.A.', 'Media Americas', 'unincorporated arrangements', 'financial institution', 'Financial Intermediaries', 'nominee arrangement', 'Shell interest', 'joint ventures', 'joint operations', 'joint arrangements', 'The Board', 'US dollars', 'Euroclear Nederland', 'uncertificated form', 'pound sterling', 'many cases', 'following organisations', 'certificate holder', 'CREST Member', 'ABN-AMRO NV', 'Such organisations', 'Interested parties', 'More information', 'useful purpose', 'significant influence', 'financial intermediary', 'Shell plc', 'joint control', 'Shell Shares', 'pounds sterling', 'securities account', 'particular entity', 'DRIP Offerors', 'Cautionary Note', 'Other DRIPs', 'Cash dividends', 'Shell Group', 'Shell companies', 'other shareholders', 'Shell subsidiaries', 'Shell ADSs', 'Members', 'London', 'Company', 'respect', 'Details', 'euros', 'contrary', 'persons', 'December', 'default', 'ADR', 'terms', 'November', 'Closing', 'Register', 'broker', 'Story', 'Taxation', 'UK', 'EFSL', 'investors', 'behalf', 'close', 'elections', 'investments', 'convenience', 'references', 'words', 'associates']",2022-10-27,2022-10-28,finance.yahoo.com
12185,Euroclear,NewsApi.org,https://finance.yahoo.com/news/shell-plc-2023-interim-dividend-060400080.html,Shell Plc 2023 Interim Dividend Timetable,SHELL PLC 2023 INTERIM DIVIDEND TIMETABLE London  October 27  2022The Board of Shell plc today announced the intended timetable for the 2023 quarterly...,SHELL PLC 2023 INTERIM DIVIDEND TIMETABLELondon  October 27  2022The Board of Shell plc today announced the intended timetable for the 2023 quarterly interim dividends.2023 Interim Dividend Timetable4th Quarter 2022 1st Quarter 2023 2nd Quarter 2023 3rd Quarter 2023 Announcement date 02-Feb-23 04-May-23 27-Jul-23 02-Nov-23 Ex- Dividend Date for ADSs 16-Feb-23 18-May-23 10-Aug-23 16-Nov-23 Ex- Dividend Date for ordinary shares 16-Feb-23 18-May-23 10-Aug-23 16-Nov-23 Record date 17-Feb-23 19-May-23 11-Aug-23 17-Nov-23 Closing date for currency election (see Note below) 03-Mar-23 05-Jun-23 25-Aug-23 01-Dec-23 Pounds sterling and euro equivalents announcement date 13-Mar-23 12-Jun-23 04-Sep-23 11-Dec-23 Payment date 27-Mar-23 26-Jun-23 18-Sep-23 20-Dec-23NoteA different currency election date may apply to shareholders holding shares in a securities account with a bank or financial institution ultimately holding through Euroclear Nederland. This may also apply to other shareholders who do not hold their shares either directly on the Register of Members or in the corporate sponsored nominee arrangement. Shareholders can contact their broker  financial intermediary  bank or financial institution for the election deadline that applies.The 2023 interim dividend timetable is also available on www.shell.com/dividend.EnquiriesMedia International: +44 207 934 5550Media Americas: +1 832 337 4355Cautionary NoteThe companies in which Shell plc directly and indirectly owns investments are separate legal entities. In this announcement â€œShellâ€  â€œShell Groupâ€ and â€œGroupâ€ are sometimes used for convenience where references are made to Shell plc and its subsidiaries in general. Likewise  the words â€œweâ€  â€œusâ€ and â€œourâ€ are also used to refer to Shell plc and its subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular entity or entities. â€˜â€˜Subsidiariesâ€™â€™  â€œShell subsidiariesâ€ and â€œShell companiesâ€ as used in this announcement refer to entities over which Shell plc either directly or indirectly has control. Entities and unincorporated arrangements over which Shell has joint control are generally referred to as â€œjoint venturesâ€ and â€œjoint operationsâ€  respectively. â€œJoint venturesâ€ and â€œjoint operationsâ€ are collectively referred to as â€œjoint arrangementsâ€. Entities over which Shell has significant influence but neither control nor joint control are referred to as â€œassociatesâ€. The term â€œShell interestâ€ is used for convenience to indicate the direct and/or indirect ownership interest held by Shell in an entity or unincorporated joint arrangement  after exclusion of all third-party interest.Story continuesForward-Looking StatementsThis announcement contains forward-looking statements (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995) concerning the financial condition  results of operations and businesses of Shell. All statements other than statements of historical fact are  or may be deemed to be  forward-looking statements. Forward-looking statements are statements of future expectations that are based on managementâ€™s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results  performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements include  among other things  statements concerning the potential exposure of Shell to market risks and statements expressing managementâ€™s expectations  beliefs  estimates  forecasts  projections and assumptions. These forward-looking statements are identified by their use of terms and phrases such as â€œaimâ€  â€œambitionâ€  â€˜â€˜anticipateâ€™â€™  â€˜â€˜believeâ€™â€™  â€˜â€˜couldâ€™â€™  â€˜â€˜estimateâ€™â€™  â€˜â€˜expectâ€™â€™  â€˜â€˜goalsâ€™â€™  â€˜â€˜intendâ€™â€™  â€˜â€˜mayâ€™â€™  â€œmilestonesâ€  â€˜â€˜objectivesâ€™â€™  â€˜â€˜outlookâ€™â€™  â€˜â€˜planâ€™â€™  â€˜â€˜probablyâ€™â€™  â€˜â€˜projectâ€™â€™  â€˜â€˜risksâ€™â€™  â€œscheduleâ€  â€˜â€˜seekâ€™â€™  â€˜â€˜shouldâ€™â€™  â€˜â€˜targetâ€™â€™  â€˜â€˜willâ€™â€™ and similar terms and phrases. There are a number of factors that could affect the future operations of Shell and could cause those results to differ materially from those expressed in the forward-looking statements included in this announcement  including (without limitation): (a) price fluctuations in crude oil and natural gas; (b) changes in demand for Shellâ€™s products; (c) currency fluctuations; (d) drilling and production results; (e) reserves estimates; (f) loss of market share and industry competition; (g) environmental and physical risks; (h) risks associated with the identification of suitable potential acquisition properties and targets  and successful negotiation and completion of such transactions; (i) the risk of doing business in developing countries and countries subject to international sanctions; (j) legislative  judicial  fiscal and regulatory developments including regulatory measures addressing climate change; (k) economic and financial market conditions in various countries and regions; (l) political risks  including the risks of expropriation and renegotiation of the terms of contracts with governmental entities  delays or advancements in the approval of projects and delays in the reimbursement for shared costs; (m) risks associated with the impact of pandemics  such as the COVID-19 (coronavirus) outbreak; and (n) changes in trading conditions. No assurance is provided that future dividend payments will match or exceed previous dividend payments. All forward-looking statements contained in this announcement are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Additional risk factors that may affect future results are contained in Shell plcâ€™s Form 20-F for the year ended December 31  2021 (available at www.shell.com/investor and www.sec.gov). These risk factors also expressly qualify all forward-looking statements contained in this announcement and should be considered by the reader. Each forward-looking statement speaks only as of the date of this announcement  October 27  2022. Neither Shell plc nor any of its subsidiaries undertake any obligation to publicly update or revise any forward-looking statement as a result of new information  future events or other information. In light of these risks  results could differ materially from those stated  implied or inferred from the forward-looking statements contained in this announcement.Shellâ€™s net carbon footprintAlso  in this announcement we may refer to Shellâ€™s â€œNet Carbon Footprintâ€ or â€œNet Carbon Intensityâ€  which include Shellâ€™s carbon emissions from the production of our energy products  our suppliersâ€™ carbon emissions in supplying energy for that production and our customersâ€™ carbon emissions associated with their use of the energy products we sell. Shell only controls its own emissions. The use of the term Shellâ€™s â€œNet Carbon Footprintâ€ or â€œNet Carbon Intensityâ€ are for convenience only and not intended to suggest these emissions are those of Shell plc or its subsidiaries.Shellâ€™s net-Zero Emissions TargetShellâ€™s operating plan  outlook and budgets are forecasted for a ten-year period and are updated every year. They reflect the current economic environment and what we can reasonably expect to see over the next ten years. Accordingly  they reflect our Scope 1  Scope 2 and Net Carbon Footprint (NCF) targets over the next ten years. However  Shellâ€™s operating plans cannot reflect our 2050 net-zero emissions target and 2035 NCF target  as these targets are currently outside our planning period. In the future  as society moves towards net-zero emissions  we expect Shellâ€™s operating plans to reflect this movement. However  if society is not net zero in 2050  as of today  there would be significant risk that Shell may not meet this target.Forward Looking Non-GAAP measuresThis announcement may contain certain forward-looking non-GAAP measures such as cash capital expenditure and divestments. We are unable to provide a reconciliation of these forward-looking Non-GAAP measures to the most comparable GAAP financial measures because certain information needed to reconcile those Non-GAAP measures to the most comparable GAAP financial measures is dependent on future events some of which are outside the control of Shell  such as oil and gas prices  interest rates and exchange rates. Moreover  estimating such GAAP measures with the required precision necessary to provide a meaningful reconciliation is extremely difficult and could not be accomplished without unreasonable effort. Non-GAAP measures in respect of future periods which cannot be reconciled to the most comparable GAAP financial measure are calculated in a manner which is consistent with the accounting policies applied in Shell plcâ€™s consolidated financial statements.The contents of websites referred to in this announcement do not form part of this announcement.We may have used certain terms  such as resources  in this announcement that the United States Securities and Exchange Commission (SEC) strictly prohibits us from including in our filings with the SEC. Investors are urged to consider closely the disclosure in our Form 20-F  File No 1-32575  available on the SEC website www.sec.gov.LEI number of Shell plc: 21380068P1DRHMJ8KU70Classification: Additional regulated information required to be disclosed under the laws of a Member State,neutral,0.0,1.0,0.0,mixed,0.11,0.16,0.73,True,English,"['Interim Dividend Timetable', 'Shell Plc', 'U.S. Private Securities Litigation Reform Act', 'euro equivalents announcement date', 'different currency election date', '2023 quarterly interim dividends', 'suitable potential acquisition', 'Ex- Dividend Date', 'indirect ownership interest', 'Enquiries Media International', 'Interim Dividend Timetable', 'financial market conditions', 'separate legal entities', 'unincorporated joint arrangement', 'securities account', 'Closing date', 'Payment date', 'intended timetable', 'election deadline', 'currency fluctuations', 'nominee arrangement', 'Media Americas', 'unincorporated arrangements', 'potential exposure', 'international sanctions', 'third-party interest', 'market share', 'financial institution', 'financial intermediary', 'financial condition', 'joint ventures', 'joint arrangements', '4th Quarter', '1st Quarter', '2nd Quarter', '3rd Quarter', '23 Pounds sterling', 'Euroclear Nederland', 'useful purpose', 'significant influence', 'historical fact', 'other things', 'price fluctuations', 'crude oil', 'natural gas', 'industry competition', 'successful negotiation', 'regulatory developments', 'regulatory measures', 'climate change', 'market risks', 'joint operations', 'Shell interest', 'future operations', 'future expectations', 'current expectations', 'developing countries', 'various countries', 'joint control', 'unknown risks', 'physical risks', 'political risks', 'Forward-Looking Statements', 'SHELL PLC', 'The Board', 'particular entity', 'actual results', 'production results', 'reserves estimates', 'ordinary shares', 'other shareholders', 'Cautionary Note', 'similar terms', 'Shell Group', 'Shell companies', 'Shell subsidiaries', 'London', 'October', 'Nov', 'ADSs', 'Aug', 'bank', 'Register', 'Members', 'broker', 'investments', 'convenience', 'references', 'words', 'associates', 'exclusion', 'Story', 'meaning', 'businesses', 'management', 'assumptions', 'uncertainties', 'performance', 'events', 'beliefs', 'forecasts', 'projections', 'phrases', 'aim', 'ambition', 'goals', 'milestones', 'objectives', 'outlook', 'plan', 'target', 'number', 'factors', 'limitation', 'changes', 'demand', 'products', 'drilling', 'loss', 'environmental', 'identification', 'properties', 'completion', 'transactions', 'fiscal', 'economic', 'regions']",2022-10-27,2022-10-28,finance.yahoo.com
12186,Euroclear,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/27/2542381/0/en/Verkkokauppa-com-decided-on-the-third-installment-of-the-quarterly-dividend.html,Verkkokauppa.com decided on the third installment of the quarterly dividend,Verkkokauppa.com decided on the third installment of the quarterly dividend  Verkkokauppa.com Oyj Stock Exchange Release Â Â  27 October 2022 at 7:45 am...,English FinnishVerkkokauppa.com decided on the third installment of the quarterly dividendVerkkokauppa.com Oyj Stock Exchange Release 27 October 2022 at 7:45 am EESTThe Board of Directors of Verkkokauppa.com Oyj has decided today  on the basis of the authorization granted by the Annual General Meeting 2022  that a dividend of EUR 0.063 per share (EUR 2 839 581.80 in total) be distributed from retained earnings.The dividend will be paid to a shareholder registered in the companyâ€™s shareholdersâ€™ register maintained by Euroclear Finland Ltd on the record date for the dividend on 31 October 2022. The dividend will be paid on 7 November 2022.Verkkokauppa.comâ€™s Annual General Meeting  held on 24 March 2022  resolved to authorize the Board of Directors to decide at its discretion on the distribution of dividends. Based on the authorization  the total amount of the quarterly dividend distribution shall not exceed EUR 0.186 per share.Following distribution of dividends resolved upon 27 October 2022  the Company does not have any valid authorizations for distribution of funds.Before the Board of Directors implements the resolution regarding the distribution of dividend  it must assess  from the viewpoint of Companyâ€™s financial position  whether the requirements in the Finnish Companies Act for the distribution of dividend are fulfilled.During 2022  Verkkokauppa.com has paid dividends  including this distribution  to its shareholders in the total amount of EUR 11.2 million  i.e. EUR 0.246 per share.For more information  please contact:Mikko ForsellCFO  Verkkokauppa.com Oyjmikko.forsell@verkkokauppa.comTel. +358 10 309 5555Marja MÃ¤kinenHead of Investor Relations and Corporate CommunicationsVerkkokauppa.com OyjMarja.makinen@verkkokauppa.comTel. +358 40 671 2999Distribution:Nasdaq HelsinkiMain mediawww.verkkokauppa.comVerkkokauppa.com empowers its customers to follow their passion by providing a wide product assortment of around 90 000 products. Verkkokauppa.com Oyj serves its retail and corporate customers through its webstore  megastores  kiosk and network of collection points as well as fast deliveries and various services. As Finlandâ€™s most popular and most visited domestic online retailer  its deliveries cover around 75 percent of the Finnish population within the next day. The Company has four megastores: in Oulu  Pirkkala  Raisio  and Helsinki  where its headquarters is also located. Verkkokauppa.com employs more than 750 people and its shares are listed on the Nasdaq Helsinki stock exchange with the ticker VERK.,neutral,0.0,1.0,0.0,negative,0.0,0.12,0.88,True,English,"['Verkkokauppa.com', 'third installment', 'quarterly dividend', 'Oyj Stock Exchange Release', 'Nasdaq Helsinki stock exchange', 'Annual General Meeting', 'wide product assortment', 'domestic online retailer', 'Finnish Companies Act', 'Euroclear Finland Ltd', 'Marja MÃ¤kinen', 'quarterly dividend distribution', 'English Finnish', 'Finnish population', 'third installment', 'record date', 'valid authorizations', 'financial position', 'Mikko Forsell', 'Investor Relations', 'Corporate Communications', 'Main media', 'collection points', 'various services', 'next day', 'total amount', 'shareholdersâ€™ register', 'corporate customers', 'fast deliveries', 'four megastores', 'Verkkokauppa.com', 'Board', 'Directors', 'basis', 'earnings', 'company', '31 October', '7 November', '24 March', 'discretion', 'dividends', '27 October', 'funds', 'resolution', 'viewpoint', 'requirements', 'information', 'CFO', 'Tel.', 'Head', 'makinen', 'passion', '90,000 products', 'webstore', 'kiosk', 'network', 'popular', '75 percent', 'Oulu', 'Pirkkala', 'Raisio', '750 people', 'shares', 'ticker', 'VERK.', '7:45']",2022-10-27,2022-10-28,globenewswire.com
12187,Euroclear,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/27/2542441/0/en/Shell-plc-Third-Quarter-2022-Interim-Dividend.html,Shell plc Third Quarter 2022 Interim Dividend,London  October 27  2022 âˆ’ The Board of Shell plc (â€œShellâ€ or the â€œCompanyâ€) today announced an interim dividend in respect of the third quarter of 2022 of US$ 0.25 per ordinary share.,London  October 27  2022 âˆ’ The Board of Shell plc (â€œShellâ€ or the â€œCompanyâ€) today announced an interim dividend in respect of the third quarter of 2022 of US$ 0.25 per ordinary share.Details relating to the third quarter 2022 interim dividendPer ordinary share Q3 2022 Shell Shares (US$) 0.25Shareholders will be able to elect to receive their dividends in US dollars  euros or pounds sterling.Absent any valid election to the contrary  persons holding their ordinary shares through Euroclear Nederland will receive their dividends in euros.Absent any valid election to the contrary  shareholders (both holding in certificated and uncertificated form (CREST members)) and persons holding their shares through the Shell Corporate Nominee will receive their dividends in pounds sterling.The pound sterling and euro equivalent dividend payments will be announced on December 5  2022.Per ADS Q3 2022 Shell ADSs (US$) 0.5Cash dividends on American Depositary Shares (â€œADSsâ€) will be paid  by default  in US dollars.Each ADS represents two ordinary shares. ADSs are evidenced by an American Depositary Receipt (â€œADRâ€) certificate. In many cases the terms ADR and ADS are used interchangeably.Dividend timetable for the third quarter 2022 interim dividendEvent Date Announcement date October 27  2022 Ex- Dividend Date for ADSs November 9  2022 Ex- Dividend Date for ordinary shares November 10  2022 Record date November 11  2022 Closing of currency election date (see Note below) November 25  2022 Pound sterling and euro equivalents announcement date December 5  2022 Payment date December 19  2022NoteA different currency election date may apply to shareholders holding shares in a securities account with a bank or financial institution ultimately holding through Euroclear Nederland. This may also apply to other shareholders who do not hold their shares either directly on the Register of Members or in the corporate sponsored nominee arrangement. Shareholders can contact their broker  financial intermediary  bank or financial institution for the election deadline that applies.Taxation - cash dividendsWith the Companyâ€™s tax residence moved to the UK  dividends paid to shareholders on their ordinary shares will not attract Dutch dividend withholding tax. This means that holders of the former A shares receive their dividends in full as Dutch dividend withholding tax is no longer withheld on these dividends. Holders of the former B shares receive their dividends directly from the Company as these dividends will no longer be paid through the Dividend Access Mechanism.If you are uncertain as to the tax treatment of any dividends you should consult your tax advisor.Dividend Reinvestment Programmes (â€œDRIPâ€)The following organisations operate Dividend Reinvestment Plans (â€œDRIPsâ€) which enable Shellâ€™s shareholders to elect to have their dividend payments used to purchase Shell shares:Equiniti Financial Services Limited (â€œEFSLâ€)  for those holding shares (a) directly on the register as certificate holder or as CREST Member and (b) via the Shell Corporate Nominee;ABN-AMRO NV (â€œABNâ€) for Financial Intermediaries holding shares via Euroclear Nederland;JPMorgan Chase Bank  N.A. (â€œJPMâ€) for holders of ADSs; andOther DRIPs may also be available from the intermediary through which investors hold their shares and ADSs.Such organisations provide their DRIPs fully on their account and not on behalf of Shell.Interested parties should contact DRIP Offerors directly.More information can be found at https://www.shell.com/dripTo be eligible to participate in the DRIPs for the next dividend  shareholders must make a valid dividend reinvestment election before the published date for the close of elections.EnquiriesMedia International: +44 207 934 5550Media Americas: +1 832 337 4355Cautionary NoteThe companies in which Shell plc directly and indirectly owns investments are separate legal entities. In this announcement â€œShellâ€  â€œShell Groupâ€ and â€œGroupâ€ are sometimes used for convenience where references are made to Shell plc and its subsidiaries in general. Likewise  the words â€œweâ€  â€œusâ€ and â€œourâ€ are also used to refer to Shell plc and its subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular entity or entities. â€˜â€˜Subsidiariesâ€™â€™  â€œShell subsidiariesâ€ and â€œShell companiesâ€ as used in this announcement refer to entities over which Shell plc either directly or indirectly has control. Entities and unincorporated arrangements over which Shell has joint control are generally referred to as â€œjoint venturesâ€ and â€œjoint operationsâ€  respectively. â€œJoint venturesâ€ and â€œjoint operationsâ€ are collectively referred to as â€œjoint arrangementsâ€. Entities over which Shell has significant influence but neither control nor joint control are referred to as â€œassociatesâ€. The term â€œShell interestâ€ is used for convenience to indicate the direct and/or indirect ownership interest held by Shell in an entity or unincorporated joint arrangement  after exclusion of all third-party interest.Forward-Looking StatementsThis announcement contains forward-looking statements (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995) concerning the financial condition  results of operations and businesses of Shell. All statements other than statements of historical fact are  or may be deemed to be  forward-looking statements. Forward-looking statements are statements of future expectations that are based on managementâ€™s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results  performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements include  among other things  statements concerning the potential exposure of Shell to market risks and statements expressing managementâ€™s expectations  beliefs  estimates  forecasts  projections and assumptions. These forward-looking statements are identified by their use of terms and phrases such as â€œaimâ€  â€œambitionâ€  â€˜â€˜anticipateâ€™â€™  â€˜â€˜believeâ€™â€™  â€˜â€˜couldâ€™â€™  â€˜â€˜estimateâ€™â€™  â€˜â€˜expectâ€™â€™  â€˜â€˜goalsâ€™â€™  â€˜â€˜intendâ€™â€™  â€˜â€˜mayâ€™â€™  â€œmilestonesâ€  â€˜â€˜objectivesâ€™â€™  â€˜â€˜outlookâ€™â€™  â€˜â€˜planâ€™â€™  â€˜â€˜probablyâ€™â€™  â€˜â€˜projectâ€™â€™  â€˜â€˜risksâ€™â€™  â€œscheduleâ€  â€˜â€˜seekâ€™â€™  â€˜â€˜shouldâ€™â€™  â€˜â€˜targetâ€™â€™  â€˜â€˜willâ€™â€™ and similar terms and phrases. There are a number of factors that could affect the future operations of Shell and could cause those results to differ materially from those expressed in the forward-looking statements included in this announcement  including (without limitation): (a) price fluctuations in crude oil and natural gas; (b) changes in demand for Shellâ€™s products; (c) currency fluctuations; (d) drilling and production results; (e) reserves estimates; (f) loss of market share and industry competition; (g) environmental and physical risks; (h) risks associated with the identification of suitable potential acquisition properties and targets  and successful negotiation and completion of such transactions; (i) the risk of doing business in developing countries and countries subject to international sanctions; (j) legislative  judicial  fiscal and regulatory developments including regulatory measures addressing climate change; (k) economic and financial market conditions in various countries and regions; (l) political risks  including the risks of expropriation and renegotiation of the terms of contracts with governmental entities  delays or advancements in the approval of projects and delays in the reimbursement for shared costs; (m) risks associated with the impact of pandemics  such as the COVID-19 (coronavirus) outbreak; and (n) changes in trading conditions. No assurance is provided that future dividend payments will match or exceed previous dividend payments. All forward-looking statements contained in this announcement are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Additional risk factors that may affect future results are contained in Shell plcâ€™s Form 20-F for the year ended December 31  2021 (available at www.shell.com/investor and www.sec.gov). These risk factors also expressly qualify all forward-looking statements contained in this announcement and should be considered by the reader. Each forward-looking statement speaks only as of the date of this announcement  October 27  2022. Neither Shell plc nor any of its subsidiaries undertake any obligation to publicly update or revise any forward-looking statement as a result of new information  future events or other information. In light of these risks  results could differ materially from those stated  implied or inferred from the forward-looking statements contained in this announcement.Shellâ€™s net carbon footprintAlso  in this announcement we may refer to Shellâ€™s â€œNet Carbon Footprintâ€ or â€œNet Carbon Intensityâ€  which include Shellâ€™s carbon emissions from the production of our energy products  our suppliersâ€™ carbon emissions in supplying energy for that production and our customersâ€™ carbon emissions associated with their use of the energy products we sell. Shell only controls its own emissions. The use of the term Shellâ€™s â€œNet Carbon Footprintâ€ or â€œNet Carbon Intensityâ€ are for convenience only and not intended to suggest these emissions are those of Shell plc or its subsidiaries.Shellâ€™s net-Zero Emissions TargetShellâ€™s operating plan  outlook and budgets are forecasted for a ten-year period and are updated every year. They reflect the current economic environment and what we can reasonably expect to see over the next ten years. Accordingly  they reflect our Scope 1  Scope 2 and Net Carbon Footprint (NCF) targets over the next ten years. However  Shellâ€™s operating plans cannot reflect our 2050 net-zero emissions target and 2035 NCF target  as these targets are currently outside our planning period. In the future  as society moves towards net-zero emissions  we expect Shellâ€™s operating plans to reflect this movement. However  if society is not net zero in 2050  as of today  there would be significant risk that Shell may not meet this target.Forward Looking Non-GAAP measuresThis announcement may contain certain forward-looking non-GAAP measures such as cash capital expenditure and divestments. We are unable to provide a reconciliation of these forward-looking Non-GAAP measures to the most comparable GAAP financial measures because certain information needed to reconcile those Non-GAAP measures to the most comparable GAAP financial measures is dependent on future events some of which are outside the control of Shell  such as oil and gas prices  interest rates and exchange rates. Moreover  estimating such GAAP measures with the required precision necessary to provide a meaningful reconciliation is extremely difficult and could not be accomplished without unreasonable effort. Non-GAAP measures in respect of future periods which cannot be reconciled to the most comparable GAAP financial measure are calculated in a manner which is consistent with the accounting policies applied in Shell plcâ€™s consolidated financial statements.The contents of websites referred to in this announcement do not form part of this announcement.We may have used certain terms  such as resources  in this announcement that the United States Securities and Exchange Commission (SEC) strictly prohibits us from including in our filings with the SEC. Investors are urged to consider closely the disclosure in our Form 20-F  File No 1-32575  available on the SEC website www.sec.gov.LEI number of Shell plc: 21380068P1DRHMJ8KU70Classification: Additional regulated information required to be disclosed under the laws of a Member State,neutral,0.0,1.0,0.0,mixed,0.25,0.16,0.6,True,English,"['Shell plc', 'Third Quarter', 'Interim Dividend', 'Equiniti Financial Services Limited', 'Dutch dividend withholding tax', 'different currency election date', 'third quarter 2022 interim dividend', 'Event Date Announcement date', 'euro equivalents announcement date', 'valid dividend reinvestment election', 'Dividend Reinvestment Programmes', 'Dividend Reinvestment Plans', 'Ex- Dividend Date', 'Dividend Access Mechanism', 'American Depositary Receipt', 'Enquiries Media International', 'indirect ownership interest', 'equivalent dividend payments', 'American Depositary Shares', 'former B shares', 'Per ADS Q3', 'JPMorgan Chase Bank', 'separate legal entities', 'former A shares', 'unincorporated joint arrangement', 'two ordinary shares', 'Shell Corporate Nominee', 'valid election', 'Dividend timetable', 'next dividend', 'Record date', 'Payment date', 'nominee arrangement', 'election deadline', 'tax residence', 'tax treatment', 'tax advisor', 'N.A.', 'Media Americas', 'unincorporated arrangements', 'financial institution', 'Financial Intermediaries', 'Shell interest', 'joint ventures', 'joint operations', 'joint arrangements', 'The Board', 'US dollars', 'Euroclear Nederland', 'uncertificated form', 'pound sterling', 'many cases', 'following organisations', 'certificate holder', 'CREST Member', 'ABN-AMRO NV', 'Such organisations', 'Interested parties', 'More information', 'useful purpose', 'significant influence', 'financial intermediary', 'Shell plc', 'joint control', 'Shell Shares', 'pounds sterling', 'securities account', 'particular entity', 'DRIP Offerors', 'Cautionary Note', 'Other DRIPs', 'Cash dividends', 'Shell Group', 'Shell companies', 'other shareholders', 'Shell subsidiaries', 'Shell ADSs', 'Members', 'London', 'Company', 'respect', 'Details', 'euros', 'contrary', 'persons', 'December', 'default', 'ADR', 'terms', 'November', 'Closing', 'Register', 'broker', 'Taxation', 'UK', 'EFSL', 'investors', 'behalf', 'close', 'elections', 'investments', 'convenience', 'references', 'words', 'associates']",2022-10-27,2022-10-28,globenewswire.com
12188,Euroclear,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/27/2542443/0/en/Shell-Plc-2023-Interim-Dividend-Timetable.html,Shell Plc 2023 Interim Dividend Timetable,SHELL PLC 2023 INTERIM DIVIDEND TIMETABLEÂ London  October 27  2022The Board of Shell plc today announced the intended timetable for the 2023 quarterly interim dividends.Â Â 2023 Interim Dividend Timetable,SHELL PLC 2023 INTERIM DIVIDEND TIMETABLELondon  October 27  2022The Board of Shell plc today announced the intended timetable for the 2023 quarterly interim dividends.2023 Interim Dividend Timetable4th Quarter 2022 1st Quarter 2023 2nd Quarter 2023 3rd Quarter 2023 Announcement date 02-Feb-23 04-May-23 27-Jul-23 02-Nov-23 Ex- Dividend Date for ADSs 16-Feb-23 18-May-23 10-Aug-23 16-Nov-23 Ex- Dividend Date for ordinary shares 16-Feb-23 18-May-23 10-Aug-23 16-Nov-23 Record date 17-Feb-23 19-May-23 11-Aug-23 17-Nov-23 Closing date for currency election (see Note below) 03-Mar-23 05-Jun-23 25-Aug-23 01-Dec-23 Pounds sterling and euro equivalents announcement date 13-Mar-23 12-Jun-23 04-Sep-23 11-Dec-23 Payment date 27-Mar-23 26-Jun-23 18-Sep-23 20-Dec-23NoteA different currency election date may apply to shareholders holding shares in a securities account with a bank or financial institution ultimately holding through Euroclear Nederland. This may also apply to other shareholders who do not hold their shares either directly on the Register of Members or in the corporate sponsored nominee arrangement. Shareholders can contact their broker  financial intermediary  bank or financial institution for the election deadline that applies.The 2023 interim dividend timetable is also available on www.shell.com/dividend.EnquiriesMedia International: +44 207 934 5550Media Americas: +1 832 337 4355Cautionary NoteThe companies in which Shell plc directly and indirectly owns investments are separate legal entities. In this announcement â€œShellâ€  â€œShell Groupâ€ and â€œGroupâ€ are sometimes used for convenience where references are made to Shell plc and its subsidiaries in general. Likewise  the words â€œweâ€  â€œusâ€ and â€œourâ€ are also used to refer to Shell plc and its subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular entity or entities. â€˜â€˜Subsidiariesâ€™â€™  â€œShell subsidiariesâ€ and â€œShell companiesâ€ as used in this announcement refer to entities over which Shell plc either directly or indirectly has control. Entities and unincorporated arrangements over which Shell has joint control are generally referred to as â€œjoint venturesâ€ and â€œjoint operationsâ€  respectively. â€œJoint venturesâ€ and â€œjoint operationsâ€ are collectively referred to as â€œjoint arrangementsâ€. Entities over which Shell has significant influence but neither control nor joint control are referred to as â€œassociatesâ€. The term â€œShell interestâ€ is used for convenience to indicate the direct and/or indirect ownership interest held by Shell in an entity or unincorporated joint arrangement  after exclusion of all third-party interest.Forward-Looking StatementsThis announcement contains forward-looking statements (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995) concerning the financial condition  results of operations and businesses of Shell. All statements other than statements of historical fact are  or may be deemed to be  forward-looking statements. Forward-looking statements are statements of future expectations that are based on managementâ€™s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results  performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements include  among other things  statements concerning the potential exposure of Shell to market risks and statements expressing managementâ€™s expectations  beliefs  estimates  forecasts  projections and assumptions. These forward-looking statements are identified by their use of terms and phrases such as â€œaimâ€  â€œambitionâ€  â€˜â€˜anticipateâ€™â€™  â€˜â€˜believeâ€™â€™  â€˜â€˜couldâ€™â€™  â€˜â€˜estimateâ€™â€™  â€˜â€˜expectâ€™â€™  â€˜â€˜goalsâ€™â€™  â€˜â€˜intendâ€™â€™  â€˜â€˜mayâ€™â€™  â€œmilestonesâ€  â€˜â€˜objectivesâ€™â€™  â€˜â€˜outlookâ€™â€™  â€˜â€˜planâ€™â€™  â€˜â€˜probablyâ€™â€™  â€˜â€˜projectâ€™â€™  â€˜â€˜risksâ€™â€™  â€œscheduleâ€  â€˜â€˜seekâ€™â€™  â€˜â€˜shouldâ€™â€™  â€˜â€˜targetâ€™â€™  â€˜â€˜willâ€™â€™ and similar terms and phrases. There are a number of factors that could affect the future operations of Shell and could cause those results to differ materially from those expressed in the forward-looking statements included in this announcement  including (without limitation): (a) price fluctuations in crude oil and natural gas; (b) changes in demand for Shellâ€™s products; (c) currency fluctuations; (d) drilling and production results; (e) reserves estimates; (f) loss of market share and industry competition; (g) environmental and physical risks; (h) risks associated with the identification of suitable potential acquisition properties and targets  and successful negotiation and completion of such transactions; (i) the risk of doing business in developing countries and countries subject to international sanctions; (j) legislative  judicial  fiscal and regulatory developments including regulatory measures addressing climate change; (k) economic and financial market conditions in various countries and regions; (l) political risks  including the risks of expropriation and renegotiation of the terms of contracts with governmental entities  delays or advancements in the approval of projects and delays in the reimbursement for shared costs; (m) risks associated with the impact of pandemics  such as the COVID-19 (coronavirus) outbreak; and (n) changes in trading conditions. No assurance is provided that future dividend payments will match or exceed previous dividend payments. All forward-looking statements contained in this announcement are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Additional risk factors that may affect future results are contained in Shell plcâ€™s Form 20-F for the year ended December 31  2021 (available at www.shell.com/investor and www.sec.gov). These risk factors also expressly qualify all forward-looking statements contained in this announcement and should be considered by the reader. Each forward-looking statement speaks only as of the date of this announcement  October 27  2022. Neither Shell plc nor any of its subsidiaries undertake any obligation to publicly update or revise any forward-looking statement as a result of new information  future events or other information. In light of these risks  results could differ materially from those stated  implied or inferred from the forward-looking statements contained in this announcement.Shellâ€™s net carbon footprintAlso  in this announcement we may refer to Shellâ€™s â€œNet Carbon Footprintâ€ or â€œNet Carbon Intensityâ€  which include Shellâ€™s carbon emissions from the production of our energy products  our suppliersâ€™ carbon emissions in supplying energy for that production and our customersâ€™ carbon emissions associated with their use of the energy products we sell. Shell only controls its own emissions. The use of the term Shellâ€™s â€œNet Carbon Footprintâ€ or â€œNet Carbon Intensityâ€ are for convenience only and not intended to suggest these emissions are those of Shell plc or its subsidiaries.Shellâ€™s net-Zero Emissions TargetShellâ€™s operating plan  outlook and budgets are forecasted for a ten-year period and are updated every year. They reflect the current economic environment and what we can reasonably expect to see over the next ten years. Accordingly  they reflect our Scope 1  Scope 2 and Net Carbon Footprint (NCF) targets over the next ten years. However  Shellâ€™s operating plans cannot reflect our 2050 net-zero emissions target and 2035 NCF target  as these targets are currently outside our planning period. In the future  as society moves towards net-zero emissions  we expect Shellâ€™s operating plans to reflect this movement. However  if society is not net zero in 2050  as of today  there would be significant risk that Shell may not meet this target.Forward Looking Non-GAAP measuresThis announcement may contain certain forward-looking non-GAAP measures such as cash capital expenditure and divestments. We are unable to provide a reconciliation of these forward-looking Non-GAAP measures to the most comparable GAAP financial measures because certain information needed to reconcile those Non-GAAP measures to the most comparable GAAP financial measures is dependent on future events some of which are outside the control of Shell  such as oil and gas prices  interest rates and exchange rates. Moreover  estimating such GAAP measures with the required precision necessary to provide a meaningful reconciliation is extremely difficult and could not be accomplished without unreasonable effort. Non-GAAP measures in respect of future periods which cannot be reconciled to the most comparable GAAP financial measure are calculated in a manner which is consistent with the accounting policies applied in Shell plcâ€™s consolidated financial statements.The contents of websites referred to in this announcement do not form part of this announcement.We may have used certain terms  such as resources  in this announcement that the United States Securities and Exchange Commission (SEC) strictly prohibits us from including in our filings with the SEC. Investors are urged to consider closely the disclosure in our Form 20-F  File No 1-32575  available on the SEC website www.sec.gov.LEI number of Shell plc: 21380068P1DRHMJ8KU70Classification: Additional regulated information required to be disclosed under the laws of a Member State,neutral,0.0,1.0,0.0,negative,0.04,0.13,0.83,True,English,"['Interim Dividend Timetable', 'Shell Plc', 'U.S. Private Securities Litigation Reform Act', 'euro equivalents announcement date', 'different currency election date', '2023 quarterly interim dividends', 'suitable potential acquisition', 'Ex- Dividend Date', 'indirect ownership interest', 'Enquiries Media International', 'Interim Dividend Timetable', 'financial market conditions', 'separate legal entities', 'unincorporated joint arrangement', 'securities account', 'Closing date', 'Payment date', 'intended timetable', 'election deadline', 'currency fluctuations', 'nominee arrangement', 'Media Americas', 'unincorporated arrangements', 'potential exposure', 'international sanctions', 'third-party interest', 'market share', 'financial institution', 'financial intermediary', 'financial condition', 'joint ventures', 'joint arrangements', '4th Quarter', '1st Quarter', '2nd Quarter', '3rd Quarter', '23 Pounds sterling', 'Euroclear Nederland', 'useful purpose', 'significant influence', 'historical fact', 'other things', 'price fluctuations', 'crude oil', 'natural gas', 'industry competition', 'successful negotiation', 'regulatory developments', 'regulatory measures', 'climate change', 'market risks', 'joint operations', 'Shell interest', 'future operations', 'future expectations', 'current expectations', 'developing countries', 'various countries', 'joint control', 'unknown risks', 'physical risks', 'political risks', 'Forward-Looking Statements', 'SHELL PLC', 'The Board', 'particular entity', 'actual results', 'production results', 'reserves estimates', 'ordinary shares', 'other shareholders', 'Cautionary Note', 'similar terms', 'Shell Group', 'Shell companies', 'Shell subsidiaries', 'London', 'October', 'Nov', 'ADSs', 'Aug', 'bank', 'Register', 'Members', 'broker', 'investments', 'convenience', 'references', 'words', 'associates', 'exclusion', 'meaning', 'businesses', 'management', 'assumptions', 'uncertainties', 'performance', 'events', 'beliefs', 'forecasts', 'projections', 'phrases', 'aim', 'ambition', 'goals', 'milestones', 'objectives', 'outlook', 'plan', 'target', 'number', 'factors', 'limitation', 'changes', 'demand', 'products', 'drilling', 'loss', 'environmental', 'identification', 'properties', 'completion', 'transactions', 'fiscal', 'economic', 'regions', 'expropriation']",2022-10-27,2022-10-28,globenewswire.com
12196,Deutsche Boerse,Bing API,https://www.wsj.com/articles/u-s-exchange-stocks-lag-behind-german-rival-11666836475,U.S. Exchange Stocks Lag Behind German Rival,Surging interest rates are benefiting exchange operator Deutsche BÃ¶rse by boosting demand for derivatives tied to borrowing costs.,Surging interest rates are benefiting exchange operator Deutsche BÃ¶rse by boosting demand for derivatives tied to borrowing costs.,negative,0.0,0.08,0.92,neutral,0.24,0.76,0.0,True,English,"['U.S. Exchange Stocks', 'German Rival', 'Surging interest rates', 'Deutsche BÃ¶rse', 'exchange operator', 'borrowing costs', 'demand', 'derivatives']",2022-10-27,2022-10-28,wsj.com
12197,Deutsche Boerse,Twitter API,Twitter,MarketsWiki Page of the Day: Benefitting from high interest rates  Deutsche BÃ¶rse's stock has beaten regional and Uâ€¦ https://t.co/nJFtI0gFJp,nan,MarketsWiki Page of the Day: Benefitting from high interest rates  Deutsche BÃ¶rse's stock has beaten regional and Uâ€¦ https://t.co/nJFtI0gFJp,neutral,0.11,0.87,0.02,neutral,0.11,0.87,0.02,True,English,"['high interest rates', 'Deutsche BÃ¶rse', 'MarketsWiki Page', 'Day', 'stock', 'regional', 'high interest rates', 'Deutsche BÃ¶rse', 'MarketsWiki Page', 'Day', 'stock', 'regional']",2022-10-27,2022-10-28,Unknown
12198,Deutsche Boerse,Twitter API,Twitter,Read how Deutsche BÃ¶rse Group is using Microsoft Azure to manage its data and shape the future of the financial serâ€¦ https://t.co/kHN5LeDwhk,nan,Read how Deutsche BÃ¶rse Group is using Microsoft Azure to manage its data and shape the future of the financial serâ€¦ https://t.co/kHN5LeDwhk,neutral,0.12,0.88,0.01,neutral,0.12,0.88,0.01,True,English,"['Deutsche BÃ¶rse Group', 'Microsoft Azure', 'financial ser', 'data', 'future', 'Deutsche BÃ¶rse Group', 'Microsoft Azure', 'financial ser', 'data', 'future']",2022-10-27,2022-10-28,Unknown
12199,Deutsche Boerse,Twitter API,Twitter,WSJmarkets: Surging interest rates are benefiting German exchange operator Deutsche BÃ¶rse by boosting demand for deâ€¦ https://t.co/1MhfPcVfla,nan,WSJmarkets: Surging interest rates are benefiting German exchange operator Deutsche BÃ¶rse by boosting demand for deâ€¦ https://t.co/1MhfPcVfla,neutral,0.03,0.96,0.01,neutral,0.03,0.96,0.01,True,English,"['Surging interest rates', 'German exchange operator', 'Deutsche BÃ¶rse', 'WSJmarkets', 'demand', 'MhfPcVfla', 'Surging interest rates', 'German exchange operator', 'Deutsche BÃ¶rse', 'WSJmarkets', 'demand', 'MhfPcVfla']",2022-10-27,2022-10-28,Unknown
12200,Deutsche Boerse,Twitter API,Twitter,U.S. Exchange Stocks Lag Behind German Rival: Surging interest rates are benefiting exchange operator Deutsche BÃ¶rsâ€¦ https://t.co/izSIkl2xW8,nan,U.S. Exchange Stocks Lag Behind German Rival: Surging interest rates are benefiting exchange operator Deutsche BÃ¶rsâ€¦ https://t.co/izSIkl2xW8,neutral,0.06,0.89,0.05,neutral,0.06,0.89,0.05,True,English,"['U.S. Exchange Stocks', 'Surging interest rates', 'Deutsche BÃ¶rs', 'exchange operator', 'German Rival', 'izSIkl2xW8', 'U.S. Exchange Stocks', 'Surging interest rates', 'Deutsche BÃ¶rs', 'exchange operator', 'German Rival', 'izSIkl2xW8']",2022-10-27,2022-10-28,Unknown
12201,Deutsche Boerse,Twitter API,Twitter,Release: Caplight secures $3 million strategic investment from Deutsche BÃ¶rse to expand derivatives trading and hedâ€¦ https://t.co/OqaKnhCNoZ,nan,Release: Caplight secures $3 million strategic investment from Deutsche BÃ¶rse to expand derivatives trading and hedâ€¦ https://t.co/OqaKnhCNoZ,neutral,0.04,0.94,0.01,neutral,0.04,0.94,0.01,True,English,"['$3 million strategic investment', 'Deutsche BÃ¶rse', 'derivatives trading', 'Release', 'Caplight', 'OqaKnhCNoZ', '$3 million strategic investment', 'Deutsche BÃ¶rse', 'derivatives trading', 'Release', 'Caplight', 'OqaKnhCNoZ']",2022-10-26,2022-10-28,Unknown
12202,EuroNext,NewsApi.org,https://finance.yahoo.com/news/pharming-group-reports-earnings-first-050000054.html,Pharming Group reports earnings for the first nine months of 2022,"Pharming Group N.V. (""Pharming"" or ""the Company"") (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) presents its preliminary  unaudited financial report for the...","Leniolisib remains on track for marketing authorization in the US and European Economic Area in H1 2023Revenues increased by 3% to US$151.0 million  compared to the first nine months of 2021Operating profit increased by 86% to US$28.4 millionStrong balance sheet and stable sales from RUCONESTÂ® underpinning continued investment in launch preparations for leniolisib and Pharming's long-term growthLEIDEN  Netherlands  Oct. 27  2022 /PRNewswire/ -- Pharming Group N.V. (""Pharming"" or ""the Company"") (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) presents its preliminary  unaudited financial report for the first nine months ended September 30  2022.Pharming_Group_NV_LogoChief Executive Officer  Sijmen de Vries  commented:""In the first nine months of 2022 Pharming continued to perform well despite challenging industry conditions. Our commercialized asset RUCONESTÂ® saw increased sales of 3% or US$151.0 million  compared to the same period last year  highlighting the continued need for a safe and effective acute hereditary angioedema therapy.From a strategic perspective  we continued to make significant progress delivering on a number of important regulatory milestones for leniolisib  a rare immunodeficiency disease. Of note  our New Drug Application for leniolisib was accepted by the US FDA for Priority Review with a PDUFA goal date of March 29  2023. Furthermore  we submitted a Marketing Authorisation Application for the product to the European Medicines Agency following the grant of accelerated assessment. We remain on track for the anticipated marketing authorization of leniolisib as a treatment of APDS in key markets next year.Looking ahead  the anticipated launch and commercialization of leniolisib will be supported by our strong balance sheet and the steady sales of RUCONESTÂ®. We will continue focusing on our strategic objectives and the internal review of our pipeline as we look to bring the unserved rare disease patient the solutions they need. We look forward to presenting more detailed plans at our full year financial results.""Story continuesStrategic highlightsDuring the first nine months of 2022  we continued to execute on our strategic objectives of building a sustainable business by focusing on RUCONESTÂ® sales  the approval  launch and commercialization of leniolisib  and the ongoing development and management of our pipeline as we prioritize our efforts on rare diseases.As announced during the half year financial results in August 2022  we initiated an internal review of our pipeline with a greater and renewed focus towards rare diseases. As a result  we will advance the development of our pipeline through a combination of internal development projects - including the development of additional indications for leniolisib  as well as OTL-105 as a gene therapy for HAE - and the potential acquisition of new  late-stage assets through in-licensing and M&A opportunities.We believe these potential acquisitions and in-licensing will be financed through a combination of positive cash flow from the RUCONESTÂ® business  anticipated future leniolisib business  as well as available cash from our strong balance sheet. If required  Pharming will access additional funding from the capital markets.Pipeline developmentleniolisibFor leniolisib  Pharming has a three-step approach planned for the coming years.The first step is the anticipated marketing authorization and commercial launch of leniolisib for the treatment of activated PI3K delta syndrome (APDS) in adults and adolescents aged 12 and older in the US during the first half of 2023. This will be followed by key markets in the European Economic Area (EEA) and the UK in the second half of 2023 and early 2024  respectively  dependent upon regulatory approval. The Company will evaluate additional countries and regions and will commercialize the product either directly or through strategic distribution partnerships.The second step includes the marketing authorization and commercial launch of leniolisib as a treatment of APDS in children as young as one year of age.The third step is the continued life cycle management of the leniolisib compound into further indications which will be disclosed when decisions have been taken.US marketWe remain on track for the anticipated commercial approval of leniolisib in the first quarter of 2023  subject to approval from the US Food and Drug Administration (FDA)  followed by the commercial launch of leniolisib in the second quarter of 2023.In the third quarter of 2022  we delivered on a number of important regulatory milestones including the filing and acceptance of a New Drug Application (NDA) for Priority Review by the FDA.As a result of receiving Priority Review  Pharming's NDA for leniolisib was assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 29  2023.In anticipation of a positive outcome from the FDA  we continued to grow our US field force and leverage our marketing capabilities for the commercialization of leniolisib.Finally  the ICD-10-CM code for APDS took effect on October 1  2022. The assignment of the ICD-10-CM code enables physicians and payors in the US to add a diagnosis of APDS to patients' health records  which will help connect these individuals with researchers studying the prevalence and course of the disease. In addition  by allocating a specific diagnosis  the new ICD-10-CM code may help confirm medical necessity in individual patients  thus improving their access to relevant care options through US health insurance plans.European Economic Area (EEA) and UK marketIn the EEA  we announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) had granted an accelerated assessment for the Marketing Authorisation Application (MAA) for leniolisib in adults and adolescents aged 12 and older. Upon further request  EMA will grant an accelerated assessment of an MAA if they decide the product is of major interest for public health  and in particular  from the viewpoint of therapeutic innovation. The accelerated assessment reduces the review timeframe from 210 days to 150 days.Further positive milestones were reached in October 2022 when we announced that we had submitted a Marketing Authorisation Application for leniolisib to the EMA. We expect to receive EMA validation of the MAA at the end of October 2022  with anticipated marketing authorization in H1 2023.Moving on to the UK market  in April 2022  the Medicines and Healthcare products Regulatory Agency (MHRA) granted Promising Innovative Medicine (PIM) designation to leniolisib for the treatment of APDS. A PIM designation is an early indication that leniolisib is a candidate for the MHRA's Early Access to Medicines Scheme. This scheme provides an opportunity for treatment options to be used in clinical practice in parallel with the later stages of the regulatory process.Finally  on September 30  2022  the UK government took the decision to extend the European Commission Decision Reliance Procedure (ECDRP) by 12 months  until December 31  2023. The ECDRP allows a company to submit a product that has received approval from EMA to the UK's MHRA. The MHRA can grant a license relying on the EMA's decision  thereby ensuring a less time consuming in-country review.The extension of the ECDRP has several benefits including aligned EU and UK dossiers  consistent labeling across the EU and UK  and the potential for an earlier Marketing Authorisation Approval. As such  Pharming has decided that the ECDRP procedure will be used for the application of leniolisib to the MHRA. Under ECDRP  if the submission of an application is made within five days of an EMA CHMP positive opinion  the MHRA will aim to determine a decision within a 67-day timeline. The anticipated MHRA decision should be known in H2 2023.Pediatric clinical developmentAs previously announced  we intend to expand access to leniolisib for the treatment of pediatric APDS. As a result  Pharming has developed a clinical plan to include children as young as one year of age. During the first half of the year  positive decisions were received from EMA and MHRA on the Pediatric Investigation Plan (PIP) for leniolisib as a treatment for APDS in children. The leniolisib PIP includes two planned  global clinical trials in pediatric patients with APDS aged 4 to 11 with a second study in patients aged 1 to 6. These two studies will support regulatory filings worldwide. Pharming expects to initiate recruitment for this pediatric program for leniolisib in the fourth quarter of 2022.OTL-105Pharming's strategic collaboration with Orchard Therapeutics to research  develop  manufacture and commercialize OTL-105  a newly disclosed investigational ex vivo autologous hematopoietic stem cell (HSC) gene therapy for the treatment of hereditary angioedema (HAE) is ongoing. The program has made good progress developing the lentiviral vector to enhance C1-inhibitor expression and is now testing in preclinical HAE disease models. We anticipate providing further updates as we move towards preparing an Investigational New Drug (IND) filing.Acute Kidney Injury (AKI)As announced at our half year 2022 financial results  following an internal review of our pipeline  we have taken the strategic decision to discontinue further development of rhC1INH therapy for Acute Kidney Injury. We are considering strategic options to gain value from the work done to date and have de-prioritized further development and investment in the large-scale production of rhC1INH through the use of our transgenic cattle herd. The herd is being maintained to allow all possible outcomes to be explored.The ongoing Phase IIb clinical trial is continuing as we evaluate these strategic options.We will update the market at our full year 2022 financial results on further progress in this area.PompeWe continue the preclinical investigation of a next-generation alpha-glucosidase therapy for the treatment of Pompe disease and will update the market on the results as appropriate.Financial SummaryAmounts in US$m except per share data YTD 2022 YTD 2021 % Change Income StatementRevenues 151.0 146.1 3 % Gross profit 139.7 130.6 7 % Operating profit 28.4 15.3 86 % Profit for the year 28.3 13.9 104 % Balance SheetCash & marketable securities 189.9 184.8 3 % Share InformationBasic earnings per share (US$) 0.043 0.022 95 % Diluted earnings per share (US$) 0.040 0.018 122 %Financial highlightsYTD Q3 2022Revenues for the first nine months of 2022 were US$151.0 million  a 3% increase compared to the first nine months of 2021 (US$146.1 million).Gross profit for the first nine months of 2022 increased 7% to US$139.7 million. This increase was driven by growth in revenues  production efficiencies and a favorable tailwind in currency translation effects.Operating costs for the first nine months of 2022 increased by US$9.8 million to US$126.9 million versus the same period last year. The increase results from a combination of increased R&D expenditure  launch preparation and manufacturing costs for leniolisib  and an increase in travel related expenses post-COVID-19. This increase was partly offset by significant one-off costs in Q3 2021 relating to the in-licensing of OTL-105 from Orchard Therapeutics.Operating profit for the first nine months of 2022 was US$28.4 million  increasing 86% versus the same period last year. This was mainly driven by the increase in other income of US$13.8 million as a result of a reduced minority stake in BioConnection communicated in our H1 2022 press release.Net profit for the first nine months of 2022 was US$28.3 million  a 104% increase compared to the same period last year (US$13.9 million). This was driven by the increase in other income of US$13.8 million.Cash and cash equivalents  together with restricted cash  decreased from US$193.0 million at the end of 2021  to US$189.9 million at the end of the third quarter 2022.OutlookFor the financial year of 2022:Single digit growth in Group revenues from RUCONESTÂ® sales. Quarterly fluctuations are expected.Subject to a positive outcome from the FDA review  we anticipate marketing authorization in the US for leniolisib at the end of Q1 2023  with an anticipated launch and commercialization in Q2 2023.Subject to a positive outcome from the EMA review  we anticipate a positive opinion from the CHMP for leniolisib  followed by the issuance of an MAA by the European Commission towards the end of H1 2023. Initial commercial launches in EU markets are planned for H2 2023.Following an anticipated positive CHMP opinion  we intend to submit an ECDRP filing for leniolisib with the MHRA in the UK in H2 2023.Pharming will continue to allocate resources towards the anticipated launch and commercialization of leniolisib with the view of accelerating future growth. Investments in launch preparations and focused clinical development for leniolisib will continue to impact profit for the remainder of 2022 and throughout 2023. However  no additional financing to support the current business is expected with the continued cash flow from RUCONESTÂ® funding these investments.Investment and continued focus on potential acquisitions and in-licensing of new  late- stage development opportunities and assets in rare diseases. Financing  if required  would come via a combination of our strong balance sheet and access to capital markets.No further specific financial guidance for 2022 is provided.Additional informationPresentationThe conference call presentation will be available on the Pharming.com website from 10:30 CET on October 27  2022.Conference CallThe conference call will begin at 13:30 CET on October 27  2022. A transcript of the call will be available on the Pharming.com website the following day at 14:30 CET.Please note  the Company will only take questions from dial-in attendees.Dial-in numbers for conference callNetherlands (Local) +31 85 888 7233United Kingdom +44 800 640 6441United Kingdom (Local) +44 20 3936 2999United States +1 855 979 6654United States (Local) +1 646 664 1960All other locations +44 20 3936 2999Access code: 497472Webcast link: https://webcast.openbriefing.com/pharming-q32022/Financial calendar 2022Credit Suisse 31st Annual Healthcare Conference: November 8 - 10Stifel Healthcare Conference 2022: November 15 - 16Jefferies London Healthcare Conference: November 15 - 17For further public information  contact:Pharming Group  Leiden  The NetherlandsHeather Robertson  Investor Relations & Corporate Communications ManagerT: +31 7 1 524 7400investor@pharming.comFTI Consulting  London  UKVictoria Foster Mitchell/Alex ShawT: +44 203 727 1000FTI Consulting  USAJim PolsonT: +1 (312) 553-6730LifeSpring Life Sciences Communication  Amsterdam  The NetherlandsLeon MelensT: +31 6 53 81 64 27E: pharming@lifespring.nlAbout Pharming Group N.V.Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare  debilitating  and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines  including small molecules  biologics  and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden  Netherlands  and has employees around the globe who serve patients in over 30 markets in North America  Europe  the Middle East  Africa  and Asia-Pacific. For more information  visit www.pharming.com and find us on LinkedIn .Auditor's involvementThe Condensed Consolidated Interim Financial Statements have not been audited by the Company's statutory auditor.Risk profileThe risks outlined in the 2021 Annual Report continued to apply in the first nine months of 2022and are expected to apply for the rest of the financial year. We continue to closely monitor the key risks and opportunities  and will respond appropriately to any emerging risk.Related party transactionsThere are no material changes in the nature  scope  and (relative) scale in this reporting periodcompared to last year.Forward-looking StatementsThis press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results  performance  or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as ""aim""  ""ambition""  ''anticipate''  ''believe''  ''could''  ''estimate''  ''expect''  ''goals''  ''intend''  ''may''  ""milestones""  ''objectives''  ''outlook''  ''plan''  ''probably''  ''project''  ''risks''  ""schedule""  ''seek''  ''should''  ''target''  ''will'' and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates  Pharming's clinical and commercial prospects  and Pharming's expectations regarding its projected working capital requirements and cash resources  which statements are subject to a number of risks  uncertainties and assumptions  including  but not limited to the scope  progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical  scientific  regulatory and technical developments. In light of these risks and uncertainties  and other risks and uncertainties that are described in Pharming's 2021 Annual Report and the Annual Report on Form 20-F for the year ended December 31  2021  filed with the U.S. Securities and Exchange Commission  the events and circumstances discussed in such forward-looking statements may not occur  and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information  future events or other information.Inside InformationThis press release relates to the disclosure of information that qualifies  or may have qualified  as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.Pharming Group N.V.Condensed Consolidated Interim Financial Statements in US Dollars (unaudited)For the period ended 30 September 2022Condensed consolidated statement of profit and lossCondensed consolidated statement of comprehensive incomeCondensed consolidated balance sheetCondensed consolidated statement of cash flowCONDENSED CONSOLIDATED STATEMENT OF PROFIT AND LOSSFor the 9-month period ended 30 September 2022Amounts in US$ '000 YTD 2022 YTD 2021 Revenues 151.001 146.101 Costs of sales (11.288) (15.500) Gross profit 139.712 130.601 Other income 15.602 1.808 Research and development (41.639) (37.580) OTL-105 in-licensing 0 (13.105) General and administrative (28.446) (22.510) Marketing and sales (56.819) (43.880) Other Operating Costs (126.904) (117.075) Operating profit 28.410 15.334 Fair value gain (loss) on revaluation derivatives 0 59 Other finance income 9.297 9.907 Other finance expenses (3.978) (4.466) Finance cost net 5.319 5.500 Share of net profits in associates using the equity method (660) 511 Profit before tax 33.069 21.345 Income tax credit (expense) (4.765) (7.412) Profit for the year 28.304 13.933 Basic earnings per share (US$) 0.043 0.022 Fully-diluted earnings per share (US$) 0.040 0.018CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOMEFor the 9-month period ended 30 September 2022Amounts in US$ '000 YTD 2022 YTD 2021 Profit for the year 28.304 13.933 Currency translation differences (26.313) (10.506) Fair value remeasurement investments (573) (1.475) Items that may be subsequently reclassified to profit or loss (26.886) (11.981) Other comprehensive income (loss)  net of tax (26.886) (11.981) Total comprehensive income (loss) for the year 1.418 1.952CONDENSED CONSOLIDATED BALANCE SHEETAs at 30 September 2022Amounts in US$ '000 30 September 2022 31 December 2021 Non-current assetsIntangible assets 70.123 83.834 Property  plant and equipment 10.812 13.222 Right-of-use assets 16.970 19.943 Long-term prepayments 210 194 Deferred tax assets 21.187 21.216 Investments accounted for using the equity method 2.845 7.201 Investment in equity instruments designated as at FVTOCI 545 1.449 Investment in debt instruments designated as at FVTPL 7.386 0 Restricted cash 197 812 Total non-current assets 130.275 147.871 Current assetsInventories 33.506 27.310 Trade and other receivables 28.828 29.983 Restricted cash 1.011 227 Cash and cash equivalents 188.703 191.924 Total current assets 252.048 249.444 Total assets 382.323 397.315EquityShare capital 7.482 7.429 Share premium 459.450 455.254 Legal reserves (24.145) 3.400 Accumulated deficit (242.533) (273.167) Shareholders' equity 200.254 192.916 Non-current liabilitiesConvertible bonds 120.005 139.007 Lease liabilities 15.227 18.456 Other financial liabilities 143 165 Total non-current liabilities 135.375 157.628Current liabilitiesConvertible bonds 1.627 1.879 Derivative financial liabilities 0 0 Trade and other payables 42.744 42.473 Lease liabilities 2.323 2.419 Total current liabilities 46.694 46.771 Total equity and liabilities 382.323 397.315CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS in US DollarFor the 9-month period ended 30 September 2022Amounts in $'000 YTD 2022 YTD 2021Profit before tax 33.069 21.345Non-cash adjustments:Depreciation  amortization  impairment 6.216 6.867Equity settled share based payments 4.522 5.706Fair value gain (loss) on revaluation of derivatives 0 (59)Gain on disposal of investment in associate (12.382) 0Other finance income (9.296) (9.907)Other finance expense 3.978 4.466Share of net profits in associates using the equity method 660 (511)Other 0 272Operating cash flows before changes in working capital 26.767 28.179Changes in working capital:Inventories (6.196) (3.941)Trade and other receivables 1.155 3.092Payables and other current liabilities 272 (5.514)Restricted Cash 169 42Total changes in working capital (4.600) (6.321)Interest received 31 51Income taxes paid (4.975) 0Net cash flows generated from (used in) operating activities 17.223 21.909Capital expenditure for property  plant and equipment (1.071) (7.451)Investment intangible assets (591) (1.544)Investment in equity instruments designated as at FVTOCI 0 (4.589)Investment in associate 7.384 0Acquisition of license 0 (1.593)Net cash flows used in investing activities 5.722 (15.177)Repayment on loans and borrowings 0 0Payment on contingent consideration 0 (25.000)Payment of lease liabilities (2.385) (2.476)Proceeds of issued convertible bonds 0 0Interests on loans and leases (3.999) (4.493)Proceeds of equity and warrants 1.124 4.237Net cash flows generated from (used in) financing activities (5.260) (27.732)Increase (decrease) of cash 17.685 (21.000)Exchange rate effects (20.906) (835)Cash and cash equivalents at 1 January 191.924 205.159Total cash and cash equivalents at 30 September 188.703 183.324Logo - https://mma.prnewswire.com/media/1778344/Pharming_Group_NV_Logo.jpgCisionView original content:https://www.prnewswire.co.uk/news-releases/pharming-group-reports-earnings-for-the-first-nine-months-of-2022-301660492.html",neutral,0.0,1.0,0.0,mixed,0.5,0.21,0.29,True,English,"['first nine months', 'Pharming Group', 'earnings', 'effective acute hereditary angioedema therapy', 'Prescription Drug User Fee Act', 'preliminary, unaudited financial report', 'full year financial results', 'unserved rare disease patient', 'half year financial results', 'Pharming Group N.V.', 'continued life cycle management', 'rare immunodeficiency disease', 'New Drug Application', 'European Economic Area', 'Strong balance sheet', 'Chief Executive Officer', 'Sijmen de Vries', 'challenging industry conditions', 'PDUFA goal date', 'European Medicines Agency', 'new, late-stage assets', 'M&A opportunities', 'PI3K delta syndrome', 'PDUFA) goal date', 'important regulatory milestones', 'first nine months', 'strategic distribution partnerships', 'Marketing Authorisation Application', 'positive cash flow', 'US field force', 'internal development projects', 'future leniolisib business', 'gene therapy', 'one year', 'Drug Administration', 'first half', 'rare diseases', 'continued investment', 'continued need', 'second half', 'first step', 'first quarter', 'available cash', 'positive outcome', 'internal review', 'sustainable business', 'strategic perspective', 'strategic objectives', 'Strategic highlights', 'marketing authorization', 'regulatory approval', 'marketing capabilities', 'Operating profit', 'long-term growth', 'Euronext Amsterdam', 'commercialized asset', 'same period', 'significant progress', 'Priority Review', 'accelerated assessment', 'key markets', 'detailed plans', 'potential acquisition', 'additional funding', 'capital markets', 'three-step approach', 'coming years', 'additional countries', 'second step', 'third step', 'second quarter', 'third quarter', 'ICD-10-CM code', 'US market', 'US Food', 'ongoing development', 'stable sales', 'steady sales', 'RUCONESTÂ® business', 'additional indications', 'commercial launch', 'The Company', 'commercial approval', 'leniolisib compound', 'RUCONESTÂ® sales', 'US FDA', 'Pipeline development', 'track', 'H1', 'Revenues', 'preparations', 'LEIDEN', 'Netherlands', 'PRNewswire', 'NASDAQ', 'Pharming_Group_NV_Logo', 'safe', 'number', 'note', 'March', 'product', 'grant', 'treatment', 'APDS', 'commercialization', 'solutions', 'Story', 'efforts', 'August', 'greater', 'focus', 'combination', 'HAE', 'licensing', 'adults', 'adolescents', 'EEA', 'UK', 'early', 'regions', 'children', 'decisions', 'filing', 'acceptance', 'NDA', 'anticipation', 'October', '2022']",2022-10-27,2022-10-28,finance.yahoo.com
12204,EuroNext,NewsApi.org,https://finance.yahoo.com/news/intertrust-delivers-accelerated-revenue-growth-051500609.html,Intertrust delivers accelerated revenue growth in Q3,Amsterdam  the Netherlands â€“ 27 October 2022 â€“ Intertrust N.V. (â€œIntertrustâ€ or â€œCompanyâ€) [Euronext: INTER]  a global leader in providing tech-enabled fund ...,Intertrust GroupAmsterdam  the Netherlands â€“ 27 October 2022 â€“ Intertrust N.V. (â€œIntertrustâ€ or â€œCompanyâ€) [Euronext: INTER]  a global leader in providing tech-enabled fund and corporate solutions  today provides a condensed Q3 and 9M 2022 trading update. Q3 2022 underlying revenue growth was 8.2% and Q3 2022 adjusted EBITA margin was 26.4%. Cash flow from operating activities of â‚¬ 31.5m in the third quarter increased 41.0% compared to last year. Intertrust confirms that the public offer by CSC is progressing as planned now CSC and Intertrust have obtained all Regulatory Clearances. Reference is made to the press release dated 17 October 2022. The Offer Period ends on 31 October 2022 at 17:40 CET. CSC and Intertrust jointly recommend to all Shareholders to tender their Shares before that time.Q3 2022 revenue was â‚¬ 159.0 million (+13.4% y-o-y). Underlying revenue growth was 8.2%  driven by double-digit growth in US Fund Services and Luxembourg  a return to growth in Cayman Islands and continued solid momentum in Rest of the World. This was only partly offset by lower revenues in the Netherlands. In the first nine months  revenue totalled â‚¬ 459.1 million (+8.3% y-o-y) with underlying revenue growth of 4.2%.Adjusted EBITA was â‚¬ 42.0 million  resulting in a 26.4% adjusted EBITA margin in Q3 2022 and reflects increased investments in the workforce  including onboarding and training of new personnel. Additionally  adjusted EBITA included â‚¬ 4.4 million one-off costs related to remediation activities. In the first nine months  adjusted EBITA amounted to â‚¬ 115.2 million  resulting in a 25.1% margin.Shankar Iyer  CEO of Intertrust: â€œWe see strong top-line momentum with accelerated revenue growth in the third quarter. Our continued investments in compliance  remediation and in our workforce support the long-term growth of our business. Our initiatives to contain costs in the current inflationary environment are beginning to bear fruit  resulting in a margin improvement compared to the previous quarter. Weâ€™ve entered the final stages of the transaction with CSC  marking a new era for the Company. We strongly believe the combination with CSC will deliver greater value for clients  colleagues and other stakeholders  driven by a truly long-term focus and enhanced efforts on compliance and remediation. We are very excited about this next chapter for the Company and our colleagues  after completion of the public offer by CSC.â€The figures provided today are unaudited. This press release contains information that qualifies  or may qualify  as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.Story continuesAttachment,neutral,0.05,0.95,0.0,mixed,0.47,0.19,0.34,True,English,"['revenue growth', 'Intertrust', 'Q3', 'EU Market Abuse Regulation', 'Q3 2022 underlying revenue growth', '9M 2022 trading update', 'US Fund Services', 'first nine months', 'current inflationary environment', 'strong top-line momentum', '4.4 million one-off costs', 'Intertrust N.V.', '26.4% adjusted EBITA margin', 'solid momentum', 'double-digit growth', 'long-term growth', 'Q3 2022 revenue', 'global leader', 'corporate solutions', 'Cash flow', 'operating activities', 'third quarter', 'last year', 'public offer', 'Regulatory Clearances', 'press release', 'Offer Period', 'Cayman Islands', 'lower revenues', 'new personnel', 'Shankar Iyer', 'margin improvement', 'previous quarter', 'final stages', 'new era', 'greater value', 'other stakeholders', 'long-term focus', 'next chapter', 'continued investments', 'Intertrust Group', 'remediation activities', '25.1% margin', 'Amsterdam', 'Netherlands', '27 October', 'Company', 'condensed', 'CSC', 'Reference', '31 October', '17:40 CET', 'Shareholders', 'Shares', 'time', 'Luxembourg', 'return', 'Rest', 'World', 'workforce', 'onboarding', 'training', 'CEO', 'compliance', 'business', 'initiatives', 'fruit', 'transaction', 'combination', 'clients', 'colleagues', 'enhanced', 'efforts', 'completion', 'figures', 'information', 'inside', 'meaning', 'Article', 'Story', 'Attachment']",2022-10-27,2022-10-28,finance.yahoo.com
12207,EuroNext,NewsApi.org,https://finance.yahoo.com/news/flow-traders-q322-trading-053000042.html,FLOW TRADERS Q322 TRADING UPDATE,FLOW TRADERS Q322 TRADING UPDATE Amsterdam  the Netherlands - Flow Traders N.V. (Euronext: FLOW) announces its unaudited Q322 trading update. Highlights Flow...,Flow Traders NVFLOW TRADERS Q322 TRADING UPDATEAmsterdam  the Netherlands - Flow Traders N.V. (Euronext: FLOW) announces its unaudited Q322 trading update.HighlightsFlow Traders recorded Normalized total income of â‚¬112.2m in Q322 comprising Normalized NTI of â‚¬111.7m reflecting a more active fixed income market and trading environment and Normalized other income of â‚¬0.4m derived from the strategic investments portfolio. YTD 9m22 Normalized total income was â‚¬346.7m vs â‚¬304.1m in YTD 9m21Flow Traders Value Traded was flat quarter-on-quarter whereas the overall ETP market was down as increases in fixed income and currency  crypto and commodity trading were offset by lower equity trading  highlighting the success of the trading diversification strategyNormalized operating expenses of â‚¬63.3m incurred in Q322 contributing to YTD 9m22 Normalized operating expenses of â‚¬186.7m. 16.5% year-on-year increase in fixed operating expenses when adjusted for effect of USD strengthening and targeted base compensation increasesNormalized employee expenses reflect increased variable remuneration due to an improved operating result  impact of strategic headcount growth and the full effect of the targeted base compensation increases639 FTEs as at 30 September 2022 compared to 611 FTEs as at 30 June 2022 - new graduate intake classes welcomed in Trading and Technology in SeptemberNormalized EBITDA in Q322 reached â‚¬48.8m representing a margin of 44% contributing to YTD 9m22 Normalized EBITDA of â‚¬159.9m with a margin of 47%Q322 Normalized net profit amounted to â‚¬34.5m with Normalized basic EPS of â‚¬0.79. YTD 9m22 Normalized net profit amounted to â‚¬116.6m with Normalized basic EPS of â‚¬2.67Regulatory Own Funds Requirement (OFR) as at 30 September 2022 was â‚¬323m  resulting in excess capital of â‚¬228m as at 30 September 2022. Trading capital stood at â‚¬634m at the end of the third quarterExisting share buyback program of up to â‚¬25m increased by a further â‚¬15m for a total size of up to â‚¬40m - â‚¬9.1m of shares already repurchased since 22 July 2022Financial Overviewâ‚¬million Q322 Q222 Change YTD 9m22 YTD 9m21 Change Normalized total income 112.2 86.2 30% 346.7 304.1 14% Normalized net trading income 111.7 83.7 33% 343.9 303.7 13% EMEA 87.4 50.4 74% 246.3 186.0 32% Americas 14.4 18.6 (23%) 54.7 66.3 (18%) APAC 9.9 14.7 (33%) 42.9 51.4 (17%) Normalized other income 0.4 2.5 (83%) 2.8 0.4 - Normalized employee expenses1 40.1 28.5 41% 122.6 111.0 10% Technology expenses 16.1 14.9 8% 44.8 36.5 23% Other expenses2 7.1 6.3 13% 19.4 13.5 43% Normalized operating expenses 63.3 49.7 27% 186.7 161.0 16% Normalized EBITDA1 48.8 36.5 34% 159.9 143.1 12% Depreciation / amortisation 4.4 3.9 12.1 11.4 Write off of (in) tangible assets - - 0.2 - Normalized profit before tax 44.5 32.6 37% 147.7 131.8 12% Normalized tax 9.9 6.4 31.0 25.7 Normalized net profit 34.5 26.1 32% 116.6 106.1 10% Normalized basic EPS3 (â‚¬) 0.79 0.60 2.67 2.42 Normalized EBITDA margin 44% 44% 47% 47%Value Traded Overviewâ‚¬billion Q322 Q222 Change YTD 9m22 YTD 9m21 Change Flow Traders ETP Value Traded 409 449 (9%) 1 379 1 131 22% Europe 178 193 (8%) 609 522 17% Americas 212 230 (8%) 697 538 30% Asia 20 26 (24%) 74 70 5% Flow Traders non-ETP Value Traded 1 182 1 165 2% 3 781 2 978 27% Flow Traders Value Traded4 1 591 1 614 (1%) 5 160 4 108 26% Equity 714 831 (14%) 2 567 2 251 14% Fixed income 344 298 15% 960 758 27% Currency  Crypto  Commodity 495 463 7% 1 489 970 53% Other 37 21 72% 141 129 10% Market ETP Value Traded5 11 410 13 676 (17%) 40 170 26 169 54% Europe 532 567 (6%) 1 866 1 503 24% Americas 9 638 11 951 (19%) 34 894 21 954 59% Asia 1 240 1 158 7% 3 411 2 712 26% Asia ex China 395 400 (1%) 1 187 1 033 15%Regional HighlightsEUROPE:Strong trading performance in the region with the successful leverage of the investments made across the fixed income business. Flow Traders once again maintained its position as the leading liquidity provider in ETPs  both on- and off-exchangeCorporate credit trading business continues to gain further traction across the market. Flow Tradersâ€™ coverage of the EM bond market has been further strengthened during the quarter. Continued to see a quote rate of >80% for the majority of the Bloomberg Barclays Corporate Bond index and have retained Top 5 Bloomberg dealer rankings for executed tickets and volume in Flow Tradersâ€™ Euro IG universeContinued to support new products and listings across the crypto space - worked extensively with exchanges and ETP issuers around the Ethereum upgrade. Further investments made by Flow Traders Capital are aligned with growing focus on DeFi given Flow Traders is one of the leading global architects for maturing this propositionAMERICAS:Acted as Lead Market Maker (LMM) on the Charles Schwab Crypto Thematic ETF USA  the iShares Water Management Multisector ETF (IWTR)  the full Bondbloxx treasury suite and on SPKX and SPKY from Convexity Shares as Flow Tradersâ€™ LMM presence in the US growsFurther build-out of the fixed income business as Flow Traders commenced pricing IG bonds in the US with 2 500 ISINs currently covered with a plan in place to expand the coverage universe to 8 000 - 12 000 ISINsASIA:Successfully obtained QFII license approval in China which is a key step in the overall China market strategy and has enabled the execution of the first on-shore tradesFlow Traders is committed to growing the Hong Kong ETP markets and as part of this has joined the HKEx Cash Market Consultative Panel - also further strengthens the continuing cooperation with HKExFlow Traders CapitalFewer investments during the third quarter given the developments across the crypto and digital asset space. Announced new investments in Crossover Markets  GoGo pool  Infinity Exchange  Kemet Trading  and Sei Network as well as providing additional funding for two existing investments. Flow Traders total investment in the third quarter amounted to â‚¬5.1m and now has a total of 23 current investments to date representing a total value of â‚¬28.5mCorporate venture capital strategy is already paying off by selecting and entering investments that provide Flow Traders with an immediate benefit for the existing core liquidity providing businessOutlookFlow Traders announces an increase of the existing share buyback program of up to â‚¬25m by an additional amount of up to â‚¬15m for a total size of up to â‚¬40m over a period of 12 months from the start of the forthcoming open period. As of 26 October 2022  the total number of shares purchased under this program since 22 July 2022 is 469 434 shares at an average price of â‚¬19.46 for a total consideration of â‚¬9.1m. The purpose of the buyback is to return excess capital to shareholders. The intention is that shares repurchased as part of this program will initially be held in treasury. 3 259 529 shares are held in treasury as at 26 October 2022 with 58% of these treasury shares repurchased for the purpose of satisfying the requirements of various employee incentive plans and the remaining 42% repurchased for the purpose of returning excess capital to shareholdersOn 21 October 2022  Flow Traders announced a proposed implementation of an updated corporate holding structure  as an enabler of its global strategic ambition. This proposed update will involve a top holding company in Bermuda and is the result of a thorough legal and capital structure review. This will be formally proposed to shareholders at an Extraordinary General Meeting  scheduled to take place on 2 December 2022 at 14.00 CETManagement Board CommentsDennis Dijkstra  CEO  stated:â€œThis quarter delivered further proof points with respect to the diligent execution of our strategic growth agenda  particularly in fixed income. Our liquidity provision across the fixed income space which includes ETFs as well as corporate credit and emerging markets sovereign bonds continues to be positively received by the buy-side and we were delighted to be the lead sponsor once again at the recent Fixed Income Leadership Summit in Nice. Another landmark for Flow Traders was the successful approval of our QFII license which is a key part of our plan to enter the mainland China market. Given the strong financial performance in the quarter and within the context of our capital allocation framework  we have elected to increase the current share buyback program to a new total size of up to â‚¬40 million. This buyback will further enhance the capital returns to our shareholders.â€œWe have also worked hard this quarter on laying the groundwork for the future. The proposed update to the corporate holding structure was announced on 21 October 2022 and is a natural enabler for the strategic ambition which the team outlined at the Capital Markets Update held in July. In addition  we created an Executive Committee in order to accelerate the implementation of our strategy as well as to ensure that our leadership talent pool grows alongside the needs of the business. Lastly  it is also pleasing that in a highly competitive employment market  we are still able to attract and recruit the best talent and we welcomed a large intake of 18 new graduates in September to complement our already highly talented team.â€Folkert Joling  Chief Trading Officer  added:â€œThe third quarter saw a more active fixed income market given interest rate and inflation impacts. This contributed to an overall strong trading performance  which was particularly evident in EMEA. Across other asset classes  realized volatility remained subdued compared to earlier in the year. Our trading footprint continues to grow as we successfully executed our first ever on-shore China trades. From a broader trading perspective  we remained focused on executing our growth plans with respect to our business lines of Equity  Fixed Income and Crypto  Currencies and Commodities. We have enduring confidence in our ability to expand our trading activities across these various asset classes going forward.â€Mike Kuehnel  Chief Financial Officer  added:â€œIndicative of the success of our trading diversification strategy  Flow Traders achieved a return on trading capital of 67% in Q3. Once again  the firmâ€™s trading capital continues to generate attractive and economically accretive returns. From an operating cost perspective  we have had to contend with a changing macro environment which has brought rising inflation as well as a strengthening US dollar. We are therefore seeking to absorb these impacts while at the same time ensuring we continue to invest in the business in order to execute our strategy and deliver sustainable returns for our stakeholders. The adjusted profit-sharing percentage continues to effectively ensure that the base compensation increases implemented in Q2 are income statement neutral as communicated before. A key focus for the remainder of this year and next is to further increase the underlying efficiency of the business as we prepare ourselves for Flow Tradersâ€™ next stage of growth.â€œA key takeaway from the recent Capital Markets Update was the importance of engaging more intensely in the ecosystem we operate and thrive in. With that in mind  we have continued to support new products and listings across the crypto space and  notably  worked with exchanges and ETP issuers around the Ethereum upgrade. The pace of our strategic investments has naturally slowed somewhat with the advent of the â€˜crypto winterâ€™ which has allowed for more time to work with partners on build-out and development. Nonetheless  Flow Traders Capital still announced five investments during the third quarter.â€œPreliminary Financial Calendar2 December 2022 EGM12 January 2023 Start Silent Period ahead of Q422 / FY22 results9 February 2023 Release Q422 / FY22 results (incl. analyst conference call)24 February 2023 Release 2022 Annual Report31 March 2023 Start Silent Period ahead of Q123 trading update21 April 2023 Release Q123 trading update (no analyst conference call)26 April 2023 AGMContact DetailsFlow Traders N.V.InvestorsJonathan BergerPhone: +31 20 7996149Email: investor.relations@flowtraders.comMediaLaura PeijsPhone: +31 20 7996125Email: press@flowtraders.comAbout Flow TradersFlow Traders is a leading global financial technology-enabled liquidity provider in financial products  historically specialized in Exchange Traded Products (ETPs)  now expanding into other asset classes. Flow Traders ensures the provision of liquidity to support the uninterrupted functioning of financial markets. This allows investors to continue to buy or sell ETPs or other financial instruments under all market circumstances. We continuously grow our organization  ensuring that our trading desks in Europe  the Americas and Asia can provide liquidity across all major exchanges  globally  24 hours a day. Founded in 2004  we continue to cultivate the entrepreneurial  innovative and team-oriented culture that has been with us since the beginning. Please visit www.flowtraders.com for more information.Normalized performanceFlow Traders makes certain adjustments to various IFRS expense and profit measures in order to derive Alternative Performance Measures (APM). The policy is to exclude or adjust items that are considered to be significant in both nature or size and where the treatment as an adjusted item provides stakeholders with useful information to assess the year-on-year or quarter-on-quarter underlying performance. On this basis  the following items were adjusted or excluded for the Q322 trading update: Removal of IFRS 2 treatment of share-based payments which include the deferral of a portion of the current year share plans as well as recognition of prior yearsâ€™ share plans. This adjustment provides insights into the relationship between the current year variable employee expenses and current year trading performance Other income line includes all the realized and unrealized results on Flow Tradersâ€™ long-term equity investments whether accounted for as Fair Value Other Comprehensive Income (FV OCI)  Fair Value Profit and Loss (FVPL) or Results of Equity Accounted Investments Exclusion of one-off expenses which relate specifically to the proposed corporate holding structure update and the Capital Markets Update. These are not considered to be part of the underlying operating expenses of the business Tax expenses are adjusted based upon the pre-tax adjustments and/or excluded items aboveNormalized to IFRS reconciliationâ‚¬million Q322 Q222 Change YTD 9m22 YTD 9m21 Change Total income 111.7 83.5 34% 343.1 303.7 13% Net trading income 111.8 84.0 33% 344.5 303.7 13% Other income (0.1) (0.5) - (1.3) - - Employee expenses1 39.9 35.4 13% 130.2 119.2 9% Technology expenses 16.1 14.9 8% 44.8 36.5 23% Other expenses 7.1 6.3 13% 19.4 11.6 67% One off expenses 0.8 8.5 (91%) 12.5 1.9 - Total operating expenses 63.9 65.1 (2%) 207.0 169.3 22% EBITDA 47.8 18.3 161% 136.2 134.5 1% Profit before tax 43.4 14.3 204% 123.7 123.2 0% Net profit 33.8 11.2 203% 97.4 98.9 (2%) Basic EPS3 (â‚¬) 0.78 0.26 2.23 2.25 Fully diluted EPS6 (â‚¬) 0.75 0.25 2.16 2.18 EBITDA margin 43% 22% 40% 44%Normalized EBITDA and margin are based on the relevant profit share percentage of operating result for the relevant financial period without any IFRS 2 adjustments for share-based payments. The profit share percentage was adjusted to 32.5% in Q222 from 35%. â‚¬0.8m of one-off expenses is also excludedTax based on estimated expected effective tax rate for the relevant financial period: Q322 - 22.3%; Q222 - 19.7%; YTD 9m22 - 21.0%; YTD 9m21 - 19.5%A summary reconciliation of Normalized to IFRS is presented below:â‚¬million Q322 Q222 YTD 9m22 YTD 9m21Normalized EBITDA 48.8 36.5 159.9 143.1 FV OCI adjustment (0.5) (2.9) (3.7) (0.3) Results of equity-accounted investments - 0.1 0.2 (0.1) One off expenses (0.8) (8.5) (12.5) - Prior year share plans (4.2) (6.2) (18.3) (18.7) Current year share plan deferral 4.4 0.4 10.6 10.5 Other variable remuneration adjustment - (1.1) - - IFRS EBITDA 47.8 18.3 136.2 134.5Normalized net profit 34.5 26.1 116.6 106.1 Profit before tax IFRS adjustments (1.1) (18.3) (24.0) (8.6) Tax difference 0.4 3.3 4.7 1.4 IFRS net profit 33.8 11.2 97.4 98.9NotesFixed employee expenses: Q322 - â‚¬19.0m; Q222 - â‚¬18.2m; YTD 9m22 - â‚¬53.3m; YTD 9m21 - â‚¬40.2m YTD 9m21 other expenses includes â‚¬1.9m of business continuity plan-related expenses previously classified as one-off expenses Weighted average shares outstanding: Q322 - 43 615 044; Q222 - 43 731 905; YTD 9m22 - 43 620 841; YTD 9m21 - 43 875 028. 43 439 853 shares outstanding as at 30 September 2022 Value traded comprises ETPs  Futures and Cash Source - Flow Traders analysis Determined by adjusting the basic EPS for the effects of all dilutive share-based payments to employeesImportant Legal InformationThis press release is prepared by Flow Traders N.V. and is for information purposes only. It is not a recommendation to engage in investment activities and you must not rely on the content of this document when making any investment decisions. The information in this document does not constitute legal  tax  or investment advice and is not to be regarded as investor marketing or marketing of any security or financial instrument  or as an offer to buy or sell  or as a solicitation of any offer to buy or sell  securities or financial instruments.The information and materials contained in this press release are provided â€˜as isâ€™ and Flow Traders N.V. or any of its affiliates (â€œFlow Tradersâ€) do not warrant the accuracy  adequacy or completeness of the information and materials and expressly disclaim liability for any errors or omissions. This press release is not intended to be  and shall not constitute in any way a binding or legal agreement  or impose any legal obligation on Flow Traders. All intellectual property rights  including trademarks  are those of their respective owners. All rights reserved. All proprietary rights and interest in or connected with this publication shall vest in Flow Traders. No part of it may be redistributed or reproduced without the prior written permission of Flow Traders.This press release may include forward-looking statements  which are based on Flow Tradersâ€™ current expectations and projections about future events  and are not guarantees of future performance. Forward looking statements are statements that are not historical facts  including statements about our beliefs and expectations. Words such as â€œmayâ€  â€œwillâ€  â€œwouldâ€  â€œshouldâ€  â€œexpectâ€  â€œintendâ€  â€œestimateâ€  â€œanticipateâ€  â€œprojectâ€  â€œbelieveâ€  â€œcouldâ€  â€œhopeâ€  â€œseekâ€  â€œplanâ€  â€œforeseeâ€  â€œaimâ€  â€œobjectiveâ€  â€œpotentialâ€  â€œgoalâ€ â€œstrategyâ€  â€œtargetâ€  â€œcontinueâ€ and similar expressions or their negatives are used to identify these forward-looking statements. By their nature  forward-looking statements involve known and unknown risks  uncertainties  assumptions and other factors because they relate to events and depend on circumstances that will occur in the future whether or not outside the control of Flow Traders. Such factors may cause actual results  performance or developments to differ materially from those expressed or implied by such forward-looking statements. Accordingly  no undue reliance should be placed on any forward-looking statements. Forward-looking statements speak only as at the date at which they are made. Flow Traders expressly disclaims any obligation or undertaking to update  review or revise any forward-looking statements contained in this press release to reflect any change in its expectations or any change in events  conditions or circumstances on which such statements are based unless required to do so by applicable law.Financial objectives are internal objectives of Flow Traders to measure its operational performance and should not be read as indicating that Flow Traders is targeting such metrics for any particular fiscal year. Flow Tradersâ€™ ability to achieve these financial objectives is inherently subject to significant business  economic and competitive uncertainties and contingencies  many of which are beyond Flow Tradersâ€™ control  and upon assumptions with respect to future business decisions that are subject to change. As a result  Flow Tradersâ€™ actual results may vary from these financial objectives  and those variations may be material.Efficiencies are net  before tax and on a run-rate basis  i.e. taking into account the full-year impact of any measure to be undertaken before the end of the period mentioned. The expected operating efficiencies and cost savings were prepared on the basis of a number of assumptions  projections and estimates  many of which depend on factors that are beyond Flow Tradersâ€™ control. These assumptions  projections and estimates are inherently subject to significant uncertainties and actual results may differ  perhaps materially  from those projected. Flow Traders cannot provide any assurance that these assumptions are correct and that these projections and estimates will reflect Flow Tradersâ€™ actual results of operations.By accepting this document you agree to the terms set out above. If you do not agree with the terms set out above please notify legal.amsterdam@nl.flowtraders.com immediately and delete or destroy this document.Market Abuse RegulationThis press release contains information within the meaning of Article 7(1) of the EU Market Abuse Regulation and is an announcement pursuant to Article 5(1) of the EU Market Abuse Regulation.Attachment,neutral,0.03,0.97,0.0,positive,0.83,0.16,0.01,True,English,"['FLOW TRADERS Q322 TRADING UPDATE', 'Charles Schwab Crypto Thematic ETF USA', 'iShares Water Management Multisector ETF', 'Bloomberg Barclays Corporate Bond index', 'Flow Tradersâ€™ Euro IG universe', 'Top 5 Bloomberg dealer rankings', 'Regulatory Own Funds Requirement', 'FLOW TRADERS Q322 TRADING UPDATE', 'new graduate intake classes', 'full Bondbloxx treasury suite', 'Corporate credit trading business', 'unaudited Q322 trading update', 'Flow Traders N.V.', 'Flow Tradersâ€™ LMM presence', 'active fixed income market', 'EM bond market', 'strategic headcount growth', 'share buyback program', 'leading liquidity provider', 'leading global architects', 'trading diversification strategy', 'Strong trading performance', 'Flow Traders NV', 'Flow Tradersâ€™ coverage', 'fixed income business', 'Lead Market Maker', 'base compensation increases', 'Change Flow Traders', 'Flow Traders Capital', 'strategic investments portfolio', 'lower equity trading', 'overall ETP market', 'net trading income', 'Value Traded Overview', 'fixed operating expenses', 'Q222 Change YTD', 'IG bonds', 'Trading capital', 'new products', 'trading environment', 'full effect', 'Financial Overview', 'crypto space', 'total income', 'other income', 'commodity trading', 'excess capital', 'ETP Value', 'ETP issuers', 'operating result', 'employee expenses', 'Normalized NTI', 'year increase', 'variable remuneration', 'net profit', 'basic EPS', 'total size', 'Other expenses2', 'tangible assets', 'successful leverage', 'quote rate', 'Ethereum upgrade', 'Further investments', 'growing focus', 'Technology expenses', 'YTD 9m22', 'Regional Highlights', 'Convexity Shares', 'third quarter', 'EBITDA margin', 'Amsterdam', 'Netherlands', 'Euronext', 'currency', 'USD', 'impact', '639 FTEs', '30 September', '611 FTEs', '30 June', 'OFR', 'end', '22 July', 'EMEA', 'Americas', 'APAC', 'EBITDA1', 'Depreciation', 'amortisation', 'tax', 'Europe', 'Asia', 'China', 'position', 'ETPs', 'exchange', 'majority', 'tickets', 'volume', 'listings', 'DeFi', 'IWTR', 'SPKX', 'SPKY', 'build']",2022-10-27,2022-10-28,finance.yahoo.com
12208,EuroNext,NewsApi.org,https://finance.yahoo.com/news/share-buyback-transaction-details-october-080000978.html,Share Buyback Transaction Details October 20 â€“ October 26  2022,Share Buyback Transaction Details October 20 â€“ October 26  2022 October 27  2022 - Wolters Kluwer (Euronext: WKL)  a global leading provider of expert...,Share Buyback Transaction Details October 20 â€“ October 26  2022October 27  2022 - Wolters Kluwer (Euronext: WKL)  a global leading provider of expert solutions  insights and services for professionals  today reports that it has repurchased 290 096 of its own ordinary shares in the period from October 20  2022  up to and including October 26  2022  for â‚¬30.0 million and at an average share price of â‚¬103.49.These repurchases are part of the share buyback program under which we intend to repurchase shares for â‚¬1 billion during 2022  as announced on August 3  2022.The cumulative amounts repurchased to date under this program are as follows:Share Buyback 2022Period Cumulative shares repurchased in period Total consideration(â‚¬ million) Average share price(â‚¬) 2022 to date 7 577 889 738.1 97.40For the period starting August 4  2022  up to and including October 31  2022  we have mandated third parties to execute â‚¬400 million in share buybacks on our behalf while for the period starting November 3  2022  up to and including December 28  2022  we have mandated another third party to execute â‚¬244 million in share buybacks on our behalf  within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the companyâ€™s Articles of Association.Repurchased shares are added to and held as treasury shares and will be used for capital reduction purposes or to meet obligations arising from share-based incentive plans.Further information is available on our website:About Wolters KluwerWolters Kluwer (WKL) is a global leader in professional information  software solutions  and services for the healthcare; tax and accounting; governance  risk and compliance; and legal and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.Story continuesWolters Kluwer reported 2021 annual revenues of â‚¬4.8 billion. The group serves customers in over 180 countries  maintains operations in over 40 countries  and employs approximately 19 800 people worldwide. The company is headquartered in Alphen aan den Rijn  the Netherlands.Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).For more information  visit www.wolterskluwer.com   follow us on Twitter   Facebook   LinkedIn   and YouTube .Media Investors/Analysts Gerbert van Genderen Stort Meg Geldens Corporate Communications Investor Relations t + 31 172 641 230 t + 31 172 641 407 press@wolterskluwer.com ir@wolterskluwer.comForward-looking Statements and Other Important Legal InformationThis report contains forward-looking statements. These statements may be identified by words such as â€œexpectâ€  â€œshouldâ€  â€œcouldâ€  â€œshallâ€ and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include  without limitation  general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; behavior of customers  suppliers  and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal  tax  and regulatory rules affecting Wolters Kluwerâ€™s businesses  as well as risks related to mergers  acquisitions  and divestments. In addition  financial risks such as currency movements  interest rate fluctuations  liquidity  and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements  whether as a result of new information  future events or otherwise.This press release contains information which is to be made publicly available under Regulation (EU) 596/2014.Attachment,neutral,0.0,1.0,0.0,mixed,0.11,0.19,0.69,True,English,"['Share Buyback Transaction Details', 'October', 'Analysts Gerbert van Genderen Stort Meg Geldens', 'Alphen aan den Rijn', 'Level 1 American Depositary Receipt', 'Corporate Communications Investor Relations', 'Share Buyback Transaction Details', 'Other Important Legal Information', 'capital reduction purposes', 'share-based incentive plans', 'deep domain knowledge', 'interest rate fluctuations', 'average share price', 'global leading provider', 'new ICT systems', 'general economic conditions', 'share buyback program', 'Wolters Kluwer shares', 'Period Cumulative shares', 'share buybacks', 'cumulative amounts', 'global leader', 'new information', 'ordinary shares', 'Repurchased shares', 'treasury shares', 'expert solutions', 'Total consideration', 'third parties', 'third party', 'relevant laws', 'Further information', 'professional information', 'software solutions', 'regulatory sectors', 'critical decisions', 'specialized technology', '2021 annual revenues', 'ADR) program', 'counter market', 'U.S.', 'Media Investors', 'similar expressions', 'actual results', 'technological developments', 'regulatory rules', 'currency movements', 'future results', 'foregoing list', 'press release', 'Forward-looking Statements', 'Euronext Amsterdam', 'Euronext 100 indices', 'financial risks', 'credit risks', 'future events', 'October', 'WKL', 'insights', 'services', 'professionals', 'repurchases', 'August', 'date', 'behalf', 'November', 'December', 'limits', 'regulations', 'company', 'Articles', 'Association', 'obligations', 'website', 'healthcare', 'tax', 'accounting', 'governance', 'compliance', 'customers', 'Story', 'group', '180 countries', 'operations', '40 countries', '19,800 people', 'Netherlands', 'AEX', 'ADRs', 'WTKWY', 'Twitter', 'Facebook', 'LinkedIn', 'YouTube', 'report', 'words', 'uncertainties', 'Factors', 'limitation', 'markets', 'behavior', 'suppliers', 'competitors', 'implementation', 'execution', 'outsourcing', 'businesses', 'mergers', 'acquisitions', 'divestments', 'addition', 'liquidity', 'intention', 'Attachment']",2022-10-27,2022-10-28,finance.yahoo.com
12209,EuroNext,NewsApi.org,https://www.businesswire.com/news/home/20221026005819/en/Ipsen-Delivers-Strong-Sales-Growth-in-the-First-Nine-Months-of-2022-and-Confirms-Its-Full-year-Guidance,Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance,PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY)  a global specialty-driven biopharmaceutical company  today presents its sales performance for the year to date and the third quarter of 2022. Sales summary1 Â  YTD 2022 YTD 2021 % chanâ€¦,PARIS--(BUSINESS WIRE)--Regulatory News:Ipsen (Euronext: IPN; ADR: IPSEY)  a global specialty-driven biopharmaceutical company  today presents its sales performance for the year to date and the third quarter of 2022.Sales summary1YTD2022 YTD2021 % change Q32022 Q32021 % change â‚¬m â‚¬m Actual CER2 â‚¬m â‚¬m Actual CER2 Oncology 1 767.2 1 565.4 12.9% 6.9% 603.1 552.3 9.2% 1.2% Neuroscience 407.7 309.6 31.7% 25.1% 160.7 103.8 54.8% 43.4% Rare Disease 33.6 37.3 -9.8% -12.5% 11.0 11.7 -5.4% -9.3% Total Sales 2 208.5 1 912.3 15.5% 9.5% 774.8 667.8 16.0% 7.6%Highlightsâ€“ Total-sales growth in the year to date of 9.5% at CER2  or 15.5% as reported  driven by the growth platforms of DysportÂ® (botulinum toxin type A)  DecapeptylÂ® (triptorelin)  CabometyxÂ® (cabozantinib) and OnivydeÂ® (irinotecan) increasing by 20.8%2; SomatulineÂ® (lanreotide) sales down by 2.8%2â€“ In the third quarter  total-sales growth of 7.6% at CER2  or 16.0% as reported  boosted by an increase in Dysport sales of 43.3%2  partly offset by a decline in Somatuline sales of 9.8%2â€“ Completion of the definitive merger agreement under which Ipsen acquired Epizyme  expanding Ipsenâ€™s presence in Oncologyâ€“ Postponement of the U.S. FDAâ€™s advisory-committee meeting for investigational palovaroteneâ€“ Full-year 2022 guidance confirmed  with total-sales growth greater than 7.0% at CER2 and a core operating margin greater than 36.0% of total salesDavid Loew  Chief Executive Officer  commented:â€œI am proud of Ipsenâ€™s performance so far this year as we continue to drive strong sales results. Our growth platforms have delivered a double-digit sales performance  reflecting improving commercial execution and the strength of our portfolio. These results have outweighed the adverse impact from competitive activity on Somatuline in the U.S. and Europe. Based on the strong sales momentum  we are confirming our guidance for the full year.I was also delighted by the enhancement of our pipeline  portfolio and organization as a result of the recent acquisition of Epizyme. In the near term  we look forward to a number of milestones for our pipeline  including Phase III data readouts in Oncology. I am pleased with the sustained progress we are making as we continue to maximize our brands  strengthen our pipeline  drive efficiencies and focus on our culture.â€Full-year 2022 guidanceIpsen has confirmed its financial guidance for FY 20223:â€“ Total-sales growth greater than 7.0%  at constant exchange rates. Based on the average level of exchange rates in September 2022  an additional favorable impact on total sales of around 6% from currencies is expectedâ€“ Core operating margin greater than 36.0% of total salesBusiness developmentIn August 2022  Ipsen and Epizyme  Inc. (Epizyme) announced that they had completed a definitive merger agreement under which Ipsen acquired Epizyme  a fully integrated  commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigenetic targets for cancer patients. Sales by Ipsen ofTazverikÂ® (tazemetostat)  consolidated from 1 September 2022  have been reflected in this announcement.Ipsen and Marengo Therapeutics  Inc. (Marengo) also announced in August 2022 a strategic partnership to advance two of Marengoâ€™s preclinical STAR platform-generated candidates into the clinic. The collaboration will leverage Marengoâ€™s proprietary R&D expertise of a novel mechanism of T-cell activation with Ipsenâ€™s global Oncology footprint for clinical development and commercialization.PalovaroteneIn October 2022  the U.S. FDA announced its decision to postpone the planned Endocrinologic and Metabolic Drugs Advisory Committee meeting for investigational palovarotene until a later date to be confirmed; the original advisory-committee meeting was scheduled for 31 October 2022. The FDA informed Ipsen that the postponement related to an FDA request for new information on palovarotene clinical-trial data and did not relate to the safety profile of palovarotene. The Company is currently working to fulfil the request.Conference callA conference call and webcast for investors and analysts will begin today at 1.30pm  Paris time. Participants can access the call and its details by registering here; webcast details can be found here. A recording will be available on ipsen.com.CalendarIpsen intends to publish its full-year results on 9 February 2023.NotesAll financial figures are in â‚¬ millions (â‚¬m). The performance shown in this announcement covers the nine-month period to 30 September 2022 (the year to date or YTD 2022) and the three-month period to 30 September 2022 (the third quarter or Q3 2022)  compared to nine-month period to 30 September 2021 (YTD 2021) and the three-month period to 30 September 2021 (Q3 2021) respectively  unless stated otherwise. Commentary is based on the performance in YTD 2022  unless stated otherwise. The performance of Consumer HealthCare  divested in July 2022  has been excluded from all commentary and comparisons to prior performance.IpsenIpsen is a global  mid-sized biopharmaceutical company focused on transformative medicines in Oncology  Rare Disease and Neuroscience. With Specialty Care sales of â‚¬2.6bn in FY 2021  Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy  the Companyâ€™s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay  France; Oxford  U.K.; Cambridge  U.S.; Shanghai  China. Ipsen has around 5 000 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information  visit ipsen.com.Total sales by therapy area and medicineYTD2022 YTD2021 % change Q32022 Q32021 % change â‚¬m â‚¬m Actual CER4 â‚¬m â‚¬m Actual CER4 Oncology 1 767.2 1 565.4 12.9% 6.9% 603.1 552.3 9.2% 1.2% Somatuline 911.9 874.4 4.3% -2.8% 311.9 313.0 -0.3% -9.8% Decapeptyl 396.0 332.6 19.1% 15.6% 131.4 110.1 19.3% 14.9% Cabometyx 327.7 258.6 26.7% 24.1% 115.5 91.8 25.9% 21.8% Onivyde 122.0 93.0 31.1% 17.1% 38.8 35.2 10.1% -5.3% Tazverik 2.8 0.0 n/a5 n/a5 2.8 0.0 n/a5 n/a5 Other Oncology 6.9 6.7 2.0% 1.6% 2.6 2.2 18.1% 18.2% Neuroscience 407.7 309.6 31.7% 25.1% 160.7 103.8 54.8% 43.4% Dysport 400.3 305.3 31.1% 24.8% 158.0 102.5 54.1% 43.3% Other Neuroscience 7.3 4.3 70.5% 49.1% 2.7 1.3 n/a5 54.1% Rare Disease 33.6 37.3 -9.8% -12.5% 11.0 11.7 -5.4% -9.3% NutropinAqÂ® 20.8 24.5 -15.3% -15.5% 6.3 7.5 -16.1% -16.4% IncrelexÂ® 12.8 12.8 -0.2% -7.4% 4.8 4.2 13.5% 3.3% Total Sales 2 208.5 1 912.3 15.5% 9.5% 774.8 667.8 16.0% 7.6%Commentary is based on the performance in YTD 2022  unless stated otherwise.â€“ Somatuline: in North America  sales fell by 3.6%4  despite continued demand growth  impacted by increased competition and adverse U.S. pricing  driven by an increased level of commercial rebates and unfavorable movements in channel mix  as well as lower wholesaler inventories. In Europe  sales declined by 9.3%4  reflecting the larger effects of the launches of generic lanreotide in more markets  including Germany  France  Spain and the Nordics. Sales in the Rest of the World grew by 34.5%4  a result of strong performances in several geographies  including Japan and Brazilâ€“ Decapeptyl: the performance was mainly driven by continued volume growth across all countries  higher volumes in China and Korea and favorable shipment phasing in Algeria. In the third quarter  sales were supported by a strong performance in China  partly reflecting the impact of a loosening of COVID-19 lockdown restrictionsâ€“ Cabometyx: the performance reflected strong volume uptakes in renal cell carcinoma across most geographies  mainly as a second-line monotherapy and  more recently  as a first-line therapy in combination with nivolumabâ€“ Onivyde: sales growth was primarily driven by a solid performance in the U.S.  as well as sales to Ipsenâ€™s ex-U.S. partner. The decline in sales in the third quarter reflected the impact of the phasing of 2022 sales to the partnerâ€“ Dysport: the performance in the year to date was driven by strong demand in most therapeutics markets  and similar growth in the aesthetics market  including increased sales to Ipsenâ€™s partner  Galderma  especially in North America and Australia. The stronger growth in the third quarter was boosted by the catch-up from the recent manufacturing-capacity increase that benefitted supply to support aesthetics-market demandâ€“ Tazverik: sales  which are in the U.S.  were consolidated from 1 September 2022Total sales by geographical areaYTD2022 YTD2021 % change Q32022 Q32021 % change â‚¬m â‚¬m Actual CER6 â‚¬m â‚¬m Actual CER6 North America 759.2 649.8 16.8% 4.0% 279.9 246.8 13.4% -2.6% Europe7 924.7 887.3 4.2% 3.7% 301.1 297.5 1.2% 1.1% Rest of the World 524.6 375.2 39.8% 32.5% 193.9 123.5 57.0% 43.7% Total Sales 2 208.5 1 912.3 15.5% 9.5% 774.8 667.8 16.0% 7.6%Commentary is based on the performance in YTD 2022.â€“ North America: sales grew by 4.0%6  driven by a continued strong performance from Dysport in the therapeutics market and  in the aesthetics market  through Galderma  and from Onivyde  partly offset by a Somatuline sales decline of 3.6%6â€“ Europe: sales growth of 3.7%6  mainly reflecting strong Cabometyx performances in France  Spain and Germany  and Decapeptylâ€™s continued market-share uptakes. Following the launch of generic lanreotide in some European markets  Somatuline sales declined by 9.3%6. Dysport sales grew by 7.6%6  driven by volume uptakes in the therapeutics marketâ€“ Rest of the World: sales growth of 32.5%6  driven by solid volume growth in both Oncology and Neuroscience. In Oncology  the increase in Decapeptyl sales reflected the strong performance in China  share gains in several markets  and favorable shipment phasing in Algeria. The strong growth of Cabometyx was also a result of market-share gains across a number of geographies. The performance also reflected good Somatuline sales  including in Japan and Brazil. In Neuroscience  the strong growth of Dysport sales was a result of volume uptakes in both therapeutics and aesthetics markets  primarily in Latin America and AustraliaAppendix: geographic breakdown of total sales by medicineYTD Total North America Europe Rest of the World 2022 2021 % change 2022 2021 % change 2022 2021 % change 2022 2021 % change â‚¬m â‚¬m Actual CER8 â‚¬m â‚¬m Actual CER8 â‚¬m â‚¬m Actual CER8 â‚¬m â‚¬m Actual CER8 Oncology 1 767.2 1 565.4 12.9% 6.9% 634.5 570.8 11.2% -1.0% 789.3 756.2 4.4% 3.8% 343.4 238.4 44.1% 35.6% Somatuline 911.9 874.4 4.3% -2.8% 525.5 485.3 8.3% -3.6% 292.7 322.1 -9.1% -9.3% 93.7 67.0 39.8% 34.5% Decapeptyl 396.0 332.6 19.1% 15.6% 0.0 0.0 - - 221.2 200.4 10.4% 10.3% 174.7 132.2 32.2% 23.5% Cabometyx 327.7 258.6 26.7% 24.1% 12.9 9.9 30.4% 18.8% 242.4 210.0 15.4% 15.1% 72.4 38.7 87.0% 74.2% Onivyde 122.0 93.0 31.1% 17.1% 93.1 75.1 23.8% 10.1% 26.5 17.5 51.8% 36.5% 2.4 0.4 n/a9 n/a 9 Tazverik 2.8 0.0 n/a9 n/a 9 2.8 0.0 n/a9 n/a 9 0.0 0.0 - - 0.0 0.0 - - Other Oncology 6.9 6.7 2.0% 1.6% 0.3 0.5 -45.1% -50.0% 6.4 6.3 3.1% 3.2% 0.2 0.0 n/a9 n/a9 Neuroscience 407.7 309.6 31.7% 25.1% 116.7 70.8 64.8% 46.3% 110.9 103.0 7.7% 7.6% 180.1 135.8 32.6% 27.3% Dysport 400.3 305.3 31.1% 24.8% 116.7 70.8 64.8% 46.3% 110.9 103.0 7.7% 7.6% 172.8 131.5 31.4% 26.5% Other Neuroscience 7.3 4.3 70.5% 49.1% 0.0 0.0 - - 0.0 0.0 - - 7.3 4.3 70.5% 49.1% Rare Disease 33.6 37.3 -9.8% -12.5% 8.1 8.2 -1.5% -12.3% 24.5 28.2 -13.0% -13.1% 1.1 1.0 13.0% 4.6% NutropinAq 20.8 24.5 -15.3% -15.5% 0.0 0.0 - - 19.9 23.7 -15.9% -16.1% 0.8 0.8 3.6% 0.5% Increlex 12.8 12.8 -0.2% -7.4% 8.0 8.2 -2.8% -13.4% 4.6 4.5 2.3% 2.5% 0.2 0.1 70.3% 25.6% Total Sales 2 208.5 1 912.3 15.5% 9.5% 759.2 649.8 16.8% 4.0% 924.7 887.3 4.2% 3.7% 524.6 375.2 39.8% 32.5%Q3 Total North America Europe Rest of the World 2022 2021 % change 2022 2021 % change 2022 2021 % change 2022 2021 % change â‚¬m â‚¬m Actual CER10 â‚¬m â‚¬m Actual CER10 â‚¬m â‚¬m Actual CER10 â‚¬m â‚¬m Actual CER10 Oncology 603.1 552.3 9.2% 1.2% 234.1 217.4 7.7% -7.4% 248.8 254.1 -2.1% -2.3% 120.2 80.8 48.8% 35.3% Somatuline 311.9 313.0 -0.3% -9.8% 193.6 183.7 5.4% -9.4% 86.0 107.6 -20.1% -19.9% 32.4 21.8 48.7% 36.1% Decapeptyl 131.4 110.1 19.3% 14.9% 0.0 0.0 - - 70.1 65.9 6.4% 6.6% 61.3 44.2 38.6% 27.2% Cabometyx 115.5 91.8 25.9% 21.8% 4.2 3.3 28.4% 13.5% 84.7 73.9 14.6% 14.4% 26.6 14.6 82.6% 61.1% Onivyde 38.8 35.2 10.1% -5.3% 33.4 30.3 10.3% -5.7% 5.4 4.7 14.6% 1.6% 0.0 0.2 n/a11 n/a11 Tazverik 2.8 0.0 n/a11 n/a11 2.8 0.0 n/a11 n/a11 0.0 0.0 - - 0.0 0.0 - - Other Oncology 2.6 2.2 18.1% 18.2% 0.1 0.1 -36.3% -43.6% 2.6 2.1 24.3% 24.9% 0.0 0.0 - - Neuroscience 160.7 103.8 54.8% 43.4% 42.6 26.7 59.7% 36.0% 44.9 34.7 29.3% 29.3% 73.3 42.4 72.7% 59.8% Dysport 158.0 102.5 54.1% 43.3% 42.6 26.7 59.7% 36.0% 44.9 34.7 29.3% 29.3% 70.5 41.1 71.5% 60.0% Other Neuroscience 2.7 1.3 n/a11 54.1% 0.0 0.0 - - 0.0 0.0 - - 2.7 1.3 n/a11 54.1% Rare Disease 11.0 11.7 -5.4% -9.3% 3.2 2.7 18.5% 2.7% 7.4 8.7 -14.6% -14.6% 0.5 0.3 44.6% 33.3% NutropinAq 6.3 7.5 -16.1% -16.4% 0.0 0.0 - - 5.9 7.2 -17.1% -17.2% 0.3 0.3 9.1% 3.7% Increlex 4.8 4.2 13.5% 3.3% 3.2 2.7 18.4% 2.7% 1.5 1.5 -2.7% -2.1% 0.1 0.0 n/a11 n/a11 Total Sales 774.8 667.8 16.0% 7.6% 279.9 246.8 13.4% -2.6% 301.1 297.5 1.2% 1.1% 193.9 123.5 57.0% 43.7%Forward-looking statementsThe forward-looking statements  objectives and targets contained herein are based on Ipsenâ€™s management strategy  current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results  performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsenâ€™s future ability to achieve its financial targets  which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words â€˜believesâ€™  â€˜anticipatesâ€™ and â€˜expectsâ€™ and similar expressions are intended to identify forward-looking statements  including Ipsenâ€™s expectations regarding future events  including regulatory filings and determinations. Moreover  the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions  which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future  and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties  notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets  notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore  the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore  Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials  or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize  actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to  general industry conditions and competition; general economic factors  including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation; global trends toward healthcare cost containment; technological advances  new medicine and patents attained by competitors; challenges inherent in new-medicine development  including obtaining regulatory approval; Ipsen's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsenâ€™s patents and other protections for innovative medicines; and the exposure to litigation  including patent litigation  and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsenâ€™s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsenâ€™s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsenâ€™s business  financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements  targets or estimates contained in this press release to reflect any change in events  conditions  assumptions or circumstances on which any such statements are based  unless so required by applicable law. Ipsenâ€™s business is subject to the risk factors outlined in its registration documents filed with the French AutoritÃ© des MarchÃ©s Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsenâ€™s 2021 Universal Registration Document  available on ipsen.com.,neutral,0.02,0.98,0.0,mixed,0.63,0.09,0.28,True,English,"['Strong Sales Growth', 'First Nine Months', 'Full-year Guidance', 'Ipsen', 'Metabolic Drugs Advisory Committee meeting', 'botulinum toxin type A', 'preclinical STAR platform-generated candidates', 'proprietary R&D expertise', 'Phase III data readouts', 'integrated, commercial-stage biopharmaceutical company', 'global specialty-driven biopharmaceutical company', 'global, mid-sized bi', 'definitive merger agreement', 'core operating margin', 'Chief Executive Officer', 'original advisory-committee meeting', 'additional favorable impact', 'novel epigenetic targets', 'global Oncology footprint', 'palovarotene clinical-trial data', 'strong sales momentum', 'constant exchange rates', 'U.S. FDA', 'strong sales results', 'Actual CER2 Oncology', 'double-digit sales performance', 'The Company', 'adverse impact', 'novel mechanism', 'The FDA', 'Sales summary1', 'Total Sales', 'BUSINESS WIRE', 'Regulatory News', 'third quarter', 'Rare Disease', 'Total-sales growth', 'growth platforms', 'David Loew', 'commercial execution', 'competitive activity', 'recent acquisition', 'near term', 'sustained progress', 'average level', 'Business development', 'transformative therapies', 'cancer patients', 'strategic partnership', 'T-cell activation', 'clinical development', 'FDA request', 'new information', 'safety profile', 'full-year results', 'financial figures', 'nine-month period', 'three-month period', 'Consumer HealthCare', 'investigational palovarotene', 'Full-year 2022 guidance', 'financial guidance', 'Conference call', 'Dysport sales', 'prior performance', 'Paris time', 'Somatuline sales', 'full year', 'Marengo Therapeutics', 'later date', 'webcast details', 'DysportÂ®', 'SomatulineÂ®', 'Ipsen', 'IPN', 'ADR', 'IPSEY', 'YTD', '2021 % change', 'Q3', 'Neuroscience', 'Highlights', 'DecapeptylÂ®', 'triptorelin', 'CabometyxÂ®', 'cabozantinib', 'OnivydeÂ®', 'lanreotide', 'increase', 'decline', 'Completion', 'Epizyme', 'presence', 'Postponement', 'strength', 'portfolio', 'Europe', 'enhancement', 'pipeline', 'organization', 'number', 'milestones', 'brands', 'efficiencies', 'culture', 'FY', 'September', 'currencies', 'August', 'announcement', 'collaboration', 'commercialization', 'October', 'decision', 'Endocrinologic', 'investors', 'analysts', '1.30pm', 'Participants', 'recording', 'Calendar', '9 February', 'Notes', 'Commentary', 'July', 'comparisons']",2022-10-28,2022-10-28,businesswire.com
12210,EuroNext,NewsApi.org,https://www.businesswire.com/news/home/20221026006002/en/ONWARD-Schedules-Webcast-to-Provide-Third-Quarter-Business-Update-and-Announces-Participation-at-Upcoming-Conferences,ONWARD Schedules Webcast to Provide Third Quarter Business Update and Announces Participation at Upcoming Conferences,EINDHOVEN  the Netherlands & LAUSANNE  Switzerland & BOSTON--(BUSINESS WIRE)--ONWARD Medical N.V. (Euronext: ONWD)  the medical technology company creating innovative therapies to restore movement  independence  and health in people with spinal cord injury  tâ€¦,EINDHOVEN  the Netherlands & LAUSANNE  Switzerland & BOSTON--(BUSINESS WIRE)--ONWARD Medical N.V. (Euronext: ONWD)  the medical technology company creating innovative therapies to restore movement  independence  and health in people with spinal cord injury  today announced that it will host a webcast to discuss its Q3 business highlights. The Company also provided information on its participation at upcoming investor and industry events.The webcast to discuss highlights from the third quarter and provide a business update will be held on November 8  2022  at 14:30 CET / 08:30 ET.To join the webcast via Zoom  please register using this link.Participants may also join by phone:+32 2 290 9360 (Belgium)+49 69 3807 9884 (Germany)+31 20 794 0854 (Netherlands)+41 22 591 0156 (Switzerland)+44 203 481 5240 (United Kingdom)+1 346 248 7799 (US)Additional telephone numbers availableWebinar ID: 840 0768 4745A recording of the webcast will be available on the Companyâ€™s website following the live event.In addition  management will participate in the following conferences in the upcoming weeks:BioFutureNovember 7-9  2022New York  NYDave Marver  CEO  will participate in the panel discussion â€œNeurotech: Non-Invasive Neuromodulation and Brain-Computer Interfacesâ€ on November 8 at 10:30am ET and will also give a company presentation on November 8 at 12pm ET.Stifel Healthcare ConferenceNovember 15-16  2022New York  NYLara Smith Weber  CFO  will give a company presentation. A replay of the presentation will be available in the events section of the ONWARD website.Kepler Chevreux & Belfiusâ€™ Life Sciences DayNovember 21  2022Virtual eventDave Marver will give a company presentation.German Equity Forum (Deutsches Eigenkapitalforum)November 28-30  2022Frankfurt  GermanyLara Smith Weber will give a company presentation on November 29th at 10:40am CET and will be available for 1-on-1 meetings.Finance AvenueDecember 3  2022Brussels  BelgiumLara Smith Weber will give a company presentation and be available for questions together with Markus Rieger  Field Clinical Specialist.Information on upcoming conferences is available in the investor section of the ONWARD website at https://ir.onwd.com/news-events.About ONWARD MedicalONWARD is a medical technology company creating innovative therapies to restore movement  independence  and health in people with spinal cord injuries. ONWARDâ€™s work builds on more than a decade of basic science and preclinical research conducted at the worldâ€™s leading neuroscience laboratories. ONWARDâ€™s ARC Therapy  which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems  is designed to deliver targeted  programmed spinal-cord stimulation to restore movement and other functions in people with spinal cord injury  ultimately improving their quality of life.ONWARD has received three Breakthrough Device Designations from the U.S. FDA encompassing both ARC-IM and ARC-EX. ARC-EX is an external  non-invasive platform consisting of a wearable stimulator and wireless programmer. Positive top line data were reported in September 2022 from the companyâ€™s first pivotal study  called Up-LIFT  evaluating the ability of ARC-EX Therapy to improve upper extremity strength and function. The company is now preparing marketing approval submissions for the U.S. and Europe. ARC-IM consists of an implantable pulse generator and lead that is placed near the spinal cord. The company completed its first-in-human use of the ARC-IM neurostimulator in May 2022.ONWARD is headquartered in Eindhoven  the Netherlands. It maintains an office in Lausanne  Switzerland  and has a growing U.S. presence in Boston  Massachusetts. The company has an academic partnership with NeuroRestore  a collaboration between the Swiss Federal Institute of Technology (EPFL) and Lausanne University Hospital (CHUV). For additional information about ONWARD  please visit ONWD.com. To access our 2022 Financial Calendar  please visit IR.ONWD.comDisclaimerCertain statements  beliefs  and opinions in this press release are forward-looking  which reflect the Company or  as appropriate  the Company directorsâ€™ current expectations and projections about future events. By their nature  forward-looking statements involve a number of risks  uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks  uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including  but not limited to  changes in demand  competition and technology  can cause actual events  performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result  the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events  conditions  assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such personâ€™s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements  which speak only as of the date of this press release.,neutral,0.0,1.0,0.0,negative,0.0,0.01,0.99,True,English,"['Third Quarter Business Update', 'ONWARD Schedules', 'Upcoming Conferences', 'Webcast', 'Participation', 'targeted, programmed spinal-cord stimulation', 'three Breakthrough Device Designations', 'Positive top line data', 'Belfiusâ€™ Life Sciences Day', 'growing U.S. presence', 'ONWARD Medical N.V.', 'Stifel Healthcare Conference', 'Lara Smith Weber', 'German Equity Forum', 'Field Clinical Specialist', 'leading neuroscience laboratories', 'U.S. FDA', 'first pivotal study', 'upper extremity strength', 'marketing approval submissions', 'Swiss Federal Institute', 'spinal cord injury', 'Additional telephone numbers', 'spinal cord injuries', 'external, non-invasive platform', 'implantable pulse generator', 'external (ARC-EX) systems', 'Lausanne University Hospital', 'Q3 business highlights', 'medical technology company', 'Non-Invasive Neuromodulation', 'BUSINESS WIRE', 'business update', 'innovative therapies', 'upcoming investor', 'third quarter', 'United Kingdom', 'Webinar ID', 'live event', 'following conferences', 'upcoming weeks', 'New York', 'Dave Marver', 'panel discussion', 'Brain-Computer Interfaces', 'Kepler Chevreux', 'Virtual event', 'Deutsches Eigenkapitalforum', '1-on-1 meetings', 'Finance Avenue', 'Markus Rieger', 'upcoming conferences', 'investor section', 'a decade', 'basic science', 'preclinical research', 'ARC Therapy', 'other functions', 'wearable stimulator', 'wireless programmer', 'human use', 'academic partnership', '2022 Financial Calendar', 'press release', 'current expectations', 'financial effects', 'additional information', 'ARC-EX Therapy', 'forward-looking statements', 'The Company', 'industry events', 'events section', 'actual events', 'company presentation', 'actual results', 'past trends', 'ONWARD website', 'ARC-IM neurostimulator', 'future events', 'ARC-EX.', 'EINDHOVEN', 'Netherlands', 'Switzerland', 'BOSTON', 'Euronext', 'ONWD', 'movement', 'independence', 'people', 'webcast', 'participation', 'November', '14:30 CET', 'Zoom', 'link', 'Participants', 'Belgium', 'Germany', 'recording', 'management', 'BioFuture', 'CEO', 'Neurotech', '10:30am', '12pm', 'CFO', 'replay', 'Frankfurt', '10:40am', 'Brussels', 'questions', 'news-events', 'work', 'world', 'quality', 'September', 'ability', 'Europe', 'May', 'office', 'Massachusetts', 'NeuroRestore', 'collaboration', 'EPFL', 'CHUV', 'Disclaimer', 'beliefs', 'opinions', 'projections', 'nature', 'risks', 'uncertainties', 'assumptions', 'outcome', 'plans', 'multitude', 'factors', 'changes', 'demand', 'competition', 'performance', 'development', 'activities', 'representation', 'obligation', 'undertaking', '08:30']",2022-10-27,2022-10-28,businesswire.com
12211,EuroNext,NewsApi.org,https://www.businesswire.com/news/home/20221027005538/en/Verimatrix-Wins-2022-CyberSecurity-Breakthrough-Award-for-Mobile-Security,Verimatrix Wins 2022 CyberSecurity Breakthrough Award for Mobile Security,AIX-EN-PROVENCE  France & SAN DIEGO--(BUSINESS WIRE)--Regulatory News: Verimatrix  (Euronext Paris: VMX) (Paris:VMX)  the leader in powering the modern connected world with people-centered security  today announced that its App Shield Pro was named Applicatioâ€¦,AIX-EN-PROVENCE  France & SAN DIEGO--(BUSINESS WIRE)--Regulatory News:Verimatrix  (Euronext Paris: VMX) (Paris:VMX)  the leader in powering the modern connected world with people-centered security  today announced that its App Shield Pro was named Application Security Solution of the Year in the 6th annual CyberSecurity Breakthrough Awards program conducted by CyberSecurity Breakthrough  a leading independent market intelligence organization that recognizes the top companies  technologies and products in the global information security market today.Part of the Verimatrix Extended Threat Defense family of products that includes a robust monitoring service  App Shield enables apps (Android APK and iOS xcarchive) to be powerfully protected in just minutes via a fast and cost-effective cloud solution. With no integrations required  developers simply upload their app and receive protection against reverse engineering  application repackaging  dynamic modification  and debuggers. It automatically detects when an app is under attack  quickly alerting and  if needed  can even terminate its own operation â€“ shutting down the threat before damage occurs.â€œWithout powerful protections  app developers are often bogged down with the additional job of finding ways to protect their vital intellectual property  source code  APIs and personal data â€ said James Johnson  managing director  CyberSecurity Breakthrough. â€œHaving to change code or deal with integrations is time-consuming and often doesn't yield the required protective results. App Shield is a no-code SaaS service that delivers breakthrough cybersecurity protection to any Android or iOS app  protecting against potentially devastating threats. Congratulations to Verimatrix for taking home the 2022 â€˜Application Security Solution of the Yearâ€™ award win.â€â€œWeâ€™re honored to see one of our Extended Threat Defense technologies obtain ongoing industry recognition  as this particular award is received alongside some of techâ€™s most recognized innovators â€ said Juha HÃ¶gmander  vice president  cybersecurity business at Verimatrix. â€œApp Shield brings automated  intelligent and self-defending technologies to companies that need it most â€“ to protect their customers as well as their bottom line.â€About CyberSecurity BreakthroughPart of Tech Breakthrough  a leading market intelligence and recognition platform for global technology innovation and leadership  the CyberSecurity Breakthrough Awards program is devoted to honoring excellence in information security and cybersecurity technology companies  products and people. The CyberSecurity Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough information security companies and products in categories including Cloud Security  Threat Detection  Risk Management  Fraud Prevention  Mobile Security  Web and Email Security  UTM  Firewall and more. For more information visit www.cybersecuritybreakthrough.com.About VerimatrixVerimatrix (Euronext Paris: VMX) helps power the modern connected world with security made for people. We protect digital content  applications  and devices with intuitive  people-centered and frictionless security. Leading brands turn to Verimatrix to secure everything from premium movies and live streaming sports  to sensitive financial and healthcare data  to mission-critical mobile applications. We enable the trusted connections our customers depend on to deliver compelling content and experiences to millions of consumers around the world. Verimatrix helps partners get to market faster  scale easily  protect valuable revenue streams  and win new business. Visit www.verimatrix.com.,neutral,0.12,0.87,0.0,mixed,0.37,0.07,0.56,True,English,"['2022 CyberSecurity Breakthrough Award', 'Mobile Security', 'Verimatrix', '6th annual CyberSecurity Breakthrough Awards program', 'leading independent market intelligence organization', 'Verimatrix Extended Threat Defense family', 'The CyberSecurity Breakthrough Awards', 'Extended Threat Defense technologies', 'global information security market', 'leading market intelligence', 'breakthrough information security companies', 'global technology innovation', 'vital intellectual property', 'required protective results', 'Juha HÃ¶gmander', 'live streaming sports', 'valuable revenue streams', 'cybersecurity technology companies', 'robust monitoring service', 'cost-effective cloud solution', 'breakthrough cybersecurity protection', 'ongoing industry recognition', 'Yearâ€™ award win', 'mission-critical mobile applications', '2022 â€˜Application Security Solution', 'modern connected world', 'Leading brands', 'Tech Breakthrough', 'cybersecurity business', 'Threat Detection', 'Cloud Security', 'Mobile Security', 'top companies', 'SaaS service', 'particular award', 'people-centered security', 'Email Security', 'frictionless security', 'self-defending technologies', 'public recognition', 'SAN DIEGO', 'BUSINESS WIRE', 'Regulatory News', 'iOS xcarchive', 'reverse engineering', 'dynamic modification', 'powerful protections', 'additional job', 'personal data', 'James Johnson', 'managing director', 'devastating threats', 'vice president', 'automated, intelligent', 'bottom line', 'Risk Management', 'Fraud Prevention', 'digital content', 'intuitive, people-centered', 'premium movies', 'sensitive financial', 'healthcare data', 'trusted connections', 'compelling content', 'new business', 'recognition platform', 'Euronext Paris', 'App Shield', 'iOS app', 'Android APK', 'source code', 'app developers', 'AIX-EN-PROVENCE', 'France', 'VMX', 'leader', 'products', 'apps', 'minutes', 'fast', 'integrations', 'debuggers', 'attack', 'operation', 'damage', 'ways', 'APIs', 'Congratulations', 'innovators', 'customers', 'excellence', 'achievements', 'categories', 'Web', 'UTM', 'Firewall', 'devices', 'everything', 'experiences', 'millions', 'consumers', 'partners']",2022-10-27,2022-10-28,businesswire.com
12212,EuroNext,NewsApi.org,https://finance.yahoo.com/news/nanobiotix-announce-third-quarter-2022-201500625.html,NANOBIOTIX to Announce Third Quarter 2022 Financial Results on November 9  2022,Conference Call and Webcast to be Held at 8:00 AM ET / 2:00 PM CET on November 10  2022PARIS and CAMBRIDGE  Mass.  Oct. 27  2022 (GLOBE NEWSWIRE...,Nanobiotix S.A.Conference Call and Webcast to be Held at 8:00 AM ET / 2:00 PM CET on November 10  2022PARIS and CAMBRIDGE  Mass.  Oct. 27  2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO â€“â€“ NASDAQ: NBTX â€“ the â€˜â€˜Companyâ€™â€™)  a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer  today announced that it will report its financial results for the third quarter ended September 30  2022  on Wednesday  November 9  2022  after the close of the US market.The announcement will be followed by a conference call and live audio webcast on Thursday  November 10  2022  at 8:00 AM ET / 2:00 PM CET. During the call  Laurent Levy  chief executive officer  and Bart Van Rhijn  chief financial officer  will briefly review the Companyâ€™s third quarter results and provide an update on business activities before taking questions from participants.A live webcast of the call may be accessed by visiting the investors section of the companyâ€™s website at www.nanobiotix.com. Participants may register for the call here. They will be able to join the call via dial-in or one-click dial-out. It is recommended to join 10 minutes prior the event start.Participants are invited to email their questions in advance to investors@nanobiotix.com.A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website.About NANOBIOTIXNanobiotix is a late-stage clinical biotechnology company pioneering disruptive  physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform  including its lead product candidate  radiotherapy-activated NBTXR3  to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.Story continuesFor more information about Nanobiotix  visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.ContactsNanobiotixCommunications DepartmentBrandon OwensVP  Communications+1 (617) 852-4835contact@nanobiotix.comInvestor Relations DepartmentKate McNeilSVP  Investor Relations+1 (609) 678-7388investors@nanobiotix.comMedia RelationsFR â€“ Ulysse CommunicationPierre-Louis Germain+ 33 (0) 6 64 79 97 51plgermain@ulysse-communication.comGlobal â€“ LifeSci AdvisorsLigia Vela-Reid+44 (0) 7413825310Lvela-reid@lifesciadvisors.com,neutral,0.0,1.0,0.0,positive,0.79,0.21,0.0,True,English,"['Third Quarter 2022 Financial Results', 'NANOBIOTIX', 'November', 'late-clinical stage biotechnology company', 'late-stage clinical biotechnology company', 'disruptive, physics-based therapeutic approaches', 'chief executive officer', 'Bart Van Rhijn', 'proprietary nanoparticle platform', 'lead product candidate', 'Media Relations FR', 'chief financial officer', 'Investor Relations Department', 'Nanobiotix S.A.', 'third quarter results', 'live audio webcast', 'Nanobiotix Communications Department', 'physics-based approaches', 'financial results', 'therapeutic options', 'live webcast', 'GLOBE NEWSWIRE', 'US market', 'Laurent Levy', 'business activities', 'event start', 'radiotherapy-activated NBTXR', 'systemic control', 'solid tumors', 'initial focus', 'neck cancers', 'Brandon Owens', 'Kate McNeil', 'Pierre-Louis Germain', 'LifeSci Advisors', 'Ligia Vela-Reid', 'treatment possibilities', 'treatment outcomes', 'Ulysse Communication', 'investors section', 'Conference Call', '8:00 AM', '2:00 PM', 'November', 'PARIS', 'CAMBRIDGE', 'Mass.', 'Euronext', 'NASDAQ', 'patients', 'Wednesday', 'close', 'announcement', 'Thursday', 'update', 'questions', 'participants', 'website', 'advance', 'replay', 'conclusion', 'millions', 'people', 'difference', 'humanity', 'pipeline', 'local', 'head', 'Story', 'information', 'LinkedIn', 'Twitter', 'Contacts', 'VP', 'plgermain', 'Global', 'Lvela-reid', 'lifesciadvisors']",2022-10-27,2022-10-28,finance.yahoo.com
12213,EuroNext,NewsApi.org,https://finance.yahoo.com/news/marie-brizard-wine-spirits-3rd-161100591.html,Marie Brizard Wine & Spirits: 3rd quarter 2022 revenues,Charenton-le-Pont  27 October 2022 3rd quarter 2022 revenues MBWS posts nine-month 2022 revenues of â‚¬135.0m  up 9.8% versus 2021 France posts YTD growth in...,Marie Brizard Wine & SpiritsCharenton-le-Pont  27 October 20223rd quarter 2022 revenuesMBWS posts nine-month 2022 revenues of â‚¬135.0m  up 9.8% versus 2021France posts YTD growth in strategic portfolio brands  including: recovery in the off-trade business  driven by the current decline in promotional pressure and supply issues among competitors; in particular  this temporarily benefited William Peel sales  which were up in the third quarter in a spirits market still in decline versus 2021; a sharp upswing in on-trade sales during the quarter  as 2022 is the first season unaffected by health restrictions since 2019.Strong growth in international sales  up 12.8% versus 2021 driven by all markets  including: growth in Europe  particularly in the UK  and in the Bulgarian and Lithuanian domestic markets  despite the Russia-Ukraine conflict; sustained performance by all strategic brands  particularly Marie Brizard and Cognac Gautier  primarily in South Korea and Australia; decline in US sales of Sobieski vodka in a market segment that remains highly competitive.The inflationary surge in raw material prices and energy costs has intensified in the second half  forcing the Group to continue to raise its prices with customers. This situation has prompted the Group to adopt a prudent stance again with regard to its business over the coming months.NB: All revenue growth figures reported herein are at constant exchange rates and consolidation scope  unless otherwise stated.Marie Brizard Wine & Spirits (Euronext: MBWS) today announces its unaudited revenues for the third quarter of 2022  covering the period from 1 July to 30 September 2022  and for the first nine months of 2022.Nine-month 2022 revenues:â‚¬m 9M 2021 Like-for-likechange Currencyimpact 9M 2022 LFL change(excl. currencyimpact) Reportedgrowth (incl.currencyimpact) France 56.8 3.6 - 60.4 +6.3% +6.3% International 65.1 8.3 1.2 74.6 +12.8% +14.6% TOTAL MBWS GROUP 121.9 11.9 1.2 135.0 +9.8% +10.7%Q3 2022 revenuesâ‚¬m Q3 2021 Like-for-likechange Currencyimpact Q3 2022 LFL change(exc. currency impact) Reportedgrowth (incl.currencyimpact) France 17.7 2.6 - 20.3 +14.7% +14.7% International 23.1 4.5 0.6 28.2 +19.4% +22.0% TOTAL MBWS GROUP 40.8 7.1 0.6 48.5 +17.3% +18.9%Breakdown by clusterFrance clusterThe France cluster posted revenues of â‚¬60.4m for the nine months ended 30 September 2022  up 6.3% versus the previous year. This performance reflects in particular the continued improvement in on-trade sales in the third quarter coupled with robust sales in the off-trade market. Consequently Q3 revenues were up 14.7% versus 2021.Story continuesRevenue growth continued for the Groupâ€™s main brands over the first nine months of 2022  in particular Marie Brizard  Sobieski and San JosÃ©. Our brands are positioned in line with customer needs in the current inflationary environment. In a declining market for under-12-year blended whisky (down 7.5% for the first nine months of 2022)  William Peel maintained its sales volumes compared to the first nine months of 2021 thanks to a competitive positioning still bolstered by the new listing obtained in the second half of 2021.However  in view of the ongoing severe supply chain disruption and sharp price rises for raw materials  particularly in the glass industry  the Group continues to adopt allocation measures per brand based on available volumes. Likewise  the necessary sales policy adjustments announced previously are being maintained and will continue in order to adapt to this changing environment.International clusterThe International cluster posted nine-month 2022 revenues of â‚¬74.6m  up 12.8% versus 2021 at constant exchange rates.Western Europe enjoyed a favourable economic climate over the first nine months  with on-trade growth confirmed versus 2021  still driven by Marie Brizard.In Spain  nine-month revenues were up 12.8% versus 2021  mainly driven by strong subcontracting business and a sustained performance by strategic brands  primarily Marie Brizard and William Peel.Scandinavia posted nine-month revenues up 30.6%  also driven by Marie Brizard sales.The Baltic States posted nine-month revenues up 13.3%  including a slight upturn in the third quarter mainly due to brand performance driven by a proactive pricing policy and a buoyant bulk market.Bulgaria confirmed its growth trend with third quarter revenues up 18.9% across the entire brand portfolio (spirits and wines) in both domestic and export markets.In Poland  Gautier and Marie Brizard sales rose sharply in the first nine months of 2022 despite a slowdown in the third quarter.In the United States  nine-month revenues continued to fall short of 2021 performance  still impacted by a highly competitive vodka market (Sobieski) and inventory adjustment by our local distributor. Marie Brizard and Gautier continue to grow in this market.Brazil revenues edged up in Q3 2022  mainly driven by local brands underpinned by a proactive pricing policy.In Asia Pacific  the positive trend in the first half of 2022 was confirmed in the third quarter by sustained performance  particularly in South Korea and Australia.OutlookOngoing increases in raw material prices  surging energy costs and continued volatility in supplier production availability are factors we have already mentioned that must be taken into account when assessing the level and performance of the Groupâ€™s business activities.If they continue  these adverse factors could have an impact on the Groupâ€™s ability to supply all of its customers (in France and abroad) and on potential flexibility in consumer demand upset by sharp price rises.Despite the level of business growth since the start of the year  the prevailing situation obliges the Group to continue to proactively adapt pricing policies with customers. The Group will therefore continue to adopt a prudent stance with regard to its business level over the coming months  usually an important period as the year draws to a close  and perhaps also at the start of 2023.Financial calendarQ4 and full-year 2022 revenues: 16 February 2023Contact Relations Investisseurs et ActionnairesGroupe MBWSEmilie Drexleremilie.drexler@mbws.comTÃ©l : +33 1 43 91 62 40 Contact PresseImage SeptClaire Doligez - Laurence Maurycdoligez@image7.fr â€“ lmaury@image7.frTÃ©l : +33 1 53 70 74 70About Marie Brizard Wine & SpiritsMarie Brizard Wine & Spirits is a wine and spirits group based in Europe and the United States. Marie Brizard Wine & Spirits stands out for its expertise  a combination of brands with a long tradition and a resolutely innovative spirit. Since the birth of the Maison Marie Brizard in 1755  the Marie Brizard Wine & Spirits Group has developed its brands in a spirit of modernity while respecting their origins. Marie Brizard Wine & Spirits is committed to offering its customers bold and trusted brands full of flavour and experiences. The Group now has a rich portfolio of leading brands in their market segments  including William Peel  Sobieski  Marie Brizard and Cognac Gautier.Marie Brizard Wine & Spirits is listed on Compartment B of Euronext Paris (FR0000060873 - MBWS) and is part of the EnterNextÂ© PEA-PME 150 index.Attachment,neutral,0.0,1.0,0.0,mixed,0.26,0.21,0.53,True,English,"['Marie Brizard Wine', '3rd quarter 2022 revenues', 'Spirits', 'ongoing severe supply chain disruption', 'necessary sales policy adjustments', 'proactive pricing policy', 'constant exchange rates', 'under-12-year blended whisky', 'favourable economic climate', 'sharp price rises', 'The Baltic States', 'first nine months', 'buoyant bulk market', 'entire brand portfolio', 'Marie Brizard Wine', 'raw material prices', 'current inflationary environment', 'strong subcontracting business', 'Marie Brizard sales', 'strategic portfolio brands', 'revenue growth figures', '3rd quarter 2022 revenues', 'William Peel sales', 'Lithuanian domestic markets', 'The International cluster', 'competitive vodka market', 'The France cluster', 'TOTAL MBWS GROUP', 'third quarter revenues', 'change Currency impact', 'supply issues', 'first season', 'coming months', 'first half', 'sharp upswing', 'US sales', 'inflationary surge', 'LFL change', 'robust sales', 'sales volumes', 'competitive positioning', 'raw materials', 'changing environment', 'United States', 'strategic brands', 'trade sales', 'international sales', 'Strong growth', 'nine-month 2022 revenues', 'unaudited revenues', 'nine-month revenues', 'Brazil revenues', 'promotional pressure', 'health restrictions', 'Russia-Ukraine conflict', 'South Korea', 'market segment', 'energy costs', 'second half', 'prudent stance', 'consolidation scope', 'previous year', 'continued improvement', 'main brands', 'San JosÃ©', 'customer needs', 'declining market', 'new listing', 'glass industry', 'allocation measures', 'available volumes', 'slight upturn', 'export markets', 'inventory adjustment', 'local distributor', 'local brands', 'Asia Pacific', 'positive trend', 'current decline', 'Sobieski vodka', 'trade business', 'YTD growth', 'growth trend', 'Q3 2022 revenues', 'Q3 revenues', 'sustained performance', 'brand performance', 'trade growth', 'Western Europe', 'Cognac Gautier', 'spirits market', '2021 performance', 'Charenton-le-Pont', 'recovery', 'competitors', 'Bulgarian', 'Australia', 'customers', 'situation', 'regard', 'NB', 'Euronext', 'period', '1 July', '30 September', 'Breakdown', 'Story', 'view', 'order', 'Spain', 'Scandinavia', 'wines', 'Poland', 'slowdown', 'confir']",2022-10-27,2022-10-28,finance.yahoo.com
12214,EuroNext,NewsApi.org,https://www.businesswire.com/news/home/20221027005801/en/Teleperformance-Acquires-PSG-Global-Solutions,Teleperformance Acquires PSG Global Solutions,PARIS--(BUSINESS WIRE)--Regulatory News: Teleperformance (Paris:TEP)  the global leader in outsourced customer and citizen experience management and related digital services  announced today that it has acquired PSG Global Solutions  LLC (â€œPSGâ€) from its manaâ€¦,PARIS--(BUSINESS WIRE)--Regulatory News:Teleperformance (Paris:TEP)  the global leader in outsourced customer and citizen experience management and related digital services  announced today that it has acquired PSG Global Solutions  LLC (â€œPSGâ€) from its management and private investors. PSG is a US-based leader in partial cycle recruitment process outsourcing (â€œRPOâ€)  offering solutions for key aspects of the recruiting and recruiting support processes. PSG will be a wholly-owned subsidiary of Teleperformance  with its founders and senior management team continuing to operate the company and covering the RPO market for the Group.Founded in 2008 and headquartered in Marina del Rey  California  PSG is a high growth  profitable  and strong cash generative company  with annual revenue of US$75 million and an annual revenue growth of c.+40% (2019-2022E CAGR).PSGâ€™s unique comprehensive solution suite  supporting its clientsâ€™ hiring activities  is composed of three business lines:- Recruiting: providing dedicated specialists for sourcing  screening and vetting candidates to be interviewed by its clientsâ€™ recruiting teams- Recruiting support: delivering a broad range of administrative support covering pre-recruiting  recruiting and post-recruiting workstreams  including credentialing  clinical referencing  onboarding  payroll and billing; it helps clients focus on core value-added decisions- Full cycle RPO: offering a comprehensive solution from job posting to candidate onboarding  outsourcing the entire function for clientsPSG has a strong and niche business model that creates significant value for its clients  driven by its digital integrated business service delivery. PSGâ€™s proprietary technology platform (Compass) and people are integrated from the ground up with automation at critical stages of the recruitment funnel (sourcing & candidate attraction  recruiting support  analytics & reporting).This acquisition is fully aligned with Teleperformanceâ€™s stated strategy of building deeper expertise along its adjacent lines of business  industry verticals and digital capabilities. By acquiring PSG  Teleperformance further strengthens its strong added-value Specialized Services activities  its major position in the dynamic US healthcare vertical and its digital recruitment practices. The Group intends to scale up PSGâ€™s RPO activity in new client verticals and new geographies. The performance of PSGâ€™s digital platform built around proprietary solutions optimizes the recruitment of talent and represents a real competitive asset. The deal creates immediate value for Teleperformance shareholders as it is expected to be accretive to EBITDA margin and earnings per share in 2022E on a proforma basis.The consideration for the transaction (enterprise value) is US$300 million at closing. The acquisition is fully financed with cash on hand. Latham & Watkins LLP acted as legal advisors to Teleperformance.Teleperformance Chairman and Chief Executive Officer Daniel Julien  said: â€œPSG delivers critical recruitment services to a large array of blue chip clients  mostly in diverse recession resilient end-markets in the United States. It is a solid organization that supports more than 110 clients with a sophisticated growing workforce of approximately 4 000 employees.Being integrated in Teleperformanceâ€™s Specialized Services activities led by Scott Klein  this acquisition will reinforce the Groupâ€™s global leadership as a provider of digital integrated business services.Together with PSGâ€™s experienced and entrepreneurial management team and its premier proprietary technology capabilities  we will continue to strengthen our solid position in the US healthcare end-market and our digital recruitment processes. This represents a significant competitive advantage in the current challenging hiring context.â€â€œThe deal creates immediate value for Teleperformance shareholders as it is expected to be accretive to EBITDA margin by c.15bps and earnings per share by nearly +3%**â€  he added.Scott W. Klein  President of Specialized Services  Teleperformance  commented: â€œThe value that PSG creates for its clients is unmatched in the RPO industry. Our ability to invest in this newest Specialized Services business will drive enhanced growth and new solutions and allow for the achievement of our never-ending focus on delivering total and complete client satisfaction! Together with PSGâ€™s management team  we notably intend to scale up the RPO activity in new client verticals and new geographies. The performance of the digital platform built around proprietary solutions optimizes the recruitment of talent and represents a real competitive asset.â€** excluding amortization of intangibles on a pro forma basis for 2022Conference call with analysts and investorsA conference call to discuss details of the transaction will be held today at 6:15 pm CEST.Dial-in-number:France: +33 (0) 1 70 37 71 66United Kingdom: +44 (0) 33 0551 0200USA: +1 212 999 6659The slides of the conference call and the recording will be available on the following link:https://www.teleperformance.com/en-us/investors/publications-and-events/other-events/Indicative investor calendarThird-quarter 2022 revenue: November 3  2022About Teleperformance GroupTeleperformance (TEP â€“ ISIN: FR0000051807 â€“ Reuters: TEPRF.PA - Bloomberg: TEP FP)  the global leader in outsourced customer and citizen experience management and related digital services  serves as a strategic partner to the worldâ€™s largest companies in many industries. It offers a One Office support services model including end-to-end digital solutions  which guarantee successful customer interaction and optimized business processes  anchored in a unique  comprehensive high touch  high tech approach. Nearly 420 000 employees  based in 88 countries  support billions of connections every year in over 265 languages and around 170 markets  in a shared commitment to excellence as part of the â€œSimpler  Faster  Saferâ€ process. This mission is supported by the use of reliable  flexible  intelligent technological solutions and compliance with the industryâ€™s highest security and quality standards  based on Corporate Social Responsibility excellence. In 2021  Teleperformance reported consolidated revenue of â‚¬7 115 million (US$8.4 billion  based on â‚¬1 = $1.18) and net profit of â‚¬557 million.Teleperformance shares are traded on the Euronext Paris market  Compartment A  and are eligible for the deferred settlement service. They are included in the following indices: CAC 40  STOXX 600  S&P Europe 350  MSCI Global Standard and Euronext Tech Leaders. In the area of corporate social responsibility  Teleperformance shares are included in the CAC 40 ESG since September 2022  the Euronext Vigeo Euro 120 index since 2015  the EURO STOXX 50 ESG index since 2020  the MSCI Europe ESG Leaders index since 2019  the FTSE4Good index since 2018 and the S&P Global 1200 ESG index since 2017.For more information: www.teleperformance.com Follow us on Twitter: @teleperformance,neutral,0.02,0.98,0.0,positive,0.67,0.33,0.0,True,English,"['PSG Global Solutions', 'Teleperformance', 'Chief Executive Officer Daniel Julien', 'partial cycle recruitment process outsourcing', 'digital integrated business service delivery', 'strong added-value Specialized Services activities', 'diverse recession resilient end-markets', 'current challenging hiring context', 'dynamic US healthcare vertical', 'digital integrated business services', 'newest Specialized Services business', 'unique comprehensive solution suite', 'premier proprietary technology capabilities', 'strong cash generative company', 'US healthcare end-market', 'related digital services', 'niche business model', 'Marina del Rey', 'core value-added decisions', 'Full cycle RPO', 'real competitive asset', 'sophisticated growing workforce', 'complete client satisfaction', 'clientsâ€™ hiring activities', 'three business lines', 'proprietary technology platform', 'digital recruitment practices', 'digital recruitment processes', 'critical recruitment services', 'significant competitive advantage', 'pro forma basis', 'citizen experience management', 'Scott W. Klein', 'blue chip clients', 'new client verticals', 'senior management team', 'annual revenue growth', 'recruiting support processes', 'clientsâ€™ recruiting teams', 'digital capabilities', 'PSG Global Solutions', 'digital platform', 'BUSINESS WIRE', 'Scott Klein', 'proprietary solutions', 'recruitment funnel', 'critical stages', 'adjacent lines', 'proforma basis', 'enhanced growth', 'new geographies', 'new solutions', 'global leader', 'significant value', 'Regulatory News', 'outsourced customer', 'US-based leader', 'key aspects', 'owned subsidiary', 'RPO market', '22E CAGR', 'dedicated specialists', 'broad range', 'post-recruiting workstreams', 'clinical referencing', 'job posting', 'entire function', 'deeper expertise', 'major position', 'RPO activity', 'EBITDA margin', 'Watkins LLP', 'legal advisors', 'large array', 'United States', 'solid organization', 'solid position', 'ending focus', 'Conference call', 'United Kingdom', 'following link', 'immediate value', 'enterprise value', 'administrative support', 'private investors', 'candidate attraction', 'RPO industry', 'The Group', 'Teleperformance shareholders', 'Teleperformance Chairman', '110 clients', 'PARIS', 'TEP', 'founders', 'California', 'candidates', 'credentialing', 'payroll', 'billing', 'Compass', 'people', 'ground', 'automation', 'analytics', 'reporting', 'acquisition', 'strategy', 'talent', 'deal', 'earnings', '2022E', 'consideration', 'transaction', 'closing', 'hand', 'Latham', '4,000 employees', 'provider', 'experienced', 'President', 'ability', 'achievement', 'total', 'amortization', 'intangibles', 'analysts', 'details', 'CEST', 'number', 'France', 'USA', 'slides', 'recording', '6:15']",2022-10-27,2022-10-28,businesswire.com
12215,EuroNext,NewsApi.org,https://finance.yahoo.com/news/nexans-welcomes-maria-lorente-fraguas-063000130.html,Nexans welcomes Maria Lorente Fraguas as Senior Corporate Vice President  Chief Human Resources Officer and member of the Executive Committee,Maria Lorente Fraguas Nexans Senior Corporate Vice President  Chief Human Resources Officer and member of the Executive Committee Nexans welcomes Maria...,"NexansMaria Lorente FraguasNexans Senior Corporate Vice President  Chief Human Resources Officer and member of the Executive CommitteeNexans welcomes Maria Lorente Fraguas as Senior Corporate Vice President Chief Human Resources Officer and member of the Executive Committee_PRESS RELEASE_Nexans is pleased to announce the arrival of Maria Lorente Fraguas as Senior Corporate Vice President & Chief Human Resources Officer  responsible also for Corporate Social ResponsibilityShe brings to the role more than 20 years of international experience in several leadership positions in product development  operations and international team managementThis leadership appointment comes at a time when Nexans is perfectly positioned to pursue and accelerate its strategy as a pure-player in electrification  placing people and the environment at the heart of its businessParis  October 27  2022 - Nexans is pleased to announce the arrival of Maria Lorente Fraguas as Senior Corporate Vice President & Chief Human Resources Officer  responsible also for Corporate Social Responsibility.Maria has more than 20 years of experience in leading international teams around the world and in a wide range of positions  including Operations  New Product Development  Transformation and Human Resources.In this role  Maria will actively contribute to Nexansâ€™ transformation and future growth in electrification. Based at the companyâ€™s headquarters in Paris  Maria is Spanish and reports to Chief Executive Officer  Christopher GuÃ©rin.Graduated from Universidad PolitÃ©cnica de Valenica  Spain and SupÃ©lec in France  Maria brings with her a strong skill-set and a great reputation for relationship building  performance  and team leadership. She joins the Group with 21 years of experience at Schlumberger where she managed international teams in senior HR  functional  and line roles around the world. She worked in eight different countries accross Europe  the Middle East  Latin America and North America  in a wide range of positions including New Product Development  Marketing  Line Management  Transformation  and most recently served as the Director of Human Resources â€“ Production Systems.Story continuesChristopher Guerin  CEO of Nexans  comments: ""I am very pleased to welcome Maria. Her track record and international profile match our ambition to be a pure player in electrification worldwide. Her rich experience in business transformation and talent development will help accelerate Nexans' transformation. I am also convinced that Maria will help integrate Corporate Social Responsibility more broadly into our strategic ambitions  which is at the heart of our priorities.â€Maria Lorente Fraguas  the newly appointed Nexans Group Senior Corporate Vice President & Chief Human Resources Director  says: â€œ The people-centric culture  the passion for innovation and the ambition for growth  anchored in value creation across the three axis of Economics  Environment and Engagement  are what attracted me to Nexans. I am thrilled to join the team and contribute to the next chapter of the companyâ€™s strategy  keeping our customers and employees at the center of everything we do.â€œAbout NEXANSFor more than a century  Nexans has played a crucial role in electrifying the planet and is committed to electrifying the future. With 25 000 staff in 42 countries  the Group is driving the change towards the new world of electrification â€” a safer  more sustainable  renewable  carbon-free world  accessible to all. In 2021  Nexans generated â‚¬6.1 billion in standard sales. The Group is a leader in the design and manufacturing of cable systems and services in five main areas of activity: Energy Production & Transmission  Distribution  Uses  Industry & Solutions and Telecom & Data. Nexans was the first player in its industry to create a Corporate Foundation to support actions that promote access to energy for disadvantaged populations worldwide. The Group is committed to helping achieve carbon neutrality by 2030.Nexans. Electrify the future.Nexans is listed on the Euronext Paris stock market  compartment A.For more information  visit www.nexans.comContact:CommunicationEdelman FranceNexans@edelman.com+33 6 27 69 14 96Emmanuel Guinotemmanuel.guinot@nexans.comMaÃ«llys Leosticmaellys.leostic@nexans.comAttachments",neutral,0.02,0.98,0.0,positive,0.99,0.01,0.0,True,English,"['Senior Corporate Vice President', 'Chief Human Resources Officer', 'Maria Lorente Fraguas', 'Executive Committee', 'Nexans', 'member', 'Nexans Group Senior Corporate Vice President', 'Nexans Senior Corporate Vice President', 'Universidad PolitÃ©cnica de', 'Chief Human Resources Officer', 'sustainable, renewable, carbon-free world', 'Euronext Paris stock market', 'Chief Human Resources Director', 'Chief Executive Officer', 'Corporate Social Responsibility', 'five main areas', 'MaÃ«llys Leostic', 'Christopher GuÃ©rin', 'eight different countries', 'Maria Lorente Fraguas', 'leading international teams', 'New Product Development', 'several leadership positions', 'international team management', 'senior HR', 'Corporate Foundation', 'new world', 'Line Management', 'Christopher Guerin', 'talent development', 'international profile', 'The Group', 'Executive Committee', 'leadership appointment', 'team leadership', 'wide range', 'SupÃ©lec', 'strong skill-set', 'great reputation', 'relationship building', 'line roles', 'Middle East', 'Latin America', 'North America', 'Production Systems', 'track record', 'pure player', 'strategic ambitions', 'people-centric culture', 'value creation', 'three axis', 'next chapter', 'a century', 'standard sales', 'cable systems', 'first player', 'disadvantaged populations', 'carbon neutrality', 'compartment A.', 'international experience', 'rich experience', 'Energy Production', 'Edelman France', 'Emmanuel Guinot', 'crucial role', 'Nexansâ€™ transformation', ""Nexans' transformation"", 'business transformation', 'future growth', '42 countries', 'member', 'arrival', '20 years', 'operations', 'time', 'strategy', 'pure-player', 'electrification', 'environment', 'heart', 'company', 'headquarters', 'Valenica', 'Spain', 'performance', '21 years', 'Schlumberger', 'functional', 'Europe', 'Marketing', 'Story', 'CEO', 'priorities', 'passion', 'innovation', 'Economics', 'Engagement', 'customers', 'employees', 'center', 'everything', 'planet', '25,000 staff', 'change', 'design', 'manufacturing', 'services', 'activity', 'Transmission', 'Distribution', 'Uses', 'Industry', 'Solutions', 'Telecom', 'Data', 'actions', 'access', 'information', 'Contact', 'Communication', 'Attachments']",2022-10-27,2022-10-28,finance.yahoo.com
12216,EuroNext,NewsApi.org,https://ca.sports.yahoo.com/news/press-release-biocartis-group-nv-154000225.html,Press release Biocartis Group NV: Results of the Extraordinary Shareholdersâ€™ Meeting held on 27 October 2022,PRESS RELEASE: REGULATED INFORMATION 27 October 2022  17:40 CEST Results of the Extraordinary Shareholdersâ€™ Meeting held on 27 October 2022 Mechelen  Belgium  27 October 2022 â€“ Biocartis Group NV (the â€˜Companyâ€™ or â€˜Biocartisâ€™)  an innovative molecular diagnosâ€¦,Biocartis NVPRESS RELEASE : REGULATED INFORMATION27 October 2022  17:40 CESTResults of the Extraordinary Shareholdersâ€™ Meeting held on 27 October 2022Mechelen  Belgium  27 October 2022 â€“ Biocartis Group NV (the â€˜Companyâ€™ or â€˜Biocartisâ€™)  an innovative molecular diagnostics company (Euronext Brussels: BCART)  held its extraordinary general shareholders' meeting today. The proposed resolution referred to in item 7 of the agenda regarding the approval and ratification of the change of control clauses in the legal documentation relating to the comprehensive recapitalization transaction of the Company was approved by the extraordinary general shareholders' meeting. However  there was no deliberation and voting on the items 2 to 6 of the agenda of the extraordinary general shareholders' meeting  because the attendance quorum to deliberate and vote on such items was not reached.Biocartis will therefore convene a second extraordinary general shareholders' meeting for the relevant agenda items  which is to be held on Monday 14 November 2022 at 2:00 p.m. (Belgian time) at the offices of the Company at Generaal de Wittelaan 11B  2800 Mechelen  Belgium. There shall be no attendance quorum for this new extraordinary general shareholders' meeting.All documents relating to the general shareholdersâ€™ meeting can be consulted on the website of the Company.--- END ---More information:Renate DegraveHead of Corporate Communications & Investor Relations Biocartise-mail rdegrave@biocartis.comtel +32 15 631 729mobile +32 471 53 60 64About BiocartisWith its revolutionary and proprietary Idyllaâ„¢ platform  Biocartis (Euronext Brussels: BCART) aspires to enable personalized medicine for patients around the world through universal access to molecular testing  by making molecular testing actionable  convenient  fast and suitable for any lab. The Idyllaâ„¢ platform is a fully automated sample-to-result  real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house access to accurate molecular information in a minimum amount of time for faster  informed treatment decisions. Idyllaâ„¢â€™s continuously expanding menu of molecular diagnostic tests address key unmet clinical needs  with a focus in oncology. This is the fastest growing segment of the molecular diagnostics market worldwide. Today  Biocartis offers tests supporting melanoma  colorectal  lung and liver cancer  as well as for COVID-19  Flu  RSV and sepsis. For more information  visit www.biocartis.com or follow Biocartis on Twitter @Biocartis_   Facebook or LinkedIn.Story continuesBiocartis and Idyllaâ„¢ are registered trademarks in Europe  the United States and other countries. The Biocartis and Idyllaâ„¢ trademark and logo are used trademarks owned by Biocartis. Please refer to the product labeling for applicable intended uses for each individual Biocartis product.This press release is not for distribution  directly or indirectly  in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933  as amended.Forward-looking statementsCertain statements  beliefs and opinions in this press release are forward-looking  which reflect the Company's or  as appropriate  the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations  financial condition  liquidity  performance  prospects  growth  strategies and the industry in which the Company operates. By their nature  forward-looking statements involve a number of risks  uncertainties  assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks  uncertainties  assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including  but not limited to  changes in demand  competition and technology  can cause actual events  performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition  even if actual results or developments are consistent with the forward-looking statements contained in this press release  those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result  the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events  conditions  assumptions or circumstances on which these forward-looking statements are based  except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements  which speak only as of the date of this press release.,neutral,0.0,1.0,0.0,mixed,0.15,0.14,0.71,True,English,"['Biocartis Group NV', 'Extraordinary Shareholdersâ€™ Meeting', 'Press release', 'Results', '27 October 2022', ""second extraordinary general shareholders' meeting"", ""new extraordinary general shareholders' meeting"", 'faster, informed treatment decisions', 'key unmet clinical needs', 'U.S. Securities Act', 'Extraordinary Shareholdersâ€™ Meeting', 'general shareholdersâ€™ meeting', 'innovative molecular diagnostics company', 'Biocartis NV PRESS RELEASE', 'molecular diagnostics market', 'comprehensive recapitalization transaction', 'Generaal de Wittelaan', 'Polymerase Chain Reaction', 'fastest growing segment', 'Biocartis Group NV', 'proprietary Idyllaâ„¢ platform', 'accurate molecular information', 'molecular diagnostic tests', 'The Idyllaâ„¢ platform', 'individual Biocartis product', 'United States Securities', 'relevant agenda items', 'molecular testing', 'product labeling', 'The Biocartis', 'REGULATED INFORMATION', 'Euronext Brussels', 'control clauses', 'legal documentation', 'attendance quorum', 'Monday 14 November', 'More information', 'Renate Degrave', 'Corporate Communications', 'Investor Relations', 'personalized medicine', 'real-time PCR', 'minimum amount', 'expanding menu', 'liver cancer', 'other countries', 'Idyllaâ„¢ trademark', 'intended uses', 'Exchange Commission', 'current expectations', 'financial condition', 'financial effects', 'Forward-looking statements', 'future periods', 'Belgian time', 'universal access', 'actual events', 'past trends', 'Company directors', 'other factors', 'actual results', 'future events', 'future performance', 'October', 'CEST', 'Mechelen', 'Belgium', 'BCART', 'resolution', 'approval', 'ratification', 'deliberation', 'offices', 'documents', 'website', 'Head', 'mail', 'revolutionary', 'patients', 'world', 'system', 'house', 'focus', 'oncology', 'melanoma', 'colorectal', 'lung', 'COVID', 'Flu', 'RSV', 'sepsis', 'Twitter', 'Facebook', 'LinkedIn', 'Story', 'trademarks', 'Europe', 'logo', 'applicable', 'distribution', 'jurisdiction', 'persons', 'restrictions', 'responsibility', 'violation', 'offer', 'invitation', 'sale', 'purchase', 'America', 'registration', 'exemption', 'beliefs', 'opinions', 'projections', 'operations', 'liquidity', 'prospects', 'growth', 'strategies', 'industry', 'nature', 'number', 'risks', 'uncertainties', 'assumptions', 'outcome', 'plans', 'multitude', 'changes', 'demand', 'competition', 'technology', 'development', 'activities', 'guarantees', 'representation', 'addition', 'warran', '27', '2:00']",2022-10-27,2022-10-28,ca.sports.yahoo.com
12217,EuroNext,NewsApi.org,https://www.businesswire.com/news/home/20221026005852/en/Eurofins-Celebrates-35-Years-of-Testing-for-Life-and-25-Years-as-Best-Performing-Share-Listed-in-Europe,Eurofins Celebrates 35 Years of Testing for Life and 25 Years as Best Performing Share Listed in Europe,LUXEMBOURG--(BUSINESS WIRE)--October marks the 35th anniversary of Eurofins (Paris:ERF). Today  the global leader in bio-analysis with 61 000 staff across a network of 940 laboratories in 59 countries  Eurofinsâ€™ growth has been characterised by its steadfast â€¦,LUXEMBOURG--(BUSINESS WIRE)--October marks the 35th anniversary of Eurofins (Paris:ERF). Today  the global leader in bio-analysis with 61 000 staff across a network of 940 laboratories in 59 countries  Eurofinsâ€™ growth has been characterised by its steadfast focus on long-term value creation for customers  employees and shareholders. Eurofins companies have consistently invested in research and development  start-up laboratories  acquisitions  physical infrastructure and IT solutions  as part of their commitment to innovating for customers and achieving scale and scientific leadership in laboratory activities that have a direct positive impact on health and the environment.October also marks 25 years since the initial public offering (IPO) of Eurofins Scientific on the Paris stock exchange on 24th October 1997. According to a commissioned study  since its IPO  Eurofins has delivered a remarkable total shareholder return (reflecting share price appreciation and reinvestment of dividends) of around 36 600%. Among all companies with listings in major European exchanges over the 25 year time span  Eurofins ranks highest in terms of total shareholder return  according to the research firm. A hypothetical investment of around â‚¬2 700 in Eurofins at the time of its IPO  plus the reinvestment of dividends  would be worth about â‚¬1 million today.Dr Gilles Martin  CEO and Founder  Eurofins: â€œ As we celebrate this milestone  I would like to extend a heartfelt thanks to our global workforce for their commitment and efforts and to the clients of all Eurofins companies for their trust. We will continue to refine our service offering and significantly invest in and strengthen our network. Through focussed investments in our unique laboratory network and IT solutions  R&D  acquisitions and organic growth  we intend to continue to improve and extend our capabilities to offer the best and most innovative testing services to our clients  while creating further opportunities for our employees and shareholders.â€To mark this anniversary  Eurofins has developed a book charting its development  growth and innovations over the past three decades.Further information available here.About Eurofinsâ€“ the global leader in bio-analysisEurofins is Testing for Life. With 61 000 staff across a network of 940 laboratories in 59 countries  Eurofinsâ€™ companies offer a portfolio of over 200 000 analytical methods.Eurofins Shares are listed on Euronext Paris Stock Exchange.,neutral,0.19,0.81,0.0,positive,0.96,0.04,0.0,True,English,"['Best Performing Share', 'Eurofins', '35 Years', 'Testing', 'Life', '25 Years', 'Europe', 'remarkable total shareholder return', 'Euronext Paris Stock Exchange', 'long-term value creation', 'direct positive impact', 'share price appreciation', 'major European exchanges', 'Dr Gilles Martin', 'innovative testing services', 'past three decades', 'initial public offering', '25 year time span', 'unique laboratory network', 'laboratory activities', 'service offering', 'BUSINESS WIRE', 'global leader', 'physical infrastructure', 'IT solutions', 'scientific leadership', 'hypothetical investment', 'global workforce', 'R&D', 'Further information', '200,000 analytical methods', 'organic growth', '35th anniversary', 'research firm', 'Eurofins Scientific', 'Eurofins Shares', 'start-up laboratories', '24th October', 'Eurofins companies', 'Eurofinsâ€™ companies', 'Eurofinsâ€™ growth', '940 laboratories', 'ERF', 'bio-analysis', '61,000 staff', '59 countries', 'focus', 'customers', 'employees', 'shareholders', 'development', 'acquisitions', 'part', 'commitment', 'scale', 'health', 'environment', '25 years', 'IPO', 'study', 'reinvestment', 'dividends', 'listings', 'terms', 'CEO', 'Founder', 'milestone', 'heartfelt', 'efforts', 'clients', 'trust', 'investments', 'capabilities', 'best', 'opportunities', 'book', 'innovations', 'Life', 'portfolio']",2022-10-27,2022-10-28,businesswire.com
12218,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/27/2542423/0/en/FLOW-TRADERS-Q322-TRADING-UPDATE.html,FLOW TRADERS Q322 TRADING UPDATE,FLOW TRADERS Q322 TRADING UPDATE   Amsterdam  the Netherlands - Flow Traders N.V. (Euronext: FLOW) announces its unaudited Q322 trading update.  ......,FLOW TRADERS Q322 TRADING UPDATEAmsterdam  the Netherlands - Flow Traders N.V. (Euronext: FLOW) announces its unaudited Q322 trading update.HighlightsFlow Traders recorded Normalized total income of â‚¬112.2m in Q322 comprising Normalized NTI of â‚¬111.7m reflecting a more active fixed income market and trading environment and Normalized other income of â‚¬0.4m derived from the strategic investments portfolio. YTD 9m22 Normalized total income was â‚¬346.7m vs â‚¬304.1m in YTD 9m21Flow Traders Value Traded was flat quarter-on-quarter whereas the overall ETP market was down as increases in fixed income and currency  crypto and commodity trading were offset by lower equity trading  highlighting the success of the trading diversification strategyNormalized operating expenses of â‚¬63.3m incurred in Q322 contributing to YTD 9m22 Normalized operating expenses of â‚¬186.7m. 16.5% year-on-year increase in fixed operating expenses when adjusted for effect of USD strengthening and targeted base compensation increasesNormalized employee expenses reflect increased variable remuneration due to an improved operating result  impact of strategic headcount growth and the full effect of the targeted base compensation increases639 FTEs as at 30 September 2022 compared to 611 FTEs as at 30 June 2022 - new graduate intake classes welcomed in Trading and Technology in SeptemberNormalized EBITDA in Q322 reached â‚¬48.8m representing a margin of 44% contributing to YTD 9m22 Normalized EBITDA of â‚¬159.9m with a margin of 47%Q322 Normalized net profit amounted to â‚¬34.5m with Normalized basic EPS of â‚¬0.79. YTD 9m22 Normalized net profit amounted to â‚¬116.6m with Normalized basic EPS of â‚¬2.67Regulatory Own Funds Requirement (OFR) as at 30 September 2022 was â‚¬323m  resulting in excess capital of â‚¬228m as at 30 September 2022. Trading capital stood at â‚¬634m at the end of the third quarterExisting share buyback program of up to â‚¬25m increased by a further â‚¬15m for a total size of up to â‚¬40m - â‚¬9.1m of shares already repurchased since 22 July 2022Financial Overviewâ‚¬million Q322 Q222 Change YTD 9m22 YTD 9m21 Change Normalized total income 112.2 86.2 30% 346.7 304.1 14% Normalized net trading income 111.7 83.7 33% 343.9 303.7 13% EMEA 87.4 50.4 74% 246.3 186.0 32% Americas 14.4 18.6 (23%) 54.7 66.3 (18%) APAC 9.9 14.7 (33%) 42.9 51.4 (17%) Normalized other income 0.4 2.5 (83%) 2.8 0.4 - Normalized employee expenses1 40.1 28.5 41% 122.6 111.0 10% Technology expenses 16.1 14.9 8% 44.8 36.5 23% Other expenses2 7.1 6.3 13% 19.4 13.5 43% Normalized operating expenses 63.3 49.7 27% 186.7 161.0 16% Normalized EBITDA1 48.8 36.5 34% 159.9 143.1 12% Depreciation / amortisation 4.4 3.9 12.1 11.4 Write off of (in) tangible assets - - 0.2 - Normalized profit before tax 44.5 32.6 37% 147.7 131.8 12% Normalized tax 9.9 6.4 31.0 25.7 Normalized net profit 34.5 26.1 32% 116.6 106.1 10% Normalized basic EPS3 (â‚¬) 0.79 0.60 2.67 2.42 Normalized EBITDA margin 44% 44% 47% 47%Value Traded Overviewâ‚¬billion Q322 Q222 Change YTD 9m22 YTD 9m21 Change Flow Traders ETP Value Traded 409 449 (9%) 1 379 1 131 22% Europe 178 193 (8%) 609 522 17% Americas 212 230 (8%) 697 538 30% Asia 20 26 (24%) 74 70 5% Flow Traders non-ETP Value Traded 1 182 1 165 2% 3 781 2 978 27% Flow Traders Value Traded4 1 591 1 614 (1%) 5 160 4 108 26% Equity 714 831 (14%) 2 567 2 251 14% Fixed income 344 298 15% 960 758 27% Currency  Crypto  Commodity 495 463 7% 1 489 970 53% Other 37 21 72% 141 129 10% Market ETP Value Traded5 11 410 13 676 (17%) 40 170 26 169 54% Europe 532 567 (6%) 1 866 1 503 24% Americas 9 638 11 951 (19%) 34 894 21 954 59% Asia 1 240 1 158 7% 3 411 2 712 26% Asia ex China 395 400 (1%) 1 187 1 033 15%Regional HighlightsEUROPE:Strong trading performance in the region with the successful leverage of the investments made across the fixed income business. Flow Traders once again maintained its position as the leading liquidity provider in ETPs  both on- and off-exchangeCorporate credit trading business continues to gain further traction across the market. Flow Tradersâ€™ coverage of the EM bond market has been further strengthened during the quarter. Continued to see a quote rate of >80% for the majority of the Bloomberg Barclays Corporate Bond index and have retained Top 5 Bloomberg dealer rankings for executed tickets and volume in Flow Tradersâ€™ Euro IG universeContinued to support new products and listings across the crypto space - worked extensively with exchanges and ETP issuers around the Ethereum upgrade. Further investments made by Flow Traders Capital are aligned with growing focus on DeFi given Flow Traders is one of the leading global architects for maturing this propositionAMERICAS:Acted as Lead Market Maker (LMM) on the Charles Schwab Crypto Thematic ETF USA  the iShares Water Management Multisector ETF (IWTR)  the full Bondbloxx treasury suite and on SPKX and SPKY from Convexity Shares as Flow Tradersâ€™ LMM presence in the US growsFurther build-out of the fixed income business as Flow Traders commenced pricing IG bonds in the US with 2 500 ISINs currently covered with a plan in place to expand the coverage universe to 8 000 - 12 000 ISINsASIA:Successfully obtained QFII license approval in China which is a key step in the overall China market strategy and has enabled the execution of the first on-shore tradesFlow Traders is committed to growing the Hong Kong ETP markets and as part of this has joined the HKEx Cash Market Consultative Panel - also further strengthens the continuing cooperation with HKExFlow Traders CapitalFewer investments during the third quarter given the developments across the crypto and digital asset space. Announced new investments in Crossover Markets  GoGo pool  Infinity Exchange  Kemet Trading  and Sei Network as well as providing additional funding for two existing investments. Flow Traders total investment in the third quarter amounted to â‚¬5.1m and now has a total of 23 current investments to date representing a total value of â‚¬28.5mCorporate venture capital strategy is already paying off by selecting and entering investments that provide Flow Traders with an immediate benefit for the existing core liquidity providing businessOutlookFlow Traders announces an increase of the existing share buyback program of up to â‚¬25m by an additional amount of up to â‚¬15m for a total size of up to â‚¬40m over a period of 12 months from the start of the forthcoming open period. As of 26 October 2022  the total number of shares purchased under this program since 22 July 2022 is 469 434 shares at an average price of â‚¬19.46 for a total consideration of â‚¬9.1m. The purpose of the buyback is to return excess capital to shareholders. The intention is that shares repurchased as part of this program will initially be held in treasury. 3 259 529 shares are held in treasury as at 26 October 2022 with 58% of these treasury shares repurchased for the purpose of satisfying the requirements of various employee incentive plans and the remaining 42% repurchased for the purpose of returning excess capital to shareholdersOn 21 October 2022  Flow Traders announced a proposed implementation of an updated corporate holding structure  as an enabler of its global strategic ambition. This proposed update will involve a top holding company in Bermuda and is the result of a thorough legal and capital structure review. This will be formally proposed to shareholders at an Extraordinary General Meeting  scheduled to take place on 2 December 2022 at 14.00 CETManagement Board CommentsDennis Dijkstra  CEO  stated:â€œThis quarter delivered further proof points with respect to the diligent execution of our strategic growth agenda  particularly in fixed income. Our liquidity provision across the fixed income space which includes ETFs as well as corporate credit and emerging markets sovereign bonds continues to be positively received by the buy-side and we were delighted to be the lead sponsor once again at the recent Fixed Income Leadership Summit in Nice. Another landmark for Flow Traders was the successful approval of our QFII license which is a key part of our plan to enter the mainland China market. Given the strong financial performance in the quarter and within the context of our capital allocation framework  we have elected to increase the current share buyback program to a new total size of up to â‚¬40 million. This buyback will further enhance the capital returns to our shareholders.â€œWe have also worked hard this quarter on laying the groundwork for the future. The proposed update to the corporate holding structure was announced on 21 October 2022 and is a natural enabler for the strategic ambition which the team outlined at the Capital Markets Update held in July. In addition  we created an Executive Committee in order to accelerate the implementation of our strategy as well as to ensure that our leadership talent pool grows alongside the needs of the business. Lastly  it is also pleasing that in a highly competitive employment market  we are still able to attract and recruit the best talent and we welcomed a large intake of 18 new graduates in September to complement our already highly talented team.â€Folkert Joling  Chief Trading Officer  added:â€œThe third quarter saw a more active fixed income market given interest rate and inflation impacts. This contributed to an overall strong trading performance  which was particularly evident in EMEA. Across other asset classes  realized volatility remained subdued compared to earlier in the year. Our trading footprint continues to grow as we successfully executed our first ever on-shore China trades. From a broader trading perspective  we remained focused on executing our growth plans with respect to our business lines of Equity  Fixed Income and Crypto  Currencies and Commodities. We have enduring confidence in our ability to expand our trading activities across these various asset classes going forward.â€Mike Kuehnel  Chief Financial Officer  added:â€œIndicative of the success of our trading diversification strategy  Flow Traders achieved a return on trading capital of 67% in Q3. Once again  the firmâ€™s trading capital continues to generate attractive and economically accretive returns. From an operating cost perspective  we have had to contend with a changing macro environment which has brought rising inflation as well as a strengthening US dollar. We are therefore seeking to absorb these impacts while at the same time ensuring we continue to invest in the business in order to execute our strategy and deliver sustainable returns for our stakeholders. The adjusted profit-sharing percentage continues to effectively ensure that the base compensation increases implemented in Q2 are income statement neutral as communicated before. A key focus for the remainder of this year and next is to further increase the underlying efficiency of the business as we prepare ourselves for Flow Tradersâ€™ next stage of growth.â€œA key takeaway from the recent Capital Markets Update was the importance of engaging more intensely in the ecosystem we operate and thrive in. With that in mind  we have continued to support new products and listings across the crypto space and  notably  worked with exchanges and ETP issuers around the Ethereum upgrade. The pace of our strategic investments has naturally slowed somewhat with the advent of the â€˜crypto winterâ€™ which has allowed for more time to work with partners on build-out and development. Nonetheless  Flow Traders Capital still announced five investments during the third quarter.â€œPreliminary Financial Calendar2 December 2022 EGM12 January 2023 Start Silent Period ahead of Q422 / FY22 results9 February 2023 Release Q422 / FY22 results (incl. analyst conference call)24 February 2023 Release 2022 Annual Report31 March 2023 Start Silent Period ahead of Q123 trading update21 April 2023 Release Q123 trading update (no analyst conference call)26 April 2023 AGMContact DetailsFlow Traders N.V.InvestorsJonathan BergerPhone: +31 20 7996149Email: investor.relations@flowtraders.comMediaLaura PeijsPhone: +31 20 7996125Email: press@flowtraders.comAbout Flow TradersFlow Traders is a leading global financial technology-enabled liquidity provider in financial products  historically specialized in Exchange Traded Products (ETPs)  now expanding into other asset classes. Flow Traders ensures the provision of liquidity to support the uninterrupted functioning of financial markets. This allows investors to continue to buy or sell ETPs or other financial instruments under all market circumstances. We continuously grow our organization  ensuring that our trading desks in Europe  the Americas and Asia can provide liquidity across all major exchanges  globally  24 hours a day. Founded in 2004  we continue to cultivate the entrepreneurial  innovative and team-oriented culture that has been with us since the beginning. Please visit www.flowtraders.com for more information.Normalized performanceFlow Traders makes certain adjustments to various IFRS expense and profit measures in order to derive Alternative Performance Measures (APM). The policy is to exclude or adjust items that are considered to be significant in both nature or size and where the treatment as an adjusted item provides stakeholders with useful information to assess the year-on-year or quarter-on-quarter underlying performance. On this basis  the following items were adjusted or excluded for the Q322 trading update: Removal of IFRS 2 treatment of share-based payments which include the deferral of a portion of the current year share plans as well as recognition of prior yearsâ€™ share plans. This adjustment provides insights into the relationship between the current year variable employee expenses and current year trading performance Other income line includes all the realized and unrealized results on Flow Tradersâ€™ long-term equity investments whether accounted for as Fair Value Other Comprehensive Income (FV OCI)  Fair Value Profit and Loss (FVPL) or Results of Equity Accounted Investments Exclusion of one-off expenses which relate specifically to the proposed corporate holding structure update and the Capital Markets Update. These are not considered to be part of the underlying operating expenses of the business Tax expenses are adjusted based upon the pre-tax adjustments and/or excluded items aboveNormalized to IFRS reconciliationâ‚¬million Q322 Q222 Change YTD 9m22 YTD 9m21 Change Total income 111.7 83.5 34% 343.1 303.7 13% Net trading income 111.8 84.0 33% 344.5 303.7 13% Other income (0.1) (0.5) - (1.3) - - Employee expenses1 39.9 35.4 13% 130.2 119.2 9% Technology expenses 16.1 14.9 8% 44.8 36.5 23% Other expenses 7.1 6.3 13% 19.4 11.6 67% One off expenses 0.8 8.5 (91%) 12.5 1.9 - Total operating expenses 63.9 65.1 (2%) 207.0 169.3 22% EBITDA 47.8 18.3 161% 136.2 134.5 1% Profit before tax 43.4 14.3 204% 123.7 123.2 0% Net profit 33.8 11.2 203% 97.4 98.9 (2%) Basic EPS3 (â‚¬) 0.78 0.26 2.23 2.25 Fully diluted EPS6 (â‚¬) 0.75 0.25 2.16 2.18 EBITDA margin 43% 22% 40% 44%Normalized EBITDA and margin are based on the relevant profit share percentage of operating result for the relevant financial period without any IFRS 2 adjustments for share-based payments. The profit share percentage was adjusted to 32.5% in Q222 from 35%. â‚¬0.8m of one-off expenses is also excludedTax based on estimated expected effective tax rate for the relevant financial period: Q322 - 22.3%; Q222 - 19.7%; YTD 9m22 - 21.0%; YTD 9m21 - 19.5%A summary reconciliation of Normalized to IFRS is presented below:â‚¬million Q322 Q222 YTD 9m22 YTD 9m21Normalized EBITDA 48.8 36.5 159.9 143.1 FV OCI adjustment (0.5) (2.9) (3.7) (0.3) Results of equity-accounted investments - 0.1 0.2 (0.1) One off expenses (0.8) (8.5) (12.5) - Prior year share plans (4.2) (6.2) (18.3) (18.7) Current year share plan deferral 4.4 0.4 10.6 10.5 Other variable remuneration adjustment - (1.1) - - IFRS EBITDA 47.8 18.3 136.2 134.5Normalized net profit 34.5 26.1 116.6 106.1 Profit before tax IFRS adjustments (1.1) (18.3) (24.0) (8.6) Tax difference 0.4 3.3 4.7 1.4 IFRS net profit 33.8 11.2 97.4 98.9NotesFixed employee expenses: Q322 - â‚¬19.0m; Q222 - â‚¬18.2m; YTD 9m22 - â‚¬53.3m; YTD 9m21 - â‚¬40.2m YTD 9m21 other expenses includes â‚¬1.9m of business continuity plan-related expenses previously classified as one-off expenses Weighted average shares outstanding: Q322 - 43 615 044; Q222 - 43 731 905; YTD 9m22 - 43 620 841; YTD 9m21 - 43 875 028. 43 439 853 shares outstanding as at 30 September 2022 Value traded comprises ETPs  Futures and Cash Source - Flow Traders analysis Determined by adjusting the basic EPS for the effects of all dilutive share-based payments to employeesImportant Legal InformationThis press release is prepared by Flow Traders N.V. and is for information purposes only. It is not a recommendation to engage in investment activities and you must not rely on the content of this document when making any investment decisions. The information in this document does not constitute legal  tax  or investment advice and is not to be regarded as investor marketing or marketing of any security or financial instrument  or as an offer to buy or sell  or as a solicitation of any offer to buy or sell  securities or financial instruments.The information and materials contained in this press release are provided â€˜as isâ€™ and Flow Traders N.V. or any of its affiliates (â€œFlow Tradersâ€) do not warrant the accuracy  adequacy or completeness of the information and materials and expressly disclaim liability for any errors or omissions. This press release is not intended to be  and shall not constitute in any way a binding or legal agreement  or impose any legal obligation on Flow Traders. All intellectual property rights  including trademarks  are those of their respective owners. All rights reserved. All proprietary rights and interest in or connected with this publication shall vest in Flow Traders. No part of it may be redistributed or reproduced without the prior written permission of Flow Traders.This press release may include forward-looking statements  which are based on Flow Tradersâ€™ current expectations and projections about future events  and are not guarantees of future performance. Forward looking statements are statements that are not historical facts  including statements about our beliefs and expectations. Words such as â€œmayâ€  â€œwillâ€  â€œwouldâ€  â€œshouldâ€  â€œexpectâ€  â€œintendâ€  â€œestimateâ€  â€œanticipateâ€  â€œprojectâ€  â€œbelieveâ€  â€œcouldâ€  â€œhopeâ€  â€œseekâ€  â€œplanâ€  â€œforeseeâ€  â€œaimâ€  â€œobjectiveâ€  â€œpotentialâ€  â€œgoalâ€ â€œstrategyâ€  â€œtargetâ€  â€œcontinueâ€ and similar expressions or their negatives are used to identify these forward-looking statements. By their nature  forward-looking statements involve known and unknown risks  uncertainties  assumptions and other factors because they relate to events and depend on circumstances that will occur in the future whether or not outside the control of Flow Traders. Such factors may cause actual results  performance or developments to differ materially from those expressed or implied by such forward-looking statements. Accordingly  no undue reliance should be placed on any forward-looking statements. Forward-looking statements speak only as at the date at which they are made. Flow Traders expressly disclaims any obligation or undertaking to update  review or revise any forward-looking statements contained in this press release to reflect any change in its expectations or any change in events  conditions or circumstances on which such statements are based unless required to do so by applicable law.Financial objectives are internal objectives of Flow Traders to measure its operational performance and should not be read as indicating that Flow Traders is targeting such metrics for any particular fiscal year. Flow Tradersâ€™ ability to achieve these financial objectives is inherently subject to significant business  economic and competitive uncertainties and contingencies  many of which are beyond Flow Tradersâ€™ control  and upon assumptions with respect to future business decisions that are subject to change. As a result  Flow Tradersâ€™ actual results may vary from these financial objectives  and those variations may be material.Efficiencies are net  before tax and on a run-rate basis  i.e. taking into account the full-year impact of any measure to be undertaken before the end of the period mentioned. The expected operating efficiencies and cost savings were prepared on the basis of a number of assumptions  projections and estimates  many of which depend on factors that are beyond Flow Tradersâ€™ control. These assumptions  projections and estimates are inherently subject to significant uncertainties and actual results may differ  perhaps materially  from those projected. Flow Traders cannot provide any assurance that these assumptions are correct and that these projections and estimates will reflect Flow Tradersâ€™ actual results of operations.By accepting this document you agree to the terms set out above. If you do not agree with the terms set out above please notify legal.amsterdam@nl.flowtraders.com immediately and delete or destroy this document.Market Abuse RegulationThis press release contains information within the meaning of Article 7(1) of the EU Market Abuse Regulation and is an announcement pursuant to Article 5(1) of the EU Market Abuse Regulation.Attachment,neutral,0.03,0.97,0.0,positive,0.87,0.12,0.01,True,English,"['FLOW TRADERS Q322 TRADING UPDATE', 'Charles Schwab Crypto Thematic ETF USA', 'iShares Water Management Multisector ETF', 'Bloomberg Barclays Corporate Bond index', 'Flow Tradersâ€™ Euro IG universe', 'Top 5 Bloomberg dealer rankings', 'Regulatory Own Funds Requirement', 'FLOW TRADERS Q322 TRADING UPDATE', 'new graduate intake classes', 'full Bondbloxx treasury suite', 'Corporate credit trading business', 'unaudited Q322 trading update', 'Flow Traders N.V.', 'Flow Tradersâ€™ LMM presence', 'active fixed income market', 'EM bond market', 'strategic headcount growth', 'share buyback program', 'leading liquidity provider', 'leading global architects', 'trading diversification strategy', 'Strong trading performance', 'Flow Tradersâ€™ coverage', 'fixed income business', 'Lead Market Maker', 'base compensation increases', 'Change Flow Traders', 'Flow Traders Capital', 'strategic investments portfolio', 'lower equity trading', 'overall ETP market', 'net trading income', 'Value Traded Overview', 'fixed operating expenses', 'Q222 Change YTD', 'IG bonds', 'Trading capital', 'new products', 'trading environment', 'full effect', 'Financial Overview', 'crypto space', 'total income', 'other income', 'commodity trading', 'excess capital', 'ETP Value', 'ETP issuers', 'operating result', 'employee expenses', 'Normalized NTI', 'year increase', 'variable remuneration', 'net profit', 'basic EPS', 'total size', 'Other expenses2', 'tangible assets', 'successful leverage', 'quote rate', 'Ethereum upgrade', 'Further investments', 'growing focus', 'Technology expenses', 'YTD 9m22', 'Regional Highlights', 'Convexity Shares', 'third quarter', 'EBITDA margin', 'Amsterdam', 'Netherlands', 'Euronext', 'currency', 'USD', 'impact', '639 FTEs', '30 September', '611 FTEs', '30 June', 'OFR', 'end', '22 July', 'EMEA', 'Americas', 'APAC', 'EBITDA1', 'Depreciation', 'amortisation', 'tax', 'Europe', 'Asia', 'China', 'position', 'ETPs', 'exchange', 'majority', 'tickets', 'volume', 'listings', 'DeFi', 'IWTR', 'SPKX', 'SPKY', 'build', 'pricing', '2,500 ISINs']",2022-10-27,2022-10-28,globenewswire.com
12219,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/27/2542476/0/en/Share-Buyback-Transaction-Details-October-20-October-26-2022.html,Share Buyback Transaction Details October 20 â€“ October 26  2022,Share Buyback Transaction Details October 20 â€“ October 26  2022        October 27  2022 - Wolters Kluwer (Euronext: WKL)  aÂ global leading provider of......,Share Buyback Transaction Details October 20 â€“ October 26  2022October 27  2022 - Wolters Kluwer (Euronext: WKL)  a global leading provider of expert solutions  insights and services for professionals  today reports that it has repurchased 290 096 of its own ordinary shares in the period from October 20  2022  up to and including October 26  2022  for â‚¬30.0 million and at an average share price of â‚¬103.49.These repurchases are part of the share buyback program under which we intend to repurchase shares for â‚¬1 billion during 2022  as announced on August 3  2022.The cumulative amounts repurchased to date under this program are as follows:Share Buyback 2022Period Cumulative shares repurchased in period Total consideration(â‚¬ million) Average share price(â‚¬) 2022 to date 7 577 889 738.1 97.40For the period starting August 4  2022  up to and including October 31  2022  we have mandated third parties to execute â‚¬400 million in share buybacks on our behalf while for the period starting November 3  2022  up to and including December 28  2022  we have mandated another third party to execute â‚¬244 million in share buybacks on our behalf  within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the companyâ€™s Articles of Association.Repurchased shares are added to and held as treasury shares and will be used for capital reduction purposes or to meet obligations arising from share-based incentive plans.Further information is available on our website:About Wolters KluwerWolters Kluwer (WKL) is a global leader in professional information  software solutions  and services for the healthcare; tax and accounting; governance  risk and compliance; and legal and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.Wolters Kluwer reported 2021 annual revenues of â‚¬4.8 billion. The group serves customers in over 180 countries  maintains operations in over 40 countries  and employs approximately 19 800 people worldwide. The company is headquartered in Alphen aan den Rijn  the Netherlands.Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).For more information  visit www.wolterskluwer.com   follow us on Twitter   Facebook   LinkedIn   and YouTube .Media Investors/Analysts Gerbert van Genderen Stort Meg Geldens Corporate Communications Investor Relations t + 31 172 641 230 t + 31 172 641 407 press@wolterskluwer.com ir@wolterskluwer.comForward-looking Statements and Other Important Legal InformationThis report contains forward-looking statements. These statements may be identified by words such as â€œexpectâ€  â€œshouldâ€  â€œcouldâ€  â€œshallâ€ and similar expressions. Wolters Kluwer cautions that such forward-looking statements are qualified by certain risks and uncertainties that could cause actual results and events to differ materially from what is contemplated by the forward-looking statements. Factors which could cause actual results to differ from these forward-looking statements may include  without limitation  general economic conditions; conditions in the markets in which Wolters Kluwer is engaged; behavior of customers  suppliers  and competitors; technological developments; the implementation and execution of new ICT systems or outsourcing; and legal  tax  and regulatory rules affecting Wolters Kluwerâ€™s businesses  as well as risks related to mergers  acquisitions  and divestments. In addition  financial risks such as currency movements  interest rate fluctuations  liquidity  and credit risks could influence future results. The foregoing list of factors should not be construed as exhaustive. Wolters Kluwer disclaims any intention or obligation to publicly update or revise any forward-looking statements  whether as a result of new information  future events or otherwise.This press release contains information which is to be made publicly available under Regulation (EU) 596/2014.Attachment,neutral,0.0,1.0,0.0,negative,0.0,0.1,0.9,True,English,"['Share Buyback Transaction Details', 'October', 'Analysts Gerbert van Genderen Stort Meg Geldens', 'Alphen aan den Rijn', 'Level 1 American Depositary Receipt', 'Corporate Communications Investor Relations', 'Share Buyback Transaction Details', 'Other Important Legal Information', 'capital reduction purposes', 'share-based incentive plans', 'deep domain knowledge', 'interest rate fluctuations', 'average share price', 'global leading provider', 'new ICT systems', 'general economic conditions', 'share buyback program', 'Wolters Kluwer shares', 'Period Cumulative shares', 'share buybacks', 'cumulative amounts', 'global leader', 'new information', 'ordinary shares', 'Repurchased shares', 'treasury shares', 'expert solutions', 'Total consideration', 'third parties', 'third party', 'relevant laws', 'Further information', 'professional information', 'software solutions', 'regulatory sectors', 'critical decisions', 'specialized technology', '2021 annual revenues', 'ADR) program', 'counter market', 'U.S.', 'Media Investors', 'similar expressions', 'actual results', 'technological developments', 'regulatory rules', 'currency movements', 'future results', 'foregoing list', 'press release', 'Forward-looking Statements', 'Euronext Amsterdam', 'Euronext 100 indices', 'financial risks', 'credit risks', 'future events', 'October', 'WKL', 'insights', 'services', 'professionals', 'repurchases', 'August', 'date', 'behalf', 'November', 'December', 'limits', 'regulations', 'company', 'Articles', 'Association', 'obligations', 'website', 'healthcare', 'tax', 'accounting', 'governance', 'compliance', 'customers', 'group', '180 countries', 'operations', '40 countries', '19,800 people', 'Netherlands', 'AEX', 'ADRs', 'WTKWY', 'Twitter', 'Facebook', 'LinkedIn', 'YouTube', 'report', 'words', 'uncertainties', 'Factors', 'limitation', 'markets', 'behavior', 'suppliers', 'competitors', 'implementation', 'execution', 'outsourcing', 'businesses', 'mergers', 'acquisitions', 'divestments', 'addition', 'liquidity', 'intention', 'Attachment']",2022-10-27,2022-10-28,globenewswire.com
12220,EuroNext,NewsApi.org,https://www.businesswire.com/news/home/20221026006085/en/Cementos-Pacasmayo-S.A.A.-Announces-Consolidated-Results-for-Third-Quarter-2022,Cementos Pacasmayo S.A.A. Announces Consolidated Results for Third Quarter 2022,LIMA  Peru--(BUSINESS WIRE)--Cementos Pacasmayo S.A.A. and subsidiaries (NYSE: CPAC; BVL: CPACASC1) (â€œthe Companyâ€ or â€œPacasmayoâ€) a leading cement company serving the Peruvian construction industry  announced today its consolidated results for the third quarâ€¦,"LIMA  Peru--(BUSINESS WIRE)--Cementos Pacasmayo S.A.A. and subsidiaries (NYSE: CPAC; BVL: CPACASC1) (â€œthe Companyâ€ or â€œPacasmayoâ€) a leading cement company serving the Peruvian construction industry  announced today its consolidated results for the third quarter (â€œ3Q22â€) and the nine months (â€œ9M22â€) ended September 30  2022. These results have been prepared in accordance with International Financial Reporting Standards (â€œIFRSâ€) and are stated in nominal Peruvian Soles (S/).3Q22 FINANCIAL AND OPERATIONAL HIGHLIGHTS:(All comparisons are to 3Q21  unless otherwise stated)Revenues increased 9.1%  mainly due to increase in average prices of bagged cement  as inflationary pressures have affected our costs of raw materials and energy.Sales volume of cement  concrete and precast decreased 5.9%  mainly due to a moderation in sales volume from the peak levels reached last year. However  if we compare sales volumes to 2Q22  these increased 6.2%.Consolidated EBITDA of S/124.9 million  a 6.5% increase  mainly due to higher prices  as well as increased operating profit  since we were able to decrease costs by using less imported clinker. This is especially relevant since both of our main kilns in Piura and Pacasmayo were in planned preventive maintenance in this quarter.Consolidated EBITDA margin of 22.6%  a 0.5 percentage point decreaseNet income of S/ 44.2 million  a 5.0% increase mainly due to increased sales and operating profit as mentioned above.9M22 FINANCIAL AND OPERATIONAL HIGHLIGHTS:(All comparisons are to 9M21  unless otherwise stated)Revenues increased 12.0%  mainly due to increase in average prices of bagged cement  as inflationary pressures have affected our costs of raw materials and energy.Sales volume of cement  concrete and precast decreased 4.4%  mainly due to a moderation in sales volume of bagged cement for self-construction as well as decreased sales for reconstruction-related projects.Consolidated EBITDA of S/372.9 million  a 19.4% increase  mainly due to higher operating profit  since we were able to decrease costs by using less imported clinker.Consolidated EBITDA margin of 23.6%  a 1.5 percentage point increase.Net income of S/ 137.9 million  a 35.7% increase mainly due to increased sales and operating profit as mentioned above.For a full version of Cementos Pacasmayoâ€™s Third Quarter 2022 Earnings Release  please visit https://www.cementospacasmayo.com.pe/inversionistas/reportesCONFERENCE CALL INFORMATION:Cementos Pacasmayo will host a conference call on Thursday  October 27  2022  to discuss these results at 11:00 a.m. Eastern/ 10:00am Lima Time.To access the call  please dial:(888)-506-0062 from within the U.S.+1 (973) 528-0011 from outside the U.S.Access code: 996674There will also be a live Audio Webcast of the event at:https://www.webcaster4.com/Webcast/Page/1644/46691About Cementos Pacasmayo S.A.A.Cementos Pacasmayo S.A.A. is a cement company  located in the Northern region of Peru. In February 2012  the Companyâ€™s shares were listed on The New York Stock Exchange - Euronext under the ticker symbol ""CPAC"". With more than 60 years of operating history  the Company produces  distributes and sells cement and cement-related materials  such as concrete blocks and ready-mix concrete. Pacasmayoâ€™s products are primarily used in construction  which has been one of the fastest-growing segments of the Peruvian economy in recent years. The Company also produces and sells quicklime for use in mining operations.",neutral,0.0,1.0,0.0,neutral,0.01,0.98,0.01,True,English,"['Cementos Pacasmayo S.A.A.', 'Consolidated Results', 'Third Quarter', 'The New York Stock Exchange', 'Cementos Pacasmayo S.A.A.', 'International Financial Reporting Standards', 'Third Quarter 2022 Earnings Release', 'less imported clinker', '0.5 percentage point decrease', 'live Audio Webcast', 'nominal Peruvian Soles', '10:00am Lima Time', 'Consolidated EBITDA margin', 'Peruvian construction industry', 'CONFERENCE CALL INFORMATION', '1.5 percentage point increase', 'higher operating profit', 'leading cement company', 'U.S.', 'The Company', '3Q22 FINANCIAL', 'Peruvian economy', 'higher prices', '11:00 a', 'operating history', '9M22 FINANCIAL', 'BUSINESS WIRE', 'nine months', 'OPERATIONAL HIGHLIGHTS', 'average prices', 'inflationary pressures', 'raw materials', 'peak levels', 'main kilns', 'preventive maintenance', 'Net income', 'reconstruction-related projects', 'full version', 'Access code', 'Northern region', 'ticker symbol', 'cement-related materials', 'growing segments', 'mining operations', 'consolidated results', 'Sales volume', 'bagged cement', 'concrete blocks', 'ready-mix concrete', 'recent years', '60 years', '6.5% increase', '5.0% increase', '19.4% increase', '35.7% increase', 'subsidiaries', 'NYSE', 'CPAC', 'BVL', 'accordance', 'IFRS', 'comparisons', '3Q21', 'Revenues', 'costs', 'energy', 'precast', 'moderation', '2Q22', 'Piura', '9M21', 'self-construction', 'cementospacasmayo', 'inversionistas', 'reportes', 'Thursday', 'October', 'Eastern', 'Page', 'February', 'shares', 'Euronext', 'products', 'quicklime', 'use']",2022-10-27,2022-10-28,businesswire.com
12221,EuroNext,NewsApi.org,https://finance.yahoo.com/news/bghl-gbp-nav-share-buy-053000044.html,BGHL GBP NAV & Share buy back,BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for...,"BOUSSARD AND GAVAUDAN HOLDING LIMITED (GBP)BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 26 Oct 2022.Estimated NAVEuro Shares Sterling Shares Estimated NAV â‚¬ 28.2017 Â£ 24.7302 Estimated MTD return -0.18 % -0.06 % Estimated YTD return -3.42 % -2.27 % Estimated ITD return 182.02 % 147.30 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close â‚¬ 22.20 N/A Premium/discount to estimated NAV -21.28 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 2 000.00 Premium/discount to estimated NAV N/A -19.13 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares 1 400 N/A Average Price â‚¬ 22.20 N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 315 188 130 254 Held in treasury 1 400 N/A Shares Issued 12 316 588 130 254Estimated BG Fund NAVClass B Euro Shares (estimated) â‚¬ 246.1882 Class GBP A Shares (estimated) Â£ 131.9167The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.Story continuesFor further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.08,0.91,0.0,mixed,0.12,0.2,0.69,True,English,"['BGHL GBP NAV', 'Share', 'The Class B Euro Shares', 'Euro Shares Sterling Shares Number', 'GAVAUDAN HOLDING LIMITED Ordinary Shares', 'BGHL Ordinary Shares Euro Shares', 'A Liquidity Enhancement Agreement', 'London Stock Exchange plc', 'N/A Sterling Shares Amsterdam', 'Guernsey Financial Services Commission', 'Class GBP A Shares', 'Dutch Financial Supervision Act', 'A N/A Average Price', 'Euro Shares Amsterdam', 'Sterling Shares Shares', 'US Investment Company Act', 'expert financial advice', 'Guernsey Policy Council', 'collective investment scheme', 'UK Listing Authority', 'other professional advice', 'BG Fund ICAV', 'Gavaudan Investment Management', 'closed-ended investment company', 'US Securities Act', 'investment manager fees', '1,400 N/A Shares', 'BG Fund NAV', 'The Shares', 'Dutch Authority', 'Emmanuel Gavaudan', 'A Premium/discount', 'A Range', 'Euronext Amsterdam', 'US persons', 'Financial Markets', 'The Directors', 'The Company', 'investment performance', 'original investment', 'investment decision', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'main market', 'United States', 'following information', 'information purposes', 'necessary approval', 'future results', 'listed securities', 'Market information', 'LSE) Market', 'BOUSSARD', 'business', 'Oct', 'returns', 'AEX', 'Transactions', 'treasury', 'respect', 'role', 'Story', 'LLP.', 'Email', 'article', 'conjunction', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2022-10-27,2022-10-28,finance.yahoo.com
12222,EuroNext,NewsApi.org,https://finance.yahoo.com/news/arcadis-announces-ceo-peter-oosterveer-045500335.html,Arcadis announces CEO Peter Oosterveerâ€™s retirement  and nominates Alan Brookes  currently COO  as his successor,Peter Oosterveer to retire after six years as Chief Executive Officer (CEO) and Chair of the Executive Board  after the Annual General Meeting in May...,Arcadis N.V.Peter Oosterveer to retire after six years as Chief Executive Officer (CEO) and Chair of the Executive Board  after the Annual General Meeting in May 2023Alan Brookes  currently Global Chief Operating Officer (COO)  nominated as new CEOAmsterdam  27 Oct. 2022 â€“ Arcadis (EURONEXT: ARCAD)  the leading global Design and Consultancy organization for natural and built assets  today announced Peter Oosterveerâ€™s decision to retire as Chief Executive Officer (CEO) after the Annual General Meeting (AGM) in May 2023  and nominating Alan Brookes (COO) as new CEO.The Supervisory Board has unanimously decided to nominate Alan Brookes  currently COO at Arcadis  as the next CEO and Chair of the Executive Board and will propose his appointment to the shareholders of Arcadis  at the AGM in May 2023.Peter joined Arcadis in 2017 as CEO and Chair of the Executive Board. He successfully led the company in achieving its 2020 strategic targets  strengthening its balance sheet  resolving legacy issues  embedding a people-first culture across the organization and driving improved financial performance. Under the 2023 business strategy â€œMaximizing Impactâ€ he led the company to become an industry leader in providing clients with sustainable solutions  a digital frontrunner. Furthermore  Peter repositioned the company for accelerated growth and scaling  as was demonstrated by the organizational transition into Global Business Areas (GBAs) and the recently announced acquisitions of IBI Group  DPS Group and Giftge Consult. Today  Arcadis is in a strong position for future profitable growth and smooth integration of recent acquisitions.Since Alan joined Arcadis in 2011 through the acquisition of EC Harris  he has established himself as an innovative leader and has been instrumental to the strategic direction and operational successes of the company. He brings significant international senior leadership experience  a strong commercial  and operational background  and extensive understanding of Arcadis. As COO he is leading the four Global Business Areas (Resilience  Mobility  Places and Intelligence)  including the Global Excellence Centers. Prior to his current role Alan headed the EMEA operations  Arcadisâ€™ largest segment at that time. He has been pivotal to the outstanding performance of UK  and the growth and improved focus in Continental Europe.Story continuesOver the next six months  Peter and Alan will collaborate closely to ensure a seamless transition.Michiel Lap  Chair of the Supervisory Board comments: â€œWe owe Peter our gratitude for the way he has transformed Arcadis into a leading integrated global design and consultancy player. Under his leadership  Arcadis has significantly improved its financial and non-financial results. Peter has united the company around a clear strategy of making impact for clients on some of the most important and pressing challenges of our time such as the energy transition and making net zero a reality for our clients. We wish Peter well and thank him for his important contributions to the company.Alan Brookes has significant experience in running international design and consultancy businesses and has been successful in transforming the company from a regional to a global operating structure. Alanâ€™s vision  drive  people and performance focus make him the right person to guide Arcadis through the next chapter of profitable growth and success. We have confidence in a smooth leadership transition  whilst ensuring the successful integration of our recent acquisitions.â€Peter Oosterveer  CEO Arcadis  comments: â€œI congratulate Alan on his nomination and look forward to working with him on the transition. Alan and I have been working closely together for the last 5 years  and he has been instrumental in implementing many of the operational and strategic initiatives which have improved the impact Arcadis has with its clients  as well as in creating strong financial and non-financial results. It has been both an honor and a privilege to lead Arcadis and I owe all Arcadians as well as the Supervisory Board my sincere thanks for the tremendous support I have received throughout my tenure. I am proud of what we have accomplished and leave the company in a very strong position to create further profitable growth. I am very pleased that the Supervisory Board has reacted constructively to my request to retire mid-way through my second term as CEO  which will allow me to enjoy more time with my family and to pursue a broad range of outside interests.â€Alan Brookes  COO Arcadis and CEO nominee  comments: â€œI am honored to be nominated to lead Arcadis at this pivotal moment. We have solid foundations to build on and with the recent acquisitions are well placed to further advance our strategy to deliver the solutions that will genuinely improve the quality of life for the clients and communities we serve. I would also like to thank Peter for his remarkable leadership at Arcadis and look forward to working closely with him during the transition period.â€For further information please contact:Arcadis Investor RelationsChristine DischMobile: +31 (0)6 1537 6020E-mail: christine.disch@arcadis.comArcadis Corporate CommunicationsTanno MassarMobile: +31 (0)6 1158 9121E-mail: tanno.massar@arcadis.comAbout ArcadisArcadis is a leading global Design & Consultancy organization for natural and built assets. Applying our deep market sector insights and collective design  consultancy  engineering  project and management services we work in partnership with our clients to deliver exceptional and sustainable outcomes throughout the lifecycle of their natural and built assets. We are 33 000 people  active in over 70 countries that generate â‚¬3.8 billion in gross revenues (including IBI group  based on 2021 full year pro forma figures). We support UN-Habitat with knowledge and expertise to improve the quality of life in rapidly growing cities around the world. www.arcadis.com.Regulated informationThis press release contains information that qualifies or may qualify as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.Attachment,neutral,0.01,0.99,0.0,mixed,0.87,0.09,0.04,True,English,"['CEO Peter Oosterveer', 'Alan Brookes', 'Arcadis', 'retirement', 'COO', 'successor', 'significant international senior leadership experience', 'four Global Business Areas', 'leading integrated global design', 'Global Chief Operating Officer', 'leading global Design', 'global operating structure', 'Global Excellence Centers', 'Chief Executive Officer', 'Annual General Meeting', 'next six months', 'The Supervisory Board', 'smooth leadership transition', 'Arcadis N.V.', 'future profitable growth', 'significant experience', 'international design', 'remarkable leadership', '2023 business strategy', 'Executive Board', 'six years', 'smooth integration', 'next chapter', 'built assets', '2020 strategic targets', 'balance sheet', 'legacy issues', 'people-first culture', 'industry leader', 'digital frontrunner', 'organizational transition', 'IBI Group', 'DPS Group', 'strong position', 'EC Harris', 'innovative leader', 'strategic direction', 'extensive understanding', 'current role', 'EMEA operations', 'largest segment', 'outstanding performance', 'Continental Europe', 'seamless transition', 'Michiel Lap', 'consultancy player', 'pressing challenges', 'energy transition', 'net zero', 'consultancy businesses', 'right person', 'successful integration', 'last 5 years', 'strategic initiatives', 'non-financial results', 'sincere thanks', 'tremendous support', 'second term', 'broad range', 'outside interests', 'pivotal moment', 'solid foundations', 'transition period', 'next CEO', 'financial performance', 'recent acquisitions', 'strong financial', 'operational successes', 'operational background', 'clear strategy', 'new CEO', 'CEO nominee', 'Consultancy organization', 'sustainable solutions', 'important contributions', 'performance focus', 'Alan Brookes', 'Maximizing Impact', 'Peter Oosterveer', 'CEO Arcadis', 'COO Arcadis', 'Chair', 'May', 'Amsterdam', 'Oct.', 'EURONEXT', 'natural', 'decision', 'AGM', 'appointment', 'shareholders', 'company', 'improved', 'clients', 'scaling', 'GBAs', 'Giftge', 'Resilience', 'Mobility', 'Places', 'Intelligence', 'time', 'UK', 'Story', 'gratitude', 'way', 'reality', 'regional', 'vision', 'drive', 'confidence', 'nomination', 'honor', 'privilege', 'Arcadians', 'tenure', 'request', 'family', 'quality', 'life', 'communities', 'information']",2022-10-27,2022-10-28,finance.yahoo.com
12223,EuroNext,NewsApi.org,https://finance.yahoo.com/news/bghl-euro-nav-share-buy-053000306.html,BGHL Euro NAV & Share buy back,BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for...,"BOUSSARD AND GAVAUDAN HOLDING LIMITED (EUR)BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 26 Oct 2022.Estimated NAVEuro Shares Sterling Shares Estimated NAV â‚¬ 28.2017 Â£ 24.7302 Estimated MTD return -0.18 % -0.06 % Estimated YTD return -3.42 % -2.27 % Estimated ITD return 182.02 % 147.30 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close â‚¬ 22.20 N/A Premium/discount to estimated NAV -21.28 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 2 000.00 Premium/discount to estimated NAV N/A -19.13 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares 1 400 N/A Average Price â‚¬ 22.20 N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 315 188 130 254 Held in treasury 1 400 N/A Shares Issued 12 316 588 130 254Estimated BG Fund NAVClass B Euro Shares (estimated) â‚¬ 246.1882 Class GBP A Shares (estimated) Â£ 131.9167The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.Story continuesFor further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.05,0.95,0.0,mixed,0.12,0.2,0.69,True,English,"['BGHL Euro NAV', 'Share', 'The Class B Euro Shares', 'Euro Shares Sterling Shares Number', 'BGHL Ordinary Shares Euro Shares', 'A Liquidity Enhancement Agreement', 'Class GBP A Shares', 'London Stock Exchange plc', 'Guernsey Financial Services Commission', 'N/A Sterling Shares Amsterdam', 'Dutch Financial Supervision Act', 'A N/A Average Price', 'Euro Shares Amsterdam', 'US Investment Company Act', 'Sterling Shares Shares', 'GAVAUDAN HOLDING LIMITED', 'expert financial advice', 'Guernsey Policy Council', 'collective investment scheme', 'UK Listing Authority', 'other professional advice', 'BG Fund ICAV', 'closed-ended investment company', 'US Securities Act', 'Gavaudan Investment Management', 'investment manager fees', 'BG Fund NAV', '1,400 N/A Shares', 'The Shares', 'Dutch Authority', 'A Premium/discount', 'A Range', 'Euronext Amsterdam', 'US persons', 'Emmanuel Gavaudan', 'Financial Markets', 'The Directors', 'The Company', 'investment performance', 'original investment', 'investment decision', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'main market', 'United States', 'following information', 'information purposes', 'necessary approval', 'future results', 'listed securities', 'Market information', 'LSE) Market', 'BOUSSARD', 'business', 'Oct', 'returns', 'AEX', 'Transactions', 'treasury', 'respect', 'role', 'Story', 'LLP.', 'Email', 'article', 'conjunction', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2022-10-27,2022-10-28,finance.yahoo.com
12224,EuroNext,NewsApi.org,https://www.businesswire.com/news/home/20221027005028/en/Boehringer-Ingelheim-Extends-the-Use-of-Medidata-Rave-for-Electronic-Data-Capture-in-Clinical-Trials,Boehringer Ingelheim Extends the Use of Medidata Rave for Electronic Data Capture in Clinical Trials,NEW YORK--(BUSINESS WIRE)--Medidata and Boehringer Ingelheim today announced a five-year renewal of their collaboration in the wider area of electronic data capture.,NEW YORK--(BUSINESS WIRE)--Medidata  a Dassault SystÃ¨mes company  and Boehringer Ingelheim today announced a five-year renewal of their collaboration in the wider area of electronic data capture. The new agreement extends the use of Rave EDC for Boehringer Ingelheim's clinical trials worldwide and includes myMedidata  Medidataâ€™s suite of innovative patient-facing technologies focused on enhancing patient centricity and diversity in decentralized clinical trials (DCTs).The agreement adds to Boehringer Ingelheimâ€™s focus on engaging patients in a meaningful way by providing Medidataâ€™s scalable patient-centered capabilities. This includes the myMedidata patient portal  a single-destination web-based platform  which provides access to electronic consent  electronic Clinical Outcome Assessment (eCOA)  and myMedidata LIVE video investigator/patient visits.â€œ As industry leaders  Boehringer Ingelheim and Medidata have a responsibility to innovate for the benefit of patients â€ said Anthony Costello  CEO Patient Cloud at Medidata. â€œ Boehringer Ingelheimâ€™s global reach across therapeutic areas is a perfect match for the scalable capabilities of myMedidata and the rest of the Medidata Clinical Cloud platform. Together  we will be able to quickly improve access and diversity of participation in a wide range of clinical programs.â€The Medidata Decentralized Clinical Trials Program â€“ the industryâ€™s only scalable  end-to-end offering â€“ is helping to revolutionize how individuals provide data  how drugs are shipped to patients  and how clinical trial data are managed and monitored. Most importantly  these remote technologies create opportunities to improve patient access  inclusion  and engagement across geographies  and improve patient diversity in clinical trials.Boehringer Ingelheim has built on Medidata technologies  including Rave EDC (electronic data capture)  Coder  TSDV (targeted source data verification)  and Safety Gateway. Boehringer Ingelheim is also exploring Medidata AI Intelligent Trials to provide advanced analytics to improve the speed  success  and quality of clinical trials  and is benefitting from Medidata Rave Imaging technology via services contracted with the companyâ€™s imaging suppliers.Medidata is a wholly owned subsidiary of Dassault SystÃ¨mes  which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform  from research to commercialization.About MedidataMedidata is leading the digital transformation of life sciences  creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical  biotech  medical device and diagnostics companies  and academic researchers accelerate value  minimize risk  and optimize outcomes. More than one million registered users across 2 000+ customers and partners access the world's most trusted platform for clinical development  commercial  and real-world data. Medidata  a Dassault SystÃ¨mes company (Euronext Paris: FR0014003TT8  DSY.PA)  is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @Medidata.About Dassault SystÃ¨mesDassault SystÃ¨mes  the 3DEXPERIENCE Company  is a catalyst for human progress. We provide business and people with collaborative 3D virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications  our customers push the boundaries of innovation  learning and production to achieve a more sustainable world for patients  citizens  and consumers. Dassault SystÃ¨mes brings value to more than 300 000 customers of all sizes  in all industries  in more than 140 countries. For more information  visit www.3ds.com3DEXPERIENCE  the Compass icon  the 3DS logo  CATIA  BIOVIA  GEOVIA  SOLIDWORKS  3DVIA  ENOVIA  NETVIBES  MEDIDATA  CENTRIC PLM  3DEXCITE  SIMULIA  DELMIA  and IFWE are commercial trademarks or registered trademarks of Dassault SystÃ¨mes  a French â€œsociÃ©tÃ© europÃ©enneâ€ (Versailles Commercial Register # B 322 306 440)  or its subsidiaries in the United States and/or other countries.,neutral,0.0,1.0,0.0,positive,0.7,0.3,0.0,True,English,"['Electronic Data Capture', 'Boehringer Ingelheim', 'Medidata Rave', 'Clinical Trials', 'Use', 'French â€œsociÃ©tÃ© europÃ©enne', 'The Medidata Decentralized Clinical Trials Program', 'collaborative 3D virtual environments', 'one million registered users', 'targeted source data verification', 'electronic Clinical Outcome Assessment', 'Medidata AI Intelligent Trials', 'Dassault SystÃ¨mes company', 'Medidata Rave Imaging technology', 'Medidata Clinical Cloud platform', 'virtual twin experiences', 'LIVE video investigator', 'electronic data capture', 'clinical trial data', 'single-destination web-based platform', 'innovative patient-facing technologies', 'scalable patient-centered capabilities', 'Versailles Commercial Register', 'New York City', 'electronic consent', 'Patient Cloud', 'scalable capabilities', 'clinical programs', 'imaging suppliers', 'clinical development', 'registered trademarks', 'Rave EDC', 'real-world data', 'trusted platform', '3DEXPERIENCE Company', 'remote technologies', '3DEXPERIENCE platform', 'Medidata technologies', 'business platform', 'Boehringer Ingelheim', 'five-year renewal', 'wider area', 'patient centricity', 'meaningful way', 'patient portal', 'patient visits', 'Anthony Costello', 'global reach', 'therapeutic areas', 'perfect match', 'wide range', 'end offering', 'Safety Gateway', 'advanced analytics', 'digital transformation', 'life sciences', 'personalized medicine', 'first end', 'end scientific', 'medical device', 'diagnostics companies', 'academic researchers', 'Euronext Paris', 'human progress', 'sustainable innovations', 'Compass icon', '3DS logo', 'CENTRIC PLM', 'commercial trademarks', 'United States', 'new agreement', 'BUSINESS WIRE', 'industry leaders', 'real world', 'sustainable world', 'other countries', 'patient access', 'patient diversity', '2,000+ customers', '140 countries', '300,000 customers', 'collaboration', 'suite', 'DCTs', 'focus', 'patients', 'responsibility', 'benefit', 'CEO', 'rest', 'participation', 'individuals', 'drugs', 'opportunities', 'inclusion', 'engagement', 'geographies', 'Coder', 'TSDV', 'speed', 'success', 'quality', 'services', 'subsidiary', 'commercialization', 'hope', 'millions', 'evidence', 'insights', 'biotech', 'value', 'risk', 'outcomes', 'More', 'partners', 'DSY', 'offices', 'needs', 'catalyst', 'people', 'applications', 'boundaries', 'learning', 'production', 'citizens', 'consumers', 'sizes', 'industries', 'information', 'CATIA', 'BIOVIA', 'GEOVIA', 'SOLIDWORKS', '3DVIA', 'ENOVIA', 'NETVIBES', '3DEXCITE', 'SIMULIA', 'DELMIA', 'IFWE', 'subsidiaries']",2022-10-27,2022-10-28,businesswire.com
12225,EuroNext,NewsApi.org,https://finance.yahoo.com/news/universal-music-group-n-v-154500949.html,Universal Music Group N.V. Reports Financial Results for the Third Quarter and Nine Months Ended September 30  2022,"Universal Music Group N.V. (""UMG"" or ""the Company"") today announced its financial results for the third quarter and nine months ended September 30  2022.","Summary Q3 Results1Revenue of â‚¬2 664 million increased 13.3% year-over-year in constant currency driven by growth across all segments.Recorded Music revenue grew 10.1% year-over-year in constant currency  Music Publishing revenue grew 6.9% year-over-year in constant currency and Merchandising and Other revenue grew 101.1% year-over-year in constant currency.Top sellers for the quarter included BTS  BLACKPINK  Ado  INI and Morgan Wallen.Adjusted EBITDA increased 9.1% year-over-year in constant currency driven by the revenue growth.Summary YTD ResultsRevenue of â‚¬7 398 million increased 15.6% year-over-year in constant currency with strong growth across all segments.Recorded Music revenue grew 10.1% year-over-year in constant currency  Music Publishing revenue grew 28.2% year-over-year in constant currency and Merchandising and Other revenue grew 80.6% year-over-year in constant currency.Adjusted EBITDA increased 10.2% year-over-year in constant currency driven by the revenue growth.HILVERSUM  Netherlands  Oct. 27  2022 /PRNewswire/ -- Universal Music Group N.V. (""UMG"" or ""the Company"") today announced its financial results for the third quarter and nine months ended September 30  2022.(PRNewsfoto/Universal Music Group)""More than ever  we are delivering a diverse and growing range of business and creative opportunities to our recording artists and songwriters "" said Sir Lucian Grainge  UMG's Chairman and CEO. ""Through our innovation  global reach  and unique understanding of the evolution of the market  we are continually improving the monetization of music and music-related content  generating high-quality revenue and recurring income from more sources than ever before.""Boyd Muir  UMG's EVP  CFO and President of Operations  said  ""Our vision of success is about maximizing the long-term value of the business. That requires not only growing revenues but also growing a broad diversity of revenue streams that help drive greater absolute EBITDA and greater value for shareholders.""Story continues1 This press release includes certain alternative performance indicators which are not defined in the International Financial Reporting Standards (""IFRS"") issued by the International Accounting Standards Board as endorsed by the EU. The descriptions of these alternative performance indicators and reconciliations of non-IFRS to IFRS measures are included in the Appendix to this press release.UMG ResultsThree Months EndedSeptember 30 %%Nine Months EndedSeptember 30 %%20222021YoYconst.20222021YoYconst. (â‚¬ millions) (unaudited) (unaudited)(unaudited)(unaudited)Revenue â‚¬ 2 664â‚¬ 2 15323.7 %13.3 %â‚¬ 7 398â‚¬ 5 98423.6 %15.6 % EBITDA â‚¬ 539â‚¬ 42626.5 %15.4 %â‚¬ 1 499â‚¬ 1 24820.1 %12.6 % EBITDA margin 20.2 %19.8 %0.4pp20.3 %20.9 %(0.6pp)Adjusted EBITDA â‚¬ 553â‚¬ 46120.0 %9.1 %â‚¬ 1 515â‚¬ 1 28617.8 %10.2 % Adjusted EBITDA margin 20.8 %21.4 %(0.6pp)20.5 %21.5 %(1.0pp)Note: % YoY indicates % change year-over-year; % const. indicates % change year-over-year adjusted for constant currency. Constant currency change is calculated by taking current year results and comparing against prior year results restated at current year rates.Q3 2022 ResultsRevenue for the third quarter of 2022 was â‚¬2 664 million  an increase of 23.7% year-over-year  or 13.3% in constant currency. Revenue includes a â‚¬71 million benefit in Recorded Music from the settlement of a copyright infringement lawsuit with an internet service provider (the ""Legal Settlement"")  as well as a â‚¬21 million negative impact in Music Publishing from a previously announced change in accounting policy.As disclosed in the UMG Annual Consolidated Financial Statements for the year ended December 31  2021  UMG adjusted its accounting policy in relation to certain revenues that are collected through societies (the ""Change in Society Accounting""). In prior years  these revenues were recognized when the relevant collection society notified UMG of the usage by the end customer and collectability was assured. Recognition of that revenue is now based on an accrual for the best available estimate of when the usage occurs and the amount of consideration which is probable to be collected. This has affected the timing of the recognition of certain revenues across financial reporting quarters.UMG's Recorded Music  Music Publishing and Merchandising and Other segments all contributed to the revenue growth in the quarter  as discussed further below.EBITDA for the quarter grew 26.5% year-over-year  or 15.4% in constant currency  to â‚¬539 million  driven by the revenue growth and the Legal Settlement. EBITDA margin was 20.2%  compared to 19.8% in the third quarter of 2021. EBITDA and EBITDA margin were impacted by share-based compensation of â‚¬14 million during the third quarter of 2022  and by â‚¬20 million of share-based compensation as well as â‚¬15 million of expenses related to UMG's listing on Euronext Amsterdam during the third quarter of 2021. Excluding these items  Adjusted EBITDA for the quarter was â‚¬553 million  up 20.0% year-over-year  or 9.1% in constant currency  driven by the revenue growth and the Legal Settlement. Adjusted EBITDA margin was 20.8%  compared to 21.4% in the third quarter of 2021.EBITDA and Adjusted EBITDA in the third quarter of 2022 included a â‚¬52 million benefit from the Legal Settlement  partially offset by the negative â‚¬7 million impact from the Change in Society Accounting.EBITDA and Adjusted EBITDA were also impacted by the timing of certain A&R expenses  which increased in the quarter but remain down year-to-date  and by revenue mix  as revenues were more heavily weighted towards Merchandising and Other revenues  which carry a significantly lower EBITDA margin than the Company's other revenues. Excluding these items  Adjusted EBITDA margin was flat versus the prior-year quarter.YTD 2022 ResultsIn the nine months ended September 30  2022  UMG's revenues of â‚¬7 398 million increased by 23.6%  or 15.6% in constant currency  compared to the nine months ended September 30  2021. This increase was driven by double-digit improvements across all segments  as discussed further below.Revenue for the nine months ended September 30  2022 includes a â‚¬123 million benefit from the Change in Society Accounting  and a â‚¬71 million benefit from the Legal Settlement  both discussed above. Revenue for the nine months ended September 30  2021 included a â‚¬41 million benefit from a catch up payment from a digital service provider ""DSP Catch-Up Payment""  previously disclosed and booked in Q2 2021. Excluding these items  revenue increased 21.2% year-over-year  or 13.3% in constant currency.For the nine months ended September 30  2022  EBITDA of â‚¬1 499 million grew 20.1% year-over-year  or 12.6% in constant currency  and EBITDA margin was 20.3% compared to 20.9% in the prior year period. EBITDA and EBITDA margin were impacted by share-based compensation of â‚¬16 million during the nine months through Q3 2022  and by â‚¬20 million of share-based compensation as well as â‚¬18 million of expenses related to UMG's listing on Euronext Amsterdam during the nine months through Q3 2021. Excluding these amounts  Adjusted EBITDA for the nine months through Q3 2022 was â‚¬1 515 million  up 17.8% compared to the comparable period in 2021  or up 10.2% in constant currency  driven by the revenue growth. Adjusted EBITDA margin contracted 1.0pp year-over-year to 20.5%.EBITDA and Adjusted EBITDA for the nine months through Q3 2022 benefitted from the Change in Society Accounting (â‚¬27 million) and the Legal Settlement (â‚¬52 million). EBITDA and Adjusted EBITDA for the nine months ended Q3 2021 benefitted from the DSP Catch-Up Payment (â‚¬26 million)  as well as from a previously disclosed recovery of an advance provision and release of historic royalties (the ""Exceptional Recovery and Release""  â‚¬20 million) in the first quarter of 2021. Excluding these items  Adjusted EBITDA grew 15.8% year-over-year  or 8.0% in constant currency  and Adjusted EBITDA margin was 19.9%  compared to 20.9% for the nine months ended Q3 2021. The contraction in Adjusted EBITDA margin was driven by revenue mix  as revenues were more heavily weighted towards lower-margin Merchandising revenues in the first nine months of 2022.Recorded MusicThree Months EndedSeptember 30 %%Nine Months EndedSeptember 30 %%20222021YoYconst.20222021YoYconst. (â‚¬ millions) (unaudited) (unaudited)(unaudited)(unaudited)Subscription and Streaming Revenue â‚¬ 1 353â‚¬ 1 13119.6 %7.7 %â‚¬ 3 876â‚¬ 3 26218.8 %10.3 % of which streaming â‚¬ 362â‚¬ 30618.3 %5.2 %â‚¬ 1 020â‚¬ 83322.4 %12.6 % of which subscription â‚¬ 991â‚¬ 82520.1 %8.7 %â‚¬ 2 856â‚¬ 2 42917.6 %9.5 % Downloads and Other Digital Revenue â‚¬ 137â‚¬ 8267.1 %55.7 %â‚¬ 275â‚¬ 23517.0 %9.1 % Physical Revenue â‚¬ 264â‚¬ 280(5.7 %)(9.6 %)â‚¬ 803â‚¬ 7428.2 %4.6 % License and Other Revenue â‚¬ 306â‚¬ 21840.4 %30.2 %â‚¬ 749â‚¬ 60923.0 %16.3 % Recorded Music Revenue â‚¬ 2 060â‚¬ 1 71120.4 %10.1 %â‚¬ 5 703â‚¬ 4 84817.6 %10.1 %Note: % YoY indicates % change year-over-year; % const. indicates % change year-over-year adjusted for constant currency.Q3 2022 ResultsRecorded Music revenues for the third quarter of 2022 were â‚¬2 060 million  up 20.4% compared to the third quarter of 2021  or 10.1% in constant currency. Subscription and streaming revenue grew 19.6% year-over-year  or 7.7% in constant currency  with subscription revenue up 20.1% year-over-year  or 8.7% in constant currency  driven by the continued healthy growth in music subscribers. Ad-supported streaming revenue grew 18.3% year-over-year  or 5.2% in constant currency  reflecting ongoing improvement in ad-based monetization  despite industry-wide ad-market pressure as a result of the uncertain macro-economic environment. Physical revenue declined 5.7% year-over-year  or 9.6% in constant currency  driven by the industry transition to digital consumption and a difficult comparison against strong physical sellers in the prior-year quarter. Downloads and other digital revenue were up 67.1% year-over-year  or 55.7% in constant currency due to the Legal Settlement. License and other revenue improved 40.4% year-over-year  or 30.2% in constant currency  driven by the strong recovery in live touring  where the Company participates in certain markets. Top sellers for the quarter included BTS  BLACKPINK  Ado  INI and Morgan Wallen  while top sellers in the prior-year quarter included Olivia Rodrigo  BTS  Billie Eilish  Drake and King & Prince.YTD 2022 ResultsIn the nine months through Q3 2022  Recorded Music revenues were â‚¬5 703 million  up 17.6% year-over-year  or 10.1% in constant currency. Subscription revenue of â‚¬2 856 million grew 17.6% year-over-year  or 9.5% in constant currency. Subscription revenue in the first nine months of 2021 benefited from the DSP Catch-Up Payment. Excluding this item  subscription revenue grew 19.6% year-over-year  or 11.3% in constant currency. Ad-supported streaming revenue of â‚¬1 020 million grew 22.4% year-over-year  or 12.6% in constant currency.Physical revenue grew 8.2% year-over-year  or 4.6% in constant currency  driven by strong vinyl demand as well as continued CD sales  particularly from BTS and King & Prince. Downloads and other digital revenue increased 17.0% year-over-year  or 9.1% in constant currency  due to the Legal Settlement. License and other revenue improved 23.0% year-over-year  or 16.3% in constant currency as a result of improvements in synchronisation  live and brand deals. Top sellers included BTS  the Encanto soundtrack  Olivia Rodrigo  Morgan Wallen and The Weeknd while top sellers in the prior year included Olivia Rodrigo  BTS  Justin Bieber  The Weeknd and Morgan Wallen.Music PublishingThree Months EndedSeptember 30 %%Nine Months EndedSeptember 30 %%20222021YoYconst.20222021YoYconst. (â‚¬ millions) (unaudited) (unaudited)(unaudited)(unaudited)Performance â‚¬ 92â‚¬ 911.1 %(4.2 %)â‚¬ 219â‚¬ 221(0.9 %)(6.4 %) Synchronisation â‚¬ 57â‚¬ 4818.8 %7.5 %â‚¬ 177â‚¬ 13927.3 %18.0 % Digital â‚¬ 234â‚¬ 18427.2 %17.0 %â‚¬ 771â‚¬ 46665.5 %53.9 % Mechanical â‚¬ 25â‚¬ 31(19.4 %)(21.9 %)â‚¬ 71â‚¬ 701.4 %(1.4 %) Other â‚¬ 10â‚¬ 911.1 %0.0 %â‚¬ 31â‚¬ 310.0 %(6.1 %) Music Publishing Revenue â‚¬ 418â‚¬ 36315.2 %6.9 %â‚¬ 1 269â‚¬ 92736.9 %28.2 %Note: % YoY indicates % change year-over-year; % const. indicates % change year-over-year adjusted for constant currency.Q3 2022 ResultsMusic Publishing revenue amounted to â‚¬418 million in the third quarter of 2022  up 15.2% year-over-year  or 6.9% in constant currency  despite a â‚¬21 million negative impact in the quarter from the Change in Society Accounting discussed above. Excluding the Change in Society Accounting  Music Publishing revenue was up 20.9% year-over-year  or 12.3% in constant currency.Within Music Publishing  digital revenue grew 27.2% year-over-year  or 17.0% in constant currency  reflecting the continued growth of streaming and subscription  partially offset by the Change in Society Accounting. Performance revenue grew 1.1% year-over-year  but fell 4.2% in constant currency  reflecting the Change in Society Accounting. Synchronisation revenue improved 18.8% year-over-year  or 7.5% in constant currency  as a result of increased income from advertising and film. Mechanical revenue fell 19.4% year-over-year  or 21.9% in constant currency  driven by a decline in industry-wide physical sales  as well as the Change in Society Accounting.YTD 2022 ResultsMusic Publishing revenue amounted to â‚¬1 269 million  up 36.9% year-over-year  or 28.2% in constant currency and included a â‚¬123 million benefit from the Change in Society Accounting discussed above. Excluding the Change in Society Accounting  Music Publishing revenue grew 23.6% year-over-year  or 15.8% in constant currency  as a result of organic growth trends and initial contributions from catalogue acquisitions made in prior years.Within Music Publishing  digital revenue grew 65.5% year-over-year  or 53.9% in constant currency  reflecting the Change in Society Accounting  as well as continued healthy growth in streaming and subscription. Synchronisation revenue grew 27.3% year-over-year  or 18.0% in constant currency  as a result of increased income from advertising  TV and film. Performance revenue declined 0.9% year-over-year  or 6.4% in constant currency  reflecting the Change in Society Accounting. Mechanical revenue grew 1.4% year-over-year  but fell 1.4% in constant currency.Merchandising and OtherThree Months EndedSeptember 30 %%Nine Months EndedSeptember 30 %%20222021YoYconst.20222021YoYconst. (â‚¬ millions) (unaudited) (unaudited)(unaudited)(unaudited)Merchandising and Other Revenue â‚¬ 189â‚¬ 84125.0 %101.1 %â‚¬ 437â‚¬ 22296.8 %80.6 %Note: % YoY indicates % change year-over-year; % const. indicates % change year-over-year adjusted for constant currency.Q3 2022 ResultsMerchandising and Other revenue of â‚¬189 million was up 125.0% year-over-year  or 101.1% in constant currency  as touring-related merchandising revenue rebounded following a COVID related slow-down in live touring in the prior year period.YTD 2022 ResultsMerchandising and Other revenue of â‚¬437 million was up 96.8% year-over-year  or 80.6% in constant currency  as touring-related merchandising revenue rebounded following a COVID related slow-down in live touring in the prior year period.Conference Call DetailsThe Company will host a conference call to discuss these results on October 27  2022 at 6:15PM CET. A link to the live audio webcast will be available on investors.universalmusic.com and a link to the replay will be available after the call.While listeners may use the webcast  a dial-in telephone number is required for investors and analysts to ask questions. Investors and analysts interested in asking questions can pre-register for a dial-in line at investors.universalmusic.com under the ""Financial Reports"" tab.Cautionary NoticeThis press release is published by Universal Music Group N.V. and contains inside information within the meaning of article 7(1) of Regulation (EU) No. 596/2014 (Market Abuse Regulation).Forward-looking statementsThis press release may contain statements that constitute forward-looking statements with respect to UMG's financial condition  results of operations  business  strategy and plans. Such forward-looking statements may be identified by the use of words such as 'profit forecast'  'expect'  'estimate'  'project'  'anticipate'  'should'  'intend'  'plan'  'probability'  'risk'  'target'  'goal'  'objective'  'will'  'endeavour'  'optimistic'  'prospects' and similar expressions or variations on such expressions. Although UMG believes that such forward-looking statements are based on reasonable assumptions  they are not guarantees of future performance. Actual results may differ materially from such forward-looking statements as a result of a number of risks and uncertainties  many of which are related to factors that are outside UMG's control  including  but not limited to  UMG's inability to compete successfully and to identify  attract  sign and retain successful recording artists and songwriters  failure of streaming and subscription adoption or revenue to grow or to grow less rapidly than anticipated  UMG's reliance on digital service providers  UMG's inability to execute its business strategy  the global nature of UMG's operations  UMG's inability to protect its intellectual property and against piracy  UMG's inability to attract and retain key personnel  changes in laws and regulations and the other risks that have been described in UMG's 2021 annual report. Accordingly  UMG cautions readers against placing undue reliance on such forward-looking statements. Such forward-looking statements are made as of the date of this press release. UMG disclaims any intention or obligation to provide  update or revise any such forward-looking statements  whether as a result of new information  future events or otherwise.Alternative Performance IndicatorsThis press release includes certain alternative performance indicators which are not defined in IFRS issued by the International Accounting Standards Board as endorsed by the EU. The descriptions of these alternative performance indicators and reconciliations of non-IFRS to IFRS measures are included in the Appendix to this press release.About Universal Music GroupAt Universal Music Group (EURONEXT: UMG)  we exist to shape culture through the power of artistry. UMG is the world leader in music-based entertainment  with a broad array of businesses engaged in recorded music  music publishing  merchandising and audiovisual content. Featuring the most comprehensive catalogue of recordings and songs across every musical genre  UMG identifies and develops artists and produces and distributes the most critically acclaimed and commercially successful music in the world. Committed to artistry  innovation and entrepreneurship  UMG fosters the development of services  platforms and business models in order to broaden artistic and commercial opportunities for our artists and create new experiences for fans. For more information on Universal Music Group N.V. visit www.universalmusic.comContactsMediaJames Murtagh-Hopkins - communicationsnl@umusic.comInvestorsErika Begun - investorrelations@umusic.comAppendixReconciliation of Adjusted EBITDAThree Months EndedSeptember 30 %Nine Months EndedSeptember 30 %20222021YoY20222021YoY (â‚¬ millions) (unaudited) (unaudited)(unaudited)(unaudited)EBITDA 53942626.5 %1 4991 24820.1 %Non-cash share-based compensation expense 14201620One time direct-listing related expenses -15-18Adjusted EBITDA 55346120.0 %1 5151 28617.8 %DEFINITIONSIn this press release  UMG presents certain financial measures when discussing UMG's performance that are not measures of financial performance or liquidity under IFRS (""non-IFRS""). These non-IFRS measures (also known as alternative performance measures or indicators) are presented because management considers them important supplemental measures of UMG's performance and believes that they are widely used in the industry in which UMG operates as a means of evaluating a company's operating performance and liquidity. UMG believes that an understanding of its sales performance  profitability  financial strength and funding requirements is enhanced by reporting the following non-IFRS measures. All non-IFRS measures should be considered in addition to  and not as a substitute for  other IFRS measures of operating and financial performance as described in this press release. In addition  it should be noted that other companies may have definitions and calculations for these non-IFRS measures that differ from those used by UMG  thereby affecting comparability.EBITDA and EBITDA marginUMG considers EBITDA and EBITDA margin  non-IFRS measures  to be relevant measures to assess the performance of its operating segments as reported in the segment data. It enables UMG to compare the operating performance of operating segments regardless of whether their performance is driven by the operating segment's organic growth or by acquisitions. EBITDA margin is EBITDA divided by revenue. To calculate EBITDA  the accounting impact of the following items is excluded from the income from Operating Profit:Adjusted EBITDA and Adjusted EBITDA marginThe difference between EBITDA and Adjusted EBITDA consists of share-based compensation expenses and certain one-time items that are deemed by management to be significant and incidental to normal business activity  including but not limited to professional fees and listing fees related to UMG's listing on Euronext Amsterdam. Adjusted EBITDA margin is Adjusted EBITDA divided by revenue. UMG considers Adjusted EBITDA and Adjusted EBITDA margin  non-IFRS measures  to be relevant measures to assess performance of its operating activities excluding items that may be incidental to normal business activity.CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/universal-music-group-nv-reports-financial-results-for-the-third-quarter-and-nine-months-ended-september-30-2022-301661116.htmlSOURCE Universal Music Group N.V.",neutral,0.0,1.0,0.0,mixed,0.25,0.28,0.47,True,English,"['Universal Music Group N.V.', 'Financial Results', 'Third Quarter', 'Nine Months', 'Universal Music Group N.V.', 'UMG Annual Consolidated Financial Statements', 'International Financial Reporting Standards', 'International Accounting Standards Board', 'financial reporting quarters', 'Sir Lucian Grainge', 'alternative performance indicators', 'copyright infringement lawsuit', 'internet service provider', 'best available estimate', 'Summary Q3 Results1', 'Summary YTD Results', 'â‚¬21 million negative impact', 'relevant collection society', 'current year rates', 'greater absolute EBITDA', 'current year results', 'Music Publishing revenue', 'prior year results', 'financial results', 'Constant currency change', 'Q3 2022 Results', 'Society Accounting', 'greater value', 'â‚¬71 million benefit', 'accounting policy', 'prior years', 'Recorded Music', 'Music revenue', 'UMG Results', 'Top sellers', 'Morgan Wallen', 'nine months', 'creative opportunities', 'recording artists', 'global reach', 'unique understanding', 'music-related content', 'recurring income', 'Boyd Muir', 'long-term value', 'broad diversity', 'press release', 'Three Months', 'end customer', 'share-based compensation', 'strong growth', 'Other revenue', 'high-quality revenue', 'revenue streams', 'Legal Settlement', 'revenue growth', 'third quarter', '12.6 % EBITDA margin', 'growing range', 'IFRS measures', 'Other segments', '15.6 % EBITDA', 'Merchandising', 'BTS', 'BLACKPINK', 'Ado', 'INI', 'HILVERSUM', 'Netherlands', 'PRNewswire', 'Company', 'PRNewsfoto', 'diverse', 'business', 'songwriters', 'Chairman', 'CEO', 'innovation', 'evolution', 'market', 'monetization', 'sources', 'EVP', 'CFO', 'President', 'Operations', 'vision', 'success', 'revenues', 'shareholders', 'Story', 'EU', 'descriptions', 'reconciliations', 'Appendix', 'YoY', '4pp', 'Note', 'increase', 'relation', 'societies', 'usage', 'collectability', 'Recognition', 'accrual', 'amount', 'consideration', 'timing', 'expenses', '23.7', '23.6']",2022-10-27,2022-10-28,finance.yahoo.com
12226,EuroNext,NewsApi.org,https://finance.yahoo.com/news/aegon-combine-dutch-operations-r-050000871.html,Aegon to combine its Dutch operations with a.s.r.,The Hague  October 27  2022 - Agreement marks pivotal step towards Aegonâ€™s ambition to build leaders in chosen markets Combination creates a leader in the...,Aegon N.V.The Hague  October 27  2022 - Agreement marks pivotal step towards Aegonâ€™s ambition to build leaders in chosen marketsCombination creates a leader in the Dutch pension  life  and non-life insurance marketsClear and compelling strategic and financial rationale  with significant synergies and long-term benefits for customers  business partners  employees  and shareholdersAegon to receive a 29.99% strategic shareholding0F 1 ) in a.s.r. with associated governance rights and EUR 2.5 billion in cash proceedsTransaction enables Aegon to accelerate its strategy of releasing capital from mature businesses and to become a leader in markets where Aegon is well positioned for growthIntention to use cash proceeds to return EUR 1.5 billion capital to shareholders and reduce leverage by up to EUR 700 million consistent with disciplined capital management approachProgress on its transformation allows Aegon to increase its 2023 dividend per share target from around EUR 0.25 to around EUR 0.30Aegon announces today it has reached an agreement with a.s.r. to combine its Dutch pension  life and non-life insurance  banking  and mortgage origination activities with a.s.r. The combination will create a leading Dutch insurance company. This step enables Aegon to accelerate its strategy and represents a major step in its ambition to become a leader in its chosen markets. Aegon will receive EUR 2.5 billion in gross cash proceeds  and a 29.99% strategic stake in a.s.r.  with associated governance rights. Aegonâ€™s Dutch asset management activities will remain part of Aegonâ€™s global asset manager. Aegon will enter into a long-term asset management agreement with a.s.r. to manage parts of the combinationâ€™s general account investments  the investments of the Premium Pension Institution (PPI) offering of Aegon Cappital  and a.s.r.â€™s mortgage funds.â€œTodayâ€™s announcement marks a major milestone in the history of our company and in our long-term ambition to create leaders in our chosen marketsâ€  said Lard Friese  CEO of Aegon. â€œBoth Aegon and a.s.r. are deeply rooted in Dutch society and share a long and rich history. Thanks to the hard work and dedication of our employees  Aegon the Netherlands has been able to improve its performance in recent years. Weâ€™re now building on that success by creating a Dutch insurance leader. Iâ€™m convinced that the combination of our companies is in the best long-term interest of all stakeholders and Dutch society at large. Customers of both companies will benefit from a more diversified product offering and strong distribution.Story continuesâ€œThis transaction provides a unique opportunity to accelerate both the return of capital to shareholders and our strategy of investing in markets where we are well positioned for growth. Our priority continues to be to further improve our operational performance and grow profitably. The increased focus and resources resulting from this transaction  will place us in a better position for the future growth of the company.â€Jos Baeten  CEO of a.s.r. said: â€œI am pleased to announce today that a.s.r. and Aegon the Netherlands  two renowned Dutch companies  deeply rooted in Dutch society  will create a leader in Dutch insurance. Together we will form a sustainable  leading insurer and strengthen our market position as the number two insurer in the market. Given the joined strength of both companies  the company will provide a good home for all Aegon the Netherlands employees  customers  and relations. As employees of a.s.r.  we will work with the new colleagues on the future of this combination. The starting point will be  one company  one culture  by leveraging the best of both organizations. We look forward to welcoming all employees  customers  and relations of Aegon the Netherlands in the near future.â€1 Value of 29.99% stake is EUR 2.4 billion based on the closing price of a.s.r.â€™s shares on October 26  2022 and 57 million shares to be received by Aegon upon closing of the transaction before any potential equity offering by a.s.r. as part of the funding of the transaction.Compelling strategic rationaleCombining the two companies will result in a strong well-diversified Dutch insurance company that will be able to deliver a broad range of attractive products and services and generate attractive shareholder returns.The combined group will:have a leading position in the Dutch pension market. This will lead to more attractive value propositions to customers as the company is well placed to capture opportunities from the upcoming pension reform;become the market leader in disability insurance and the number three player in property and casualty insurance  facilitating a more competitive product offering;have enhanced scale in the origination and servicing of Dutch mortgages  creating the opportunity for more streamlined and improved operations;have stronger distribution activities by combining Aegonâ€™s and a.s.r.â€™s expertise  resources  and platforms in this area; anddeliver significant synergies through the integration of the closed individual life portfolios of the two companies into one platform.The combination will be well positioned to further extend its role in the Dutch insurance market in the field of sustainability and ESG and contribute to finding solutions to the main challenges society faces that have a clear relationship with the core activities of the new combination.Combining the two companies is expected to lead to substantial cost synergies and diversification benefits. Aegon will benefit from a.s.r.â€™s improved operating capital generation and capital synergies through its 29.99% stake in the company. Aegon will bring to a.s.r. significant risk management capabilities and accelerate the implementation of a Partial Internal Model for the calculation of the Solvency II required capital of the combination.Leveraging Aegon Asset Managementâ€™s capabilitiesAegon has agreed an exclusive long-term partnership with a.s.r. to manage the illiquid investments that are part of the general account of the combined businesses. In addition  it will continue to be the asset manager for the investments of Aegon Cappitalâ€™s PPI proposition and will take over the management of a.s.r.â€™s mortgage funds. Through these steps  Aegon Asset Management will further strengthen its position as a provider in the Dutch market of fiduciary services  retirement multi-assets & solutions  fixed income  including alternative fixed income investments and responsible investing.Governance of combinationAegon N.V. will be a 29.99% strategic  supportive shareholder in a.s.r.  allowing Aegon to participate in the financial benefits that the combination will bring. Furthermore  Aegon will have the right to nominate two candidates for the a.s.r. Supervisory Board. Lard Friese  CEO of Aegon N.V will be nominated as a non-independent member  and Danielle Jansen Heijtmajer  Chair of the Supervisory Board of Aegon the Netherlands  will be nominated as an independent member of the Supervisory Board of a.s.r.. The non-independent member has an affirmative vote within a.s.r.â€™s Supervisory Board on certain topics  in line with the size of Aegonâ€™s shareholding.Integration and organization of companiesThe activities of a.s.r. and Aegon the Netherlands will be integrated after closing of the transaction to maximize the potential of the two businesses and fully benefit from their combined reach  scale  and resources. The integration is expected to impact employees in both companies. The integration will be largely completed within three years  and the intention is to minimize the number of redundancies through natural attrition and by helping people to the greatest extent possible to find jobs either inside or outside of the combination. The process will be executed in a fair  diligent  and open way  respecting the talents and strengths of people in both organizations. Employees of the combination will benefit from the sharing of best practices and greater long-term career opportunities within a larger  more diversified Dutch company.The a.s.r. brand will be the leading brand of the combination. The Aegon brand will remain in use in the pension and mortgage markets for three years after closing of the transaction. There will be no change for the brands of Aegonâ€™s other entities  including TKP  Knab  Robidus and Nedasco.Accelerating transformationThe transaction represents a major step in the transformation of Aegon  building on the successful execution of the strategy outlined at the Capital Markets Day of December 2020 to create leaders in chosen markets. The transaction forms a leader in the Dutch insurance market and enables Aegon to increase its focus on creating advantaged businesses in chosen markets outside the Netherlands.In the US  Aegon will build upon Transamericaâ€™s leading positions in both individual life insurance solutions and the workplace pension business  investing capital to profitably grow its market share in selected product lines. Additionally  Transamerica will continue to take management actions designed to further improve the risk-return profile of the business. In the UK  Aegonâ€™s ambition is to continue to profitably grow both the Retail and Workplace channels of its leading platform business by improving its customer propositions  service capabilities and digital experience for advisors  employers  and customers. The transaction allows Aegon Asset Management to strengthen its position in retirement-related investment solutions  alternative fixed income investments and responsible investing  and to build leadership in these areas. In its growth markets  Aegon will continue to look to invest capital in value-added growth opportunities. More details will be shared on the plans to profitably grow the strategic businesses in Aegonâ€™s core markets  its growth markets  and its global asset manager at a Capital Markets Day in the second quarter of 2023.Use of proceeds and financial implicationsAegon anticipates that it will return EUR 1.5 billion of the cash proceeds to shareholders  barring unforeseen circumstances  to offset the dilutive effect of the transaction on free cash flow per share. Furthermore  the company intends to reduce its gross financial leverage by up to EUR 700 million.A priority for Aegon moving forward is to drive sustainable  profitable growth for Transamerica and to execute upon additional in-force management actions designed to improve the risk-return profile of the business. It is anticipated that this will require funding and therefore Aegon expects to maintain its Cash Capital at the Holding above the middle of the operating range of EUR 0.5 billion to EUR 1.5 billion in the near term. Surplus Cash Capital at the Holding above the operating range will be subject to continued disciplined capital management  whereby capital that is not used for value-added growth opportunities will be returned to shareholders over time.Update on financial targets; increase in dividend per shareOn completion of the transaction  Aegon will replace its full ownership of the cash flow and profits of its Dutch businesses with its 29.99% strategic stake in a.s.r.. In the near term  this is expected to translate into lower free cash flow  improving over time as synergies emerge from the combination. On completion of the capital return to shareholders and realization of the synergies  Aegon anticipates that its free cash flow on a per share basis will be higher than pre-transaction levels.The progress that Aegon has made on its transformation allows the company to increase its pay-out ratio and rebase the targeted dividend per share over 2023 from the current level of around 25 eurocents to around 30 eurocents.All other financial targets will be updated in due course.The transaction is expected to reduce IFRS shareholdersâ€™ equity by EUR 3.3 billion based on the balance sheet position on June 30  2022. This includes the impact from the settlement of a tax position at closing of the transaction  which is not anticipated to have a material impact on Aegonâ€™s Cash Capital at the Holding.Group supervision implicationsAegon will engage with its college of supervisors on the implications for group supervision upon closing of the intended transaction. Regardless of the outcome  Aegon intends to maintain its head office in the Netherlands. Its shares will remain listed on Euronext in Amsterdam and the New York Stock Exchange.Indicative timelinesThe closing of the transaction is subject to customary conditions  including regulatory and antitrust approvals  shareholder approvals  and the completion of the works council consultation processes of both Aegon and a.s.r..Aegon will convene an Extraordinary General Meeting of Shareholders (EGM) and request approval for the proposed combination between Aegon the Netherlands and a.s.r.. The EGM is expected to be held on January 18  2023. The Board of the Association Aegon has been informed of Aegonâ€™s ambition to accelerate its strategy and the proposed combination with a.s.r.. The Board is supportive and will seek the approval from its members for its support.Based on the required steps  and necessary approvals  the transaction is expected to close in the second half of 2023.About AegonAegon is an integrated  diversified  international financial services group. The company offers investment  protection  and retirement solutions  with a strategic focus on three core markets (the United States  the United Kingdom  and the Netherlands)  three growth markets (Spain & Portugal  Brazil  and China)  and one global asset manager. Aegon's purpose of Helping people live their best lives runs through all its activities. As a leading global investor and employer  the company seeks to have a positive impact by addressing critical environmental and societal issues  with a focus on climate change and inclusion & diversity. Aegon is headquartered in The Hague  the Netherlands  and listed on Euronext Amsterdam and the New York Stock Exchange. More information can be found at aegon.com.About a.s.r.a.s.r. Nederland N.V. ranks among the top 3 insurers in the Netherlands. a.s.r. offers products and services in the fields of insurance  pensions and mortgages for consumers  self-employed persons  and employers. In addition  a.s.r. is active as an asset manager for third parties. a.s.r. is listed on Euronext Amsterdam and included in the AMX Index. For further information please visit www.asrnl.com.Additional informationConference call analysts and investorsToday  at 10:00 a.m. CET  Aegonâ€™s management will host a conference call for analysts and investors. The conference call and Q&A can be followed via a live audio webcast on aegon.com. A replay will be available as soon as possible after the conference call on aegon.com.To join the conference call  you will need to register via the following registration link. Directly after registration you will receive an email with the call details and a personal pin to enter the conference call.Call detailsNL: + 31 20 795 2755UK: + 44 20 8610 3526US: + 1 646 307 1951Passcode: you will receive a personal pin upon registrationJoint digital press conferenceToday at 08:00 hrs. CET  Lard Friese  CEO of Aegon N.V.  and Jos Baeten  CEO van a.s.r. will host a joint digital press conference. Please  follow this link to join the press conference.Contacts Media relations Investor relations Carolien van der Giessen Jan Willem Weidema+31 (0)6 11 95 33 67 +31(0) 70 344 8028 carolien.vandergiessen@aegon.com janwillem.weidema@aegon.comForward-looking statementsThe statements contained in this document that are not historical facts are forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. The following are words that identify such forward-looking statements: aim  believe  estimate  target  intend  may  expect  anticipate  predict  project  counting on  plan  continue  want  forecast  goal  should  would  could  is confident  will  and similar expressions as they relate to Aegon. These statements may contain information about financial prospects  economic conditions and trends and involve risks and uncertainties. In addition  any statements that refer to sustainability  environmental and social targets  commitments  goals  efforts and expectations and other events or circumstances that are partially dependent on future events are forward-looking statements. These statements are not guarantees of future performance and involve risks  uncertainties and assumptions that are difficult to predict. Aegon undertakes no obligation  and expressly disclaims any duty  to publicly update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements  which merely reflect company expectations at the time of writing. Actual results may differ materially and adversely from expectations conveyed in forward-looking statements due to changes caused by various risks and uncertainties. Such risks and uncertainties include but are not limited to the following:Unexpected delays  difficulties  and expenses in executing against our environmental  climate  diversity and inclusion or other â€œESGâ€ targets  goals and commitments  and changes in laws or regulations affecting us  such as changes in data privacy  environmental  safety and health laws;Changes in general economic and/or governmental conditions  particularly in the United States  the Netherlands and the United Kingdom;Civil unrest  (geo-) political tensions  military action or other instability in a country or geographic region;Changes in the performance of financial markets  including emerging markets  such as with regard to: The frequency and severity of defaults by issuers in Aegonâ€™s fixed income investment portfolios; The effects of corporate bankruptcies and/or accounting restatements on the financial markets and the resulting decline in the value of equity and debt securities Aegon holds; The effects of declining creditworthiness of certain public sector securities and the resulting decline in the value of government exposure that Aegon holds;Changes in the performance of Aegonâ€™s investment portfolio and decline in ratings of Aegonâ€™s counterparties;Lowering of one or more of Aegonâ€™s debt ratings issued by recognized rating organizations and the adverse impact such action may have on Aegonâ€™s ability to raise capital and on its liquidity and financial condition;Lowering of one or more of insurer financial strength ratings of Aegonâ€™s insurance subsidiaries and the adverse impact such action may have on the written premium  policy retention  profitability and liquidity of its insurance subsidiaries;The effect of the European Unionâ€™s Solvency II requirements and other regulations in other jurisdictions affecting the capital Aegon is required to maintain;Changes affecting interest rate levels and continuing low or rapidly changing interest rate levels;Changes affecting currency exchange rates  in particular the EUR/USD and EUR/GBP exchange rates;Changes in the availability of  and costs associated with  liquidity sources such as bank and capital markets funding  as well as conditions in the credit markets in general such as changes in borrower and counterparty creditworthiness;Increasing levels of competition in the United States  the Netherlands  the United Kingdom and emerging markets;Catastrophic events  either manmade or by nature  including by way of example acts of God  acts of terrorism  acts of war and pandemics  could result in material losses and significantly interrupt Aegonâ€™s business;The frequency and severity of insured loss events;Changes affecting longevity  mortality  morbidity  persistence and other factors that may impact the profitability of Aegonâ€™s insurance products;Aegonâ€™s projected results are highly sensitive to complex mathematical models of financial markets  mortality  longevity  and other dynamic systems subject to shocks and unpredictable volatility. Should assumptions to these models later prove incorrect  or should errors in those models escape the controls in place to detect them  future performance will vary from projected results;Reinsurers to whom Aegon has ceded significant underwriting risks may fail to meet their obligations;Changes in customer behavior and public opinion in general related to  among other things  the type of products Aegon sells  including legal  regulatory or commercial necessity to meet changing customer expectations;Customer responsiveness to both new products and distribution channels;As Aegonâ€™s operations support complex transactions and are highly dependent on the proper functioning of information technology  operational risks such as system disruptions or failures  security or data privacy breaches  cyberattacks  human error  failure to safeguard personally identifiable information  changes in operational practices or inadequate controls including with respect to third parties with which we do business may disrupt Aegonâ€™s business  damage its reputation and adversely affect its results of operations  financial condition and cash flows;The impact of acquisitions and divestitures  restructurings  product withdrawals and other unusual items  including Aegonâ€™s ability to integrate acquisitions and to obtain the anticipated results and synergies from acquisitions;Aegonâ€™s failure to achieve anticipated levels of earnings or operational efficiencies  as well as other management initiatives related to cost savings  Cash Capital at Holding  gross financial leverage and free cash flow;Changes in the policies of central banks and/or governments;Litigation or regulatory action that could require Aegon to pay significant damages or change the way Aegon does business;Competitive  legal  regulatory  or tax changes that affect profitability  the distribution cost of or demand for Aegonâ€™s products;Consequences of an actual or potential break-up of the European monetary union in whole or in part  or the exit of the United Kingdom from the European Union and potential consequences if other European Union countries leave the European Union;Changes in laws and regulations  particularly those affecting Aegonâ€™s operationsâ€™ ability to hire and retain key personnel  taxation of Aegon companies  the products Aegon sells  and the attractiveness of certain products to its consumers;Regulatory changes relating to the pensions  investment  and insurance industries in the jurisdictions in which Aegon operates;Standard setting initiatives of supranational standard setting bodies such as the Financial Stability Board and the International Association of Insurance Supervisors or changes to such standards that may have an impact on regional (such as EU)  national or US federal or state level financial regulation or the application thereof to Aegon  including the designation of Aegon by the Financial Stability Board as a Global Systemically Important Insurer (G-SII); andChanges in accounting regulations and policies or a change by Aegon in applying such regulations and policies  voluntarily or otherwise  which may affect Aegonâ€™s reported results  shareholdersâ€™ equity or regulatory capital adequacy levels.This document contains information that qualifies  or may qualify  as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (596/2014). Further details of potential risks and uncertainties affecting Aegon are described in its filings with the Netherlands Authority for the Financial Markets and the US Securities and Exchange Commission  including the Annual Report. These forward-looking statements speak only as of the date of this document. Except as required by any applicable law or regulation  Aegon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Aegonâ€™s expectations with regard thereto or any change in events  conditions or circumstances on which any such statement is based.Attachment,neutral,0.05,0.95,0.0,positive,0.79,0.2,0.01,True,English,"['Dutch operations', 's.r.', 'Aegon', 'disciplined capital management approach', 'Dutch asset management activities', 'long-term asset management agreement', 'two renowned Dutch companies', 'diversified Dutch insurance company', 'leading Dutch insurance company', 'global asset manager', 'diversified product offering', 'sustainable, leading insurer', 'number two insurer', 'number three player', 'stronger distribution activities', 'Premium Pension Institution', 'upcoming pension reform', 'best long-term interest', 'attractive shareholder returns', 'potential equity offering', 'competitive product offering', 'closed individual life', 'a.s.r.', 'gross cash proceeds', 'Dutch pension, life', 'general account investments', 'mortgage origination activities', 'attractive value propositions', 'Dutch pension market', 'EUR 1.5 billion capital', 'Compelling strategic rationale', 'Aegon N.V.', 'Dutch insurance leader', 'life insurance markets', 'cash proceeds Transaction', 'Dutch society', 'Dutch mortgages', 'two companies', 'long-term benefits', 'non-life insurance', 'disability insurance', 'casualty insurance', 'leading position', 'attractive products', 'financial rationale', 'mortgage funds', '29.99% strategic shareholding0F', 'long-term ambition', 'The Hague', 'significant synergies', 'business partners', 'governance rights', 'mature businesses', 'share target', 'major milestone', 'Lard Friese', 'hard work', 'recent years', 'strong distribution', 'Jos Baeten', 'joined strength', 'good home', 'new colleagues', 'starting point', 'one company', 'one culture', 'closing price', 'broad range', 'combined group', '29.99% strategic stake', 'pivotal step', 'major step', 'market position', 'near future', 'rich history', 'unique opportunity', 'operational performance', '57 million shares', 'market leader', 'Aegon Cappital', 'future growth', 'markets Combination', 'Netherlands employees', '1 Value', '29.99% stake', 'leaders', 'Clear', 'customers', 'shareholders', 'associated', 'strategy', 'Intention', 'leverage', 'Progress', 'transformation', '2023 dividend', 'banking', 'parts', 'announcement', 'CEO', 'dedication', 'success', 'stakeholders', 'priority', 'focus', 'resources', 'relations', 'organizations', 'October', 'funding', 'services', 'opportunities', 'property', 'scale', 'servicing', 'streamlined', 'improved', 'operations', 'expertise', 'platforms', 'area', 'deliver', 'integration']",2022-10-27,2022-10-28,finance.yahoo.com
12227,EuroNext,NewsApi.org,https://finance.yahoo.com/news/hipay-group-050000157.html,HiPay Group:,HiPay Group HiPay regains growth momentum with 16% increase in Q3 revenue Quarterly payment volume of 1.7 billion euros  an 18% increase compared to the...,HiPay GroupHiPay GroupHiPay regains growth momentumwith 16% increase in Q3 revenueQuarterly payment volume of 1.7 billion euros  an 18% increase compared to the third quarter of 2021Revenue1 of 14.3 million euros for the period  a 16% increase compared to 2021Continuous business growth offering positive prospects  and positioning HiPay as the European leader in omni-channel paymentsParis  27 October 2022: HiPay (code ISIN FR0012821916 â€“ ALHYP)  a fintech specialising in omni-channel payments  announces its third quarter 2022 revenue.Q3 - in millions of euros Q3 2022 Q3 2021 Var. % Payment volume 1 748 1 478 +18 % Revenue1 14.3 12.3 +16 % From January to September - in millions of euros 9M 2022 9M 2021 Var.% Payment volume 5 342 4 678 +14 % Revenue1 41.8 39.1 +7 %A major increase in payment volumeDuring the third quarter of 2022  payment volume reached 1.7 billion euros  which corresponds to an 18% increase compared to the third quarter of 2021.This performance reflects an acceleration compared to the first half of the year  despite a macroeconomic environment that remains challenging. (Recall that during the first half of 2022  e-commerce product sales decreased by approximately 15%. Source: Fevad) Growth over the first nine months of 2022 is now up 14%  an acceleration of two points compared to the first half. Payment volume growth continues to be spread across our main market segments: France  iGaming and International.Itâ€™s worth noting that the development of the omni-channel offering is taking shape. In-store payment volume represents 9% of flows in France since the beginning of the year (vs. 3% in 2021). This has enabled HiPay to establish its position as an omni-channel payment specialist.An upturn in business once again results in double-digit quarterly revenue growthThird quarter 2022 revenue reached 14.3 million euros  an increase of 2 million euros and a 16% increase compared to the third quarter of 2021  despite the end of Direct Banking payment methods in the iGaming segment  whose volumes have shifted to other less profitable payment methods. Adjusted for this unfavourable mix effect  revenue growth reached an increase of 22% for the quarter  which is in line with performance over 2019-2021 (CAGR of 25% over the first 9 months of the year).Story continuesThe ratio of revenue to payment volumes  which reflects HiPay's ability to monetise its services  shows stabilisation. This ratio reached 0.82% in the third quarter of 2022 (vs 0.84% in 2021)  impacted by the iGaming payment mix effect for -1 bp (basis points) and by the growth in payment volumes at points of sale for -2 bp.Cumulated over the first 9 months of the year  the iGaming payment mix effect cost HiPay 2.7 million euros in revenue  i.e.  -7 growth points. The revenue ratio on payment volume thus reached 0.78% (vs. 0.84% in 2021). The erosion of -6 bps is explained by -5 bps from the iGaming payment method mix and -3 bps from the growth of payment volume at points of sale. Consequently  excluding these two mix effects  the monetisation of payment volume increased by 0.02 pts  which reflects the business strategy pursued over the course of several half-year periods.The negative mix effect on revenue caused by the end of the use of Direct Banking payments in the iGaming segment  having taken place in 2021  is expected to continue until the end of the fourth quarter of 2022  but no further.Robust momentum in HiPayâ€™s business in France and abroad offers promising future prospectsHiPayâ€™s European expansion continues through new agreements with the following retail players:In Italy   with the strengthening of its strategic partnership with IC Intracom  users of the HiPay MOTO solution  in addition to the launch of the Salutea parapharmaceutical siteIn Portugal   through the agreement with Mr Blue  which bolsters HiPay's status as e-commerce Fashion Retail payment expert in this marketIn Spain   through its work with Aladinia  the Spanish leader in gift experiences.In the United Kingdom  through the signing of Bludiode.com  an international electronic goods merchantAdditionally  the iGaming business continues to grow. HiPay now works with Matchem and its website Genybet.fr (Paristurf Group) in the French market and also offers physical payment solutions in Belgian gaming halls through the deployment of the 'Bancontact QR code' payment method.In France  HiPay has established its position as a multi-specialist through several agreements over a wide variety of industries (beauty  fashion  footwear  furniture/decor  gardening  cooking/gastronomy)  including Mecatechnic  Reborn and NotShy.Additionally  the attractiveness of its Unified Commerce offering has grown significantly  with nearly 20% of new omni-channel support contracts signed  which is in line with its set goals for 2022.This Unified Commerce offering was presented at the beginning of the quarter at a meeting co-organised with Nepting & Pebix Avem  longtime partners of HiPay  and is already enjoying a particularly favourable response from French customers in the second half of 2022.2023 financial calendarBelow is HiPayâ€™s 2023 financial calendar. The dates in this calendar are approximate and are subject to change.Events Date 2022 revenue 23 February 2023 (pre-market hours) 2022 year-end results 6 April 2023 (pre-market hours) Annual results presentation 6 April 2023 at 16:00 Revenue for the first quarter of 2023 11 May 2023 (pre-market hours) General Meeting 2023 1 June 2023 at 10:00 Revenue for the first half of 2023 27 July 2023 (pre-market hours) Results for the first half of 2023 14 September 2023 (pre-market hours) Presentation of results for the first half of 2023 14 September 2023 at 16:00 Revenue for the third quarter of 2023 26 October 2023 (pre-market hours)Next financial communication: 23 February 2023 - 2022 revenue***About HiPayHiPay is a global payment services provider. Using the power of payment data  we help our sellers grow by giving them a 360Â° overview of their business.More information at hipay.com. You can also find us on LinkedIn.HiPay Group is listed on Euronext Growth (ISIN: FR0012821916 â€“ ALHYP).ContactsPRAnnie Hurley (CMO)+33 (0)6 81 16 07 52ahurley@hipay.comInvestor RelationsJÃ©rÃ´me Daguet (CFO)+33 (0)7 86 53 93 93jdaguet@hipay.comThis release does not constitute a sale offer or the solicitation of an offer to purchase HiPay securities. If you would like more information about HiPay Group  please visit the Investors section on our website hipay.com. This release may contain provisional declarations. Although HiPay Group believes that these declarations are based on hypotheses that are reasonable on the releaseâ€™s publication date  they are by nature subject to risk and uncertainty that can lead to differences between the actual figures and those indicated or inferred in these declarations. HiPay Group operates in one of the most volatile sectors where new risk factors can emerge. HiPay Group does not have any obligation to update these provisional declarations based on new information  events or circumstances.Attachment,neutral,0.0,1.0,0.0,mixed,0.45,0.16,0.4,True,English,"['HiPay Group', 'other less profitable payment methods', ""Bancontact QR code' payment method"", 'e-commerce Fashion Retail payment expert', 'Direct Banking payment methods', 'international electronic goods merchant', 'iGaming payment method mix', 'new omni-channel support contracts', 'iGaming payment mix effect', 'double-digit quarterly revenue growth', 'e-commerce product sales', 'unfavourable mix effect', 'negative mix effect', 'following retail players', 'Direct Banking payments', 'physical payment solutions', 'two mix effects', 'Salutea parapharmaceutical site', 'Belgian gaming halls', 'Quarterly payment volume', 'Unified Commerce offering', 'omni-channel payment specialist', 'several half-year periods', 'promising future prospects', 'store payment volume', 'main market segments', 'first nine months', 'Payment volume growth', 'HiPay MOTO solution', 'Continuous business growth', 'third quarter 2022 revenue', 'omni-channel offering', 'new agreements', 'omni-channel payments', 'iGaming segment', 'payment volumes', 'iGaming business', 'positive prospects', 'first 9 months', 'several agreements', 'first half', 'growth momentum', 'Q3 revenue', 'European leader', 'fintech specialising', 'macroeconomic environment', 'two points', 'fourth quarter', 'Robust momentum', 'European expansion', 'strategic partnership', 'IC Intracom', 'Mr Blue', 'Spanish leader', 'gift experiences', 'United Kingdom', 'Bludiode.com', 'Genybet.fr', 'Paristurf Group', 'French market', 'wide variety', 'set goals', 'Pebix Avem', 'longtime partners', 'favourable re', 'business strategy', '1.7 billion euros', '14.3 million euros', '2 million euros', 'basis points', 'revenue ratio', 'HiPay Group', 'major increase', '16% increase', '18% increase', 'Revenue1', 'ALHYP', 'millions', 'January', 'September', '9M', 'performance', 'acceleration', 'Source', 'Fevad', 'France', 'development', 'shape', 'flows', 'beginning', 'position', 'upturn', 'end', 'line', 'CAGR', 'Story', 'ability', 'services', 'stabilisation', 'erosion', 'monetisation', '0.02 pts', 'course', 'use', 'place', 'Italy', 'strengthening', 'addition', 'launch', 'Portugal', 'status', 'Spain', 'work', 'Aladinia', 'signing', 'Matchem', 'website', 'deployment', 'multi-specialist', 'industries', 'beauty', 'footwear', 'furniture/decor', 'gardening', 'cooking', 'gastronomy', 'Mecatechnic', 'Reborn', 'NotShy', 'attractiveness', 'meeting', 'Nepting']",2022-10-27,2022-10-28,finance.yahoo.com
12228,EuroNext,NewsApi.org,https://finance.yahoo.com/news/exel-industries-4th-quarter-2021-160600070.html,EXEL Industries: 4th quarter 2021â€“2022 sales up 22.8%,Fourth quarter 2021â€“2022 sales up 22.8% Record Q4 organic growth driven by agricultural equipment Q4 sales(July 2022â€“September 2022)2020â€“20212021â€“2022Change ...,EXEL INDUSTRIESFourth quarter 2021â€“2022 sales up 22.8%Record Q4 organic growthdriven by agricultural equipmentQ4 sales(July 2022â€“September 2022)2020â€“2021 2021â€“2022 Change in value(â‚¬m) Change(%) Reported Reported Reported LFL* Reported LFL* AGRICULTURAL SPRAYING88.9 122.5 +33.6 +26.5 +37.8% +29.9% SUGAR BEET HARVESTERS71.7 85.3 +13.5 +9.5 +18.9% +13.3% LEISURE23.1 28.1 +5.0 -2.2 +21.7% -9.6% INDUSTRY58.7 61.7 +3.0 +0.2 +5.1% +0.3% EXEL Industries Group 242.4 297.5 +55.2 +34.0 +22.8% +14.0%12-month sales(October 2021â€“September 2022)2020â€“2021 2021â€“2022 Change in value(â‚¬m) Change(%) Reported Reported Reported LFL* Reported LFL* AGRICULTURAL SPRAYING380.9 442.3 +61.4 +48.2 +16.1% +12.7% SUGAR BEET HARVESTERS135.5 146.3 +10.8 +5.2 +8.0% +3.8% LEISURE132.4 138.9 +6.5 -26.9 +4.9% -20.3% INDUSTRY227.9 249.5 +21.6 +12.5 +9.5% +5.5% EXEL Industries Group 876.8 977.0 +100.3 +39.0 +11.4% +4.4%* Like-for-like (LFL) = at constant foreign exchange rates and scopeQ4 2021â€“2022 salesThe EXEL Industries Group posted record sales of â‚¬297.5 million for the fourth quarter of 2021â€“2022  up 22.8%  driven by both external (changes in consolidation scope and foreign exchange rates  notably USD) and internal factors  mainly organic growth in agricultural equipment. At constant consolidation scope and foreign exchange rates  the Group recorded growth of 14.0%  despite persistent supply chain issues in its various businesses  particularly in agricultural spraying and sugar beet harvesters.The change in consolidation scope arising from the Groupâ€™s two recent acquisitions (EXEL Yachting and G.F.) contributed â‚¬5.2 million to fourth quarter sales.AGRICULTURAL SPRAYING: UP 37.8%After peaking in spring 2022  accentuated by the conflict in Ukraine  agricultural commodity prices fell slightly during the summer and stabilized at levels still well above pre-COVID prices. Against this backdrop  demand remained strong in all regions  particularly North America  while the component shortage shows no sign of abating.The exceptionally well-stocked order book enabled the various Group companies to mitigate sales seasonality and carry out a significant amount of billing during the quarter.Story continuesSUGAR BEET HARVESTERS: UP 18.9%After a third quarter particularly impacted by component shortages and a resurgence of COVID in Germany  business caught up strongly in the fourth quarter  resulting in record billings for sales of sugar beet harvesters.LEISURE: UP 21.7%The garden equipment market declined in the Groupâ€™s three main operating regions (the United Kingdom  France and Italy). In this context and after a series of challenging quarters (IT migration)  Q4 business came close to the previous yearâ€™s levels  bolstered by a more favorable basis of comparison than in previous quarters.The EXEL Yachting business posted a satisfactory quarterly performance with deliveries in line with forecasts.INDUSTRY: UP 5.1%At constant consolidation scope and foreign exchange rates  business was stable during the quarter: technical hoses and industrial spraying saw a slight slowdown in volumes in Europe  offset by ongoing robust momentum in Asia and  to a lower extent  the USA.Situation in Ukraine and RussiaThe new sanctions announced in early October do not affect Group products any more than the previous sanctions. As previously announced  EXEL Industries has maintained its operations in Russia (agricultural equipment and industrial spraying) but has taken care to ensure that deliveries are made in compliance with international regulations. The Group has been able to maintain overall sales volumes in the region.FY 2021â€“2022 salesFull-year 2021â€“2022 sales amounted to â‚¬977.0 million  up 11.4%. Growth at constant consolidation scope and foreign exchange rates was 4.4%. EXEL Industriesâ€™ concern was to adjust prices across all of its business lines  in response to rising raw material and component costs. This policy implemented throughout the year offset certain volume declines due to shortages (mainly agricultural equipment) or to the market slowdown (gardening). The currency effect was particularly favorable to the agricultural spraying and industry segments.The change in consolidation scope represented sales of â‚¬29.8 million for the year.AGRICULTURAL SPRAYING: UP 16.1%The agricultural spraying business was impacted by varying trends during the year: on the one hand  Group brands were hard hit by persisting component shortages despite very different production bases (Europe  the USA). Prices were increased throughout the period in order to pass on price increases implemented by supplier. On the other hand  order intake was boosted by the stabilization of agricultural commodity prices at globally high levels  giving the Group clear visibility over the coming fiscal year.SUGAR BEET HARVESTERS: UP 8.0%After recovering in 2020â€“2021  sales remained strong during the fiscal year ended. In addition  component shortages allowed the Group to clear a large volume of used machine inventories. Lastly  prices were increased to offset increases in production costs (steel and other components).LEISURE: UP 4.9%The gardening business was impacted by three factors during the year. After two exceptional years in terms of volumes  markets returned to pre-COVID levels. Meanwhile  challenges related to the migration of IT systems curbed leisure business volumes by around â‚¬10 million. Prices were increased during the year to offset significant increases in the cost of raw materials and logistics. Lastly  the acquisition of G.F. on February 15  2022  resulted in a scope effect increasing sales for this activity by approximately â‚¬20 million.A new sales  marketing and industrial drive launched in the nautical business is expected to impact the coming years.INDUSTRY: UP 9.5%The underlying markets (mainly automotive  furniture and industry) experienced contrasting trends. However  the industrial spraying business continued to post high volumes throughout the year in line with the previous year.The technical hose division was impacted by declining volumes in the gardening business  while the B2B business was impacted by falling demand towards the end of the year.Yves Belegaud  Chief Executive Officer of the EXEL Industries Group  said:â€œThe strong commitment of our teams in the fourth quarter and the successful integration of our latest acquisitions allowed us to post record sales. This excellent performance was achieved in a challenging and volatile environment in which shortages have not been recovered. However  the Group is confident in its ability to continue its development  underpinned by the various business sectors in which it operates and a well-stocked order book.â€Upcoming eventsDecember 20  2022  before market opening: 2021â€“2022 full-year results.January 25  2023  before market opening: Q1 2022â€“2023 sales.About EXEL IndustriesEXEL Industries is a French family-owned group that designs  manufactures and markets capital equipment and provides associated services that enable its customers to improve efficiency and productivity or enhance their well-being while achieving their CSR objectives.Driven by an innovation strategy for 70 years  EXEL Industries has based its development on innovative ideas designed to offer customers unique  efficient  competitive and user-friendly products.Since its inception  the Group has recorded significant growth in each of its markets through both organic growth and corporate acquisitions  underpinned by a stable shareholder base guided by a long-term development strategy. EXEL Industries employs approximately 3 546 permanent employees spread across 27 countries and five continents.The Group posted FY 2020â€“2021 sales of â‚¬877 million.Euronext Paris  SRD Long only â€“ compartment B (Mid Cap) EnterNextÂ© PEA-PME 150 index (symbol: EXE/ISIN FR0004527638)Press release available onsite www.EXEL-industries.comYves BELEGAUDChief Executive Officeryves.belegaud@EXEL-industries.com Thomas GERMAINGroup Chief Financial Officer / Investor relationsdirection.communication@EXEL-industries.comAttachment,neutral,0.0,0.99,0.0,mixed,0.28,0.16,0.56,True,English,"['EXEL Industries', '4th quarter', 'sales', 'persistent supply chain issues', 'three main operating regions', 'constant foreign exchange rates', 'The EXEL Yachting business', 'Record Q4 organic growth', 'The EXEL Industries Group', 'agricultural equipment Q4 sales', 'SUGAR BEET HARVESTERS', 'two recent acquisitions', 'satisfactory quarterly performance', 'ongoing robust momentum', 'rising raw material', 'different production bases', 'garden equipment market', 'constant consolidation scope', 'LFL* AGRICULTURAL SPRAYING', 'agricultural commodity prices', 'various Group companies', 'coming fiscal year', 'agricultural spraying business', 'overall sales volumes', 'fourth quarter sales', 'Q4 business', 'The Group', 'record billings', 'various businesses', 'market slowdown', 'record sales', 'industrial spraying', 'business lines', 'external (changes', 'internal factors', 'G.F.', 'North America', 'component shortage', 'significant amount', 'United Kingdom', 'challenging quarters', 'IT migration', 'favorable basis', 'previous quarters', 'technical hoses', 'slight slowdown', 'lower extent', 'new sanctions', 'Group products', 'previous sanctions', 'international regulations', 'component costs', 'volume declines', 'currency effect', 'varying trends', 'one hand', 'Group brands', 'price increases', 'other hand', 'clear visibility', 'third quarter', '12-month sales', 'order book', 'previous year', 'order intake', 'COVID prices', 'early October', 'high levels', 'industry segments', 'shortages', '2022 sales', 'July', 'September', 'value', 'LEISURE', 'spring', 'conflict', 'Ukraine', 'summer', 'backdrop', 'demand', 'abating', 'seasonality', 'Story', 'resurgence', 'Germany', 'France', 'Italy', 'context', 'series', 'comparison', 'deliveries', 'forecasts', 'Europe', 'Asia', 'USA', 'Situation', 'Russia', 'operations', 'care', 'compliance', 'FY', 'Full-year', 'concern', 'response', 'policy', 'gardening', 'period', 'supplier', 'stabilization', 'addition']",2022-10-27,2022-10-28,finance.yahoo.com
12229,EuroNext,NewsApi.org,https://finance.yahoo.com/news/shell-announces-commencement-share-buyback-060300937.html,Shell announces commencement of a share buyback programme,Shell plc Shell announces commencement of a share buyback programmeOctober 27  2022Shell plc (the â€˜companyâ€™) today announces the commencement of a $4 billion...,Shell plcShell announces commencement of a share buyback programmeOctober 27  2022Shell plc (the â€˜companyâ€™) today announces the commencement of a $4 billion share buyback programme covering an aggregate contract term of approximately three months (the â€˜programmeâ€™). The purpose of the programme is to reduce the issued share capital of the company. All shares repurchased as part of the programme will be cancelled. It is intended that  subject to market conditions  the programme will be completed prior to the companyâ€™s Q4 results announcement  scheduled for February 2  2023.The company has entered into an arrangement with a single broker consisting of three irrevocable  non-discretionary contracts  to enable the purchase of ordinary shares on both London market exchanges (the London Stock Exchange and/or on BATS and/or on Chi-X) (pursuant to two â€˜London contractsâ€™) and Netherlands exchanges (Euronext Amsterdam and/or on CBOE Europe DXE and/or on Turquoise Europe) (pursuant to one â€˜Netherlands contractâ€™) for a period up to and including January 27  2023. The aggregate maximum consideration for the purchase of ordinary shares under the London contracts is $2 billion and the maximum consideration for the purchase of ordinary shares under the Netherlands contract is $2 billion. Purchases under the London contracts will be carried out in accordance with the companyâ€™s authority1 to repurchase shares on-market and will be effected within certain contractually agreed parameters. Purchases under the Netherlands contract will be carried out in accordance with the companyâ€™s authority1 to repurchase shares off-market pursuant to the off-market share buyback contract approved by its shareholders and the parameters set out therein.The maximum number of ordinary shares which may be purchased or committed to be purchased by the company under the programme (across all three contracts) is 528 919 217  which is the maximum number remaining as of the date of this announcement pursuant to the relevant authorities granted by shareholders at the company's 2022 Annual General Meeting1.The broker will make its trading decisions in relation to the company's securities independently of the company.The programme will be conducted in accordance with Chapter 12 of the Listing Rules  Article 5 of the Market Abuse Regulation 596/2014/EU dealing with buy-back programmes (â€˜EU MARâ€™) and EU MAR as â€œonshoredâ€ into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020)  and as amended  supplemented  restated  novated  substituted or replaced including by relevant statutory instruments (including  The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310))  from time to time and the Commission Delegated Regulation (EU) 2016/1052 (the â€˜EU MAR Delegated Regulationâ€™) and the EU MAR Delegated Regulation as â€œonshoredâ€ into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020)  and as amended  supplemented  restated  novated  substituted or replaced including by relevant statutory instruments (including  The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310))  from time to time.1 The existing shareholder authorities to buy back shares granted at the company's 2022 Annual General Meeting will expire at the earlier of the close of business on August 24  2023  and the end of the date of the company's 2023 Annual General Meeting. The company expects to seek renewal of shareholder authority to buy back shares at subsequent Annual General Meetings.EnquiriesMedia International: +44 (0) 207 934 5550Media Americas: +1 832 337 4355CAUTIONARY STATEMENTThe companies in which Shell plc directly and indirectly owns investments are separate legal entities. In this announcement â€œShellâ€  â€œShell Groupâ€ and â€œGroupâ€ are sometimes used for convenience where references are made to Shell plc and its subsidiaries in general. Likewise  the words â€œweâ€  â€œusâ€ and ourâ€ are also used to refer to Shell plc and its subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular entity or entities. â€˜â€˜Subsidiariesâ€™â€™  â€œShell subsidiariesâ€ and â€œShell companiesâ€ as used in this announcement refer to entities over which Shell plc either directly or indirectly has control. Entities and unincorporated arrangements over which Shell has joint control are generally referred to as â€œjoint venturesâ€ and â€œjoint operationsâ€  respectively. â€œJoint venturesâ€ and â€œjoint operationsâ€ are collectively referred to as â€œjoint arrangementsâ€. Entities over which Shell has significant influence but neither control nor joint control are referred to as â€œassociatesâ€. The term â€œShell interestâ€ is used for convenience to indicate the direct and/or indirect ownership interest held by Shell in an entity or unincorporated joint arrangement  after exclusion of all third-party interest.Forward-Looking StatementsThis announcement contains forward-looking statements (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995) concerning the financial condition  results of operations and businesses of Shell. All statements other than statements of historical fact are  or may be deemed to be  forward-looking statements. Forward-looking statements are statements of future expectations that are based on managementâ€™s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results  performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements include  among other things  statements concerning the potential exposure of Shell to market risks and statements expressing managementâ€™s expectations  beliefs  estimates  forecasts  projections and assumptions. These forward-looking statements are identified by their use of terms and phrases such as â€œaimâ€  â€œambitionâ€  â€˜anticipateâ€™â€™  â€˜â€˜believeâ€™â€™  â€˜â€˜couldâ€™â€™  â€˜â€˜estimateâ€™â€™  â€˜â€˜expectâ€™â€™  â€˜â€˜goalsâ€™â€™  â€˜â€˜intendâ€™â€™  â€˜â€˜mayâ€™â€™  â€œmilestonesâ€  â€˜â€˜objectivesâ€™â€™  â€˜â€˜outlookâ€™â€™  â€˜â€˜planâ€™â€™  â€˜â€˜probablyâ€™â€™  â€˜â€˜projectâ€™â€™  â€˜â€˜risksâ€™â€™  â€œscheduleâ€  â€˜â€˜seekâ€™â€™  â€˜â€˜shouldâ€™â€™  â€˜â€˜targetâ€™â€™  â€˜â€˜willâ€™â€™ and similar terms and phrases. There are a number of factors that could affect the future operations of Shell and could cause those results to differ materially from those expressed in the forward-looking statements included in this announcement  including (without limitation): (a) price fluctuations in crude oil and natural gas; (b) changes in demand for Shellâ€™s products; (c) currency fluctuations; (d) drilling and production results; (e) reserves estimates; (f) loss of market share and industry competition; (g) environmental and physical risks; (h) risks associated with the identification of suitable potential acquisition properties and targets  and successful negotiation and completion of such transactions; (i) the risk of doing business in developing countries and countries subject to international sanctions; (j) legislative  judicial  fiscal and regulatory developments including regulatory measures addressing climate change; (k) economic and financial market conditions in various countries and regions; (l) political risks  including the risks of expropriation and renegotiation of the terms of contracts with governmental entities  delays or advancements in the approval of projects and delays in the reimbursement for shared costs; (m) risks associated with the impact of pandemics  such as the COVID-19 (coronavirus) outbreak; and (n) changes in trading conditions. No assurance is provided that future dividend payments will match or exceed previous dividend payments. All forward-looking statements contained in this announcement are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Additional risk factors that may affect future results are contained in Shell plcâ€™s Form 20-F for the year ended December 31  2021 (available at www.shell.com/investor and www.sec.gov). These risk factors also expressly qualify all forward-looking statements contained in this announcement and should be considered by the reader. Each forward-looking statement speaks only as of the date of this announcement  October 27  2022. Neither Shell plc nor any of its subsidiaries undertake any obligation to publicly update or revise any forward-looking statement as a result of new information  future events or other information. In light of these risks  results could differ materially from those stated  implied or inferred from the forward-looking statements contained in this announcement.Shellâ€™s net carbon footprintAlso  in this announcement we may refer to Shellâ€™s â€œNet Carbon Footprintâ€ or â€œNet Carbon Intensityâ€  which include Shellâ€™s carbon emissions from the production of our energy products  our suppliersâ€™ carbon emissions in supplying energy for that production and our customersâ€™ carbon emissions associated with their use of the energy products we sell. Shell only controls its own emissions. The use of the term Shellâ€™s â€œNet Carbon Footprintâ€ or â€œNet Carbon Intensityâ€ are for convenience only and not intended to suggest these emissions are those of Shell plc or its subsidiaries.Shellâ€™s net-Zero Emissions TargetShellâ€™s operating plan  outlook and budgets are forecasted for a ten-year period and are updated every year. They reflect the current economic environment and what we can reasonably expect to see over the next ten years. Accordingly  they reflect our Scope 1  Scope 2 and Net Carbon Footprint (NCF) targets over the next ten years. However  Shellâ€™s operating plans cannot reflect our 2050 net-zero emissions target and 2035 NCF target  as these targets are currently outside our planning period. In the future  as society moves towards net-zero emissions  we expect Shellâ€™s operating plans to reflect this movement. However  if society is not net zero in 2050  as of today  there would be significant risk that Shell may not meet this target.Forward Looking Non-GAAP measuresThis announcement may contain certain forward-looking non-GAAP measures such as cash capital expenditure and divestments. We are unable to provide a reconciliation of these forward-looking Non-GAAP measures to the most comparable GAAP financial measures because certain information needed to reconcile those Non-GAAP measures to the most comparable GAAP financial measures is dependent on future events some of which are outside the control of Shell  such as oil and gas prices  interest rates and exchange rates. Moreover  estimating such GAAP measures with the required precision necessary to provide a meaningful reconciliation is extremely difficult and could not be accomplished without unreasonable effort. Non-GAAP measures in respect of future periods which cannot be reconciled to the most comparable GAAP financial measure are calculated in a manner which is consistent with the accounting policies applied in Shell plcâ€™s consolidated financial statements.The contents of websites referred to in this announcement do not form part of this announcement.We may have used certain terms  such as resources  in this announcement that the United States Securities and Exchange Commission (SEC) strictly prohibits us from including in our filings with the SEC. Investors are urged to consider closely the disclosure in our Form 20-F  File No 1-32575  available on the SEC website www.sec.gov.,neutral,0.01,0.99,0.0,mixed,0.32,0.19,0.5,True,English,"['share buyback programme', 'Shell', 'commencement', 'subsequent Annual General Meetings', 'three irrevocable, non-discretionary contracts', 'EU MAR Delegated Regulation', '$4 billion share buyback programme', 'market share buyback contract', 'Commission Delegated Regulation', '2022 Annual General Meeting', '2023 Annual General Meeting', 'Market Abuse Regulation', 'relevant statutory instruments', 'EU Exit) Regulations', 'London Stock Exchange', 'CBOE Europe DXE', 'The Market Abuse', 'Enquiries Media International', 'indirect ownership interest', 'Brexit transition period', 'two â€˜London contracts', 'existing shareholder authorities', 'aggregate maximum consideration', 'aggregate contract term', 'London market exchanges', 'Q4 results announcement', 'separate legal entities', 'three contracts', 'share capital', 'relevant authorities', 'three months', 'Netherlands contract', 'market conditions', 'Netherlands exchanges', 'Turquoise Europe', 'shareholder authority', 'Media Americas', 'maximum number', 'Shell interest', 'Euronext Amsterdam', 'trading decisions', 'Listing Rules', 'buy-back programmes', 'European Union', 'CAUTIONARY STATEMENT', 'particular entity', 'unincorporated arrangements', 'joint ventures', 'joint operations', 'joint arrangements', 'significant influence', 'Shell plc', 'Withdrawal Agreement', 'single broker', 'useful purpose', 'joint control', 'ordinary shares', 'Shell Group', 'Shell companies', 'UK law', 'Shell subsidiaries', 'commencement', 'October', 'company', 'February', 'purchase', 'BATS', 'Chi-X', 'January', 'accordance', 'authority1', 'parameters', 'shareholders', 'date', 'relation', 'securities', 'Chapter', 'Article', 'end', '31 December', 'time', 'close', 'business', 'August', 'renewal', 'investments', 'convenience', 'references', 'words', 'terms', 'associates', '11:00', '44']",2022-10-27,2022-10-28,finance.yahoo.com
12230,EuroNext,NewsApi.org,https://finance.yahoo.com/news/geojunxion-gojxn-pleased-publish-2021-060000461.html,GeoJunxion (GOJXN.AS) is pleased to publish its 2021-22 Annual Accounts for the year ending 30 June 2022  showing significant improvements in all financial KPIs  including positive cash-flow.,Capelle aan den IJssel  The Netherlands â€“ 27 October 2022 â€“ GeoJunxion (GOJXN.AS) publishes its 2021-22 Annual Accounts for the 12-months accounting year...,GeoJunxion N.V.Capelle aan den IJssel  The Netherlands â€“ 27 October 2022 â€“ GeoJunxion (GOJXN.AS) publishes its 2021-22 Annual Accounts for the 12-months accounting year ending 30 June 2022  showing significant improvements in all financial KPIs  including positive cash-flow.We are pleased to present the GeoJunxion Annual Report for the accounting year 2021-22. It covers the 12-months period from 1 July 2021 to 30 June 2022. We remark that comparative financials for the past accounting year 2020-21 relate to the 18-months period from 1 January 2020 to 30 June 2021.A full copy of the GeoJunxion Annual Report 2021/22 is attached to this press release and can be found on the companyâ€™s website www.geojunxion.com  under the Investor Relations and Financial News sections.The 2021-22 accounting year was  once again  an eventful period during which the company continued its transformation and turnaround. For the third year in a row  we realized a substantial top line growth  while slightly reducing operating expenses  on a like for like basis. We also achieved Cash-Flow positive  as well as significant improvements on all the other financial KPIs. This is even more remarkable  because it was achieved during a time still impacted by the COVID-19 pandemic and increasing concerns about the global economy due to the ramifications of the war in Ukraine with high energy prices and increased inflation.A summary of the key financials is provided in the table below:Due to the change in the period of the accounting year 2020-21 (to 18 months)  it is more difficult to analyze and compare the financials of the accounting year 2021-22 with the previous accounting years. As already remarked  the current accounting year covers the period from 1 July 2021 to 30 June 2022 (12 months)  while the previous accounting year 2020-21 covers the period from 1 January 2020 to 30 June 2021 (18 months). Additionally  the accounting year 2019 was based on a 12-month period but from 1 January 2019 to 31 December 2019. To enable easier comparison  we also include below the income statement for the current accounting year and the pro-forma income statement for the two previous years  covering the same 12-months period from 1 July to 30 June the following year. This enables a clearer view of the revenue growth and significant improvements in all financial KPIs  comparing the same period.Story continuesRevenue increased year-over-year by 40% to â‚¬2.371.000 in 2021-22 compared to â‚¬1.698.000 in the same period in 2020-21. It is very encouraging to highlight that this growth is not only due to non-recurring service revenue  but also the recurring service revenue increased substantially year-over-year (+72%) and recurring licenses remained essentially stable compared with the previous year.Costs for maps and data increased by 20 8% compared to the 12-months period of the prior year. These costs are related to content purchased to maintain and enrich the database and to hosting cost for delivering our data solutions via the cloud.Personnel expenses decreased in 2021-22  showing a 3% saving compared to the same period in 2020-21 despite a 40% higher revenue. The main drivers for this are a reduction in certain management roles in February 2022 and lower use of outsourced resources in the Netherlands and India during the second half of the accounting year.The depreciation cost on tangible fixed assets remained nearly flat year over year while amortization costs on intangible assets slightly increased. This increase is due to higher capitalized development costs and the amortization of these assets. Capitalized development costs are currently amortized over a period of 7 years  while before 2018  they were amortized over a longer period (15 to 20 years). Note that the book value of the database is subject to impairment testing. This means that the book value is compared to the value in use for the company. Per 30 June 2022  an impairment test was executed. This did not show a requirement for any additional impairment loss.Other operating expenses decreased more than 13% compared to the same period in 2020-21. This is the result of the implementation of a strict spending review  cost control measures  integration of tools and simplification of the group structure.Total Operating Expenses showed a reduction of 3% and Net Operating Expenses showed a reduction of 7% compared with the previous 12-months period. This confirms the general positive mood in which the company is operating today  capable of â€œdelivering more with lessâ€.Operating Result  despite still negative  shows an improvement of 63%  while the Net Loss was reduced by 46%  compared with the previous year.The net cash flow from operating activities in 2021-22 amounted to a positive cash inflow of â‚¬131.000 compared to cash outflow of â‚¬1.035.000 in the same period in 2020-21. This is primarily due to the significant improvement in the operating result and more favorable invoicing and collection terms negotiated with our customers and suppliers. During the accounting year 2021-22 there were no financing transactions  while  during the 2020-21 12-months period  a private placement was completed in December 2020  raising â‚¬825.000 in equity funding.As an independent player  GeoJunxion focuses on creating â€œmap agnosticâ€ products  i.e.  designed to be fully integrated into any commercial and open-source brand of maps or utilized in developing smart solutions for a large variety of use cases in different industries and market sectors.GeoJunxion activities are directed towards establishing long-term relationships with its customers  through the creation of a recurring business model rather than one-off projects or transactions. Although the relationship may start with a proof-of-concept or a one-off project  most of our high value datasets require frequent and continuous updates to maintain or increase their value. As a result  the one-off project or proof-of-concept is often only a first step  followed by a recurring service or a license contract. As a result  converting the initial  one-off project into a recurring  predictable and sustainable revenue stream. In most cases  GeoJunxion also retains the IP and ownership of the newly developed datasets which can then be resold to other customers  thereby leveraging the initial investment and converting it into a virtuous business cycle.The GeoJunxion mission remains focused on improving road safety and contributing to a more sustainable world  reducing the environmental impact through intelligent solutions which enable more environmentally conscious decisions.GeoJunxion has valued diversity  integration and investment in social responsibility for years. We are committed to offering our daily contribution towards a better and more sustainable work environment. For this reason  the company has applied for PSO certification in 2020. PSO is the Dutch abbreviation for â€œPrestatieladder Socialer Ondernemenâ€  Performance ladder Social Entrepreneurship. In July 2022 we achieved Level 2 PSO certification  as one of the first publicly listed organizations in the Netherlands.FINANCIAL OUTLOOKLooking at the future  despite the general uncertainty pictured by the European Central Bank  GeoJunxion expects to see its top line to continue growing by 25 to 30% year over year. This expectation is built on orders booked in the first quarter of 2022-23 and a solid pipeline of opportunities. As a result of inflationary pressure and growing staff costs to deliver the projects  we expect our cost base to increase by 5 to 10%. GeoJunxion is reasonably confident to convert the above-mentioned guidance into positive EBITDA and EBIT close to break-even. On this basis  cash flow is  once again  expected to be positive for the accounting year 2022-23.FORWARD-LOOKING STATEMENTS / IMPORTANT NOTICEThis document contains certain forward-looking statements with respect to the financial position and results of GeoJunxion. We have based these forward-looking statements on our current expectations and projections about future events. This includes assumptions regarding our present and future business strategies  operations  and the environment in which we will operate in the future. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements  and you should not place undue reliance on them.Many of these risks and uncertainties relate to factors that are beyond the companyâ€™s ability to control or estimate precisely  such as timing of placement of orders of our customers  exchange-rate and interest-rate fluctuations  labor and other cost inflation  changes in tax rates  regulatory and legal changes  the rate of technological change  the competitive landscape  political developments in countries in which the company operates and the risk of a slowdown in the market.The forward-looking statements contained herein speak only as of the date they are made. We do not assume any obligation to update any public information or forward-looking statement in this document to reflect events or circumstances after the date of this document  except as may be required by applicable laws.Signed byThe Management BoardThe Supervisory BoardThis is a public announcement by GeoJunxion N.V.  pursuant to article 17  paragraph 1 of the European Market Abuse Regulation (596/2014). This public announcement does not constitute an offer  or solicitation of an offer  to buy or offer securities in GeoJunxion N.V.E ndsAbout GeoJunxionGeoJunxion is the crossroads where fundamental  location-aware content connects with superior  customised intelligence and highly focused innovations to empower exceptional experiences. With an emphasis on safety and sustainability  we are constantly expanding our portfolio to meet the demands of a diverse and fast-evolving market. Building on decades of experience in mapping  the company focuses on high value  dynamic content and building environmentally conscious applications  which enrich safety in everyday life. With location-aware content at our core  we know where our strengths lie and have the know-how and technology needed to offer unrivalled  intelligent products and services.GeoJunxion NV is listed on the regulated market of Euronext Amsterdam  under the symbol GOJXN.AS.GeoJunxion Press ContactTel: +31 (0)10 885 1200Email: info@geojunxion.comAttachments,positive,0.5,0.49,0.01,mixed,0.51,0.12,0.37,True,English,"['2021-22 Annual Accounts', 'GOJXN.AS', 'significant improvements', 'financial KPIs', 'positive cash-flow', 'GeoJunxion', 'year', '30 June', 'Capelle aan den IJssel', 'substantial top line growth', 'higher capitalized development costs', '2021-22 Annual Accounts', 'high energy prices', 'strict spending review', 'general positive mood', 'GeoJunxion N.V.', 'GeoJunxion Annual Report', 'Financial News sections', 'net cash flow', 'positive cash inflow', 'Other operating expenses', 'Total Operating Expenses', 'pro-forma income statement', 'tangible fixed assets', 'cost control measures', 'two previous years', 'recurring service revenue', 'other financial KPIs', 'additional impairment loss', 'Net Operating Expenses', 'past accounting year', '2021-22 accounting year', 'current accounting year', 'previous accounting years', '12-months accounting year', 'previous 12-months period', 'same 12-months period', '40% higher revenue', 'Net Loss', 'recurring licenses', 'cash outflow', 'Personnel expenses', 'revenue growth', 'operating activities', 'impairment testing', 'to 20 years', 'positive cash-flow', 'third year', 'prior year', 'Operating Result', 'same period', 'GOJXN.AS', 'significant improvements', 'full copy', 'press release', 'Investor Relations', 'COVID-19 pandemic', 'global economy', 'easier comparison', 'clearer view', 'main drivers', 'management roles', 'outsourced resources', 'second half', 'depreciation cost', 'intangible assets', 'group structure', 'favorable invoicing', 'collection terms', '18-months period', 'eventful period', '12-month period', 'longer period', 'amortization costs', 'comparative financials', 'key financials', 'book value', 'The Netherlands', 'data solutions', 'lower use', '7 years', '27 October', '30 June', '1 July', '1 January', 'company', 'website', 'transformation', 'turnaround', 'like', 'basis', 'time', 'concerns', 'ramifications', 'war', 'Ukraine', 'inflation', 'summary', 'table', 'change', '18 months', '31 December', 'Story', 'maps', 'content', 'database', 'cloud', '3% saving', 'reduction', 'February', 'India', 'increase', 'requirement', 'implementation', 'integration', 'tools', 'simplification', 'less', 'customers', 'suppliers']",2022-10-27,2022-10-28,finance.yahoo.com
12231,EuroNext,NewsApi.org,https://finance.yahoo.com/news/2022-q3-revenue-report-160000932.html,2022 Q3 Revenue Report,The transition to a geographical rebalancing of revenue continues Operational transition still underway in FranceDynamic growth of activities outside France ...,SOLUTIONS 30The transition to a geographical rebalancing of revenue continuesOperational transition still underway in FranceDynamic growth of activities outside FranceConfirmation of long-term outlook driven by excellent momentum outside FrancePriority given to organic growth and maintaining a financial structure with low debtGrowth to pick up in 2023 and profitability to improve in tandemIn millions of euros 9 months Q3 2022 2021 % change 2022 2021 % change Total 656.8 653.5 +0.5% 212.4 212.1 +0.1% From France 318.6 391.8 -18.7% 96.7 121.5 -20.4% From Benelux 152.1 114.2 +33.2% 53.6 39.3 +36.5% From other countries 186.1 147.5 +26.2% 62.1 51.3 +21.0%55% of group revenue generated outside of FranceConsolidated revenueIn the third quarter of 2022  Solutions 30 posted consolidated revenue of â‚¬212.4 million  up 0.1% compared to the same period in 2021 (-2.4% on an organic basis).In line with previous quarters  performance in France continues to be impacted by the operational transition linked to the maturity of certain markets. Elsewhere in Europe  activities are growing quickly as the roll-out of fiber-optic networks gets underway in most of the countries where Solutions 30 operates.For the first nine months of 2022  Solutions 30â€™s consolidated revenue amounted to â‚¬656.8 million  up +0.5% (-1.8% on an organic basis).Revenue by regionFrance: In the third quarter of 2022  Solutions 30 had revenue of â‚¬96.7 million  down 20.4% compared to the third quarter of 2021.With â‚¬68.9 million in revenue  the telecom business is down 20.0% compared to the third quarter of 2021. This decline in business reflects the maturity of the market after the record levels of activity observed during the COVID crisis  which accelerated the deployment of ultra-fast broadband in France. The industry as a wholeâ€”customers as well as service providers and subcontractorsâ€”has been forced to adapt and adjust to new ways of cooperating and to a temporary lack of visibility brought on by macroeconomic uncertainties. As a result  the operational conditions under which contracts are executed have significantly deteriorated in recent months and been aggravated by the current inflationary situation.Story continuesThis has implications for the entire industry and pricing renegotiations are underway. In this context  Solutions 30 is continuing its operational transition by building on its strong competitive advantages: a diversified customer and business portfolio  a healthy financial structure with little debt  and an agile organization.Revenue from the energy business amounted to â‚¬11.5 million  compared with â‚¬19.7 million a year earlier. This decline of 41.4% is due to the end of smart electricity meter deployments in France (activity down 79.6%). Even though revenue from the new energy transition and electric mobility verticals is still suffering from supply chain disruptions  it increased by 31%. However  this growth does not yet compensate for the decline in the companyâ€™s historic verticals.The IT business posted revenue of â‚¬11.2 million  stable compared to last yearâ€™s third quarter  while the security and payments business is up 12.9%  generating â‚¬5.1 million in revenue  compared to â‚¬4.5 million a year earlier.Over the first nine months of the year  revenue is down 18.7% to â‚¬318.6 million.Benelux: Revenue for the third quarter of 2022 was â‚¬53.6 million compared to â‚¬39.3 million a year earlier  representing pure organic growth of 36.5% and reflecting the excellent dynamics of the Belgian and Dutch markets.The growth of the telecom business is accelerating due to the rapid ramp-up of the contracts signed with Fiberklaar  Open Dutch Fiber  and Unifiber. Revenue from fiber activities alone increased 4.5 times over the quarter  growing the telecom business by 40.1% and resulting in quarterly revenue of â‚¬40.3 million compared to â‚¬28.8 million a year earlier.For the energy business  revenue was â‚¬9.5 million compared to â‚¬6.6 million a year earlier  a purely organic increase of 43.0%  thanks to the deployment of smart meters in Flanders on behalf of Fluvius.Quarterly revenue from the IT business remained stable at â‚¬2.1 million while revenue from the retail and security businesses was â‚¬1.7 million  compared to â‚¬1.8 million for the third quarter of 2021.Over the first nine months of 2022  revenue grew by 33.2% to â‚¬152.1 million  compared to â‚¬114.2 million a year earlier.In all other countries  the group posted quaterly revenue of â‚¬62.1 million  an increase of 21.0% (10.4% organic growth) compared to the same period in 2021.In Germany  revenue began to grow again and is up 7% to â‚¬16.2 million  compared to â‚¬15.1 million a year earlier. As expected  the efforts made by the group to adapt its organization  as well as updated pricing conditions for certain major contracts  are starting to bear fruit.In Italy  revenue grew by 19% in the third quarter of 2022 to â‚¬14.8 million  driven by the pursuit of TIMâ€™s ultra-fast infrastructure deployments in Piedmont and the Aosta Valley  which began in the first quarter of 2021.On the Iberian peninsula  revenue grew by 8% to â‚¬14.4 million  thanks to positive dynamics in the telecommunications sector (fiber and 5th generation mobile networks)  a strong uptick in installations of charging stations for electric vehicles  and pricing increases obtained from several customers.In Poland  the group posted revenue of â‚¬7.9 million  up 35% (23% organic growth). Solutions 30 continues to gain market share in this country  while the integration of Sirtel into the portfolio of activities for 5G networks is progressing well. The organization put in place will ensure the companyâ€™s ability to support its customersâ€™ growth. The mobile networks business is growing rapidly and now accounts for nearly 10% of revenue.Finally  in the United Kingdom  Solutions 30 posted â‚¬8.8 million in revenue during the quarter  up 92% (-11% on an organic basis). Solutions 30 has streamlined its operations to focus on higher-potential markets and the diversification of its services into fiber-optic networks  while the integration of Monoâ€™s operations continues.In all these countries  the group posted revenue of â‚¬186.1 million for the first nine months of 2022  an increase of 26.2% (15.8% on an organic basis) compared to the first nine months of 2021.OutlookIn response to current inflationary pressure  Solutions 30 is increasing its prices  both on new and existing contracts. The group has also taken measures to strictly control operating costs with the aim of preserving a solid financial structure with little debt. Such a structure will protect its ability to finance growth through acquisitions  increase its agility  strengthen its competitive advantages  and preserve its future capacity to pursue consolidation in its sector.In France  the market is in transition  which has led to limited short-term visibility. Against this backdrop  Solutions 30 will pursue its action plan to restore growth and a more normal level of profitability. This plan involves (i) winning marketshare in the mature telecoms sector where a second phase of consolidation is expected to take place; (ii) developing new  high-growth activities  especially in the energy sector where demand remains strong  driven by the major challenges of energy independence  the transition to new energies  and the electrification of vehicles; and (iii) seeking out synergies between the various businesses  accompanied by a reallocation of technicians to businesses with greater potential.In the Benelux and other countries  growth will remain strong through the end of the year  with the same momentum it saw in the third quarter.For the group as a whole  the fourth-quarter trend should be in line with the first nine months of the year and 2022 revenue should remain at the same levels as in 2021. The increase in the EBITDA margin at the end of the year is subject to ongoing price negotiations.From 2023  Solutions 30 should return to more dynamic growth  driven by the development momentum of its activities outside France. It should also see an overall improvement in its profitability. The group has solid growth drivers and an effective model to self-finance its development  both of which will help it consolidate its position at the crossroads of the digital transformation and the energy transition.Upcoming event2022 Q4 Revenue and 2022 Annual Revenue Reports | January 26  2022About Solutions 30 SEThe Solutions 30 group is the European leader in solutions for new technologies. Its mission is to make the technological developments that are transforming our daily lives accessible to everyone  individuals and businesses alike. Yesterday  it was computers and the Internet. Today  itâ€™s digital technology. Tomorrow  it will be technologies that make the world even more interconnected in real time. With more than 50 million call-outs carried out since it was founded and a network of more than 15 000 local technicians  Solutions 30 currently covers all of France  Italy  Germany  the Netherlands  Belgium  Luxembourg  the Iberian Peninsula  the United Kingdom  and Poland. The share capital of Solutions 30 SE consists of 107 127 984 shares  equal to the number of theoretical votes that can be exercised.Solutions 30 SE is listed on the Euronext Paris exchange (ISIN FR0013379484- code S30). Indexes: MSCI Europe ex-UK Small Cap | SBF 120 | CAC Mid 60 | NEXT 150 | CAC Technology | CAC PME.Visit our website for more information: www.solutions30.comContactIndividual Shareholders:Investor Relations - Tel: +33 1 86 86 00 63 - shareholders@solutions30.comAnalysts/Investors:Nathalie Boumendil - Tel: +33 6 85 82 41 95 - nathalie.boumendil@solutions30.comPress - Image 7:Charlotte Le Barbier - Tel: +33 6 78 37 27 60 - clebarbier@image7.frLeslie Jung - Tel: +33 6 78 70 05 55 - ljung@image7.frAttachment,neutral,0.0,1.0,0.0,mixed,0.37,0.1,0.53,True,English,"['2022 Q3 Revenue Report', 'smart electricity meter deployments', 'current inflationary situation', 'strong competitive advantages', 'supply chain disruptions', 'electric mobility verticals', 'first nine months', 'healthy financial structure', 'Open Dutch Fiber', 'pure organic growth', 'new energy transition', 'smart meters', 'first quarter', 'new ways', 'historic verticals', 'recent months', 'energy business', 'organic basis', 'geographical rebalancing', 'Operational transition', 'long-term outlook', 'excellent momentum', 'low debt', 'same period', 'previous quarters', 'fiber-optic networks', 'record levels', 'COVID crisis', 'ultra-fast broadband', 'service providers', 'temporary lack', 'macroeconomic uncertainties', 'operational conditions', 'pricing renegotiations', 'diversified customer', 'little debt', 'excellent dynamics', 'Dutch markets', 'rapid ramp-up', 'pricing conditions', 'Aosta Valley', 'third quarter', 'telecom business', 'business portfolio', 'IT business', 'payments business', 'fiber activities', 'organic increase', 'Dynamic growth', 'other countries', 'entire industry', 'agile organization', 'last year', 'security businesses', 'major contracts', 'Consolidated revenue', 'quarterly revenue', 'group revenue', '9 months', 'SOLUTIONS', 'France', 'Confirmation', 'Priority', 'profitability', 'tandem', 'millions', 'euros', 'change', 'Benelux', 'line', 'performance', 'maturity', 'Europe', 'roll', 'region', 'activity', 'customers', 'subcontractors', 'visibility', 'result', 'Story', 'implications', 'context', 'end', 'company', 'Belgian', 'Fiberklaar', 'Unifiber', 'Flanders', 'behalf', 'Fluvius', 'retail', 'Germany', 'efforts', 'fruit', 'Italy', 'pursuit', 'TIM', 'Piedmont', '2']",2022-10-27,2022-10-28,finance.yahoo.com
12232,EuroNext,NewsApi.org,https://finance.yahoo.com/news/third-quarter-2022-sales-050000004.html,THIRD-QUARTER 2022 SALES,THIRD-QUARTER 2022 SALES Record quarter with same-day sales growth up 16.3%Acceleration in volume growth capturing electrification trends & additional...,"REXELTHIRD-QUARTER 2022 SALESRecord quarter with same-day sales growth up 16.3%Acceleration in volume growth capturing electrification trends & additional selling price increase2022 guidance upgraded for the second timeâ†’ Sales of â‚¬4 816.6m in Q3 2022  up +16.3% on a same-day basis  accelerating after a robust start to the yearâ†’ Record quarter driven by acceleration in volume growth (c. 750bps contribution in Q3 22 vs +60bps in Q2 22)  demonstrating our ability to fully capture the boost in electrification  notably in Europeâ†’ Strong selling price increase on non-cable products in all geographies (900bps contribution)  reflecting pass-through of the rise in production costsâ†’ Robust growth in our three end-markets with Residential  Commercial and Industrial up double digitsâ†’ Double-digit growth in all three geographies. Strong momentum in the US reflecting good underlying demand and internal transformationâ†’ Strategic focus on organic growth and M&A translating into +35.5% reported sales growth in Q3 22â†’ Digital penetration up c. +240bps  representing c. 25% of Group revenues in Q3 22  with +467bps improvement in the US  now at c. 18% of digital salesâ†’ FY 22 guidance upgraded for same-day sales growth and adjusted Ebita marginâ†’ Share buyback with â‚¬60m completed (c. 3.7 million shares)Key figures (â‚¬m) Q3 2022 YoY change 9m 2022 YoY change Sales on a reported basis 4 816.6 +35.5% 13 899.4 +31.0% On a constant and actual-day basis +15.5% +15.4% On a constant and same-day basis +16.3% +14.7% Same-day sales growth by geography Europe 2 292.5 +15.9% 6 947.5 +13.2% France 808.3 +10.2% 2 570.8 +9.3% Scandinavia 292.3 +21.2% 878.8 +14.0% Benelux 268.0 +27.0% 792.1 +19.8% Germany 258.8 +25.7% 726.6 +19.4% UK 194.8 +9.5% 613.9 +12.2% North America 2 142.3 +17.3% 5 893.0 +18.5% US 1 753.6 +18.1% 4 788.2 +19.5% Canada 388.7 +14.0% 1 104.8 +14.3% Asia-Pacific 381.8 +12.7% 1 058.9 +5.0% China 164.2 +12.7% 453.4 +1.7% Australia 161.8 +12.7% 445.5 +7.4%Guillaume TEXIER  Chief Executive Officer  said:â€œRexel benefited in the third quarter from solid underlying markets as well as accelerating demand for electrification  driven by the high price of energy  especially in Europe. These results and trends enable us to upgrade our full-year targets for 2022  which should be another record year  both in sales and profitability.Our strong third quarter is also an excellent illustration of how our new strategy  Power Up 2025  allows us to tap into high growth segments of the electrical materials market  driven by powerful and resilient mega trends such as sustainability  energy transition or resource and labor scarcity.These trends  combined with a very strong backlog and our relentless focus on efficiency and digital  position us well for the future  in an economic environment that continues to offer little visibility.â€SALES REVIEW FOR THE PERIOD ENDED SEPTEMBER 30  2022Unless otherwise stated  all comments are on a constant and adjusted basis and  for sales  at same number of working days.Story continuesSALESIn Q3  sales were up +35.5% year-on-year on a reported basis and +16.3% on a constant and same-day basis  reflecting positive momentum in all three geographies.Key figures (â‚¬m) Q3 2022 YoY change 9m 2022 YoY change Sales on a reported basis 4 816.6 +35.5% 13 899.4 +31.0% On a constant and actual-day basis +15.5% +15.4% On a constant and same-day basis +16.3% +14.7%In the third quarter  Rexel posted record sales of â‚¬4 816.6m  up +35.5% on a reported basis  with a well-balanced contribution from both organic growth and M&A. It includes :A positive constant and same-day sales growth of +16.3%A negative calendar effect of (0.8)%A positive currency effect of â‚¬235.2m (i.e. +6.6% of Q3 2021 sales)   mainly due to the appreciation of the US & Canadian dollars against the euro;A positive net scope effect of â‚¬380.7m (i.e. +10.7% of Q3 2021 sales)  mainly due to Mayer acquisition in the US.On a constant and same-day basis  sales were up +16.3% resulting from :Accelerating trends in all 3 geographies with North America up +17.3%  Europe up +15.9% and Asia-Pacific up +12.7%.Robust volume growth  reflecting favorable underlying demand as well as our ability to benefit from electrification trends and growing demand for energy efficiency solutions amid rising energy costs  as illustrated by above-Group average growth of product categories such as PV  EV or HVAC.By geography :North America is up +10.1% in volume in the quarter  twice the Q2 22 growth of +5.1%  notably thanks to favorable trends in Project activity and sustained demand in ProximityEurope is up +5.7% in volume vs (0.5)% in Q2 22 on market share gains  an easier base effect and strong demand in electrificationAsia-Pacific is up +4.1% in volume vs (13.6)% in Q2 22  benefiting from the post-lockdown recovery in China and positive momentum in Australia.A favorable pricing environment for non-cable products (900bps contribution in the quarter)  resulting from an additional rise recorded in Q3 2022  offsetting the lower expected carryover effect of price increases passed in 2021. Those additional rises in selling price result from the overall rise of production costs from our suppliers  notably reflecting increases in wages and energy costs.A neutral copper-cable price contribution (-0.2% contribution in Q3 2022)  resulting from the lower copper price during the quarter compared to Q3 21.Further growth in digitalization in all three geographies  with a strong increase in the US. Digital sales now represent c. 25% of sales  up c. 240bps  with North America up +409bps (16.9% of sales)  Europe up +127bps (35.2% of sales) and Asia-Pacific up +49bps (5.5% of sales).In the quarter  supply chain tensions improved slightly overall  with the exception of semi-conductors. This â€œscarcity environmentâ€ continues to be an opportunity for Rexel  as we help our customers deal with product and labor availability shortages to unlock productivity gains.In 9m 2022  Rexel posted sales of â‚¬13 899.4m   up +31.0% on a reported basis  including:A positive constant and same-day sales growth of +14.7% including a positive impact of +1.9% from the change in copper-based cable prices (vs a positive impact of +5.2% in 9m 2021)A positive calendar effect of +0.7%A positive currency effect of â‚¬516.2m (i.e. +4.9% of 9m 2021 sales)  mainly due to the appreciation of the US & Canadian dollars against the euroA positive net scope effect of â‚¬916.1m (i.e. +8.6% of 9m 2021 sales)  mainly resulting from the acquisition of Mayer in the USEurope (48% of Group sales): +15.9% in Q3 on a constant and same-day basisIn the third quarter  sales in Europe increased by +15.9% on a reported basis  including a positive currency effect of +0.6%  or â‚¬10.9m  mainly due to the appreciation of the Swiss Franc against the euro and a positive scope effect of +0.7%  or â‚¬14.3m  resulting from the acquisition of Trilec in Belgium. The calendar effect stood at (1.5)% in the quarter. On a constant and same-day basis  sales were up +15.9% in Q3 accelerating versus +10.4% posted in Q2 22.Key figures (â‚¬m) Q3 2022 YoY change 9m 2022 YoY change Europe 2 292.5 +15.9% 6 947.5 +13.2% France 808.3 +10.2% 2 570.8 +9.3% Scandinavia 292.3 +21.2% 878.8 +14.0% Benelux 268.0 +27.0% 792.1 +19.8% Germany 258.8 +25.7% 726.6 +19.4% UK 194.8 +9.5% 613.9 +12.2% Switzerland 158.7 +6.3% 451.7 +5.2%Overall in Europe  sales growth acceleration is largely driven by the boost in volumes (+5.7% in Q3 22 vs (0.5)% in Q2 22)  resulting from market outperformance  a more favorable base effect and robust demand in electrification product categories: PV  HVAC  EV (12% of sales) were up more than 80%  contributing for 650bps to same-day sales growth in the quarter. In an environment of rising energy prices  the payback of energy efficiency projects has been significantly shortened  from 9 years on average to up to 1 year depending on countries. In addition  through PV solutions  customers increase their energy autonomy.Sales in France (35% of the regionâ€™s sales) were up +10.2%  driven by continued market share gains amid labor and product scarcity. The environment remains favorable in the renovation construction business (both residential and commercial). Electric Vehicles  Photovoltaic and HVAC contributed for c. 200bps. The quarter was also marked by higher digital penetration (c. 29% of sales  up c. 260bps).Sales in Scandinavia (13% of the regionâ€™s sales) were up +21.2%. Robust sales growth in Sweden  the largest country  was driven by the Residential market  largely boosted by our ability to serve PV demand. The Commercial and Industrial segments also contributed to the overall growth.Benelux (12% of the regionâ€™s sales) grew by +27.0%  thanks to renewable energy products (PV/EV/HVAC representing 18% of sales  up c. 90% yoy and contributing for 1 110bps)  in a context of rising energy prices.Sales in Germany (11% of the regionâ€™s sales) posted strong +25.7% growth  with further market share gains while increasing business selectivity. Growth during the quarter was supported by Residential and Industrial markets. PV demand was a major growth driver (up c. 280%  contributing for 1 270bps)  driven by the focus on increasing the countryâ€™s energy independence in the context of the war in Ukraine. Industrial demand was driven by machine manufacturers  automotive and energy & water markets.In the UK (8% of the regionâ€™s sales)  sales increased by +9.5%  mostly from the Commercial segment. The country benefited from a strong selling price contribution to compensate for currency depreciation on imported products.North America (44% of Group sales): +17.3% in Q3 on a constant and same-day basisIn the third quarter  sales in North America increased by +70.0% on a reported basis  including a positive currency effect of +15.5%  or â‚¬195.6m  from the appreciation of the US & Canadian dollars against the euro  and a positive scope effect of +29.3%  or â‚¬368.7m  from the acquisition of Mayer and  to a lesser extent  Horizon Solutions in the US. On a constant and same-day basis  sales were up +17.3%  driven by the US and Canada.Key figures (â‚¬m) Q3 2022 YoY change 9m 2022 YoY change North America 2 142.3 +17.3% 5 893.0 +18.5% United States 1 753.6 +18.1% 4 788.2 +19.5% Gulf Central +40.8% +38.4% Mountain Plains +38.6% +36.1% California +33.5% +20.1% Midwest +28.9% +20.8% Florida +21.5% +21.6% Northwest +15.2% +20.0% Southeast +13.8% +13.9% Northeast +13.6% +6.9% Mayer +2.7% +11.6% Canada 388.7 +14.0% 1 104.8 +14.3%In the US (82% of the regionâ€™s sales)  sales posted solid +18.1% growth on a same-day basis  accelerating compared to Q2 22 with above average trends in Gulf Central (Industrial automation and Oil & Gas)  Mountain Plains (Commercial segment in large cities) and California (Commercial business). By market  all three end-markets grew at a similar pace with further positive development in Commercial  Residential and Industrial. We recorded a growth acceleration in our Projects activity and a steady level of order intake.In Canada (18% of the regionâ€™s sales)  sales grew by +14.0% on a same-day basis. It was notably driven by the Industrial end-market up c. 25%  contributing for c. 1 060bps notably boosted by robust demand in oil & gas and mining  contributing to growth for 190bps and 100bps respectively.Asia-Pacific (8% of Group sales): +12.7% in Q3 on a constant and same-day basisIn the third quarter  sales in Asia-Pacific were up +20.6% on a reported basis  including a positive currency effect of +9.1%  or â‚¬28.7m  mainly due to the appreciation of the Chinese renminbi and the Australian dollar against the euro and a negative scope effect of (0.7)%  or â‚¬(2.3)m  related to the disposal of Rexel Saudi Arabia in Q4 2021. On a constant and same-day basis  sales were up +12.7%.Key figures (â‚¬m) Q3 2022 YoY change 9m 2022 YoY change Asia-Pacific 381.8 +12.7% 1 058.9 +5.0% China 164.2 +12.7% 453.4 +1.7% Australia 161.8 +12.7% 445.5 +7.4%In the Pacific (51% of the regionâ€™s sales)  sales were up +14.8% on a constant and same-day basis: In Australia (83% of Pacificâ€™s sales)  sales increased by +12.7%  accelerating from 5% in Q2  driven by robust growth in all segments  particularly Commercial  amid labor scarcity.In Asia (49% of the regionâ€™s sales)  sales increased by +10.6% on a constant and same-day basis: In China (88% of Asiaâ€™s sales)  sales were up +12.7%. The acceleration post lockdown was supported by demand from machinery  automotive  power and renewables. The quarter benefited from selling price increases.FY 2022 OUTLOOKFollowing stronger than projected activity  we are upgrading our FY 22 guidance for the second time.We now anticipate for 2022  at comparable scope of consolidation and exchange rates:Same-day sales growth of c. 12% (vs 7%-9% previously)An adjusted EBITA 1 margin of c. 7.2%  including 70bps of non-recurring items (vs 6.7%  including 50bps of non-recurring items)Free cash flow conversion2 above 60% (unchanged)1 Excluding (i) amortization of PPA and (ii) the non-recurring effect related to changes in copper-based cable prices.2 FCF Before interest and tax/EBITDAaLNB: The estimated impacts per quarter of (i) calendar effects by geography  (ii) changes in the consolidation scope and (iii) currency fluctuations (based on assumptions of average rates over the rest of the year for the Group's main currencies) are detailed in appendix 2.CALENDARFebruary 16  2023 Full-year 2022 resultsApril 20  2023 First-quarter 2023 salesApril 20  2023 Annual Shareholdersâ€™ MeetingFINANCIAL INFORMATIONA slideshow of the third quarter 2022 sales is available on the Groupâ€™s website.ABOUT REXEL GROUPRexel  worldwide expert in the multichannel professional distribution of products and services for the energy world  addresses three main markets: residential  commercial  and industrial. The Group supports its residential  commercial  and industrial customers by providing a tailored and scalable range of products and services in energy management for construction  renovation  production  and maintenance. Rexel operates through a network of over 1 900 branches in 24 countries  with more than 26 000 employees. The Groupâ€™s sales were â‚¬14.7 billion in 2021.Rexel is listed on the Eurolist market of Euronext Paris (compartment A  ticker RXL  ISIN code FR0010451203). It is included in the following indices: CAC Next 20  SBF 120  CAC Large 60  CAC 40 ESG  CAC AllTrade  CAC AllShares  FTSE EuroMid  and STOXX600. Rexel is also part of the following SRI indices: FTSE4Good  Dow Jones Sustainability Index Europe  Euronext Vigeo Europe 120 and Eurozone 120  STOXXÂ® Global ESG Environmental Leaders  and S&P Global Sustainability Yearbook 2022  in recognition of its performance in terms of Corporate Social Responsibility (CSR).For more information  visit www.rexel.com/en.CONTACTSFINANCIAL ANALYSTS / INVESTORSLudovic DEBAILLEUX +33 1 42 85 76 12 ludovic.debailleux@rexel.comPRESSBrunswick: Thomas KAMM +33 1 53 96 83 92 tkamm@brunswickgroup.comGLOSSARYREPORTED EBITA (Earnings Before Interest  Taxes and Amortization) is defined as operating income before amortization of intangible assets recognized upon purchase price allocation and before other income and other expenses.ADJUSTED EBITA is defined as Reported EBITA excluding the estimated non-recurring net impact from changes in copper-based cable prices.EBITDA (Earnings Before Interest  Taxes  Depreciation and Amortization) is defined as operating income before depreciation and amortization and before other income and other expenses.EBITDAaL is defined as EBITDAafter deduction of lease payment following the adoption of IFRS16.RECURRING NET INCOME is defined as net income restated for non-recurring copper effect  other expenses and income  non-recurring financial expenses  net of tax effect associated with the above items.FREE CASH FLOW is defined as cash from operating activities minus net capital expenditure.NET DEBT is defined as financial debt less cash and cash equivalents. Net debt includes debt hedge derivatives.APPENDIXFor appendix  please open the pdf file by clicking on the link at the end of the press release.DISCLAIMERThe Group is exposed to fluctuations in copper prices in connection with its distribution of cable products. Cables accounted for approximately 17% of the Group's sales and copper accounts for approximately 60% of the composition of cables. This exposure is indirect since cable prices also reflect copper suppliers' commercial policies and the competitive environment in the Group's markets. Changes in copper prices have an estimated so-called ""recurring"" effect and an estimated so called ""non-recurring"" effect on the Group's performance assessed as part of the monthly internal reporting process of the Rexel Group: i) the recurring effect related to the change in copper-based cable prices corresponds to the change in value of the copper part included in the sales price of cables from one period to another. This effect mainly relates to the Groupâ€™s sales; ii) the non-recurring effect related to the change in copper-based cable prices corresponds to the effect of copper price variations on the sales price of cables between the time they are purchased and the time they are sold  until all such inventory has been sold (direct effect on gross profit). Practically  the non-recurring effect on gross profit is determined by comparing the historical purchase price for copper-based cable and the supplier price effective at the date of the sale of the cables by the Rexel Group. Additionally  the non-recurring effect on EBITA corresponds to the non-recurring effect on gross profit  which may be offset  when appropriate  by the non-recurring portion of changes in the distribution and administrative expenses.The impact of these two effects is assessed for as much of the Groupâ€™s total cable sales as possible  over each period. Group procedures require that entities that do not have the information systems capable of such exhaustive calculations to estimate these effects based on a sample representing at least 70% of the sales in the period. The results are then extrapolated to all cables sold during the period for that entity. Considering the sales covered. the Rexel Group considers such estimates of the impact of the two effects to be reasonable.This document may contain statements of future expectations and other forward-looking statements. By their nature  they are subject to numerous risks and uncertainties  including those described in the Universal Registration Document registered with the French AutoritÃ© des MarchÃ©s Financiers (AMF) on March 10  2022 under number D.22-0083.These forward-looking statements are not guarantees of Rexel's future performance  Rexel's actual results of operations  financial condition and liquidity as well as development of the industry in which Rexel operates may differ materially from those made in or suggested by the forward-looking statements contained in this release. The forward-looking statements contained in this communication speak only as of the date of this communication and Rexel does not undertake  unless required by law or regulation  to update any of the forward-looking statements after this date to conform such statements to actual results to reflect the occurrence of anticipated results or otherwise.The market and industry data and forecasts included in this document were obtained from internal surveys  estimates  experts and studies  where appropriate  as well as external market research  publicly available information and industry publications. Rexel  its affiliates  directors  officers  advisors and employees have not independently verified the accuracy of any such market and industry data and forecasts and make no representations or warranties in relation thereto. Such data and forecasts are included herein for information purposes only.This document includes only summary information and must be read in conjunction with Rexelâ€™s Universal Registration Document registered with the AMF on March 10  2022 under number D.22-0083  as well as the financial statements and consolidated result and activity report for the 2021 fiscal year which may be obtained from Rexelâ€™s website (www.rexel.com).Attachment",neutral,0.0,1.0,0.0,mixed,0.73,0.15,0.12,True,English,"['THIRD-QUARTER', 'SALES', 'additional selling price increase', 'Strong selling price increase', 'positive net scope effect', 'negative calendar effect', 'easier base effect', 'Chief Executive Officer', 'solid underlying markets', 'electrical materials market', 'PERIOD ENDED SEPTEMBER', 'positive currency effect', 'market share gains', 'favorable pricing environment', 'good underlying demand', 'high growth segments', 'Group average growth', 'rising energy costs', 'resilient mega trends', 'favorable underlying demand', 'energy efficiency solutions', 'strong third quarter', 'same-day sales growth', 'Robust volume growth', 'high price', 'Robust growth', 'Strong momentum', 'strong backlog', 'positive momentum', 'strong demand', 'production costs', 'Group revenues', 'Share buyback', 'economic environment', 'additional rise', 'Double-digit growth', 'organic growth', 'favorable trends', 'robust start', 'energy transition', 'same-day basis', 'second time', 'non-cable products', 'three end-markets', 'internal transformation', 'Strategic focus', 'M&A', '+467bps improvement', 'Ebita margin', '3.7 million shares', 'Key figures', 'North America', 'Guillaume TEXIER', 'full-year targets', 'excellent illustration', 'new strategy', 'labor scarcity', 'relentless focus', 'little visibility', 'same number', 'working days', 'Canadian dollars', 'Mayer acquisition', 'growing demand', 'product categories', 'Project activity', 'post-lockdown recovery', 'Record quarter', '750bps contribution', '900bps contribution', 'actual-day basis', 'adjusted basis', 'reported basis', 'SALES REVIEW', 'record sales', 'positive constant', 'Q2 22 growth', 'Digital penetration', 'three geographies', 'FY 22 guidance', 'digital sales', 'record year', 'electrification trends', 'Q3 2021 sales', 'geography Europe', '2022 guidance', '3 geographies', 'REXEL', 'THIRD-QUARTER', 'Acceleration', 'ability', 'boost', 'pass', 'Residential', 'Commercial', 'Industrial', 'c.', 'YoY', 'France', 'Scandinavia', 'Benelux', 'Germany', 'UK', 'Canada', 'Asia-Pacific', 'China', 'Australia', 'results', 'Power', 'resource', 'future', 'THE', 'comments', 'Story', 'balanced', 'appreciation', 'PV', 'HVAC', 'Proximity']",2022-10-27,2022-10-28,finance.yahoo.com
12233,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/27/2542413/0/en/Intertrust-delivers-accelerated-revenue-growth-in-Q3.html,Intertrust delivers accelerated revenue growth in Q3,Amsterdam  the Netherlands â€“ 27 October 2022 â€“ Intertrust N.V. (â€œIntertrustâ€ or â€œCompanyâ€) [Euronext: INTER]  a global leader in providing tech-enabled fund and corporate solutions  today provides a condensed Q3 and 9M 2022 trading update. Q3 2022 underlying â€¦,Amsterdam  the Netherlands â€“ 27 October 2022 â€“ Intertrust N.V. (â€œIntertrustâ€ or â€œCompanyâ€) [Euronext: INTER]  a global leader in providing tech-enabled fund and corporate solutions  today provides a condensed Q3 and 9M 2022 trading update. Q3 2022 underlying revenue growth was 8.2% and Q3 2022 adjusted EBITA margin was 26.4%. Cash flow from operating activities of â‚¬ 31.5m in the third quarter increased 41.0% compared to last year. Intertrust confirms that the public offer by CSC is progressing as planned now CSC and Intertrust have obtained all Regulatory Clearances. Reference is made to the press release dated 17 October 2022. The Offer Period ends on 31 October 2022 at 17:40 CET. CSC and Intertrust jointly recommend to all Shareholders to tender their Shares before that time.Q3 2022 revenue was â‚¬ 159.0 million (+13.4% y-o-y). Underlying revenue growth was 8.2%  driven by double-digit growth in US Fund Services and Luxembourg  a return to growth in Cayman Islands and continued solid momentum in Rest of the World. This was only partly offset by lower revenues in the Netherlands. In the first nine months  revenue totalled â‚¬ 459.1 million (+8.3% y-o-y) with underlying revenue growth of 4.2%.Adjusted EBITA was â‚¬ 42.0 million  resulting in a 26.4% adjusted EBITA margin in Q3 2022 and reflects increased investments in the workforce  including onboarding and training of new personnel. Additionally  adjusted EBITA included â‚¬ 4.4 million one-off costs related to remediation activities. In the first nine months  adjusted EBITA amounted to â‚¬ 115.2 million  resulting in a 25.1% margin.Shankar Iyer  CEO of Intertrust: â€œWe see strong top-line momentum with accelerated revenue growth in the third quarter. Our continued investments in compliance  remediation and in our workforce support the long-term growth of our business. Our initiatives to contain costs in the current inflationary environment are beginning to bear fruit  resulting in a margin improvement compared to the previous quarter. Weâ€™ve entered the final stages of the transaction with CSC  marking a new era for the Company. We strongly believe the combination with CSC will deliver greater value for clients  colleagues and other stakeholders  driven by a truly long-term focus and enhanced efforts on compliance and remediation. We are very excited about this next chapter for the Company and our colleagues  after completion of the public offer by CSC.â€The figures provided today are unaudited. This press release contains information that qualifies  or may qualify  as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.Attachment,neutral,0.05,0.95,0.0,mixed,0.38,0.25,0.37,True,English,"['revenue growth', 'Intertrust', 'Q3', 'EU Market Abuse Regulation', 'Q3 2022 underlying revenue growth', '9M 2022 trading update', 'US Fund Services', 'first nine months', 'current inflationary environment', 'strong top-line momentum', '4.4 million one-off costs', 'Intertrust N.V.', '26.4% adjusted EBITA margin', 'solid momentum', 'double-digit growth', 'long-term growth', 'Q3 2022 revenue', 'global leader', 'corporate solutions', 'Cash flow', 'operating activities', 'third quarter', 'last year', 'public offer', 'Regulatory Clearances', 'press release', 'Offer Period', 'Cayman Islands', 'lower revenues', 'new personnel', 'Shankar Iyer', 'margin improvement', 'previous quarter', 'final stages', 'new era', 'greater value', 'other stakeholders', 'long-term focus', 'next chapter', 'continued investments', 'remediation activities', '25.1% margin', 'Amsterdam', 'Netherlands', '27 October', 'Company', 'condensed', 'CSC', 'Reference', '31 October', '17:40 CET', 'Shareholders', 'Shares', 'time', 'Luxembourg', 'return', 'Rest', 'World', 'workforce', 'onboarding', 'training', 'CEO', 'compliance', 'business', 'initiatives', 'fruit', 'transaction', 'combination', 'clients', 'colleagues', 'enhanced', 'efforts', 'completion', 'figures', 'information', 'inside', 'meaning', 'Article', 'Attachment']",2022-10-27,2022-10-28,globenewswire.com
12234,EuroNext,NewsApi.org,https://www.prnewswire.co.uk/news-releases/tetragon-financial-group-limited-announcement-of-dividend-and-intention-to-conduct-tender-offer-301660623.html,Tetragon Financial Group Limited Announcement of Dividend and Intention to Conduct Tender Offer,LONDON  Oct. 27  2022 /PRNewswire/ -- Dividend Announcement: On 26 October 2022  the Board of Directors of Tetragon declared a dividend of U.S.$0.11 (11.00 cents) per share in respect of the third quarter of 2022. The ex-dividend date is 1 November 2022. The â€¦,LONDON  Oct. 27  2022 /PRNewswire/ --Dividend Announcement:On 26 October 2022  the Board of Directors of Tetragon declared a dividend of U.S.$0.11 (11.00 cents) per share in respect of the third quarter of 2022. The ex-dividend date is 1 November 2022. The record date is 2 November 2022. Payment of the dividend will take place from 25 November 2022.Tetragon's website (www.tetragoninv.com) includes information on Tetragon's Optional Stock Dividend Plan for those shareholders electing to receive dividends in the form of Tetragon shares. Shareholders may elect to receive dividends in the form of Tetragon shares by making a dividend share election up to 14 November 2022. If no election is made  the dividend will be paid in cash from 25 November 2022.Cash dividends may be received in Sterling by those shareholders making a dividend currency election up to 14 November 2022. If no election is made  the dividend will be paid in U.S. dollars from 25 November 2022.Intention to Conduct a Tender Offer:Tetragon intends to conduct a tender offer for a number of Tetragon non-voting shares with a maximum value of up to U.S.$25 million  to be held as treasury shares. J.P. Morgan Securities plc (which conducts its U.K. investment banking business as J.P. Morgan Cazenove) will act as dealer manager in the tender offer  which will use a modified Dutch auction structure. Details of this planned tender offer will be announced shortly. A repurchase of Tetragon shares at a price below NAV will be accretive to its fully diluted NAV per share.About Tetragon:Tetragon is a closed-ended investment company that invests in a broad range of assets  including public and private equities and credit (including distressed securities and structured credit)  convertible bonds  real estate  venture capital  infrastructure  bank loans and TFG Asset Management  a diversified alternative asset management business. Where appropriate  through TFG Asset Management  Tetragon seeks to own all  or a portion  of asset management companies with which it invests in order to enhance the returns achieved on its capital. Tetragon's investment objective is to generate distributable income and capital appreciation. It aims to provide stable returns to investors across various credit  equity  interest rate  inflation and real estate cycles. The company's non-voting shares are traded on Euronext in Amsterdam  a regulated market of Euronext Amsterdam N.V.  and on the Specialist Fund Segment of the main market of the London Stock Exchange. For more information please visit the company's website at www.tetragoninv.com.Tetragon: Press Inquiries:Yuko Thomas Investor Relations ir@tetragoninv.com Prosek Partners Pro-tetragon@prosek.comUnited States Ryan FitzGibbon Remy Marin +1 646 818 9298 +1 646 818 9234 United Kingdom Henrietta Dehn Alexa Bethell +44 7717 281 665 +44 7940 166 251This release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (2014/596/EU)  or EU MAR  and of the UK version of EU MAR as it forms part of UK law by virtue of the European Union (Withdrawal) Act (as amended).This release does not contain or constitute an offer to sell or a solicitation of an offer to purchase securities in the United States or any other jurisdiction. The securities of Tetragon have not been and will not be registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States or to U.S. persons unless they are registered under applicable law or exempt from registration. Tetragon does not intend to register any portion of its securities in the United States or to conduct a public offer of securities in the United States. In addition  Tetragon has not been and will not be registered under the U.S. Investment Company Act of 1940 and investors will not be entitled to the benefits of such Act. Tetragon is registered in the public register of the Netherlands Authority for the Financial Markets under Section 1:107 of the Dutch Financial Markets Supervision Act as an alternative investment fund from a designated state.SOURCE Tetragon Financial Group Limited,neutral,0.0,0.99,0.0,negative,0.0,0.13,0.87,True,English,"['Tetragon Financial Group Limited Announcement', 'Tender Offer', 'Dividend', 'Intention', 'United Kingdom Henrietta Dehn Alexa Bethell', 'United States Ryan FitzGibbon Remy Marin', 'U.K. investment banking business', 'diversified alternative asset management business', 'J.P. Morgan Securities plc', 'SOURCE Tetragon Financial Group Limited', 'Dutch Financial Markets Supervision Act', 'J.P. Morgan Cazenove', 'U.S. Investment Company Act', 'Yuko Thomas Investor Relations', 'Optional Stock Dividend Plan', 'U.S. Securities Act', 'Euronext Amsterdam N.V.', 'EU Market Abuse Regulation', 'U.S. dollars', 'U.S. persons', 'alternative investment fund', 'Dutch auction structure', 'TFG Asset Management', 'asset management companies', 'closed-ended investment company', 'Specialist Fund Segment', 'London Stock Exchange', 'real estate cycles', 'investment objective', 'Dividend Announcement', 'regulated market', 'main market', 'distressed securities', 'third quarter', 'ex-dividend date', 'record date', 'maximum value', 'treasury shares', 'dealer manager', 'broad range', 'private equities', 'convertible bonds', 'bank loans', 'distributable income', 'interest rate', 'voting shares', 'Press Inquiries', 'Prosek Partners', 'UK version', 'UK law', 'European Union', 'other jurisdiction', 'applicable law', 'Netherlands Authority', 'Tender Offer', 'venture capital', 'capital appreciation', 'public register', 'currency election', 'structured credit', 'stable returns', 'public offer', 'Tetragon shares', 'share election', 'Cash dividends', 'Oct.', 'PRNewswire', '26 October', 'Board', 'Directors', 'respect', '1 November', '2 November', 'Payment', 'place', '25 November', 'website', 'information', 'shareholders', '14 November', 'Sterling', 'Intention', 'number', 'Details', 'repurchase', 'price', 'NAV', 'assets', 'infrastructure', 'portion', 'order', 'investors', 'equity', 'inflation', 'release', 'inside', 'meaning', 'Article', 'virtue', 'solicitation', 'registration', 'addition', 'benefits', 'Section']",2022-10-27,2022-10-28,prnewswire.co.uk
12235,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/27/2543118/0/en/Press-release-Biocartis-Group-NV-Results-of-the-Extraordinary-Shareholders-Meeting-held-on-27-October-2022.html,Press release Biocartis Group NV: Results of the Extraordinary Shareholdersâ€™ Meeting held on 27 October 2022,PRESS RELEASE: REGULATED INFORMATION  27 October 2022  17:40 CEST    Results of the Extraordinary Shareholdersâ€™ MeetingÂ held on 27 October 2022 ...,English DutchPRESS RELEASE : REGULATED INFORMATION27 October 2022  17:40 CESTResults of the Extraordinary Shareholdersâ€™ Meeting held on 27 October 2022Mechelen  Belgium  27 October 2022 â€“ Biocartis Group NV (the â€˜Companyâ€™ or â€˜Biocartisâ€™)  an innovative molecular diagnostics company (Euronext Brussels: BCART)  held its extraordinary general shareholders' meeting today. The proposed resolution referred to in item 7 of the agenda regarding the approval and ratification of the change of control clauses in the legal documentation relating to the comprehensive recapitalization transaction of the Company was approved by the extraordinary general shareholders' meeting. However  there was no deliberation and voting on the items 2 to 6 of the agenda of the extraordinary general shareholders' meeting  because the attendance quorum to deliberate and vote on such items was not reached.Biocartis will therefore convene a second extraordinary general shareholders' meeting for the relevant agenda items  which is to be held on Monday 14 November 2022 at 2:00 p.m. (Belgian time) at the offices of the Company at Generaal de Wittelaan 11B  2800 Mechelen  Belgium. There shall be no attendance quorum for this new extraordinary general shareholders' meeting.All documents relating to the general shareholdersâ€™ meeting can be consulted on the website of the Company.--- END ---More information:Renate DegraveHead of Corporate Communications & Investor Relations Biocartise-mail rdegrave@biocartis.comtel +32 15 631 729mobile +32 471 53 60 64About BiocartisWith its revolutionary and proprietary Idyllaâ„¢ platform  Biocartis (Euronext Brussels: BCART) aspires to enable personalized medicine for patients around the world through universal access to molecular testing  by making molecular testing actionable  convenient  fast and suitable for any lab. The Idyllaâ„¢ platform is a fully automated sample-to-result  real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house access to accurate molecular information in a minimum amount of time for faster  informed treatment decisions. Idyllaâ„¢â€™s continuously expanding menu of molecular diagnostic tests address key unmet clinical needs  with a focus in oncology. This is the fastest growing segment of the molecular diagnostics market worldwide. Today  Biocartis offers tests supporting melanoma  colorectal  lung and liver cancer  as well as for COVID-19  Flu  RSV and sepsis. For more information  visit www.biocartis.com or follow Biocartis on Twitter @Biocartis_   Facebook or LinkedIn.Biocartis and Idyllaâ„¢ are registered trademarks in Europe  the United States and other countries. The Biocartis and Idyllaâ„¢ trademark and logo are used trademarks owned by Biocartis. Please refer to the product labeling for applicable intended uses for each individual Biocartis product.This press release is not for distribution  directly or indirectly  in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933  as amended.Forward-looking statementsCertain statements  beliefs and opinions in this press release are forward-looking  which reflect the Company's or  as appropriate  the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations  financial condition  liquidity  performance  prospects  growth  strategies and the industry in which the Company operates. By their nature  forward-looking statements involve a number of risks  uncertainties  assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks  uncertainties  assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including  but not limited to  changes in demand  competition and technology  can cause actual events  performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition  even if actual results or developments are consistent with the forward-looking statements contained in this press release  those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result  the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events  conditions  assumptions or circumstances on which these forward-looking statements are based  except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements  which speak only as of the date of this press release.,neutral,0.0,1.0,0.0,mixed,0.09,0.08,0.83,True,English,"['Biocartis Group NV', 'Extraordinary Shareholdersâ€™ Meeting', 'Press release', 'Results', '27 October 2022', ""second extraordinary general shareholders' meeting"", ""new extraordinary general shareholders' meeting"", 'faster, informed treatment decisions', 'key unmet clinical needs', 'U.S. Securities Act', 'Extraordinary Shareholdersâ€™ Meeting', 'general shareholdersâ€™ meeting', 'innovative molecular diagnostics company', 'molecular diagnostics market', 'comprehensive recapitalization transaction', 'Generaal de Wittelaan', 'Polymerase Chain Reaction', 'fastest growing segment', 'applicable intended uses', 'proprietary Idyllaâ„¢ platform', 'accurate molecular information', 'molecular diagnostic tests', 'The Idyllaâ„¢ platform', 'Biocartis Group NV', 'United States Securities', 'individual Biocartis product', 'relevant agenda items', 'molecular testing', 'product labeling', 'English Dutch', 'PRESS RELEASE', 'REGULATED INFORMATION', 'Euronext Brussels', 'control clauses', 'legal documentation', 'attendance quorum', 'Monday 14 November', 'More information', 'Renate Degrave', 'Corporate Communications', 'Investor Relations', 'personalized medicine', 'real-time PCR', 'minimum amount', 'expanding menu', 'liver cancer', 'other countries', 'Idyllaâ„¢ trademark', 'Exchange Commission', 'current expectations', 'financial condition', 'financial effects', 'The Biocartis', 'Forward-looking statements', 'future periods', 'Belgian time', 'universal access', 'actual events', 'past trends', 'other factors', 'actual results', 'future events', 'future performance', 'October', 'Mechelen', 'Belgium', 'BCART', 'resolution', 'approval', 'ratification', 'deliberation', 'offices', 'documents', 'website', 'Head', 'mail', 'revolutionary', 'patients', 'world', 'system', 'house', 'focus', 'oncology', 'melanoma', 'colorectal', 'lung', 'COVID', 'Flu', 'RSV', 'sepsis', 'Twitter', 'Facebook', 'LinkedIn', 'trademarks', 'Europe', 'logo', 'distribution', 'jurisdiction', 'persons', 'restrictions', 'responsibility', 'violation', 'offer', 'invitation', 'sale', 'purchase', 'America', 'registration', 'exemption', 'beliefs', 'opinions', 'projections', 'operations', 'liquidity', 'prospects', 'growth', 'strategies', 'industry', 'nature', 'number', 'risks', 'uncertainties', 'assumptions', 'outcome', 'plans', 'multitude', 'changes', 'demand', 'competition', 'technology', 'development', 'activities', 'guarantees', 'representation', 'addition', 'warranties', '27', '2:00']",2022-10-27,2022-10-28,globenewswire.com
12236,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/27/2543142/0/en/CBI-Future-Rave-the-new-label-launched-by-David-Guetta-and-Morten-is-teaming-up-with-AlphaVerse-to-develop-a-metaverse-dedicated-to-the-new-music-genre-created-by-these-world-renow.html,CBI: Future Rave  the new label launched by David Guetta and Morten  is teaming up with AlphaVerse to develop a metaverse dedicated to the new music genre created by these world-renowned DJs and music producers,Future Rave  the new label launched by David Guetta and Morten  is teaming up with AlphaVerse to develop a metaverse dedicated to the new music genre created by these world-renowned DJs and music producers,French EnglishFuture Rave  the new label launched by David Guetta and Morten  is teaming up with AlphaVerse to develop a metaverse dedicated to the new music genre created by these world-renowned DJs and music producersDavid Guetta and Morten will deploy their new Future Rave label in the metaverseA new universe will be created within AlphaVerse  CBIâ€™s metaverse  for sharing  finding new artists  creating and exchanging with the communityThis project is supported by Blockchain Artists Agency (BAA)  the blockchain talent management agencyCRYPTO BLOCKCHAIN INDUSTRIES (CBI  Euronext Growth Paris: FR0014007LW0  ALCBI) is today announcing an agreement with Future Rave  the music label co-founded by David Guetta and Morten  the world-renowned DJs and music producers  to develop a dedicated universe for the new music genre created by this duo. Future Rave will offer concert and entertainment experiences  creation tools and various NFTs  and will lead a community within the metaverse around this new genre.Future Rave is a music genre created through a collaboration between these two world-renowned DJs that offers a more underground approach to electronic dance music and has attracted a large community of fans and new creators. Thanks to AlphaVerse  Future Rave will harness the blockchain to create innovative experiences around music and support the development of new sounds and the emergence of new artists. The universe will include free-access forums for exchanging  streaming tracks and concerts  and NFTs to offer exclusive experiences  as well as community management and content creation tools. One of this worldâ€™s objectives will be to identify new artists who will be able to share tracks within the community  and this metaverse will contain previously unreleased and exclusive tracks.The Future Rave universe will offer a permanent platform for this new music genre  which is very popular both within the metaverse and in the real world. This initiative will help develop this new sound and its culture in order to continue pushing the limits and exploring all the opportunities that electronic music has to offer.The project bringing together Future Rave and AlphaVerse is brought by Blockchain Artists Agency (BAA)  a talent agency that is 50% owned by CBI in partnership with Jean-Charles Carre and Michael Wiesenfeld. This talent representation agency  specialized in marketing and managing talents and brands within the world of the blockchain  NFTs and metaverses  supports its clients - sports professionals and artists - to showcase their projects and rights and create value in the blockchain arena.Following Beat AlphaVerse  in partnership with United at Home  the charity initiative supported by David Guetta  Xave  the music platform currently being acquired by CBI  and Rave Age (rave music)  this is the fourth dedicated music universe developed by CBI  each with a specific focus.Learn more at https://alphaverse.comDisclaimer:The realisation of projects  as well as their operational budget and financing plan  remain fundamentally subject to uncertainties  and the non-realisation of the underlying assumptions may have a significant impact on the value of assets and liabilities.ABOUT CBICRYPTO BLOCKCHAIN INDUSTRIES (â€œCBIâ€) is a French company that develops  operates and invests in video games  business applications and selected projects relating to the blockchain  non-fungible tokens (â€œNFTsâ€) and cryptocurrencies. Founded by FrÃ©dÃ©ric Chesnais  a renowned gaming industry entrepreneur and blockchain pioneer  CBI aims to develop and unlock value from a portfolio of blockchain activities across multiple industries (video games  finance  logistics  etc.) with a view to capitalizing on this technology  either directly or through partnerships. CBI has already made several investments and is currently launching AlphaVerse  a blockchain technology-based virtual world  or metaverse. CBI shares are listed on the E2 compartment (Public offer) of the Euronext Growth Paris stock exchange. Learn more at www.cbicorp.io.ContactCBIFrÃ©dÃ©ric CHESNAISPDGfredchesnais@cbicorp.iowww.cbicorp.io Listing SponsorAtout CapitalRodolphe OSSOLArodolphe.ossola@atoutcapital.com Financial communicationCalyptusMaisie Mouret+33 1 53 65 68 68cbi@calyptus.netABOUT BLOCKCHAIN ARTISTS AGENCY (BAA)A talent representation agency specializing in marketing & leveraging talents and brands within the world of NFTs and metaverses. BAA team is made of dedicated  service-oriented  and creative individuals striving to maximize its clients' exposure and revenues within the world of NFTs and Virtual worlds (aka. Metaverse) BAA team members have an out-of-the-box mindset  and an unmatched experience in the video game and entertainment industry  representing athletes and artists alike. www.baa.agency.ABOUT FUTURE RAVEOver the past few years  world-renowned DJ & producer David Guetta and Danish phenomenon MORTEN created a brand-new dance music culture by unleashing their pioneering 'Future Rave' sound. Emerging from their desire to play something new in their sets  the inventive genre reflects their vision on the future of electronic dance music: fresh and innovative. Both David & MORTEN are heavily inspired by the underground  and they have made it their trademark to bring sounds and formats from the underground and present it to the masses. With Future Rave  the duo is bringing the best elements of both the EDM and underground scenes together  while keeping the cutting-edge sound ever-evolving. Future Rave builds bridges between the energy and the hooks of EDM  the futuristic sounds of techno and the emotion of trance and (future) house. Supported by the entire industry  DJs worldwide are loving this new era in dance music and bring the hard-hitting sound to their sets. Future Rave isn't just a sound  it brought a wave of new energy to the DJ community and created an entirely new culture amongst fans of electronic dance music.Attachment,neutral,0.01,0.99,0.0,mixed,0.3,0.3,0.4,True,English,"['new music genre', 'new label', 'music producers', 'Future Rave', 'David Guetta', 'world-renowned DJs', 'CBI', 'Morten', 'AlphaVerse', 'metaverse', 'Euronext Growth Paris stock exchange', 'FrÃ©dÃ©ric Chesnais', 'renowned gaming industry entrepreneur', 'brand-new dance music culture', 'fourth dedicated music universe', ""pioneering 'Future Rave' sound"", 'The Future Rave universe', 'blockchain talent management agency', 'blockchain technology-based virtual world', 'new Future Rave label', 'talent representation agency', 'blockchain, non-fungible tokens', 'electronic dance music', 'CRYPTO BLOCKCHAIN INDUSTRIES', 'content creation tools', 'io Listing Sponsor', 'Blockchain Artists Agency', 'two world-renowned DJs', 'new music genre', 'BAA team members', 'talent agency', 'dedicated universe', 'new sound', 'music label', 'new label', 'electronic music', 'rave music', 'Virtual worlds', 'entertainment industry', 'new universe', 'new genre', 'multiple industries', 'blockchain arena', 'blockchain pioneer', 'blockchain activities', 'baa.agency', 'new artists', 'music producers', 'music platform', 'Rave Age', 'community management', 'new creators', 'French English', 'David Guetta', 'entertainment experiences', 'underground approach', 'innovative experiences', 'free-access forums', 'exclusive experiences', 'permanent platform', 'Jean-Charles Carre', 'Michael Wiesenfeld', 'sports professionals', 'specific focus', 'operational budget', 'financing plan', 'underlying assumptions', 'significant impact', 'French company', 'video games', 'business applications', 'several investments', 'E2 compartment', 'Public offer', 'PDG fredchesnais', 'Atout Capital', 'Financial communication', 'Maisie Mouret', 'creative individuals', 'box mindset', 'unmatched experience', 'Danish phenomenon', 'streaming tracks', 'exclusive tracks', 'real world', 'charity initiative', ""clients' exposure"", 'large community', 'various NFTs', 'Beat AlphaVerse', 'CBI shares', 'Rodolphe OSSOLA', 'Morten', 'metaverse', 'project', 'ALCBI', 'agreement', 'duo', 'concert', 'collaboration', 'fans', 'development', 'emergence', 'exchanging', 'objectives', 'unreleased', 'order', 'limits', 'opportunities', 'partnership', 'marketing', 'talents', 'brands', 'rights', 'value', 'United', 'Home', 'Xave', 'Disclaimer', 'realisation', 'uncertainties', 'assets', 'liabilities', 'cryptocurrencies', 'portfolio', 'finance', 'logistics', 'view', 'cbicorp', 'Contact', 'Calyptus', 'revenues', 'athletes', 'past', 'years', 'des']",2022-10-27,2022-10-28,globenewswire.com
12237,EuroNext,NewsApi.org,https://seekingalpha.com/article/4549871-growth-is-around-the-corner-for-golar-lng,Golar LNG Stock: Growth Is Around The Corner (NASDAQ:GLNG),Golar has completed a massive transformation process and is well-positioned for growth. Here's what investors need to know.,"LeestatNote: Golar LNG (NASDAQ:GLNG) is a company focused on floating liquefied natural gas (FLNG) facilities. I suggest readers review an interview from March 2020 in which I offer a detailed analysis of the company  with an update in May 2021 and a new update in January 2022. I believe these articles will provide a good basis for the one that follows.There has been a lot happening since my last article at the beginning of the year. I suppose the most important event from an external point of view is the fact that Golar's stock price has performed extremely well in a rough market  rising 85% in contrast to the S&P's 20% drop  according to the Seeking Alpha tracker.As value investors know all too well  Mr. Market is a manic-depressive animal whose irrational mood sometimes offers the opportunity to buy very high-quality assets at very attractive prices. Investors have gone from hate to love in a short period of time  causing a huge swing in the stock price in a period when Golar has not added any new projects/assets to his portfolio. There is no doubt that the environment has improved after the Russian invasion  but I firmly believe that the biggest driver of such an amazing performance is that Golar has delivered  alleviating most of the concerns surrounding the company in recent years.I would say that Mr. Karl Fredrik Staubo was key to achieving such a significant improvement. The market was somewhat dubious when he was named CEO in May 2021  as both the experienced CEO and CFO had just resigned from the company without giving much detail  suggesting that Golar's business was deteriorating  and Karl seemed too young to take on such a large responsibility. Since then  however  Karl has proven at every conference that he is a shark who wakes up angry every morning looking to create shareholder value. There is no doubt that he has done an excellent job at the helm  despite the haphazard nature of the events that have unfolded.Under Karl's leadership  Golar has undertaken a massive transformation process to crystallize value  strengthen the balance sheet and simplify the corporate structure. This year alone  the company has spun off its LNG carrier fleet and raised $275 million  sold approximately one-third of its New Fortress shares (NFE) raising $250 million  sold Golar Tundra FSRU for $350 million and agreed to sell the steam turbine carrier Golar Arctic as a converted FSRU to Italy's Snam for $288 million.In addition  the company has increased utilization of Hilli FLNG to mid-2026 and has reached swap agreements for 75% of 2H 2022  all of 2023  and half of its 2024 TTF-linked exposure at a staggering price  locking in a total of $274M while maintaining upside Brent exposure. It is worth remembering that prior to that  Golar had already started the process of unlocking value by selling Hygo and GMLP to New Fortress for $5 billion EV.All of these smart decisions have helped the company regain investor confidence  and are the main reason why Golar has soared from $11 per share when Karl came on board as CEO to the current >$25/share. The market ignored the company because it thought Golar's business was too complex and the balance sheet was weak. However  these two nagging arguments have been softened. In fact  Golar has a strong balance sheet with a net cash position  and valuing the company has never been easier. The company has two assets  only one of which is generating profits (Hilli FLNG)  while the other is under construction and will be deployed by the end of 2023 (Gimi FLNG). In addition  Golar has public stakes in NFE  CoolCo  and Avenir LNG.Hilli FLNGHilli is the world's best-performing FLNG. It is the only proven design that has excelled with 100% uptime  which has given Golar a unique reputation among its competitors. The asset has three sources of revenue:The base tolling tariff (T1 & T2)  which has been generating around $66 million of EBITDA/year  occasionally increased due to overproduction. The Brent bonus tariff which contributes $2.7 million for every dollar of Brent crude oil price above $60 up to $102. The TTF gas tariff (T3) based on 0.2 Mpta  which has recently been extended until mid-2026. As I mentioned earlier  Golar has hedged most of the European gas exposure for the next few years  ensuring cash flow visibility at huge TTF gas prices - i.e.  levels where energy is equivalent to a Brent oil price of $300/bbl.Hilli's FLNG is a cash cow  as Golar's share of debt and interest service is $50 per year (based on current high LIBOR rates of 3%)  implying that this asset alone will generate over $570 million of free cash flow to equity through 2024  which is over 21% of market capitalization in 2.5 years (40% if we exclude cash and marketable securities). It should be noted that Hilli is a tax-free asset and has almost no capex needs.Although Hilli's cash flow generation profile might surprise you  there is room for improvement  as Hilli is not yet fully utilized. But how much is this asset worth? You might be aware that Exmar recently sold its FLNG Tango to Eni for $572-$694 million. The final price depends on the barge's performance in the first six months on site. Knowing that the FLNG Tango performed above expectations in its short period of operations with YPF in 2020 and that the asset has been well maintained in the lay-up period  I expect the final price to be close to the upper range  being the only FLNG deal and showing how valuable an FLNG is.The Tango floating liquefaction plant  built in 2017  has an LNG storage capacity of 16 100mÂ³ and a liquefaction capacity of up to 0.6 million tonnes per year  while Hilli Episeyo FLNG is 294m in length with a storage capacity of 125 000m3  and was designed to produce about 2.4 million tonnes per year of LNG. In addition  Hilli has much higher specifications as it can perform in a more complex environment.Therefore  knowing that Tango FLNG was sold for $660 million and has one-quarter of the liquefaction capacity of Hilli FLNG as well as much lower specifications  we should argue that Hilli is worth at least $2.6 bn. Being very conservative  I am valuing Hilli at a significant discount to the price we reach by comparing a fair and recent transaction. Using a 10% WACC  we reach a value of $1.27 billion or $11.8/share. You can see my estimates in the following image.Hilli FLNG DCF model (Own elaboration based on my estimates)Be aware that Hilli's current contract with Perenco ends in mid-2026  but the asset has a long life left. I have argued in the past that Hilli will not leave Cameroon  but Golar has begun to explore other options in case Perenco does not make significant commitments. According to Cypriot and Greek media  Energean CEO Mathios Rigas proposed connecting Energean's gas fields in offshore Israel to a Hilli floating liquefied natural gas unit that would be stationed off Vasilikos  Cyprus  by the end of 2026  just after the current contract expires.That said  I remain confident that Perenco will increase production and extend the contract in late 2023 or early 2024 because if Hilli exits Cameroon  it will be extremely difficult for Perenco to monetize the remaining reserves. Therefore  once it happens  our valuation of Hilli will increase accordingly.In addition  our utilization rate  and therefore the valuation of the asset  could prove to be very conservative. It should be noted that Gazprom Marketing & Trading is now Hilli's off-taker. After the war  this entity has been under federal trusteeship and recapitalized with a contribution of about $10 billion from the German government. Following that liquidity injection  it was then renamed SEFE Securing European Energy and will soon be nationalized  so the buyer of Hilli liquified gas is now Germany  which is desperately seeking to increase its LNG supply. I understand that SEFE is in talks with Perenco about the possibility of adding at least 0.2 million tons and likely more  depending on production capacity. Based on the conservative assumptions well below the forward curve I provided above  an addition of 0.2 MPTA  which will only increase utilization to 66%  will generate an extra $350M from 2023 to mid-2026.Gimi FLNGGimi's conversion has continued steadily according to plan. Golar's latest earning presentation shows that the asset is 86% complete. However  Keppel has not been immune to the current logistical and inflation issues and Golar had to contribute an extra $35 million (70% of $50 million) to secure the delivery date. The Gimi FLNG will set sail in H1 2023 and will begin its 20-year contract by the end of that year. Golar owns 70% of Gimi  which has a $4.3bn order backlog. This means that Gimi will start contributing $151 million of EBITDA each year starting by Q4 2023 for the next 20 years  so despite recent minor difficulties  Gimi's economics look terrific. Be aware that according to current specifics  Gimi should be able to produce 10% more  so EBITDA could end up being higher than what I am modeling.Gimi's valuation is easier than Hilli's as there are no moving parts such as TTF or Brent exposure. $151M EBITDA  16-year straight debt amortization curve  which might be conservative on a 25+ year life and a 20-year contract value at a 5% interest rate. I understand that the company will refinance and increase the leverage of the asset once it is online  but it is something I am not modeling yet. I used a WACC of 8%. The lower discount rate than Hilli's is because BP is an extraordinary counterparty  and our profit forecast is less uncertain  as revenues are fixed and hedged against inflation. Therefore  according to my model  the asset is worth about $1.5 billion  and after deducting Golar's share debt and remaining capex  we reach an equity value of just under $0.8 billion or $7.2/share.Golar Marketable Securities and Net DebtAfter repayments on Golar's credit facilities  corporate debt is only the $300M unsecured Norwegian bond  with Golar's cash position being in excess of $700M after the latest sales. Note that I am considering Golar Arctic's net proceeds. Remember that Golar will convert its trading steam turbine LNG carrier  Golar Arctic  to an FSRU and upon conversion  ownership of the asset will be transferred to Snam  which will pay â‚¬269.0M  but the conversion has a cost of $160M and is expected to take up to two years. All in all  Golar has a net corporate cash position (excluding Golar's share of Hilli and Gimi debt) of $400M.In addition  Golar holds marketable securities that could be liquidated in a short period of time for $845M. These are comprised of 12.4M shares of NFE  which at the current price of $50.7 implies $629M (or $806M taking the $65 consensus TP)  and 12.5M shares of CoolCo company worth $169M  which is listed on the Euronext market. We expect a dual listing in the U.S. in the coming months  and Avenir LNG stake is worth $47M.As Golar's management has pointed out on numerous occasions during recent conferences  Golar is not a holding company; therefore  I expect Golar to divest all of those holdings to fund FLNG's growth and that is the reason why I am not applying any holding discount. Due to the illiquidity of the CoolCo stake and the incredible prospects for LNG shipping  I personally expect Golar to distribute those shares as a special dividend to its shareholders once the company is listed on the U.S. market.Lastly  Golar's corporate costs are 21M per year  so after applying a multiple of 8x  we deduct $168M from our valuation. However  I am aware that core costs may decrease significantly after the CoolCo spin-off.Golar Sum Of Parts Target Price (Own elaboration based on my estimates)We reach a target price of $29 based on current assets  which implies an attractive upside from current prices. I am comfortable with this valuation as I consider myself very conservative. Conservatism is shown by playing with what-if scenarios. In the scenario where Golar does not grow further  we should expect FCF of $325M in 2024 after debt service (interest and debt amortization). Most of the FCF is fixed  so my estimates are accurate enough. Golar has stated that they will start paying dividends as soon as Gimi is online and if they have no capex growth needs  based on the stability of their income stream  I believe they will pay all free cash flow as a dividend  like Tor Olav Troim is famous for  because his ability to allocate capital where it creates the most value. If we take the current market cap of $2.7Bn and exclude listed securities and net cash (likely also distributed under that scenario)  we reach a potential yearly dividend yield of >22% (12% to market cap). Given these figures  it is fair to say that my current valuation is conservative  even if we do not consider FLNG growth.FLNG GrowthThe upside based on current assets is attractive but would not by itself justify Golar as one of our top holdings. However  I would like to emphasize that the target price I showed you is not considering any growth and at this point  I think growth is more exciting than current assets. I firmly believe that Golar will be able to deliver three projects in the next 12-18 months  one of them starting this year.The environment for FLNG has never been more favorable. The lack of global supply became apparent after COVID-19  as demonstrated by high gas prices. Global supply was not able to catch up with strong demand  but the global gas market broke down following the Russian invasion. Unsurprisingly  Europe has cut ties with Russia and decided to move away from dependence on Russian gas. It should be known that the annual gas demand in Europe is about 500 bcm of which 400 bcm is imported and Russia used to supply (mostly by pipeline) 45% of it  up to 55/60% in the closest countries like Germany  while Norway supplies about 25% of European imports and LNG imports add another 25%. The remaining 5% is supplied by Algeria  Azerbaijan  Libya and Iran.Gazprom's gas exports to Europe (UBS research )As can be seen  Russia already serves only 14% of total imports  creating a huge imbalance between demand and supply that is unlikely to be fixed soon as there is not enough LNG infrastructure to replace Russia in the short term. Nor is the European regasification infrastructure large enough  nor is the global liquefaction capacity. Initially  I expected Russia to restart Nord Stream pipeline flows  as I felt they had cut off pipeline flows using gas as a weapon to gain leverage in a tough negotiation  but I do not foresee volumes coming back after the recent Nord Stream pipeline explosion.Russia's daily exports to Europe (CoolCo presentation)Note that daily Russian gas flows in H1 2022 were significantly lower than in 2019 but much higher than today. While I continue to expect Russian gas to flow to Europe via Ukraine at the current level  I see downside rather than upside risk.Therefore  I expect gas prices in Europe to remain extremely high  as suggested by the forward curve. In fact  I expect gas prices on average for 2023 to be higher than in 2022 due to a greater challenge to refill storage next year with the loss of Russian flows.You might see that the price of gas in Europe has plummeted due to the oversupply. That's fair enough  as natural gas prices are driven by daily supply and demand  as it is a commodity that trades in the present  unlike equities  which discount the future. Current demand is not strong as unseasonable weather depresses it  while storage is full because Europe has rushed to buy all available LNG so as not to run out of gas during the winter. However  winter is coming and Europe's consumption will be 2-4x higher than it is now  while pipeline supply will remain tight. Moreover  even though storage is full  European storage only covers two to three months of consumption.Months of gas storage per country (Oxford Economics)Therefore  the European pain is not over yet  and the gas price will increase significantly in the coming weeks  as the current forward curve suggests (around â‚¬140MWh compared to the â‚¬15MWh it used to trade or â‚¬40/50MWh now). In addition  we should be grateful to China for remaining in a continuous lockdown. This is the first year in which LNG imports from China have not grown; on the contrary  we would be required to pay even higher prices to attract LNG cargoes to Europe.As can be concluded  the only way for Europe to normalize its energy situation is to build LNG infrastructure and secure capacity. Moving away from Russia means that Europe will have to seek up to 150 bcm or 110 million tons of LNG. Europe has already taken the first big step by ordering enough regasification terminals to process LNG  but it remains to be seen how they will be able to secure LNG capacity over the next few years. I don't think the U.S. will be able to supply such a large amount of LNG because it does not have sufficient LNG liquefaction capacity  but even if it could do so over the next decade  I would not expect Europe to make the same mistake a second time and rely on a single source.As reported in the news  Europe is actively targeting Africa. This continent has unique advantages  such as proximity and proven African gas fields associated with a low cost of supply. It is evident that Africa is set to occupy a key place among European gas suppliers.Africa's competitive advantages (Golar presentation)Also  as shown in the picture  Golar's liquefaction technology is one of the lowest cost and carbon footprint solutions in the world  including onshore liquefaction facilities in the United States. It is known that Golar can supply gas to Europe or Asia at $5 MMBtu  which means it can easily make huge profits in almost every scenario. Golar is aware of this huge opportunity and is looking not to be a single service provider but to make it an integrated project. In fact  it is rumored that Golar and New Fortress could partner and revive Fortuna FLNG.Golar's integrated project economics (Golar presentation)Fortuna FLNG is a project that Golar knows very well  as it was going to be FID in 2018 teaming up with Schlumberger (SLB) among others  but eventually  after a key manager left the company  Schlumberger rejected the project to focus on its core business and killed the project. As time has proven  Schlumberger made a big mistake  but I think the current economics are even better now than they were then.The Fortuna FLNG integrated project required $2 billion to obtain the first gas  of which $1.2 billion would be financed with debt and would be used entirely for the start of commercial operations. We should factor inflation into these figures  but I believe this is a project that Golar should be able to afford.As shown in the figure  the payback of the project under current conditions is about one year  which provides an astonishing IRR. Most importantly  however  it is environmentally friendly and has a low break-even cost. Europe will prioritize this ""green"" gas and even in a very challenging market  the Asian LNG market has never been consistently below $5 MMBtu  which means that even in the worst situation  this project will not burn cash. That said  I would like to stress that the world has changed after Europe realized the huge energy risk it was taking from Russia's concentration of gas suppliers and even if the war is resolved and we move on  the price of gas will be structurally higher  as it is known that the cost of LNG imports  which requires liquefaction  shipping and regasification  is much higher than that of Russian pipeline gas.The growth of Golar FLNG is a matter of time. In fact  the company has publicly stated that an FLNG project will be announced before the end of the year and I don't expect Golar to go back on its word. There are many candidates  Kosmos (KOS) reported at the last earnings conference that they want to move forward with the Greater Tortue expansion. In fact  they said they expect to reach an FID in the coming months and expect first gas by the end of 2026. Based on my conversations with them  I would guess that the fact that they haven't moved forward yet would be because they are considering increasing the size of the project from the estimated 2.5 Mpta to 3.5-5 Mpta.As seen  there are many FLNG candidates for Golar and I am not sure what deal Golar will take  but I expect three FLNG projects in the next 18 months  with one being in the next few weeks. Why am I so confident? Golar has the most efficient and proven solution that can be delivered quickly. It is also the most environmentally friendly solution  which is the first step in participating in a large gas project these days.At this point  one might ask  if the current global gas market imbalance has been so clear for a year now and has been intensified by the Russian invasion  why hasn't Golar announced an FLNG project yet?It is a fair question  but it shows the overall lack of knowledge of the sector among investors. The FID of an LNG project is very complex. It is a huge infrastructure project that requires the intervention of many players at the same time and tons of money. The FEED  EPC award  project financing  host government agreements  environmental firms  financing due diligence  offtake contracts - all have to go down and integrate with each other. Just one example: most of the financing will be done through ECAs  tied to a percentage of the procurement  which in turn is tied to the FEED and the EPC award. It quickly becomes clear how complex all this is. Moreover  it is a binary outcome. All parties could have been working for years and in the end  one of them leaves the table and all the work is lost.An offshore gas project is a big infrastructure headache; however  when FID is done and Golar's expertise is on the table  the returns are amazing  as we have seen on Hilli's FLNG.Golar's FLNG designs (Golar presentation)Golar is uniquely positioned for FLNG growth and has three different alternatives that cover all customer needs. The MKI and MK II designs are conversions that could be deployed in three years  while the largest new-build design (MK III) will require four years to be operational.Based on the current balance sheet  I expect Golar to be able to move forward with 3 FLNG growth projects in parallel in the next 18 months that could increase my target price by $25/share (depending on final capex and generation specifications)  reaching a total of over $50/share. Dividend capacity can be huge by the end of 2026 and could justify a higher valuation. Moreover  once time passes and Golar keeps delivering FLNG projects  the target price could eventually grow up to $100/share by 2030.ConclusionEarlier this year  I called Golar a strong buy and titled my analysis ""2022 Is Set to Be the True Inflection Point."" The company has delivered on plan and the market has rewarded them closing most of the gap between price and value. However  the current market price is ignoring Golar's ability to grow  which I understand as the company has not announced any FLNG projects since 2019.Golar is well positioned for growth and should be able to pursue three FLNG projects in parallel  which should raise the target price above $50/share. In addition  I remain very confident in my core holding due to the low downside  as Golar's cash flow generation is set to quadruple and should offer a huge dividend yield should growth fail to materialize.Golar has a fiduciary duty to Europe to advance FLNG growth by helping Europe regain control of the energy chaos. The environment has never been better and the company is in advanced talks with many credible players which prompted them to be confident enough to guide for an FLNG FID before the end of the year.",neutral,0.01,0.99,0.0,mixed,0.47,0.08,0.44,True,English,"['Golar LNG Stock', 'Growth', 'The', 'Corner', 'NASDAQ', 'GLNG', 'floating liquefied natural gas', 'The TTF gas tariff', 'The Brent bonus tariff', 'current high LIBOR rates', 'cash flow generation profile', 'huge TTF gas prices', 'Brent crude oil price', 'Mr. Karl Fredrik Staubo', 'base tolling tariff', 'Brent oil price', 'European gas exposure', 'upside Brent exposure', 'Seeking Alpha tracker', 'steam turbine carrier', 'cash flow visibility', 'free cash flow', 'net cash position', 'two nagging arguments', 'LNG carrier fleet', 'massive transformation process', 'New Fortress shares', 'strong balance sheet', 'Golar Tundra FSRU', 'Hilli FLNG Hilli', 'attractive prices', 'huge swing', '2024 TTF-linked exposure', 'cash cow', 'stock price', 'Mr. Market', 'staggering price', 'two assets', 'Avenir LNG', 'new projects/assets', 'FLNG) facilities', 'detailed analysis', 'good basis', 'last article', 'important event', 'external point', 'S&P', 'manic-depressive animal', 'irrational mood', 'high-quality assets', 'Russian invasion', 'biggest driver', 'amazing performance', 'large responsibility', 'excellent job', 'haphazard nature', 'corporate structure', 'swap agreements', '$5 billion EV.', 'smart decisions', 'investor confidence', 'main reason', 'Gimi FLNG', 'public stakes', 'performing FLNG', 'unique reputation', 'three sources', 'interest service', 'marketable securities', 'capex needs', 'FLNG Tango', 'new update', 'rough market', 'market capitalization', 'Golar LNG', 'short period', 'significant improvement', 'experienced CEO', 'shareholder value', 'recent years', 'Golar Arctic', 'tax-free asset', 'value investors', 'current >$', '2.5 years', 'Leestat', 'Note', 'NASDAQ', 'GLNG', 'company', 'readers', 'interview', 'March', 'May', 'January', 'articles', 'one', 'lot', 'beginning', 'fact', 'contrast', '20% drop', 'opportunity', 'hate', 'love', 'time', 'portfolio', 'doubt', 'environment', 'concerns', 'CFO', 'business', 'conference', 'events', 'leadership', 'Italy', 'Snam', 'addition', 'utilization', '2H', 'half', 'total', 'Hygo', 'GMLP', 'board', 'profits', 'construction', 'end', 'CoolCo', 'world', 'design', 'competitors', 'revenue', 'EBITDA', 'overproduction', 'dollar', '0.2 Mpta', 'mid-20', 'next', 'levels', 'energy', 'debt', 'equity', 'room', 'Exmar']",2022-10-27,2022-10-28,seekingalpha.com
12238,EuroNext,NewsApi.org,https://ca.sports.yahoo.com/news/gtt-nine-month-2022-revenues-154500101.html,GTT: Nine-month 2022 revenues stand at â‚¬222 million  in line with expectations; strong order momentum continues,Nine-month 2022 revenues stand at â‚¬222 million  in line with expectations; strong order momentum continues Record orders: 134 LNG carriers during the first nine months2022 targets confirmed Paris â€“ October 27  2022. GTT  the technological expert in membrane câ€¦,GTTNine-month 2022 revenues stand at â‚¬222 million in line with expectations;strong order momentum continuesRecord orders : 134 LNG carriers during the first nine months2022 targets confirmedParis â€“ October 27  2022. GTT  the technological expert in membrane containment systems used to transport and store liquefied gases  today announces its revenues for the first nine months of 2022.Commenting on the results  Philippe BerterottiÃ¨re  Chairman and CEO of GTT  said: â€œWith 134 LNG carrier orders  our core business during the first nine months of 2022 has broken all previous sales records  highlighting the continuation of particularly strong momentum. The surge in demand for LNG  particularly in Europe  is fuelling further demand for LNG carriers  underpinned by investment in liquefaction plants and increased construction capacity at shipyards.In the LNG as fuel business  GTT booked 42 orders during the first nine months of 2022. While the high price of LNG in Europe could slow order intake in the short term  GTT is convinced of the relevance of its solutions and the potential of this activity over the medium and long term.GTT maintains a tireless focus on R&D to meet its customersâ€™ energy transition needs and the tightening requirements they face. Over the first nine months  we obtained numerous approvals from classification societies to develop new technologies in a wide range of fields  particularly in LNG as fuel  but also for the design of a hydrogen carrier and an innovative design for a three-tank LNG carrier.From a financial perspective  Q3 2022 revenues were up 4.1% versus Q3 2021. As expected  nine-month 2022 revenues were down compared to the same period in 2021 due to an unfavourable base effect  which is gradually disappearing thanks to the strong order momentum.In addition  the Group confirms its 2022 targets with results expected to reach the lower half of the initial target range  as announced in the first half results release.â€Story continuesBusiness activity during the first nine months- Continued momentum in LNG carrier ordersIn the first nine months of 2022  GTT booked 134 orders for LNG carriers  including 46 in the third quarter  in line with the excellent sales momentum achieved in the first half of the year. Delivery is scheduled between Q3 2024 and Q2 2027. In particular  58 orders for projects in Qatar were received during the first nine months.- Dynamic order intake of LNG-powered vesselsIn addition to the 38 orders for LNG-powered vessels received in the first half of 2022  four new orders were received in the third quarter of 2022  bringing the total to 42 orders for the first nine months. While the high price of LNG in Europe could slow order intake in the short term  GTT is convinced of the relevance of its solutions and the potential of this business over the medium and long term.- New licensing agreements with Chinese shipyardsIn the third quarter of 2022  GTT signed two new Technical Assistance and Licensing Agreements (TALA)  with the Yangzijiang Shipbuilding and China Merchants Heavy Industries shipyards for the construction of GTT membrane containment systems. This brings to five the number of construction sites now operating in China and contributes to increasing vessel construction capacity.- Smart Shipping: new contractIn July  GTT signed a contract with Antarctica21  the worldâ€™s leading operator of fly and cruise expeditions to Antarctica  to install â€œGTT Digitalâ€ smart shipping solutions in its cutting-edge expedition vessel Magellan Explorer.- â‚¬86 million State support for Hydrogen IPCEI1 project confirms the relevance of Elogen positioningFollowing the selection by the European Commission of Elogenâ€™s â€œgigafactoryâ€ project and the strengthening of its R&D division as part of the Hydrogen IPCEI  Elogen has been awarded a maximum of â‚¬86 million in subsidies by the French government. An agreement regarding this subsidy will shortly be signed with Bpifrance. For the record  the Elogen gigafactory will start production in 2025 with a production capacity of over 1 GW.Furthermore  in July 2022  Elogen was selected by Symbio to supply an electrolyser with an initial capacity of 2.5 MW for Symbioâ€™s new fuel cell plant. This new contract represents an important milestone for Elogen  as it highlights the companyâ€™s ability to deploy its technologies on multi-megawatt capacities for large industrial projects.Finally  as previously announced  in the first half of 2022 Elogen entered into several international partnerships for the manufacture and sale of electrolysers for producing green hydrogen:with HiFraser Group in Australia and New Zealand;with Valmax Technology Corporation in South Korea;with Charbone HydrogÃ¨ne in North America.Innovation: development of new technologies in a wide range of fieldsIn the first half of 2022  GTT received several approvals in principle from classification societies  including:Bureau Veritas for a new LNG conversion concept for large-capacity container ships;ClassNK for a new design of LNG fuel tank with 2 bar gauge pressure applicable to PCTC 2 vessels as well as LNG-powered cruise ships;DNV for an innovative LNG-powered PCTC vessel design;Lloydâ€™s Register for GTTâ€™s future NEXT1 containment system;Bureau Veritas for Shear-Water  a ballast-free vessel concept for LNG bunkering and refuelling vessels.In the third quarter of 2022  GTT obtained five new approvals in principle from:DNV for a containment system enabling the transport of liquid hydrogen  as well as the concept for a hydrogen carrier vessel. Both approvals in principle were obtained in the framework of the cooperation agreement with Shell announced early 2022 and reflect the progress of this project;Lloydâ€™s Register for a new digital solution named â€œPOWERâ€ designed to optimise transhipment operations between LNG carriers and floating units;Bureau Veritas for the design of a LNG-powered and â€œNH3-readyâ€ Very Large Crude Carrier;Bureau Veritas and DNV for an innovative three-tank LNG carrier concept.Order book at September 30  2022On January 1  2022  GTTâ€™s order book excluding LNG as fuel comprised 161 units  and subsequently changed as follows:Deliveries completed: 21 LNG carriers  4 ethane carriers  1 FLNG;Orders received: 134 LNG carriers.At September 30  2022  the order book excluding LNG as fuel stood at 269 units  breaking down as follows:250 LNG carriers;2 ethane carriers;2 FSUs;3 GBSs;12 onshore storage tanks.Regarding LNG as fuel  following the delivery of four vessels  and orders for 42 container ship tanks  the number of vessels in the order book stood at 70 units at September 30  2022.Evolution of consolidated revenues for the first nine months of 2022(in thousands of euros) 9M 2021 9M 2022 Change Revenues 240 025 222 037 -7.5% Newbuilds 224 281 200 385 -10.7% LNG carriers/VLEC 194 767 174 749 -10.3% FSUs3 9 660 13 578 +40.6% FSRUs4 8 054 - nm FLNGs5 2 202 1 218 -44.7% Onshore storage tanks 1 468 4 680 +218.8% GBSs6 2 521 3 303 +31.1% LNG-powered vessels 5 610 2 857 -49.1% Electrolysers 3 316 2 980 -10.1% Services 12 428 18 672 +50.2%Consolidated revenues for the first nine months of 2022 were â‚¬222.0 million  down 7.5% compared to the first nine months of 2021. The third quarter 2022 revenues amounted to â‚¬77.8 million  up 4.1% compared to the third quarter 2021.Newbuild revenues totalled â‚¬200.4 million  down 10.7% compared with the first nine months of 2021  when the cycle was still at its peak. Royalties amounted to â‚¬174.7 million from LNG and ethane carriers  â‚¬13.6 million from FSUs  â‚¬1.2 million from FLNGs  â‚¬4.7 million from onshore storage tanks and â‚¬3.3 million from GBSs. LNG as fuel royalties (â‚¬2.9 million) were not yet impacted by the high order intake in 2021 and 2022.Nine-month revenues from the Elogen electrolyser business amounted to â‚¬3.0 million  in a context of increasing commercial dynamic.Revenues from services rose sharply  up 50.2% to â‚¬18.7 million  driven by growth in digital services and engineering studies mainly related to the conversion of LNG carriers into FSRUs.Update on exposure to RussiaWork on projects in which the Group is involved in Russia is currently continuing  in compliance with the applicable sanction regimes.In Russia  the Group is involved in tank design for 15 ice-breaking LNG carriers currently being built at the Zvezda Shipbuilding Complex (Zvezda)  as well as in the design of 3 GBSs7 currently under construction at Saren B.V.8 At October 1  2022  revenues of â‚¬74 million have yet to be recognised by 2025 for ice-breaking LNG carriers  including â‚¬4 million in Q4 2022. Revenues of â‚¬12 million have yet to be recognised for 2027 for GBSs  including â‚¬1 million in Q4 2022.Given the impact of international sanctions on LNG liquefaction projects in Russia  the continuation and successful execution of these contracts are still exposed to risks of postponement or cancellation. In particular  sanctions are still affecting Russian imports of certain products and equipment used in current projects  including the Zvezda project. Furthermore  as previously announced  in July Saren B.V. notified GTT of its intention to terminate the contract between them. The termination date has not yet been finally set. In this context  GTT continues to investigate solutions to ensure the proper implementation and integrity of its technology  in strict compliance with international sanctions.As a reminder  other orders in progress in Asian shipyards for six ice-breaking LNG carriers and two FSUs9 are specifically intended for Russian Arctic projects. These projects are currently proceeding according to plan. At October 1  2022  these orders represented total revenues of â‚¬31 million for GTT  to be recognized by 2024  including â‚¬7 million in Q4 2022.Finally  eight conventional LNG carriers ordered by international shipowners  under construction in Asian shipyards  are intended for the Arctic LNG 2 project  but can operate in all types of conditions.2022 outlook confirmedIn its 2021 annual results press release dated February 17  2022  the Group issued the following targets for 2022  assuming no significant order deferrals or cancellations:consolidated revenues of between â‚¬290 million and â‚¬320 million consolidated EBITDA of between â‚¬140 million and â‚¬170 million a dividend amount for the 2022 financial year at least equivalent to the 2021 dividend.Given delays in shipbuilding schedules for certain vessels during the first nine months of 2022  the Group confirms its forecast that revenues and EBITDA will reach the lower half of the ranges announced in February.In the longer term  the Group should benefit from the current strong order momentum and expects to achieve significantly higher revenues and earnings from 2023 onwards versus 2022.***First nine months of 2022 activity update presentationPhilippe BerterottiÃ¨re  Chairman and Chief Executive Officer  and Virginie Aubagnac  Chief Financial Officer  will comment on GTTâ€™s business during the first nine months of 2022 and answer questions from the financial community during a conference call to be held  in English  on Thursday  October 27  2022 at 6:15 p.m. Paris time.This conference will also be broadcast live on GTTâ€™s website (www.gtt.fr/finance).To participate in the conference call  please dial one of the following numbers five to ten minutes before the start of the conference:France: +33 1 70 91 87 04UK: +44 1 212 818 004USA: +1 718 705 87 96Confirmation code: 130114The presentation document will be available on the website on October 27  2022 from 17:45 p.m.Financial agendaPayment of an interim dividend of â‚¬1.55 per share for the 2022 financial year: December 15  20222022 full year results release: February 16  2023 (after close of trading)Shareholdersâ€™ Meeting: June 7  2023About GTTGTT is a technological expert in containment systems with cryogenic membranes used to transport and store liquefied gases. For over 50 years  GTT has been designing and providing cutting-edge technologies for a better energy performance  which combine operational efficiency and safety  to equip LNG carriers  floating terminals  land storage  and multi-gas carriers. GTT also develops systems dedicated to the use of LNG as fuel  as well as a full range of services  including digital services in the field of Smart Shipping. The Group is also active in hydrogen through its subsidiary Elogen  which designs and assembles electrolysers notably for the production of green hydrogen.GTT is listed on Euronext Paris  Compartment A (ISIN FR0011726835 Euronext Paris: GTT) and is notably included in SBF 120  Stoxx Europe 600 and MSCI Small Cap indicesInvestor relations contact:information-financiere@gtt.fr / +33 1 30 23 20 87Media contact:press@gtt.fr / +33 1 30 23 48 45For more information  visit www.gtt.fr.Important noticeThe figures presented here are those customarily used and communicated to the markets by GTT. This message includes forward-looking information and statements. Such statements include financial projections and estimates  the assumptions on which they are based  as well as statements about projects  objectives and expectations regarding future operations  profits  or services  or future performance. Although GTT management believes that these forward-looking statements are reasonable  investors and GTT shareholders should be aware that such forward-looking information and statements are subject to many risks and uncertainties that are generally difficult to predict and beyond the control of GTT  and may cause results and developments to differ significantly from those expressed  implied or predicted in the forwardlooking statements or information. Such risks include those explained or identified in the public documents filed by GTT with the French Financial Markets Authority (AMF â€“ AutoritÃ© des MarchÃ©s Financiers)  including those listed in the â€œRisk Factorsâ€ section of the GTT Registration Document filed with the AMF on 27 April 2021  and the half-year financial report released on 28 July 2021. Investors and GTT shareholders should note that if some or all of these risks are realised they may have a significant unfavourable impact on GTT1 Important Project of Common European Interest2 PCTC (Pure Car and Truck Carriers): carriers of light vehicles  trucks and rolling stock3 Floating Storage Unit4 Floating Storage Regasification Unit5 Floating Liquefied Natural Gas vessel6 Gravity Based Structures: underwater tanks7 Gravity Based Structure - underwater tanks8 Saren B.V. is a joint venture between Saipem and RÃ¶nesans.9 Floating Storage UnitAttachment,positive,0.82,0.18,0.0,mixed,0.61,0.16,0.23,True,English,"['strong order momentum', 'Nine-month 2022 revenues', 'GTT', 'line', 'expectations', 'China Merchants Heavy Industries shipyards', 'customersâ€™ energy transition needs', 'GTT Digitalâ€ smart shipping solutions', 'two new Technical Assistance', 'new fuel cell plant', 'new LNG conversion concept', 'GTT membrane containment systems', 'first half results release', 'Philippe BerterottiÃ¨re', 'previous sales records', 'unfavourable base effect', 'cutting-edge expedition vessel', 'Valmax Technology Corporation', 'Charbone HydrogÃ¨ne', 'large-capacity container ships', 'first nine months', 'excellent sales momentum', 'several international partnerships', 'R&D division', 'large industrial projects', 'Dynamic order intake', 'strong order momentum', 'initial target range', 'Hydrogen IPCEI1 project', 'New licensing agreements', 'three-tank LNG carrier', 'four new orders', 'vessel construction capacity', '134 LNG carrier orders', 'strong momentum', 'hydrogen carrier', 'initial capacity', 'New Zealand', 'Chinese shipyards', 'Continued momentum', 'gigafactoryâ€ project', 'several approvals', 'new technologies', 'new contract', 'new design', 'wide range', 'lower half', 'green hydrogen', 'fuel business', 'technological expert', 'liquefied gases', 'liquefaction plants', 'high price', 'short term', 'long term', 'tireless focus', 'tightening requirements', 'numerous approvals', 'classification societies', 'financial perspective', 'same period', 'third quarter', 'LNG-powered vessels', 'Yangzijiang Shipbuilding', 'construction sites', 'leading operator', 'cruise expeditions', 'Magellan Explorer', 'State support', 'European Commission', 'French government', 'important milestone', 'multi-megawatt capacities', 'South Korea', 'North America', 'Bureau Veritas', '134 LNG carriers', 'Nine-month 2022 revenues', 'core business', 'production capacity', 'innovative design', 'HiFraser Group', 'Elogen positioning', 'Elogen gigafactory', 'Record orders', 'Business activity', 'Q3 2022 revenues', '42 orders', '134 orders', '58 orders', '38 orders', 'line', 'expectations', '2022 targets', 'Paris', 'October', 'Chairman', 'CEO', 'continuation', 'surge', 'demand', 'investment', 'relevance', 'potential', 'medium', 'fields', 'addition', 'Story', 'year', 'Delivery', 'Q2', 'Qatar', 'total', 'TALA', 'number', 'July', 'Antarctica21', 'world', 'fly', 'million', 'selection', 'strengthening', 'maximum', 'subsidies', 'subsidy', 'Bpifrance', '1 GW.', 'Symbio', 'electrolyser', '2.5 MW', 'company', 'ability', 'manufacture', 'Australia', 'Innovation', 'development', 'principle', 'ClassNK', 'â‚¬']",2022-10-27,2022-10-28,ca.sports.yahoo.com
12239,EuroNext,NewsApi.org,https://finance.yahoo.com/news/coface-reports-record-result-84-153600367.html,Coface reports a new record result of â‚¬84.0m in Q3-2022. Annualised return on tangible equity at 16.4%,Coface reports a new record result of â‚¬84.0m in Q3-2022. Annualised return on tangible equity at 16.4% Paris  27 October 2022 â€“ 17.35 Turnover of first nine ...,"Coface SACoface reports a new record result of â‚¬84.0m in Q3-2022. Annualised return on tangible equity at 16.4%Paris  27 October 2022 â€“ 17.35Turnover of first nine months : â‚¬ 1 363 m  up 1 5.2 % at constant FX and perimeter and up 17.7 % on a reported basis Trade Credit Insurance premiums growing by 16.6% driven by high client activity in still inflationary environment Client retention at record highs (93.5%); pricing down (-3.0%) in line with H1-22 Business information momentum continues (revenues up +15.6% at constant FX)9M-2022 n et loss ratio at 36.9%  up by 11.5 ppts ; n et combined ratio at 63.8 %   up by 7.7 ppts Gross loss ratio up by 5.0 ppts at 30.2%  as normalization of risk environment continues Net cost ratio down by (3.8) ppts at 26.9% reflecting continued operating leverage and higher reinsurance commissions Q3-2022 net combined ratio at 59.6% on continued low loss ratioNet income (group share) at â‚¬ 228.4 m  including â‚¬ 84.0 m for Q 3 -2022 ; annualised RoATE 1 at 16 . 4 % Successful early refinancing of its grandfathered T2 debt  de-risking 2024 deadline Moodyâ€™s confirmed its credit rating for Coface and raised its outlook to ""Positive""Unless otherwise indicated  change comparisons refer to the results as at 30 September 2021.Xavier Durand  Cofaceâ€™s Chief Executive Officer  commented:â€œThe third quarter brought no improvement in terms of the major risks facing the global economy: monetary tightening remains aggressive as inflation remains high  the conflict in Ukraine is continuing and the European energy crisis remains acute. The situation in the United Kingdom served as a reminder that governments have little financial leeway and that fiscal and monetary policies need to be aligned. As expected  global growth forecasts have been downgraded.Bankruptcies are continuing to rise  especially in developed countries. Coface maintains its prudent reserving policy on Russia. This environment did not prevent Coface from achieving record net income of â‚¬84m in the third quarter  with the YTD figure now totalling â‚¬228m  higher than in fiscal year 2021. This corresponds to annualised return on tangible equity of 16.4%.Investments in adjacent businesses are continuing. Information services (+15.6%) and factoring (+13.0%) recorded continued growth in turnover. Coface is also continuing to focus on service quality  reflected in the record high retention rate and an improvement in the net promoter score (NPS) to 38%.We welcome Moodyâ€™s decision to assign our credit rating a positive outlook. This acknowledges the work done by all of Coface's teams over the past few years and our strengths at the beginning of a more complex stage in the economic cycle.""Story continuesKey figures at 30 September 2022The Board of Directors of COFACE SA examined the consolidated financial statements at 30 September 2022 (non-audited figures) at its meeting of 27 October 2022. The Audit Committee at its meeting on 26 October 2022 also previously reviewed them.Income statements items in â‚¬m 9M-21 9M-22 % %ex. FX* Gross earned premiums 969.5 1 152.1 +18.8% +16.6% Services revenue 188.9 211.0 +11.7% +7.9% REVENUE 1 158.4 1 363.1 +17.7% +15.2% UNDERWRITING INCOME/LOSS AFTER REINSURANCE 235.2 295.7 +25.7% +29.8% Investment income  net of management expenses 30.9 39.1 +26.5% +26.8% CURRENT OPERATING INCOME 266.1 334.8 +25.8% +29.4% Other operating income / expenses (0.8) (5.0) +499.8% +484.7% OPERATING INCOME 265.3 329.8 +24.3% +28.0% NET INCOME 190.9 228.4 +19.6% +24.7% Key ratios 9M-21 9M-22 % %ex. FX* Loss ratio net of reinsurance 25.4% 36.9% +11.5 ppts Cost ratio net of reinsurance 30.7% 26.9% (3.8) ppts COMBINED RATIO NET OF REINSURANCE 56.1% 63.8% +7.7 ppts Balance sheet items in â‚¬m 2021 9M-22 % %ex. FX* Total Equity (group share) 2 141.0 1 955.2 (8.7)%* Also excludes scope impact1. TurnoverCoface recorded a consolidated turnover of â‚¬1 363.1m over the first nine months of 2022  up +15.2% at constant FX and perimeter compared to 9M-21. On a reported basis (at current FX and perimeter)  turnover was up +17.7%.Revenues from insurance activities (including bonding and Single Risk) increased by +16.6% at constant FX and perimeter (and by +18.8% at current FX) compared to 9M-21. Growth benefited from an increase in client activity and continued high retention.The retention rate reached a record level of 93.5%  up +1.4% compared to 9M-21. New business totalled â‚¬82m  down â‚¬20m compared to 9M-21 in an increasingly competitive market.The growth in Cofaceâ€™s client activity had a positive impact of +11.1% over 9M-22. This record increase for the first nine months reflects the scale of the recent economic recovery and inflation. The price effect continued to reverse  coming in at -3.0% in 9M-22  in line with the -3.0% fall in H1-22. This is largely due to previous very low loss experience.Revenues from other activities were up +7.9% compared to 9M-21  still with contrasting trends in the different businesses. Turnover from factoring rose +13.0%  mainly due to the increase in volumes refinanced in Poland. Revenues from information services continued to grow  rising +15.6% (vs. +13.4% in 9M-21). Fee and commission income (collection fees) was impacted by the decline in claims to be recovered and dropped -37.9% while commissions were up by +6.7%.Total revenue - in â‚¬m(by country of invoicing) 9M-21 9M-22 Variation %ex. FX2 Northern Europe 250.4 277.3 +10.7% +9.6% Western Europe 233.6 271.0 +16.0% +14.8% Central & Eastern Europe 115.3 135.6 +17.6% +16.8% Mediterranean & Africa 313.8 362.0 +15.4% +17.2% North America 99.3 125.1 +26.0% +12.4% Latin America 55.3 78.2 +41.3% +29.8% Asia Pacific 90.7 114.0 +25.7% +16.6% Total Group 1 158.4 1 363.1 +17.7% +15.2%In Northern Europe  turnover increased by +9.6% at constant FX (+10.7% at current FX). Trade credit insurance benefited from the increase in client activity and a high retention rate. Factoring turnover increased by +7.0%.In Western Europe  turnover was up by +14.8% at constant FX (+16.0% at current FX) thanks to a high retention rate and client activity.In Central and Eastern Europe  turnover was up by +16.8% and by +17.6% at constant FX  due to high retention  and growth in trade credit insurance driven by client activity. Factoring turnover continued to increase significantly  rising by +36.9%.In Mediterranean and Africa  a region driven by Italy and Spain  turnover grew by +17.2% and by +15.4% at current FX. This was due to high levels of new business and high retention. Revenues from services increased by +27.7%.In North America  turnover increased +12.4% at constant FX and +26.0% as reported  driven by high client activity and positive FX effect  which were partially offset by premium refunds.In Latin America  turnover was up +29.8% at constant FX and +41.3% at current FX  driven by strong retention as well as growth in client activity driven by the rise in commodity prices.In Asia-Pacific  turnover increased +16.6% at constant FX and +25.7% at current FX. This growth was driven by high retention and increased client activity as well as a positive currency effect.2. ResultCombined ratioThe combined ratio  net of reinsurance  stood at 63.8% for 9M-22 (a rise of 7.7 points compared to 9M-21).(i) Loss ratioThe gross loss ratio stood at 30.2%  up 5.0 ppts compared to the previous year. This reflects an increased claims frequency since H1-21  with the number of claims close to pre-Covid levels and the return of relatively large claims  which nevertheless remain below average. Coface increased its provisions relating to the residual exposure in Russia.The Groupâ€™s reserving policy remains unchanged. Strict management of past claims enabled Coface to record 53.1 ppts of recoveries. The loss ratio for the 2022 underwriting year is still high at 80.9%  signalling that Coface anticipates an increase in the number of bankruptcies in the coming quarters  and an increase in reserves on Russia.The loss ratio net of reinsurance came out at 36.9%  up by 11.5 ppts compared to 9M-21.(ii) Cost ratioCoface is following its strict policy of cost management. In the third quarter 2022  costs rose by +16.0% at constant FX and perimeter  and +20.1% at current FX. This increase is in line with the growth in turnover  even though Coface continued to invest. The cost ratio before reinsurance was 32.2%  an improvement of 0.8 ppt over one year.The cost ratio  net of reinsurance was 26.9% for the first nine months  an improvement of 3.8 ppts year-on-year  reflecting lower gross cost ratio and higher reinsurance commissions.Financial resultNet financial income for 9M-22 was â‚¬39.1m  up by â‚¬8.2m compared to 9M-21. This figure includes â‚¬10.7m in realised capital gains and positive hedging results as well as a currency effect of â‚¬3.2m. This performance was achieved against a particularly turbulent market backdrop  primarily due to the effectiveness of hedging policies.The portfolioâ€™s current yield (i.e. excluding capital gains  depreciation and FX impact) is â‚¬29.5m (compared to â‚¬25.2m in 9M-21). The accounting yield3  excluding capital gains and depreciation  stood at 1.0% in 9M-22  up compared to the previous year (0.9%)  mainly due to higher reinvestment rates.Operating income and net incomeOperating income for 9M-22 was â‚¬329.8m  up +24.3%  mainly due to increased growth and a still low loss ratio.The effective tax rate was 26%  compared to 24% for 9M-21.In total  net income (group share) was â‚¬228.4m  up +19.6% compared to 9M-21  of which â‚¬84.0m in Q3-22.3. Shareholdersâ€™ equity & solvencyAt 30 September 2022  Group shareholdersâ€™ equity stood at â‚¬1 955.2m  down â‚¬185.8m  or -8.7% (compared to â‚¬2 141.0m at 31 December 2021).This change is mainly due to the positive net income of â‚¬228.4m  the payment of the dividend (-â‚¬224.8m) and the fall in unrealised capital gains (-â‚¬240.5m).The annualised return on average tangible equity (RoATE) was 16.4% at 30 September 2022  mainly due to the improvement in underwriting income.4. OutlookThe risks threatening global growth were confirmed in the third quarter. The leading central banks continued to tighten monetary policy in a bid to curb inflation  which remains high. There was no improvement in the conflict in Ukraine and the energy crisis in Europe remains acute. European countries are taking substantial financial measures to limit the consequences of the crisis but there are considerable disparities in the extent of their intervention and the lack of coordination is undermining their effectiveness. The Chinese economy continues to be periodically affected by local lockdowns and is facing the consequences of the bursting of the property market bubble.As expected  growth forecasts for the global economy continue to be downgraded. Coface has lowered its financial outlook for 49 economic sectors  following significant downgrades to its country risk assessments in the second quarter.It is continuing to monitor the worsening economic environment. With its strong underwriting discipline and its reserving policy  which remains unchanged  Coface is well positioned to successfully navigate this more complex stage in the economic cycle. The raising of its credit rating outlook by Moodyâ€™s attests to the robustness of Coface's business model and its careful risk management.Coface is continuing to invest in expanding its service activities such as information services (growth of +15.6%) and factoring (+13.0%). Its record retention rate (93.5%) and the steady rise in its net promoter score (NPS) to 38% reflect client recognition of its constant focus on service quality.Conference call for financial analystsCofaceâ€™s results for 9M-2022 will be discussed with financial analysts during the conference call on Thursday 27 October at 18.00 (Paris time). Dial one of the following numbers:The presentation will be available (in English only) at the following address:http://www.coface.com/Investors/financial-results-and-reportsAppendixQuarterly resultsIncome statement items in â‚¬m - Quarterly figures Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Q2-22 Q3-22 % %ex. FX* Gross earned premiums 312.1 326.7 330.7 343.2 361.3 392.7 398.1 +20.4% +17.6% Services revenue 65.9 63.4 59.6 66.3 69.5 71.4 70.1 +17.6% +10.2% REVENUE 377.9 390.1 390.4 409.5 430.8 464.1 468.2 +19.9% +16.4% UNDERWRITING INCOME(LOSS) AFTER REINSURANCE 74.3 81.5 79.4 38.7 84.9 98.1 112.7 +41.9% +51.7% Investment income  net of management expenses 5.7 10.1 15.0 11.3 12.3 12.0 14.7 (2.3)% (13.5)% CURRENT OPERATING INCOME 80.0 91.6 94.5 49.9 97.2 110.1 127.4 +34.9% +42.0% Other operating income / expenses (0.4) 0.8 (1.3) (2.3) (1.2) (3.2) (0.7) (49.0)% (58.6)% OPERATING INCOME 79.6 92.4 93.2 47.6 96.1 106.9 126.8 +36.0% +43.4% NET INCOME 56.4 66.9 67.7 32.9 66.2 78.2 84.0 +24.1% +33.9% Income tax rate 24.6% 23.0% 23.3% 20.6% 27.2% 23.0% 27.0% + 3.7 pptsCumulated resultsIncome statement items in â‚¬mCumulated figures Q1-21 H1-21 9M-21 FY-21 Q1-22 H1-22 9M-22 % % ex. FX* Gross earned premiums 312.1 638.7 969.5 1 312.6 361.3 754.0 1 152.1 +18.8% +16.6% Services revenue 65.9 129.3 188.9 255.2 69.5 140.9 211.0 +11.7% +7.9% REVENUE 377.9 768.0 1 158.4 1 567.9 430.8 894.9 1 363.1 +17.7% +15.2% UNDERWRITING INCOME(LOSS)AFTER REINSURANCE 74.3 155.8 235.2 273.9 84.9 183.0 295.7 +25.7% +29.8% Investment income net of management expenses 5.7 15.9 30.9 42.2 12.3 24.4 39.1 +26.5% +26.8% CURRENT OPERATING INCOME 80.0 171.6 266.1 316.0 97.2 207.3 334.8 +25.8% +29.4% Other operating income / expenses (0.4) 0.4 (0.8) (3.2) (1.2) (4.3) (5.0) +499.8% +484.7% OPERATING INCOME 79.6 172.1 265.3 312.9 96.1 203.0 329.8 +24.3% +28.0% NET INCOME 56.4 123.2 190.9 223.8 66.2 144.4 228.4 +19.6% +24.7% Income tax rate 24.6% 23.8% 23.6% 23.2% 27.2% 25.1% 25.8% + 2.2 ppts* Also excludes scope impactCONTACTSANALYSTS / INVESTORSThomas JACQUET: +33 1 49 02 12 58 â€“ thomas.jacquet@coface.comBenoÃ®t CHASTEL: +33 1 49 02 22 28 â€“ benoit.chastel@coface.comMEDIA RELATIONSSaphia GAOUAOUI: +33 1 49 02 14 91 â€“ saphia.gaouaoui@coface.comCorentin HENRY: +33 1 49 02 23 94 â€“ corentin.henry@coface.comFINANCIAL CALENDAR 2022/2023(subject to change)FY-2022 results: 16 February 2023 (after market close)Annual General Shareholdersâ€™ Meeting 2022: 16 May 2023FINANCIAL INFORMATIONThis press release  as well as COFACE SAâ€™s integral regulatory information  can be found on the Groupâ€™s website:http://www.coface.com/InvestorsFor regulated information on Alternative Performance Measures (APM)  please refer to our Interim Financial Report for H1-2022 and our 2021 Universal Registration Document (see part 3.7 â€œKey financial performance indicatorsâ€).Regulated documents posted by COFACE SA have been secured and authenticated with the blockchain technology by Wiztrust. You can check the authenticity on the website www.wiztrust.com.COFACE: FOR TRADEWith more than 75 years of experience and the most extensive international network  Coface is one of the leader in trade credit insurance and adjacent specialty services  including Factoring  Single Risk insurance  Bonding and Information services. Cofaceâ€™s experts work to the beat of the global economy  helping ~50 000 clients build successful  growing  and dynamic businesses across the world. Coface helps companies in their credit decisions. The Group's services and solutions strengthen their ability to sell by protecting them against the risks of non-payment in their domestic and export markets. In 2021  Coface employed ~4 538 people and registered a turnover of â‚¬1.57 billion.www.coface.comCOFACE SA is quoted in Compartment A of Euronext ParisCode ISIN: FR0010667147 / MnÃ©monique : COFADISCLAIMER - Certain declarations featured in this press release may contain forecasts that notably relate to future events  trends  projects or targets. By nature  these forecasts include identified or unidentified risks and uncertainties  and may be affected by many factors likely to give rise to a significant discrepancy between the real results and those stated in these declarations. Please refer to chapter 5 â€œMain risk factors and their management within the Groupâ€ of the Coface Group's 2021 Universal Registration Document filed with AMF on 6 April 2022 under the number D.22-0244 in order to obtain a description of certain major factors  risks and uncertainties likely to influence the Coface Group's businesses. The Coface Group disclaims any intention or obligation to publish an update of these forecasts  or provide new information on future events or any other circumstance.1 Return on average tangible equity2 Also excludes scope impact3 Book yield calculated on the average of the investment portfolio excluding non-consolidated subsidiaries.Attachment",neutral,0.01,0.99,0.0,mixed,0.27,0.24,0.48,True,English,"['new record result', 'Annualised return', 'tangible equity', 'Coface', 'Q3-20', 'previous very low loss experience', 'n et combined ratio', 'H1-22 Business information momentum', 'record high retention rate', 'low loss ratio', 'net combined ratio', 'COMBINED RATIO NET', 'first nine months', 'Successful early refinancing', 'grandfathered T2 debt', 'Chief Executive Officer', 'European energy crisis', 'little financial leeway', 'prudent reserving policy', 'Balance sheet items', 'net promoter score', 'Net cost ratio', 'Cost ratio net', 'consolidated financial statements', 'The Audit Committee', 'recent economic recovery', 'Income statements items', 'new record result', 'continued operating leverage', 'Gross loss ratio', 'record net income', 'high client activity', 'higher reinsurance commissions', 'global growth forecasts', 'Other operating income', 'Credit Insurance premiums', 'New business', '9M-2022 n', 'Information services', 'Client retention', 'record highs', 'record level', 'global economy', 'economic cycle', 'The Board', 'insurance activities', 'other activities', 'credit rating', 'continued growth', 'Investment income', 'Annualised return', 'tangible equity', 'constant FX', 'group share', 'change comparisons', 'Xavier Durand', 'third quarter', 'major risks', 'monetary tightening', 'United Kingdom', 'monetary policies', 'developed countries', 'YTD figure', 'adjacent businesses', 'service quality', 'positive outlook', 'complex stage', 'Key ratios', 'Total Equity', 'current FX', 'Single Risk', 'competitive market', 'record increase', 'price effect', 'contrasting trends', 'different businesses', 'inflationary environment', 'risk environment', 'consolidated turnover', 'basis Trade', 'fiscal year', 'Key figures', 'Services revenue', 'management expenses', 'positive impact', 'Coface SA', 'Q3-20', '27 October', 'perimeter', 'pricing', 'line', 'revenues', '11.5 ppts', '7.7 ppts', '5.0 ppts', 'normalization', 'RoATE', 'Moody', 'results', '30 September', 'improvement', 'terms', 'conflict', 'Ukraine', 'situation', 'reminder', 'governments', 'Bankruptcies', 'Russia', 'Investments', 'factoring', 'NPS', 'decision', 'work', 'teams', 'past', 'years', 'strengths', 'beginning', 'Story', 'Directors', 'meeting', '26 October', 'INCOME/LOSS', 'scope', 'bonding', 'scale', '9M-22', 'volumes', 'Pola', '30.', '59', 'â‚¬']",2022-10-27,2022-10-28,finance.yahoo.com
12240,EuroNext,NewsApi.org,https://finance.yahoo.com/news/maisons-du-monde-third-quarter-050000291.html,Maisons du Monde: THIRD-QUARTER AND NINE-MONTH 2022 ACTIVITY,PRESS RELEASE THIRD-QUARTER AND NINE-MONTH 2022 ACTIVITY Q3 2022 activity in line with expectations in a persistently challenging environment Full-year...,"MAISONS DU MONDEPRESS RELEASETHIRD-QUARTER AND NINE-MONTH 2022 ACTIVITYQ3 2022 activity in line with expectations in a persistently challenging environmentFull-year guidance unchangedGroup GMV: 9M at â‚¬948m (-2.5% yoy  +16.3% vs 9M 2019)Q3 at â‚¬304.3m (-3.1% yoy  +12% vs Q3 2019)Strong marketplace GMV momentum in Q3: â‚¬30.2m  +124.2% yoyGroup sales: 9M at â‚¬882.4m (-5.9% yoy  +8% vs 9M 2019)Q3 at â‚¬278.5m (-8.2% yoy  +2.5% vs Q3 2019) Good performance of back-to-school commercial initiatives Improved inventory levelsCost and cash savings action plan announced in May fully on track  further initiatives launched to support 2023 performanceFY22 guidance unchangedNANTES â€“ 27 October 2022  07:00 CEST â€“ Maisons du Monde (Euronext Paris: MDM; ISIN: FR0013153541)  the European leader in inspirational and affordable home & living  published the Groupâ€™s sales for the third quarter and first nine months of 2022. Conference call to be held today at 09:00 CEST (see details on page 7).Julie Walbaum  Chief Executive Officer  commented:â€œOur third-quarter 2022 performance is in line with our expectations in a global environment that remains very challenging. The commercial initiatives we implemented since the end of May as well as our sustained efforts in inventory replenishment have been bearing fruit and should continue to support our activity through the end of the year. As a result  notwithstanding the high inflation and soft discretionary spending  we are still expecting sales improvement in Q4  benefiting from higher inventory levels  sustained promotional activity and a more favorable base effect online. The cost and cash savings action plan that we started in Q2 is also delivering its effects as planned.Story continuesConsequently  we keep our full year 2022 objectives unchanged. We remain fully confident in the fundamental strengths of Maisons du Monde that combines a love brand  a broad range of desirable and increasingly sustainable home & living products  with a unique omnichannel business model.â€Q3 key commercial developmentsDuring the period  Maisons du Monde continued to strengthen its direct-to-consumer love brand through creativity  inspiration and engagement  as well as to further deploy its unique omnichannel model.Brand and customersTotal active customers reached 2.1 million at 30 September 2022  of which 687 000 new customers (32% of the active customer base). Omnichannel customers grew by +8% over the quarter. Maisons du Mondeâ€™s Instagram community grew by +5% yoy  reaching 5.4 million followers across Europe.CollectionsMaisons du Monde released over the summer its Autumn-Winter collections  inviting consumers to open up to the world  through an inspiring exploration of 6 world spotlights. The collections cover over 2 300 products  from the natural fabrics and handcrafted designs of the Ussel theme to the colored ceramics and joyful textiles of the Montevideo range which includes the charming extravagance of the British Bloomsbury collection. These collections speak to what our target consumers are presently seeking: cocooning and optimism. MdMâ€™s collections have been endorsed by industry experts across Europe  as demonstrated by the yoy 61% increase in press mentions.Furthermore  fulfilling its mission to be the most desirable and sustainable home & living brand in Europe  Maisons du Monde teamed up with pioneer designer and key opinion leader in sustainable fashion Sakina Mâ€™Sa to create a limited-edition collection of 25 inspirational and sustainable decoration products (ceramics made in Europe and organic cotton for textiles).Commercial and operational initiativesDuring Q3  Maisons du Monde implemented various initiatives to facilitate the shopping experience and enhance customer satisfaction:Launch of the marketplace in a third country: already featuring 157 partner brands and 31 000 items  the marketplace was launched in Italy in September and the first weeks have been very promisingLaunch of a new innovative financing payment solution in France: in a context of constrained purchasing power  Maisons du Monde developed  in partnership with the Alma fintech  a very consumer-friendly and free-of-charge split payment solution. Take rate has been high from the start and consumer feedback is excellentLarge contract won by our B2B teams for the Stade de France  involving revamping of several spaces including VIP bars  and the temporary transformation of a gallery into a hotel room for summer eventsOrganization of our 4th annual â€œRendez-vous DÃ©coâ€  a digital event attended by more than 2 000 architects and designers this year  where Maisons du Monde provides its views on home and living trends.Maisons du Monde has also focused on two major 2022 operational priorities:Active management of its store network. At 30 September 2022  Maisons du Monde had 352 stores  compared to 350 at the end of June  opening three new stores in France  Italy and Spain while closing one in ItalySignificant progress in inventory replenishment  notably on furniture with an immediate availability ratio of 72% end of September vs 58% at the end of June 2022.ESG commitmentMaisons du Mondeâ€™s ESG objectives are embedded in its corporate project. Teams made good progress on MdMâ€™s trajectory with major achievements:Development of its sustainable product offering with 31% of Autumn/Winter collections integrated into the â€˜Good is Beautifulâ€™ selectionCreation of 6 â€˜Good is Beautifulâ€™ living spaces for people in need  in partnership with local non-profit organizations (for example  La Fondation des Femmes in Paris)Complete deployment of â€˜Good is Beautifulâ€™ ambassadors in 100% of storesRoll-out from October 2022 in the store network of the energy sobriety plan to save on store heating and lighting  as well as in the logistics warehouses and at the Groupâ€™s headquarters.Q3 financial resultsSummary of sales(in â‚¬million) Q3 22 Q3 21 %Change 9M 22 9M 21 %Change Group GMV 304.3 313.9 -3.1% 948.0 972.4 -2.5% Sales 278.5 303.4 -8.2% 882.4 937.8 -5.9% % like-for-like change1 -9.6% -4.0% -7.8% +19.1% Sales by distribution channel Stores 198.9 217.9 -8.7% 606.0 591.4 +2.5% % of sales 71.4% 71.8% 68.7% 63.1% Online 79.6 85.5 -6.9% 276.4 346.3 -20.2% % of sales 28.6% 28.2% 31.3% 36.9% Sales by geography France 146.8 164.1 -10.6% 459.4 496.3 -7.4% % of sales 52.7% 54.1% 52.1% 52.9% International 131.7 139.3 -5.5% 423.0 441.5 -4.2% % of sales 47.3% 45.9% 47.9% 47.1% Sales by product category Decoration 164.2 178.6 -8.1% 491.6 510.5 -3.7% % of sales 58.9% 58.9% 55.7% 54.4% Furniture 114.3 124.8 -8.4% 390.8 427.2 -8.5% % of sales 41.1% 41.1% 44.3% 45.6%GMV of â‚¬304.3 million (-3.1% yoy); Sales of â‚¬278.5 million (-8.2% yoy)After a second quarter that declined 8.3% yoy  impacted by a sudden material slowdown beginning mid-May  the third quarter sales performance was broadly similar but with a different monthly sequence. The sales trend in July was in line with what we saw in May/June  down in low double digits  while August was stable yoy boosted by a higher inventory level compared to 2021. September activity  while still negative yoy  was substantially better than the previous months thanks to improving traffic trends in stores and higher promotional activity yoy to support sales conversion and manage the excess inventory risk.GMV and Sales by channelMdMâ€™s omnichannel strategy  of which the marketplace is an integral component  continues to demonstrate its relevance and to support its completive edge.Q3 online GMV was â‚¬103.4 million  an increase of 7.7% thanks to a combination of robust marketplace GMV growth in France (+80%) as well as a strong contribution from the Q2 2022 launch of the marketplace in Spain. Consequently  the marketplace accounted for a material share of total online GMV in Q3:The French marketplace GMV was 42% of total French online GMVThe Spanish marketplace totaled 39% of total Spanish online GMVOverall the marketplace accounted for 29% of total online GMV in Q3.SalesQ3 online sales were â‚¬79.6 million (-6.9% yoy)  representing 29% of Group sales over the quarter. Traffic was up close to +15%  recovering from -13% in the first half. Compared to the same period in 2019  traffic was up more than two-thirds.Q3 store sales amounted â‚¬198.9 million. After a positive H1 2022 performance  partly driven by the H1 2021 base effect during which stores were partially closed  Q3 was down 8.7% with a 9% yoy decline in traffic.Sales by categoryQ3 Decoration sales amounted to â‚¬164.2 million  down 8.1% yoy  and accounted for 59% of total 3rd quarter sales and 61% of sales in France  the vast majority of which (83%) occurred in stores. Frames  lighting and tableware performed particularly well.Q3 Furniture sales totaled â‚¬114.3 million  down 8.4% yoy. 45% of furniture sales occurred online thanks to a dynamic international activity. Best-sellers included armchairs  sofas  tables and outdoor furniture.Sales by geographyQ3 sales in France reached â‚¬146.8 million  down -10.6%. Online sales in France were down -5.4% yoy and increased +12% compared to Q3 2019. Stores sales accounted for 73% of the total sales in France.Q3 international sales totaled â‚¬131.7 million  down -5.5% yoy and up +9.7% compared to the same period in 2019. Combined sales in Spain and Italy (58% of total international sales) were unchanged yoy and increased +4.4% and +1.7%  respectively  compared to Q3 2019. Combined sales in Belgium  Germany and Switzerland (34% of total international sales) decreased -12.6% yoy and were up +8.7% vs Q3 2019.9M financial summaryAs a result of the above  9M GMV was at â‚¬948 million (-2.5% yoy) and sales were at â‚¬882.4 million(-5.9% yoy). Compared to 9M 2019  9M 2022 GMV increased by +16.3% while 9M 2022 sales were +8.3% higher.Looking at channels  9M online GMV was â‚¬337 million  that is down 11.5% yoy but up 54% vs 9M 2019. Over the period  online represented 36% of total Groupâ€™s GMV  compared to 27% of Groupâ€™s GMV in 2019. Part of this success lies in the outstanding performance of the marketplace  which accounted for â‚¬76 million for the 9M 2022 period  that is 22% of total online GMV. In terms of sales  9M online sales were â‚¬276.4 million (-20.2% yoy; +26.5% vs 2019  while 9M store sales stood at â‚¬606 million (+2.5% yoy; +1.6% vs 2019).Looking at categories  9M decoration sales declined only 3.7% yoy to â‚¬492 million despite a high H1 2021 comparable base and the decrease in store traffic from May to September 2022.9M furniture sales decreased -8.5% yoy to â‚¬391 million  impacted by supply chain disruptions that led to limited availability  combined with increasingly constrained consumer purchasing power.Looking at geographies  9M sales in France reached â‚¬459 million (52% of total sales)  down 7.4% vs 9M 2021  and stable vs 9M 2019. 9M international sales totaled â‚¬423 million  down 4.2% vs 9M 2021 but up +19% vs 9M 2019. Nine-month sales in the two largest countries  Italy and Spain  were up +6% and stable yoy  respectively  vs 9M 2021.Q4 prioritiesCommercial activityFor the remainder of the year  the Group continues to execute its commercial plan to support traffic and sales both in stores and online  striking a balance between driving revenues and preserving margins.Several initiatives will be implemented by the end of the year:Roll-out of tactical promotional activityTest of a new digital solution in French stores to facilitate sales conversion and boost CRM capabilitiesRoll-out of the in-store marketplace in ItalyLaunch of the Rhinov interior designer service in Italy and Spain.Update on H2 2022 cost and cash savings planThe current inflationary environment has led to a reallocation of discretionary consumer spending away from the home and living sector  a much higher promotional competitive environment and increased input costs. In the face of this new reality  the Group implemented in May 2022 an action plan to contain cost and protect cash  targeting an extra â‚¬5 million gross margin and â‚¬20 million cost adjustments to reduce the impact of rising inflation. As of 30 September 2022  the execution of the plan is on track and MdM teams are fully focused on preparing and optimizing the 2023 equation.2022 capex  originally planned at around â‚¬90 million  has been revised downward and now is expected to be in the â‚¬70 million-â‚¬75 million range for the year. Regarding working capital requirement  the Group has made good progress in:adjusting its H2 2022 shipping plans to mitigate excess inventory risk while rebuilding inventories in select product families to support Q4 2022 and Q1 2023 salesand simultaneously negotiating with suppliers to reorganize manufacturing and purchasing planning  as well as to optimize payment terms.OutlookThe current economic environment remains challenging with still rising inflation across Europe and short-term consumption trends impacted by the current energy crisis.However  Q4 2022 sales are expected to improve over Q3 2022  thanks to improved furniture inventory levels  sustained promotional activity and a favorable base effect.Thanks to all actions engaged since end of Q2 2022 on sales  costs and cash  Maisons du Monde leaves its full-year 2022 objectives unchanged:Top line decrease in the mid-single digit rangeAn EBIT margin of 5% or aboveFCF of â‚¬10 million to 30 millionReduction of the Groupâ€™s carbon intensity: CO2 neutrality for scopes 1 and 2Dividend payout ratio of 30% to 40%Update on share buyback programOn 29 July 2022  the Group launched a second share repurchase program with an objective to repurchase up to 10% of its outstanding shares at market price over a period of several months. At 30 September 2022  the Group had purchased 1 151 846 of its own shares  i.e. 25% of the program  at an average price per share of â‚¬9.74. The shares acquired by December under this new buyback program are intended to be cancelled before year end  thereby reducing Maisons du Mondeâ€™s share capital.***Store Network(In units) Number of stores at end of: Q1 20 Q2 20 Q3 20 Q4 20 FY 20 Q1 21 Q2 21 Q3 21 Q4 21 FY 21 Q1 22 Q2 22 Q3 22 France 228 227 227 228 228 223 222 220 219 219 215 214 215 Italy 48 48 48 49 49 49 49 48 50 50 49 49 49 Spain 27 27 27 27 27 26 28 28 30 30 30 31 32 Belgium 23 23 23 24 24 25 26 26 27 27 25 25 25 Germany 11 10 10 11 11 11 12 12 12 12 12 12 12 Switzerland 9 9 9 9 9 10 10 11 12 12 12 12 12 Luxembourg 3 3 3 3 3 3 3 3 3 3 3 3 3 Portugal 1 1 1 1 1 1 1 1 3 3 3 3 3 Austria - - - - - 1 1 1 1 1 1 1 1 Number of stores 350 348 348 352 352 349 352 350 357 357 350 350 352 Net openings -6 -2 0 +4 -4 -3 +3 -2 +7 +5 -7 0 +2 Sales area (K sqm) 415.7 413.6 414.2 420.2 420.2 419.0 424.4 424.5 432.9 432.9 427.8 428.9 433.0 Change (K sqm) -1.5 -2.1 +0.6 +6.0 +3.0 -1.2 +5.3 +0.6 +8.0 +12.7 -5.1 +1.1 +4.1***Disclaimer: Forward Looking StatementThis press release contains certain statements that constitute ""forward-looking statements "" including but not limited to statements that are predictions of or indicate future events  trends  plans or objectives  based on certain assumptions or which do not directly relate to historical or current facts. Such forward-looking statements are based on management's current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from the future results expressed  forecasted or implied by such forward- looking statements. Accordingly  no representation is made that any of these statements or forecasts will come to pass or that any forecast results will be achieved. Any forward-looking statements included in this press release speak only as of the date hereof and will not give rise to updates or revision. For a more complete list and description of such risks and uncertainties  refer to Maisons du Mondeâ€™s filings with the French AutoritÃ© des marchÃ©s financiers.***About Maisons du MondeMaisons du Monde  a uniquely positioned and beloved brand across Europe  stands as the European leader in inspirational and affordable home & living. It offers a wide and constantly renewed range of furniture and home accessories across multiple styles. Creativity  inspiration and engagement are the brandâ€™s core pillars. Leveraging its distinctive direct-to-consumer omnichannel model  the company generates over 50% of its sales digitally  through its online platform and in-store digital sales and operates 352 stores across 9 European countries. End 2020  the Group launched a curated marketplace to complement its offering and become the reference one-stop shop in inspirational and affordable home and living. In November 2021  Maisons du Monde unveiled its company purpose: â€œInspiring everyone to open up to the world  to create together unique  warm and sustainable places to live.â€corporate.maisonsdumonde.com***ContactsInvestor Relations Press Relations Carole AlexandreTel: (+33) 6 30 85 12 78 Pierre BarbeTel: (+33) 6 23 23 08 51 calexandre@maisonsdumonde.com pbarbe@maisonsdumonde.comConference call for investors and analystsDate: 27 October at 09:00 CESTSpeakers: Julie Walbaum  CEO and RÃ©gis Massuyeau  CFOConnection details:Q3-9M 2022 activity - Webcast Connection Details To access the webcast :https://edge.media-server.com/mmc/p/hcx5tf6ePlease connect using the link above at least 15 minutes prior to the scheduled start time (09:00 CEST).NB: You will be able to ask a question during the Q&A session in the Chat sectionin writing only!If you would like to ask an audio question during the Q&A session  please follow the â€œAudio Q&A Conference Call Connection Detailsâ€ instructions below.Q3-9M 2022 activity - â€œAudioâ€ Q&A Conference Call Connection DetailsPlease register using the link below at least 15 minutes prior to the scheduled start time (09:00 CEST).Participants will receive via e-mail a unique Direct Event Passcode and a Registrant ID.Please connect to one of the numbers provided in the e-mail and follow directions to be connected to the Q&A conference call. https://register.vevent.com/register/BI8fb3c47c0610466fba66f1965c512feb***Financial calendar26 January 2023: Full Year 2022 Sales09 March 2023: Full Year 2022 Financial Results1 Represents the percentage change in sales from the Groupâ€™s retail stores  websites and B2B activities  net of product returns between one financial period (N) and the comparable preceding financial period (N-1)  excluding changes in sales attributable to stores that opened or were closed during either of the comparable periods. Sales attributable to stores that closed temporarily for refurbishment during any of the periods are included.Attachment",neutral,0.0,1.0,0.0,positive,0.77,0.21,0.03,True,English,"['Maisons du Monde', 'NINE-MONTH 2022 ACTIVITY', 'THIRD-QUARTER', 'new innovative financing payment solution', 'charge split payment solution', 'cash savings action plan', 'two major 2022 operational priorities', 'unique omnichannel business model', 'Strong marketplace GMV momentum', 'Q3 key commercial developments', 'unique omnichannel model', 'Chief Executive Officer', 'soft discretionary spending', 'favorable base effect', 'key opinion leader', 'Sakina Mâ€™Sa', 'constrained purchasing power', 'Maisons du Monde', 'first nine months', 'higher inventory levels', 'British Bloomsbury collection', 'three new stores', 'active customer base', 'full year 2022 objectives', 'Stade de France', 'Total active customers', 'inventory levels Cost', 'sustainable decoration products', 'consumer love brand', '687,000 new customers', 'Omnichannel customers', 'operational initiatives', 'Group GMV', 'Active management', 'European leader', 'inventory replenishment', 'limited-edition collection', 'customer satisfaction', 'first weeks', 'sustainable fashion', 'commercial initiatives', 'PRESS RELEASE', 'challenging environment', 'Full-year guidance', 'FY22 guidance', 'Euronext Paris', 'Conference call', 'Julie Walbaum', 'global environment', 'high inflation', 'fundamental strengths', 'broad range', 'sustainable home', 'Instagram community', '5.4 million followers', 'inspiring exploration', 'natural fabrics', 'handcrafted designs', 'Ussel theme', 'Montevideo range', 'charming extravagance', 'industry experts', 'yoy 61% increase', 'press mentions', 'pioneer designer', 'organic cotton', 'shopping experience', 'third country', '157 partner brands', 'Alma fintech', 'Take rate', 'consumer feedback', 'Large contract', 'B2B teams', 'several spaces', 'VIP bars', 'temporary transformation', 'hotel room', 'DÃ©co', 'digital event', 'store network', 'Significant progress', 'immediate av', 'various initiatives', 'affordable home', 'living products', 'living brand', 'living trends', 'Good performance', 'sales improvement', 'third quarter', 'sustained efforts', 'promotional activity', '6 world spotlights', 'colored ceramics', 'joyful textiles', 'target consumers', 'summer events', 'Group sales', 'Autumn-Winter collections', 'third-quarter 2022 performance', 'Q3 2022 activity', '2,300 products', '352 stores', '2023 performance', 'NINE-MONTH', 'line', 'expectations', '9M', 'school', 'May', 'track', 'NANTES', '27 October', '07:00 CEST', 'MDM', 'ISIN', 'inspirational', '09:00 CEST', 'details', 'page', 'fruit', 'result', 'Q2', 'effects', 'Story', 'desirable', 'period', 'creativity', 'engagement', '30 September', 'cocooning', 'optimism', 'mission', 'Launch', '31,000 items', 'Italy', 'context', 'partnership', 'friendly', 'start', 'excellent', 'revamping', 'gallery', 'Organization', 'Rendez', '2,000 architects', 'designers', 'views', 'June', 'Spain', 'furniture']",2022-10-27,2022-10-28,finance.yahoo.com
12241,EuroNext,NewsApi.org,https://finance.yahoo.com/news/arcadis-trading-q3-2022-050000700.html,Arcadis Trading Update Q3 2022,Continued strong client demand and improved performance Strong client demand for energy transition solutions  new mobility and industrial manufacturingNet...,"Arcadis N.V.Continued strong client demand and improved performanceStrong client demand for energy transition solutions  new mobility and industrial manufacturingNet revenue at â‚¬740 million; organic growth of 10.9% 1 )Organic backlog growth year-on-year of 5.0% 1)Operating EBITA margin improved to 10.3% (Q3â€˜21: 9.5%)Net Working Capital improved to 13.8% (Q3â€˜21: 14.0%) and DSO to 72 days (Q3â€˜21: 74 days)Accelerating strategy through the acquisitions of IBI Group  DPS Group and Giftge Consult  and the divestments of a number of non-core operationsAmsterdam  27 October 2022 â€“ Arcadis (EURONEXT: ARCAD)  the leading global Design & Consultancy organization for natural and built assets  sees a continued growing client demand across its Global Business Areas (GBAs)  resulting in an organic net revenue growth of 10.9%  and an organic backlog growth of 5.0%. Operating EBITA margin increased to 10.3% (last year: 9.5%)  driven by improved performance across the GBAs.Peter Oosterveer  CEO Arcadis  comments:â€œDuring the last quarter  we have continued to see growing client demand across our three Global Business Areas. Our Resilience business continues to benefit from increased client demand for sustainability advisory  energy transition and climate adaptation solutions. In our Places business we have enjoyed large wins in North America and Germany  and increased demand from manufacturing and governmental clients. For our Mobility business  significant rail wins in the Netherlands and a growing demand for smart mobility solutions from highways and public transport clients created strong results.We have also made significant progress in optimizing our portfolio and focusing our efforts on geographies where we see the most attractive opportunities. This has resulted in the divestments of operations in Singapore  Malaysia  our Design and Engineering business in Hong Kong  Switzerland and our environmental restoration business in France. These follow the divestments made earlier on in the year; of our operations in Thailand  Czech Republic and Slovakia.Story continuesAs we look ahead to 2023  our focus is on fully embedding both IBI and DPS into our four Global Business Areas  and the shaping of our fourth GBA â€œIntelligenceâ€. Through these acquisitions  we not only significantly grow our presence in North America and Europe  but we will also be in the position to provide complementary client services and solutions in high growth markets  including life sciences  semiconductors  and industrial manufacturing.Although the evolving geo-political situation and inflationary headwinds remain firmly on our radar  our record backlog and continued focus on the optimization of our portfolio  combined with the exciting new growth opportunities IBI  DPS and Giftge Consulting offer  position us well to meet our strategic targets. I can only be very proud of all the teams across Arcadis that have kept the right focus on our clients in these busy and exciting times for our company.â€KEY FIGURESAs the acquisition of the IBI Group has been formally closed on 27th of September 2022  the Arcadis consolidated financial statements include IBI consolidated data for balance sheet items (those items having an impact on NWC% and DSO calculated for Arcadis as a whole). Arcadis backlog includes IBI backlog as well. As the three days of P&L of IBI Group between September 27th and September 30th have been considered as non-significant  P&L data and corresponding KPIâ€™s (e.g. EBITDA  order intake  FCF) for the third quarter represent Arcadis standalone data.in â‚¬ millions Third quarter Year-to-date Period ended 30 September 2022 2022 2021 change 2022 2021 change Gross revenues 1 003 828 21% 2 851 2 489 15% Net revenues 740 636 16% 2 158 1 912 13% Organic growth1) 10.9% 4.8% 8.2% 3.9% Operating EBITDA2) 101 83 21% 284 252 12% Operating EBITDA margin 13.6% 13.1% 13.2% 13.2% EBITA 27 57 -52% 158 171 -8% EBITA margin 3.7% 9.0% 7.3% 9.0% Operating EBITA2) 76 60 26% 208 177 18% Operating EBITA margin 10.3% 9.5% 9.7% 9.2% Free Cash Flow3) 38 75 -50% 27 105 -74% Net Working Capital %4) 13.8% 14.0% Days Sales Outstanding4) 72 74 Net Debt4) 880 298 195% Backlog net revenues4) 2 813 2 126 32% Backlog organic growth (y-o-y)1) 5.0%1) Underlying growth excluding the impact of currency movements  acquisitions or footprint reductions  such as the Middle East  winddowns or divestments2) This excludes the net result on divestment of consolidated companies  and acquisitions  restructuring  and integration-related costs. The Operating EBITDA is used when calculating the strategic target: average net debt / (Operating) EBITDA  guided for 1.5-2.5x3) Free Cash flow: Cash Flow from Operations corrected for Capex and Lease liabilities4) Including IBI Group  transaction closing per 27th of September 2022INCOME STATEMENTNet revenues totaled â‚¬740 million and increased organically by 10.9%. Growth was driven by all three GBAs  with Resilience and Mobility being exceptionally strong in North America and the UK. The currency impact was 9%. The operating EBITA margin improved to 10.3% (Q3â€˜21: 9.5%)  driven by all three GBAs  and a significant year-on-year improvement driven by Places from improved operational efficiencies  despite lower working days in the UK and Australia due to Queen Elizabethâ€™s funeral.Non-operating costs were â‚¬49 million and include transaction costs related to the three recently announced acquisitions  and a net loss on divestments of operations in Singapore  Malaysia  Hong Kong (Design & Engineering business)  Switzerland and France (Environmental Restoration business). These net losses had no impact on Free Cash Flow.ORDER INTAKE &BACKLOGAt the end of September 2022 backlog reached a record high level of â‚¬2 813 million (Q3â€˜21: â‚¬2 126 million)  of which â‚¬530 million was added through the acquisition of the IBI Group. Strong order intake  with almost no cancellations in the quarter resulted in a solid organic backlog growth of 5.0% year-over-year  with a positive contribution of all three GBAs.BALANCE SHEET & CASH FLOWNet working capital as a percentage of annualized gross revenues was 13.8% (Q3â€˜21: 14.0%)  globally in line with last year performance. Days Sales Outstanding (DSO) decreased to 72 days (Q3â€˜21: 74 days). Net debt increased to â‚¬880 million (Q3â€˜21: â‚¬298 million)  including the â‚¬600 million bridge loan for IBI acquisition and IBI net debt of â‚¬54 million.Free cash flow generation during the quarter was â‚¬38 million and below last yearâ€™s (Q3â€˜21: â‚¬75 million)  driven by sharp revenue growth elevating working capital levels  and some transaction costs relating to the recent acquisitions. Free cash flow generation year-to-date was â‚¬27 million (Q3â€˜21: â‚¬105 million)  which was impacted by a normalization of working capital levels compared to 2021.STRATEGIC PROGRESSFocus & Scale is one of the three key pillars of our â€œMaximizing Impactâ€ business strategy for 2021-2023. Arcadis has focused on driving operational efficiencies through the implementation of the GBA model  focus on key clients  and greater use of the Global Excellence Centers (GECs)  as well as investing in high growth markets  for instance through the acquisitions of IBI  DPS and Giftge Consult.At the same time  â€œFocus & Scaleâ€ triggered a portfolio assessment  reviewing operations on their scalability  growth potential  financial performance  and scope of services. This has resulted in the following divestment of non-core operations  from a geographic or business point of view: Singapore  Malaysia  Hong Kong (Design & Engineering business)  Switzerland and France (Environmental Restoration business)  representing ~900 people and â‚¬47 million of annual net revenues. This was in addition to the divestments of Czech Republic  Slovakia and Thailand that occurred in the first half of 2022  representing ~190 people and â‚¬11 million of annual net revenues.The recent acquisitions of IBI  DPS and Giftge  together with the divestments  have rebalanced the geographic and business portfolio  and repositioned Arcadis towards high growth and resilient markets such as placemaking and urban planning in North America  and industrial manufacturing engineering in the US and Europe. The creation of the fourth GBA â€œIntelligence""  will enhance Arcadisâ€™ position as a digital leader  and ability to serve its clients in a more efficient way across all phases of the asset lifecycle. The backlog for Intelligence at the end of the third quarter was â‚¬112 million  representing 4% of the total Arcadis backlog.PERFORMANCE BY GLOBAL BUSINESS AREARESILIENCE(43% of net revenues) in â‚¬ millions Third quarter Year-to-date Period ended 30 September 2022 2022 2021 change 2022 2021 change Net revenues 320 259 24% 909 771 18% Organic growth1) 13.7% 9.7% Backlog net revenues 943 Backlog organic growth (y-o-y)1) 5.4%Resilience showed continued solid revenue and backlog growth for the third quarter  driven by continued strong client demand in energy transition  climate adaptation and mitigation  including a new commission as lead designer of a flood defense for Battery Park  New York City  complementing resiliency work for southeast and lower Manhattan. Revenue growth was supported by the successful onboarding of new hires  especially in the US.The Resilience business closed the quarter at a backlog of â‚¬943 million  representing 34% of total Arcadis backlog.PLACES(32% of net revenues) in â‚¬ millions Third quarter Year-to-date Period ended 30 September 2022 2022 2021 change 2022 2021 change Net revenues 234 209 12% 697 656 6% Organic growth1) 3.6% 2.8% Backlog net revenues 1 216 Backlog organic growth (y-o-y)1) 2.1%Revenue and backlog growth in the third quarter were driven by a strong Continental Europe and US  with good demand for sustainable and intelligent buildings  including the development of datacenters and automotive giga-factories for electric vehicle battery production. Revenue and backlog growth was somewhat hampered by weakening market circumstances in China.The absolute backlog of Places increased by 29% year-on-year to â‚¬1 216 million. The position includes the backlog of IBI Group  which was marked by strong order intake in the third quarter and excludes the divested countries in Southeast Asia. These strategic decisions led to a significant repositioning of the Places backlog  now representing 43% of total Arcadis backlog  with an increased focus on North America and Europe.MOBILITY(25% of net revenues) in â‚¬ millions Third quarter Year-to-date Period ended 30 September 2022 2022 2021 change 2022 2021 change Net revenues 186 168 11% 552 485 14% Organic growth1) 15.4% 12.5% Backlog net revenues 542 Backlog organic growth (y-o-y)1) 9.0%Stellar revenue growth for Mobility in the third quarter was driven by the UK  Australia and the US. A strong backlog development came from large highway and rail wins; such as for ProRail in the Netherlands  and a growing demand for smart mobility solutions from highways and public transport clients. At the end of Q3  mobility backlog amounted to â‚¬542 million  representing 19% of total Arcadis backlog.IBIâ€™s experience in developing digital tools including Travel-IQ will further help to pursue new opportunities and strengthen our Mobility business both in North America and across the world.Financial calendar:16 February 2023 â€“ Q4 & FY 2022 Results4 May 2023 â€“ Q1 2023 Trading Update27 July 2023 â€“ Q2 & HY 2023 Results26 October 2023 â€“ Q3 2023 Trading UpdateFor further information please contact:Arcadis Investor RelationsChristine DischMobile: +31 (0)6 1537 6020E-mail: christine.disch@arcadis.comArcadis Corporate CommunicationsTanno MassarMobile: +31 (0)6 1158 9121E-mail: tanno.massar@arcadis.comAnalyst meetingArcadis will hold an analyst webcast to discuss the Q3results for 2022. The analyst meeting will be held at 10.00 hours CET today. The webcast can be accessed via the investor relations section on the companyâ€™s website at: https://channel.royalcast.com/landingpage/arcadisinvestors/20221027_1/About ArcadisArcadis is a leading global Design & Consultancy organization for natural and built assets. Applying our deep market sector insights and collective design  consultancy  engineering  project and management services we work in partnership with our clients to deliver exceptional and sustainable outcomes throughout the lifecycle of their natural and built assets. We are 33 000 people  active in over 70 countries that generate â‚¬3.8 billion in revenues. We support UN-Habitat with knowledge and expertise to improve the quality of life in rapidly growing cities around the world. www.arcadis.com.Regulated informationThis press release contains information that qualifies or may qualify as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.Forward looking statementsStatements included in this press release that are not historical facts (including any statements concerning investment objectives  other plans and objectives of management for future operations or economic performance  or assumptions or forecasts related thereto) are forward-looking statements. These statements are only predictions and are not guarantees. Actual events or the results of our operations could differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements are typically identified by the use of terms such as â€œmayâ€  â€œwillâ€  â€œshouldâ€  â€œexpectâ€  â€œcouldâ€  â€œintendâ€  â€œplanâ€  â€œanticipateâ€  â€œestimateâ€  â€œbelieveâ€  â€œcontinueâ€  â€œpredictâ€  â€œpotentialâ€ or the negative of such terms and other comparable terminology. The forward-looking statements are based upon our current expectations  plans  estimates  assumptions and beliefs that involve numerous risks and uncertainties. Assumptions relating to the foregoing involve judgments with respect to  among other things  future economic  competitive and market conditions and future business decisions  all of which are difficult or impossible to predict accurately and many of which are beyond our control. Although we believe that the expectations reflected in such forward-looking statements are based on reasonable assumptions  our actual results and performance could differ materially from those set forth in the forward-looking statements.Attachments",neutral,0.0,1.0,0.0,positive,0.76,0.23,0.0,True,English,"['Arcadis Trading Update', 'four Global Business Areas', 'three Global Business Areas', 'exciting new growth opportunities', 'organic net revenue growth', 'evolving geo-political situation', 'complementary client services', 'environmental restoration business', 'Net Working Capital', 'climate adaptation solutions', 'high growth markets', 'Giftge Consulting offer', 'Free Cash Flow', 'average net debt', 'significant rail wins', 'balance sheet items', 'strong client demand', 'growing client demand', 'public transport clients', 'Organic backlog growth', 'P&L data', 'Arcadis N.V.', 'energy transition solutions', 'smart mobility solutions', 'Backlog net revenues', 'Operating EBITA margin', 'IBI consolidated data', 'The Operating EBITDA', 'organic growth', 'growing demand', 'new mobility', 'attractive opportunities', 'exciting times', 'Places business', 'Mobility business', 'Engineering business', 'strong results', 'standalone data', 'EBITDA margin', 'net result', 'large wins', 'significant progress', 'record backlog', 'consolidated companies', 'IBI backlog', 'three days', 'Resilience business', 'Gross revenues', 'Accelerating strategy', 'Consultancy organization', 'built assets', 'Peter Oosterveer', 'last quarter', 'sustainability advisory', 'North America', 'Hong Kong', 'Czech Republic', 'life sciences', 'inflationary headwinds', 'strategic targets', 'financial statements', 'Arcadis backlog', 'corresponding KPI', 'order intake', 'third quarter', 'date Period', 'currency movements', 'Middle East', 'integration-related costs', '1.5-2.5x', 'Lease liabilities', 'INCOME STATEMENT', 'three GBAs', 'IBI Group', 'industrial manufacturing', 'Days Sales', 'CEO Arcadis', 'DPS Group', 'last year', 'right focus', 'currency impact', 'core operations', '72 days', 'performance', 'DSO', 'acquisitions', 'divestments', 'number', 'Amsterdam', 'EURONEXT', 'natural', 'continued', 'comments', 'Germany', 'Netherlands', 'highways', 'portfolio', 'efforts', 'geographies', 'Singapore', 'Malaysia', 'Design', 'Switzerland', 'France', 'Thailand', 'Slovakia', 'Story', 'shaping', 'Intelligence', 'presence', 'Europe', 'position', 'semiconductors', 'radar', 'optimization', 'teams', 'busy', 'company', 'FIGURES', '27th', 'September', 'FCF', '2021 change', 'footprint', 'reductions', 'winddowns', 'restructuring', 'Capex', 'transaction', 'UK', '10.', '5.0', '74', 'â‚¬', '30']",2022-10-27,2022-10-28,finance.yahoo.com
12242,EuroNext,NewsApi.org,https://finance.yahoo.com/news/argenx-reports-third-quarter-2022-050000534.html,argenx Reports Third Quarter 2022 Financial Results and Provides Business Update,$131 million in third quarter VYVGARTÂ® (efgartigimod alfa-fcab) global net product sales Filed Biologics License Application (BLA) for subcutaneous (SC...,argenx SE$131 million in third quarter VYVGARTÂ® (efgartigimod alfa-fcab) global net product salesFiled Biologics License Application (BLA) for subcutaneous (SC) efgartigimod for treatment of generalized myasthenia gravis (gMG)Hans de Haard  Ph.D. to retire as Chief Scientific Officer (CSO) in January 2023Management to host conference call today at 2:30 pm CET (8:30 am ET)October 27  2022Amsterdam  the Netherlands â€“ argenx SE (Euronext & Nasdaq: ARGX)  a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases  today announced its third quarter 2022 financial results and provided a business update and outlook for the remainder of the year.â€œWe had a strong third quarter of our global VYVGART launch now underway in our priority territories of the U.S.  Japan and the EU. I am proud of what our teams have achieved  working cross-functionally to set a new treatment standard in gMG and serve as many patients as possible. Looking ahead  we are ready to support a SC efgartigimod launch in the first half of 2023 so that gMG patients can have multiple ways to individualize their treatment â€ said Tim Van Hauwermeiren  Chief Executive Officer of argenx. â€œgMG is also just the beginning and we are committed to advancing our immunology pipeline of efgartigimod  ARGX-117 and ARGX-119 with eight ongoing clinical trials in severe autoimmune diseases and more to start by the end of the year. We believe we are well on our way to realizing our goal of becoming a leading  multi-product immunology company and that we have the right team  a differentiated pipeline  and a sustainable discovery engine to continue innovating on behalf of patients.â€THIRD QUARTER 2022 AND RECENT BUSINESS UPDATEVYVGART LaunchVYVGART is the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S.  Japan and the European Union (EU). VYVGART is approved in the United States (U.S.) and the EU for the treatment of adult gMG patients who are anti-acetylcholine receptor (AChR) antibody positive and in Japan for adult gMG patients who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).Story continuesGenerated global net VYVGART revenues of $131 million in the third quarter of 2022Received European Commission (EC) approval on August 11  2022; commercial launch in Germany initiated on September 1  2022Approval decisions expected in 2023 in Canada  China through Zai Lab  and Israel through MedisonExpanded large-scale manufacturing capabilities and capacity through collaboration with FUJIFILM Diosynth Biotechnologies to provide drug substance manufacturing of efgartigimodEfgartigimod Research and Developmentargenx is positioned to expand its leadership position in FcRn blockade to include ten total autoimmune indications in the pipeline by the end of 2022Neuromuscular franchise Submitted BLA to the U.S. Food and Drug Administration (FDA) for SC efgartigimod for gMG; approval decision and commercial launch expected in first half of 2023 Topline data from registrational ADHERE trial of SC efgartigimod for chronic inflammatory demyelinating polyneuropathy (CIDP) on track for first quarter of 2023 Registrational ALKIVIA trial ongoing of SC efgartigimod for three subtypes of idiopathic inflammatory myopathies (myositis)  including immune-mediated necrotizing myopathy  anti-synthetase syndrome and dermatomyositis; interim analysis planned of first 30 patients of each subtypeHematology franchise Topline data from second registrational ADVANCE-SC trial of SC efgartigimod for primary immune thrombocytopenia (ITP) expected in second half of 2023Dermatology franchise Topline data from registrational ADDRESS trial of SC efgartigimod for pemphigus vulgaris and foliaceus expected in second half of 2023 Registrational BALLAD trial ongoing of SC efgartigimod for bullous pemphigoid with interim analysis planned of first 40 patientsProof-of-concept trials to launch in 2022 in collaboration with Zai Lab and IQVIA Zai Lab to launch trials in lupus nephritis and membranous nephropathy with argenx to lead global registrational programs for each potential indication IQVIA to launch trial in primary Sjogrenâ€™s syndrome; trial ongoing in COVID-19-mediated postural orthostatic tachycardia syndrome (POTS)Pipeline Progressargenx is developing ARGX-117 and ARGX-119  which both have pipeline-in-a-product potential for multiple autoimmune indications. Additional candidates that emerged from the Immunology Innovation Program are in development by partners or spin-off companies.ARGX-117 (C2 inhibitor) Proof-of-concept ARDA trial ongoing to evaluate safety  tolerability  and potential dosing regimen in multifocal motor neuropathy (MMN) Proof-of-concept trial expected to start following regulatory discussions for prevention of delayed graft function and/or allograft failure after kidney transplantationARGX-119 (muscle-specific kinase (MuSK) agonist) Phase 1 dose-escalation trial in healthy volunteers expected to start after Clinical Trial Application filing in fourth quarter of 2022 with subsequent Phase 1b trial to assess early signal detection in patientsLEO Pharma exercised exclusive  worldwide option to ARGX-112 targeting IL22 receptor; decision triggered â‚¬5 million payment to argenxHans de Haard  Ph.D. to retire as CSO on January 1  2023 and transition to consultant within Immunology Innovation Program and strategic advisor to Research and Development Committee of argenx Board of DirectorsSuccession plans underway for Peter Ulrichts  Ph.D.  Head of Clinical Science at argenx  to assume CSO roleNomination of Ana Cespedes as non-executive director to Board of DirectorsAna Cespedesâ€™s appointment is pending approval  which is expected to occur at an extraordinary general meeting of shareholders to be held in December 2022. She is Chief Operating Officer of IAVI  a global organization dedicated to developing accessible vaccines and antibodies for infectious diseases. She brings robust experience across a broad range of critical areas for commercialization and access  as well as for organizational effectiveness.THIRD QUARTER 2022 FINANCIAL RESULTSARGENX SEUNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENT OF PROFIT OR LOSSThree Months Ended Nine Months Ended September 30  September 30  (in thousands of $ except for shares and EPS) 2022 2021 2022 2021 Product net sales $ 131 329 $ â€” $ 227 325 $ â€” Collaboration revenue 6 652 857 9 262 471 255 Other operating income 8 508 6 248 26 565 34 479 Total operating income 146 489 7 105 263 152 505 734 Cost of sales (10 264) â€” (16 646) â€” Research and development expenses (236 681) (139 440) (515 568) (413 347) Selling  general and administrative expenses (108 181) (80 623) (336 845) (210 222) Total operating expenses (355 126) (220 062) (869 059) (623 568) Operating income/(loss) $ (208 637) $ (212 957) $ (605 907) $ (117 834) Financial income 8 007 805 13 740 2 434 Financial expense (785) (1 100) (2 916) (3 474) Exchange gains/(losses) (39 609) (17 615) (92 991) (35 990) Profit/(Loss) for the period before taxes $ (241 024) $ (230 866) $ (688 074) $ (154 863) Income tax (expense)/benefit $ 5 982 $ (2 749) $ 17 096 $ (15 584) Profit/(Loss) for the period $ (235 042) $ (233 614) $ (670 978) $ (170 447) Profit/(Loss) for the period attributable to: Owners of the parent (235 042) (233 614) (670 978) (170 447) Weighted average number of shares outstanding 55 203 655 51 466 674 54 049 119 50 932 324 Basic profit/(loss) per share (in $) (4.26) (4.54) (12.41) (3.35) Diluted profit/(loss) per share (in $) (4.26) (4.54) (12.41) (3.35) Net increase/(decrease) in cash  cash equivalents and current financial assets compared to year-end 2021 and 2020 $ 48 813 $ 537 518 Cash  cash equivalents and current financial assets at the end of the period $ 2 385 541 $ 2 533 969DETAILS OF THE FINANCIAL RESULTSTotal operating income for the third quarter and year-to-date in 2022 was $146.5 million and $263.2 million  respectively  compared to $7.1 million and $505.7 million for the same periods in 2021  and consists of:Product net sales from the sales of VYVGART for the three months ended September 30  2022 were $131.3 million. The product net sales in the nine months ended September 30  2022 were $227.3 million. No product net sales were recognized during the same period in 2021.Collaboration revenue for the third quarter and year-to-date in 2022 was $6.7 million and $9.3 million  respectively  compared to $0.1 million and $471.3 million for the same periods in 2021. The collaboration revenue during the three months ended September 30  2022 primarily relates to milestone revenue of the â‚¬5 million triggered by the option exercised by LEO Pharma to enter into a commercial license for ARGX-112. The collaboration revenue for the three and nine months ended September 30  2021 was primarily attributable to the recognition of the transaction price as a consequence of the termination of the collaboration agreement with Janssen  resulting in the recognition of $315.1 million and the closing of the strategic collaboration for efgartigimod with Zai Lab  resulting in the recognition of $151.9 million in collaboration revenue.Other operating income for the third quarter and year-to-date in 2022 was $8.5 million  and $26.6 million  respectively  compared to $6.2 million and $34.5 million for the same periods in 2021. During the nine months ended September 30  2022  and September 30  2021  the fair value of the argenx profit share in AgomAb Therapeutics NV increased by $4.3 million and $11.2 million respectively. The increase is a result of the extension of a Series B financing round by AgomAb for which argenx maintains a profit share in exchange for granting the license for the use of HGF-mimetic antibodies from the SIMPLE Antibodyâ„¢ platform.Total operating expenses for the third quarter and year-to-date in 2022 were $355.1 million and $869.1 million  respectively  compared to $220.1 million and $623.6 million for the same periods in 2021  and consists of:Cost of sales for the third quarter and year-to-date in 2022 was $10.3 million and $16.6 million  respectively. The cost of sales were recognized with respect to the sale of VYVGART during 2022. There were no cost of sales recognized in the comparable prior year periods.Research and development expenses for the third quarter and year-to-date in 2022 were $236.7 million and $515.6 million  respectively  compared to $139.4 million and $413.3 million for the same periods in 2021. The research and development expenses mainly relate to external research and development expenses and personnel expenses incurred in the clinical development of efgartigimod in various indications and the expansion of other clinical and preclinical pipeline candidates. The increase in research and development expense during the third quarter 2022 is mainly driven by the recognition of the priority review voucher submitted with the BLA filing for SC efgartigimod for the treatment of gMG  which resulted in an expense of $99.1 million.Selling  general and administrative expenses for the third quarter and year-to-date in 2022 were $108.2 million and $336.8 million  respectively  compared to $80.6 million and $210.2 million for the same periods in 2021. The selling  general and administrative expenses mainly relate to professional and marketing fees linked to the commercialization of VYVGART in the U.S.  Japan and the EU and personnel expenses.Exchange losses for the third quarter and year-to-date in 2022 were $39.6 million and $93.0 million  respectively  compared to $17.6 million and $36.0 million for the same periods in 2021. Exchange losses are mainly attributable to unrealized exchange rate losses on cash  cash equivalents and current financial assets position in Euro.Income tax for the third quarter and year-to-date in 2022 was $6.0 million and $17.1 of tax income  respectively  compared to $2.7 million and $15.6 million of tax expense for the same periods in 2021. Tax income for the three months ended September 30  2022 consists of $7.3 million of income tax expense and $13.3 million of deferred tax income  compared to $4.3 million of income tax expense and $1.6 million of deferred tax income for the same period in 2021.Net loss for the third quarter and year-to-date in 2022 was $235.0 million and $671.0 million  respectively  compared to net loss of $233.6 million and $170.4 million for the same periods in 2021.Cash  cash equivalents and current financial assets totaled $2 385.5 million as of September 30  2022  compared to $2 336.7 million as of December 31  2021. Cash and cash equivalents and current financial assets increased primarily as a result of the closing of a global offering of shares  which resulted in the receipt of $761.0 million in net proceeds in March 2022  offset by net cash flows used in operating activities.FINANCIAL GUIDANCEBased on current plans to fund anticipated operating expenses and capital expenditures  argenx continues to expect its 2022 cash burn to be up to $1 billion. This will support the global VYVGART launches  clinical development of efgartigimod in 10 indications and ARGX-117 in two indications  investment in the global supply chain  and continued focus on pipeline expansion through the Immunology Innovation Program.EXPECTED 2023 FINANCIAL CALENDARMarch 2  2023: FY 2022 financial results and business updateMay 4  2023: Q1 2023 financial results and business updateJuly 27  2023: HY 2023 financial results and business updateOctober 27  2023: Q3 2023 financial results and business updateCONFERENCE CALL DETAILSThe third quarter 2022 financial results and business update will be discussed during a conference call and webcast presentation today at 2:30 pm CEST/8:30 am ET. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website.Dial-in numbers:Please dial in 15 minutes prior to the live call.Belgium 32 800 50 201United Kingdom 44 800 358 0970United States 1 888 415 4250All other locations 1 646 960 0294About argenxargenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP)  argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S.  Japan and the EU. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information  visit www.argenx.com and follow us on LinkedIn  Twitter  and Instagram.For further information  please contact:Media:Kelsey Kirkkkirk@argenx.comInvestors:Beth DelGiaccobdelgiacco@argenx.combdelgiacco@argenx.comForward-looking StatementsThe contents of this announcement include statements that are  or may be deemed to be  â€œforward-looking statements.â€ These forward-looking statements can be identified by the use of forward-looking terminology  including the terms â€œbelieves â€ â€œhope â€ â€œestimates â€ â€œanticipates â€ â€œexpects â€ â€œintends â€ â€œmay â€ â€œwill â€ or â€œshouldâ€ and include statements argenx makes regarding the VYVGART launch strategy to make VYVGART available in the EU  China  Canada and select other regions  the approval and commercial launch following the submission of the Biologics License Application to the U.S. Food and Drug Administration for Subcutaneous (SC) Efgartigimod for Treatment of Generalized Myasthenia Gravis and the long-term safety and tolerability of SC Efgartigimod; Zai Lab and Medisonâ€™s respective pending approvals in China and Israel; its position to expand its leadership position in FcRn blockade to include ten autoimmune indications by the end of 2022; the therapeutic potential of its product candidates; the intended results of its strategy and its collaboration partnersâ€™  advancement of  and anticipated clinical development and regulatory milestones and plans  including the timing of planned clinical trials; the design of future clinical trials and the timing and outcome of regulatory filings and regulatory approvals; its expectation that its 2022 cash burn will be up to $1 billion and the 2022 business and financial outlook and related plans. By their nature  forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenxâ€™s actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors  including the effects of the COVID-19 pandemic  inflation and deflation and the corresponding fluctuations in interest rates; regional instability and conflicts  such as the conflict between Russia and Ukraine  argenxâ€™s expectations regarding the inherent uncertainties associated with competitive developments  preclinical and clinical trial and product development activities and regulatory approval requirements; argenxâ€™s reliance on collaborations with third parties; estimating the commercial potential of argenxâ€™s product candidates; argenxâ€™s ability to obtain and maintain protection of intellectual property for its technologies and drugs; argenxâ€™s limited operating history; and argenxâ€™s ability to obtain additional funding for operations and to complete the development and commercialization of its product candidates. A further list and description of these risks  uncertainties and other risks can be found in argenxâ€™s U.S. Securities and Exchange Commission (SEC) filings and reports  including in argenxâ€™s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties  the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release  including any forward-looking statements  except as may be required by law.,neutral,0.0,1.0,0.0,mixed,0.62,0.23,0.15,True,English,"['Third Quarter 2022 Financial Results', 'Business Update', 'argenx', 'COVID-19-mediated postural orthostatic tachycardia syndrome', 'chronic inflammatory demyelinating polyneuropathy', 'ten total autoimmune indications', 'leading, multi-product immunology company', 'global net product sales', 'European Commission (EC) approval', 'global net VYVGART revenues', 'third quarter 2022 financial results', 'second registrational ADVANCE-SC trial', 'eight ongoing clinical trials', 'global immunology company', 'global registrational programs', 'idiopathic inflammatory myopathies', 'severe autoimmune diseases', 'multiple autoimmune indications', 'Biologics License Application', 'generalized myasthenia gravis', 'Hans de Haard', 'Chief Scientific Officer', 'Tim Van Hauwermeiren', 'Chief Executive Officer', 'sustainable discovery engine', 'steroidal immunosuppressive therapies', 'large-scale manufacturing capabilities', 'FUJIFILM Diosynth Biotechnologies', 'Immunology Innovation Program', 'multifocal motor neuropathy', 'registrational ADHERE trial', 'Registrational ALKIVIA trial', 'registrational ADDRESS trial', 'Registrational BALLAD trial', 'Phase 1 dose-escalation trial', 'neonatal Fc receptor', 'drug substance manufacturing', 'primary immune thrombocytopenia', 'potential dosing regimen', 'strong third quarter', 'RECENT BUSINESS UPDATE', 'concept ARDA trial', 'global VYVGART launch', 'new treatment standard', 'U.S. Food', 'subcutaneous (SC) efgartigimod', 'adult gMG patients', 'IQVIA Zai Lab', 'SC efgartigimod launch', 'product potential', 'European Union', 'concept trial', 'immunology pipeline', 'Approval decisions', 'anti-synthetase syndrome', 'second half', 'multiple ways', 'anti-acetylcholine receptor', 'Drug Administration', 'first quarter', 'primary Sjogren', 'commercial launch', 'potential indication', 'many patients', 'first 30 patients', 'first 40 patients', 'Ph.D.', 'conference call', 'priority territories', 'first half', 'right team', 'FcRn) blocker', 'United States', 'AChR) antibody', 'sufficient response', 'Efgartigimod Research', 'leadership position', 'FcRn blockade', 'Neuromuscular franchise', 'Topline data', 'three subtypes', 'immune-mediated necrotizing', 'interim analysis', 'Hematology franchise', 'Dermatology franchise', 'pemphigus vulgaris', 'bullous pemphigoid', 'lupus nephritis', 'Additional candidates', 'spin-off companies', 'C2 inhibitor', 'regulatory discussions', 'graft function', 'allograft failure', 'kidney transplantation', 'muscle-specific kinase', 'MuSK) agonist', 'healthy volunteers', 'differentiated pipeline', 'Pipeline Progress', 'argenx SE', 'VYVGARTÂ®', 'alfa-fcab', 'BLA', 'CSO', 'January', 'Management', 'October', 'Amsterdam', 'Netherlands', 'Euronext', 'Nasdaq', 'ARGX', 'lives', 'people', 'remainder', 'year', 'Japan', 'teams', 'beginning', 'end', 'goal', 'behalf', 'steroids', 'ISTs', 'Story', 'August', 'Germany', 'September', 'Canada', 'China', 'Israel', 'Medison', 'capacity', 'collaboration', 'Development', 'FDA', 'CIDP', 'track', 'myositis', 'myopathy', 'ITP', 'Proof', 'nephropathy', 'POTS', 'partners', 'safety', 'tolerability', 'MMN', 'prevention', 'delayed', '2:30', '2023']",2022-10-27,2022-10-28,finance.yahoo.com
12243,EuroNext,NewsApi.org,https://ca.sports.yahoo.com/news/solid-growth-154500563.html,Solid growth,Nine-month 2022 revenueâ‚¬1 723.3 millionTotal growth: 13.4%Organic growth: 6.3% Third quarter 2022Total growth: 14.3%Organic growth: 5.3% Paris  27th October 2022 â€“ Our results at the end of September 2022 show sustained growth  despite some challenges in Euroâ€¦,"IPSOSNine-month 2022 revenueâ‚¬1 723.3 millionTotal growth: 13.4%Organic growth: 6.3%Third quarter 2022Total growth: 14.3%Organic growth: 5.3%Paris  27th October 2022 â€“ Our results at the end of September 2022 show sustained growth  despite some challenges in Europe and China. Over the nine first months  Ipsos posted a 13.4% growth  of which 6.3% organic  confirming that we are on track to finish 2022 well. Excluding the temporary net positive impact of Covid-related contracts  our underlying organic growth is 9.2% at the end of September.The average cumulative organic growth at the end of September is 32% over the last two years and 19% over the last three years  which demonstrates our regular performance and strong operating model.PERFORMANCE BY QUARTER2022 vs. 2021 In millions ofEuros 2022Revenue Totalgrowth Organicgrowth 1st quarter 547.8 17.5% 12.3% (1) 2nd quarter 574.0 8.9% 2.1% 3rd quarter 601.5 14.3% 5.3%* Revenue 1 723.3 13.4 % 6.3 %*(1) Covid-related contracts were maintained at least in part until March 31  2022* Underlying organic growth is 6.9% for the third quarter and 9.2% for the Nine-month 2022  excluding the temporary net positive impact of Covid-related contracts (specific pandemic monitoring projects for governments  minus contracts that could not be executed because of the health situation).Looking specifically at the third quarter  total growth is 14.3%  of which 5.3% organic and 8.0% currency effects. Taking out the temporary net positive impact of Covid-related contracts  organic growth amounts to 6.9% for this quarter.PERFORMANCE BY REGION9-month 2022 vs 2021 In millions of Euros 9-month 2022Revenue Contribution Total growth Organic growth EMEA 743.3 43% 1.6% 0% Americas 678.7 39% 27.2% 14% Asia-Pacific 301.3 17% 18.5% 10% Revenue 1 723.3 100% 13.4 % 6.3 %By region  our business in EMEA remains stable. This reflects the consequence of the war in Ukraine  combined with the end of Covid contracts. Taking out the impact of these contracts  the underlying organic business for EMEA is growing by more than 5%.Story continuesBoth North America and Latin America have double-digit growth this year. USA  which is our largest country and one of our strategic priorities  delivers excellent results.Despite lockdowns hampering our Chinese business  our Asia-Pacific business has bounced back in 2022. The related organic growth for the region is up by 10% and highlights very good performances in India and Korea.PERFORMANCE BY AUDIENCEIn millions of Euros 9-month 2022 revenue Contribution 9-month 2022 vs 2021organic growthConsumers1 802.2 47% 12.5% Customers and employees2 352.6 20% 8% Citizens3 283.3 16% -7.5% Doctors and patients4 285.1 17% 3.5% Revenue 1 723.3 100% 6.3%Breakdown of Service Lines by audience segment:1- Brand Health Tracking  Creative Excellence  Innovation  Ipsos UU  Ipsos MMA  Market Strategy & Understanding  Observer (excl. public sector)  Social Intelligence Analytics  Strategy32- Automotive & Mobility Development  Audience Measurement  Customer Experience  Channel Performance (including Retail Performance and Mystery Shopping)  Media development  Capabilities3- Public Affairs  Corporate Reputation4- Pharma (quantitative and qualitative)When we look at our different audiences  we have most growth in our consumer-facing segments as the world unlocks. In particular  double-digit growth is experienced in the Service Lines that focus on measuring and analyzing brand growth and expression.Good growth is also noted in our work focusing on customers and employees  which reflects an increasing interest of our clients in measuring and assessing their own client experiences and also in ensuring the quality of their HR plans.After massive growth during the 2020-21 period spurred by large scale Covid-testing programmes in Europe  our work among citizens has fallen back in 2022. However  the underlying business excluding Covid contracts records a double-digit growth  confirming the need for governments to better understand citizensâ€™ expectations and behaviours in an uncertain and inflationary world.Finally  our work with doctors and patients has seen moderate growth in 2022  impacted by an unfavorable base effect after a rapid expansion during the pandemic.OUTLOOKWe are confident that we can deliver better performance than promised at this start of the year: we now expect organic growth in 2022 to be closer to 6% than 5% and a level of operating margin comparable to that of last year. Hence  we confirm a consistently higher level of profitability than in the past.As the business prepares for 2023  we are in a good place. If some clients become more cautious for the coming months  we see no significant slowdown in our orders. Our order book at the end of September for 2023 is up by 8% compared to last year.Despite current economic uncertainties  we are confident on our ability to deliver the 2022-25 growth plan launched in June this year  considering our large geographic spread and the diversity of sectors we serve.ABOUT IPSOSIpsos is one of the largest market research companies in the world  present in 90 markets and employing more than 18 000 people.Our passionately curious research professionals  analysts and scientists have built unique multi-specialist capabilities that provide true understanding and powerful insights into the actions  opinions and motivations of citizens  consumers  patients  customers or employees. Our 75 solutions are based on primary data from our surveys  social media monitoring  and qualitative or observational techniques.Our tagline ""Game Changers"" sums up our ambition to help our 5 000 customers move confidently through a rapidly changing world.Founded in France in 1975  Ipsos has been listed on the Euronext Paris since July 1  1999. The company is part of the SBF 120 and Mid-60 indices and is eligible for the Deferred Settlement Service (SRD). ISIN code FR0000073298  Reuters ISOS.PA  Bloomberg IPS:FPwww.ipsos.comAttachment",positive,0.84,0.15,0.01,mixed,0.52,0.12,0.36,True,English,"['Solid growth', 'Corporate Reputation 4- Pharma', 'large scale Covid-testing programmes', 'temporary net positive impact', 'specific pandemic monitoring projects', '1- Brand Health Tracking', 'average cumulative organic growth', 'Total growth Organic growth', 'large geographic spread', 'Social Intelligence Analytics', 'unfavorable base effect', 'current economic uncertainties', 'nine first months', 'last two years', 'last three years', 'strong operating model', '2022-25 growth plan', 'related organic growth', 'underlying organic growth', 'underlying organic business', 'Revenue Total growth', '9-month 2022 revenue Contribution', 'brand growth', 'health situation', 'underlying business', 'operating margin', 'coming months', 'sustained growth', 'double-digit growth', 'most growth', 'Good growth', 'massive growth', 'moderate growth', 'last year', '27th October', '8.0% currency effects', 'North America', 'Latin America', 'largest country', 'strategic priorities', 'good performances', 'Service Lines', 'Creative Excellence', 'Market Strategy', 'public sector', 'Mobility Development', 'Customer Experience', 'Mystery Shopping', 'Media development', 'Public Affairs', 'different audiences', 'consumer-facing segments', 'increasing interest', 'client experiences', 'HR plans', '2020-21 period', 'rapid expansion', 'good place', 'significant slowdown', 'order book', 'Chinese business', 'Third quarter', 'Covid-related contracts', '1st quarter', '2nd quarter', '3rd quarter', 'Covid contracts', 'audience segment', 'Audience Measurement', 'excellent results', 'Ipsos UU', 'Ipsos MMA', 'citizensâ€™ expectations', 'inflationary world', 'higher level', 'regular performance', 'Channel Performance', 'Retail Performance', 'Nine-month 2022 revenue', 'REGION 9-month', 'Asia-Pacific business', '5.3% organic', '13.4% growth', 'Paris', 'end', 'September', 'challenges', 'Europe', 'China', 'millions', 'Euros', 'part', 'March', 'governments', 'EMEA', 'Americas', 'consequence', 'war', 'Ukraine', 'Story', 'USA', 'lockdowns', 'very', 'India', 'Korea', 'Consumers1', 'Customers', 'employees2', 'Citizens3', 'Doctors', 'patients4', 'Breakdown', 'Innovation', 'Understanding', 'Observer', 'Strategy3', 'Automotive', 'Capabilities', 'qualitative', 'expression', 'work', 'clients', 'quality', 'need', 'behaviours', 'OUTLOOK', 'start', 'profitability', 'past', 'orders', 'June', 'diversity', 'sectors', '9.']",2022-10-27,2022-10-28,ca.sports.yahoo.com
12244,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/27/2542450/0/en/Nexans-welcomes-Maria-Lorente-Fraguas-as-Senior-Corporate-Vice-President-Chief-Human-Resources-Officer-and-member-of-the-Executive-Committee.html,Nexans welcomes Maria Lorente Fraguas as Senior Corporate Vice President  Chief Human Resources Officer and member of the Executive Committee,Nexans welcomes Maria Lorente Fraguas as Senior Corporate Vice President Chief Human Resources Officer and member of the Executive Committee        ...,"English FrenchNexans welcomes Maria Lorente Fraguas as Senior Corporate Vice President Chief Human Resources Officer and member of the Executive Committee_PRESS RELEASE_Nexans is pleased to announce the arrival of Maria Lorente Fraguas as Senior Corporate Vice President & Chief Human Resources Officer  responsible also for Corporate Social Responsibilityas Senior Corporate Vice President & Chief Human Resources Officer  responsible also for Corporate Social Responsibility She brings to the role more than 20 years of international experience in several leadership positions in product development  operations and international team managementThis leadership appointment comes at a time when Nexans is perfectly positioned to pursue and accelerate its strategy as a pure-player in electrification  placing people and the environment at the heart of its businessParis  October 27  2022 - Nexans is pleased to announce the arrival of Maria Lorente Fraguas as Senior Corporate Vice President & Chief Human Resources Officer  responsible also for Corporate Social Responsibility.Maria has more than 20 years of experience in leading international teams around the world and in a wide range of positions  including Operations  New Product Development  Transformation and Human Resources.In this role  Maria will actively contribute to Nexansâ€™ transformation and future growth in electrification. Based at the companyâ€™s headquarters in Paris  Maria is Spanish and reports to Chief Executive Officer  Christopher GuÃ©rin.Graduated from Universidad PolitÃ©cnica de Valenica  Spain and SupÃ©lec in France  Maria brings with her a strong skill-set and a great reputation for relationship building  performance  and team leadership. She joins the Group with 21 years of experience at Schlumberger where she managed international teams in senior HR  functional  and line roles around the world. She worked in eight different countries accross Europe  the Middle East  Latin America and North America  in a wide range of positions including New Product Development  Marketing  Line Management  Transformation  and most recently served as the Director of Human Resources â€“ Production Systems.Christopher Guerin  CEO of Nexans  comments: ""I am very pleased to welcome Maria. Her track record and international profile match our ambition to be a pure player in electrification worldwide. Her rich experience in business transformation and talent development will help accelerate Nexans' transformation. I am also convinced that Maria will help integrate Corporate Social Responsibility more broadly into our strategic ambitions  which is at the heart of our priorities.â€Maria Lorente Fraguas  the newly appointed Nexans Group Senior Corporate Vice President & Chief Human Resources Director  says: â€œ The people-centric culture  the passion for innovation and the ambition for growth  anchored in value creation across the three axis of Economics  Environment and Engagement  are what attracted me to Nexans. I am thrilled to join the team and contribute to the next chapter of the companyâ€™s strategy  keeping our customers and employees at the center of everything we do.â€œAbout NEXANSFor more than a century  Nexans has played a crucial role in electrifying the planet and is committed to electrifying the future. With 25 000 staff in 42 countries  the Group is driving the change towards the new world of electrification â€” a safer  more sustainable  renewable  carbon-free world  accessible to all. In 2021  Nexans generated â‚¬6.1 billion in standard sales. The Group is a leader in the design and manufacturing of cable systems and services in five main areas of activity: Energy Production & Transmission  Distribution  Uses  Industry & Solutions and Telecom & Data. Nexans was the first player in its industry to create a Corporate Foundation to support actions that promote access to energy for disadvantaged populations worldwide. The Group is committed to helping achieve carbon neutrality by 2030.Nexans. Electrify the future.Nexans is listed on the Euronext Paris stock market  compartment A.For more information  visit www.nexans.comContact:CommunicationEdelman FranceNexans@edelman.com+33 6 27 69 14 96Emmanuel Guinotemmanuel.guinot@nexans.comMaÃ«llys Leosticmaellys.leostic@nexans.comAttachments",neutral,0.02,0.98,0.0,positive,0.97,0.03,0.0,True,English,"['Senior Corporate Vice President', 'Chief Human Resources Officer', 'Maria Lorente Fraguas', 'Executive Committee', 'Nexans', 'member', 'Nexans Group Senior Corporate Vice President', 'Universidad PolitÃ©cnica de', 'Chief Human Resources Officer', 'sustainable, renewable, carbon-free world', 'Euronext Paris stock market', 'Chief Human Resources Director', 'senior HR, functional', 'Chief Executive Officer', 'Corporate Social Responsibility', 'five main areas', 'MaÃ«llys Leostic', 'Christopher GuÃ©rin', 'eight different countries', 'leading international teams', 'New Product Development', 'Maria Lorente Fraguas', 'several leadership positions', 'international team management', 'Corporate Foundation', 'new world', 'Executive Committee', 'Line Management', 'Christopher Guerin', 'talent development', 'international profile', 'The Group', 'leadership appointment', 'team leadership', 'English French', 'wide range', 'SupÃ©lec', 'strong skill-set', 'great reputation', 'relationship building', 'line roles', 'Middle East', 'Latin America', 'North America', 'Production Systems', 'track record', 'pure player', 'strategic ambitions', 'people-centric culture', 'value creation', 'three axis', 'next chapter', 'a century', 'standard sales', 'cable systems', 'first player', 'disadvantaged populations', 'carbon neutrality', 'compartment A.', 'international experience', 'rich experience', 'Energy Production', 'Edelman France', 'Emmanuel Guinot', 'crucial role', 'business transformation', 'Nexansâ€™ transformation', ""Nexans' transformation"", 'future growth', '42 countries', 'member', 'arrival', '20 years', 'operations', 'time', 'strategy', 'pure-player', 'electrification', 'environment', 'heart', 'company', 'headquarters', 'Valenica', 'Spain', 'performance', '21 years', 'Schlumberger', 'Europe', 'Marketing', 'CEO', 'priorities', 'passion', 'innovation', 'Economics', 'Engagement', 'customers', 'employees', 'center', 'everything', 'planet', '25,000 staff', 'change', 'design', 'manufacturing', 'services', 'activity', 'Transmission', 'Distribution', 'Uses', 'Industry', 'Solutions', 'Telecom', 'Data', 'actions', 'access', 'information', 'Contact', 'Communication', 'Attachments']",2022-10-27,2022-10-28,globenewswire.com
12245,EuroNext,NewsApi.org,https://www.hospitalitynet.org/news/4113190.html,Third-quarter 2022 revenue of â‚¬1 149 million up 83% like-for-like,The sharp improvement in activity seen since the start of the year was confirmed in the third quarter of 2022. For the second consecutive quarter  the Groupâ€™s RevPAR exceeded its 2019 level and Asia is now the only country performing below its pre-crisis leveâ€¦,RECORD ACTIVITY IN THE QUARTER REVPAR ABOVE 2019 LEVELPICK-UP IN PACE OF ROOM OPENINGSEBITDA EXPECTED TO REACH THE UPPER END OF THE â‚¬610 MILLION TO â‚¬640 MILLION RANGESÃ©bastien Bazin  Chairman and Chief Executive Officer of Accor  said: â€œBusiness momentum remained very strong in the quarter  with the Groupâ€™s RevPAR and revenue well above their 2019 levels. Excluding Asia-Pacific  where activity is now recovering  all regions saw growth compared with 2019. These strong performances  coupled with strict operational and financial discipline  give us confidence in our ability to reach the upper end of our full-year EBITDA guidance range  which should be between â‚¬610 million and â‚¬640 million.â€The sharp improvement in activity seen since the start of the year was confirmed in the third quarter of 2022. For the second consecutive quarter  the Groupâ€™s RevPAR exceeded its 2019 level and Asia is now the only country performing below its pre-crisis level. Demand from domestic and international leisure travelers was very strong over the summer  leading to a significant increase in prices  and September benefited from renewed demand from business travelers for major trade shows and fairs.During the third quarter of 2022  Accor opened 93 hotels representing 15 300 rooms  i.e.  net unit growth of 2.4% in the last 12 months. This represents a significant increase in the number of rooms opened compared with the first semester of 2022.At end-September 2022  the Group had a hotel portfolio of 789 152 rooms (5 357 hotels) and a pipeline of 212 000 rooms (1 218 hotels).For 2022  the Group is confirming its forecast of net network growth of around 3.5%.Consolidated revenueThe Group reported Q3 2022 revenue of â‚¬1 149 million  up 83% like-for-like compared with Q3 2021. By activity  this growth breaks down into an 84% increase for HotelServices and 80% for Hotel Assets & Other. To provide a comparison with RevPAR (change presented versus 2019 throughout this release)  the like-for-like increase in revenue versus Q3 2019 is 9%.Changes in the consolidation scope  mainly due to the consolidation of Ennismore  and the reopening of Pullman Montparnasse contributed positively by â‚¬14 million.Currency effects had a positive impact of â‚¬60 million  mainly linked to the US dollar (-14%).Source: AccorHotelServices revenueHotelServices  which includes fees from Management & Franchise (M&F) and Services to Owners  reported â‚¬874 million in revenue  up 84% like-for-like versus Q3 2021 (up 9% like-for-like versus Q3 2019). This increase provides confirmation of the sharp improvement in activity seen since the start of the year.Revenue in Management & Franchise (M&F) stood at â‚¬308 million  up 93% like-for-like versus Q3 2021 (up 10% like-for-like versus Q3 2019)  with regional performances correlated to the business recovery in the countries considered.Source: AccorThe Groupâ€™s RevPAR was up 14% overall in Q3 2022 versus Q3 2019  confirming the sharp improvement in activity seen since the start of the year  with Group RevPAR exceeding its 2019 level for the second consecutive quarter.In Q3 2022  RevPAR in South Europe was 11% above the Q3 2019 level.In France   Q3 2022 RevPAR was up 11% versus Q3 2019. The country enjoyed a very strong summer season thanks to demand from domestic and international leisure travelers. The return of international travelers boosted the performance in the Paris region  which is now in line with the regional cities. In September  demand from business travelers contributed to the ongoing rebound in occupancy rates  which are now close to pre-crisis levels.  Q3 2022 RevPAR was up 11% versus Q3 2019. The country enjoyed a very strong summer season thanks to demand from domestic and international leisure travelers. The return of international travelers boosted the performance in the Paris region  which is now in line with the regional cities. In September  demand from business travelers contributed to the ongoing rebound in occupancy rates  which are now close to pre-crisis levels. In Spain  RevPAR was up 9% in Q3 2022 versus Q3 2019.In Q3 2022  RevPAR in North Europe was up 9% versus Q3 2019  a very sharp sequential improvement compared with the previous quarter.Germany was the main contributor to this strong sequential improvement. It caught up to the rest of Europe after seeing a delayed business recovery  as it took longer to lift its Covid-related health restrictions.was the main contributor to this strong sequential improvement. It caught up to the rest of Europe after seeing a delayed business recovery  as it took longer to lift its Covid-related health restrictions. The uptrend in the United Kingdom has been confirmed over the entire quarter  confirming RevPAR levels above those of Q3 2019.RevPAR continued to improve sequentially in Asia-Pacific at +9 percentage points between Q2 2022 and Q3 2022. It was down 9% in Q3 2022 versus Q3 2019.Pacific confirmed the performance already seen in Q2 2022 with a 15% increase in Q3 2022 versus Q3 2019. This increase was strongly driven by prices.There were some  albeit moderate  signs of improvement in China   with a slight recovery in activity over the summer. However  the restrictions implemented as part of the strict enforcement of its â€œzero-Covidâ€ policy continued to have an adverse impact on activity.  with a slight recovery in activity over the summer. However  the restrictions implemented as part of the strict enforcement of its â€œzero-Covidâ€ policy continued to have an adverse impact on activity. In South East Asia  RevPAR was down 21% in Q3 2022 versus Q3 2019. Here as well  there were signs of a recovery with notably the return of international guests.In the India  Middle East  Africa & Turkey region  RevPAR was up 68% versus Q3 2019  boosted by hyperinflation and the very strong summer season in Turkey.The United Arab Emirates continued to perform well thanks to demand from leisure and business travelerscontinued to perform well thanks to demand from leisure and business travelers In Saudi Arabia  the nature of the activity makes it dependent on the seasonality of the religious calendar.In the Americas  Q3 2022 RevPAR was 12% higher than in Q3 2019.In North/Central America and the Caribbean   Q3 2022 RevPAR was slightly above the 2019 level  driven by a sharp increase in prices.and the   Q3 2022 RevPAR was slightly above the 2019 level  driven by a sharp increase in prices. In South America  and particularly Brazil  the pick-up in business volumes was notably impressive. Occupancy rates improved and remained above the 2019 level throughout Q3 2022.Services to Owners revenue  which includes the Sales  Marketing  Distribution and Loyalty division  as well as shared services and the reimbursement of hotel staff costs  came to â‚¬566 million in the third quarter of 2022  up 8% compared with 2019.Hotel Assets & Other revenueAt end-September 2022  this segment  which includes owned and leased hotels  represented 115 hotels and 22 656 rooms.Revenue in the â€œHotel Assets & Otherâ€ segment was up 80% like-for-like in Q3 2022 versus Q3 2021 (up 6% like-for-like versus Q3 2019). This segment  which is very closely tied to activity in Australia  continued to benefit from demand from leisure travelers in the coastal areas. The major cities are starting to benefit from renewed demand from business travelers.Since early 2021  this segment has included concierge services  luxury home rentals  private sales of hotel stays and digital services for hotel owners. All these activities benefited from the uptrend in tourism.EBITDA guidance for FY22Thanks to the positive impact of marketing and sales investments made in first half of 2022  the strict discipline maintained on cost base and the strong pace of activity  the Group is rising its 2022 EBITDA guidance on September 28  2022. Initially announced at above â‚¬550 million  it was then revised upwards to â‚¬610 million to â‚¬640 million. The Group is now confident it can reach the upper end of this full-year EBITDA guidance range.Events in third-quarter 2022On July 5  2022  the Group announced that it is changing its structure to capitalize on the transformation undertaken in recent years  consolidate its leadership positions  focus its efforts  strengthen its know-how  accelerate its growth and continue to improve its profitability. As such  Accor will leverage two divisions comprising separate and distinctive expertise with the aim of further strengthening the excellence of each of these business lines  improving their operational and financial performance  offering its owners and guests even more relevant products and services  and attracting the best talents.From October 1  2022  Accor will be structured around two dedicated divisions:â€œEconomy  Midscale & Premium Divisionâ€  comprising notably the Groupâ€™s brands ibis  Novotel  Mercure  SwissÃ´tel  MÃ¶venpick and Pullman.â€œLuxury & Lifestyle Divisionâ€  bringing together Accorâ€™s luxury brands as well as the Groupâ€™s Lifestyle entity  Ennismore.To support the implementation and ensure the roll-out of this new structure  Accorâ€™s Board of Directors has confirmed its support for the Groupâ€™s leadership and unanimously decided to propose the renewal of SÃ©bastien Bazinâ€™s term as Chairman and CEO at the next Annual General Meeting called to approve the 2022 financial statements.On September 28  2022  Accor announced that it entered into exclusive negotiations with Valesco Group to sell its Paris headquarters building  â€œSequana Towerâ€  for â‚¬465 million. The disposal is subject to a 12-year sale and leaseback agreement. The transaction  which is subject to the usual due diligence procedures  is expected to be completed by the end of the year. It is part of the Group's asset-light strategy  which aims to simplify Accor's balance sheet structure.Source: AccorSource: AccorSource: AccorAbout Accor  a world-leading hospitality groupAccor is a world leading hospitality group consisting of 5 300 properties and 10 000 food and beverage venues throughout 110 countries. The group has one of the industry's most diverse and fully-integrated hospitality ecosystems encompassing more than 40 luxury  premium  midscale and economy hotel brands  entertainment and nightlife venues  restaurants and bars  branded private residences  shared accommodation properties  concierge services  co-working spaces and more. Accor's unmatched position in lifestyle hospitality â€“ one of the fastest growing categories in the industry â€“ is led by Ennismore  a joint venture  which Accor holds a majority shareholding. Ennismore is a creative hospitality company with a global collective of entrepreneurial and founder-built brands with purpose at their heart. Accor boasts an unrivalled portfolio of distinctive brands and more than 230 000 team members worldwide. Members benefit from the company's comprehensive loyalty program â€“ ALL â€“ Accor Live Limitless â€“ a daily lifestyle companion that provides access to a wide variety of rewards  services and experiences. Through its global sustainability commitments (such as achieving Net Zero Carbon emissions by 2050  global elimination of single use plastics in its hotels' guest experience  etc.)  Accor Solidarity  RiiSE and ALL Heartist Fund initiatives  the Group is focused on driving positive action through business ethics  responsible tourism  environmental sustainability  community engagement  diversity and inclusivity. Founded in 1967  Accor SA is headquartered in France and publicly listed on the Euronext Paris Stock Exchange (ISIN code: FR0000120404) and on the OTC Market (Ticket: ACCYY) in the United States. For more information visit group.accor.com or follow Accor on Twitter  Facebook  LinkedIn  and Instagram.Charlotte ThouvardSenior Vice President Group External CommunicationsAccor,neutral,0.01,0.99,0.0,mixed,0.43,0.23,0.34,True,English,"['Third-quarter 2022 revenue', 'full-year EBITDA guidance range', 'ROOM OPENINGS EBITDA', 'SÃ©bastien Bazin', 'Chief Executive Officer', 'major trade shows', 'Covid-related health restrictions', 'strong sequential improvement', 'strong summer season', 'second consecutive quarter', 'net unit growth', 'net network growth', 'international leisure travelers', 'sharp sequential improvement', 'international travelers', 'strong performances', 'sharp improvement', 'â‚¬640 MILLION RANGE', 'business travelers', 'third quarter', 'previous quarter', 'entire quarter', 'UPPER END', 'Business momentum', 'strict operational', 'financial discipline', 'last 12 months', 'first semester', 'hotel portfolio', 'Hotel Assets', 'Pullman Montparnasse', 'Currency effects', 'positive impact', 'US dollar', 'M&F', 'regional performances', 'business recovery', 'Paris region', 'regional cities', 'ongoing rebound', 'occupancy rates', 'main contributor', 'United Kingdom', '+9 percentage points', 'pre-crisis levels', 'consolidation scope', 'South Europe', 'North Europe', 'Consolidated revenue', 'QUARTER REVPAR', 'significant increase', 'RECORD ACTIVITY', 'RevPAR levels', 'The Group', 'HotelServices revenue', 'Group RevPAR', 'Q3 2022 revenue', 'Q3 2019 level', '2019 levels', 'â‚¬610 MILLION', '84% increase', '15% increase', 'PICK-UP', 'PACE', 'Chairman', 'Accor', 'Asia-Pacific', 'regions', 'confidence', 'ability', 'start', 'country', 'domestic', 'prices', 'September', 'demand', 'fairs', '93 hotels', '15,300 rooms', 'number', '789,152 rooms', 'pipeline', '212,000 rooms', 'forecast', 'Other', 'comparison', 'change', 'release', 'Ennismore', 'reopening', 'Source', 'fees', 'Management', 'Franchise', 'Owners', 'confirmation', 'countries', 'France', 'return', 'Spain', 'Germany', 'uptrend', 'Q2']",2022-10-27,2022-10-28,hospitalitynet.org
12246,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/27/2542927/0/en/Stellantis-Hordain-First-Plant-in-the-World-to-Produce-Hydrogen-powered-Electric-and-Combustion-Engine-Commercial-Vehicles.html,Stellantis Hordain: First Plant in the World to Produce Hydrogen-powered  Electric and Combustion Engine Commercial Vehicles,Stellantis Hordain: First Plant in the World to Produce Hydrogen-powered  Electric and Combustion Engine Commercial Vehicles  New investment at Hordain...,Stellantis Hordain: First Plant in the World to Produce Hydrogen-powered  Electric and Combustion Engine Commercial VehiclesNew investment at Hordain is scaling up production of the Peugeot Expert  CitroÃ«n Jumpy and Opel Vivaro fuel cell light commercial vehicles to an industrial levelFrom 2024  the site will have a production capacity of 5 000 vehicles per year  reaffirming Stellantis' ambition to be the first mass-produced manufacturer of hydrogen-powered utility vehiclesAnnouncement confirms the Stellantis commitment to its 12 industrial sites in France  and to the Companyâ€™s ethical desire not to separate its electric and internal combustion engine businesses  to engage all its employees in the energy transitionHORDAIN  FRANCE  October 27  2022 â€“ During his visit to the Hordain site in the northern Hauts-de-France region today  Stellantis CEO Carlos Tavares announced the mass production of Peugeot  CitroÃ«n and Opel light commercial vehicles in a hydrogen-powered version equipped with a fuel cell.â€œIâ€™m very proud of the work done by the management and employees at Hordain  who have made their site the first in the world to combine three types of energy  made possible by the flexibility of our manufacturing system. Todayâ€™s announcement demonstrates the Stellantis commitment to investing in France in the latest technologies  and to supporting low-carbon mobility based on the â€œOne Companyâ€ principle â€ Tavares stated. â€œStellantis has succeeded in moving on to the next step in automotive history  in a transition managed in conjunction with our social partners at our 12 industrial sites across seven French regions  where we are proud to have laid historical roots.â€These hydrogen-powered vehicles will be assembled on the siteâ€™s multi-energy line  which already produces the electric and combustion engine versions of the â€œK-Zeroâ€ daily. Using a reinforced platform from body-in-white onwards  the hydrogen-powered models will then follow the usual stages of paintwork and assembly  on the same production line as combustion engine and electric vehicles  before they enter the new 8 000-mÂ² facility that focuses solely on the final tuning.A dedicated team will install the tank  the additional batteries  and the fuel cell on a production line at the Hordain site that halves the adjustment time compared to the previous small-scale process  where the fuel cell was assembled at a pilot workshop in RÃ¼sselsheim.This industrialization of hydrogen-powered light commercial vehicles â€“ accompanied by â‚¬10 million in investments with financial support from the French government â€“ is a new step for Hordain  where 43% of models for the Peugeot  CitroÃ«n  Opel  Vauxhall  Fiat and Toyota brands are already available in a zero-emission electric version.The â€œK-zeroâ€ vehicles with a fuel cell are intended for long-distance freight professionals who require a longer range (400 km)  the fastest possible charging time (3 minutes) and no compromises on charging capacity (1000 kg of payload).Launched in 2021  Stellantis is the first manufacturer in the world to market this type of vehicle.Inaugurated in 1994  the Hordain site lies at the heart of the industrial strategy at the Stellantis commercial vehicles division. This benchmark site assembles light commercial vehicles and passenger cars from the â€œK-Zeroâ€ family. Hordain employs 2 440 people on three shifts  with daily production of 628 vehicles. The site assembled 144 650 vehicles in 2021 and produced its millionth â€œK-Zeroâ€ in summer 2022.# # #About StellantisStellantis N.V. (NYSE / MTA / Euronext Paris: STLA) is one of the worldâ€™s leading automakers and a mobility provider. Its storied and iconic brands embody the passion of their visionary founders and todayâ€™s customers in their innovative products and services  including Abarth  Alfa Romeo  Chrysler  CitroÃ«n  Dodge  DS Automobiles  Fiat  JeepÂ®  Lancia  Maserati  Opel  Peugeot  Ram  Vauxhall  Free2move and Leasys. Powered by our diversity  we lead the way the world moves â€“ aspiring to become the greatest sustainable mobility tech company  not the biggest  while creating added value for all stakeholders as well as the communities in which it operates. For more information  visit www.stellantis.com.@Stellantis Stellantis Stellantis StellantisFor more information  please contact:Jean-Charles LEFEBVRE â€“ +33 6 19 34 73 30 â€“ j.c.lefebvre@stellantis.comcommunications@stellantis.comwww.stellantis.comAttachment,neutral,0.0,1.0,0.0,positive,0.75,0.25,0.0,True,English,"['Combustion Engine Commercial Vehicles', 'Stellantis Hordain', 'First Plant', 'World', 'Hydrogen-powered', 'Electric', 'Opel Vivaro fuel cell light commercial vehicles', 'greatest sustainable mobility tech company', 'Opel light commercial vehicles', 'internal combustion engine businesses', 'hydrogen-powered light commercial vehicles', 'fastest possible charging time', 'Combustion Engine Commercial Vehicles', 'Stellantis commercial vehicles division', 'Stellantis CEO Carlos Tavares', 'combustion engine versions', 'One Companyâ€ principle', 'previous small-scale process', 'long-distance freight professionals', 'seven French regions', 'new 8,000-mÂ² facility', 'hydrogen-powered utility vehicles', 'first mass-produced manufacturer', 'CitroÃ«n Jumpy', 'same production line', 'Stellantis N.V.', 'zero-emission electric version', 'hydrogen-powered vehicles', 'low-carbon mobility', 'adjustment time', 'charging capacity', 'mobility provider', 'hydrogen-powered version', 'first manufacturer', 'K-zeroâ€ vehicles', 'electric vehicles', 'French government', 'First Plant', 'New investment', 'multi-energy line', 'new step', 'industrial level', 'production capacity', '12 industrial sites', 'ethical desire', 'mass production', 'three types', 'manufacturing system', 'latest technologies', 'next step', 'automotive history', 'social partners', 'historical roots', 'usual stages', 'final tuning', 'dedicated team', 'additional batteries', 'pilot workshop', 'RÃ¼sselsheim', 'financial support', 'Toyota brands', 'longer range', 'industrial strategy', 'passenger cars', 'three shifts', 'daily production', 'Euronext Paris', 'leading automakers', 'iconic brands', 'visionary founders', 'innovative products', 'Alfa Romeo', 'DS Automobiles', ""Stellantis' ambition"", 'Stellantis commitment', 'hydrogen-powered models', 'Stellantis Stellantis', 'K-Zeroâ€ family', 'millionth â€œK-Zero', 'benchmark site', 'Jean-Charles LEFEBVRE', 'Stellantis Hordain', 'Peugeot Expert', 'France region', 'energy transition', 'Hordain site', '5,000 vehicles', '628 vehicles', '144,650 vehicles', 'World', 'year', 'Announcement', 'employees', 'visit', 'management', 'flexibility', 'conjunction', 'platform', 'paintwork', 'assembly', 'tank', 'industrialization', 'investments', 'Vauxhall', 'Fiat', '400 km', 'minutes', 'compromises', '1000 kg', 'payload', 'heart', '2,440 people', 'summer', 'NYSE', 'MTA', 'STLA', 'storied', 'passion', 'customers', 'services', 'Abarth', 'Chrysler', 'Dodge', 'JeepÂ®', 'Lancia', 'Maserati', 'Ram', 'Free2move', 'Leasys', 'diversity', 'way', 'value', 'stakeholders', 'communities', 'information', 'Attachment']",2022-10-27,2022-10-28,globenewswire.com
12247,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/27/2542418/0/en/BGHL-GBP-NAV-Share-buy-back.html,BGHL GBP NAV & Share buy back,BOUSSARD & GAVAUDAN HOLDING LIMITED      Ordinary Shares      The Directors of Boussard & Gavaudan...,"BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 26 Oct 2022.Estimated NAVEuro Shares Sterling Shares Estimated NAV â‚¬ 28.2017 Â£ 24.7302 Estimated MTD return -0.18 % -0.06 % Estimated YTD return -3.42 % -2.27 % Estimated ITD return 182.02 % 147.30 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close â‚¬ 22.20 N/A Premium/discount to estimated NAV -21.28 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 2 000.00 Premium/discount to estimated NAV N/A -19.13 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares 1 400 N/A Average Price â‚¬ 22.20 N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 315 188 130 254 Held in treasury 1 400 N/A Shares Issued 12 316 588 130 254Estimated BG Fund NAVClass B Euro Shares (estimated) â‚¬ 246.1882 Class GBP A Shares (estimated) Â£ 131.9167The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.For further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.08,0.91,0.0,negative,0.0,0.23,0.77,True,English,"['BGHL GBP NAV', 'Share', 'The Class B Euro Shares', 'GAVAUDAN HOLDING LIMITED Ordinary Shares', 'Euro Shares Sterling Shares Number', 'BGHL Ordinary Shares Euro Shares', 'A Liquidity Enhancement Agreement', 'Class GBP A Shares', 'London Stock Exchange plc', 'Guernsey Financial Services Commission', 'Dutch Financial Supervision Act', 'N/A Sterling Shares Amsterdam', 'A N/A Average Price', 'US Investment Company Act', 'Euro Shares Amsterdam', 'Sterling Shares Shares', 'expert financial advice', 'Guernsey Policy Council', 'collective investment scheme', 'other professional advice', 'BG Fund ICAV', 'Gavaudan Investment Management', 'closed-ended investment company', 'UK Listing Authority', 'US Securities Act', 'investment manager fees', 'BG Fund NAV', '1,400 N/A Shares', 'The Shares', 'Dutch Authority', 'Emmanuel Gavaudan', 'A Premium/discount', 'A Range', 'N/A GBX', 'Euronext Amsterdam', 'US persons', 'Financial Markets', 'The Directors', 'The Company', 'investment performance', 'original investment', 'investment decision', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'United States', 'following information', 'information purposes', 'necessary approval', 'main market', 'future results', 'listed securities', 'Market information', 'BOUSSARD', 'business', 'Oct', 'returns', 'AEX', 'LSE', 'Transactions', 'treasury', 'respect', 'role', 'LLP.', 'Email', 'article', 'conjunction', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2022-10-27,2022-10-28,globenewswire.com
12248,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/27/2543124/0/en/GTT-Nine-month-2022-revenues-stand-at-222-million-in-line-with-expectations-strong-order-momentum-continues.html,GTT: Nine-month 2022 revenues stand at â‚¬222 million  in line with expectations; strong order momentum continues,Nine-month 2022 revenues stand at â‚¬222 million  in line with expectations; strong order momentum continues  Record orders: 134 LNG carriers during the......,English FrenchNine-month 2022 revenues stand at â‚¬222 million in line with expectations;strong order momentum continuesRecord orders : 134 LNG carriers during the first nine months2022 targets confirmedParis â€“ October 27  2022. GTT  the technological expert in membrane containment systems used to transport and store liquefied gases  today announces its revenues for the first nine months of 2022.Commenting on the results  Philippe BerterottiÃ¨re  Chairman and CEO of GTT  said: â€œWith 134 LNG carrier orders  our core business during the first nine months of 2022 has broken all previous sales records  highlighting the continuation of particularly strong momentum. The surge in demand for LNG  particularly in Europe  is fuelling further demand for LNG carriers  underpinned by investment in liquefaction plants and increased construction capacity at shipyards.In the LNG as fuel business  GTT booked 42 orders during the first nine months of 2022. While the high price of LNG in Europe could slow order intake in the short term  GTT is convinced of the relevance of its solutions and the potential of this activity over the medium and long term.GTT maintains a tireless focus on R&D to meet its customersâ€™ energy transition needs and the tightening requirements they face. Over the first nine months  we obtained numerous approvals from classification societies to develop new technologies in a wide range of fields  particularly in LNG as fuel  but also for the design of a hydrogen carrier and an innovative design for a three-tank LNG carrier.From a financial perspective  Q3 2022 revenues were up 4.1% versus Q3 2021. As expected  nine-month 2022 revenues were down compared to the same period in 2021 due to an unfavourable base effect  which is gradually disappearing thanks to the strong order momentum.In addition  the Group confirms its 2022 targets with results expected to reach the lower half of the initial target range  as announced in the first half results release.â€Business activity during the first nine months- Continued momentum in LNG carrier ordersIn the first nine months of 2022  GTT booked 134 orders for LNG carriers  including 46 in the third quarter  in line with the excellent sales momentum achieved in the first half of the year. Delivery is scheduled between Q3 2024 and Q2 2027. In particular  58 orders for projects in Qatar were received during the first nine months.- Dynamic order intake of LNG-powered vesselsIn addition to the 38 orders for LNG-powered vessels received in the first half of 2022  four new orders were received in the third quarter of 2022  bringing the total to 42 orders for the first nine months. While the high price of LNG in Europe could slow order intake in the short term  GTT is convinced of the relevance of its solutions and the potential of this business over the medium and long term.- New licensing agreements with Chinese shipyardsIn the third quarter of 2022  GTT signed two new Technical Assistance and Licensing Agreements (TALA)  with the Yangzijiang Shipbuilding and China Merchants Heavy Industries shipyards for the construction of GTT membrane containment systems. This brings to five the number of construction sites now operating in China and contributes to increasing vessel construction capacity.- Smart Shipping: new contractIn July  GTT signed a contract with Antarctica21  the worldâ€™s leading operator of fly and cruise expeditions to Antarctica  to install â€œGTT Digitalâ€ smart shipping solutions in its cutting-edge expedition vessel Magellan Explorer.- â‚¬86 million State support for Hydrogen IPCEI1 project confirms the relevance of Elogen positioningFollowing the selection by the European Commission of Elogenâ€™s â€œgigafactoryâ€ project and the strengthening of its R&D division as part of the Hydrogen IPCEI  Elogen has been awarded a maximum of â‚¬86 million in subsidies by the French government. An agreement regarding this subsidy will shortly be signed with Bpifrance. For the record  the Elogen gigafactory will start production in 2025 with a production capacity of over 1 GW.Furthermore  in July 2022  Elogen was selected by Symbio to supply an electrolyser with an initial capacity of 2.5 MW for Symbioâ€™s new fuel cell plant. This new contract represents an important milestone for Elogen  as it highlights the companyâ€™s ability to deploy its technologies on multi-megawatt capacities for large industrial projects.Finally  as previously announced  in the first half of 2022 Elogen entered into several international partnerships for the manufacture and sale of electrolysers for producing green hydrogen:with HiFraser Group in Australia and New Zealand;with Valmax Technology Corporation in South Korea;with Charbone HydrogÃ¨ne in North America.Innovation: development of new technologies in a wide range of fieldsIn the first half of 2022  GTT received several approvals in principle from classification societies  including:Bureau Veritas for a new LNG conversion concept for large-capacity container ships;ClassNK for a new design of LNG fuel tank with 2 bar gauge pressure applicable to PCTC 2 vessels as well as LNG-powered cruise ships;vessels as well as LNG-powered cruise ships; DNV for an innovative LNG-powered PCTC vessel design;Lloydâ€™s Register for GTTâ€™s future NEXT1 containment system;Bureau Veritas for Shear-Water  a ballast-free vessel concept for LNG bunkering and refuelling vessels.In the third quarter of 2022  GTT obtained five new approvals in principle from:DNV for a containment system enabling the transport of liquid hydrogen  as well as the concept for a hydrogen carrier vessel. Both approvals in principle were obtained in the framework of the cooperation agreement with Shell announced early 2022 and reflect the progress of this project;Lloydâ€™s Register for a new digital solution named â€œPOWERâ€ designed to optimise transhipment operations between LNG carriers and floating units;Bureau Veritas for the design of a LNG-powered and â€œNH3-readyâ€ Very Large Crude Carrier;Bureau Veritas and DNV for an innovative three-tank LNG carrier concept.Order book at September 30  2022On January 1  2022  GTTâ€™s order book excluding LNG as fuel comprised 161 units  and subsequently changed as follows:Deliveries completed: 21 LNG carriers  4 ethane carriers  1 FLNG;Orders received: 134 LNG carriers.At September 30  2022  the order book excluding LNG as fuel stood at 269 units  breaking down as follows:250 LNG carriers;2 ethane carriers;2 FSUs;3 GBSs;12 onshore storage tanks.Regarding LNG as fuel  following the delivery of four vessels  and orders for 42 container ship tanks  the number of vessels in the order book stood at 70 units at September 30  2022.Evolution of consolidated revenues for the first nine months of 2022(in thousands of euros) 9M 2021 9M 2022 Change Revenues 240 025 222 037 -7.5% Newbuilds 224 281 200 385 -10.7% LNG carriers/VLEC 194 767 174 749 -10.3% FSUs3 9 660 13 578 +40.6% FSRUs4 8 054 - nm FLNGs5 2 202 1 218 -44.7% Onshore storage tanks 1 468 4 680 +218.8% GBSs6 2 521 3 303 +31.1% LNG-powered vessels 5 610 2 857 -49.1% Electrolysers 3 316 2 980 -10.1% Services 12 428 18 672 +50.2%Consolidated revenues for the first nine months of 2022 were â‚¬222.0 million  down 7.5% compared to the first nine months of 2021. The third quarter 2022 revenues amounted to â‚¬77.8 million  up 4.1% compared to the third quarter 2021.Newbuild revenues totalled â‚¬200.4 million  down 10.7% compared with the first nine months of 2021  when the cycle was still at its peak. Royalties amounted to â‚¬174.7 million from LNG and ethane carriers  â‚¬13.6 million from FSUs  â‚¬1.2 million from FLNGs  â‚¬4.7 million from onshore storage tanks and â‚¬3.3 million from GBSs. LNG as fuel royalties (â‚¬2.9 million) were not yet impacted by the high order intake in 2021 and 2022.Nine-month revenues from the Elogen electrolyser business amounted to â‚¬3.0 million  in a context of increasing commercial dynamic.Revenues from services rose sharply  up 50.2% to â‚¬18.7 million  driven by growth in digital services and engineering studies mainly related to the conversion of LNG carriers into FSRUs.Update on exposure to RussiaWork on projects in which the Group is involved in Russia is currently continuing  in compliance with the applicable sanction regimes.In Russia  the Group is involved in tank design for 15 ice-breaking LNG carriers currently being built at the Zvezda Shipbuilding Complex (Zvezda)  as well as in the design of 3 GBSs7 currently under construction at Saren B.V.8 At October 1  2022  revenues of â‚¬74 million have yet to be recognised by 2025 for ice-breaking LNG carriers  including â‚¬4 million in Q4 2022. Revenues of â‚¬12 million have yet to be recognised for 2027 for GBSs  including â‚¬1 million in Q4 2022.Given the impact of international sanctions on LNG liquefaction projects in Russia  the continuation and successful execution of these contracts are still exposed to risks of postponement or cancellation. In particular  sanctions are still affecting Russian imports of certain products and equipment used in current projects  including the Zvezda project. Furthermore  as previously announced  in July Saren B.V. notified GTT of its intention to terminate the contract between them. The termination date has not yet been finally set. In this context  GTT continues to investigate solutions to ensure the proper implementation and integrity of its technology  in strict compliance with international sanctions.As a reminder  other orders in progress in Asian shipyards for six ice-breaking LNG carriers and two FSUs9 are specifically intended for Russian Arctic projects. These projects are currently proceeding according to plan. At October 1  2022  these orders represented total revenues of â‚¬31 million for GTT  to be recognized by 2024  including â‚¬7 million in Q4 2022.Finally  eight conventional LNG carriers ordered by international shipowners  under construction in Asian shipyards  are intended for the Arctic LNG 2 project  but can operate in all types of conditions.2022 outlook confirmedIn its 2021 annual results press release dated February 17  2022  the Group issued the following targets for 2022  assuming no significant order deferrals or cancellations:consolidated revenues of between â‚¬290 million and â‚¬320 million consolidated EBITDA of between â‚¬140 million and â‚¬170 million a dividend amount for the 2022 financial year at least equivalent to the 2021 dividend.Given delays in shipbuilding schedules for certain vessels during the first nine months of 2022  the Group confirms its forecast that revenues and EBITDA will reach the lower half of the ranges announced in February.In the longer term  the Group should benefit from the current strong order momentum and expects to achieve significantly higher revenues and earnings from 2023 onwards versus 2022.***First nine months of 2022 activity update presentationPhilippe BerterottiÃ¨re  Chairman and Chief Executive Officer  and Virginie Aubagnac  Chief Financial Officer  will comment on GTTâ€™s business during the first nine months of 2022 and answer questions from the financial community during a conference call to be held  in English  on Thursday  October 27  2022 at 6:15 p.m. Paris time.This conference will also be broadcast live on GTTâ€™s website (www.gtt.fr/finance).To participate in the conference call  please dial one of the following numbers five to ten minutes before the start of the conference:France: +33 1 70 91 87 04UK: +44 1 212 818 004USA: +1 718 705 87 96Confirmation code: 130114The presentation document will be available on the website on October 27  2022 from 17:45 p.m.Financial agendaPayment of an interim dividend of â‚¬1.55 per share for the 2022 financial year: December 15  20222022 full year results release: February 16  2023 (after close of trading)Shareholdersâ€™ Meeting: June 7  2023About GTTGTT is a technological expert in containment systems with cryogenic membranes used to transport and store liquefied gases. For over 50 years  GTT has been designing and providing cutting-edge technologies for a better energy performance  which combine operational efficiency and safety  to equip LNG carriers  floating terminals  land storage  and multi-gas carriers. GTT also develops systems dedicated to the use of LNG as fuel  as well as a full range of services  including digital services in the field of Smart Shipping. The Group is also active in hydrogen through its subsidiary Elogen  which designs and assembles electrolysers notably for the production of green hydrogen.GTT is listed on Euronext Paris  Compartment A (ISIN FR0011726835 Euronext Paris: GTT) and is notably included in SBF 120  Stoxx Europe 600 and MSCI Small Cap indicesInvestor relations contact:information-financiere@gtt.fr / +33 1 30 23 20 87Media contact:press@gtt.fr / +33 1 30 23 48 45For more information  visit www.gtt.fr.Important noticeThe figures presented here are those customarily used and communicated to the markets by GTT. This message includes forward-looking information and statements. Such statements include financial projections and estimates  the assumptions on which they are based  as well as statements about projects  objectives and expectations regarding future operations  profits  or services  or future performance. Although GTT management believes that these forward-looking statements are reasonable  investors and GTT shareholders should be aware that such forward-looking information and statements are subject to many risks and uncertainties that are generally difficult to predict and beyond the control of GTT  and may cause results and developments to differ significantly from those expressed  implied or predicted in the forwardlooking statements or information. Such risks include those explained or identified in the public documents filed by GTT with the French Financial Markets Authority (AMF â€“ AutoritÃ© des MarchÃ©s Financiers)  including those listed in the â€œRisk Factorsâ€ section of the GTT Registration Document filed with the AMF on 27 April 2021  and the half-year financial report released on 28 July 2021. Investors and GTT shareholders should note that if some or all of these risks are realised they may have a significant unfavourable impact on GTT1 Important Project of Common European Interest2 PCTC (Pure Car and Truck Carriers): carriers of light vehicles  trucks and rolling stock3 Floating Storage Unit4 Floating Storage Regasification Unit5 Floating Liquefied Natural Gas vessel6 Gravity Based Structures: underwater tanks7 Gravity Based Structure - underwater tanks8 Saren B.V. is a joint venture between Saipem and RÃ¶nesans.9 Floating Storage UnitAttachment,positive,0.82,0.18,0.0,mixed,0.57,0.1,0.33,True,English,"['strong order momentum', 'Nine-month 2022 revenues', 'GTT', 'line', 'expectations', 'China Merchants Heavy Industries shipyards', 'customersâ€™ energy transition needs', 'GTT Digitalâ€ smart shipping solutions', 'two new Technical Assistance', 'new fuel cell plant', 'new LNG conversion concept', 'GTT membrane containment systems', 'first half results release', 'Philippe BerterottiÃ¨re', 'previous sales records', 'unfavourable base effect', 'cutting-edge expedition vessel', 'â‚¬86 million State support', 'Valmax Technology Corporation', 'Charbone HydrogÃ¨ne', 'large-capacity container ships', 'first nine months', 'excellent sales momentum', 'several international partnerships', 'R&D division', 'large industrial projects', 'Dynamic order intake', 'strong order momentum', 'initial target range', 'three-tank LNG carrier', 'Hydrogen IPCEI1 project', 'New licensing agreements', 'LNG fuel tank', 'four new orders', 'vessel construction capacity', '134 LNG carrier orders', 'strong momentum', 'hydrogen carrier', 'initial capacity', 'New Zealand', 'Chinese shipyards', 'Continued momentum', 'gigafactoryâ€ project', 'several approvals', 'new technologies', 'new contract', 'new design', 'wide range', 'lower half', 'fuel business', 'green hydrogen', '134 LNG carriers', 'English French', 'technological expert', 'liquefied gases', 'liquefaction plants', 'high price', 'short term', 'long term', 'tireless focus', 'tightening requirements', 'numerous approvals', 'classification societies', 'financial perspective', 'same period', 'third quarter', 'LNG-powered vessels', 'Yangzijiang Shipbuilding', 'construction sites', 'leading operator', 'cruise expeditions', 'Magellan Explorer', 'European Commission', 'French government', 'important milestone', 'multi-megawatt capacities', 'South Korea', 'North America', 'Bureau Veritas', 'Nine-month 2022 revenues', 'core business', 'production capacity', 'innovative design', 'HiFraser Group', 'Elogen positioning', 'Elogen gigafactory', 'Record orders', 'Business activity', 'Q3 2022 revenues', '42 orders', '134 orders', '58 orders', '38 orders', 'line', 'expectations', '2022 targets', 'Paris', 'October', 'Chairman', 'CEO', 'continuation', 'surge', 'demand', 'investment', 'relevance', 'potential', 'medium', 'fields', 'addition', 'year', 'Delivery', 'Q2', 'Qatar', 'total', 'TALA', 'number', 'July', 'Antarctica21', 'world', 'fly', 'selection', 'strengthening', 'maximum', 'subsidies', 'subsidy', 'Bpifrance', '1 GW.', 'Symbio', 'electrolyser', '2.5 MW', 'company', 'ability', 'manufacture', 'Australia', 'Innovation', 'development', 'principle', 'ClassNK']",2022-10-27,2022-10-28,globenewswire.com
12249,EuroNext,NewsApi.org,https://www.prnewswire.co.uk/news-releases/universal-music-group-nv-reports-financial-results-for-the-third-quarter-and-nine-months-ended-september-30-2022-301661160.html,Universal Music Group N.V. Reports Financial Results for the Third Quarter and Nine Months Ended September 30  2022,Summary Q3 Results1 Revenue of â‚¬2 664 million increased 13.3% year-over-year in constant currency driven by growth across all segments. Recorded Music revenue grew 10.1% year-over-year in constant currency  Music Publishing revenue grew 6.9% year-over-year inâ€¦,"Summary Q3 Results1Revenue of â‚¬2 664 million increased 13.3% year-over-year in constant currency driven by growth across all segments.Recorded Music revenue grew 10.1% year-over-year in constant currency  Music Publishing revenue grew 6.9% year-over-year in constant currency and Merchandising and Other revenue grew 101.1% year-over-year in constant currency.Top sellers for the quarter included BTS  BLACKPINK  Ado  INI and Morgan Wallen.Adjusted EBITDA increased 9.1% year-over-year in constant currency driven by the revenue growth.Summary YTD ResultsRevenue of â‚¬7 398 million increased 15.6% year-over-year in constant currency with strong growth across all segments.Recorded Music revenue grew 10.1% year-over-year in constant currency  Music Publishing revenue grew 28.2% year-over-year in constant currency and Merchandising and Other revenue grew 80.6% year-over-year in constant currency.Adjusted EBITDA increased 10.2% year-over-year in constant currency driven by the revenue growth.HILVERSUM  Netherlands  Oct. 27  2022 /PRNewswire/ -- Universal Music Group N.V. (""UMG"" or ""the Company"") today announced its financial results for the third quarter and nine months ended September 30  2022.UMG""More than ever  we are delivering a diverse and growing range of business and creative opportunities to our recording artists and songwriters "" said Sir Lucian Grainge  UMG's Chairman and CEO. ""Through our innovation  global reach  and unique understanding of the evolution of the market  we are continually improving the monetization of music and music-related content  generating high-quality revenue and recurring income from more sources than ever before.""Boyd Muir  UMG's EVP  CFO and President of Operations  said  ""Our vision of success is about maximizing the long-term value of the business. That requires not only growing revenues but also growing a broad diversity of revenue streams that help drive greater absolute EBITDA and greater value for shareholders.""1 This press release includes certain alternative performance indicators which are not defined in the International Financial Reporting Standards (""IFRS"") issued by the International Accounting Standards Board as endorsed by the EU. The descriptions of these alternative performance indicators and reconciliations of non-IFRS to IFRS measures are included in the Appendix to this press release.UMG ResultsThree Months EndedSeptember 30 %%Nine Months EndedSeptember 30 %%20222021YoYconst.20222021YoYconst. (â‚¬ millions) (unaudited) (unaudited)(unaudited)(unaudited)Revenue â‚¬ 2 664â‚¬ 2 15323.7 %13.3 %â‚¬ 7 398â‚¬ 5 98423.6 %15.6 % EBITDA â‚¬ 539â‚¬ 42626.5 %15.4 %â‚¬ 1 499â‚¬ 1 24820.1 %12.6 % EBITDA margin 20.2 %19.8 %0.4pp20.3 %20.9 %(0.6pp)Adjusted EBITDA â‚¬ 553â‚¬ 46120.0 %9.1 %â‚¬ 1 515â‚¬ 1 28617.8 %10.2 % Adjusted EBITDA margin 20.8 %21.4 %(0.6pp)20.5 %21.5 %(1.0pp)Note: % YoY indicates % change year-over-year; % const. indicates % change year-over-year adjusted for constant currency. Constant currency change is calculated by taking current year results and comparing against prior year results restated at current year rates.Q3 2022 ResultsRevenue for the third quarter of 2022 was â‚¬2 664 million  an increase of 23.7% year-over-year  or 13.3% in constant currency. Revenue includes a â‚¬71 million benefit in Recorded Music from the settlement of a copyright infringement lawsuit with an internet service provider (the ""Legal Settlement"")  as well as a â‚¬21 million negative impact in Music Publishing from a previously announced change in accounting policy.As disclosed in the UMG Annual Consolidated Financial Statements for the year ended December 31  2021  UMG adjusted its accounting policy in relation to certain revenues that are collected through societies (the ""Change in Society Accounting""). In prior years  these revenues were recognized when the relevant collection society notified UMG of the usage by the end customer and collectability was assured. Recognition of that revenue is now based on an accrual for the best available estimate of when the usage occurs and the amount of consideration which is probable to be collected. This has affected the timing of the recognition of certain revenues across financial reporting quarters.UMG's Recorded Music  Music Publishing and Merchandising and Other segments all contributed to the revenue growth in the quarter  as discussed further below.EBITDA for the quarter grew 26.5% year-over-year  or 15.4% in constant currency  to â‚¬539 million  driven by the revenue growth and the Legal Settlement. EBITDA margin was 20.2%  compared to 19.8% in the third quarter of 2021. EBITDA and EBITDA margin were impacted by share-based compensation of â‚¬14 million during the third quarter of 2022  and by â‚¬20 million of share-based compensation as well as â‚¬15 million of expenses related to UMG's listing on Euronext Amsterdam during the third quarter of 2021. Excluding these items  Adjusted EBITDA for the quarter was â‚¬553 million  up 20.0% year-over-year  or 9.1% in constant currency  driven by the revenue growth and the Legal Settlement. Adjusted EBITDA margin was 20.8%  compared to 21.4% in the third quarter of 2021.EBITDA and Adjusted EBITDA in the third quarter of 2022 included a â‚¬52 million benefit from the Legal Settlement  partially offset by the negative â‚¬7 million impact from the Change in Society Accounting.EBITDA and Adjusted EBITDA were also impacted by the timing of certain A&R expenses  which increased in the quarter but remain down year-to-date  and by revenue mix  as revenues were more heavily weighted towards Merchandising and Other revenues  which carry a significantly lower EBITDA margin than the Company's other revenues. Excluding these items  Adjusted EBITDA margin was flat versus the prior-year quarter.YTD 2022 ResultsIn the nine months ended September 30  2022  UMG's revenues of â‚¬7 398 million increased by 23.6%  or 15.6% in constant currency  compared to the nine months ended September 30  2021. This increase was driven by double-digit improvements across all segments  as discussed further below.Revenue for the nine months ended September 30  2022 includes a â‚¬123 million benefit from the Change in Society Accounting  and a â‚¬71 million benefit from the Legal Settlement  both discussed above. Revenue for the nine months ended September 30  2021 included a â‚¬41 million benefit from a catch up payment from a digital service provider ""DSP Catch-Up Payment""  previously disclosed and booked in Q2 2021. Excluding these items  revenue increased 21.2% year-over-year  or 13.3% in constant currency.For the nine months ended September 30  2022  EBITDA of â‚¬1 499 million grew 20.1% year-over-year  or 12.6% in constant currency  and EBITDA margin was 20.3% compared to 20.9% in the prior year period. EBITDA and EBITDA margin were impacted by share-based compensation of â‚¬16 million during the nine months through Q3 2022  and by â‚¬20 million of share-based compensation as well as â‚¬18 million of expenses related to UMG's listing on Euronext Amsterdam during the nine months through Q3 2021. Excluding these amounts  Adjusted EBITDA for the nine months through Q3 2022 was â‚¬1 515 million  up 17.8% compared to the comparable period in 2021  or up 10.2% in constant currency  driven by the revenue growth. Adjusted EBITDA margin contracted 1.0pp year-over-year to 20.5%.EBITDA and Adjusted EBITDA for the nine months through Q3 2022 benefitted from the Change in Society Accounting (â‚¬27 million) and the Legal Settlement (â‚¬52 million). EBITDA and Adjusted EBITDA for the nine months ended Q3 2021 benefitted from the DSP Catch-Up Payment (â‚¬26 million)  as well as from a previously disclosed recovery of an advance provision and release of historic royalties (the ""Exceptional Recovery and Release""  â‚¬20 million) in the first quarter of 2021. Excluding these items  Adjusted EBITDA grew 15.8% year-over-year  or 8.0% in constant currency  and Adjusted EBITDA margin was 19.9%  compared to 20.9% for the nine months ended Q3 2021. The contraction in Adjusted EBITDA margin was driven by revenue mix  as revenues were more heavily weighted towards lower-margin Merchandising revenues in the first nine months of 2022.Recorded MusicThree Months EndedSeptember 30 %%Nine Months EndedSeptember 30 %%20222021YoYconst.20222021YoYconst. (â‚¬ millions) (unaudited) (unaudited)(unaudited)(unaudited)Subscription and Streaming Revenue â‚¬ 1 353â‚¬ 1 13119.6 %7.7 %â‚¬ 3 876â‚¬ 3 26218.8 %10.3 % of which streaming â‚¬ 362â‚¬ 30618.3 %5.2 %â‚¬ 1 020â‚¬ 83322.4 %12.6 % of which subscription â‚¬ 991â‚¬ 82520.1 %8.7 %â‚¬ 2 856â‚¬ 2 42917.6 %9.5 % Downloads and Other Digital Revenue â‚¬ 137â‚¬ 8267.1 %55.7 %â‚¬ 275â‚¬ 23517.0 %9.1 % Physical Revenue â‚¬ 264â‚¬ 280(5.7 %)(9.6 %)â‚¬ 803â‚¬ 7428.2 %4.6 % License and Other Revenue â‚¬ 306â‚¬ 21840.4 %30.2 %â‚¬ 749â‚¬ 60923.0 %16.3 % Recorded Music Revenue â‚¬ 2 060â‚¬ 1 71120.4 %10.1 %â‚¬ 5 703â‚¬ 4 84817.6 %10.1 %Note: % YoY indicates % change year-over-year; % const. indicates % change year-over-year adjusted for constant currency.Q3 2022 ResultsRecorded Music revenues for the third quarter of 2022 were â‚¬2 060 million  up 20.4% compared to the third quarter of 2021  or 10.1% in constant currency. Subscription and streaming revenue grew 19.6% year-over-year  or 7.7% in constant currency  with subscription revenue up 20.1% year-over-year  or 8.7% in constant currency  driven by the continued healthy growth in music subscribers. Ad-supported streaming revenue grew 18.3% year-over-year  or 5.2% in constant currency  reflecting ongoing improvement in ad-based monetization  despite industry-wide ad-market pressure as a result of the uncertain macro-economic environment. Physical revenue declined 5.7% year-over-year  or 9.6% in constant currency  driven by the industry transition to digital consumption and a difficult comparison against strong physical sellers in the prior-year quarter. Downloads and other digital revenue were up 67.1% year-over-year  or 55.7% in constant currency due to the Legal Settlement. License and other revenue improved 40.4% year-over-year  or 30.2% in constant currency  driven by the strong recovery in live touring  where the Company participates in certain markets. Top sellers for the quarter included BTS  BLACKPINK  Ado  INI and Morgan Wallen  while top sellers in the prior-year quarter included Olivia Rodrigo  BTS  Billie Eilish  Drake and King & Prince.YTD 2022 ResultsIn the nine months through Q3 2022  Recorded Music revenues were â‚¬5 703 million  up 17.6% year-over-year  or 10.1% in constant currency. Subscription revenue of â‚¬2 856 million grew 17.6% year-over-year  or 9.5% in constant currency. Subscription revenue in the first nine months of 2021 benefited from the DSP Catch-Up Payment. Excluding this item  subscription revenue grew 19.6% year-over-year  or 11.3% in constant currency. Ad-supported streaming revenue of â‚¬1 020 million grew 22.4% year-over-year  or 12.6% in constant currency.Physical revenue grew 8.2% year-over-year  or 4.6% in constant currency  driven by strong vinyl demand as well as continued CD sales  particularly from BTS and King & Prince. Downloads and other digital revenue increased 17.0% year-over-year  or 9.1% in constant currency  due to the Legal Settlement. License and other revenue improved 23.0% year-over-year  or 16.3% in constant currency as a result of improvements in synchronisation  live and brand deals. Top sellers included BTS  the Encanto soundtrack  Olivia Rodrigo  Morgan Wallen and The Weeknd while top sellers in the prior year included Olivia Rodrigo  BTS  Justin Bieber  The Weeknd and Morgan Wallen.Music PublishingThree Months EndedSeptember 30 %%Nine Months EndedSeptember 30 %%20222021YoYconst.20222021YoYconst. (â‚¬ millions) (unaudited) (unaudited)(unaudited)(unaudited)Performance â‚¬ 92â‚¬ 911.1 %(4.2 %)â‚¬ 219â‚¬ 221(0.9 %)(6.4 %) Synchronisation â‚¬ 57â‚¬ 4818.8 %7.5 %â‚¬ 177â‚¬ 13927.3 %18.0 % Digital â‚¬ 234â‚¬ 18427.2 %17.0 %â‚¬ 771â‚¬ 46665.5 %53.9 % Mechanical â‚¬ 25â‚¬ 31(19.4 %)(21.9 %)â‚¬ 71â‚¬ 701.4 %(1.4 %) Other â‚¬ 10â‚¬ 911.1 %0.0 %â‚¬ 31â‚¬ 310.0 %(6.1 %) Music Publishing Revenue â‚¬ 418â‚¬ 36315.2 %6.9 %â‚¬ 1 269â‚¬ 92736.9 %28.2 %Note: % YoY indicates % change year-over-year; % const. indicates % change year-over-year adjusted for constant currency.Q3 2022 ResultsMusic Publishing revenue amounted to â‚¬418 million in the third quarter of 2022  up 15.2% year-over-year  or 6.9% in constant currency  despite a â‚¬21 million negative impact in the quarter from the Change in Society Accounting discussed above. Excluding the Change in Society Accounting  Music Publishing revenue was up 20.9% year-over-year  or 12.3% in constant currency.Within Music Publishing  digital revenue grew 27.2% year-over-year  or 17.0% in constant currency  reflecting the continued growth of streaming and subscription  partially offset by the Change in Society Accounting. Performance revenue grew 1.1% year-over-year  but fell 4.2% in constant currency  reflecting the Change in Society Accounting. Synchronisation revenue improved 18.8% year-over-year  or 7.5% in constant currency  as a result of increased income from advertising and film. Mechanical revenue fell 19.4% year-over-year  or 21.9% in constant currency  driven by a decline in industry-wide physical sales  as well as the Change in Society Accounting.YTD 2022 ResultsMusic Publishing revenue amounted to â‚¬1 269 million  up 36.9% year-over-year  or 28.2% in constant currency and included a â‚¬123 million benefit from the Change in Society Accounting discussed above. Excluding the Change in Society Accounting  Music Publishing revenue grew 23.6% year-over-year  or 15.8% in constant currency  as a result of organic growth trends and initial contributions from catalogue acquisitions made in prior years.Within Music Publishing  digital revenue grew 65.5% year-over-year  or 53.9% in constant currency  reflecting the Change in Society Accounting  as well as continued healthy growth in streaming and subscription. Synchronisation revenue grew 27.3% year-over-year  or 18.0% in constant currency  as a result of increased income from advertising  TV and film. Performance revenue declined 0.9% year-over-year  or 6.4% in constant currency  reflecting the Change in Society Accounting. Mechanical revenue grew 1.4% year-over-year  but fell 1.4% in constant currency.Merchandising and OtherThree Months EndedSeptember 30 %%Nine Months EndedSeptember 30 %%20222021YoYconst.20222021YoYconst. (â‚¬ millions) (unaudited) (unaudited)(unaudited)(unaudited)Merchandising and Other Revenue â‚¬ 189â‚¬ 84125.0 %101.1 %â‚¬ 437â‚¬ 22296.8 %80.6 %Note: % YoY indicates % change year-over-year; % const. indicates % change year-over-year adjusted for constant currency.Q3 2022 ResultsMerchandising and Other revenue of â‚¬189 million was up 125.0% year-over-year  or 101.1% in constant currency  as touring-related merchandising revenue rebounded following a COVID related slow-down in live touring in the prior year period.YTD 2022 ResultsMerchandising and Other revenue of â‚¬437 million was up 96.8% year-over-year  or 80.6% in constant currency  as touring-related merchandising revenue rebounded following a COVID related slow-down in live touring in the prior year period.Conference Call DetailsThe Company will host a conference call to discuss these results on October 27  2022 at 6:15PM CET. A link to the live audio webcast will be available on investors.universalmusic.com and a link to the replay will be available after the call.While listeners may use the webcast  a dial-in telephone number is required for investors and analysts to ask questions. Investors and analysts interested in asking questions can pre-register for a dial-in line at investors.universalmusic.com under the ""Financial Reports"" tab.Cautionary NoticeThis press release is published by Universal Music Group N.V. and contains inside information within the meaning of article 7(1) of Regulation (EU) No. 596/2014 (Market Abuse Regulation).Forward-looking statementsThis press release may contain statements that constitute forward-looking statements with respect to UMG's financial condition  results of operations  business  strategy and plans. Such forward-looking statements may be identified by the use of words such as 'profit forecast'  'expect'  'estimate'  'project'  'anticipate'  'should'  'intend'  'plan'  'probability'  'risk'  'target'  'goal'  'objective'  'will'  'endeavour'  'optimistic'  'prospects' and similar expressions or variations on such expressions. Although UMG believes that such forward-looking statements are based on reasonable assumptions  they are not guarantees of future performance. Actual results may differ materially from such forward-looking statements as a result of a number of risks and uncertainties  many of which are related to factors that are outside UMG's control  including  but not limited to  UMG's inability to compete successfully and to identify  attract  sign and retain successful recording artists and songwriters  failure of streaming and subscription adoption or revenue to grow or to grow less rapidly than anticipated  UMG's reliance on digital service providers  UMG's inability to execute its business strategy  the global nature of UMG's operations  UMG's inability to protect its intellectual property and against piracy  UMG's inability to attract and retain key personnel  changes in laws and regulations and the other risks that have been described in UMG's 2021 annual report. Accordingly  UMG cautions readers against placing undue reliance on such forward-looking statements. Such forward-looking statements are made as of the date of this press release. UMG disclaims any intention or obligation to provide  update or revise any such forward-looking statements  whether as a result of new information  future events or otherwise.Alternative Performance IndicatorsThis press release includes certain alternative performance indicators which are not defined in IFRS issued by the International Accounting Standards Board as endorsed by the EU. The descriptions of these alternative performance indicators and reconciliations of non-IFRS to IFRS measures are included in the Appendix to this press release.About Universal Music GroupAt Universal Music Group (EURONEXT: UMG)  we exist to shape culture through the power of artistry. UMG is the world leader in music-based entertainment  with a broad array of businesses engaged in recorded music  music publishing  merchandising and audiovisual content. Featuring the most comprehensive catalogue of recordings and songs across every musical genre  UMG identifies and develops artists and produces and distributes the most critically acclaimed and commercially successful music in the world. Committed to artistry  innovation and entrepreneurship  UMG fosters the development of services  platforms and business models in order to broaden artistic and commercial opportunities for our artists and create new experiences for fans. For more information on Universal Music Group N.V. visit www.universalmusic.comContactsMediaJames Murtagh-Hopkins - communicationsnl@umusic.comInvestorsErika Begun - investorrelations@umusic.comAppendixReconciliation of Adjusted EBITDAThree Months EndedSeptember 30 %Nine Months EndedSeptember 30 %20222021YoY20222021YoY (â‚¬ millions) (unaudited) (unaudited)(unaudited)(unaudited)EBITDA 53942626.5 %1 4991 24820.1 %Non-cash share-based compensation expense 14201620One time direct-listing related expenses -15-18Adjusted EBITDA 55346120.0 %1 5151 28617.8 %DEFINITIONSIn this press release  UMG presents certain financial measures when discussing UMG's performance that are not measures of financial performance or liquidity under IFRS (""non-IFRS""). These non-IFRS measures (also known as alternative performance measures or indicators) are presented because management considers them important supplemental measures of UMG's performance and believes that they are widely used in the industry in which UMG operates as a means of evaluating a company's operating performance and liquidity. UMG believes that an understanding of its sales performance  profitability  financial strength and funding requirements is enhanced by reporting the following non-IFRS measures. All non-IFRS measures should be considered in addition to  and not as a substitute for  other IFRS measures of operating and financial performance as described in this press release. In addition  it should be noted that other companies may have definitions and calculations for these non-IFRS measures that differ from those used by UMG  thereby affecting comparability.EBITDA and EBITDA marginUMG considers EBITDA and EBITDA margin  non-IFRS measures  to be relevant measures to assess the performance of its operating segments as reported in the segment data. It enables UMG to compare the operating performance of operating segments regardless of whether their performance is driven by the operating segment's organic growth or by acquisitions. EBITDA margin is EBITDA divided by revenue. To calculate EBITDA  the accounting impact of the following items is excluded from the income from Operating Profit:amortization of intangible assets; impairment losses on goodwill and other intangibles; other income and expenses related to transactions with shareowners (except when directly recognized in equity); depreciation of tangible assets including right of use assets; (gains)/losses on the sale of tangible assets  including right of use assets and intangible assets; (income)/losses from equity affiliates; restructuring expenses; and other non-recurring items.Adjusted EBITDA and Adjusted EBITDA marginThe difference between EBITDA and Adjusted EBITDA consists of share-based compensation expenses and certain one-time items that are deemed by management to be significant and incidental to normal business activity  including but not limited to professional fees and listing fees related to UMG's listing on Euronext Amsterdam. Adjusted EBITDA margin is Adjusted EBITDA divided by revenue. UMG considers Adjusted EBITDA and Adjusted EBITDA margin  non-IFRS measures  to be relevant measures to assess performance of its operating activities excluding items that may be incidental to normal business activity.Logo - https://mma.prnewswire.com/media/512308/UMG.jpgSOURCE Universal Music Group N.V.",neutral,0.0,1.0,0.0,mixed,0.23,0.21,0.56,True,English,"['Universal Music Group N.V.', 'Financial Results', 'Third Quarter', 'Nine Months', 'Universal Music Group N.V.', 'UMG Annual Consolidated Financial Statements', 'International Financial Reporting Standards', 'International Accounting Standards Board', 'financial reporting quarters', 'Sir Lucian Grainge', 'alternative performance indicators', 'copyright infringement lawsuit', 'internet service provider', 'best available estimate', 'Euronext Amsterdam durin', 'Summary Q3 Results1', 'Summary YTD Results', 'â‚¬21 million negative impact', 'relevant collection society', 'current year rates', 'greater absolute EBITDA', 'current year results', 'Music Publishing revenue', 'prior year results', 'financial results', 'Constant currency change', 'Q3 2022 Results', 'Society Accounting', 'greater value', 'â‚¬71 million benefit', 'accounting policy', 'prior years', 'Recorded Music', 'Music revenue', 'Top sellers', 'Morgan Wallen', 'nine months', 'growing range', 'creative opportunities', 'recording artists', 'global reach', 'unique understanding', 'music-related content', 'recurring income', 'Boyd Muir', 'long-term value', 'broad diversity', 'press release', 'UMG Results', 'Three Months', 'end customer', 'share-based compensation', 'strong growth', 'Other revenue', 'high-quality revenue', 'revenue streams', 'Legal Settlement', 'revenue growth', 'third quarter', '12.6 % EBITDA margin', 'IFRS measures', 'Other segments', 'growing revenues', '15.6 % EBITDA', 'Merchandising', 'BTS', 'BLACKPINK', 'Ado', 'INI', 'HILVERSUM', 'Netherlands', 'PRNewswire', 'Company', 'diverse', 'business', 'songwriters', 'Chairman', 'CEO', 'innovation', 'evolution', 'market', 'monetization', 'sources', 'EVP', 'CFO', 'President', 'Operations', 'vision', 'success', 'shareholders', 'descriptions', 'reconciliations', 'Appendix', 'YoY', '0.4pp', 'Note', 'increase', 'relation', 'societies', 'usage', 'collectability', 'Recognition', 'accrual', 'amount', 'consideration', 'timing', 'expenses', 'listing', '23.7', '23.6']",2022-10-27,2022-10-28,prnewswire.co.uk
12250,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/27/2542385/0/en/Aegon-to-combine-its-Dutch-operations-with-a-s-r.html,Aegon to combine its Dutch operations with a.s.r.,The Hague  October 27  2022 - Agreement marks pivotal step towards Aegonâ€™s ambition to build leaders in chosen markets  Combination creates a leader in...,English DutchThe Hague  October 27  2022 - Agreement marks pivotal step towards Aegonâ€™s ambition to build leaders in chosen marketsCombination creates a leader in the Dutch pension  life  and non-life insurance marketsClear and compelling strategic and financial rationale  with significant synergies and long-term benefits for customers  business partners  employees  and shareholdersAegon to receive a 29.99% strategic shareholding0F 1 ) in a.s.r. with associated governance rights and EUR 2.5 billion in cash proceedsin a.s.r. with associated governance rights and EUR 2.5 billion in cash proceeds Transaction enables Aegon to accelerate its strategy of releasing capital from mature businesses and to become a leader in markets where Aegon is well positioned for growthIntention to use cash proceeds to return EUR 1.5 billion capital to shareholders and reduce leverage by up to EUR 700 million consistent with disciplined capital management approachProgress on its transformation allows Aegon to increase its 2023 dividend per share target from around EUR 0.25 to around EUR 0.30Aegon announces today it has reached an agreement with a.s.r. to combine its Dutch pension  life and non-life insurance  banking  and mortgage origination activities with a.s.r. The combination will create a leading Dutch insurance company. This step enables Aegon to accelerate its strategy and represents a major step in its ambition to become a leader in its chosen markets. Aegon will receive EUR 2.5 billion in gross cash proceeds  and a 29.99% strategic stake in a.s.r.  with associated governance rights. Aegonâ€™s Dutch asset management activities will remain part of Aegonâ€™s global asset manager. Aegon will enter into a long-term asset management agreement with a.s.r. to manage parts of the combinationâ€™s general account investments  the investments of the Premium Pension Institution (PPI) offering of Aegon Cappital  and a.s.r.â€™s mortgage funds.â€œTodayâ€™s announcement marks a major milestone in the history of our company and in our long-term ambition to create leaders in our chosen marketsâ€  said Lard Friese  CEO of Aegon. â€œBoth Aegon and a.s.r. are deeply rooted in Dutch society and share a long and rich history. Thanks to the hard work and dedication of our employees  Aegon the Netherlands has been able to improve its performance in recent years. Weâ€™re now building on that success by creating a Dutch insurance leader. Iâ€™m convinced that the combination of our companies is in the best long-term interest of all stakeholders and Dutch society at large. Customers of both companies will benefit from a more diversified product offering and strong distribution.â€œThis transaction provides a unique opportunity to accelerate both the return of capital to shareholders and our strategy of investing in markets where we are well positioned for growth. Our priority continues to be to further improve our operational performance and grow profitably. The increased focus and resources resulting from this transaction  will place us in a better position for the future growth of the company.â€Jos Baeten  CEO of a.s.r. said: â€œI am pleased to announce today that a.s.r. and Aegon the Netherlands  two renowned Dutch companies  deeply rooted in Dutch society  will create a leader in Dutch insurance. Together we will form a sustainable  leading insurer and strengthen our market position as the number two insurer in the market. Given the joined strength of both companies  the company will provide a good home for all Aegon the Netherlands employees  customers  and relations. As employees of a.s.r.  we will work with the new colleagues on the future of this combination. The starting point will be  one company  one culture  by leveraging the best of both organizations. We look forward to welcoming all employees  customers  and relations of Aegon the Netherlands in the near future.â€1 Value of 29.99% stake is EUR 2.4 billion based on the closing price of a.s.r.â€™s shares on October 26  2022 and 57 million shares to be received by Aegon upon closing of the transaction before any potential equity offering by a.s.r. as part of the funding of the transaction.Compelling strategic rationaleCombining the two companies will result in a strong well-diversified Dutch insurance company that will be able to deliver a broad range of attractive products and services and generate attractive shareholder returns.The combined group will:have a leading position in the Dutch pension market. This will lead to more attractive value propositions to customers as the company is well placed to capture opportunities from the upcoming pension reform;become the market leader in disability insurance and the number three player in property and casualty insurance  facilitating a more competitive product offering;have enhanced scale in the origination and servicing of Dutch mortgages  creating the opportunity for more streamlined and improved operations;have stronger distribution activities by combining Aegonâ€™s and a.s.r.â€™s expertise  resources  and platforms in this area; anddeliver significant synergies through the integration of the closed individual life portfolios of the two companies into one platform.The combination will be well positioned to further extend its role in the Dutch insurance market in the field of sustainability and ESG and contribute to finding solutions to the main challenges society faces that have a clear relationship with the core activities of the new combination.Combining the two companies is expected to lead to substantial cost synergies and diversification benefits. Aegon will benefit from a.s.r.â€™s improved operating capital generation and capital synergies through its 29.99% stake in the company. Aegon will bring to a.s.r. significant risk management capabilities and accelerate the implementation of a Partial Internal Model for the calculation of the Solvency II required capital of the combination.Leveraging Aegon Asset Managementâ€™s capabilitiesAegon has agreed an exclusive long-term partnership with a.s.r. to manage the illiquid investments that are part of the general account of the combined businesses. In addition  it will continue to be the asset manager for the investments of Aegon Cappitalâ€™s PPI proposition and will take over the management of a.s.r.â€™s mortgage funds. Through these steps  Aegon Asset Management will further strengthen its position as a provider in the Dutch market of fiduciary services  retirement multi-assets & solutions  fixed income  including alternative fixed income investments and responsible investing.Governance of combinationAegon N.V. will be a 29.99% strategic  supportive shareholder in a.s.r.  allowing Aegon to participate in the financial benefits that the combination will bring. Furthermore  Aegon will have the right to nominate two candidates for the a.s.r. Supervisory Board. Lard Friese  CEO of Aegon N.V will be nominated as a non-independent member  and Danielle Jansen Heijtmajer  Chair of the Supervisory Board of Aegon the Netherlands  will be nominated as an independent member of the Supervisory Board of a.s.r.. The non-independent member has an affirmative vote within a.s.r.â€™s Supervisory Board on certain topics  in line with the size of Aegonâ€™s shareholding.Integration and organization of companiesThe activities of a.s.r. and Aegon the Netherlands will be integrated after closing of the transaction to maximize the potential of the two businesses and fully benefit from their combined reach  scale  and resources. The integration is expected to impact employees in both companies. The integration will be largely completed within three years  and the intention is to minimize the number of redundancies through natural attrition and by helping people to the greatest extent possible to find jobs either inside or outside of the combination. The process will be executed in a fair  diligent  and open way  respecting the talents and strengths of people in both organizations. Employees of the combination will benefit from the sharing of best practices and greater long-term career opportunities within a larger  more diversified Dutch company.The a.s.r. brand will be the leading brand of the combination. The Aegon brand will remain in use in the pension and mortgage markets for three years after closing of the transaction. There will be no change for the brands of Aegonâ€™s other entities  including TKP  Knab  Robidus and Nedasco.Accelerating transformationThe transaction represents a major step in the transformation of Aegon  building on the successful execution of the strategy outlined at the Capital Markets Day of December 2020 to create leaders in chosen markets. The transaction forms a leader in the Dutch insurance market and enables Aegon to increase its focus on creating advantaged businesses in chosen markets outside the Netherlands.In the US  Aegon will build upon Transamericaâ€™s leading positions in both individual life insurance solutions and the workplace pension business  investing capital to profitably grow its market share in selected product lines. Additionally  Transamerica will continue to take management actions designed to further improve the risk-return profile of the business. In the UK  Aegonâ€™s ambition is to continue to profitably grow both the Retail and Workplace channels of its leading platform business by improving its customer propositions  service capabilities and digital experience for advisors  employers  and customers. The transaction allows Aegon Asset Management to strengthen its position in retirement-related investment solutions  alternative fixed income investments and responsible investing  and to build leadership in these areas. In its growth markets  Aegon will continue to look to invest capital in value-added growth opportunities. More details will be shared on the plans to profitably grow the strategic businesses in Aegonâ€™s core markets  its growth markets  and its global asset manager at a Capital Markets Day in the second quarter of 2023.Use of proceeds and financial implicationsAegon anticipates that it will return EUR 1.5 billion of the cash proceeds to shareholders  barring unforeseen circumstances  to offset the dilutive effect of the transaction on free cash flow per share. Furthermore  the company intends to reduce its gross financial leverage by up to EUR 700 million.A priority for Aegon moving forward is to drive sustainable  profitable growth for Transamerica and to execute upon additional in-force management actions designed to improve the risk-return profile of the business. It is anticipated that this will require funding and therefore Aegon expects to maintain its Cash Capital at the Holding above the middle of the operating range of EUR 0.5 billion to EUR 1.5 billion in the near term. Surplus Cash Capital at the Holding above the operating range will be subject to continued disciplined capital management  whereby capital that is not used for value-added growth opportunities will be returned to shareholders over time.Update on financial targets; increase in dividend per shareOn completion of the transaction  Aegon will replace its full ownership of the cash flow and profits of its Dutch businesses with its 29.99% strategic stake in a.s.r.. In the near term  this is expected to translate into lower free cash flow  improving over time as synergies emerge from the combination. On completion of the capital return to shareholders and realization of the synergies  Aegon anticipates that its free cash flow on a per share basis will be higher than pre-transaction levels.The progress that Aegon has made on its transformation allows the company to increase its pay-out ratio and rebase the targeted dividend per share over 2023 from the current level of around 25 eurocents to around 30 eurocents.All other financial targets will be updated in due course.The transaction is expected to reduce IFRS shareholdersâ€™ equity by EUR 3.3 billion based on the balance sheet position on June 30  2022. This includes the impact from the settlement of a tax position at closing of the transaction  which is not anticipated to have a material impact on Aegonâ€™s Cash Capital at the Holding.Group supervision implicationsAegon will engage with its college of supervisors on the implications for group supervision upon closing of the intended transaction. Regardless of the outcome  Aegon intends to maintain its head office in the Netherlands. Its shares will remain listed on Euronext in Amsterdam and the New York Stock Exchange.Indicative timelinesThe closing of the transaction is subject to customary conditions  including regulatory and antitrust approvals  shareholder approvals  and the completion of the works council consultation processes of both Aegon and a.s.r..Aegon will convene an Extraordinary General Meeting of Shareholders (EGM) and request approval for the proposed combination between Aegon the Netherlands and a.s.r.. The EGM is expected to be held on January 18  2023. The Board of the Association Aegon has been informed of Aegonâ€™s ambition to accelerate its strategy and the proposed combination with a.s.r.. The Board is supportive and will seek the approval from its members for its support.Based on the required steps  and necessary approvals  the transaction is expected to close in the second half of 2023.About AegonAegon is an integrated  diversified  international financial services group. The company offers investment  protection  and retirement solutions  with a strategic focus on three core markets (the United States  the United Kingdom  and the Netherlands)  three growth markets (Spain & Portugal  Brazil  and China)  and one global asset manager. Aegon's purpose of Helping people live their best lives runs through all its activities. As a leading global investor and employer  the company seeks to have a positive impact by addressing critical environmental and societal issues  with a focus on climate change and inclusion & diversity. Aegon is headquartered in The Hague  the Netherlands  and listed on Euronext Amsterdam and the New York Stock Exchange. More information can be found at aegon.com.About a.s.r.a.s.r. Nederland N.V. ranks among the top 3 insurers in the Netherlands. a.s.r. offers products and services in the fields of insurance  pensions and mortgages for consumers  self-employed persons  and employers. In addition  a.s.r. is active as an asset manager for third parties. a.s.r. is listed on Euronext Amsterdam and included in the AMX Index. For further information please visit www.asrnl.com.Additional informationConference call analysts and investorsToday  at 10:00 a.m. CET  Aegonâ€™s management will host a conference call for analysts and investors. The conference call and Q&A can be followed via a live audio webcast on aegon.com. A replay will be available as soon as possible after the conference call on aegon.com.To join the conference call  you will need to register via the following registration link. Directly after registration you will receive an email with the call details and a personal pin to enter the conference call.Call detailsNL: + 31 20 795 2755UK: + 44 20 8610 3526US: + 1 646 307 1951Passcode: you will receive a personal pin upon registrationJoint digital press conferenceToday at 08:00 hrs. CET  Lard Friese  CEO of Aegon N.V.  and Jos Baeten  CEO van a.s.r. will host a joint digital press conference. Please  follow this link to join the press conference.Contacts Media relations Investor relations Carolien van der Giessen Jan Willem Weidema+31 (0)6 11 95 33 67 +31(0) 70 344 8028 carolien.vandergiessen@aegon.com janwillem.weidema@aegon.comForward-looking statementsThe statements contained in this document that are not historical facts are forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. The following are words that identify such forward-looking statements: aim  believe  estimate  target  intend  may  expect  anticipate  predict  project  counting on  plan  continue  want  forecast  goal  should  would  could  is confident  will  and similar expressions as they relate to Aegon. These statements may contain information about financial prospects  economic conditions and trends and involve risks and uncertainties. In addition  any statements that refer to sustainability  environmental and social targets  commitments  goals  efforts and expectations and other events or circumstances that are partially dependent on future events are forward-looking statements. These statements are not guarantees of future performance and involve risks  uncertainties and assumptions that are difficult to predict. Aegon undertakes no obligation  and expressly disclaims any duty  to publicly update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements  which merely reflect company expectations at the time of writing. Actual results may differ materially and adversely from expectations conveyed in forward-looking statements due to changes caused by various risks and uncertainties. Such risks and uncertainties include but are not limited to the following:Unexpected delays  difficulties  and expenses in executing against our environmental  climate  diversity and inclusion or other â€œESGâ€ targets  goals and commitments  and changes in laws or regulations affecting us  such as changes in data privacy  environmental  safety and health laws;Changes in general economic and/or governmental conditions  particularly in the United States  the Netherlands and the United Kingdom;Civil unrest  (geo-) political tensions  military action or other instability in a country or geographic region;Changes in the performance of financial markets  including emerging markets  such as with regard to: The frequency and severity of defaults by issuers in Aegonâ€™s fixed income investment portfolios; The effects of corporate bankruptcies and/or accounting restatements on the financial markets and the resulting decline in the value of equity and debt securities Aegon holds; The effects of declining creditworthiness of certain public sector securities and the resulting decline in the value of government exposure that Aegon holds;Changes in the performance of Aegonâ€™s investment portfolio and decline in ratings of Aegonâ€™s counterparties;Lowering of one or more of Aegonâ€™s debt ratings issued by recognized rating organizations and the adverse impact such action may have on Aegonâ€™s ability to raise capital and on its liquidity and financial condition;Lowering of one or more of insurer financial strength ratings of Aegonâ€™s insurance subsidiaries and the adverse impact such action may have on the written premium  policy retention  profitability and liquidity of its insurance subsidiaries;The effect of the European Unionâ€™s Solvency II requirements and other regulations in other jurisdictions affecting the capital Aegon is required to maintain;Changes affecting interest rate levels and continuing low or rapidly changing interest rate levels;Changes affecting currency exchange rates  in particular the EUR/USD and EUR/GBP exchange rates;Changes in the availability of  and costs associated with  liquidity sources such as bank and capital markets funding  as well as conditions in the credit markets in general such as changes in borrower and counterparty creditworthiness;Increasing levels of competition in the United States  the Netherlands  the United Kingdom and emerging markets;Catastrophic events  either manmade or by nature  including by way of example acts of God  acts of terrorism  acts of war and pandemics  could result in material losses and significantly interrupt Aegonâ€™s business;The frequency and severity of insured loss events;Changes affecting longevity  mortality  morbidity  persistence and other factors that may impact the profitability of Aegonâ€™s insurance products;Aegonâ€™s projected results are highly sensitive to complex mathematical models of financial markets  mortality  longevity  and other dynamic systems subject to shocks and unpredictable volatility. Should assumptions to these models later prove incorrect  or should errors in those models escape the controls in place to detect them  future performance will vary from projected results;Reinsurers to whom Aegon has ceded significant underwriting risks may fail to meet their obligations;Changes in customer behavior and public opinion in general related to  among other things  the type of products Aegon sells  including legal  regulatory or commercial necessity to meet changing customer expectations;Customer responsiveness to both new products and distribution channels;As Aegonâ€™s operations support complex transactions and are highly dependent on the proper functioning of information technology  operational risks such as system disruptions or failures  security or data privacy breaches  cyberattacks  human error  failure to safeguard personally identifiable information  changes in operational practices or inadequate controls including with respect to third parties with which we do business may disrupt Aegonâ€™s business  damage its reputation and adversely affect its results of operations  financial condition and cash flows;The impact of acquisitions and divestitures  restructurings  product withdrawals and other unusual items  including Aegonâ€™s ability to integrate acquisitions and to obtain the anticipated results and synergies from acquisitions;Aegonâ€™s failure to achieve anticipated levels of earnings or operational efficiencies  as well as other management initiatives related to cost savings  Cash Capital at Holding  gross financial leverage and free cash flow;Changes in the policies of central banks and/or governments;Litigation or regulatory action that could require Aegon to pay significant damages or change the way Aegon does business;Competitive  legal  regulatory  or tax changes that affect profitability  the distribution cost of or demand for Aegonâ€™s products;Consequences of an actual or potential break-up of the European monetary union in whole or in part  or the exit of the United Kingdom from the European Union and potential consequences if other European Union countries leave the European Union;Changes in laws and regulations  particularly those affecting Aegonâ€™s operationsâ€™ ability to hire and retain key personnel  taxation of Aegon companies  the products Aegon sells  and the attractiveness of certain products to its consumers;Regulatory changes relating to the pensions  investment  and insurance industries in the jurisdictions in which Aegon operates;Standard setting initiatives of supranational standard setting bodies such as the Financial Stability Board and the International Association of Insurance Supervisors or changes to such standards that may have an impact on regional (such as EU)  national or US federal or state level financial regulation or the application thereof to Aegon  including the designation of Aegon by the Financial Stability Board as a Global Systemically Important Insurer (G-SII); andChanges in accounting regulations and policies or a change by Aegon in applying such regulations and policies  voluntarily or otherwise  which may affect Aegonâ€™s reported results  shareholdersâ€™ equity or regulatory capital adequacy levels.This document contains information that qualifies  or may qualify  as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation (596/2014). Further details of potential risks and uncertainties affecting Aegon are described in its filings with the Netherlands Authority for the Financial Markets and the US Securities and Exchange Commission  including the Annual Report. These forward-looking statements speak only as of the date of this document. Except as required by any applicable law or regulation  Aegon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Aegonâ€™s expectations with regard thereto or any change in events  conditions or circumstances on which any such statement is based.Attachment,neutral,0.05,0.95,0.0,positive,0.83,0.17,0.01,True,English,"['Dutch operations', 's.r.', 'Aegon', 'Dutch asset management activities', 'long-term asset management agreement', 'two renowned Dutch companies', 'diversified Dutch insurance company', 'leading Dutch insurance company', 'global asset manager', 'diversified product offering', 'sustainable, leading insurer', 'number two insurer', 'number three player', 'stronger distribution activities', 'Premium Pension Institution', 'upcoming pension reform', 'best long-term interest', 'capital management approach', 'attractive shareholder returns', 'a.s.r.', 'potential equity offering', 'competitive product offering', 'EUR 1.5 billion capital', 'general account investments', 'Dutch pension, life', 'mortgage origination activities', 'attractive value propositions', 'Dutch pension market', 'gross cash proceeds', 'Compelling strategic rationale', 'Dutch insurance leader', 'life insurance markets', 'two companies', 'English Dutch', 'Dutch society', 'Dutch mortgages', 'long-term benefits', 'non-life insurance', 'disability insurance', 'casualty insurance', 'leading position', 'attractive products', 'financial rationale', 'mortgage funds', '29.99% strategic shareholding0F', 'long-term ambition', 'The Hague', 'significant synergies', 'business partners', 'governance rights', 'mature businesses', 'share target', 'major milestone', 'Lard Friese', 'hard work', 'recent years', 'strong distribution', 'Jos Baeten', 'joined strength', 'good home', 'new colleagues', 'starting point', 'one company', 'one culture', 'closing price', 'broad range', 'combined group', '29.99% strategic stake', 'pivotal step', 'major step', 'market position', 'near future', 'rich history', 'unique opportunity', 'operational performance', '57 million shares', 'market leader', 'Aegon Cappital', 'future growth', 'markets Combination', 'Netherlands employees', '1 Value', '29.99% stake', 'leaders', 'Clear', 'customers', 'shareholders', 'associated', 'Transaction', 'strategy', 'Intention', 'leverage', 'disciplined', 'Progress', 'transformation', '2023 dividend', 'banking', 'parts', 'announcement', 'CEO', 'dedication', 'success', 'stakeholders', 'priority', 'focus', 'resources', 'relations', 'organizations', 'October', 'funding', 'services', 'opportunities', 'property', 'scale', 'servicing', 'streamlined', 'improved', 'operations', 'expertise', 'platforms', 'area']",2022-10-27,2022-10-28,globenewswire.com
12251,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/27/2543129/0/en/Solid-growth.html,Solid growth,Nine-month 2022 revenueâ‚¬1 723.3Â millionTotal growth: 13.4%Organic growth: 6.3%          Third quarter 2022Total growth: 14.3%Organic growth: 5.3%        ...,"English FrenchNine-month 2022 revenueâ‚¬1 723.3 millionTotal growth: 13.4%Organic growth: 6.3%Third quarter 2022Total growth: 14.3%Organic growth: 5.3%Paris  27th October 2022 â€“ Our results at the end of September 2022 show sustained growth  despite some challenges in Europe and China. Over the nine first months  Ipsos posted a 13.4% growth  of which 6.3% organic  confirming that we are on track to finish 2022 well. Excluding the temporary net positive impact of Covid-related contracts  our underlying organic growth is 9.2% at the end of September.The average cumulative organic growth at the end of September is 32% over the last two years and 19% over the last three years  which demonstrates our regular performance and strong operating model.PERFORMANCE BY QUARTER2022 vs. 2021 In millions ofEuros 2022Revenue Totalgrowth Organicgrowth 1st quarter 547.8 17.5% 12.3% (1) 2nd quarter 574.0 8.9% 2.1% 3rd quarter 601.5 14.3% 5.3%* Revenue 1 723.3 13.4 % 6.3 %*(1) Covid-related contracts were maintained at least in part until March 31  2022* Underlying organic growth is 6.9% for the third quarter and 9.2% for the Nine-month 2022  excluding the temporary net positive impact of Covid-related contracts (specific pandemic monitoring projects for governments  minus contracts that could not be executed because of the health situation).Looking specifically at the third quarter  total growth is 14.3%  of which 5.3% organic and 8.0% currency effects. Taking out the temporary net positive impact of Covid-related contracts  organic growth amounts to 6.9% for this quarter.PERFORMANCE BY REGION9-month 2022 vs 2021 In millions of Euros 9-month 2022Revenue Contribution Total growth Organic growth EMEA 743.3 43% 1.6% 0% Americas 678.7 39% 27.2% 14% Asia-Pacific 301.3 17% 18.5% 10% Revenue 1 723.3 100% 13.4 % 6.3 %By region  our business in EMEA remains stable. This reflects the consequence of the war in Ukraine  combined with the end of Covid contracts. Taking out the impact of these contracts  the underlying organic business for EMEA is growing by more than 5%.Both North America and Latin America have double-digit growth this year. USA  which is our largest country and one of our strategic priorities  delivers excellent results.Despite lockdowns hampering our Chinese business  our Asia-Pacific business has bounced back in 2022. The related organic growth for the region is up by 10% and highlights very good performances in India and Korea.PERFORMANCE BY AUDIENCEIn millions of Euros 9-month 2022 revenue Contribution 9-month 2022 vs 2021organic growthConsumers1 802.2 47% 12.5% Customers and employees2 352.6 20% 8% Citizens3 283.3 16% -7.5% Doctors and patients4 285.1 17% 3.5% Revenue 1 723.3 100% 6.3%Breakdown of Service Lines by audience segment:1- Brand Health Tracking  Creative Excellence  Innovation  Ipsos UU  Ipsos MMA  Market Strategy & Understanding  Observer (excl. public sector)  Social Intelligence Analytics  Strategy32- Automotive & Mobility Development  Audience Measurement  Customer Experience  Channel Performance (including Retail Performance and Mystery Shopping)  Media development  Capabilities3- Public Affairs  Corporate Reputation4- Pharma (quantitative and qualitative)When we look at our different audiences  we have most growth in our consumer-facing segments as the world unlocks. In particular  double-digit growth is experienced in the Service Lines that focus on measuring and analyzing brand growth and expression.Good growth is also noted in our work focusing on customers and employees  which reflects an increasing interest of our clients in measuring and assessing their own client experiences and also in ensuring the quality of their HR plans.After massive growth during the 2020-21 period spurred by large scale Covid-testing programmes in Europe  our work among citizens has fallen back in 2022. However  the underlying business excluding Covid contracts records a double-digit growth  confirming the need for governments to better understand citizensâ€™ expectations and behaviours in an uncertain and inflationary world.Finally  our work with doctors and patients has seen moderate growth in 2022  impacted by an unfavorable base effect after a rapid expansion during the pandemic.OUTLOOKWe are confident that we can deliver better performance than promised at this start of the year: we now expect organic growth in 2022 to be closer to 6% than 5% and a level of operating margin comparable to that of last year. Hence  we confirm a consistently higher level of profitability than in the past.As the business prepares for 2023  we are in a good place. If some clients become more cautious for the coming months  we see no significant slowdown in our orders. Our order book at the end of September for 2023 is up by 8% compared to last year.Despite current economic uncertainties  we are confident on our ability to deliver the 2022-25 growth plan launched in June this year  considering our large geographic spread and the diversity of sectors we serve.ABOUT IPSOSIpsos is one of the largest market research companies in the world  present in 90 markets and employing more than 18 000 people.Our passionately curious research professionals  analysts and scientists have built unique multi-specialist capabilities that provide true understanding and powerful insights into the actions  opinions and motivations of citizens  consumers  patients  customers or employees. Our 75 solutions are based on primary data from our surveys  social media monitoring  and qualitative or observational techniques.Our tagline ""Game Changers"" sums up our ambition to help our 5 000 customers move confidently through a rapidly changing world.Founded in France in 1975  Ipsos has been listed on the Euronext Paris since July 1  1999. The company is part of the SBF 120 and Mid-60 indices and is eligible for the Deferred Settlement Service (SRD). ISIN code FR0000073298  Reuters ISOS.PA  Bloomberg IPS:FPwww.ipsos.comAttachment",positive,0.84,0.15,0.01,mixed,0.55,0.09,0.36,True,English,"['Solid growth', 'Corporate Reputation 4- Pharma', 'large scale Covid-testing programmes', 'temporary net positive impact', 'specific pandemic monitoring projects', '1- Brand Health Tracking', 'average cumulative organic growth', 'Total growth Organic growth', 'large geographic spread', 'Social Intelligence Analytics', 'unfavorable base effect', 'current economic uncertainties', 'nine first months', 'last two years', 'last three years', 'strong operating model', '2022-25 growth plan', 'related organic growth', 'underlying organic growth', 'underlying organic business', 'Revenue Total growth', '9-month 2022 revenue Contribution', 'brand growth', 'health situation', 'underlying business', 'operating margin', 'coming months', 'sustained growth', 'double-digit growth', 'most growth', 'Good growth', 'massive growth', 'moderate growth', 'last year', 'English French', '27th October', '8.0% currency effects', 'North America', 'Latin America', 'largest country', 'strategic priorities', 'good performances', 'Service Lines', 'Creative Excellence', 'Market Strategy', 'public sector', 'Mobility Development', 'Customer Experience', 'Mystery Shopping', 'Media development', 'Public Affairs', 'different audiences', 'consumer-facing segments', 'increasing interest', 'client experiences', 'HR plans', '2020-21 period', 'rapid expansion', 'good place', 'significant slowdown', 'order book', 'Chinese business', 'Third quarter', 'Covid-related contracts', '1st quarter', '2nd quarter', '3rd quarter', 'Covid contracts', 'audience segment', 'Ipsos UU', 'Ipsos MMA', 'Audience Measurement', 'excellent results', 'citizensâ€™ expectations', 'inflationary world', 'higher level', 'regular performance', 'Channel Performance', 'Retail Performance', 'Nine-month 2022 revenue', 'REGION 9-month', 'Asia-Pacific business', '5.3% organic', '13.4% growth', 'Paris', 'end', 'September', 'challenges', 'Europe', 'China', 'millions', 'Euros', 'part', 'March', 'governments', 'EMEA', 'Americas', 'consequence', 'war', 'Ukraine', 'USA', 'lockdowns', 'very', 'India', 'Korea', 'Consumers1', 'Customers', 'employees2', 'Citizens3', 'Doctors', 'patients4', 'Breakdown', 'Innovation', 'Understanding', 'Observer', 'Strategy3', 'Automotive', 'Capabilities', 'expression', 'work', 'clients', 'quality', 'need', 'behaviours', 'OUTLOOK', 'start', 'profitability', 'past', 'orders', 'June', 'diversity', 'sectors', '9.']",2022-10-27,2022-10-28,globenewswire.com
12252,EuroNext,NewsApi.org,https://finance.yahoo.com/news/bic-third-quarter-nine-months-154000486.html,BIC: THIRD QUARTER & NINE MONTHS 2022 RESULTS,BIC THIRD QUARTER & NINE MONTHS 2022 RESULTS Continued Growth Momentum in all Divisions and Resilience to External HeadwindsFull-Year 2022 Net Sales Outlook ...,"Societe BICBIC THIRD QUARTER & NINE MONTHS 2022 RESULTSContinued Growth Momentum in all Divisions and Resilience to External HeadwindsFull-Year 2022 Net Sales Outlook UpgradedClichy  France â€“ October 27  2022Continued growth momentum - Q3 Net Sales growth of 10.5% at constant currenciesHuman Expression: Robust Back-to-School season (sell-out) in the Northern Hemisphere with market share gains in our three key countries (France  the US  and Mexico). Double-digit growth in Brazil and IndiaFlame For Life: +13% growth in added-value products and high-single to double-digit growth in all key countries driven by distribution gains and innovationBlade Excellence: Market share gains in all regions driven by added-value products. Continued expansion of our B2B business BIC Blade-TechResilience to external headwinds - Input cost inflation and investments in Growth (Brand Support and OPEX) partially offset by favorable pricing and Net Sales operating leverage.Solid Operating Cash Flow (+357.8 million euros)Improvement in Working Capital driven by efficient cash collection9M 2022 Net Sales1 707.2 Mâ‚¬+13.8% at constant currencies 9M 2022 EBIT261.9 Mâ‚¬9M 2022 adjusted EBIT268.5Mâ‚¬ 9M 2022adjusted EBIT margin15.7% 9M 2022 EPS4.22â‚¬ / -34.1%9M 2022 adjusted EPS4.53â‚¬ / +19.2% 9M 2022Free Cash Flow150.7Mâ‚¬ Net Cash Position(End of September)347.0â‚¬""With our Horizon strategic plan in full motion  we are winning where it counts  delivering robust 9-month results with strong momentum across all divisions. Continued distribution and market share gains in all regions  coupled with successful new product launches  demonstrate our ability to fuel growth  while maintaining strong cash flow and a solid balance sheet.Despite an ongoing volatile global environment  we are confident we will meet our Horizon plan trajectory  organically growing Net Sales around 5% in 2023  backed by consumer trust and commercial effectivenessâ€ said CEO  Gonzalve Bich.Story continues2022 Outlook Update (based on current market assumptions1F1)Given the third quarter strong top line performance  Full Year 2022 Net Sales are now expected to grow between +11% and +13% at constant currencies (previously 10% to 12%)  including 1 to 2 points growth from acquisitions. Q4 Net Sales growth will be driven by both volumes and prices. We maintain our target of over 200 million euros in Free Cash Flow.Despite input cost inflation  continued investment in Brand support  and OPEX aimed at fueling growth  Full Year 2022 adjusted EBIT is expected to grow in absolute terms.Strong Momentum in all divisions9M 2022 Group Net Sales increased 11.6% on a comparative basis  13.8% at Constant Currencies  and 11.3% on a 12-month rolling basis2. Year-to-date and quarterly growth were driven by volume increase  favorable mix  and the successful implementation of price increases in all regions. All divisions and regions contributed to 9M and Q3 performance.In Human Expression   9M organic growth continued to be driven by our Core Writing Instruments and Coloring segments. The 2022 Back-to-School season was solid in Europe  North America  and Mexico  notably in the Ball Pen  Mechanical Pen  and Coloring segments. Capitalizing on our value positioning  we gained market share in all key countries  outperforming in classic and added-value segments. India and African countries continued to recover from the pandemic and achieved high-double-digit growth. In Brazil  the strong recovery of the Stationery market  which grew double-digit year-to-date  coupled with a strong commercial execution from our teams  should support a solid 2022-2023 Back-to-School season.Added-value Lighters grew 13% in value and accounted for 35% of the Flame For Life 9M Net Sales. In the US  BIC EZ Reach utility pocket lighter continued to be incremental to the overall category and reached over 5% of the Pocket lighter market  driven by accelerated distribution  notably in convenience stores  and efficient Brand Support. Net Sales grew double-digit in Europe  driven by both Western and Eastern countries. Brazil's performance continued to be fueled by demand for more flame occasions.In Blade Excellence  we gained market share in all key regions (US  Europe  and Latin America). Our value-added products fueled the performance  driven by the ongoing success of our Flex and Soleil ranges. BIC Blade-Tech B2B business continued to ramp up and contributed to 20% of the total Blade Excellence Year-to-Date Net Sales growth.Input cost inflation and investment in Growth (Brand Support and OPEX) partially offset by favorable pricing and Net Sales operating leverage9M 2022 Gross Profit margin decreased by 2.5 points to 48.9% as reported  and by 2.8 points excluding Inkbox. Input cost inflation (- 5.6 pts) and unfavorable FX (-1.1 pts)  mainly EUR/USD hedging rate (-1.2 pts)  were partially offset by favorable fixed cost absorption (+2.1 pts)  pricing (+1.7 pts)  and the positive contribution of Inkbox (+0.3 pts). 9M 2022 Adjusted EBIT increased by 8.0%. Adjusted EBIT margin was 15.7%  a decrease of 2.1 pts compared to 9M 2021 as reported and -1.2 pts excluding Inkbox. Net Sales operating leverage (+4.2 pts) was more than offset by the increase in Brand Support (-0.9 pts)  OPEX (-1.6 pts)  and the negative impact from recent acquisitions  including Inkbox (-0.9 pts).Q3 Gross Profit margin decreased by 3.4 pts at 47.4% notably driven by higher FX. Q3 adjusted EBIT margin declined -5.9 pts driven by higher Brand Support and OPEX  as well as the negative impact from recent acquisitions investments in growth partially offset by Net Sales Operating leverage.Total input cost inflation weighed 79 million euros on 9M adjusted EBIT (including 31 million euros in Q3). For the balance of the year  we expect approximately 30 million euros headwinds from input cost inflation  including electricity prices. The Full Year impact will be more than offset by volume increase  price adjustments  and additional savings  and allow us to grow adjusted Full-Year EBIT in absolute terms  although at a slower pace than Net Sales.9M Net Cash from Operating Activities reached 208.1 million euros  fueled by solid business performance. The -88.1 million euros change in Net Current Working Capital was driven by Trade and other Receivables (-56.6Mâ‚¬)  as a result of strong Net Sales growth  and by an increase in Inventory levels (-93.5Mâ‚¬  of which 38 million euros of input cost inflation from Raw Materials  Freight  and Electricity).9M 2022 Free Cash Flow before acquisitions and disposals was +150.7 million euros. Net Cash position at the end of September was 347.0 million euros and included -73.3 million euros paid for the acquisitions  mainly Inkbox.horizon strategic plan in actionThe execution of BIC's Horizon strategic plan continued to drive our robust performance in Q3.Consumer-centricity and InnovationThe BIC Ecolutions lighter  designed with a 16% lower environmental impact  was successfully launched in the US during the summer and is now being gradually deployed in Europe.Leveraging our BIC Soleil Escape and BIC Bamboo shavers' continued success (2.2% market share in value for Escape year-to-date and 1.3 % for Bamboo  doubling since March 2022)  we are launching BIC EasyRinse  our new breakthrough innovation in Blade Excellence. With a new patented technology  this new shaver answers a key consumer unmet need  identified by our market and consumer insights teams. Its unique design provides an ultra-smooth shaving experience. BIC EasyRinse will be available for both men and women in both disposable and hybrid versions. It will be launched online in the US in Q4 and available at retailers starting 2023.E-commerceE-commerce sales grew 10% since the beginning of the year. Core e-commerce sales were driven by Omniretailers channel (+27% growth) and Developing Markets  with outstanding performance in Brazil and Mexico. All three divisions contributed to growth. We gained market share in the U.S in both Stationery and Shavers  and in the UK in Stationery. Our core DTC business (www.bic.com ) continues to ramp-up  boosted by successful limited editions in partnership with premium brands and artists.Revenue Growth ManagementWe continued to focus on simplifying our portfolio to meet consumer needs. Net Sales per SKU growth held strong at 25%  with progress in all three divisions  combined with a net SKU reduction of 10.3%. We delivered 79% of Full-Year expected price and mix  and we continue to invest pricing analytics and price pack architecture to deliver packs and pricing that meet consumer needs and expectations  while driving profitability.GovernanceOn October 27  the Board of Directors acknowledged the resignation of Inna Kostuk  one of the two Directors representing the employees  simultaneously with the termination of her functions at BIC. The Group Committee (""ComitÃ© de Groupe"") will appoint a new Director representing employees within the next few months. The Board would like to thank Inna for her valuable contributions during her tenure.Key Operational FiguresGroupin million euros Q3 2021 Q3 2022 9M 2021 9M 2022 Group Net Sales 478.4 580.1 1 395.1 1 707.2 Change as reported +8.2% +21.3% +14.6% +22.4% Change on a comparative basis +5.0% +7.6% +16.1% +11.6% Change on a constant currency basis +8.5% +10.5% +19.8% +13.8% EBIT Margin 17.2% 11.1% 29.8% 15.3% Adjusted EBIT Margin 17.2% 11.3% 17.8% 15.7% EPS (in euros) 1.28 1.06 6.40 4.22 Adjusted EPS (in euros) 1.28 1.14 3.80 4.53 Free Cash Flow before acquisitions and disposals 128.6 128.3 232.3 150.7 Net Cash Position 475.4 347.0 475.4 347.0Human Expressionin million euros Q3 2021 Q3 2022 9M 2021 9M 2022 Net Sales 197.5 225.2 530.7 663.2 Change as reported +22.4% +14.1% +16.6% +25.0% Change on a comparative basis +15.9% +2.1% +13.5% +14.4% Change at constant currency +22.8% +6.6% +20.4% +18.4% Adjusted EBIT 12.7 (1.2) 40.3 34.3 Adjusted EBIT Margin 6.5% (0.6) % 7.6% 5.2%Flame For Lifein million euros Q3 2021 Q3 2022 9M 2021 9M 2022 Net Sales 170.7 216.0 538.1 652.0 Change as reported (0.2) % +26.5% +22.5% +21.2% Change on a comparative basis (2.1) % +11.0% +26.5% +9.9% Change at constant currency +0.1% +12.4% +29.2% +10.8% Adjusted EBIT 68.6 74.8 214.2 241.6 Adjusted EBIT Margin 40.2% 34.6% 39.8% 37.1%Blade Excellencein million euros Q3 2021 Q3 2022 9M 2021 9M 2022 Net Sales 104.6 132.6 304.9 372.9 Change as reported +1.6% +26.8% +0.4% +22.3% Change on a comparative basis +1.1% +12.3% +5.7% +11.5% Change at constant currency +1.9% +14.7% +6.2% +12.8% Adjusted EBIT 18.5 13.3 50.9 56.6 Adjusted EBIT Margin 17.7% 10.0% 16.7% 15.2%NET SALES  EARNINGS BEFORE INTEREST AND TAXES (EBIT)  AND ADJUSTED EBITin million euros Q3 2021 Q3 2022 9M 2021 9M 2022 Net Sales 478.4 580.1 1 395.1 1 707.2 Gross Profit 242.9 275.0 716.7 834.8 Gross Profit margin 50.8% 47.4% 51.4% 48.9% EBITDA 87.7 84.6 470.2 332.1 EBIT 82.5 64.3 415.1 261.9 EBIT margin 17.2% 11.1% 29.8% 15.3% Non-recurring items (see details page 12) - 1.3 (166.5) 6.6 Adjusted EBIT 82.5 65.6 248.6 268.5 Adjusted EBIT margin 17.2% 11.3% 17.8% 15.7%9M 2022 Gross Profit margin decreased by 2.5 points to 48.9% as reported  and by 2.8 points excluding Inkbox. Input cost inflation and unfavorable FX  mainly EUR/USD hedging rate  were partially offset by favorable fixed cost absorption  positive pricing  and the contribution of Inkbox. 9M 2022 Adjusted EBIT margin was 15.7%  a decrease of 2.1 pts compared to 9M 2021 as reported and -1.2 points excluding Inkbox. Net Sales operating leverage more than offset the increase in Brand Support  OPEX  and the negative impact from recent acquisitions  including Inkbox.Q3 Gross Profit margin decreased by 3.4 pts at 47.4%. Q3 adjusted EBIT margin declined -5.9 pts driven by higher Brand Support and OPEX  the impact from recent acquisitions' investments in growth  partially offset by Net Sales Operating leverage.T he Human Expression division's 9M 2022 adjusted EBIT margin was 5.2% compared to 7.6% in 9M 2021. The decrease was driven by input cost inflation and the impact of Inkbox  partly offset by Net Sales operating leverage and favorable fixed cost absorption. Q3 adjusted EBIT margin was -0.6%  a 7.1 pts decrease as a result of higher OPEX  and adverse FX (EUR/USD hedging rate).Flame for Life Division ' s 9M 2022 adjusted EBIT margin was 37.1% compared to 39.8% in 9M 2021  due to higher Raw Materials  Freight and Electricity costs and an increase in Brand Support driven by the BIC EZ Reach advertising campaign in the US. This was partially offset by Net Sales operating leverage and favorable fixed cost absorption. Q3 2022 adjusted EBIT margin was 34.6% compared to 40.2% in Q3 2021 due to higher OPEX and adverse FX (EUR/USD hedging rate).Blade Excellence Division's 9M 2022 adjusted EBIT margin was 15.2% compared to 16.7% in 9M 2021  driven by higher manufacturing costs ( including Electricity and Freight costs) and higher Brand support. This was partly offset by Net Sales operating leverage  favorable fixed cost absorption  and the positive contribution from BIC Blade-Tech B2B business. Q3 2022 adjusted EBIT margin was 10.0% compared to 17.7% in Q3 2021 due to higher Raw Materials and manufacturing costs (including Electricity and Freight costs)  higher OPEX  and adverse FX (EUR/USD hedging rate).Key components of the change in Adjusted EBIT margin Q1 2022 vs. Q1 2021Q2 2022 vs. Q2 2021Q3 2022 vs. Q3 20219M 2022 vs. 9M 2021(in points) Â· Change in Gross Profit +0.2 (3.9) (3.4) (2.5) Â· Brand Support (0.5) (1.8) (0.8) (1.0) Â· OPEX and other expenses3 +5.4 +1.3 (1.7) +1.4 Total change in Adjusted EBIT margin +5.1 (4.4) (5.9) (2.1)NET INCOME AND EPSin million euros Q3 2021 Q3 2022 9M 2021 9M 2022 EBIT 82.5 64.3 415.1 261.9 Finance revenue/costs (0.7) 0.7 (4.7) (3.4) Income before Tax 81.9 65.0 410.4 258.6 Net Income Group share 57.3 46.8 287.5 186.2 Adjusted Net Income Group Share 57.6 50.3 170.4 200.1 Adjusted EPS Group Share (in euros) 1.28 1.14 3.80 4.53 EPS Group Share (in euros) 1.28 1.06 6.40 4.22NET CASH POSITIONCHANGE IN NET CASH POSITION 20212022in million euros Net Cash position (beginning of period â€“ December) 183.9 400.1 Net Cash from operating activities +276.6 +208.1 Â· Of which operating cash flow +336.3 +357.8 Â· Of which change in working capital (19.4) (88.1) Others4 (40.3) (61.6) CAPEX5 (44.3) (57.4) Dividend payment (80.9) (94.7) Share buyback program (31.2) (43.7) Net Cash from the liquidity contract +0.5 +1.9 Proceed from the sale of Clichy Headquarters +173.9 - Proceed from Pimaco divestiture +3.8 +1.1 Acquisitions6 (7.2) (73.3) Other items +0.3 +4.9 Net Cash position (end of period â€“ September) +475.4 +347.0At the end of September 2022  Net Cash position was 347.0 million euros. Net Cash from operating activities was impacted by an increase in working capital due to higher inventory levels  of which 38 million euros of input cost inflation  and an increase in Trade Accounts Receivables. Q3 improvement in Working Capital was driven by efficient cash collection of Trade Receivables. Net Cash was also impacted by the acquisitions of Inkbox (January 2022)  Tattly (August 2022)  and AMI (September 2022).SHAREHOLDERS' REMUNERATIONIn line with our disciplined capital allocation framework  we continued our commitment to attractive shareholder returns with a balance of dividend and buybacks with:2.15 euros per share of ordinary dividend paid in June 2022 43.7 million euros in share buybacks were completed by SOCIÃ‰TÃ‰ BIC at the end of September 2022. 833 406 shares were purchased at an average price of 52.44 euros.OPERATIONAL TRENDS BY DIVISIONHUMAN EXPRESSIONThe Human Expression Division's 9M 2022 Net Sales grew 18.4% at constant currency  14.4% on a comparative basis and 17.6% on a 12-month rolling basis. In Q3  Net Sales grew 6.6% at constant currency and 2.1% on a comparative basis. Q3 Net Sales growth was affected by customersâ€™ request for earlier Back-to-School orders which where shipped during the first half.In Europe  9M performance was driven by both Southern Europe (Italy  Spain) and Eastern Europe (Poland  Romania)  boosted by efficient promotional activities. Back-to-School sell-out performance was robust. In France  we consolidated our leadership position  outperforming the market for the 16th consecutive year and gaining 1.4 pts7 in value. This was driven by all segments  including Core Stationery and Coloring. The iconic 4-Color contributed to 50% of our share gain. In the UK  we maintained our #1 brand position  outperforming the market (+1.2 pts)8 thanks to the strong performance of the Pens segment (BIC Cristal and BIC 4-Color)  Coloring felt pens  and pencils.In the US  the Stationery market grew 1.9% in value9  and BIC gained +0.5 pts in value share fueled by both core stationery and added-value segments (Coloring and Gel)  as well as good performance in e-commerce. As expected  the Back-to-School sell-out was robust  driven by our core stationery segments  such as Mechanical Pencils  where we gained close to 3 points of value share.In Brazil  Net Sales more than doubled thanks to favorable pricing and strong market momentum. The Stationery market grew double-digit10  and BIC reached a historical high of over 50% of market share in value. This was driven by continued strong in-store execution and the performance of both classic (Ball Pen) and added value products such as BIC Intensity. In Mexico  the market grew more than 60% in value with the return to classrooms  and we gained +0.6pts11 boosted by Coloring and Marking segments. During the Back-to-School season  we consolidated our leadership position  gaining share for the second consecutive season in the Modern Mass Channel  supported by strong in-store visibility  efficient communication campaigns  and good performance in e-commerce. Cello Net Sales in India increased double-digit  boosted by a continued rebound of the market and solid double-digit growth in e-commerce thanks to a favorable mix.FLAME FOR LIFEThe Flame for Life Division's 9M 2022 Net Sales grew 10.8% at constant currency  9.9% on a comparative basis  and 8.4% on a 12-month rolling basis . In Q3  Net Sales grew 12.4% at constant currency and 11.0% on a comparative basis.In the US  BIC continued to successfully outperform the total lighter market (down -10.2% in volume and -3.7% in value12)  gaining share in both volumes (+ 2.3 pts) and value (+ 1.0 pt). Our utility pocket lighter BIC EZ Reach continued to outperform the market  reaching over 5% of market share in value  driven by accelerated distribution and efficient Brand Support. EZ Reach represented almost 7% of BIC pocket lighter sales in the US. BIC successfully gained share in the Utility lighter segment  gaining +3.4 points in value versus 3 years ago  before the Covid pandemic.In Europe  Net Sales grew double-digit driven by both Western (France Italy  Germany  Belgium) and Eastern countries (Poland  Turkey) with the ongoing recovery in traditional channels  price increases  and the success of added-value products such as decorated lighters.In Latin America  the lighter market in Brazil grew 3.3% in value13  and we continued to successfully gain market share (+0.8 pts)   driven by distribution gains in decorated lighters with a new collection launch. BIC's double-digit Net Sales growth was fueled by the continued demand for more flame occasions and high barriers for imported lighters  in addition to the successful implementation of price increases.BLADE EXCELLENCEThe Blade Excellence Division's 9M 2022 Net Sales grew 12.8% at constant currency  11.5% on a comparative basis  and 8.5% on a 12-month rolling basis. In Q3  Net Sales grew 14.7% at constant currency and 12.3% on a comparative basis.In Europe  BIC continued to gain market share in both France (+1.6 pts in value) and the UK (+0.4 pts in value)14 fueled by the success of 3-blade products in both female and male segments. Net Sales growth was driven by continued focus on distribution gains in Eastern countries (Romania  Poland  Greece) where we gained sizable market share leveraging on promotional effectiveness. Added-value products  such as the Flex and Soleil ranges  contributed successfully to growth.In the US  BIC outperformed the Disposable market (+0.9 pts in value)15 thanks to continued consumer preference for value premium products in the Women's segment. BIC was the only major Women's Disposable shaver brand to grow year-to-date and gained 1.5 pts market share in value. Our Soleil range continued to perform successfully  helped by our innovative shaver  BIC Soleil Escape  which reached 2.2% of the market  less than one year after its launch.In Brazil and Mexico  we continued to perform well in added-value segments such as 3-blades leading to solid double-digit growth in both countries. In Brazil  after four years of successful share gain  we continued to outperform the market (+1.3 pts in value)16. A proof point of our successful trade-up strategy in the region  we reached a historical record with close to 25% market share in value driven by premium male and female products (Comfort 3  Hybrid and Simply Soleil). In Mexico  we maintained our share in a market up mid-single digit in value  with the continued solid performance of both Flex and Soleil ranges in the traditional channel. In the Modern Mass Channel  the BIC Comfort 3 Hybrid shaver was the #1 item  followed by BIC Simply Soleil  powered by efficient promotional activity.APPENDIX2022 MARKET ASSUMPTIONSOur 2022 outlook is based on the following market assumptions26F6F17:Market trends (in value):Europe : Low to mid-single-digit decrease in Stationery  flat to low single-digit decrease in Lighters  flat to low-single-digit increase in ShaversUS : Low to mid-single-digit decrease in Stationery market Low to mid-single-digit decrease for total pocket Lighter market Slight decrease in the total one-piece Shaver marketLatin America: double-digit increase in Stationery; Low to mid-single-digit decrease in Lighters and low to mid-single-digit increase in ShaversIndia: double-digit increase in StationeryEBIT drivers:Gross Profit: Increase in volumes and prices Higher Raw Materials and Sea and Air Freight costs Unfavorable FX impact Positive contribution from InkboxAdjusted EBIT: Increase in Brand Support to support Net Sales growth â€“ increase in R&D and OPEX to support long-term growth and innovation Additional savings Negative impact on 2022 EBIT from 2022 acquisitionsFree Cash Flow before Acquisitions and Disposals drivers:Approximately 100 million euros in CAPEXCurrency: 2022 USD-EUR hedging rate: 1.1750Q3 NET SALES BY GEOGRAPHY Q3 2021Q3 2022% As reported% at constant currencies% On a comparative basisin million euros Group 478.4 580.1 +21.3% +10.5% +7.6% Europe 155.4 173.6 +11.7% +10.5% +10.5% North America 194.7 236.9 +21.7% +3.9% +1.0% Latin America 72.6 108.5 +49.4% +34.2% +24.9% Middle East and Africa 31.3 32.0 +1.9% (4.5)% (4.5)% Asia and Oceania (including India) 24.3 29.1 +20.1% +11.9% +11.9%9M NET SALES BY GEOGRAPHY 9M 20219M 2022% As reported% at constant currencies% On a comparative basisin million euros Group 1 395.1 1 707.2 +22.4% +13.8% +11.6% Europe 447.5 510.6 +14.1% +13.9% +13.9% North America 601.1 735.8 +22.4% +8.9% +6.5% Latin America 198.5 288.2 +45.2% +31.3% +24.3% Middle East and Africa 82.5 89.0 +8.0% +1.6% +1.6% Asia and Oceania (including India) 65.5 83.6 +27.5% +20.8% +20.8%Q3 NET SALES BY DIVISION Q3 2021Q3 2022Change as reportedFX impact18 Change in Perimeter 19 Argentina impact20 Change on a Comparative basisin million euros (in points) (in points) (in points) Group 478.4 580.1 +21.3% +11.4 +1.3 +1.0 +7.6% Stationery- Human Expression 197.5 225.2 +14.1% +8.0 +3.0 +1.0 +2.1% Lighters- Flame for Life 170.7 216.0 +26.5% +14.6 (0.0) +0.9 +11.0% Shavers- Blade Excellence 104.6 132.6 +26.8% +12.9 (0.0) +1.6 +12.3% Other Products 5.7 6.3 +11.5% (0.1) (0.0) (0.0) +11.6%9M NET SALES BY DIVISION 9M 20219M 2022Change as reported FX impact Change in Perimeter Argentina impact Change on a Comparative basis in million euros (in points) (in points) (in points) Group 1 395.1 1 707.2 +22.4% +9.0 +1.1 +0.7 +11.6% Stationery- Human Expression 530.7 663.2 +25.0% +7.0 +2.6 +1.0 +14.4% Lighters- Flame for Life 538.1 652.0 +21.2% +10.7 (0.0) +0.6 +9.9% Shavers- Blade Excellence 304.9 372.9 +22.3% +9.9 (0.0) +0.9 +11.5% Other Products 21.3 19.1 (10.5)% (0.1) (0.0) (0.0) (10.4)% EBIT BY DIVISION Q3 2021Q3 2022 9M 2021 9M 2022 in million euros Group 82.5 64.3 415.1 261.9 Margin 17.2% 11.1% 29.8% 15.3% Stationery- Human Expression 12.7 (2.6) 41.9 30.9 Margin 6.5% (1.1) % 7.9% 4.7% Lighters- Flame for Life 68.6 74.8 212.4 240.7 Margin 40.2% 34.6% 39.5% 36.9% Shavers- Blade Excellence 18.5 13.3 50.8 54.4 Margin 17.7% 10.0% 16.7% 14.6% Other Products (1.0) (0.1) (4.0) (3.9) Unallocated costs (16.3) (21.1) 114.0 (60.2)ADJUSTED EBIT BY DIVISION Q3 2021Q3 20229M 20219M 2022in million euros Group 82.5 65.6 248.6 268.5 Margin 17.2% 11.3% 17.8% 15.7% Stationery- Human Expression 12.7 (1.2) 40.3 34.3 Margin 6.5% (0.6) % 7.6% 5.2% Lighters- Flame for Life 68.6 74.8 214.2 241.6 Margin 40.2% 34.6% 39.8% 37.1% Shavers- Blade Excellence 18.5 13.3 50.9 56.6 Margin 17.7% 10.0% 16.7% 15.2% Other Products (1.0) (0.1) (3.9) (3.9) Unallocated costs (16.3) (21.1) (52.8) (60.2)IMPACT OF CHANGE IN PERIMETER AND CURRENCY FLUCTUATIONS ON NET SALES (EXCLUDES ARS) (in %) Q3 2021 Q3 2022 9M 2021 9M 2022 Perimeter +2.5 +1.3 +2.8 +1.1 Currencies +0.2 +11.3 (4.5) +9.0 Of which USD (0.6) +7.2 (3.2) +5.8 Of which BRL +0.1 +1.4 (0.9) +1.3 Of which MXN +0.4 +0.9 +0.1 +0.7 Of which AUD +0.0 +0.2 +0.1 +0.1 Of which ZAR +0.2 +0.0 +0.1 +0.0 Of which INR (0.0) +0.2 (0.1) +0.2 Of which RUB and UAH (0.0) +1.1 (0.3) +0.6Sensitivity to net sales and income before tax (IBT) of USD-EUR fluctuation 9M 2021 9M 2022 +/- 5% change in USD impact on Net Sales 2.1% 2.1% +/- 5% change in USD impact on IBT 0.9% 1.2%Non-recurring Items Q3 2021Q3 20229M 20219M 2022in million euros Clichy Headquarters Sale Gain - - +167.7 - Pimaco divestiture gain - - +3.0 - Restructuring costs related to BIC's transformation plan. - - (4.2) - Acquisition costs related to Inkbox  Tattly and AMI  Rocketbook earnout and Djeep price adjustment - (1.3) - (3.6) Ukraine operations impairment - - - (3.0)CONDENSED PROFIT AND LOSS Q3 2021Q3 20229M 20219M 2022in million euros Net Sales 478.4 580.1 1 395.1 1 707.2 Cost of goods 235.5 305.1 678.4 872.4 Gross profit 242.9 275.0 716.7 834.8 Administrative & net other operating expenses/ (gain) 160.4 210.7 301.6 572.9 EBIT 82.5 64.3 415.1 261.9 Finance revenue/costs (0.7) 0.7 (4.7) (3.4) Income before tax 81.9 65.0 410.4 258.6 Income tax expense (24.5) (18.2) (122.9) (72.4) Net Income Group Share 57.3 46.8 287.5 186.2 Earnings per Share Group Share (in euros) 1.28 1.06 6.40 4.22 Average number of shares outstanding (net of treasury shares) 44 890 535 44 130 016 44 890 535 44 130 016CONDENSED BALANCE SHEET in million euros September 30 2021 September 30 2022 Non-current assets 1 044 454 1 239 192 Current assets 958 377 1 202 082 TOTAL ASSETS 2 523 778 2 864 284 Shareholders' equity 1 682 506 1 921 075 Non-current liabilities 223 335 181 217 Current liabilities 617 936 761 992 TOTAL LIABILITIES & SHAREHOLDERS' EQUITY 2 523 778 2 864 284RECONCILIATION WITH ALTERNATIVE PERFORMANCE MEASURESADJUSTED EBIT RECONCILIATION Q3 2021Q3 20229M 20219M 2022in million euros EBIT 82.5 64.3 415.1 261.9 Restructuring costs (Transformation plan) - - +4.2 - Clichy Headquarters sales capital gain - - (167.7) - Pimaco divestiture capital gain - - (3.0) - Acquisition costs related to Inkbox  Tattly and AMI - +1.3 - +2.9 Rocketbook earnout/ Djeep price adjustment - - - +0.7 Ukraine operations impairment - - - +3.0 Adjusted EBIT 82.5 65.6 248.6 268.5ADJUSTED EPS RECONCILIATION Q3 2021Q3 20229M 20219M 2022in euros EPS 1.28 1.06 6.40 4.22 Restructuring costs (Transformation plan) - - +0.07 - Argentina hyperinflationary accounting (IAS29) - +0.06 +0.04 +0.15 Clichy Headquarters sales capital gain - - (2.67) - Pimaco divestiture capital gain - - - - Acquisition costs related to Inkbox  Tattly and AMI - +0.02 - +0.05 Rocketbook earnout/ Djeep price adjustment - - - +0.05 Ukraine operations impairment - - - +0.06 Adjusted EPS 1.28 1.14 3.80 4.53Free Cash Flow reconciliation September 30  2021September 30  2022in million euros - rounded figures Net Cash from operating activities (1) +276.6 +208.1 Capital expenditure (2) (44.3) (57.4) Free Cash Flow before acquisition and disposals (1) - (2) 232.3 150.7SHARE BUYBACK PROGRAMSOCIETE BICNumber of shares acquiredAverage weighted price (in â‚¬)Amount (in Mâ‚¬)January 2022 23 100 50.19 1.2 February 2022 113 568 47.70 5.4 March 2022 140 897 46.48 6.5 April 2022 75 550 47.85 3.6 May 2022 126 028 56.52 7.1 June 2022 94 358 52.72 5.0 July 2022 57 250 55 95 3.1 August 2022 111 305 58.07 6.5 September 2022 91 350 57.58 5.3 Total 833 406 52.44 43.7CAPITAL AND VOTING RIGHTSAs of September 30  2022  the total number of issued shares of SOCIÃ‰TÃ‰ BIC is 44 677 929 shares  representing:65 713 727 voting rights 64 762 104 voting rights excluding shares without voting rightTotal number of treasury shares held at the end of September 2022: 951 623.GLOSSARYConstant currency basis: constant currency figures are calculated by translating the current year figures at prior Year monthly average exchange rates.Organic change or Comparative basis: at constant currencies and constant perimeter. Figures at constant perimeter exclude the impact of acquisitions and/or disposals that occurred during the current year and/or during the previous year  until their anniversary date. All Net Sales category comments are made on a comparative basis. Organic change excludes Argentina Net Sales for both 2021 and 2022.On a 12 -month r olling basis at constant currency: last 12-month Net Sales variance vs. last year last 12-month at constant currencyEBITDA: EBIT before Depreciation and Amortization (excluding amortization of right of use under IFRS 16 standard)  and impairment.Adjusted EBIT: adjusted means excluding normalized items.Adjusted EBIT margin: a djusted EBIT as a percentage of Net Sales.Net Cash from operating activities: Cash generated from principal activities of the entity and other activities that are not investing or financing activities.Free Cash Flow: Net cash flow from operating activities less capital expenditures (CAPEX). Free cash flow does not include acquisitions and proceeds from the sale of businesses.Net cash position: Cash and cash equivalents + Other current financial assets - Current borrowings - Non-current borrowings (except financial liabilities following IFRS 16 implementation)SOCIETE BIC consolidated financial statements as of September 30  2022  were approved by the Board of Directors on October 27  2022. A presentation related to this announcement is also available on the BIC website (www.bic.com). This document contains forward-looking statements. Although BIC believes its expectations are based on reasonable assumptions  these statements are subject to many risks and uncertainties. A description of the risks borne by BIC appears in the section  ""Risks Management"" in BIC's 2021 Universal Registration Document filed with the French financial markets authority (AMF) on March 25  2022.ABOUT BICA world leader in stationery  lighters and shavers  BIC brings simplicity and joy to everyday Life. For more than 75 years  the Company has honored the tradition of providing high-quality  affordable  essential products to consumers everywhere. Through this unwavering dedication  BIC has become one of the most recognized brands and is a trademark registered worldwide. Today  BIC products are sold in more than 160 countries around the world and feature iconic brands such as BIC Kidsâ„¢  BIC FlexTM  BodyMark by BICTM  CelloÂ®  Djeep  Lucky Stationery  Rocketbook  SoleilÂ®  Tipp-ExÂ®  Us. TM  Wite-OutÂ®  Inkbox and more. In 2021  BIC Net Sales were 1 831.9 million euros. The Company is listed on ""Euronext Paris"" "" is part of the SBF120 and CAC Mid 60 indexes and is recognized for its commitment to sustainable development and education. It received an A- Leadership score from CDP. For more  visit www.bic.com or follow us on LinkedIn  Instagram  Twitter  or YouTube.Find more about BIC's Horizon Plan in our Investor Insights Newsletters.BIC's Q3 and 9M earnings conference call and webcast will be hosted by Gonzalve Bich  CEO  and Chad Spooner  CFO on Friday  October 28 2022  at 8:30 AM CET time:To participate to the webcast: https://channel.royalcast.com/bic/#!/bic/20221028_1To participate to the conference call:From France: +33 (0) 1 70 37 71 66 From the UK: +44 (0) 33 0551 0200 From the USA: +1 212 999 6659 Vocal access code: Â« BIC Â»CONTACTSSophie Palliez-CapianVP  Corporate Stakeholder Engagement+33 1 45 19 55 28+ 33 87 89 3351Sophie.palliez@bicworld.comAlbane de La Tour dâ€™ArtaiseSenior Manager  Institutional Press Relations+ 33 1 45 19 51 51+ 33 7 85 88 19 48Albane.DeLaTourDArtaise@bicworld.comIsabelle de SegonzacImage 7+ 33 6 89 87 61 39isegonzac@image7.fr2023 AGENDAALL DATES TO BE CONFIRMED4th Quarter and Full-Year 2022 Results February 14  2023 1st Quarter 2023 Results April 25  2023 2022 AGM May 17  20231 See market assumptions page 9Non audited figures2 See glossary3 Other expenses include notably Freight & Distribution and R&D4 Income tax paid and payment related to employee benefits.5 Including -6.1 million euros in 2022 and -0.6 million euros in 2021 related to CAPEX payable change6 Haco Industries Ltd  Rocketbook & Djeep in 2021  Inkbox  Tattly  AMI and Rocketbook & Djeep in 20227 IRI Modern Trade  BTS 13 weeks ending 25-SEP8 YTD September 2022 - IRI9 YTD September 2022 - NPD10 YTD August 2022 â€“ Nielsen  Modern Trade only 16% market coverage11 YTD August 2022 â€“ NPD - estimated 45% market coverage12 Period ending 1 October 2022 â€“ IRI  estimated 70% market coverage13 YTD September Nielsen14 YTD August 2022  Nielsen15 YTD 1 October 2022 - IRI16 YTD August 2022 â€“ Nielsen  estimated 62% coverage17 Euromonitor and BIC estimates18 Forex impact excluding Argentinian Peso (ARS)19 Mainly acquisition of Inkbox20 See glossaryAttachment",neutral,0.0,0.99,0.0,mixed,0.71,0.15,0.14,True,English,"['THIRD QUARTER', 'NINE MONTHS', 'BIC', '2022 RESULTS', 'BIC EZ Reach utility pocket lighter', 'third quarter strong top line performance', 'B2B business BIC Blade-Tech', 'BIC Blade-Tech B2B business', 'successful new product launches', 'ongoing volatile global environment', 'Net Sales operating leverage', 'Full-Year 2022 Net Sales Outlook', '9M 2022 Gross Profit margin', 'favorable fixed cost absorption', '9M 2022 Group Net Sales', 'Solid Operating Cash Flow', 'Q4 Net Sales growth', 'BIC THIRD QUARTER', 'Full Year 2022 Net Sales', 'Q3 Net Sales growth', 'Pocket lighter market', '9M 2022 Net Sales', '9M Net Sales', 'Free Cash Flow', 'strong cash flow', 'Input cost inflation', 'efficient cash collection', 'Horizon strategic plan', 'solid balance sheet', 'Horizon plan trajectory', 'Core Writing Instruments', 'EUR/USD hedging rate', 'current market assumptions1F', '12-month rolling basis', 'strong commercial execution', 'robust 9-month results', 'market share gains', '9M organic growth', 'efficient Brand Support', 'three key countries', 'Continued Growth Momentum', 'total Blade Excellence', '1 to 2 points growth', 'Societe BIC', 'strong momentum', 'Q3 performance', '2022 Outlook Update', 'successful implementation', 'strong recovery', 'solid 2022-20', 'ongoing success', 'full motion', 'Stationery market', 'Continued expansion', 'commercial effectiveness', 'comparative basis', 'favorable mix', 'distribution gains', 'Double-digit growth', 'quarterly growth', 'EBIT margin', 'African countries', 'Eastern countries', 'favorable pricing', 'Continued distribution', 'NINE MONTHS', 'External Headwinds', 'constant currencies', 'Human Expression', 'School season', 'Northern Hemisphere', 'Working Capital', 'consumer trust', 'Gonzalve Bich', '200 million euros', 'absolute terms', 'volume increase', 'price increases', 'Coloring segments', 'North America', 'Ball Pen', 'Mechanical Pen', 'added-value segments', 'overall category', 'convenience stores', 'Latin America', 'value-added products', 'Soleil ranges', 'unfavorable FX', 'positive contribution', 'value products', 'value positioning', 'key regions', 'flame occasions', '+13% growth', '2022 RESULTS', '2.5 points', '2.8 points', 'Divisions', 'Resilience', 'Clichy', 'France', 'October', 'Mexico', 'Brazil', 'India', 'Life', 'single', 'innovation', 'investments', 'OPEX', 'Improvement', 'EPS', 'End', 'September', 'ability', 'CEO', 'Story', 'acquisitions', 'volumes', 'prices', 'target', '2022 Back', 'Europe', 'classic', 'pandemic', 'teams', 'Western', 'demand', 'Flex', 'Inkbox', '1.9', '5.6', '1.1', '2.1', '7']",2022-10-27,2022-10-28,finance.yahoo.com
12253,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/27/2542442/0/en/Shell-announces-commencement-of-a-share-buyback-programme.html,Shell announces commencement of a share buyback programme,Shell plc  Shell announces commencement of a share buyback programmeOctober 27  2022Shell plc (the â€˜companyâ€™) today announces the commencement of a $4......,Shell plcShell announces commencement of a share buyback programmeOctober 27  2022Shell plc (the â€˜companyâ€™) today announces the commencement of a $4 billion share buyback programme covering an aggregate contract term of approximately three months (the â€˜programmeâ€™). The purpose of the programme is to reduce the issued share capital of the company. All shares repurchased as part of the programme will be cancelled. It is intended that  subject to market conditions  the programme will be completed prior to the companyâ€™s Q4 results announcement  scheduled for February 2  2023.The company has entered into an arrangement with a single broker consisting of three irrevocable  non-discretionary contracts  to enable the purchase of ordinary shares on both London market exchanges (the London Stock Exchange and/or on BATS and/or on Chi-X) (pursuant to two â€˜London contractsâ€™) and Netherlands exchanges (Euronext Amsterdam and/or on CBOE Europe DXE and/or on Turquoise Europe) (pursuant to one â€˜Netherlands contractâ€™) for a period up to and including January 27  2023. The aggregate maximum consideration for the purchase of ordinary shares under the London contracts is $2 billion and the maximum consideration for the purchase of ordinary shares under the Netherlands contract is $2 billion. Purchases under the London contracts will be carried out in accordance with the companyâ€™s authority1 to repurchase shares on-market and will be effected within certain contractually agreed parameters. Purchases under the Netherlands contract will be carried out in accordance with the companyâ€™s authority1 to repurchase shares off-market pursuant to the off-market share buyback contract approved by its shareholders and the parameters set out therein.The maximum number of ordinary shares which may be purchased or committed to be purchased by the company under the programme (across all three contracts) is 528 919 217  which is the maximum number remaining as of the date of this announcement pursuant to the relevant authorities granted by shareholders at the company's 2022 Annual General Meeting1.The broker will make its trading decisions in relation to the company's securities independently of the company.The programme will be conducted in accordance with Chapter 12 of the Listing Rules  Article 5 of the Market Abuse Regulation 596/2014/EU dealing with buy-back programmes (â€˜EU MARâ€™) and EU MAR as â€œonshoredâ€ into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020)  and as amended  supplemented  restated  novated  substituted or replaced including by relevant statutory instruments (including  The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310))  from time to time and the Commission Delegated Regulation (EU) 2016/1052 (the â€˜EU MAR Delegated Regulationâ€™) and the EU MAR Delegated Regulation as â€œonshoredâ€ into UK law from the end of the Brexit transition period (at 11:00 pm on 31 December 2020) through the European Union (Withdrawal) Act 2018 (as amended by the European Union (Withdrawal Agreement) Act 2020)  and as amended  supplemented  restated  novated  substituted or replaced including by relevant statutory instruments (including  The Market Abuse (Amendment) (EU Exit) Regulations (SI 2019/310))  from time to time.1 The existing shareholder authorities to buy back shares granted at the company's 2022 Annual General Meeting will expire at the earlier of the close of business on August 24  2023  and the end of the date of the company's 2023 Annual General Meeting. The company expects to seek renewal of shareholder authority to buy back shares at subsequent Annual General Meetings.EnquiriesMedia International: +44 (0) 207 934 5550Media Americas: +1 832 337 4355CAUTIONARY STATEMENTThe companies in which Shell plc directly and indirectly owns investments are separate legal entities. In this announcement â€œShellâ€  â€œShell Groupâ€ and â€œGroupâ€ are sometimes used for convenience where references are made to Shell plc and its subsidiaries in general. Likewise  the words â€œweâ€  â€œusâ€ and ourâ€ are also used to refer to Shell plc and its subsidiaries in general or to those who work for them. These terms are also used where no useful purpose is served by identifying the particular entity or entities. â€˜â€˜Subsidiariesâ€™â€™  â€œShell subsidiariesâ€ and â€œShell companiesâ€ as used in this announcement refer to entities over which Shell plc either directly or indirectly has control. Entities and unincorporated arrangements over which Shell has joint control are generally referred to as â€œjoint venturesâ€ and â€œjoint operationsâ€  respectively. â€œJoint venturesâ€ and â€œjoint operationsâ€ are collectively referred to as â€œjoint arrangementsâ€. Entities over which Shell has significant influence but neither control nor joint control are referred to as â€œassociatesâ€. The term â€œShell interestâ€ is used for convenience to indicate the direct and/or indirect ownership interest held by Shell in an entity or unincorporated joint arrangement  after exclusion of all third-party interest.Forward-Looking StatementsThis announcement contains forward-looking statements (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995) concerning the financial condition  results of operations and businesses of Shell. All statements other than statements of historical fact are  or may be deemed to be  forward-looking statements. Forward-looking statements are statements of future expectations that are based on managementâ€™s current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results  performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements include  among other things  statements concerning the potential exposure of Shell to market risks and statements expressing managementâ€™s expectations  beliefs  estimates  forecasts  projections and assumptions. These forward-looking statements are identified by their use of terms and phrases such as â€œaimâ€  â€œambitionâ€  â€˜anticipateâ€™â€™  â€˜â€˜believeâ€™â€™  â€˜â€˜couldâ€™â€™  â€˜â€˜estimateâ€™â€™  â€˜â€˜expectâ€™â€™  â€˜â€˜goalsâ€™â€™  â€˜â€˜intendâ€™â€™  â€˜â€˜mayâ€™â€™  â€œmilestonesâ€  â€˜â€˜objectivesâ€™â€™  â€˜â€˜outlookâ€™â€™  â€˜â€˜planâ€™â€™  â€˜â€˜probablyâ€™â€™  â€˜â€˜projectâ€™â€™  â€˜â€˜risksâ€™â€™  â€œscheduleâ€  â€˜â€˜seekâ€™â€™  â€˜â€˜shouldâ€™â€™  â€˜â€˜targetâ€™â€™  â€˜â€˜willâ€™â€™ and similar terms and phrases. There are a number of factors that could affect the future operations of Shell and could cause those results to differ materially from those expressed in the forward-looking statements included in this announcement  including (without limitation): (a) price fluctuations in crude oil and natural gas; (b) changes in demand for Shellâ€™s products; (c) currency fluctuations; (d) drilling and production results; (e) reserves estimates; (f) loss of market share and industry competition; (g) environmental and physical risks; (h) risks associated with the identification of suitable potential acquisition properties and targets  and successful negotiation and completion of such transactions; (i) the risk of doing business in developing countries and countries subject to international sanctions; (j) legislative  judicial  fiscal and regulatory developments including regulatory measures addressing climate change; (k) economic and financial market conditions in various countries and regions; (l) political risks  including the risks of expropriation and renegotiation of the terms of contracts with governmental entities  delays or advancements in the approval of projects and delays in the reimbursement for shared costs; (m) risks associated with the impact of pandemics  such as the COVID-19 (coronavirus) outbreak; and (n) changes in trading conditions. No assurance is provided that future dividend payments will match or exceed previous dividend payments. All forward-looking statements contained in this announcement are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Additional risk factors that may affect future results are contained in Shell plcâ€™s Form 20-F for the year ended December 31  2021 (available at www.shell.com/investor and www.sec.gov). These risk factors also expressly qualify all forward-looking statements contained in this announcement and should be considered by the reader. Each forward-looking statement speaks only as of the date of this announcement  October 27  2022. Neither Shell plc nor any of its subsidiaries undertake any obligation to publicly update or revise any forward-looking statement as a result of new information  future events or other information. In light of these risks  results could differ materially from those stated  implied or inferred from the forward-looking statements contained in this announcement.Shellâ€™s net carbon footprintAlso  in this announcement we may refer to Shellâ€™s â€œNet Carbon Footprintâ€ or â€œNet Carbon Intensityâ€  which include Shellâ€™s carbon emissions from the production of our energy products  our suppliersâ€™ carbon emissions in supplying energy for that production and our customersâ€™ carbon emissions associated with their use of the energy products we sell. Shell only controls its own emissions. The use of the term Shellâ€™s â€œNet Carbon Footprintâ€ or â€œNet Carbon Intensityâ€ are for convenience only and not intended to suggest these emissions are those of Shell plc or its subsidiaries.Shellâ€™s net-Zero Emissions TargetShellâ€™s operating plan  outlook and budgets are forecasted for a ten-year period and are updated every year. They reflect the current economic environment and what we can reasonably expect to see over the next ten years. Accordingly  they reflect our Scope 1  Scope 2 and Net Carbon Footprint (NCF) targets over the next ten years. However  Shellâ€™s operating plans cannot reflect our 2050 net-zero emissions target and 2035 NCF target  as these targets are currently outside our planning period. In the future  as society moves towards net-zero emissions  we expect Shellâ€™s operating plans to reflect this movement. However  if society is not net zero in 2050  as of today  there would be significant risk that Shell may not meet this target.Forward Looking Non-GAAP measuresThis announcement may contain certain forward-looking non-GAAP measures such as cash capital expenditure and divestments. We are unable to provide a reconciliation of these forward-looking Non-GAAP measures to the most comparable GAAP financial measures because certain information needed to reconcile those Non-GAAP measures to the most comparable GAAP financial measures is dependent on future events some of which are outside the control of Shell  such as oil and gas prices  interest rates and exchange rates. Moreover  estimating such GAAP measures with the required precision necessary to provide a meaningful reconciliation is extremely difficult and could not be accomplished without unreasonable effort. Non-GAAP measures in respect of future periods which cannot be reconciled to the most comparable GAAP financial measure are calculated in a manner which is consistent with the accounting policies applied in Shell plcâ€™s consolidated financial statements.The contents of websites referred to in this announcement do not form part of this announcement.We may have used certain terms  such as resources  in this announcement that the United States Securities and Exchange Commission (SEC) strictly prohibits us from including in our filings with the SEC. Investors are urged to consider closely the disclosure in our Form 20-F  File No 1-32575  available on the SEC website www.sec.gov.,neutral,0.01,0.99,0.0,mixed,0.32,0.19,0.5,True,English,"['share buyback programme', 'Shell', 'commencement', 'subsequent Annual General Meetings', 'three irrevocable, non-discretionary contracts', 'EU MAR Delegated Regulation', '$4 billion share buyback programme', 'market share buyback contract', 'Commission Delegated Regulation', '2022 Annual General Meeting', '2023 Annual General Meeting', 'Market Abuse Regulation', 'relevant statutory instruments', 'EU Exit) Regulations', 'London Stock Exchange', 'CBOE Europe DXE', 'The Market Abuse', 'Enquiries Media International', 'indirect ownership interest', 'Brexit transition period', 'two â€˜London contracts', 'existing shareholder authorities', 'aggregate maximum consideration', 'aggregate contract term', 'London market exchanges', 'Q4 results announcement', 'separate legal entities', 'three contracts', 'share capital', 'relevant authorities', 'three months', 'Netherlands contract', 'market conditions', 'Netherlands exchanges', 'Turquoise Europe', 'shareholder authority', 'Media Americas', 'maximum number', 'Shell interest', 'Euronext Amsterdam', 'trading decisions', 'Listing Rules', 'buy-back programmes', 'European Union', 'CAUTIONARY STATEMENT', 'particular entity', 'unincorporated arrangements', 'joint ventures', 'joint operations', 'joint arrangements', 'significant influence', 'Shell plc', 'Withdrawal Agreement', 'single broker', 'useful purpose', 'joint control', 'ordinary shares', 'Shell Group', 'Shell companies', 'UK law', 'Shell subsidiaries', 'commencement', 'October', 'company', 'February', 'purchase', 'BATS', 'Chi-X', 'January', 'accordance', 'authority1', 'parameters', 'shareholders', 'date', 'relation', 'securities', 'Chapter', 'Article', 'end', '31 December', 'time', 'close', 'business', 'August', 'renewal', 'investments', 'convenience', 'references', 'words', 'terms', 'associates', '11:00', '44']",2022-10-27,2022-10-28,globenewswire.com
12254,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/27/2543144/0/en/2022-Q3-Revenue-Report.html,2022 Q3 Revenue Report,The transition to a geographical rebalancing of revenue continues   Operational transition still underway in FranceDynamic growth of activities outside......,English FrenchThe transition to a geographical rebalancing of revenue continuesOperational transition still underway in FranceDynamic growth of activities outside FranceConfirmation of long-term outlook driven by excellent momentum outside FrancePriority given to organic growth and maintaining a financial structure with low debtGrowth to pick up in 2023 and profitability to improve in tandemIn millions of euros 9 months Q3 2022 2021 % change 2022 2021 % change Total 656.8 653.5 +0.5% 212.4 212.1 +0.1% From France 318.6 391.8 -18.7% 96.7 121.5 -20.4% From Benelux 152.1 114.2 +33.2% 53.6 39.3 +36.5% From other countries 186.1 147.5 +26.2% 62.1 51.3 +21.0%55% of group revenue generated outside of FranceConsolidated revenueIn the third quarter of 2022  Solutions 30 posted consolidated revenue of â‚¬212.4 million  up 0.1% compared to the same period in 2021 (-2.4% on an organic basis).In line with previous quarters  performance in France continues to be impacted by the operational transition linked to the maturity of certain markets. Elsewhere in Europe  activities are growing quickly as the roll-out of fiber-optic networks gets underway in most of the countries where Solutions 30 operates.For the first nine months of 2022  Solutions 30â€™s consolidated revenue amounted to â‚¬656.8 million  up +0.5% (-1.8% on an organic basis).Revenue by regionFrance: In the third quarter of 2022  Solutions 30 had revenue of â‚¬96.7 million  down 20.4% compared to the third quarter of 2021.With â‚¬68.9 million in revenue  the telecom business is down 20.0% compared to the third quarter of 2021. This decline in business reflects the maturity of the market after the record levels of activity observed during the COVID crisis  which accelerated the deployment of ultra-fast broadband in France. The industry as a wholeâ€”customers as well as service providers and subcontractorsâ€”has been forced to adapt and adjust to new ways of cooperating and to a temporary lack of visibility brought on by macroeconomic uncertainties. As a result  the operational conditions under which contracts are executed have significantly deteriorated in recent months and been aggravated by the current inflationary situation.This has implications for the entire industry and pricing renegotiations are underway. In this context  Solutions 30 is continuing its operational transition by building on its strong competitive advantages: a diversified customer and business portfolio  a healthy financial structure with little debt  and an agile organization.Revenue from the energy business amounted to â‚¬11.5 million  compared with â‚¬19.7 million a year earlier. This decline of 41.4% is due to the end of smart electricity meter deployments in France (activity down 79.6%). Even though revenue from the new energy transition and electric mobility verticals is still suffering from supply chain disruptions  it increased by 31%. However  this growth does not yet compensate for the decline in the companyâ€™s historic verticals.The IT business posted revenue of â‚¬11.2 million  stable compared to last yearâ€™s third quarter  while the security and payments business is up 12.9%  generating â‚¬5.1 million in revenue  compared to â‚¬4.5 million a year earlier.Over the first nine months of the year  revenue is down 18.7% to â‚¬318.6 million.Benelux: Revenue for the third quarter of 2022 was â‚¬53.6 million compared to â‚¬39.3 million a year earlier  representing pure organic growth of 36.5% and reflecting the excellent dynamics of the Belgian and Dutch markets.The growth of the telecom business is accelerating due to the rapid ramp-up of the contracts signed with Fiberklaar  Open Dutch Fiber  and Unifiber. Revenue from fiber activities alone increased 4.5 times over the quarter  growing the telecom business by 40.1% and resulting in quarterly revenue of â‚¬40.3 million compared to â‚¬28.8 million a year earlier.For the energy business  revenue was â‚¬9.5 million compared to â‚¬6.6 million a year earlier  a purely organic increase of 43.0%  thanks to the deployment of smart meters in Flanders on behalf of Fluvius.Quarterly revenue from the IT business remained stable at â‚¬2.1 million while revenue from the retail and security businesses was â‚¬1.7 million  compared to â‚¬1.8 million for the third quarter of 2021.Over the first nine months of 2022  revenue grew by 33.2% to â‚¬152.1 million  compared to â‚¬114.2 million a year earlier.In all other countries  the group posted quaterly revenue of â‚¬62.1 million  an increase of 21.0% (10.4% organic growth) compared to the same period in 2021.In Germany  revenue began to grow again and is up 7% to â‚¬16.2 million  compared to â‚¬15.1 million a year earlier. As expected  the efforts made by the group to adapt its organization  as well as updated pricing conditions for certain major contracts  are starting to bear fruit.In Italy  revenue grew by 19% in the third quarter of 2022 to â‚¬14.8 million  driven by the pursuit of TIMâ€™s ultra-fast infrastructure deployments in Piedmont and the Aosta Valley  which began in the first quarter of 2021.On the Iberian peninsula  revenue grew by 8% to â‚¬14.4 million  thanks to positive dynamics in the telecommunications sector (fiber and 5th generation mobile networks)  a strong uptick in installations of charging stations for electric vehicles  and pricing increases obtained from several customers.In Poland  the group posted revenue of â‚¬7.9 million  up 35% (23% organic growth). Solutions 30 continues to gain market share in this country  while the integration of Sirtel into the portfolio of activities for 5G networks is progressing well. The organization put in place will ensure the companyâ€™s ability to support its customersâ€™ growth. The mobile networks business is growing rapidly and now accounts for nearly 10% of revenue.Finally  in the United Kingdom  Solutions 30 posted â‚¬8.8 million in revenue during the quarter  up 92% (-11% on an organic basis). Solutions 30 has streamlined its operations to focus on higher-potential markets and the diversification of its services into fiber-optic networks  while the integration of Monoâ€™s operations continues.In all these countries  the group posted revenue of â‚¬186.1 million for the first nine months of 2022  an increase of 26.2% (15.8% on an organic basis) compared to the first nine months of 2021.OutlookIn response to current inflationary pressure  Solutions 30 is increasing its prices  both on new and existing contracts. The group has also taken measures to strictly control operating costs with the aim of preserving a solid financial structure with little debt. Such a structure will protect its ability to finance growth through acquisitions  increase its agility  strengthen its competitive advantages  and preserve its future capacity to pursue consolidation in its sector.In France  the market is in transition  which has led to limited short-term visibility. Against this backdrop  Solutions 30 will pursue its action plan to restore growth and a more normal level of profitability. This plan involves (i) winning marketshare in the mature telecoms sector where a second phase of consolidation is expected to take place; (ii) developing new  high-growth activities  especially in the energy sector where demand remains strong  driven by the major challenges of energy independence  the transition to new energies  and the electrification of vehicles; and (iii) seeking out synergies between the various businesses  accompanied by a reallocation of technicians to businesses with greater potential.In the Benelux and other countries  growth will remain strong through the end of the year  with the same momentum it saw in the third quarter.For the group as a whole  the fourth-quarter trend should be in line with the first nine months of the year and 2022 revenue should remain at the same levels as in 2021. The increase in the EBITDA margin at the end of the year is subject to ongoing price negotiations.From 2023  Solutions 30 should return to more dynamic growth  driven by the development momentum of its activities outside France. It should also see an overall improvement in its profitability. The group has solid growth drivers and an effective model to self-finance its development  both of which will help it consolidate its position at the crossroads of the digital transformation and the energy transition.Upcoming event2022 Q4 Revenue and 2022 Annual Revenue Reports | January 26  2022About Solutions 30 SEThe Solutions 30 group is the European leader in solutions for new technologies. Its mission is to make the technological developments that are transforming our daily lives accessible to everyone  individuals and businesses alike. Yesterday  it was computers and the Internet. Today  itâ€™s digital technology. Tomorrow  it will be technologies that make the world even more interconnected in real time. With more than 50 million call-outs carried out since it was founded and a network of more than 15 000 local technicians  Solutions 30 currently covers all of France  Italy  Germany  the Netherlands  Belgium  Luxembourg  the Iberian Peninsula  the United Kingdom  and Poland. The share capital of Solutions 30 SE consists of 107 127 984 shares  equal to the number of theoretical votes that can be exercised.Solutions 30 SE is listed on the Euronext Paris exchange (ISIN FR0013379484- code S30). Indexes: MSCI Europe ex-UK Small Cap | SBF 120 | CAC Mid 60 | NEXT 150 | CAC Technology | CAC PME.Visit our website for more information: www.solutions30.comContactIndividual Shareholders:Investor Relations - Tel: +33 1 86 86 00 63 - shareholders@solutions30.comAnalysts/Investors:Nathalie Boumendil - Tel: +33 6 85 82 41 95 - nathalie.boumendil@solutions30.comPress - Image 7:Charlotte Le Barbier - Tel: +33 6 78 37 27 60 - clebarbier@image7.frLeslie Jung - Tel: +33 6 78 70 05 55 - ljung@image7.frAttachment,neutral,0.0,1.0,0.0,mixed,0.36,0.07,0.57,True,English,"['2022 Q3 Revenue Report', 'smart electricity meter deployments', 'current inflationary situation', 'strong competitive advantages', 'supply chain disruptions', 'ultra-fast infrastructure deployments', 'electric mobility verticals', 'first nine months', 'healthy financial structure', 'Open Dutch Fiber', 'pure organic growth', 'new energy transition', 'smart meters', 'first quarter', 'ultra-fast broadband', 'new ways', 'historic verticals', 'recent months', 'energy business', 'organic basis', 'English French', 'geographical rebalancing', 'Operational transition', 'long-term outlook', 'excellent momentum', 'low debt', 'same period', 'previous quarters', 'fiber-optic networks', 'record levels', 'COVID crisis', 'service providers', 'temporary lack', 'macroeconomic uncertainties', 'operational conditions', 'pricing renegotiations', 'diversified customer', 'little debt', 'excellent dynamics', 'Dutch markets', 'rapid ramp-up', 'pricing conditions', 'Aosta Valley', 'Iberian penin', 'third quarter', 'telecom business', 'business portfolio', 'IT business', 'payments business', 'fiber activities', 'organic increase', 'Dynamic growth', 'other countries', 'entire industry', 'agile organization', 'last year', 'security businesses', 'major contracts', 'Consolidated revenue', 'quarterly revenue', 'group revenue', '9 months', 'France', 'Confirmation', 'Priority', 'profitability', 'tandem', 'millions', 'euros', 'change', 'Benelux', 'Solutions', 'line', 'performance', 'maturity', 'Europe', 'roll', 'region', 'activity', 'customers', 'subcontractors', 'visibility', 'result', 'implications', 'context', 'end', 'company', 'Belgian', 'Fiberklaar', 'Unifiber', 'Flanders', 'behalf', 'Fluvius', 'retail', 'Germany', 'efforts', 'fruit', 'Italy', 'pursuit', 'TIM', 'Piedmont', '4', '2']",2022-10-27,2022-10-28,globenewswire.com
12255,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/27/2543159/0/en/EXEL-Industries-4th-quarter-2021-2022-sales-up-22-8.html,EXEL Industries: 4th quarter 2021â€“2022 sales up 22.8%,Fourth quarter 2021â€“2022 sales up 22.8%  Record Q4 organic growth driven by agricultural equipment   Q4 sales(July 2022â€“September......,English FrenchFourth quarter 2021â€“2022 sales up 22.8%Record Q4 organic growthdriven by agricultural equipmentQ4 sales(July 2022â€“September 2022)2020â€“2021 2021â€“2022 Change in value(â‚¬m) Change(%) Reported Reported Reported LFL* Reported LFL* AGRICULTURAL SPRAYING88.9 122.5 +33.6 +26.5 +37.8% +29.9% SUGAR BEET HARVESTERS71.7 85.3 +13.5 +9.5 +18.9% +13.3% LEISURE23.1 28.1 +5.0 -2.2 +21.7% -9.6% INDUSTRY58.7 61.7 +3.0 +0.2 +5.1% +0.3% EXEL Industries Group 242.4 297.5 +55.2 +34.0 +22.8% +14.0%12-month sales(October 2021â€“September 2022)2020â€“2021 2021â€“2022 Change in value(â‚¬m) Change(%) Reported Reported Reported LFL* Reported LFL* AGRICULTURAL SPRAYING380.9 442.3 +61.4 +48.2 +16.1% +12.7% SUGAR BEET HARVESTERS135.5 146.3 +10.8 +5.2 +8.0% +3.8% LEISURE132.4 138.9 +6.5 -26.9 +4.9% -20.3% INDUSTRY227.9 249.5 +21.6 +12.5 +9.5% +5.5% EXEL Industries Group 876.8 977.0 +100.3 +39.0 +11.4% +4.4%* Like-for-like (LFL) = at constant foreign exchange rates and scopeQ4 2021â€“2022 salesThe EXEL Industries Group posted record sales of â‚¬297.5 million for the fourth quarter of 2021â€“2022  up 22.8%  driven by both external (changes in consolidation scope and foreign exchange rates  notably USD) and internal factors  mainly organic growth in agricultural equipment. At constant consolidation scope and foreign exchange rates  the Group recorded growth of 14.0%  despite persistent supply chain issues in its various businesses  particularly in agricultural spraying and sugar beet harvesters.The change in consolidation scope arising from the Groupâ€™s two recent acquisitions (EXEL Yachting and G.F.) contributed â‚¬5.2 million to fourth quarter sales.AGRICULTURAL SPRAYING: UP 37.8%After peaking in spring 2022  accentuated by the conflict in Ukraine  agricultural commodity prices fell slightly during the summer and stabilized at levels still well above pre-COVID prices. Against this backdrop  demand remained strong in all regions  particularly North America  while the component shortage shows no sign of abating.The exceptionally well-stocked order book enabled the various Group companies to mitigate sales seasonality and carry out a significant amount of billing during the quarter.SUGAR BEET HARVESTERS: UP 18.9%After a third quarter particularly impacted by component shortages and a resurgence of COVID in Germany  business caught up strongly in the fourth quarter  resulting in record billings for sales of sugar beet harvesters.LEISURE: UP 21.7%The garden equipment market declined in the Groupâ€™s three main operating regions (the United Kingdom  France and Italy). In this context and after a series of challenging quarters (IT migration)  Q4 business came close to the previous yearâ€™s levels  bolstered by a more favorable basis of comparison than in previous quarters.The EXEL Yachting business posted a satisfactory quarterly performance with deliveries in line with forecasts.INDUSTRY: UP 5.1%At constant consolidation scope and foreign exchange rates  business was stable during the quarter: technical hoses and industrial spraying saw a slight slowdown in volumes in Europe  offset by ongoing robust momentum in Asia and  to a lower extent  the USA.Situation in Ukraine and RussiaThe new sanctions announced in early October do not affect Group products any more than the previous sanctions. As previously announced  EXEL Industries has maintained its operations in Russia (agricultural equipment and industrial spraying) but has taken care to ensure that deliveries are made in compliance with international regulations. The Group has been able to maintain overall sales volumes in the region.FY 2021â€“2022 salesFull-year 2021â€“2022 sales amounted to â‚¬977.0 million  up 11.4%. Growth at constant consolidation scope and foreign exchange rates was 4.4%. EXEL Industriesâ€™ concern was to adjust prices across all of its business lines  in response to rising raw material and component costs. This policy implemented throughout the year offset certain volume declines due to shortages (mainly agricultural equipment) or to the market slowdown (gardening). The currency effect was particularly favorable to the agricultural spraying and industry segments.The change in consolidation scope represented sales of â‚¬29.8 million for the year.AGRICULTURAL SPRAYING: UP 16.1%The agricultural spraying business was impacted by varying trends during the year: on the one hand  Group brands were hard hit by persisting component shortages despite very different production bases (Europe  the USA). Prices were increased throughout the period in order to pass on price increases implemented by supplier. On the other hand  order intake was boosted by the stabilization of agricultural commodity prices at globally high levels  giving the Group clear visibility over the coming fiscal year.SUGAR BEET HARVESTERS: UP 8.0%After recovering in 2020â€“2021  sales remained strong during the fiscal year ended. In addition  component shortages allowed the Group to clear a large volume of used machine inventories. Lastly  prices were increased to offset increases in production costs (steel and other components).LEISURE: UP 4.9%The gardening business was impacted by three factors during the year. After two exceptional years in terms of volumes  markets returned to pre-COVID levels. Meanwhile  challenges related to the migration of IT systems curbed leisure business volumes by around â‚¬10 million. Prices were increased during the year to offset significant increases in the cost of raw materials and logistics. Lastly  the acquisition of G.F. on February 15  2022  resulted in a scope effect increasing sales for this activity by approximately â‚¬20 million.A new sales  marketing and industrial drive launched in the nautical business is expected to impact the coming years.INDUSTRY: UP 9.5%The underlying markets (mainly automotive  furniture and industry) experienced contrasting trends. However  the industrial spraying business continued to post high volumes throughout the year in line with the previous year.The technical hose division was impacted by declining volumes in the gardening business  while the B2B business was impacted by falling demand towards the end of the year.Yves Belegaud  Chief Executive Officer of the EXEL Industries Group  said:â€œThe strong commitment of our teams in the fourth quarter and the successful integration of our latest acquisitions allowed us to post record sales. This excellent performance was achieved in a challenging and volatile environment in which shortages have not been recovered. However  the Group is confident in its ability to continue its development  underpinned by the various business sectors in which it operates and a well-stocked order book.â€Upcoming eventsDecember 20  2022  before market opening: 2021â€“2022 full-year results.January 25  2023  before market opening: Q1 2022â€“2023 sales.About EXEL IndustriesEXEL Industries is a French family-owned group that designs  manufactures and markets capital equipment and provides associated services that enable its customers to improve efficiency and productivity or enhance their well-being while achieving their CSR objectives.Driven by an innovation strategy for 70 years  EXEL Industries has based its development on innovative ideas designed to offer customers unique  efficient  competitive and user-friendly products.Since its inception  the Group has recorded significant growth in each of its markets through both organic growth and corporate acquisitions  underpinned by a stable shareholder base guided by a long-term development strategy. EXEL Industries employs approximately 3 546 permanent employees spread across 27 countries and five continents.The Group posted FY 2020â€“2021 sales of â‚¬877 million.Euronext Paris  SRD Long only â€“ compartment B (Mid Cap) EnterNextÂ© PEA-PME 150 index (symbol: EXE/ISIN FR0004527638)Press release available onsite www.EXEL-industries.comYves BELEGAUDChief Executive Officeryves.belegaud@EXEL-industries.com Thomas GERMAINGroup Chief Financial Officer / Investor relationsdirection.communication@EXEL-industries.comAttachment,neutral,0.0,0.99,0.0,mixed,0.33,0.05,0.61,True,English,"['EXEL Industries', '4th quarter', 'sales', 'persistent supply chain issues', 'three main operating regions', 'constant foreign exchange rates', 'The EXEL Yachting business', 'Record Q4 organic growth', 'The EXEL Industries Group', 'agricultural equipment Q4 sales', 'SUGAR BEET HARVESTERS', 'two recent acquisitions', 'satisfactory quarterly performance', 'ongoing robust momentum', 'rising raw material', 'different production bases', 'garden equipment market', 'constant consolidation scope', 'LFL* AGRICULTURAL SPRAYING', 'agricultural commodity prices', 'various Group companies', 'coming fiscal year', 'agricultural spraying business', 'overall sales volumes', 'fourth quarter sales', 'Q4 business', 'The Group', 'record billings', 'various businesses', 'market slowdown', 'record sales', 'industrial spraying', 'business lines', 'English French', 'external (changes', 'internal factors', 'G.F.', 'North America', 'component shortage', 'significant amount', 'United Kingdom', 'challenging quarters', 'IT migration', 'favorable basis', 'previous quarters', 'technical hoses', 'slight slowdown', 'lower extent', 'new sanctions', 'Group products', 'previous sanctions', 'international regulations', 'component costs', 'volume declines', 'currency effect', 'varying trends', 'one hand', 'Group brands', 'price increases', 'other hand', 'clear visibility', 'large volum', 'third quarter', '12-month sales', 'order book', 'previous year', 'order intake', 'COVID prices', 'early October', 'high levels', 'industry segments', 'shortages', '2022 sales', 'July', 'September', 'value', 'LEISURE', 'spring', 'conflict', 'Ukraine', 'summer', 'backdrop', 'demand', 'abating', 'seasonality', 'resurgence', 'Germany', 'France', 'Italy', 'context', 'series', 'comparison', 'deliveries', 'forecasts', 'Europe', 'Asia', 'USA', 'Situation', 'Russia', 'operations', 'care', 'compliance', 'FY', 'Full-year', 'concern', 'response', 'policy', 'gardening', 'period', 'supplier', 'stabilization', 'addition']",2022-10-27,2022-10-28,globenewswire.com
12256,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/27/2542433/0/en/GeoJunxion-GOJXN-AS-is-pleased-to-publish-its-2021-22-Annual-Accounts-for-the-year-ending-30-June-2022-showing-significant-improvements-in-all-financial-KPIs-including-positive-cas.html,GeoJunxion (GOJXN.AS) is pleased to publish its 2021-22 Annual Accounts for the year ending 30 June 2022  showing significant improvements in all financial KPIs  including positive cash-flow.,Capelle aan den IJssel  The Netherlands â€“ 27 October 2022 â€“ GeoJunxion (GOJXN.AS) publishes its 2021-22 Annual Accounts for the 12-months accounting year ending 30 June 2022  showing significant improvements in all financial KPIs  including positive cash-flow.,English DutchCapelle aan den IJssel  The Netherlands â€“ 27 October 2022 â€“ GeoJunxion (GOJXN.AS) publishes its 2021-22 Annual Accounts for the 12-months accounting year ending 30 June 2022  showing significant improvements in all financial KPIs  including positive cash-flow.We are pleased to present the GeoJunxion Annual Report for the accounting year 2021-22. It covers the 12-months period from 1 July 2021 to 30 June 2022. We remark that comparative financials for the past accounting year 2020-21 relate to the 18-months period from 1 January 2020 to 30 June 2021.A full copy of the GeoJunxion Annual Report 2021/22 is attached to this press release and can be found on the companyâ€™s website www.geojunxion.com  under the Investor Relations and Financial News sections.The 2021-22 accounting year was  once again  an eventful period during which the company continued its transformation and turnaround. For the third year in a row  we realized a substantial top line growth  while slightly reducing operating expenses  on a like for like basis. We also achieved Cash-Flow positive  as well as significant improvements on all the other financial KPIs. This is even more remarkable  because it was achieved during a time still impacted by the COVID-19 pandemic and increasing concerns about the global economy due to the ramifications of the war in Ukraine with high energy prices and increased inflation.A summary of the key financials is provided in the table below:Due to the change in the period of the accounting year 2020-21 (to 18 months)  it is more difficult to analyze and compare the financials of the accounting year 2021-22 with the previous accounting years. As already remarked  the current accounting year covers the period from 1 July 2021 to 30 June 2022 (12 months)  while the previous accounting year 2020-21 covers the period from 1 January 2020 to 30 June 2021 (18 months). Additionally  the accounting year 2019 was based on a 12-month period but from 1 January 2019 to 31 December 2019. To enable easier comparison  we also include below the income statement for the current accounting year and the pro-forma income statement for the two previous years  covering the same 12-months period from 1 July to 30 June the following year. This enables a clearer view of the revenue growth and significant improvements in all financial KPIs  comparing the same period.Revenue increased year-over-year by 40% to â‚¬2.371.000 in 2021-22 compared to â‚¬1.698.000 in the same period in 2020-21. It is very encouraging to highlight that this growth is not only due to non-recurring service revenue  but also the recurring service revenue increased substantially year-over-year (+72%) and recurring licenses remained essentially stable compared with the previous year.Costs for maps and data increased by 20 8% compared to the 12-months period of the prior year. These costs are related to content purchased to maintain and enrich the database and to hosting cost for delivering our data solutions via the cloud.Personnel expenses decreased in 2021-22  showing a 3% saving compared to the same period in 2020-21 despite a 40% higher revenue. The main drivers for this are a reduction in certain management roles in February 2022 and lower use of outsourced resources in the Netherlands and India during the second half of the accounting year.The depreciation cost on tangible fixed assets remained nearly flat year over year while amortization costs on intangible assets slightly increased. This increase is due to higher capitalized development costs and the amortization of these assets. Capitalized development costs are currently amortized over a period of 7 years  while before 2018  they were amortized over a longer period (15 to 20 years). Note that the book value of the database is subject to impairment testing. This means that the book value is compared to the value in use for the company. Per 30 June 2022  an impairment test was executed. This did not show a requirement for any additional impairment loss.Other operating expenses decreased more than 13% compared to the same period in 2020-21. This is the result of the implementation of a strict spending review  cost control measures  integration of tools and simplification of the group structure.Total Operating Expenses showed a reduction of 3% and Net Operating Expenses showed a reduction of 7% compared with the previous 12-months period. This confirms the general positive mood in which the company is operating today  capable of â€œdelivering more with lessâ€.Operating Result  despite still negative  shows an improvement of 63%  while the Net Loss was reduced by 46%  compared with the previous year.The net cash flow from operating activities in 2021-22 amounted to a positive cash inflow of â‚¬131.000 compared to cash outflow of â‚¬1.035.000 in the same period in 2020-21. This is primarily due to the significant improvement in the operating result and more favorable invoicing and collection terms negotiated with our customers and suppliers. During the accounting year 2021-22 there were no financing transactions  while  during the 2020-21 12-months period  a private placement was completed in December 2020  raising â‚¬825.000 in equity funding.As an independent player  GeoJunxion focuses on creating â€œmap agnosticâ€ products  i.e.  designed to be fully integrated into any commercial and open-source brand of maps or utilized in developing smart solutions for a large variety of use cases in different industries and market sectors.GeoJunxion activities are directed towards establishing long-term relationships with its customers  through the creation of a recurring business model rather than one-off projects or transactions. Although the relationship may start with a proof-of-concept or a one-off project  most of our high value datasets require frequent and continuous updates to maintain or increase their value. As a result  the one-off project or proof-of-concept is often only a first step  followed by a recurring service or a license contract. As a result  converting the initial  one-off project into a recurring  predictable and sustainable revenue stream. In most cases  GeoJunxion also retains the IP and ownership of the newly developed datasets which can then be resold to other customers  thereby leveraging the initial investment and converting it into a virtuous business cycle.The GeoJunxion mission remains focused on improving road safety and contributing to a more sustainable world  reducing the environmental impact through intelligent solutions which enable more environmentally conscious decisions.GeoJunxion has valued diversity  integration and investment in social responsibility for years. We are committed to offering our daily contribution towards a better and more sustainable work environment. For this reason  the company has applied for PSO certification in 2020. PSO is the Dutch abbreviation for â€œPrestatieladder Socialer Ondernemenâ€  Performance ladder Social Entrepreneurship. In July 2022 we achieved Level 2 PSO certification  as one of the first publicly listed organizations in the Netherlands.FINANCIAL OUTLOOKLooking at the future  despite the general uncertainty pictured by the European Central Bank  GeoJunxion expects to see its top line to continue growing by 25 to 30% year over year. This expectation is built on orders booked in the first quarter of 2022-23 and a solid pipeline of opportunities. As a result of inflationary pressure and growing staff costs to deliver the projects  we expect our cost base to increase by 5 to 10%. GeoJunxion is reasonably confident to convert the above-mentioned guidance into positive EBITDA and EBIT close to break-even. On this basis  cash flow is  once again  expected to be positive for the accounting year 2022-23.FORWARD-LOOKING STATEMENTS / IMPORTANT NOTICEThis document contains certain forward-looking statements with respect to the financial position and results of GeoJunxion. We have based these forward-looking statements on our current expectations and projections about future events. This includes assumptions regarding our present and future business strategies  operations  and the environment in which we will operate in the future. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements  and you should not place undue reliance on them.Many of these risks and uncertainties relate to factors that are beyond the companyâ€™s ability to control or estimate precisely  such as timing of placement of orders of our customers  exchange-rate and interest-rate fluctuations  labor and other cost inflation  changes in tax rates  regulatory and legal changes  the rate of technological change  the competitive landscape  political developments in countries in which the company operates and the risk of a slowdown in the market.The forward-looking statements contained herein speak only as of the date they are made. We do not assume any obligation to update any public information or forward-looking statement in this document to reflect events or circumstances after the date of this document  except as may be required by applicable laws.Signed byThe Management BoardThe Supervisory BoardThis is a public announcement by GeoJunxion N.V.  pursuant to article 17  paragraph 1 of the European Market Abuse Regulation (596/2014). This public announcement does not constitute an offer  or solicitation of an offer  to buy or offer securities in GeoJunxion N.V.E ndsAbout GeoJunxionGeoJunxion is the crossroads where fundamental  location-aware content connects with superior  customised intelligence and highly focused innovations to empower exceptional experiences. With an emphasis on safety and sustainability  we are constantly expanding our portfolio to meet the demands of a diverse and fast-evolving market. Building on decades of experience in mapping  the company focuses on high value  dynamic content and building environmentally conscious applications  which enrich safety in everyday life. With location-aware content at our core  we know where our strengths lie and have the know-how and technology needed to offer unrivalled  intelligent products and services.GeoJunxion NV is listed on the regulated market of Euronext Amsterdam  under the symbol GOJXN.AS.GeoJunxion Press ContactTel: +31 (0)10 885 1200Email: info@geojunxion.comAttachments,positive,0.5,0.49,0.01,mixed,0.48,0.1,0.42,True,English,"['2021-22 Annual Accounts', 'GOJXN.AS', 'significant improvements', 'financial KPIs', 'positive cash-flow', 'GeoJunxion', 'year', '30 June', 'Capelle aan den IJssel', 'substantial top line growth', 'higher capitalized development costs', '2021-22 Annual Accounts', 'high energy prices', 'strict spending review', 'general positive mood', 'Financial News sections', 'GeoJunxion Annual Report', 'net cash flow', 'positive cash inflow', 'Other operating expenses', 'Total Operating Expenses', 'pro-forma income statement', 'tangible fixed assets', 'cost control measures', 'two previous years', 'recurring service revenue', 'other financial KPIs', 'additional impairment loss', 'Net Operating Expenses', 'past accounting year', '2021-22 accounting year', 'current accounting year', 'previous accounting years', '12-months accounting year', 'previous 12-months period', 'same 12-months period', '40% higher revenue', 'Net Loss', 'recurring licenses', 'cash outflow', 'Personnel expenses', 'revenue growth', 'operating activities', 'impairment testing', 'to 20 years', 'positive cash-flow', 'third year', 'prior year', 'Operating Result', 'same period', 'English Dutch', 'GOJXN.AS', 'significant improvements', 'full copy', 'press release', 'Investor Relations', 'COVID-19 pandemic', 'global economy', 'easier comparison', 'clearer view', 'main drivers', 'management roles', 'outsourced resources', 'second half', 'depreciation cost', 'intangible assets', 'group structure', 'favorable invoicing', 'collection terms', 'financing tran', '18-months period', 'eventful period', '12-month period', 'longer period', 'amortization costs', 'comparative financials', 'key financials', 'book value', 'The Netherlands', 'data solutions', 'lower use', '7 years', '27 October', '30 June', '1 July', '1 January', 'company', 'website', 'transformation', 'turnaround', 'like', 'basis', 'time', 'concerns', 'ramifications', 'war', 'Ukraine', 'inflation', 'summary', 'table', 'change', '18 months', '31 December', 'maps', 'content', 'database', 'cloud', '3% saving', 'reduction', 'February', 'India', 'increase', 'requirement', 'implementation', 'integration', 'tools', 'simplification', 'less', 'customers', 'suppliers']",2022-10-27,2022-10-28,globenewswire.com
12257,EuroNext,NewsApi.org,https://ca.sports.yahoo.com/news/cegedim-growth-continued-third-quarter-154500523.html,Cegedim: Growth continued in the third quarter of 2022,PRESS RELEASE Quarterly financial information as of September 30  2022IFRS - Regulated information - Not audited Cegedim: Growth continued in the third quarter of 2022 Q3 2022 revenues grew 6.7%All operating divisions contributed to growthGrowth for the firstâ€¦,Cegedim SAPRESS RELEASEQuarterly financial information as of September 30  2022IFRS - Regulated information - Not auditedCegedim: Growth continued in the third quarter of 2022Q3 2022 revenues grew 6.7%All operating divisions contributed to growthGrowth for the first nine months came to 6.6%Cegedim SantÃ©: starting to rev its enginesBoulogne-Billancourt  France  October 27  2022  after the market closeRevenueThird quarter Change Q3 2022 / 2021 First 9 months Change 9M 2022 / 2021 in millions of euros 2022 2021 Reported Like for like 2022 2021 Reported Like for like(1)(2) Software & services 75.2 71.3 +5.5% +3.7% 220.8 211.5 +4.4% +3.3% Flow 21.5 19.8 +8.8% +8.8% 66.7 61.5 +8.5% +8.4% Data & Marketing 22.8 21.8 +4.5% +3.7% 72.8 66.5 +9.4% +9.1% BPO 13.0 11.4 +13.6% +13.6% 38.4 34.4 +11.8% +11.8% Corporate and others 0.8 0.5 +41.1% +41.1% 2.1 2.0 +2.5% +2.5% Cegedim 133.3 124.8 +6.7% +5.6% 400.8 376.0 +6.6% +5.9%(1) At constant scope and exchange rates.(2) The positive currency impact of 0.2% was mainly due to the pound sterling. The positive scope effect of 0.5% was attributable to the first-time consolidation of Kobus Tech  Mesdocteurs  Laponi and Clinityx.Consolidated third quarter revenues rose 6.7% as reported and 5.6% like for like(1) compared with the same period in 2021.Revenues to end-September rose 6.6% as reported and 5.9% like for like(1) compared with the same period in 2021  confirming the healthy trajectory we saw in the second quarter.Analysis of business trends by divisionSoftware & ServicesSoftware and Services Third quarter Change Q3 2022 / 2021 First 9 months Change 9M 2022 / 2021 in millions of euros 2022 2021 Reported Like for like 2022 2021 Reported Like for like Cegedim SantÃ© 18.5 15.4 +20.0% +12.6% 50.3 45.9 +9.5% +5.9% Insurance  HR  Pharmacies and other services 44.7 42.3 +5.7% +5.5% 134.5 126.3 +6.5% +6.4% International businesses 12.0 13.6 (11.6)% (11.6)% 36.0 39.3 (8.4)% (9.8)% Software & Services 75.2 71.3 5.5% 3.7% 220.8 211.5 4.4% 3.3%Cegedim SantÃ©â€™s capital increase allowed it to implement a development plan that has boosted its like-for-like growth rate into the double digits over the third quarter.Story continuesThe divisionâ€™s other businesses in France posted growth rates in line with their business plans: Software & Services for clients in the insurance  HR  and pharmacy sectors all made positive contributions through end-September.On the other hand  international businesses are still awaiting a turnaround. Computerization services for healthcare professionals in the UK are a good example  as tender offers by UK health authorities arenâ€™t scheduled to take place until late 2023.FlowFlow Third quarter Change Q3 2022 / 2021 First 9 months Change 9M 2022 / 2021 in millions of euros 2022 2021 Reported Like for like 2022 2021 Reported Like for like e-business 12.9 11.3 +13.5% +13.6% 40.1 35.3 +13.5% +13.4% Third-party payment 8.6 8.4 +2.5% +2.5% 26.6 26.2 +1.7% +1.7% Flow 21.5 19.8 8.8% 8.8% 66.7 61.5 8.5% 8.4%Process digitalization and electronic data flows continue to do well both in France and abroad  with growth in the double digits. The clear recovery seen in Germany and the UK in the first half continued in the third quarter  boosting the weight of international business to 13% of the total.Third-party payment flows in France decreased during the pandemic but have ramped back up as healthcare spending has risen in France.Data & MarketingData & Marketing Third quarter Change Q3 2022 / 2021 First 9 months Change 9M 2022 / 2021 in millions of euros 2022 2021 Reported Like for like 2022 2021 Reported Like for like Data 14.3 13.0 +10.1% +8.7% 40.4 37.2 +8.5% +8.1% Marketing 8.5 8.8 (3.7)% (3.7)% 32.4 29.3 +10.5% +10.5% Data & Marketing 22.8 21.8 4.5% 3.7% 72.8 66.5 9.4% 9.1%The data business continued its strong showing from the first half. Clinityx  which the Group acquired in July  is now consolidated in this unit.The majority of the Groupâ€™s marketing activities are non-recurring  and the business did not manage to repeat its second-quarter performance. It was disadvantaged by the comparison with the post-Covid recovery in Q3 2021. Even so  cumulative growth to end-September was still above 10%.BPOBPO Third quarter Change Q3 2022 / 2021 First 9 months Change 9M 2022 / 2021 in millions of euros 2022 2021 Reported Like for like 2022 2021 Reported Like for like Insurance BPO 8.1 7.1 +13.8% +13.8% 23.7 21.8 +9.0% +9.0% HR BPO 4.9 4.3 +13.3% +13.3% 14.7 12.6 +16.5% +16.5% BPO 13.0 11.4 13.6% 13.6% 38.4 34.4 11.8% 11.8%BPO services continue to expandâ€”both for clientsâ€™ HR departments and for insurance companies and mutualsâ€”and third-quarter growth was in the double digits.HighlightsApart from the items cited below  to the best of the companyâ€™s knowledge  there were no events or changes during Q3 2022 that would materially alter the Groupâ€™s financial situation.War in UkraineThe Group does not do business in Russia or Ukraine and has no assets exposed to those countries.Acquisition of SediaOn July 19  2022  Cegedim e-business rounded out its Hospitalis offering by acquiring Sedia.Sedia has specialized in software that tracks medical instrumentation usage since 1985. Thanks to this acquisition  Hospitalis now offers a medical device and implantable medical device (MD/IMD) tracking service. The service is responsible for 900 000 scans annually and has tracked more than 8 million IMDs. The newest component in the Hospitalis range  Sedia offers health  financial  and logistical tracking of MD/IMDs that are on consignment or have been lent or purchased outright.Sedia is profitable. It will begin contributing to the Groupâ€™s consolidation scope on August 1  2022.Acquisition of ClinityxOn July 28  2022  Cegedim strengthened its position in the real-world data sector by acquiring Clinityx.Clinityx  a health start-up founded in 2018  aims to make real-word data research easier by providing a robust scientific  technical  and regulatory environment. Clinityx partners with academic establishments to build data warehouses paired with the SNDS  the French administrative healthcare database  enriching the health data and ensuring their good governance and security. The company also provides consulting services and manages all aspects of real-world studies from protocol design to final report  using data from its own warehouses  the SNDS  and other databases.Clinityx is profitable. It began contributing to the Groupâ€™s consolidation scope on August 1  2022.Significant transactions and events post September 30  2022Allianz contractAllianz France and Cegedim Insurance Solutionsâ€”a major provider of software solutions and services for the personal protection insurance sectorâ€”have signed a 15-year strategic partnership under which Allianz will outsource the management of insurance policy portfolios in the Group Health  Individual Health  and Group Personal Protection segments in France to Cegedim Insurance Solutions. The deal covers 1.3 million beneficiaries. As part of the partnership  the Allianz France staff that currently perform these duties will be transferred to Cegedim.OutlookBased on 9M 2022 revenues up 5.9% like for like(1)  and despite the public health  economic  geopolitical  and monetary uncertainty facing the world  the Group is confident it can grow revenues by 5% like for like(1) in 2022.There is a delay of several months between wage increases and the annual increase in salaries indexed to  for example  the Syntec index in France. The negative impact of that delay  combined with the Cegedim SantÃ© development plan launch  will be a headwind for recurring operating income.WEBCAST ON OCTOBER 27  2022  AT 6:15 PM PARIS TIME The webcast is available at: www.cegedim.fr/webcast The 9M 2022 revenues presentation is available:On the website: https://www.cegedim.fr/finance/documentation/Pages/presentations.aspxAnd on the Cegedim IR smartphone app  available at https://www.cegedim.fr/finance/profil/Pages/CegedimIR.aspx202 3 Financial calendar2023 January 26 after the close FY 2022 revenuesFinancial Calendar available on the website: https://www.cegedim.com/finance/agenda/Pages/default.aspxDisclaimerThis press release is available in French and in English. In the event of any difference between the two versions  the original French version takes precedence. This press release may contain inside information. It was sent to Cegedimâ€™s authorized distributor on October 27  2022  no earlier than 5:45 pm Paris time.The figures cited in this press release include guidance on Cegedim's future financial performance targets. This forward-looking information is based on the opinions and assumptions of the Groupâ€™s senior management at the time this press release is issued and naturally entails risks and uncertainty. For more information on the risks facing Cegedim  please refer to Chapter 7  â€œRisk managementâ€  section 7.2  â€œRisk factors and insuranceâ€  and Chapter 3  â€œOverview of the financial yearâ€  section 3.6  â€œOutlookâ€  of the 2021 Universal Registration Document filled with the AMF on April 1st  2022  under number D.22-0232.About Cegedim:Founded in 1969  Cegedim is an innovative technology and services company in the field of digital data flow management for healthcare ecosystems and B2B  and a business software publisher for healthcare and insurance professionals. Cegedim employs more than 5 600 people in more than 10 countries and generated revenue of â‚¬525 million in 2021.Cegedim SA is listed in Paris (EURONEXT: CGM).To learn more  please visit: www.cegedim.frAnd follow Cegedim on Twitter@CegedimGroup  LinkedIn and Facebook.Aude BalleydierCegedimMedia Relationsand Communications ManagerTel.: +33 (0)1 49 09 68 81aude.balleydier@cegedim.frJÃ©rÃ´me MoreauCegedimGroup Controller Directorin charge of the Financial CommunicationTel.: +33 (0)1 46 10 72 62jerome.moreau@cegedim.comCÃ©line Pardo.BecomingMedia RelationsTel.: +33 (0)6 52 08 13 66cegedim@becoming-group.comAnnexesBreakdown of revenue by quarter and divisionYear 2022in â‚¬ million Q1 Q2 Q3 Q4 Total Software & services 71.2 74.4 75.2 220.8 Flow 22.6 22.6 21.5 66.7 Data & marketing 22.5 27.6 22.8 72.8 BPO 12.3 13.1 13.0 38.4 Corporate and others 0.7 0.7 0.8 2.1 Group revenue 129.2 138.3 133.3 400.8Year 2021in â‚¬ million Q1 Q2 Q3 Q4 Total Software & services 68.8 71.4 71.3 80.4 292.0 Flow 21.0 20.7 19.8 22.7 84.2 Data & marketing 19.9 24.8 21.8 31.9 98.4 BPO 11.7 11.2 11.4 13.0 47.3 Corporate and others 1.0 0.5 0.5 0.7 2.7 Group revenue 122.5 128.7 124.8 148.7 524.7Breakdown of revenue by geographic zone  currency and division at September 30  2022as a % of consolidated revenuesGeographic zone Currency France EMEAex. France Americas Euro GBP Others Software & services +83.7% +16.2% +0.1% +86.6% +11.7% +1.7% Flow +92.5% +7.5% +0.0% +95.5% +4.5% +0.0% Data & marketing +97.6% +2.4% +0.0% +97.6% +0.0% +2.4% BPO +100.0% +0.0% +0.0% +100.0% +0.0% +0.0% Corporate and others +99.6% +0.4% +0.0% +100.0% +0.0% +0.0% Cegedim 89.3% 10.6% 0.1% 91.4% 7.2% 1.4%Attachment,neutral,0.01,0.99,0.0,mixed,0.44,0.19,0.37,True,English,"['third quarter', 'Cegedim', 'Growth', 'First 9 months Change 9M', 'Consolidated third quarter revenues', 'BPO Third quarter Change', 'Flow Third quarter Change', 'first nine months', 'positive currency impact', 'positive scope effect', 'Quarterly financial information', 'Third-party payment flows', 'UK health authorities', 'electronic data flows', 'clientsâ€™ HR departments', 'first half', 'second quarter', 'positive contributions', 'Regulated information', 'constant scope', 'financial situation', 'PRESS RELEASE', 'operating divisions', 'exchange rates', 'pound sterling', 'first-time consolidation', 'Kobus Tech', 'same period', 'healthy trajectory', 'International businesses', 'capital increase', 'development plan', 'double digits', 'other businesses', 'other hand', 'healthcare professionals', 'good example', 'tender offers', 'Process digitalization', 'clear recovery', 'healthcare spending', 'strong showing', 'second-quarter performance', 'Covid recovery', 'Q3 2022 revenues', 'HR BPO', 'Cegedim SA', 'business trends', 'business plans', 'growth rate', 'cumulative growth', 'insurance companies', 'third-quarter growth', 'other services', 'Computerization services', 'Insurance BPO', 'The Group', 'BPO services', 'marketing activities', 'data business', 'division Software', 'September', 'IFRS', 'engines', 'Boulogne-Billancourt', 'France', 'millions', 'euros', 'Corporate', 'others', 'Mesdocteurs', 'Laponi', 'Clinityx', 'Analysis', 'Pharmacies', 'Story', 'line', 'sectors', 'turnaround', 'place', 'Germany', 'weight', 'total', 'pandemic', 'July', 'unit', 'majority', 'comparison', 'mutuals', 'Highlights', 'items', 'company', 'knowledge', 'events', 'changes', 'Ukraine', 'Russia', 'assets', 'countries', 'Acquisition', 'Sedia']",2022-10-27,2022-10-28,ca.sports.yahoo.com
12258,EuroNext,NewsApi.org,https://ca.sports.yahoo.com/news/danone-making-progress-renew-danone-154500680.html,Danone: Making progress on Renew Danone Further growth acceleration in the third quarter,2022 Third-Quarter SalesPress release â€“ Paris  October 27  2022 Making progress on Renew DanoneFurther growth acceleration in the third quarter Q3 net sales up +19.1% on a reported basis and +9.5% on a like-for-like (LFL) basis  with price up +10.9%  and voluâ€¦,DANONE2022 Third-Quarter SalesPress release â€“ Paris  October 27  2022Making progress on Renew DanoneFurther growth acceleration in the third quarterQ3 net sales up +19.1% on a reported basis and +9.5% on a like-for-like (LFL) basis  with price up +10.9%  and volume/mix down -1.4%; proforma volume/mix -0.2% excluding EDP RussiaAccelerated like-for-like sales growth in all geographies and categories +11.2% in North America driven by balanced competitive growth across categories +6.0% in Europe led by Specialized Nutrition and Waters +6.8% in China  North Asia & Oceania led by Specialized Nutrition in China and EDP in Japan +13.6% in Rest of the World with price-led growth across all countries and categoriesPortfolio management: initiation of a process to transfer the effective control of the EDP Russia business2022 guidance upgraded: LFL net sales growth now expected between +7 and +8%  versus +5 to +6% previously; recurring operating margin above 12% confirmed1Antoine de Saint-Affrique: CEO statementâ€œIn what remains a challenging environment  we continue to display consistent progress in all aspects of our Renew agenda  with active portfolio management and a disciplined approach to boosting our winners  fixing our underperformers and driving our core  as exemplified by the ongoing transformation of our European dairy platform.Q3 was another quarter of strong growth  with sales up +9.5% on a like-for-like basis  led by a sequential growth acceleration across all our categories and geographies. We now expect LFL sales growth between +7 and +8% in the full-year 2022.We continue to implement pricing actions in a responsible and disciplined manner  while focusing on the quality of our execution and reinvesting behind our brands and capabilities. This shows in the performance of our Specialized Nutrition business  led by Aptamil  in Waters  where our evian  Bonafont and Aqua brands continue to perform strongly in the marketplace  but also in EDP  with the resilience of portfolio  notably in the US  Canada and Japan.â€Story continuesI. 2022 THIRD-QUARTER SALESâ‚¬ million except % Q32021 Q32022 Reported change LFL SalesGrowth Volume/Mix Growth 9M2021 9M2022 Reported change LFL SalesGrowth Volume/MixGrowthBY GEOGRAPHICAL ZONE Europe 2 122 2 246 +5.9% +6.0% -2.0% 6 264 6 628 +5.8% +5.6% +0.4% North America2 1 413 1 813 +28.3% +11.2% +1.0% 4 120 4 953 +20.2% +8.6% +1.5% China  North Asia & Oceania2 801 940 +17.3% +6.8% +5.2% 2 231 2 611 +17.0% +7.8% +5.8% Rest of the World 1 822 2 335 +28.1% +13.6% -5.9% 5 396 6 509 +20.6% +11.0% -3.0%BY CATEGORY EDP3 3 269 3 862 +18.1% +6.3% -6.0% 9 686 10 946 +13.0% +5.2% -3.6% Specialized Nutrition 1 777 2 134 +20.1% +12.2% +3.3% 5 294 6 174 +16.6% +11.0% +5.3% Waters 1 112 1 338 +20.4% +14.4% +4.4% 3 031 3 580 +18.1% +12.3% +4.2% TOTAL 6 158 7 334 +19.1% +9.5% -1.4% 18 011 20 700 +14.9% +8.1% +0.4%In the third quarter of 2022  consolidated sales stood at â‚¬7.3 bn  up +9.5% on a like-for-like basis  with price up +10.9% and volume/mix down -1.4%. On a reported basis  sales increased by +19.1%  benefiting notably from a positive forex impact of +7.6%  reflecting in particular the appreciation of the US dollar and various Asian and Latin American currencies against the euro. Reported sales were also driven by a positive organic contribution of hyperinflation geographies to growth of +1.4%  as well as a slightly negative scope effect of -0.2%  resulting mainly from the impact of the disposal of Vega.Performance by geographical zoneEUROPEEurope posted sales growth of +6.0% in Q3 2022 on a like-for-like basis  driven by +8.0% growth in price  while volume/mix declined by -2.0%. EDP registered +2.2% growth in the region  with a contrasted performance by geography  with sales and volumes impacted by portfolio choices and temporary delivery suspensions in some countries such as Germany and Belgium. Other countries benefited from the good momentum of key brands like Actimel  Danone  Yopro and Danette. Specialized Nutrition posted +9.5% growth  led by Aptamil  which registered broad-based and competitive growth in the quarter. Waters reported +9.2% growth  supported by all brands.NORTH AMERICANorth America sales were up by +11.2% in Q3 2022 on a like-for-like basis. Growth was balanced and competitive  driven by accelerated pricing  up +10.2%  and by the continued roll-out of Revenue Growth Management (RGM) initiatives  leading to resilient volume/mix  at +1.0%. In EDP  growth was led by both Dairy  with International Delight  Activia and Oikos up double digits  and Plant-based  with Silk up high single digits. Growth in the region was also sustained by the strong momentum in Waters and Specialized Nutrition.CHINA  NORTH ASIA & OCEANIAChina  North Asia & Oceania posted sales growth of +6.8% in Q3 2022 on a like-for-like basis  with price up +1.6% and volume/mix up +5.2%. In China  Infant Milk Formula sales registered competitive growth on a high base  led by Aptamil  which continued to gain share in international and domestic labels. Adult Nutrition and Pediatric Specialties registered another quarter of outstanding growth  while in Waters  Mizoneâ€™s performance improved sequentially and market shares stabilized  despite challenging operating conditions. Beyond China  sales in Japan accelerated further  led by Bio and Oikos functional propositions.REST OF THE WORLDRest of the World registered sales growth of +13.6% in Q3 2022 on a like-for-like basis  driven by price up +19.5%  while volume/mix declined by -5.9%. Excluding EDP Russia  volume/mix was down -1.7% in the region. In Indonesia  sales increased by double digits  led by Aqua in Waters and by SGM and Bebelac in Specialized Nutrition  with resilient market share supported by disciplined execution. In Latin America  sales were up double digits  with all categories contributing.II. 2022 GUIDANCE UPGRADEDPrice-led like-for-like sales growth now expected between +7 and +8%  versus +5 to +6% previously; recurring operating margin expected above 12%.III. MAJOR DEVELOPMENTS OVER THE PERIODAugust 31  2022 : Danone successfully issued a â‚¬600 million bond with a 10-year maturity and a 3.071% coupon. The settlement took place on September 7  2022  and the bonds are listed on Euronext Paris.October 3  2022: Danone announced that two senior leaders  Gilbert Ghostine  Chief Executive Officer of Firmenich  and Lise Kingo  former Chief Executive Officer and Executive Director of the United Nations Global Compact  have been co-opted to join the Board of Directors as independent members  starting October 15 and December 1 respectively. They will replace Guido Barilla and CÃ©cile Cabanis.October 14  2022: Danone has initiated a process to transfer the effective control of its EDP business in Russia  considering that this is the best option to ensure long-term local business continuity for its employees  consumers and partners. Once closed  the transaction  which will be subject to regulatory approvals  will result in the deconsolidation of Danoneâ€™s EDP Russia business. It could result in a write-off of up to â‚¬1 billion3.Proforma Like-for-like sales growth and volume/mix growth by quarter excluding EDP Russia business (unaudited figures):Q1 2022 Q2 2022 Q3 2022 LFL SalesGrowth Volume/Mix Growth LFL SalesGrowth Volume/Mix Growth LFL SalesGrowth Volume/Mix Growth Rest of the World incl. EDP Russia +7.0% -2.2% +12.3% -0.8% +13.6% -5.9% Rest of the World excl. EDP Russia +7.9% -0.1% +14.9% +4.2% +16.9% -1.7% Total Company incl. EDP Russia +7.1% +2.2% +7.7% +0.9% +9.5% -1.4% Total Company excl. EDP Russia +7.3% +3.0% +8.1% +2.2% +10.0% -0.2%October 24  2022: Danone and Royal Unibrew agreed not to complete the contemplated sale to Royal Unibrew of Aqua dâ€™Or  Danoneâ€™s Water and Beverageâ€™s business in Denmark  that was announced on November 16  2021. The Parties have determined that they will not be able to fulfil the closing conditions  including the approval by the Danish Competition and Consumer Authority. The Parties have therefore withdrawn the notification of the transaction to the Danish Competition and Consumer Authority. Aqua dâ€™Or remains under review.IV. IFRS STANDARDS AND FINANCIAL INDICATORS NOT DEFINED IN IFRSIAS29: impact on reported dataDanone has been applying IAS 29 in hyperinflation countries as defined in IFRS  except for Turkey in view of the unmaterial impact. Adoption of IAS 29 in these hyperinflationary countries requires its non-monetary assets and liabilities and its income statement to be restated to reflect the changes in the general pricing power of its functional currency  leading to a gain or loss on the net monetary position included in the net income. Moreover  its financial statements are converted into euros using the closing exchange rate of the relevant period.IAS 29: impact on reported dataâ‚¬ million except % Q3 2022 Sales 1.4 Sales growth (%) +0.02%Breakdown by quarter of 9M 2022 sales after application of IAS 299M 2022 sales correspond to the addition of:Q3 2022 reported sales;Q1 and Q2 2022 sales resulting from the application of IAS29 until September 30  2022 to sales of entities of hyperinflation countries (application of the inflation rate until September 30  2022 and translation into euros using September 30  2022 closing rate) and provided in the table below for information (unaudited data).â‚¬ million Q1 20221 Q2 20222 Q3 2022 9M 2022 Europe 2 114 2 267 2 246 6 628 North America 1 477 1 662 1 813 4 953 China  North Asia & Oceania 735 936 940 2 611 Rest of the World 1 936 2 237 2 335 6 509 Total 6 263 7 103 7 334 20 7001Results from the application of IAS29 until September 30  2022 to Q1 sales of entities of hyperinflation countries.2Results from the application of IAS29 until September 30  2022 to Q2 sales of entities of hyperinflation countries.Financial indicators not defined in IFRSDue to rounding  the sum of values presented may differ from totals as reported. Such differences are not material.Like-for-like changes in sales  recurring operating income and recurring operating margin reflect Danone's organic performance and essentially exclude the impact of:changes in consolidation scope  with indicators related to a given fiscal year calculated on the basis of previous-year scope  both previous-year and current-year scopes excluding entities in countries under hyperinflation according to IAS 29 during the previous year (as for Argentinian entities since January 1 st   2019  and except for Turkey);changes in applicable accounting principles;changes in exchange rates with both previous-year and current-year indicators calculated using the same exchange rates (the exchange rate used is a projected annual rate determined by Danone for the current year and applied to both previous and current years).Bridge from reported data to like-for-like data(â‚¬ million except %) Q3 2021 Like-for-like change Impact of changesin scope of consolidation Impact of changes in exchange rates & others incl. IAS29 Organic contribution from hyperinflation countries Reported change Q3 2022 Sales 6 158 +9.5% -0.2% +8.4% +1.4% +19.1% 7 334Recurring operating income is defined as Danoneâ€™s operating income excluding Other operating income and expenses. Other operating income and expenses comprise items that  because of their significant or unusual nature  cannot be viewed as inherent to Danoneâ€™s recurring activity and have limited predictive value  thus distorting the assessment of its recurring operating performance and its evolution. These mainly include:capital gains and losses on disposals of fully consolidated companies;impairment charges on intangible assets with indefinite useful lives;costs related to strategic restructurings or transformation plans;costs related to major external growth transactions;costs related to major crisis and major litigations;in connection with of IFRS 3 (Revised) and IAS 27 (Revised) relating to business combinations  (i) acquisition costs related to business combinations  (ii) revaluation profit or loss accounted for following a loss of control  and (iii) changes in earn-outs relating to business combinations and subsequent to acquisition date.Recurring operating margin is defined as Recurring operating income over Sales ratio.o o O o oFORWARD-LOOKING STATEMENTSThis press release contains certain forward-looking statements concerning Danone. In some cases  you can identify these forward-looking statements by forward-looking words  such as â€œestimateâ€  â€œexpectâ€  â€œanticipateâ€  â€œprojectâ€  â€œplanâ€  â€œintendâ€  â€œobjectiveâ€  â€œbelieveâ€  â€œforecastâ€  â€œguidanceâ€  â€œforeseeâ€  â€œlikelyâ€  â€œmayâ€  â€œshouldâ€  â€œgoalâ€  â€œtargetâ€  â€œmightâ€  â€œwillâ€  â€œcouldâ€  â€œpredictâ€  â€œcontinueâ€  â€œconvincedâ€ and â€œconfident â€ the negative or plural of these words and other comparable terminology. Forward looking statements in this document include  but are not limited to  predictions of future activities  operations  direction  performance and results of Danone.Although Danone believes its expectations are based on reasonable assumptions  these forward-looking statements are subject to numerous risks and uncertainties  which could cause actual results to differ materially from those anticipated in these forward-looking statements. For a detailed description of these risks and uncertainties  please refer to the â€œRisk Factorâ€ section of Danoneâ€™s Universal Registration Document (the current version of which is available at www.danone.com ).Subject to regulatory requirements  Danone does not undertake to publicly update or revise any of these forward-looking statements. This document does not constitute an offer to sell  or a solicitation of an offer to buy Danone securities.The presentation to analysts and investors will be broadcast live today from 6:00 p.m. (Paris time)on Danoneâ€™s website ( www.danone.com ) .Related slides will also be available on the website in the Investors section.APPENDIX â€“ Sales by geographical zone and by category (in â‚¬ million)First quarter Second quarter Third quarter 2021 2022 2021 2022 2021 2022BY GEOGRAPHICAL ZONE Europe 1 987 2 114 2 155 2 267 2 122 2 246 North America4 1 316 1 477 1 391 1 662 1 413 1 813 China  North Asia & Oceania2 598 735 832 936 801 940 Rest of the World 1 756 1 909 1 793 2 202 1 822 2 335BY CATEGORY EDP3 3 149 3 365 3 254 3 684 3 269 3 862 Specialized Nutrition 1 719 1 919 1 793 2 106 1 777 2 134 Waters 790 951 1 125 1 277 1 112 1 338 TOTAL 5 657 6 236 6 171 7 067 6 158 7 334First quarter2022 Second quarter 2022 Third quarter2022 Reported change Like-for-like change Reported change Like-for-like change Reported change Like-for-like changeBY GEOGRAPHICAL ZONE Europe +6.4% +5.7% +5.2% +5.1% +5.9% +6.0% North America1 +12.2% +5.5% +19.5% +8.9% +28.3% +11.2% China  North Asia & Oceania2 +22.9% +15.3% +12.5% +3.3% +17.3% +6.8% Rest of the World +8.7% +7.0% +22.8% +12.3% +28.1% +13.6%BY CATEGORY EDP +6.9% +3.6% +13.2% +5.6% +18.1% +6.3% Specialized Nutrition +11.7% +9.5% +17.5% +11.4% +20.1% +12.2% Waters +20.5% +15.9% +13.6% +7.9% +20.4% +14.4% TOTAL +10.2% +7.1% +14.5% +7.7% +19.1% +9.5%All references in this document to Like-for-like (LFL) changes  Recurring operating margin  correspond to financial indicators not defined in IFRS. Their definitions  as well as their reconciliation with financial statements  are listed on pages 4 and 5.1United States and Canada; 2China  Japan  Australia and New Zealand; 3Essential Dairy and Plant-based3Based on the accounts and foreign exchange rates as of June 30th  20221United States and Canada; 2China  Japan  Australia and New Zealand; 3Essential Dairy and Plant-basedAttachment,neutral,0.06,0.94,0.0,mixed,0.61,0.12,0.28,True,English,"['growth acceleration', 'third quarter', 'Renew Danone', 'progress', 'Infant Milk Formula sales', 'LFL net sales growth', 'LFL Sales Growth Volume', 'recurring operating margin', 'Antoine de Saint-Affrique', 'Latin American currencies', 'positive organic contribution', 'negative scope effect', 'temporary delivery suspensions', 'European dairy platform', 'positive forex impact', 'I. 2022 THIRD-QUARTER SALES', 'active portfolio management', 'Revenue Growth Management', 'sequential growth acceleration', 'Specialized Nutrition business', 'Q3 net sales', 'EDP Russia business', 'North America sales', 'GEOGRAPHICAL ZONE Europe', 'proforma volume', 'LFL) basis', 'consolidated sales', 'North Asia', 'North America2', 'Press release', 'competitive growth', 'price-led growth', 'effective control', 'CEO statement', 'challenging environment', 'Renew agenda', 'disciplined approach', 'ongoing transformation', 'strong growth', 'disciplined manner', 'CATEGORY EDP3', 'various Asian', 'portfolio choices', 'good momentum', 'continued roll-out', 'RGM) initiatives', 'double digits', 'single digits', 'strong momentum', 'domestic labels', 'Adult Nutri', 'third quarter', 'consistent progress', 'pricing actions', 'Aqua brands', 'US dollar', 'key brands', 'International Delight', 'high base', 'Renew Danone', 'Mix Growth', 'hyperinflation geographies', 'Other countries', 'resilient volume/mix', '+8.0% growth', '+2.2% growth', '+9.5% growth', '+9.2% growth', 'Paris', 'categories', 'balanced', 'Waters', 'China', 'Oceania', 'Japan', 'Rest', 'World', 'initiation', 'process', '2022 guidance', 'aspects', 'winners', 'underperformers', 'core', 'full-year', 'responsible', 'quality', 'execution', 'capabilities', 'performance', 'Aptamil', 'evian', 'Bonafont', 'marketplace', 'resilience', 'Canada', 'Story', 'change', 'TOTAL', 'appreciation', 'disposal', 'Vega', 'region', 'contrasted', 'geography', 'volumes', 'Germany', 'Belgium', 'Actimel', 'Yopro', 'Danette', 'broad-based', 'Oikos', 'Silk', 'share']",2022-10-27,2022-10-28,ca.sports.yahoo.com
12259,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/27/2542388/0/en/THIRD-QUARTER-2022-SALES.html,THIRD-QUARTER 2022 SALES,THIRD-QUARTER 2022 SALES Record quarter with same-day sales growth up 16.3%Acceleration in volume growth capturing electrification trends &...,"English FrenchTHIRD-QUARTER 2022 SALESRecord quarter with same-day sales growth up 16.3%Acceleration in volume growth capturing electrification trends & additional selling price increase2022 guidance upgraded for the second timeâ†’ Sales of â‚¬4 816.6m in Q3 2022  up +16.3% on a same-day basis  accelerating after a robust start to the yearâ†’ Record quarter driven by acceleration in volume growth (c. 750bps contribution in Q3 22 vs +60bps in Q2 22)  demonstrating our ability to fully capture the boost in electrification  notably in Europeâ†’ Strong selling price increase on non-cable products in all geographies (900bps contribution)  reflecting pass-through of the rise in production costsâ†’ Robust growth in our three end-markets with Residential  Commercial and Industrial up double digitsâ†’ Double-digit growth in all three geographies. Strong momentum in the US reflecting good underlying demand and internal transformationâ†’ Strategic focus on organic growth and M&A translating into +35.5% reported sales growth in Q3 22â†’ Digital penetration up c. +240bps  representing c. 25% of Group revenues in Q3 22  with +467bps improvement in the US  now at c. 18% of digital salesâ†’ FY 22 guidance upgraded for same-day sales growth and adjusted Ebita marginâ†’ Share buyback with â‚¬60m completed (c. 3.7 million shares)Key figures (â‚¬m) Q3 2022 YoY change 9m 2022 YoY change Sales on a reported basis 4 816.6 +35.5% 13 899.4 +31.0% On a constant and actual-day basis +15.5% +15.4% On a constant and same-day basis +16.3% +14.7% Same-day sales growth by geography Europe 2 292.5 +15.9% 6 947.5 +13.2% France 808.3 +10.2% 2 570.8 +9.3% Scandinavia 292.3 +21.2% 878.8 +14.0% Benelux 268.0 +27.0% 792.1 +19.8% Germany 258.8 +25.7% 726.6 +19.4% UK 194.8 +9.5% 613.9 +12.2% North America 2 142.3 +17.3% 5 893.0 +18.5% US 1 753.6 +18.1% 4 788.2 +19.5% Canada 388.7 +14.0% 1 104.8 +14.3% Asia-Pacific 381.8 +12.7% 1 058.9 +5.0% China 164.2 +12.7% 453.4 +1.7% Australia 161.8 +12.7% 445.5 +7.4%Guillaume TEXIER  Chief Executive Officer  said:â€œRexel benefited in the third quarter from solid underlying markets as well as accelerating demand for electrification  driven by the high price of energy  especially in Europe. These results and trends enable us to upgrade our full-year targets for 2022  which should be another record year  both in sales and profitability.Our strong third quarter is also an excellent illustration of how our new strategy  Power Up 2025  allows us to tap into high growth segments of the electrical materials market  driven by powerful and resilient mega trends such as sustainability  energy transition or resource and labor scarcity.These trends  combined with a very strong backlog and our relentless focus on efficiency and digital  position us well for the future  in an economic environment that continues to offer little visibility.â€SALES REVIEW FOR THE PERIOD ENDED SEPTEMBER 30  2022Unless otherwise stated  all comments are on a constant and adjusted basis and  for sales  at same number of working days.SALESIn Q3  sales were up +35.5% year-on-year on a reported basis and +16.3% on a constant and same-day basis  reflecting positive momentum in all three geographies.Key figures (â‚¬m) Q3 2022 YoY change 9m 2022 YoY change Sales on a reported basis 4 816.6 +35.5% 13 899.4 +31.0% On a constant and actual-day basis +15.5% +15.4% On a constant and same-day basis +16.3% +14.7%In the third quarter  Rexel posted record sales of â‚¬4 816.6m  up +35.5% on a reported basis  with a well-balanced contribution from both organic growth and M&A. It includes :A positive constant and same-day sales growth of +16.3%A negative calendar effect of (0.8)%A positive currency effect of â‚¬235.2m (i.e. +6.6% of Q3 2021 sales)   mainly due to the appreciation of the US & Canadian dollars against the euro;  mainly due to the appreciation of the US & Canadian dollars against the euro; A positive net scope effect of â‚¬380.7m (i.e. +10.7% of Q3 2021 sales)  mainly due to Mayer acquisition in the US.On a constant and same-day basis  sales were up +16.3% resulting from :Accelerating trends in all 3 geographies with North America up +17.3%  Europe up +15.9% and Asia-Pacific up +12.7%.Robust volume growth  reflecting favorable underlying demand as well as our ability to benefit from electrification trends and growing demand for energy efficiency solutions amid rising energy costs  as illustrated by above-Group average growth of product categories such as PV  EV or HVAC.By geography :North America is up +10.1% in volume in the quarter  twice the Q2 22 growth of +5.1%  notably thanks to favorable trends in Project activity and sustained demand in ProximityEurope is up +5.7% in volume vs (0.5)% in Q2 22 on market share gains  an easier base effect and strong demand in electrificationAsia-Pacific is up +4.1% in volume vs (13.6)% in Q2 22  benefiting from the post-lockdown recovery in China and positive momentum in Australia.A favorable pricing environment for non-cable products (900bps contribution in the quarter)  resulting from an additional rise recorded in Q3 2022  offsetting the lower expected carryover effect of price increases passed in 2021. Those additional rises in selling price result from the overall rise of production costs from our suppliers  notably reflecting increases in wages and energy costs.A neutral copper-cable price contribution (-0.2% contribution in Q3 2022)  resulting from the lower copper price during the quarter compared to Q3 21.Further growth in digitalization in all three geographies  with a strong increase in the US. Digital sales now represent c. 25% of sales  up c. 240bps  with North America up +409bps (16.9% of sales)  Europe up +127bps (35.2% of sales) and Asia-Pacific up +49bps (5.5% of sales).In the quarter  supply chain tensions improved slightly overall  with the exception of semi-conductors. This â€œscarcity environmentâ€ continues to be an opportunity for Rexel  as we help our customers deal with product and labor availability shortages to unlock productivity gains.In 9m 2022  Rexel posted sales of â‚¬13 899.4m   up +31.0% on a reported basis  including:A positive constant and same-day sales growth of +14.7% including a positive impact of +1.9% from the change in copper-based cable prices (vs a positive impact of +5.2% in 9m 2021)A positive calendar effect of +0.7%A positive currency effect of â‚¬516.2m (i.e. +4.9% of 9m 2021 sales)  mainly due to the appreciation of the US & Canadian dollars against the euroA positive net scope effect of â‚¬916.1m (i.e. +8.6% of 9m 2021 sales)  mainly resulting from the acquisition of Mayer in the USEurope (48% of Group sales): +15.9% in Q3 on a constant and same-day basisIn the third quarter  sales in Europe increased by +15.9% on a reported basis  including a positive currency effect of +0.6%  or â‚¬10.9m  mainly due to the appreciation of the Swiss Franc against the euro and a positive scope effect of +0.7%  or â‚¬14.3m  resulting from the acquisition of Trilec in Belgium. The calendar effect stood at (1.5)% in the quarter. On a constant and same-day basis  sales were up +15.9% in Q3 accelerating versus +10.4% posted in Q2 22.Key figures (â‚¬m) Q3 2022 YoY change 9m 2022 YoY change Europe 2 292.5 +15.9% 6 947.5 +13.2% France 808.3 +10.2% 2 570.8 +9.3% Scandinavia 292.3 +21.2% 878.8 +14.0% Benelux 268.0 +27.0% 792.1 +19.8% Germany 258.8 +25.7% 726.6 +19.4% UK 194.8 +9.5% 613.9 +12.2% Switzerland 158.7 +6.3% 451.7 +5.2%Overall in Europe  sales growth acceleration is largely driven by the boost in volumes (+5.7% in Q3 22 vs (0.5)% in Q2 22)  resulting from market outperformance  a more favorable base effect and robust demand in electrification product categories: PV  HVAC  EV (12% of sales) were up more than 80%  contributing for 650bps to same-day sales growth in the quarter. In an environment of rising energy prices  the payback of energy efficiency projects has been significantly shortened  from 9 years on average to up to 1 year depending on countries. In addition  through PV solutions  customers increase their energy autonomy.Sales in France (35% of the regionâ€™s sales) were up +10.2%  driven by continued market share gains amid labor and product scarcity. The environment remains favorable in the renovation construction business (both residential and commercial). Electric Vehicles  Photovoltaic and HVAC contributed for c. 200bps. The quarter was also marked by higher digital penetration (c. 29% of sales  up c. 260bps).(35% of the regionâ€™s sales) were up +10.2%  driven by continued market share gains amid labor and product scarcity. The environment remains favorable in the renovation construction business (both residential and commercial). Electric Vehicles  Photovoltaic and HVAC contributed for c. 200bps. The quarter was also marked by higher digital penetration (c. 29% of sales  up c. 260bps). Sales in Scandinavia (13% of the regionâ€™s sales) were up +21.2%. Robust sales growth in Sweden  the largest country  was driven by the Residential market  largely boosted by our ability to serve PV demand. The Commercial and Industrial segments also contributed to the overall growth.(13% of the regionâ€™s sales) were up +21.2%. Robust sales growth in Sweden  the largest country  was driven by the Residential market  largely boosted by our ability to serve PV demand. The Commercial and Industrial segments also contributed to the overall growth. Benelux (12% of the regionâ€™s sales) grew by +27.0%  thanks to renewable energy products (PV/EV/HVAC representing 18% of sales  up c. 90% yoy and contributing for 1 110bps)  in a context of rising energy prices.(12% of the regionâ€™s sales) grew by +27.0%  thanks to renewable energy products (PV/EV/HVAC representing 18% of sales  up c. 90% yoy and contributing for 1 110bps)  in a context of rising energy prices. Sales in Germany (11% of the regionâ€™s sales) posted strong +25.7% growth  with further market share gains while increasing business selectivity. Growth during the quarter was supported by Residential and Industrial markets. PV demand was a major growth driver (up c. 280%  contributing for 1 270bps)  driven by the focus on increasing the countryâ€™s energy independence in the context of the war in Ukraine. Industrial demand was driven by machine manufacturers  automotive and energy & water markets.(11% of the regionâ€™s sales) posted strong +25.7% growth  with further market share gains while increasing business selectivity. Growth during the quarter was supported by Residential and Industrial markets. PV demand was a major growth driver (up c. 280%  contributing for 1 270bps)  driven by the focus on increasing the countryâ€™s energy independence in the context of the war in Ukraine. Industrial demand was driven by machine manufacturers  automotive and energy & water markets. In the UK (8% of the regionâ€™s sales)  sales increased by +9.5%  mostly from the Commercial segment. The country benefited from a strong selling price contribution to compensate for currency depreciation on imported products.North America (44% of Group sales): +17.3% in Q3 on a constant and same-day basisIn the third quarter  sales in North America increased by +70.0% on a reported basis  including a positive currency effect of +15.5%  or â‚¬195.6m  from the appreciation of the US & Canadian dollars against the euro  and a positive scope effect of +29.3%  or â‚¬368.7m  from the acquisition of Mayer and  to a lesser extent  Horizon Solutions in the US. On a constant and same-day basis  sales were up +17.3%  driven by the US and Canada.Key figures (â‚¬m) Q3 2022 YoY change 9m 2022 YoY change North America 2 142.3 +17.3% 5 893.0 +18.5% United States 1 753.6 +18.1% 4 788.2 +19.5% Gulf Central +40.8% +38.4% Mountain Plains +38.6% +36.1% California +33.5% +20.1% Midwest +28.9% +20.8% Florida +21.5% +21.6% Northwest +15.2% +20.0% Southeast +13.8% +13.9% Northeast +13.6% +6.9% Mayer +2.7% +11.6% Canada 388.7 +14.0% 1 104.8 +14.3%In the US (82% of the regionâ€™s sales)  sales posted solid +18.1% growth on a same-day basis  accelerating compared to Q2 22 with above average trends in Gulf Central (Industrial automation and Oil & Gas)  Mountain Plains (Commercial segment in large cities) and California (Commercial business). By market  all three end-markets grew at a similar pace with further positive development in Commercial  Residential and Industrial. We recorded a growth acceleration in our Projects activity and a steady level of order intake.(82% of the regionâ€™s sales)  sales posted solid +18.1% growth on a same-day basis  accelerating compared to Q2 22 with above average trends in Gulf Central (Industrial automation and Oil & Gas)  Mountain Plains (Commercial segment in large cities) and California (Commercial business). By market  all three end-markets grew at a similar pace with further positive development in Commercial  Residential and Industrial. We recorded a growth acceleration in our Projects activity and a steady level of order intake. In Canada (18% of the regionâ€™s sales)  sales grew by +14.0% on a same-day basis. It was notably driven by the Industrial end-market up c. 25%  contributing for c. 1 060bps notably boosted by robust demand in oil & gas and mining  contributing to growth for 190bps and 100bps respectively.Asia-Pacific (8% of Group sales): +12.7% in Q3 on a constant and same-day basisIn the third quarter  sales in Asia-Pacific were up +20.6% on a reported basis  including a positive currency effect of +9.1%  or â‚¬28.7m  mainly due to the appreciation of the Chinese renminbi and the Australian dollar against the euro and a negative scope effect of (0.7)%  or â‚¬(2.3)m  related to the disposal of Rexel Saudi Arabia in Q4 2021. On a constant and same-day basis  sales were up +12.7%.Key figures (â‚¬m) Q3 2022 YoY change 9m 2022 YoY change Asia-Pacific 381.8 +12.7% 1 058.9 +5.0% China 164.2 +12.7% 453.4 +1.7% Australia 161.8 +12.7% 445.5 +7.4%In the Pacific (51% of the regionâ€™s sales)  sales were up +14.8% on a constant and same-day basis: In Australia (83% of Pacificâ€™s sales)  sales increased by +12.7%  accelerating from 5% in Q2  driven by robust growth in all segments  particularly Commercial  amid labor scarcity.In Asia (49% of the regionâ€™s sales)  sales increased by +10.6% on a constant and same-day basis: In China (88% of Asiaâ€™s sales)  sales were up +12.7%. The acceleration post lockdown was supported by demand from machinery  automotive  power and renewables. The quarter benefited from selling price increases.FY 2022 OUTLOOKFollowing stronger than projected activity  we are upgrading our FY 22 guidance for the second time.We now anticipate for 2022  at comparable scope of consolidation and exchange rates:Same-day sales growth of c. 12% (vs 7%-9% previously)An adjusted EBITA 1 margin of c. 7.2%  including 70bps of non-recurring items (vs 6.7%  including 50bps of non-recurring items)margin of c. 7.2%  including 70bps of non-recurring items (vs 6.7%  including 50bps of non-recurring items) Free cash flow conversion2 above 60% (unchanged)1 Excluding (i) amortization of PPA and (ii) the non-recurring effect related to changes in copper-based cable prices.2 FCF Before interest and tax/EBITDAaLNB: The estimated impacts per quarter of (i) calendar effects by geography  (ii) changes in the consolidation scope and (iii) currency fluctuations (based on assumptions of average rates over the rest of the year for the Group's main currencies) are detailed in appendix 2.CALENDARFebruary 16  2023 Full-year 2022 resultsApril 20  2023 First-quarter 2023 salesApril 20  2023 Annual Shareholdersâ€™ MeetingFINANCIAL INFORMATIONA slideshow of the third quarter 2022 sales is available on the Groupâ€™s website.ABOUT REXEL GROUPRexel  worldwide expert in the multichannel professional distribution of products and services for the energy world  addresses three main markets: residential  commercial  and industrial. The Group supports its residential  commercial  and industrial customers by providing a tailored and scalable range of products and services in energy management for construction  renovation  production  and maintenance. Rexel operates through a network of over 1 900 branches in 24 countries  with more than 26 000 employees. The Groupâ€™s sales were â‚¬14.7 billion in 2021.Rexel is listed on the Eurolist market of Euronext Paris (compartment A  ticker RXL  ISIN code FR0010451203). It is included in the following indices: CAC Next 20  SBF 120  CAC Large 60  CAC 40 ESG  CAC AllTrade  CAC AllShares  FTSE EuroMid  and STOXX600. Rexel is also part of the following SRI indices: FTSE4Good  Dow Jones Sustainability Index Europe  Euronext Vigeo Europe 120 and Eurozone 120  STOXXÂ® Global ESG Environmental Leaders  and S&P Global Sustainability Yearbook 2022  in recognition of its performance in terms of Corporate Social Responsibility (CSR).For more information  visit www.rexel.com/en.CONTACTSFINANCIAL ANALYSTS / INVESTORSLudovic DEBAILLEUX +33 1 42 85 76 12 ludovic.debailleux@rexel.comPRESSBrunswick: Thomas KAMM +33 1 53 96 83 92 tkamm@brunswickgroup.comGLOSSARYREPORTED EBITA (Earnings Before Interest  Taxes and Amortization) is defined as operating income before amortization of intangible assets recognized upon purchase price allocation and before other income and other expenses.ADJUSTED EBITA is defined as Reported EBITA excluding the estimated non-recurring net impact from changes in copper-based cable prices.EBITDA (Earnings Before Interest  Taxes  Depreciation and Amortization) is defined as operating income before depreciation and amortization and before other income and other expenses.EBITDAaL is defined as EBITDAafter deduction of lease payment following the adoption of IFRS16.RECURRING NET INCOME is defined as net income restated for non-recurring copper effect  other expenses and income  non-recurring financial expenses  net of tax effect associated with the above items.FREE CASH FLOW is defined as cash from operating activities minus net capital expenditure.NET DEBT is defined as financial debt less cash and cash equivalents. Net debt includes debt hedge derivatives.APPENDIXFor appendix  please open the pdf file by clicking on the link at the end of the press release.DISCLAIMERThe Group is exposed to fluctuations in copper prices in connection with its distribution of cable products. Cables accounted for approximately 17% of the Group's sales and copper accounts for approximately 60% of the composition of cables. This exposure is indirect since cable prices also reflect copper suppliers' commercial policies and the competitive environment in the Group's markets. Changes in copper prices have an estimated so-called ""recurring"" effect and an estimated so called ""non-recurring"" effect on the Group's performance assessed as part of the monthly internal reporting process of the Rexel Group: i) the recurring effect related to the change in copper-based cable prices corresponds to the change in value of the copper part included in the sales price of cables from one period to another. This effect mainly relates to the Groupâ€™s sales; ii) the non-recurring effect related to the change in copper-based cable prices corresponds to the effect of copper price variations on the sales price of cables between the time they are purchased and the time they are sold  until all such inventory has been sold (direct effect on gross profit). Practically  the non-recurring effect on gross profit is determined by comparing the historical purchase price for copper-based cable and the supplier price effective at the date of the sale of the cables by the Rexel Group. Additionally  the non-recurring effect on EBITA corresponds to the non-recurring effect on gross profit  which may be offset  when appropriate  by the non-recurring portion of changes in the distribution and administrative expenses.The impact of these two effects is assessed for as much of the Groupâ€™s total cable sales as possible  over each period. Group procedures require that entities that do not have the information systems capable of such exhaustive calculations to estimate these effects based on a sample representing at least 70% of the sales in the period. The results are then extrapolated to all cables sold during the period for that entity. Considering the sales covered. the Rexel Group considers such estimates of the impact of the two effects to be reasonable.This document may contain statements of future expectations and other forward-looking statements. By their nature  they are subject to numerous risks and uncertainties  including those described in the Universal Registration Document registered with the French AutoritÃ© des MarchÃ©s Financiers (AMF) on March 10  2022 under number D.22-0083.These forward-looking statements are not guarantees of Rexel's future performance  Rexel's actual results of operations  financial condition and liquidity as well as development of the industry in which Rexel operates may differ materially from those made in or suggested by the forward-looking statements contained in this release. The forward-looking statements contained in this communication speak only as of the date of this communication and Rexel does not undertake  unless required by law or regulation  to update any of the forward-looking statements after this date to conform such statements to actual results to reflect the occurrence of anticipated results or otherwise.The market and industry data and forecasts included in this document were obtained from internal surveys  estimates  experts and studies  where appropriate  as well as external market research  publicly available information and industry publications. Rexel  its affiliates  directors  officers  advisors and employees have not independently verified the accuracy of any such market and industry data and forecasts and make no representations or warranties in relation thereto. Such data and forecasts are included herein for information purposes only.This document includes only summary information and must be read in conjunction with Rexelâ€™s Universal Registration Document registered with the AMF on March 10  2022 under number D.22-0083  as well as the financial statements and consolidated result and activity report for the 2021 fiscal year which may be obtained from Rexelâ€™s website (www.rexel.com).Attachment",neutral,0.0,1.0,0.0,mixed,0.77,0.14,0.09,True,English,"['THIRD-QUARTER', 'SALES', 'additional selling price increase', 'Strong selling price increase', 'positive net scope effect', 'negative calendar effect', 'easier base effect', 'Chief Executive Officer', 'solid underlying markets', 'electrical materials market', 'PERIOD ENDED SEPTEMBER', 'positive currency effect', 'market share gains', 'favorable pricing environment', 'good underlying demand', 'high growth segments', 'Group average growth', 'rising energy costs', 'resilient mega trends', 'favorable underlying demand', 'energy efficiency solutions', 'strong third quarter', 'same-day sales growth', 'Robust volume growth', 'high price', 'Robust growth', 'Strong momentum', 'strong backlog', 'positive momentum', 'strong demand', 'production costs', 'Group revenues', 'Share buyback', 'economic environment', 'Double-digit growth', 'organic growth', 'favorable trends', 'robust start', 'energy transition', 'same-day basis', 'English French', 'second time', 'non-cable products', 'three end-markets', 'internal transformation', 'Strategic focus', 'M&A', '+467bps improvement', 'Ebita margin', '3.7 million shares', 'Key figures', 'North America', 'Guillaume TEXIER', 'full-year targets', 'excellent illustration', 'new strategy', 'labor scarcity', 'relentless focus', 'little visibility', 'same number', 'working days', 'Canadian dollars', 'Mayer acquisition', 'growing demand', 'product categories', 'Project activity', 'post-lockdown recovery', 'Record quarter', '750bps contribution', '900bps contribution', 'actual-day basis', 'adjusted basis', 'reported basis', 'SALES REVIEW', 'record sales', 'positive constant', 'Q2 22 growth', 'Digital penetration', 'three geographies', 'FY 22 guidance', 'digital sales', 'record year', 'electrification trends', 'Q3 2021 sales', 'geography Europe', '2022 guidance', '3 geographies', 'THIRD-QUARTER', 'Acceleration', 'ability', 'boost', 'pass', 'rise', 'Residential', 'Commercial', 'Industrial', 'c.', 'YoY', 'France', 'Scandinavia', 'Benelux', 'Germany', 'UK', 'Canada', 'Asia-Pacific', 'China', 'Australia', 'Rexel', 'results', 'Power', 'resource', 'future', 'THE', 'comments', 'balanced', 'appreciation', 'PV', 'HVAC', 'Proximity']",2022-10-27,2022-10-28,globenewswire.com
12269,Euroclear,NewsApi.org,https://www.prnewswire.com/news-releases/euroclear-continues-to-outperform-despite-volatile-financial-markets-as-it-accelerates-business-strategy-and-investments-301662268.html,Euroclear continues to outperform  despite volatile financial markets  as it accelerates business strategy and investments,BRUSSELS  Oct. 28  2022 /PRNewswire/ -- Euroclear today provides an update on its performance to the end of the third quarter 2022. Financial Summary Euroclear continued to deliver a strong financial performance to the end of the third quarter 2022  with the â€¦,"BRUSSELS  Oct. 28  2022 /PRNewswire/ -- Euroclear today provides an update on its performance to the end of the third quarter 2022.Financial SummaryCash balances related to Sanctions on Russia ""Business as usual"" Cash BalancesEuroclear continued to deliver a strong financial performance to the end of the third quarter 2022  with the underlying business performing well and benefitting from its diversified  resilient business model.The group also reported higher interest earnings due to rising interest rates on cash balances as well as increased cash balances from frozen assets due to Russian sanctions.At the end of the third quarter  2022 net profit increased 95% to EUR 667 million  of which EUR 426 million resulted from the strong underlying business performance.Euroclear Holding(â‚¬ m) YTDSept 2021 YTDSept 2022 Russiansanctionsimpacts YTDSept 2022Underlying Underlyingvs 2021Operating income 1 199 1 725 335 1 390 191 16 % Business income 1 133 1 202 -5 1 208 74 7 % Interest  banking & other income 65 522 340 182 117 179 %Operating expenses -723 -824 -13 -811 -88 -12 %Operating profit before Impairment 476 901 322 579 103 22 %Impairment -16 -13 -1 -12 4Pre tax profit 460 888 321 567 107 23 % Tax -118 -221 -80 -140 -22 -19 % Net profit 342 667 241 426 84 25 %EPS 110.3 211.9135.5Business income operating margin 36.2 % 31.5 %32.9 %EBITDA margin (EBITDA/oper.income) 46.2 % 57.0 %47.5 %Note: 2021 figures (except for EPS) have been restated to includeMFEX pro forma  in order to allow like-for-like comparison.Year-to-date operating income was up 44% year-on-year to EUR 1 725 million.An increase of 92% in earnings per share to EUR 211.9 per share  reflected the increase in net profit.Underlying Business Performance & HighlightsExcluding the impact of frozen assets due to the Russian sanctions  Euroclear's underlying business continues to perform strongly. Adjusted net profit rose by 25% to EUR 426 million.Business income was up 7% to EUR 1 208 million  reflecting continued solid growth of Euroclear's business lines. The diversification of the business has provided a hedge against market volatility over recent months. Interest  banking  and other income increased by 179% to EUR 182 million.Operating Expenses increased to EUR 811 million  up 12% compared to the prior year  as Euroclear continued to invest in its technology and service offering  as well as being impacted by inflation.Inflationary pressures on costs  as well as the broader impact of the macro-economic environment  are monitored at the level of each of operating entity. Only Euroclear Bank benefits directly from the compensating effect of higher interest rates.Overall  Euroclear expects expenditure to remain above its ""through-the-cycle"" target of 4-6% p.a. in 2023 as a result of accelerating investment in both its strategy and the resilience of the business  coupled with continued inflationary pressures on the cost base. However  profitability is expected to rise as inflation headwinds are more than offset by higher net interest income from subsequent rate increases.The key operating metrics  shown below  underpinned the strong business performance during the period.Market volatility remains high  driving transaction volumes to record levels.Equity market valuations have fallen significantly during 2022 which has led to declines in assets under custody and fund asset under custody during the period.The impact of lower equity markets is mitigated by the group's diversified and subscription-like business model. Approximately three quarters of the group's business income is decoupled from financial market valuations.Euroclear sees sustained demand for collateral management and lending services from a broad range of market participants as they seek to reduce credit risk in volatile financial market conditions.Q3 YTD 2022 Change vs Q3 YTD 2021 Assets under Custody EUR 34.9 trillion -3.5 % Number of Transactions 229 million +4.3 % Turnover EUR 791.8 trillion +8.1 % Fund Assets under Custody EUR 2.8 trillion -2.7 % Collateral Highway EUR 1.9 trillion +7.5 %In the third quarter  Euroclear outlined its updated strategic vision and targets to its investors. Through its strategy  the group will continue to focus on meeting the evolving needs of all financial market participants from issuers to investors.In addition  Euroclear will increase its focus on ESG  data-driven and digital innovations and expanding its global reach.Illustrating this strategic focus  Euroclear enhanced its offering in sustainable finance through an investment in Impact Cubed  a leading provider of ESG tech-enabled analytics and data science solutions. This investment complements Euroclear's investment in Greenomy  a provider of data and reporting for issuers to comply with EU sustainable finance legislation.International investor appetite for global market access as part of their diversified holdings remains robust and issuers continue to seek to benefit from an international investor base. Euroclear's strategic focus on meeting these demands continued to deliver growth  despite the headwinds resulting from the Russia's invasion of Ukraine. Assets under custody from international and emerging markets were up 18% year-on-year to EUR 1.7 trillion.One year ago  Euroclear acquired MFEX as part of its expanded funds platform. Considerable progress has been made to integrate MFEX and enhance the group's end-to-end funds offering. This is reflected through the new MFEXbyEuroclear branding for all group funds solutions.Implications of Russian sanctionsThe sanctions imposed by the US  the EU  and other jurisdictions  as well as Russian countermeasures  resulted in a loss of Russia-related business income which was more than compensated by increased interest income.The cash on the balance sheet has increased as blocked coupon payments and redemptions accumulate. At the end of September  Euroclear Bank's balance sheet increased by â‚¬88.7 billion year-on-year to a total of EUR 119.9 billion.As per Euroclear's standard process  the cash balances arising from the sanctions are invested which  depending on the prevailing interest rates  results in interest income. Over the nine months  revenues on cash balances arising from sanctions on Russia was EUR 340 million.With the growth of sanctioned liabilities and the increase of interest rates  the materiality of revenues on cash balances arising from sanctions on Russia on the group's financial results is unprecedented. As such  the Board considers it necessary to separate these earnings from the underlying financial results when assessing the company's performance and resources.The Board expects interest income to continue to grow materially as blocked payments and redemptions continue to accumulate in a rising interest rate environment.As previously outlined  while this is expected to have an impact on the balance sheet  it should not result in material change in credit risk profile and therefore will not have a meaningful impact on the group's capital ratios.The Board recognises that the unexpected profit should be managed prudently  in line with its corporate purpose and considering its responsibilities towards stakeholders and society. Euroclear continues to act in a transparent manner with all authorities involved. The Board will continue to act cautiously by retaining any profits related to the Russian sanctions until the situation becomes clearer.Commenting on the resultsLieve Mostrey  Chief Executive Officer""Despite an extraordinary context  we continued to deliver an excellent business performance  with financial results above our strategic 'through-the-cycle"" targets.The group benefits from a diversified business model which allows us to focus on supporting clients through these uncertain times  providing robust infrastructure and fulfilling our duties with respect to the sanctions on Russia.Our results show that we are on the right path. We are now accelerating investments to deliver on our long-term strategy and drive value for all our stakeholders.""AnnexesInterest income is driven by the prevailing interest rates in each currency of the cash balances held by the group. As at 30 September 2022  cash balances totaled EUR 111.7 billion  of which EUR 85.8 billion related to the sanctions on Russia.The proportion of cash balances by currency is as follows:Euroclear Bank and Euroclear Investments are the two group issuing entities. The summary income statements and financial positions at Q3 YTD for both entities are shown below.Q3 2022Q3 2021Variance Euroclear Bank Income StatementNet interest income550.969.3481.6Net fee and commission income771.2686.784.5Other income-12.57.2-19.7Total operating income1 309.6763.2546.4Administrative expenses-485.2-440.8-44.4Operating profit before impairment and taxation824.4322.4502.0Result for the period618.4244.2374.3Euroclear Bank Statement of Financial PositionShareholders' equity2 424.21 924.7499.5Debt securities issued and funds borrowed (incl. subordinated debt)5 191.86 869.7-1 678.0Total assets119 887.731 209.188 678.6Euroclear Investments Income StatementDividend313.4540.1-226.7Net gains/(losses) on non trading financial assets at FVPL-473.6-43.5-430.1Other income2.91.41.6Total operating income-157.3498.0-655.3Administrative expenses-3.4-1.1-2.3Operating profit before impairment and taxation-160.7496.9-657.6Result for the period-42.9507.3-550.3Euroclear Investments Statement of Financial PositionShareholders' equity460.8757.3-296.6Debt securities issued and funds borrowed1 654.71 653.31.5Total assets of which2 116.02 449.1-333.1Loans and advances at amortised cost (excluding intercompany)85.955.830.1Fair Value through Other Comprehensive Income (FVOCI) financial assets299.0311.1-12.1Intercompany loans (at amortised cost and FVPL)853.41 275.9-422.5Note: At the end of Q3  Euroclear Investments received a dividend from Euroclear SA which was more than offset by unrealised fairmarket valuation. An increasing interest rate environment has impacted Euroclear Investment's intra-group loans (assets) recognised at fair market value in line with IFRS 9. Liabilities have not been impacted  due to being recognised at acquisitioncost  in line with accounting standards. As a result  Euroclear Investments demonstrates a significant loss on non-trading financialassets for Q3 2022 compared to Q3 2021  resulting in a negative operating profit. This accounting treatment has no impact onEuroclear group's earnings capacity nor on the ability for Euroclear Investments to reimburse its debt.Note to editorsEuroclear group is the financial industry's trusted provider of post trade services. Guided by its purpose  Euroclear innovates to bring safety  efficiency and connections to financial markets for sustainable economic growth.Euroclear provides settlement and custody of domestic and cross-border securities for bonds  equities and derivatives  and investment funds. As a proven  resilient capital market infrastructure  Euroclear is committed to delivering risk-mitigation  automation and efficiency at scale for its global client franchise.The Euroclear group comprises Euroclear Bank  the International CSD  as well as Euroclear Belgium  Euroclear Finland  Euroclear France  Euroclear Nederland  Euroclear Sweden  Euroclear UK & International  and MFEXbyEuroclear.SOURCE Euroclear",neutral,0.04,0.91,0.06,mixed,0.08,0.36,0.56,True,English,"['volatile financial markets', 'business strategy', 'Euroclear', 'investments', 'EU sustainable finance legislation', 'volatile financial market conditions', 'diversified, resilient business model', 'strong underlying business performance', 'higher net interest income', 'Business income operating margin', 'subsequent rate increases', 'lower equity markets', 'ESG tech-enabled analytics', 'International investor appetite', 'strong financial performance', 'subscription-like business model', 'higher interest rates', 'Equity market valuations', 'financial market valuations', 'rising interest rates', 'key operating metrics', 'strong business performance', 'financial market participants', 'global market access', 'data science solutions', 'higher interest earnings', 'Russian sanctions impacts', 'Pre tax profit', 'continued inflationary pressures', 'Q3 YTD 2021 Assets', 'Financial Summary', 'Operating income', 'market volatility', '2022 net profit', 'Operating profit', 'EBITDA margin', 'global reach', 'business lines', 'other income', 'oper.income', 'Operating expenses', 'operating entity', 'third quarter', 'Cash balances', 'frozen assets', 'solid growth', 'recent months', 'macro-economic environment', 'compensating effect', 'cost base', 'transaction volumes', 'record levels', 'three quarters', 'sustained demand', 'collateral management', 'lending services', 'broad range', 'credit risk', 'Fund Assets', 'Collateral Highway', 'strategic vision', 'evolving needs', 'digital innovations', 'service offering', 'broader impact', 'inflation headwinds', 'strategic focus', 'Impact Cubed', 'leading provider', 'prior year', 'Euroclear Holding', 'Euroclear Bank', 'BRUSSELS', 'PRNewswire', 'update', 'group', 'Sept', 'banking', 'Impairment', 'EPS', 'Note', '2021 figures', 'MFEX', 'order', 'comparison', 'share', 'Highlights', 'diversification', 'hedge', 'technology', 'costs', 'Only', 'expenditure', 'cycle', 'target', 'result', 'investment', 'strategy', 'resilience', 'profitability', 'period', 'declines', 'custody', 'Change', 'Number', 'Transactions', 'Turnover', 'investors', 'issuers', 'addition', 'data-driven', 'Greenomy', 'reporting']",2022-10-28,2022-10-28,prnewswire.com
12270,Euroclear,NewsApi.org,https://www.prnewswire.com/news-releases/euroclear-continues-to-outperform-despite-volatile-financial-markets-as-it-accelerates-business-strategy-and-investments-301662280.html,Euroclear continues to outperform  despite volatile financial markets  as it accelerates business strategy and investments,BRUSSELS  Oct. 28  2022 /PRNewswire/ -- Euroclear today provides an update on its performance to the end of the third quarter 2022. Financial Summary Euroclear continued to deliver a strong financial performance to the end of the third quarter 2022  with the â€¦,"BRUSSELS  Oct. 28  2022 /PRNewswire/ -- Euroclear today provides an update on its performance to the end of the third quarter 2022.Financial SummaryCash balances related to Sanctions on Russia ""Business as usual"" Cash BalancesEuroclear continued to deliver a strong financial performance to the end of the third quarter 2022  with the underlying business performing well and benefitting from its diversified  resilient business model.The group also reported higher interest earnings due to rising interest rates on cash balances as well as increased cash balances from frozen assets due to Russian sanctions.At the end of the third quarter  2022 net profit increased 95% to EUR 667 million  of which EUR 426 million resulted from the strong underlying business performance.Euroclear Holding(â‚¬ m) YTDSept 2021 YTDSept 2022 Russiansanctionsimpacts YTDSept 2022Underlying Underlyingvs 2021Operating income 1 199 1 725 335 1 390 191 16 % Business income 1 133 1 202 -5 1 208 74 7 % Interest  banking & other income 65 522 340 182 117 179 %Operating expenses -723 -824 -13 -811 -88 -12 %Operating profit before Impairment 476 901 322 579 103 22 %Impairment -16 -13 -1 -12 4Pre tax profit 460 888 321 567 107 23 % Tax -118 -221 -80 -140 -22 -19 % Net profit 342 667 241 426 84 25 %EPS 110.3 211.9135.5Business income operating margin 36.2 % 31.5 %32.9 %EBITDA margin (EBITDA/oper.income) 46.2 % 57.0 %47.5 %Note: 2021 figures (except for EPS) have been restated to includeMFEX pro forma  in order to allow like-for-like comparison.Year-to-date operating income was up 44% year-on-year to EUR 1 725 million.An increase of 92% in earnings per share to EUR 211.9 per share  reflected the increase in net profit.Underlying Business Performance & HighlightsExcluding the impact of frozen assets due to the Russian sanctions  Euroclear's underlying business continues to perform strongly. Adjusted net profit rose by 25% to EUR 426 million.Business income was up 7% to EUR 1 208 million  reflecting continued solid growth of Euroclear's business lines. The diversification of the business has provided a hedge against market volatility over recent months. Interest  banking  and other income increased by 179% to EUR 182 million.Operating Expenses increased to EUR 811 million  up 12% compared to the prior year  as Euroclear continued to invest in its technology and service offering  as well as being impacted by inflation.Inflationary pressures on costs  as well as the broader impact of the macro-economic environment  are monitored at the level of each of operating entity. Only Euroclear Bank benefits directly from the compensating effect of higher interest rates.Overall  Euroclear expects expenditure to remain above its ""through-the-cycle"" target of 4-6% p.a. in 2023 as a result of accelerating investment in both its strategy and the resilience of the business  coupled with continued inflationary pressures on the cost base. However  profitability is expected to rise as inflation headwinds are more than offset by higher net interest income from subsequent rate increases.The key operating metrics  shown below  underpinned the strong business performance during the period.Market volatility remains high  driving transaction volumes to record levels.Equity market valuations have fallen significantly during 2022 which has led to declines in assets under custody and fund asset under custody during the period.The impact of lower equity markets is mitigated by the group's diversified and subscription-like business model. Approximately three quarters of the group's business income is decoupled from financial market valuations.Euroclear sees sustained demand for collateral management and lending services from a broad range of market participants as they seek to reduce credit risk in volatile financial market conditions.Q3 YTD 2022 Change vs Q3 YTD 2021 Assets under Custody EUR 34.9 trillion -3.5 % Number of Transactions 229 million +4.3 % Turnover EUR 791.8 trillion +8.1 % Fund Assets under Custody EUR 2.8 trillion -2.7 % Collateral Highway EUR 1.9 trillion +7.5 %In the third quarter  Euroclear outlined its updated strategic vision and targets to its investors. Through its strategy  the group will continue to focus on meeting the evolving needs of all financial market participants from issuers to investors.In addition  Euroclear will increase its focus on ESG  data-driven and digital innovations and expanding its global reach.Illustrating this strategic focus  Euroclear enhanced its offering in sustainable finance through an investment in Impact Cubed  a leading provider of ESG tech-enabled analytics and data science solutions. This investment complements Euroclear's investment in Greenomy  a provider of data and reporting for issuers to comply with EU sustainable finance legislation.International investor appetite for global market access as part of their diversified holdings remains robust and issuers continue to seek to benefit from an international investor base. Euroclear's strategic focus on meeting these demands continued to deliver growth  despite the headwinds resulting from the Russia's invasion of Ukraine. Assets under custody from international and emerging markets were up 18% year-on-year to EUR 1.7 trillion.One year ago  Euroclear acquired MFEX as part of its expanded funds platform. Considerable progress has been made to integrate MFEX and enhance the group's end-to-end funds offering. This is reflected through the new MFEXbyEuroclear branding for all group funds solutions.Implications of Russian sanctionsThe sanctions imposed by the US  the EU  and other jurisdictions  as well as Russian countermeasures  resulted in a loss of Russia-related business income which was more than compensated by increased interest income.The cash on the balance sheet has increased as blocked coupon payments and redemptions accumulate. At the end of September  Euroclear Bank's balance sheet increased by â‚¬88.7 billion year-on-year to a total of EUR 119.9 billion.As per Euroclear's standard process  the cash balances arising from the sanctions are invested which  depending on the prevailing interest rates  results in interest income. Over the nine months  revenues on cash balances arising from sanctions on Russia was EUR 340 million.With the growth of sanctioned liabilities and the increase of interest rates  the materiality of revenues on cash balances arising from sanctions on Russia on the group's financial results is unprecedented. As such  the Board considers it necessary to separate these earnings from the underlying financial results when assessing the company's performance and resources.The Board expects interest income to continue to grow materially as blocked payments and redemptions continue to accumulate in a rising interest rate environment.As previously outlined  while this is expected to have an impact on the balance sheet  it should not result in material change in credit risk profile and therefore will not have a meaningful impact on the group's capital ratios.The Board recognises that the unexpected profit should be managed prudently  in line with its corporate purpose and considering its responsibilities towards stakeholders and society. Euroclear continues to act in a transparent manner with all authorities involved. The Board will continue to act cautiously by retaining any profits related to the Russian sanctions until the situation becomes clearer.Commenting on the resultsLieve Mostrey  Chief Executive Officer""Despite an extraordinary context  we continued to deliver an excellent business performance  with financial results above our strategic 'through-the-cycle"" targets.The group benefits from a diversified business model which allows us to focus on supporting clients through these uncertain times  providing robust infrastructure and fulfilling our duties with respect to the sanctions on Russia.Our results show that we are on the right path. We are now accelerating investments to deliver on our long-term strategy and drive value for all our stakeholders.""AnnexesInterest income is driven by the prevailing interest rates in each currency of the cash balances held by the group. As at 30 September 2022  cash balances totaled EUR 111.7 billion  of which EUR 85.8 billion related to the sanctions on Russia.The proportion of cash balances by currency is as follows:Euroclear Bank and Euroclear Investments are the two group issuing entities. The summary income statements and financial positions at Q3 YTD for both entities are shown below.Q3 2022Q3 2021Variance Euroclear Bank Income StatementNet interest income550.969.3481.6Net fee and commission income771.2686.784.5Other income-12.57.2-19.7Total operating income1 309.6763.2546.4Administrative expenses-485.2-440.8-44.4Operating profit before impairment and taxation824.4322.4502.0Result for the period618.4244.2374.3Euroclear Bank Statement of Financial PositionShareholders' equity2 424.21 924.7499.5Debt securities issued and funds borrowed (incl. subordinated debt)5 191.86 869.7-1 678.0Total assets119 887.731 209.188 678.6Euroclear Investments Income StatementDividend313.4540.1-226.7Net gains/(losses) on non trading financial assets at FVPL-473.6-43.5-430.1Other income2.91.41.6Total operating income-157.3498.0-655.3Administrative expenses-3.4-1.1-2.3Operating profit before impairment and taxation-160.7496.9-657.6Result for the period-42.9507.3-550.3Euroclear Investments Statement of Financial PositionShareholders' equity460.8757.3-296.6Debt securities issued and funds borrowed1 654.71 653.31.5Total assets of which2 116.02 449.1-333.1Loans and advances at amortised cost (excluding intercompany)85.955.830.1Fair Value through Other Comprehensive Income (FVOCI) financial assets299.0311.1-12.1Intercompany loans (at amortised cost and FVPL)853.41 275.9-422.5Note: At the end of Q3  Euroclear Investments received a dividend from Euroclear SA which was more than offset by unrealised fairmarket valuation. An increasing interest rate environment has impacted Euroclear Investment's intra-group loans (assets) recognised at fair market value in line with IFRS 9. Liabilities have not been impacted  due to being recognised at acquisitioncost  in line with accounting standards. As a result  Euroclear Investments demonstrates a significant loss on non-trading financialassets for Q3 2022 compared to Q3 2021  resulting in a negative operating profit. This accounting treatment has no impact onEuroclear group's earnings capacity nor on the ability for Euroclear Investments to reimburse its debt.Note to editorsEuroclear group is the financial industry's trusted provider of post trade services. Guided by its purpose  Euroclear innovates to bring safety  efficiency and connections to financial markets for sustainable economic growth.Euroclear provides settlement and custody of domestic and cross-border securities for bonds  equities and derivatives  and investment funds. As a proven  resilient capital market infrastructure  Euroclear is committed to delivering risk-mitigation  automation and efficiency at scale for its global client franchise.The Euroclear group comprises Euroclear Bank  the International CSD  as well as Euroclear Belgium  Euroclear Finland  Euroclear France  Euroclear Nederland  Euroclear Sweden  Euroclear UK & International  and MFEXbyEuroclear.Photo: https://mma.prnewswire.com/media/1932189/Euroclear_chart_1.jpgPhoto: https://mma.prnewswire.com/media/1932190/Euroclear_chart_2.jpgLogo: https://mma.prnewswire.com/media/832898/Euroclear_Logo.jpgSOURCE Euroclear",neutral,0.04,0.91,0.06,mixed,0.08,0.36,0.56,True,English,"['volatile financial markets', 'business strategy', 'Euroclear', 'investments', 'EU sustainable finance legislation', 'volatile financial market conditions', 'diversified, resilient business model', 'strong underlying business performance', 'higher net interest income', 'Business income operating margin', 'subsequent rate increases', 'lower equity markets', 'ESG tech-enabled analytics', 'International investor appetite', 'strong financial performance', 'subscription-like business model', 'higher interest rates', 'Equity market valuations', 'financial market valuations', 'rising interest rates', 'key operating metrics', 'strong business performance', 'financial market participants', 'global market access', 'data science solutions', 'higher interest earnings', 'Russian sanctions impacts', 'Pre tax profit', 'continued inflationary pressures', 'Q3 YTD 2021 Assets', 'Financial Summary', 'Operating income', 'market volatility', '2022 net profit', 'Operating profit', 'EBITDA margin', 'global reach', 'business lines', 'other income', 'oper.income', 'Operating expenses', 'operating entity', 'third quarter', 'Cash balances', 'frozen assets', 'solid growth', 'recent months', 'macro-economic environment', 'compensating effect', 'cost base', 'transaction volumes', 'record levels', 'three quarters', 'sustained demand', 'collateral management', 'lending services', 'broad range', 'credit risk', 'Fund Assets', 'Collateral Highway', 'strategic vision', 'evolving needs', 'digital innovations', 'service offering', 'broader impact', 'inflation headwinds', 'strategic focus', 'Impact Cubed', 'leading provider', 'prior year', 'Euroclear Holding', 'Euroclear Bank', 'BRUSSELS', 'PRNewswire', 'update', 'group', 'Sept', 'banking', 'Impairment', 'EPS', 'Note', '2021 figures', 'MFEX', 'order', 'comparison', 'share', 'Highlights', 'diversification', 'hedge', 'technology', 'costs', 'Only', 'expenditure', 'cycle', 'target', 'result', 'investment', 'strategy', 'resilience', 'profitability', 'period', 'declines', 'custody', 'Change', 'Number', 'Transactions', 'Turnover', 'investors', 'issuers', 'addition', 'data-driven', 'Greenomy', 'reporting']",2022-10-28,2022-10-28,prnewswire.com
12271,Euroclear,NewsApi.org,https://www.uppermichiganssource.com/prnewswire/2022/10/28/euroclear-continues-outperform-despite-volatile-financial-markets-it-accelerates-business-strategy-investments/,Euroclear continues to outperform  despite volatile financial markets  as it accelerates business strategy and investments,,"Euroclear continues to outperform  despite volatile financial markets  as it accelerates business strategy and investmentsEuroclear continues to outperform  despite volatile financial markets  as it accelerates business strategy and investmentsBRUSSELS  Oct. 28  2022 /PRNewswire/ -- Euroclear today provides an update on its performance to the end of the third quarter 2022.Financial SummaryEuroclear continued to deliver a strong financial performance to the end of the third quarter 2022  with the underlying business performing well and benefitting from its diversified  resilient business model.The group also reported higher interest earnings due to rising interest rates on cash balances as well as increased cash balances from frozen assets due to Russian sanctions.At the end of the third quarter  2022 net profit increased 95% to EUR 667 million  of which EUR 426 million resulted from the strong underlying business performance.Euroclear Holding(â‚¬ m) YTDSept 2021 YTDSept 2022 Russiansanctionsimpacts YTDSept 2022Underlying Underlyingvs 2021Operating income 1 199 1 725 335 1 390 191 16 % Business income 1 133 1 202 -5 1 208 74 7 % Interest  banking & other income 65 522 340 182 117 179 %Operating expenses -723 -824 -13 -811 -88 -12 %Operating profit before Impairment 476 901 322 579 103 22 %Impairment -16 -13 -1 -12 4Pre tax profit 460 888 321 567 107 23 % Tax -118 -221 -80 -140 -22 -19 % Net profit 342 667 241 426 84 25 %EPS 110.3 211.9135.5Business income operating margin 36.2 % 31.5 %32.9 %EBITDA margin (EBITDA/oper.income) 46.2 % 57.0 %47.5 %Note: 2021 figures (except for EPS) have been restated to includeMFEX pro forma  in order to allow like-for-like comparison.Year-to-date operating income was up 44% year-on-year to EUR 1 725 million.An increase of 92% in earnings per share to EUR 211.9 per share  reflected the increase in net profit.Underlying Business Performance & HighlightsExcluding the impact of frozen assets due to the Russian sanctions  Euroclear's underlying business continues to perform strongly. Adjusted net profit rose by 25% to EUR 426 million.Business income was up 7% to EUR 1 208 million  reflecting continued solid growth of Euroclear's business lines. The diversification of the business has provided a hedge against market volatility over recent months. Interest  banking  and other income increased by 179% to EUR 182 million.Operating Expenses increased to EUR 811 million  up 12% compared to the prior year  as Euroclear continued to invest in its technology and service offering  as well as being impacted by inflation.Inflationary pressures on costs  as well as the broader impact of the macro-economic environment  are monitored at the level of each of operating entity. Only Euroclear Bank benefits directly from the compensating effect of higher interest rates.Overall  Euroclear expects expenditure to remain above its ""through-the-cycle"" target of 4-6% p.a. in 2023 as a result of accelerating investment in both its strategy and the resilience of the business  coupled with continued inflationary pressures on the cost base. However  profitability is expected to rise as inflation headwinds are more than offset by higher net interest income from subsequent rate increases.The key operating metrics  shown below  underpinned the strong business performance during the period.Market volatility remains high  driving transaction volumes to record levels.Equity market valuations have fallen significantly during 2022 which has led to declines in assets under custody and fund asset under custody during the period.The impact of lower equity markets is mitigated by the group's diversified and subscription-like business model. Approximately three quarters of the group's business income is decoupled from financial market valuations.Euroclear sees sustained demand for collateral management and lending services from a broad range of market participants as they seek to reduce credit risk in volatile financial market conditions.Q3 YTD 2022 Change vs Q3 YTD 2021 Assets under Custody EUR 34.9 trillion -3.5 % Number of Transactions 229 million +4.3 % Turnover EUR 791.8 trillion +8.1 % Fund Assets under Custody EUR 2.8 trillion -2.7 % Collateral Highway EUR 1.9 trillion +7.5 %In the third quarter  Euroclear outlined its updated strategic vision and targets to its investors. Through its strategy  the group will continue to focus on meeting the evolving needs of all financial market participants from issuers to investors.In addition  Euroclear will increase its focus on ESG  data-driven and digital innovations and expanding its global reach.Illustrating this strategic focus  Euroclear enhanced its offering in sustainable finance through an investment in Impact Cubed  a leading provider of ESG tech-enabled analytics and data science solutions. This investment complements Euroclear's investment in Greenomy  a provider of data and reporting for issuers to comply with EU sustainable finance legislation.International investor appetite for global market access as part of their diversified holdings remains robust and issuers continue to seek to benefit from an international investor base. Euroclear's strategic focus on meeting these demands continued to deliver growth  despite the headwinds resulting from the Russia's invasion of Ukraine. Assets under custody from international and emerging markets were up 18% year-on-year to EUR 1.7 trillion.One year ago  Euroclear acquired MFEX as part of its expanded funds platform. Considerable progress has been made to integrate MFEX and enhance the group's end-to-end funds offering. This is reflected through the new MFEXbyEuroclear branding for all group funds solutions.Implications of Russian sanctionsThe sanctions imposed by the US  the EU  and other jurisdictions  as well as Russian countermeasures  resulted in a loss of Russia-related business income which was more than compensated by increased interest income.The cash on the balance sheet has increased as blocked coupon payments and redemptions accumulate. At the end of September  Euroclear Bank's balance sheet increased by â‚¬88.7 billion year-on-year to a total of EUR 119.9 billion.As per Euroclear's standard process  the cash balances arising from the sanctions are invested which  depending on the prevailing interest rates  results in interest income. Over the nine months  revenues on cash balances arising from sanctions on Russia was EUR 340 million.With the growth of sanctioned liabilities and the increase of interest rates  the materiality of revenues on cash balances arising from sanctions on Russia on the group's financial results is unprecedented. As such  the Board considers it necessary to separate these earnings from the underlying financial results when assessing the company's performance and resources.The Board expects interest income to continue to grow materially as blocked payments and redemptions continue to accumulate in a rising interest rate environment.As previously outlined  while this is expected to have an impact on the balance sheet  it should not result in material change in credit risk profile and therefore will not have a meaningful impact on the group's capital ratios.The Board recognises that the unexpected profit should be managed prudently  in line with its corporate purpose and considering its responsibilities towards stakeholders and society. Euroclear continues to act in a transparent manner with all authorities involved. The Board will continue to act cautiously by retaining any profits related to the Russian sanctions until the situation becomes clearer.Commenting on the resultsLieve Mostrey  Chief Executive Officer""Despite an extraordinary context  we continued to deliver an excellent business performance  with financial results above our strategic 'through-the-cycle"" targets.The group benefits from a diversified business model which allows us to focus on supporting clients through these uncertain times  providing robust infrastructure and fulfilling our duties with respect to the sanctions on Russia.Our results show that we are on the right path. We are now accelerating investments to deliver on our long-term strategy and drive value for all our stakeholders.""AnnexesInterest income is driven by the prevailing interest rates in each currency of the cash balances held by the group. As at 30 September 2022  cash balances totaled EUR 111.7 billion  of which EUR 85.8 billion related to the sanctions on Russia.The proportion of cash balances by currency is as follows:Cash balances related to Sanctions on Russia (PRNewswire)""Business as usual"" Cash Balances (PRNewswire)Euroclear Bank and Euroclear Investments are the two group issuing entities. The summary income statements and financial positions at Q3 YTD for both entities are shown below.Q3 2022Q3 2021Variance Euroclear Bank Income StatementNet interest income550.969.3481.6Net fee and commission income771.2686.784.5Other income-12.57.2-19.7Total operating income1 309.6763.2546.4Administrative expenses-485.2-440.8-44.4Operating profit before impairment and taxation824.4322.4502.0Result for the period618.4244.2374.3Euroclear Bank Statement of Financial PositionShareholders' equity2 424.21 924.7499.5Debt securities issued and funds borrowed (incl. subordinated debt)5 191.86 869.7-1 678.0Total assets119 887.731 209.188 678.6Euroclear Investments Income StatementDividend313.4540.1-226.7Net gains/(losses) on non trading financial assets at FVPL-473.6-43.5-430.1Other income2.91.41.6Total operating income-157.3498.0-655.3Administrative expenses-3.4-1.1-2.3Operating profit before impairment and taxation-160.7496.9-657.6Result for the period-42.9507.3-550.3Euroclear Investments Statement of Financial PositionShareholders' equity460.8757.3-296.6Debt securities issued and funds borrowed1 654.71 653.31.5Total assets of which2 116.02 449.1-333.1Loans and advances at amortised cost (excluding intercompany)85.955.830.1Fair Value through Other Comprehensive Income (FVOCI) financial assets299.0311.1-12.1Intercompany loans (at amortised cost and FVPL)853.41 275.9-422.5Note: At the end of Q3  Euroclear Investments received a dividend from Euroclear SA which was more than offset by unrealised fairmarket valuation. An increasing interest rate environment has impacted Euroclear Investment's intra-group loans (assets) recognised at fair market value in line with IFRS 9. Liabilities have not been impacted  due to being recognised at acquisitioncost  in line with accounting standards. As a result  Euroclear Investments demonstrates a significant loss on non-trading financialassets for Q3 2022 compared to Q3 2021  resulting in a negative operating profit. This accounting treatment has no impact onEuroclear group's earnings capacity nor on the ability for Euroclear Investments to reimburse its debt.Note to editorsEuroclear group is the financial industry's trusted provider of post trade services. Guided by its purpose  Euroclear innovates to bring safety  efficiency and connections to financial markets for sustainable economic growth.Euroclear provides settlement and custody of domestic and cross-border securities for bonds  equities and derivatives  and investment funds. As a proven  resilient capital market infrastructure  Euroclear is committed to delivering risk-mitigation  automation and efficiency at scale for its global client franchise.The Euroclear group comprises Euroclear Bank  the International CSD  as well as Euroclear Belgium  Euroclear Finland  Euroclear France  Euroclear Nederland  Euroclear Sweden  Euroclear UK & International  and MFEXbyEuroclear.Euroclear logo (PRNewswire)View original content to download multimedia:SOURCE Euroclear",neutral,0.04,0.91,0.06,mixed,0.31,0.29,0.4,True,English,"['volatile financial markets', 'business strategy', 'Euroclear', 'investments', 'volatile financial market conditions', 'diversified, resilient business model', 'strong underlying business performance', 'higher net interest income', 'Business income operating margin', 'volatile financial markets', 'subsequent rate increases', 'lower equity markets', 'ESG tech-enabled analytics', 'data science solutions', 'strong financial performance', 'subscription-like business model', 'higher interest rates', 'Equity market valuations', 'financial market valuations', 'rising interest rates', 'key operating metrics', 'strong business performance', 'financial market participants', 'date operating income', 'higher interest earnings', 'Russian sanctions impacts', 'Pre tax profit', 'continued inflationary pressures', 'Q3 YTD 2021 Assets', 'Financial Summary', 'market volatility', 'Operating profit', '2022 net profit', 'other income', 'Operating expenses', 'EBITDA margin', 'oper.income', 'operating entity', 'business lines', 'third quarter', 'cash balances', 'frozen assets', 'solid growth', 'recent months', 'macro-economic environment', 'compensating effect', 'cost base', 'transaction volumes', 'record levels', 'three quarters', 'sustained demand', 'collateral management', 'lending services', 'broad range', 'credit risk', 'Collateral Highway', 'strategic vision', 'evolving needs', 'digital innovations', 'global reach', 'sustainable finance', 'leading provider', 'business strategy', 'service offering', 'broader impact', 'inflation headwinds', 'strategic focus', 'Impact Cubed', 'prior year', 'Euroclear Holding', 'Euroclear Bank', 'investments', 'BRUSSELS', 'PRNewswire', 'update', 'group', 'Sept', 'banking', 'Impairment', 'EPS', 'Note', '2021 figures', 'MFEX', 'order', 'comparison', 'share', 'Highlights', 'diversification', 'hedge', 'technology', 'costs', 'Only', 'expenditure', 'cycle', 'target', 'result', 'resilience', 'profitability', 'period', 'declines', 'custody', 'Change', 'Number', 'Transactions', 'Turnover', 'investors', 'issuers', 'addition', 'data-driven', 'Greenomy']",2022-10-28,2022-10-28,uppermichiganssource.com
12272,Euroclear,Bing API,https://www.asiaone.com/business/euroclear-continues-outperform-despite-volatile-financial-markets-it-accelerates-business,Euroclear continues to outperform  despite volatile financial markets  as it accelerates business strategy and investments,Euroclear today provides an update on its performance to the end of the third quarter 2022. Financial Summary Euroclear continued to deliver,"BRUSSELS  Oct. 28  2022 /PRNewswire/ -- Euroclear today provides an update on its performance to the end of the third quarter 2022.Financial SummaryEuroclear continued to deliver a strong financial performance to the end of the third quarter 2022  with the underlying business performing well and benefitting from its diversified  resilient business model.The group also reported higher interest earnings due to rising interest rates on cash balances as well as increased cash balances from frozen assets due to Russian sanctions.At the end of the third quarter  2022 net profit increased 95% to EUR 667 million  of which EUR 426 million resulted from the strong underlying business performance.Euroclear Holding(â‚¬ m) YTDSept 2021 YTDSept 2022 Russiansanctionsimpacts YTDSept 2022Underlying Underlyingvs 2021Operating income 1 199 1 725 335 1 390 191 16 % Business income 1 133 1 202 -5 1 208 74 7 % Interest  banking & other income 65 522 340 182 117 179 %Operating expenses -723 -824 -13 -811 -88 -12 %Operating profit before Impairment 476 901 322 579 103 22 %Impairment -16 -13 -1 -12 4Pre tax profit 460 888 321 567 107 23 % Tax -118 -221 -80 -140 -22 -19 % Net profit 342 667 241 426 84 25 %EPS 110.3 211.9135.5Business income operating margin 36.2 % 31.5 %32.9 %EBITDA margin (EBITDA/oper.income) 46.2 % 57.0 %47.5 %Note: 2021 figures (except for EPS) have been restated to includeMFEX pro forma  in order to allow like-for-like comparison.Year-to-date operating income was up 44% year-on-year to EUR 1 725 million.An increase of 92% in earnings per share to EUR 211.9 per share  reflected the increase in net profit.Underlying Business Performance & HighlightsExcluding the impact of frozen assets due to the Russian sanctions  Euroclear's underlying business continues to perform strongly. Adjusted net profit rose by 25% to EUR 426 million.Business income was up 7% to EUR 1 208 million  reflecting continued solid growth of Euroclear's business lines. The diversification of the business has provided a hedge against market volatility over recent months. Interest  banking  and other income increased by 179% to EUR 182 million.Operating Expenses increased to EUR 811 million  up 12% compared to the prior year  as Euroclear continued to invest in its technology and service offering  as well as being impacted by inflation.Inflationary pressures on costs  as well as the broader impact of the macro-economic environment  are monitored at the level of each of operating entity. Only Euroclear Bank benefits directly from the compensating effect of higher interest rates.Overall  Euroclear expects expenditure to remain above its ""through-the-cycle"" target of 4-6% p.a. in 2023 as a result of accelerating investment in both its strategy and the resilience of the business  coupled with continued inflationary pressures on the cost base. However  profitability is expected to rise as inflation headwinds are more than offset by higher net interest income from subsequent rate increases.The key operating metrics  shown below  underpinned the strong business performance during the period.Market volatility remains high  driving transaction volumes to record levels.Equity market valuations have fallen significantly during 2022 which has led to declines in assets under custody and fund asset under custody during the period.The impact of lower equity markets is mitigated by the group's diversified and subscription-like business model. Approximately three quarters of the group's business income is decoupled from financial market valuations.Euroclear sees sustained demand for collateral management and lending services from a broad range of market participants as they seek to reduce credit risk in volatile financial market conditions.Q3 YTD 2022 Change vs Q3 YTD 2021 Assets under Custody EUR 34.9 trillion -3.5 % Number of Transactions 229 million +4.3 % Turnover EUR 791.8 trillion +8.1 % Fund Assets under Custody EUR 2.8 trillion -2.7 % Collateral Highway EUR 1.9 trillion +7.5 %In the third quarter  Euroclear outlined its updated strategic vision and targets to its investors. Through its strategy  the group will continue to focus on meeting the evolving needs of all financial market participants from issuers to investors.In addition  Euroclear will increase its focus on ESG  data-driven and digital innovations and expanding its global reach.Illustrating this strategic focus  Euroclear enhanced its offering in sustainable finance through an investment in Impact Cubed  a leading provider of ESG tech-enabled analytics and data science solutions. This investment complements Euroclear's investment in Greenomy  a provider of data and reporting for issuers to comply with EU sustainable finance legislation.International investor appetite for global market access as part of their diversified holdings remains robust and issuers continue to seek to benefit from an international investor base. Euroclear's strategic focus on meeting these demands continued to deliver growth  despite the headwinds resulting from the Russia's invasion of Ukraine. Assets under custody from international and emerging markets were up 18% year-on-year to EUR 1.7 trillion.One year ago  Euroclear acquired MFEX as part of its expanded funds platform. Considerable progress has been made to integrate MFEX and enhance the group's end-to-end funds offering. This is reflected through the new MFEXbyEuroclear branding for all group funds solutions.Implications of Russian sanctionsThe sanctions imposed by the US  the EU  and other jurisdictions  as well as Russian countermeasures  resulted in a loss of Russia-related business income which was more than compensated by increased interest income.The cash on the balance sheet has increased as blocked coupon payments and redemptions accumulate. At the end of September  Euroclear Bank's balance sheet increased by â‚¬88.7 billion year-on-year to a total of EUR 119.9 billion.As per Euroclear's standard process  the cash balances arising from the sanctions are invested which  depending on the prevailing interest rates  results in interest income. Over the nine months  revenues on cash balances arising from sanctions on Russia was EUR 340 million.With the growth of sanctioned liabilities and the increase of interest rates  the materiality of revenues on cash balances arising from sanctions on Russia on the group's financial results is unprecedented. As such  the Board considers it necessary to separate these earnings from the underlying financial results when assessing the company's performance and resources.The Board expects interest income to continue to grow materially as blocked payments and redemptions continue to accumulate in a rising interest rate environment.As previously outlined  while this is expected to have an impact on the balance sheet  it should not result in material change in credit risk profile and therefore will not have a meaningful impact on the group's capital ratios.The Board recognises that the unexpected profit should be managed prudently  in line with its corporate purpose and considering its responsibilities towards stakeholders and society. Euroclear continues to act in a transparent manner with all authorities involved. The Board will continue to act cautiously by retaining any profits related to the Russian sanctions until the situation becomes clearer.Commenting on the resultsLieve Mostrey  Chief Executive Officer""Despite an extraordinary context  we continued to deliver an excellent business performance  with financial results above our strategic 'through-the-cycle"" targets.The group benefits from a diversified business model which allows us to focus on supporting clients through these uncertain times  providing robust infrastructure and fulfilling our duties with respect to the sanctions on Russia.Our results show that we are on the right path. We are now accelerating investments to deliver on our long-term strategy and drive value for all our stakeholders.""AnnexesInterest income is driven by the prevailing interest rates in each currency of the cash balances held by the group. As at 30 September 2022  cash balances totaled EUR 111.7 billion  of which EUR 85.8 billion related to the sanctions on Russia.The proportion of cash balances by currency is as follows:Cash balances related to Sanctions on Russia""Business as usual"" Cash BalancesEuroclear Bank and Euroclear Investments are the two group issuing entities. The summary income statements and financial positions at Q3 YTD for both entities are shown below.Q3 2022Q3 2021Variance Euroclear Bank Income StatementNet interest income550.969.3481.6Net fee and commission income771.2686.784.5Other income-12.57.2-19.7Total operating income1 309.6763.2546.4Administrative expenses-485.2-440.8-44.4Operating profit before impairment and taxation824.4322.4502.0Result for the period618.4244.2374.3Euroclear Bank Statement of Financial PositionShareholders' equity2 424.21 924.7499.5Debt securities issued and funds borrowed (incl. subordinated debt)5 191.86 869.7-1 678.0Total assets119 887.731 209.188 678.6Euroclear Investments Income StatementDividend313.4540.1-226.7Net gains/(losses) on non trading financial assets at FVPL-473.6-43.5-430.1Other income2.91.41.6Total operating income-157.3498.0-655.3Administrative expenses-3.4-1.1-2.3Operating profit before impairment and taxation-160.7496.9-657.6Result for the period-42.9507.3-550.3Euroclear Investments Statement of Financial PositionShareholders' equity460.8757.3-296.6Debt securities issued and funds borrowed1 654.71 653.31.5Total assets of which2 116.02 449.1-333.1Loans and advances at amortised cost (excluding intercompany)85.955.830.1Fair Value through Other Comprehensive Income (FVOCI) financial assets299.0311.1-12.1Intercompany loans (at amortised cost and FVPL)853.41 275.9-422.5Note: At the end of Q3  Euroclear Investments received a dividend from Euroclear SA which was more than offset by unrealised fairmarket valuation. An increasing interest rate environment has impacted Euroclear Investment's intra-group loans (assets) recognised at fair market value in line with IFRS 9. Liabilities have not been impacted  due to being recognised at acquisitioncost  in line with accounting standards. As a result  Euroclear Investments demonstrates a significant loss on non-trading financialassets for Q3 2022 compared to Q3 2021  resulting in a negative operating profit. This accounting treatment has no impact onEuroclear group's earnings capacity nor on the ability for Euroclear Investments to reimburse its debt.Note to editorsEuroclear group is the financial industry's trusted provider of post trade services. Guided by its purpose  Euroclear innovates to bring safety  efficiency and connections to financial markets for sustainable economic growth.Euroclear provides settlement and custody of domestic and cross-border securities for bonds  equities and derivatives  and investment funds. As a proven  resilient capital market infrastructure  Euroclear is committed to delivering risk-mitigation  automation and efficiency at scale for its global client franchise.The Euroclear group comprises Euroclear Bank  the International CSD  as well as Euroclear Belgium  Euroclear Finland  Euroclear France  Euroclear Nederland  Euroclear Sweden  Euroclear UK & International  and MFEXbyEuroclear.",neutral,0.04,0.91,0.06,mixed,0.26,0.26,0.47,True,English,"['volatile financial markets', 'business strategy', 'Euroclear', 'investments', 'EU sustainable finance legislation', 'volatile financial market conditions', 'diversified, resilient business model', 'strong underlying business performance', 'higher net interest income', 'Business income operating margin', 'subsequent rate increases', 'lower equity markets', 'ESG tech-enabled analytics', 'International investor appetite', 'strong financial performance', 'like business model', 'higher interest rates', 'Equity market valuations', 'financial market valuations', 'rising interest rates', 'key operating metrics', 'strong business performance', 'financial market participants', 'global market access', 'data science solutions', 'higher interest earnings', 'Russian sanctions impacts', 'Pre tax profit', 'continued inflationary pressures', 'Financial Summary', 'Operating income', 'market volatility', '2022 net profit', 'Operating profit', 'EBITDA margin', 'global reach', 'business lines', 'other income', 'oper.income', 'Operating expenses', 'operating entity', 'diversified holdings', 'third quarter', 'cash balances', 'solid growth', 'recent months', 'macro-economic environment', 'compensating effect', 'cost base', 'transaction volumes', 'record levels', 'three quarters', 'sustained demand', 'collateral management', 'lending services', 'broad range', 'credit risk', 'Collateral Highway', 'strategic vision', 'evolving needs', 'digital innovations', 'frozen assets', 'Fund Assets', 'prior year', 'service offering', 'broader impact', 'inflation headwinds', 'strategic focus', 'Impact Cubed', 'leading provider', 'Q3 YTD', 'Euroclear Holding', 'Euroclear Bank', '2021 Assets', 'BRUSSELS', 'PRNewswire', 'update', 'group', 'Sept', 'banking', 'Impairment', 'EPS', 'Note', '2021 figures', 'MFEX', 'order', 'comparison', 'share', 'Highlights', 'diversification', 'hedge', 'technology', 'costs', 'Only', 'expenditure', 'cycle', 'target', 'result', 'investment', 'strategy', 'resilience', 'profitability', 'period', 'declines', 'custody', 'subscription', 'Change', 'Number', 'Transactions', 'Turnover', 'investors', 'issuers', 'addition', 'data-driven', 'Greenomy', 'reporting']",2022-10-28,2022-10-28,asiaone.com
12273,Euroclear,Bing API,https://finance.yahoo.com/news/information-trading-swedish-depository-receipts-125500113.html,Information about trading of Swedish Depository Receipts of Baltic Horizon Fund on Nasdaq Stockholm stock exchange,Northern Horizon Capital AS hereby announces that the first day of trading with the Swedish depository receipts (the â€œSDRsâ€) of Baltic Horizon Fund on Nasdaq Stockholm stock exchange (â€œNasdaq Stockholmâ€) will occur on 31 October 2022.,Baltic Horizon Fund / Northern Horizon CapitalNorthern Horizon Capital AS hereby announces that the first day of trading with the Swedish depository receipts (the â€œSDRsâ€) of Baltic Horizon Fund on Nasdaq Stockholm stock exchange (â€œNasdaq Stockholmâ€) will occur on 31 October 2022.Approximately 92% of the Baltic Horizon Fund units (the â€œUnitsâ€) which were held in Euroclear Sweden were converted into SDRs during the SDR offering period. The unitholders who are still holders of the Units held in Euroclear Sweden will have possibility to convert the Units into the SDRs until the end of October after which Euroclear Sweden will appoint a sales agent to sell such Units and pay out the proceeds (less sales costs and any applicable taxes) to the cash account connected with the respective Swedish Investorâ€™s securities account. The price for such sale may differ from the current market price of the Units trading on Nasdaq Tallinn stock exchange. More information about converting is available here .For additional information  please contact:Tarmo KarotamBaltic Horizon Fund managerE-mail tarmo.karotam@nh-cap.comwww.baltichorizon.comBaltic Horizon Fund is a registered contractual public closed-end real estate fund that is managed by Alternative Investment Fund Manager license holder Northern Horizon Capital AS.Distribution: GlobeNewswire  Nasdaq Tallinn  Nasdaq Stockholm  www.baltichorizon.com,neutral,0.0,1.0,0.0,neutral,0.01,0.99,0.0,True,English,"['Nasdaq Stockholm stock exchange', 'Swedish Depository Receipts', 'Baltic Horizon Fund', 'Information', 'trading', 'contractual public closed-end real estate fund', 'Alternative Investment Fund Manager license holder', 'Tarmo Karotam Baltic Horizon Fund manager', 'Northern Horizon Capital AS', 'Nasdaq Tallinn stock exchange', 'Baltic Horizon Fund units', 'Nasdaq Stockholm stock exchange', 'Swedish depository receipts', 'SDR offering period', 'respective Swedish Investor', 'less sales costs', 'current market price', 'sales agent', 'first day', 'Euroclear Sweden', 'applicable taxes', 'cash account', 'securities account', 'More information', 'additional information', 'trading', 'SDRs', '31 October', 'unitholders', 'possibility', 'proceeds', 'converting', 'mail', 'baltichorizon', 'registered', 'Distribution', 'GlobeNewswire']",2022-10-28,2022-10-28,finance.yahoo.com
12274,Euroclear,Bing API,https://www.globalinvestorgroup.com/articles/3699392/euroclear-reports-95-year-on-year-increase-in-q3-net-profit,Euroclear reports 95% year-on year increase in Q3 net profit,Euroclear has reported a 95% year-on-year increase of net profit to â‚¬667 million (Â£575 million) at the end of the third quarter  the firm said on Friday. The increase in net profit was due to an increase of 92% in earnings per share to â‚¬211.,If you are an existing subscriber please sign in to read this article in full.Sign up for a free trialTake a complimentary trial to Global Investor Group and gain access to a wealth of news  analysis and data across the Asset Management  Securities Finance  Custody  Fund Services and Derivatives markets from across the suite of Global Investor Products.,neutral,0.01,0.99,0.0,neutral,0.05,0.95,0.0,True,English,"['Q3 net profit', 'year increase', 'Euroclear', 'Global Investor Group', 'Global Investor Products', 'existing subscriber', 'free trial', 'complimentary trial', 'Asset Management', 'Securities Finance', 'Fund Services', 'Derivatives markets', 'article', 'access', 'wealth', 'news', 'analysis', 'data', 'Custody', 'suite']",2022-10-28,2022-10-28,globalinvestorgroup.com
12275,Euroclear,Bing API,https://www.avanza.se/placera/pressmeddelanden/2022/10/28/emplicure-emplicure-notice-to-extraordinary-general-meeting-in-emplicure-ab-publ.html,Emplicure: Notice to Extraordinary General Meeting in Emplicure AB (publ) (beQuoted),"Shareholders in Emplicure AB (publ)  org.nr 556967-7189 ("" Emplicure "" or ""the Company "") are hereby convened to the Extraordinary General Meeting on Monday 14 November 2022 at 11 am at the Company's premises ","NOTICE TO EXTRAORDINARY GENERAL MEETING IN EMPLICURE AB (PUBL)Shareholders in Emplicure AB (publ)  org.nr 556967-7189 (""Emplicure"" or ""the Company"") are hereby convened to the Extraordinary General Meeting on Monday 14 November 2022 at 11 am at the Company's premises  Virdings allÃ© 32B  Uppsala.Notification etc.Shareholders who wish to participate at the Extraordinary General Meeting must:be registered in their own name (not nominee-registered) in the share register kept by Euroclear Sweden AB on Friday 4 November 2022  andnotify their participation so that the notification is received by the Company no later than Thursday 10 November 2022 via e-mail to info@emplicure.com.Such notification shall include the shareholder's name  personal identification number or company registration number (or similar)  address and daytime telephone number  number of shares  details on advisors (no more than two)  if any  and where applicable  details of representatives or proxies.Nominee-registered sharesIn order to be entitled to vote and participate at the general meeting  shareholders whose shares are registered in the name of a nominee must notify their participation and temporarily re-register their shares in their own names in the share register maintained by Euroclear Sweden AB the record date of the Extraordinary General Meeting. Shareholders must therefore advise their nominees well in advance of such date. Voting rights registration which have been requested by the shareholders at such time that the registration has been done by nominee not later than Tuesday 8 November 2022 will be considered when producing the share register.ProxyShareholders represented by proxy must submit a dated proxy. If the proxy is executed by a legal person  a certified copy of the certificate of registration or equivalent must be attached. The proxy may not be valid for a period longer than five years from its issuance. The original proxy and certificate of registration should be submitted to the Company by post at the address mentioned above in due time prior to the general meeting. The Company provides a proxy form at request  and it is also available at the Company's website  www.emplicure.com.Number of Shares and votesAt the time of issuing this notice  there are a total of 26 460 512 shares in the Company. The total number of votes amounts to 26 460 512. The Company does not hold any shares in itself.Proposed agendaOpening of the general meeting and election of chairman of the general meeting Preparation and approval of the voting list Election of one or two persons to verify the minutes Approval of the agenda Determination as to whether the meeting has been duly convened Resolution on approval of the transfer of shares in the subsidiary Amplicon AB to Amplicon's CEO Thomas Hammargren Closing of the general meetingProposals to resolutionsItem 6 - Resolution on approval of the transfer of shares in the subsidiary Amplicon AB to Amplicon's CEO Thomas HammargrenThe board's assessment is that Tomas Hammargren  the CEO of the Company's subsidiary Amplicon AB (""Amplicon"")  is of great importance to Amplicon's further development and the successful commercialization of the products developed by Amplicon. The board therefore believes that it is important and in the interests of all shareholders that Tomas Hammargren has a personal long-term ownership commitment in Amplicon  which can be expected to contribute to an increased interest in Amplicon's operations and earnings development as well as increase the CEO's motivation and align interests with the Company and its shareholders.Therefore  the board of Emplicure  conditional on the approval of the general meeting  has decided to offer Tomas Hammargren to acquire shares in Amplicon according to the following conditions:Tomas Hammargren or a company wholly owned by Tomas Hammargren is offered to acquire 1 250 shares in Amplicon  corresponding to five percent of the total number of outstanding shares in Amplicon.The price for the shares amounts to a total of SEK 805 000  which corresponds to the board's assessment of the market value of the shares. The board's assessment is based on a valuation of Amplicon carried out by BDO on behalf of the Company.The transfer must be conditional on Emplicure and Tomas Hammargren entering into a customary shareholder agreement.The transfer requires the approval of the general meeting in Emplicure according to chapter 16 in the Companies Act. The board proposes that the general meeting resolves to approve the transfer of shares in Amplicon to Thomas Hammargren or a company wholly owned by Thomas Hammargren on the terms stated above. For its validity  the resolution requires the support of shareholders with at least nine tenths (9/10) of both the votes cast and the shares represented at the meeting.Information at the Extraordinary General MeetingThe board of directors and the managing director shall  upon request by any shareholder and where the board of directors determines that it can be done without material harm to the Company  provide information of circumstances which may affect the assessment of a matter on the agenda.DocumentationDocuments according to the Swedish Companies Act will  where applicable  be held available at the Company's office with address Virdings allÃ© 32B  754 50 Uppsala no later than two weeks before the meeting  at the latest 31 October 2022. The documents will also be sent  without charge  to shareholders who so request and inform the Company of their postal address. The documents will also be held available at the extraordinary general meeting.Uppsala in October 2022Emplicure AB (publ)The board of directorsFor additional information  please contactHÃ¥kan EngqvistCEOPhone: +46 702 569 500Email: hakan.engqvist@emplicure.comErik MagnussonCFOPhone: +46 708 565 245Email: erik.magnusson@emplicure.comCertified AdviserEmplicure AB (publ) is listed on the Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank.The following documents can be retrieved from beQuotedNotice-EGM-Emplicure-AB-2022-10-28.pdfEmplicure develops new and innovative products by combining existing and approved active substances with advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain and on abuse-deterrent formulations. The subsidiary Amplicon AB develops consumer products with oral nicotine as the first product. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com",neutral,0.02,0.98,0.0,negative,0.0,0.32,0.68,True,English,"['Extraordinary General Meeting', 'Emplicure AB', 'Notice', 'personal long-term ownership commitment', 'personal identification number', 'daytime telephone number', 'customary shareholder agreement', 'EXTRAORDINARY GENERAL MEETING', 'Euroclear Sweden AB', 'Voting rights registration', 'subsidiary Amplicon AB', 'company registration number', 'voting list', 'Monday 14 November', 'share register', 'Friday 4 November', 'Thursday 10 November', 'Tuesday 8 November', 'legal person', 'certified copy', 'five years', 'two persons', 'Thomas Hammargren', 'Tomas Hammargren', 'great importance', 'successful commercialization', 'following conditions', 'five percent', 'market value', 'Companies Act', 'nine tenths', 'managing director', 'material harm', 'EMPLICURE AB', 'total number', 'record date', 'agenda Determination', 'earnings development', 'Such notification', 'due time', 'original proxy', 'proxy form', 'minutes Approval', 'Nominee-registered shares', 'outstanding shares', 'The Company', '26,460,512 shares', '1,250 shares', 'NOTICE', 'PUBL', 'Shareholders', 'premises', 'Virdings', 'Uppsala', 'name', 'participation', 'mail', 'info', 'address', 'details', 'advisors', 'representatives', 'proxies', 'order', 'nominees', 'advance', 'dated', 'certificate', 'equivalent', 'period', 'issuance', 'post', 'request', 'website', 'votes', 'Opening', 'election', 'chairman', 'Preparation', 'Resolution', 'transfer', 'CEO', 'Proposals', 'Item', 'board', 'assessment', 'products', 'interests', 'increased', 'operations', 'motivation', 'price', 'SEK', 'BDO', 'behalf', 'chapter', 'terms', 'validity', 'support', 'directors', '11']",2022-10-28,2022-10-28,avanza.se
12276,Euroclear,Bing API,https://www.europapress.es/comunicados/internacional-00907/noticia-comunicado-euroclear-continues-to-outperform-despite-volatile-financial-markets-as-it-accelerates-business-strategy-and-investmen-20221028130730.html,Euroclear continues to outperform  despite volatile financial markets  as it accelerates business strategy and investmen,Euroclear continued to deliver a strong financial performance to the end of the third quarter 2022  with the underlying business performing well and benefitting from its diversified  resilient business model. The group also reported higher interest ...,Euroclear continued to deliver a strong financial performance to the end of the third quarter 2022  with the underlying business performing well and benefitting from its diversified  resilient business model. The group also reported higher interest ...,neutral,0.34,0.6,0.06,neutral,0.15,0.84,0.0,True,English,"['volatile financial markets', 'business strategy', 'Euroclear', 'investmen', 'diversified, resilient business model', 'strong financial performance', 'underlying business', 'third quarter', 'higher interest', 'Euroclear', 'end', 'group']",2022-10-28,2022-10-28,europapress.es
12277,Euroclear,Bing API,https://www.privataaffarer.se/egetis-presents-nomination-committee-for-the-2023-annual-general-meeting-1666684800,Egetis presents Nomination Committee for the 2023 Annual General Meeting,Egetis Therapeutics AB (publ) (NASDAQ Stockholm: EGTX) today announced the composition of the Nomination Committee for the 2023 Annual General Meeting (AGM) to be held on April 27  2023  at 3.00 pm (CEST) in Stockholm ,Stockholm  Sweden  October 25  2022. Egetis Therapeutics AB (publ) (NASDAQ Stockholm: EGTX) today announced the composition of the Nomination Committee for the 2023 Annual General Meeting (AGM) to be held on April 27  2023  at 3.00 pm (CEST) in Stockholm  Sweden. The Nomination Committee is composed of members appointed by the three largest shareholders in terms of voting rights  that have accepted the invitation to join the Committee  based on the information received from Euroclear Sweden AB on 30 September 2022.The Nomination Committee comprises the following members:Cidro FÃ¶rvaltning AB: Peter LindellFjÃ¤rde AP-fonden: Jan SÃ¤rlvikAvla Holding AB: Kennet RoothThomas LÃ¶nngren  Chairman of the Board of Directors  will co-opt to the Nomination Committee.In total  the Nomination Committee represents approximately 27.3 % of the total number of shares and votes in the Company. All representatives are independent in relation to the Company and its executive management.The Committee's assignment is to present proposals regarding Chairman and other members of the Board  as well as remuneration to the BoardÂ´s members  to the AGM. The Nomination Committee shall also submit proposals for appointment and remuneration of auditors. Further  the Committee shall submit proposals regarding the process to appoint the Nomination Committee for the AGM in 2024.Shareholders who wish to submit proposals to the Nomination Committee can do so by email to info@egetis.com (please label emails â€˜Nomination Committeeâ€™). Proposals should be submitted no later than January 9  2023.,neutral,0.0,0.99,0.0,neutral,0.0,1.0,0.0,True,English,"['2023 Annual General Meeting', 'Nomination Committee', 'Egetis', 'Cidro FÃ¶rvaltning AB', 'Egetis Therapeutics AB', 'Avla Holding AB', '2023 Annual General Meeting', 'FjÃ¤rde AP-fonden', 'Jan SÃ¤rlvik', 'Thomas LÃ¶nngren', 'three largest shareholders', 'Euroclear Sweden AB', 'The Nomination Committee', 'voting rights', 'Peter Lindell', 'Kennet Rooth', 'executive management', 'following members', 'total number', 'other members', 'Stockholm', 'EGTX', 'composition', 'AGM', 'April', 'terms', 'invitation', 'information', '30 September', 'Chairman', 'Board', 'Directors', 'shares', 'votes', 'Company', 'representatives', 'relation', 'assignment', 'proposals', 'remuneration', 'appointment', 'auditors', 'process', 'email', 'January', '3.00']",2022-10-28,2022-10-28,privataaffarer.se
12278,Euroclear,Bing API,https://www.easternherald.com/2022/10/28/euroclear-continues-to-outperform-despite-volatile-financial-markets-as-it-accelerates-business-strategy-and-investments/,Euroclear continues to outperform  despite volatile financial markets  as it accelerates business strategy and investments,Euroclear continued to deliver a strong financial performance to the end of the third quarter 2022  with the underlying business performing well and benefitting from its diversified  resilient business model.,BRUSSELS  Oct. 28  2022 /PRNewswire/ â€” Euroclear today provides an update on its performance to the end of the third quarter 2022.Financial SummaryEuroclear continued to deliver a strong financial performance to the end of the third quarter 2022  with the underlying business performing well and benefitting from its diversified  resilient business model.The group also reported higher interest earnings due to rising interest rates on cash balances as well as increased cash balances from frozen assets due to Russian sanctions.At the end of the third quarter  2022 net profit increased 95% to EUR 667 million  of which EUR 426 million resulted from the strong underlying business performance.Euroclear Holding (â‚¬ m) YTDSept 2021 YTDSept 2022 Russiansanctionsimpacts YTDSept 2022Underlying Underlyingvs 2021 Operating income 1 199 1 725 335 1 390 191 16 % Business income 1 133 1 202 -5 1 208 74 7 % Interest  banking & other income 65 522 340 182 117 179 % Operating expenses -723 -824 -13 -811 -88 -12 % Operating profit before Impairment 476 901 322 579 103 22 % Impairment -16 -13 -1 -12 4 Pre tax profit 460 888 321 567 107 23 % Tax -118 -221 -80 -140 -22 -19 % Net profit 342 667 241 426 84 25 % EPS 110.3 211.9 135.5 Business income operating margin 36.2 % 31.5 % 32.9 % EBITDA margin (EBITDA/oper.income) 46.2 % 57.0 % 47.5 % Note: 2021 figures (except for EPS) have been restated to includeMFEX pro forma  in order to allow like-for-like comparison.Year-to-date operating income was up 44% year-on-year to EUR 1 725 million.An increase of 92% in earnings per share to EUR 211.9 per share  reflected the increase in net profit.Underlying Business Performance & HighlightsExcluding the impact of frozen assets due to the Russian sanctions  Euroclearâ€™s underlying business continues to perform strongly. Adjusted net profit rose by 25% to EUR 426 million.-Advertisement-Business income was up 7% to EUR 1 208 million  reflecting continued solid growth of Euroclearâ€™s business lines. The diversification of the business has provided a hedge against market volatility over recent months. Interest  banking  and other income increased by 179% to EUR 182 million.Operating Expenses increased to EUR 811 million  up 12% compared to the prior year  as Euroclear continued to invest in its technology and service offering  as well as being impacted by inflation.Inflationary pressures on costs  as well as the broader impact of the macro-economic environment  are monitored at the level of each of operating entity. Only Euroclear Bank benefits directly from the compensating effect of higher interest rates.Overall  Euroclear expects expenditure to remain above its â€œthrough-the-cycleâ€ target of 4-6% p.a. in 2023 as a result of accelerating investment in both its strategy and the resilience of the business  coupled with continued inflationary pressures on the cost base. However  profitability is expected to rise as inflation headwinds are more than offset by higher net interest income from subsequent rate increases.The key operating metrics  shown below  underpinned the strong business performance during the period.Market volatility remains high  driving transaction volumes to record levels.Equity market valuations have fallen significantly during 2022 which has led to declines in assets under custody and fund asset under custody during the period.The impact of lower equity markets is mitigated by the groupâ€™s diversified and subscription-like business model. Approximately three quarters of the groupâ€™s business income is decoupled from financial market valuations.Euroclear sees sustained demand for collateral management and lending services from a broad range of market participants as they seek to reduce credit risk in volatile financial market conditions.Q3 YTD 2022 Change vs Q3 YTD 2021 Assets under Custody EUR 34.9 trillion -3.5 % Number of Transactions 229 million +4.3 % Turnover EUR 791.8 trillion +8.1 % Fund Assets under Custody EUR 2.8 trillion -2.7 % Collateral Highway EUR 1.9 trillion +7.5 %In the third quarter  Euroclear outlined its updated strategic vision and targets to its investors. Through its strategy  the group will continue to focus on meeting the evolving needs of all financial market participants from issuers to investors.-Advertisement-In addition  Euroclear will increase its focus on ESG  data-driven and digital innovations and expanding its global reach.Illustrating this strategic focus  Euroclear enhanced its offering in sustainable finance through an investment in Impact Cubed  a leading provider of ESG tech-enabled analytics and data science solutions. This investment complements Euroclearâ€™s investment in Greenomy  a provider of data and reporting for issuers to comply with EU sustainable finance legislation.International investor appetite for global market access as part of their diversified holdings remains robust and issuers continue to seek to benefit from an international investor base. Euroclearâ€™s strategic focus on meeting these demands continued to deliver growth  despite the headwinds resulting from the Russiaâ€™s invasion of Ukraine. Assets under custody from international and emerging markets were up 18% year-on-year to EUR 1.7 trillion.One year ago  Euroclear acquired MFEX as part of its expanded funds platform. Considerable progress has been made to integrate MFEX and enhance the groupâ€™s end-to-end funds offering. This is reflected through the new MFEXbyEuroclear branding for all group funds solutions.Implications of Russian sanctionsThe sanctions imposed by the US  the EU  and other jurisdictions  as well as Russian countermeasures  resulted in a loss of Russia-related business income which was more than compensated by increased interest income.The cash on the balance sheet has increased as blocked coupon payments and redemptions accumulate. At the end of September  Euroclear Bankâ€™s balance sheet increased by â‚¬88.7 billion year-on-year to a total of EUR 119.9 billion.-Advertisement-As per Euroclearâ€™s standard process  the cash balances arising from the sanctions are invested which  depending on the prevailing interest rates  results in interest income. Over the nine months  revenues on cash balances arising from sanctions on Russia was EUR 340 million.With the growth of sanctioned liabilities and the increase of interest rates  the materiality of revenues on cash balances arising from sanctions on Russia on the groupâ€™s financial results is unprecedented. As such  the Board considers it necessary to separate these earnings from the underlying financial results when assessing the companyâ€™s performance and resources.The Board expects interest income to continue to grow materially as blocked payments and redemptions continue to accumulate in a rising interest rate environment.As previously outlined  while this is expected to have an impact on the balance sheet  it should not result in material change in credit risk profile and therefore will not have a meaningful impact on the groupâ€™s capital ratios.The Board recognises that the unexpected profit should be managed prudently  in line with its corporate purpose and considering its responsibilities towards stakeholders and society. Euroclear continues to act in a transparent manner with all authorities involved. The Board will continue to act cautiously by retaining any profits related to the Russian sanctions until the situation becomes clearer.-Advertisement-Commenting on the resultsLieve Mostrey  Chief Executive Officerâ€œDespite an extraordinary context  we continued to deliver an excellent business performance  with financial results above our strategic â€˜through-the-cycleâ€ targets.The group benefits from a diversified business model which allows us to focus on supporting clients through these uncertain times  providing robust infrastructure and fulfilling our duties with respect to the sanctions on Russia.Our results show that we are on the right path. We are now accelerating investments to deliver on our long-term strategy and drive value for all our stakeholders.â€AnnexesInterest income is driven by the prevailing interest rates in each currency of the cash balances held by the group. As at 30 September 2022  cash balances totaled EUR 111.7 billion  of which EUR 85.8 billion related to the sanctions on Russia.The proportion of cash balances by currency is as follows:Euroclear Bank and Euroclear Investments are the two group issuing entities. The summary income statements and financial positions at Q3 YTD for both entities are shown below.-Advertisement-Q3 2022 Q3 2021 Variance Euroclear Bank Income Statement Net interest income 550.9 69.3 481.6 Net fee and commission income 771.2 686.7 84.5 Other income -12.5 7.2 -19.7 Total operating income 1 309.6 763.2 546.4 Administrative expenses -485.2 -440.8 -44.4 Operating profit before impairment and taxation 824.4 322.4 502.0 Result for the period 618.4 244.2 374.3 Euroclear Bank Statement of Financial Position Shareholdersâ€™ equity 2 424.2 1 924.7 499.5 Debt securities issued and funds borrowed (incl. subordinated debt) 5 191.8 6 869.7 -1 678.0 Total assets 119 887.7 31 209.1 88 678.6 Euroclear Investments Income Statement Dividend 313.4 540.1 -226.7 Net gains/(losses) on non trading financial assets at FVPL -473.6 -43.5 -430.1 Other income 2.9 1.4 1.6 Total operating income -157.3 498.0 -655.3 Administrative expenses -3.4 -1.1 -2.3 Operating profit before impairment and taxation -160.7 496.9 -657.6 Result for the period -42.9 507.3 -550.3 Euroclear Investments Statement of Financial Position Shareholdersâ€™ equity 460.8 757.3 -296.6 Debt securities issued and funds borrowed 1 654.7 1 653.3 1.5 Total assets of which 2 116.0 2 449.1 -333.1 Loans and advances at amortised cost (excluding intercompany) 85.9 55.8 30.1 Fair Value through Other Comprehensive Income (FVOCI) financial assets 299.0 311.1 -12.1 Intercompany loans (at amortised cost and FVPL) 853.4 1 275.9 -422.5 Note: At the end of Q3  Euroclear Investments received a dividend from Euroclear SA which was more than offset by unrealised fairmarket valuation. An increasing interest rate environment has impacted Euroclear Investmentâ€™s intra-group loans (assets) recognised at fair market value in line with IFRS 9. Liabilities have not been impacted  due to being recognised at acquisitioncost  in line with accounting standards. As a result  Euroclear Investments demonstrates a significant loss on non-trading financialassets for Q3 2022 compared to Q3 2021  resulting in a negative operating profit. This accounting treatment has no impact onEuroclear groupâ€™s earnings capacity nor on the ability for Euroclear Investments to reimburse its debt.Note to editorsEuroclear group is the financial industryâ€™s trusted provider of post trade services. Guided by its purpose  Euroclear innovates to bring safety  efficiency and connections to financial markets for sustainable economic growth.Euroclear provides settlement and custody of domestic and cross-border securities for bonds  equities and derivatives  and investment funds. As a proven  resilient capital market infrastructure  Euroclear is committed to delivering risk-mitigation  automation and efficiency at scale for its global client franchise.The Euroclear group comprises Euroclear Bank  the International CSD  as well as Euroclear Belgium  Euroclear Finland  Euroclear France  Euroclear Nederland  Euroclear Sweden  Euroclear UK & International  and MFEXbyEuroclear.Photo: https://mma.prnewswire.com/media/1932189/Euroclear_chart_1.jpgPhoto: https://mma.prnewswire.com/media/1932190/Euroclear_chart_2.jpgLogo: https://mma.prnewswire.com/media/832898/Euroclear_Logo.jpgView original content:https://www.prnewswire.co.uk/news-releases/euroclear-continues-to-outperform-despite-volatile-financial-markets-as-it-accelerates-business-strategy-and-investments-301662280.html,neutral,0.04,0.91,0.06,mixed,0.23,0.29,0.47,True,English,"['volatile financial markets', 'business strategy', 'Euroclear', 'investments', 'EU sustainable finance legislation', 'volatile financial market conditions', 'diversified, resilient business model', 'strong underlying business performance', 'higher net interest income', 'Business income operating margin', 'subsequent rate increases', 'lower equity markets', 'ESG tech-enabled analytics', 'International investor appetite', 'strong financial performance', 'subscription-like business model', 'higher interest rates', 'Equity market valuations', 'financial market valuations', 'rising interest rates', 'international investor base', 'key operating metrics', 'strong business performance', 'financial market participants', 'global market access', 'data science solutions', 'higher interest earnings', 'Russian sanctions impacts', '4 Pre tax profit', 'continued inflationary pressures', 'Q3 YTD 2021 Assets', 'Financial Summary', '32.9 % EBITDA margin', 'Operating income', 'market volatility', '2022 net profit', 'Operating profit', 'cost base', 'global reach', 'business lines', 'other income', 'EBITDA/oper.income', 'Operating expenses', 'operating entity', 'diversified holdings', 'third quarter', 'cash balances', 'frozen assets', 'recent months', 'macro-economic environment', 'compensating effect', 'transaction volumes', 'record levels', 'three quarters', 'sustained demand', 'collateral management', 'lending services', 'broad range', 'credit risk', 'Collateral Highway', 'strategic vision', 'evolving needs', 'digital innovations', 'strategic focus', 'solid growth', 'prior year', 'service offering', 'broader impact', 'inflation headwinds', 'Impact Cubed', 'leading provider', 'Euroclear Holding', 'Euroclear Bank', 'BRUSSELS', 'PRNewswire', 'update', 'group', 'Sept', 'banking', 'Impairment', 'EPS', 'Note', '2021 figures', 'MFEX', 'order', 'comparison', 'share', 'Highlights', 'Advertisement', 'diversification', 'hedge', 'technology', 'costs', 'Only', 'expenditure', 'cycle', 'target', 'result', 'investment', 'strategy', 'resilience', 'profitability', 'period', 'declines', 'custody', 'Change', 'Number', 'Transactions', 'Turnover', 'investors', 'issuers', 'addition', 'data-driven', 'Greenomy', 'reporting', 'demands', '1.5']",2022-10-28,2022-10-28,easternherald.com
12279,Euroclear,Twitter API,Twitter,Labor shortages and higher costs may drive self-checkout adoptions #AAA Websites Euroclear Fintech https://t.co/f36TZICq1L #regtech,nan,Labor shortages and higher costs may drive self-checkout adoptions #AAA Websites Euroclear Fintech https://t.co/f36TZICq1L #regtech,neutral,0.01,0.91,0.08,neutral,0.01,0.91,0.08,True,English,"['Labor shortages', 'higher costs', 'self-checkout adoptions', 'Labor shortages', 'higher costs', 'self-checkout adoptions']",2022-10-28,2022-10-28,Unknown
12280,Euroclear,Twitter API,Twitter,Those seeking to bring down the CFPB should be careful what they wish for #AAA Websites Euroclear Fintech https://t.co/dPQZUKHSC9 #regtech,nan,Those seeking to bring down the CFPB should be careful what they wish for #AAA Websites Euroclear Fintech https://t.co/dPQZUKHSC9 #regtech,neutral,0.49,0.5,0.01,neutral,0.49,0.5,0.01,True,English,"['CFPB', 'regtech', 'CFPB', 'regtech']",2022-10-28,2022-10-28,Unknown
12281,Euroclear,Twitter API,Twitter,Truliant puts South Carolina branch expansion into motion #AAA Websites Euroclear Fintech https://t.co/sKPOFAaVvH #regtech,nan,Truliant puts South Carolina branch expansion into motion #AAA Websites Euroclear Fintech https://t.co/sKPOFAaVvH #regtech,neutral,0.0,0.99,0.0,neutral,0.0,0.99,0.0,True,English,"['South Carolina branch expansion', 'Truliant', 'motion', 'Fintech', 'South Carolina branch expansion', 'Truliant', 'motion', 'Fintech']",2022-10-28,2022-10-28,Unknown
12282,Euroclear,Twitter API,Twitter,Broadridge Fully Automates Corporate Action and Dividend Events  Managed Through Euroclear CREST https://t.co/K0IM8zkKcU #business,nan,Broadridge Fully Automates Corporate Action and Dividend Events  Managed Through Euroclear CREST https://t.co/K0IM8zkKcU #business,neutral,0.0,0.99,0.0,neutral,0.0,0.99,0.0,True,English,"['Corporate Action', 'Dividend Events', 'Euroclear CREST', 'Broadridge', 'K0IM8zkKcU', 'business', 'Corporate Action', 'Dividend Events', 'Euroclear CREST', 'Broadridge', 'K0IM8zkKcU', 'business']",2022-10-28,2022-10-28,Unknown
12283,Euroclear,Twitter API,Twitter,Euroclear continues to outperform  despite volatile financialmarkets  as it accelerates business strategy and inveâ€¦ https://t.co/xC3rwzmSz7,nan,Euroclear continues to outperform  despite volatile financialmarkets  as it accelerates business strategy and inveâ€¦ https://t.co/xC3rwzmSz7,neutral,0.14,0.83,0.03,neutral,0.14,0.83,0.03,True,English,"['volatile financial markets', 'business strategy', 'Euroclear', 'inve', 'volatile financial markets', 'business strategy', 'Euroclear', 'inve']",2022-10-28,2022-10-28,Unknown
12284,Euroclear,Twitter API,Twitter,Euroclear continues to outperform  despite volatile financial markets  as it accelerates business strategy andÂ inveâ€¦ https://t.co/DuTTOVye3b,nan,Euroclear continues to outperform  despite volatile financial markets  as it accelerates business strategy andÂ inveâ€¦ https://t.co/DuTTOVye3b,neutral,0.05,0.93,0.02,neutral,0.05,0.93,0.02,True,English,"['volatile financial markets', 'business strategy', 'Euroclear', 'DuTTOVye3b', 'volatile financial markets', 'business strategy', 'Euroclear', 'DuTTOVye3b']",2022-10-28,2022-10-28,Unknown
12285,Euroclear,Twitter API,Twitter,Euroclear continues to outperform  despite volatile financial markets  as it accelerates business strategy and inveâ€¦ https://t.co/BeazjlW5U3,nan,Euroclear continues to outperform  despite volatile financial markets  as it accelerates business strategy and inveâ€¦ https://t.co/BeazjlW5U3,neutral,0.06,0.93,0.02,neutral,0.06,0.93,0.02,True,English,"['volatile financial markets', 'business strategy', 'Euroclear', 'BeazjlW5U3', 'volatile financial markets', 'business strategy', 'Euroclear', 'BeazjlW5U3']",2022-10-28,2022-10-28,Unknown
12286,Euroclear,Twitter API,Twitter,Euroclear continues to outperform  despite volatile financial markets  as it accelerates business strategy andÂ inveâ€¦ https://t.co/VZBs0LtFu4,nan,Euroclear continues to outperform  despite volatile financial markets  as it accelerates business strategy andÂ inveâ€¦ https://t.co/VZBs0LtFu4,neutral,0.19,0.79,0.03,neutral,0.19,0.79,0.03,True,English,"['volatile financial markets', 'business strategy', 'Euroclear', 'VZBs0LtFu4', 'volatile financial markets', 'business strategy', 'Euroclear', 'VZBs0LtFu4']",2022-10-28,2022-10-28,Unknown
12287,Euroclear,Twitter API,Twitter,Euroclear continues to outperform  despite volatile financial markets  as it accelerates business strategy andÂ inveâ€¦ https://t.co/jGOuFU86qS,nan,Euroclear continues to outperform  despite volatile financial markets  as it accelerates business strategy andÂ inveâ€¦ https://t.co/jGOuFU86qS,neutral,0.1,0.88,0.03,neutral,0.1,0.88,0.03,True,English,"['volatile financial markets', 'business strategy', 'Euroclear', 'volatile financial markets', 'business strategy', 'Euroclear']",2022-10-28,2022-10-28,Unknown
12288,Euroclear,Twitter API,Twitter,Euroclear continues to outperform  despite volatile financial markets  as it accelerates business strategy andÂ inveâ€¦ https://t.co/GTIoYK8cQw,nan,Euroclear continues to outperform  despite volatile financial markets  as it accelerates business strategy andÂ inveâ€¦ https://t.co/GTIoYK8cQw,neutral,0.16,0.82,0.02,neutral,0.16,0.82,0.02,True,English,"['volatile financial markets', 'business strategy', 'Euroclear', 'GTIoYK8cQw', 'volatile financial markets', 'business strategy', 'Euroclear', 'GTIoYK8cQw']",2022-10-28,2022-10-28,Unknown
12289,Euroclear,Twitter API,Twitter,Euroclear:Euroclear continues to outperform  despite volatile financial markets  as it accelerates business strategâ€¦ https://t.co/J0ggAUbBG3,nan,Euroclear:Euroclear continues to outperform  despite volatile financial markets  as it accelerates business strategâ€¦ https://t.co/J0ggAUbBG3,neutral,0.09,0.89,0.02,neutral,0.09,0.89,0.02,True,English,"['volatile financial markets', 'business strateg', 'Euroclear', 'J0ggAUbBG3', 'volatile financial markets', 'business strateg', 'Euroclear', 'J0ggAUbBG3']",2022-10-28,2022-10-28,Unknown
12290,Euroclear,Twitter API,Twitter,Meet @AnVanDoorselaer  Wellbeing  Diversity &amp; Inclusion Officer  who works in HR &amp; supports Euroclear in building aâ€¦ https://t.co/4meatmh1ER,nan,Meet @AnVanDoorselaer  Wellbeing  Diversity &amp; Inclusion Officer  who works in HR &amp; supports Euroclear in building aâ€¦ https://t.co/4meatmh1ER,neutral,0.06,0.93,0.01,neutral,0.06,0.93,0.01,True,English,"['Inclusion Officer', 'Wellbeing', 'Diversity', 'amp', 'HR', 'Euroclear', 'meatmh1ER', 'Inclusion Officer', 'Wellbeing', 'Diversity', 'amp', 'HR', 'Euroclear', 'meatmh1ER']",2022-10-28,2022-10-28,Unknown
12291,Euroclear,Twitter API,Twitter,What banks need to watch two weeks until the midterms #AAA Websites Euroclear Fintech https://t.co/BcZd5vQvll #regtech,nan,What banks need to watch two weeks until the midterms #AAA Websites Euroclear Fintech https://t.co/BcZd5vQvll #regtech,neutral,0.01,0.99,0.0,neutral,0.01,0.99,0.0,True,English,"['banks', 'midterms', 'Fintech', 'BcZd5vQvll', 'banks', 'midterms', 'Fintech', 'BcZd5vQvll']",2022-10-28,2022-10-28,Unknown
12292,Euroclear,Twitter API,Twitter,Live updates from the Most Powerful Women in Banking gala #AAA Websites Euroclear Fintech https://t.co/7nuadqYtpO #regtech,nan,Live updates from the Most Powerful Women in Banking gala #AAA Websites Euroclear Fintech https://t.co/7nuadqYtpO #regtech,neutral,0.02,0.97,0.0,neutral,0.02,0.97,0.0,True,English,"['Most Powerful Women', 'AAA Websites Euroclear', 'Live updates', 'Banking gala', 'Fintech', 'nuadqYtpO', 'Most Powerful Women', 'AAA Websites Euroclear', 'Live updates', 'Banking gala', 'Fintech', 'nuadqYtpO']",2022-10-28,2022-10-28,Unknown
12293,Deutsche Boerse,Bing API,https://www.thetradenews.com/leaders-in-trading-2022-meet-the-nominees-for-outstanding-post-trade-services-provider/,Leaders in Trading 2022: Meet the nominees forâ€¦. Outstanding Post-Trade Services Provider,Learn more about the five firms shortlisted for our Editorsâ€™ Choice Award for Outstanding Post-Trade Services Provider this year: including DTCC  Deutsche BÃ¶rse  Euronext  LCH and OSTTRA.,The TRADE is happy to introduce the shortlist for our Editorsâ€™ Choice  Outstanding Post-Trade Services Provider. The shortlisted post-trade services providers have all experienced great years and achieved outstanding performance. Learn more about our shortlisted candidates below  including DTCC  Deutsche BÃ¶rse  Euronext  LCH and OSTTRA.DTCCEarlier this year  the Depository Trust & Clearing Corporationâ€™s (DTCC) went live with its distributed ledger technology (DLT) based settlement platform in a parallel production environment  processing up to 160 000 transactions per day. Named Project Ion  the platform has been in the works since May 2020  with a view to support a netted T+0 settlement cycle  as well as T+2  T+1 and extended cycles.Going live in parallel to existing settlement infrastructure  the project is processing an average of over 100 000 bilateral equity transactions per day  and almost 160 000 transactions on peak days. The Depository Trust Companyâ€™s (DTC) classic settlement systems remaining the authoritative record. Project ION has been developed in collaboration with the likes of BNY Mellon  Citi and JP Morgan.Elsewhere  DTCC Institutional Trade Processing (ITP) provides an open  post-trade infrastructure that aims to remove redundancies and manual processing across asset classes in an effort to create a place where users can manage the entire trade lifecycle  from post-execution to settlement  on one platform.Deutsche BÃ¶rseDeutsche BÃ¶rse Groupâ€™s clearing houses  Eurex Clearing AG and European Commodity Clearing AG  act as central counterparties  i.e. as buyer to each seller and as seller to each buyer  to minimise credit default risk. The clearing houses offer efficient clearing of a wide range of transaction types  both on-exchange and over-the-counter (OTC).Deutsche BÃ¶rse recently acquired the North American Nodal Exchange by the EEX Group  adding a third clearing house  Nodal Clear  to its roster.Towards the end of last year  Deutsche BÃ¶rse rolled out a major technology overhaul with the launch of digital post-trade platform. The fully digital post-trade platform provides same-day-issuance and paperless  automated straight-through processing for the entire value chain of issuance  custody  settlement  and asset servicing for digital securities.Working with distributed ledger technology (DLT) specialist  Digital Asset  as a partner on the project  the German exchange groupâ€™s new initiative uses a cloud-backed and DLT-ready platform to enable the digitisation of financial products with continuing access to both existing central and distributed infrastructures and markets.EuronextEuronext serves as the largest pan-European exchange and market infrastructure  connecting seven markets across the continent. The last year has proved fruitful for the exchange with surging trading volumes alongside a series of successful acquisitions.In August  Euronext reported a particularly â€˜solidâ€™ Q2 driven by the sustained dynamism of non-volume activities and of trading operations. The exchange reported a 14% increase in revenue and income in Q2 of this year  compared to the same period last year  which reached â‚¬374.7 million â€“ driven by the growth of non-volume related business and trading activities.Non-volume related revenue accounted for 59% of Euronextâ€™s Q2 total revenue this year  while trading revenue grew to â‚¬129.2 million  a 15.6% increase compared to the same period last year â€“ a result linked to robust performance across all asset classes in a volatile market environment. Growth was also driven by the recent Borsa Italiana acquisition  which also bumped up the exchangeâ€™s strong Q1 results.Elsewhere  Euronext reported that net income  share of the parent company shareholders was up 37.2% to â‚¬118.9 million  an increase by â‚¬32.2 million compared to the same period last year.LCHGlobal clearing house LCH  which is part of the post-trade division of London Stock Exchange Group (LSEG)  has had an impressive year with several revenue increases across its business. LCH continues to partner with market participants globally to offer clearing services and provide risk management capabilities across a range of asset classes  including OTC and listed interest rates  fixed income  FX  CDS  equities and commodities.The clearing house has helped reduce systemic risk and strengthen stability in financial markets alongside allowing participants to benefit from capital and operational efficiencies. In 2021  LSEG post-trade experienced improved revenue figures  with total income rising to Â£483 million  which was an increase by 8.5% compared to 2022. This comprised of Â£191m for OTC derivatives; Â£122m for securities and repo; Â£49m for non-cash collateral and Â£121m for net trade income (NTI). Elsewhere  LCH has seen growth across its services and record clearing activity in H1 2022.OSTTRAOSTTRA was formed in 2021 through the combination of four businesses that have been involved in the post-trade for over 20 years  namely MarkitServ  Traiana  TriOptima and Reset. The combination of these businesses allows OSTTRA to play a role in supporting global financial markets  connecting thousands of counterparties via its multi-asset networks that support the post-trade lifecycle from trade capture  through portfolio optimisation  to clearing and settlement services.OSTTRA boasts over 9 000 connections on its network  including major banks  investment managers and clearing houses. The firm processes over 80 million trades monthly  including matching  confirming and booking transactions  managing credit limits and reconciling portfolios. Every second  OSTTRA performs over 10 trillion calculations  optimising counterparty risk  margin and capital efficiency.As a company  OSTTRA looks to keep pace with market reforms. Through ongoing dialogue with regulators and market participants  OSTTRA responds to new regulatory mandates with standardised solutions and workflows that minimise costs and compliance risks for its customers.Elsewhere  to manage market volatility  OSTTRA continually works with its client base to automate and streamline new steps in post trade workflows to improve efficiency and reduce operational risk during peak market volumes.,positive,0.97,0.03,0.0,positive,0.81,0.18,0.0,True,English,"['Outstanding Post-Trade Services Provider', 'Leaders', 'Trading', 'nominees', 'recent Borsa Italiana acquisition', 'paperless, automated straight-through processing', 'European Commodity Clearing AG', 'London Stock Exchange Group', 'North American Nodal Exchange', 'Deutsche BÃ¶rse Group', 'The Depository Trust Company', 'Outstanding Post-Trade Services Provider', 'DTCC Institutional Trade Processing', 'Global clearing house LCH', 'parent company shareholders', 'Eurex Clearing AG', 'entire trade lifecycle', 'major technology overhaul', 'entire value chain', 'strong Q1 results', 'listed interest rates', 'distributed ledger technology', 'credit default risk', 'risk management capabilities', 'third clearing house', 'German exchange group', 'up to 160,000 transactions', '100,000 bilateral equity transactions', 'Non-volume related revenue', 'volatile market environment', 'several revenue increases', 'open, post-trade infrastructure', 'largest pan-European exchange', 'surging trading volumes', 'T+0 settlement cycle', 'classic settlement systems', 'post-trade services providers', 'parallel production environment', 'volume related business', 'net trade income', 'existing settlement infrastructure', 'digital post-trade platform', 'Q2 total revenue', 'The TRADE', 'manual processing', 'EEX Group', 'clearing services', 'outstanding performance', 'Nodal Clear', 'market infrastructure', 'distributed infrastructures', 'systemic risk', 'post-trade division', 'trading revenue', 'Clearing Corporation', 'clearing houses', 'efficient clearing', 'clearing activity', 'Digital Asset', 'existing central', 'volume activities', 'net income', 'total income', 'revenue figures', 'settlement platform', 'trading operations', 'trading activities', 'one platform', 'DLT-ready platform', 'LSEG post-trade', 'Editorsâ€™ Choice', 'shortlisted candidates', 'DLT) based', 'extended cycles', 'peak days', 'authoritative record', 'BNY Mellon', 'JP Morgan', 'asset classes', 'central counterparties', 'transaction types', 'asset servicing', 'digital securities', 'DLT) specialist', 'new initiative', 'financial products', 'continuing access', 'successful acquisitions', 'solidâ€™ Q2', 'sustained dynamism', 'same period', 'robust performance', 'fixed income', 'operational efficiencies', 'cash collateral', 'market participants', 'last year', 'impressive year', 'seven markets', 'financial markets', 'great years', 'Project Ion', 'wide range', 'OTC derivatives', 'four businesses', '20 years', 'Euronext', 'OSTTRA', 'works', 'May', 'view', 'average', 'collaboration', 'likes', 'Citi', 'ITP', 'redundancies', 'effort', 'place', 'users', 'post-execution', 'buyer', 'seller', 'roster', 'launch', 'same-day-issuance', 'custody', 'partner', 'cloud-backed', 'digitisation', 'continent', 'series', 'August', '14% increase', 'growth', '15.6% increase', 'FX', 'CDS', 'equities', 'commodities', 'stability', 'capital', 'repo', 'H1', 'combination', 'MarkitServ', 'Traiana', 'TriOptima', 'Reset', '+1']",2022-10-28,2022-10-28,thetradenews.com
12294,Deutsche Boerse,Twitter API,Twitter,Surging interest rates are benefiting German exchange operator Deutsche BÃ¶rse by boosting demand for derivatives tiâ€¦ https://t.co/sNmFDs3xSN,nan,Surging interest rates are benefiting German exchange operator Deutsche BÃ¶rse by boosting demand for derivatives tiâ€¦ https://t.co/sNmFDs3xSN,neutral,0.11,0.88,0.02,neutral,0.11,0.88,0.02,True,English,"['Surging interest rates', 'German exchange operator', 'Deutsche BÃ¶rse', 'demand', 'derivatives', 'Surging interest rates', 'German exchange operator', 'Deutsche BÃ¶rse', 'demand', 'derivatives']",2022-10-28,2022-10-28,Unknown
12295,Deutsche Boerse,Twitter API,Twitter,Deutsche BÃ¶rse makes strategic investment into private derivatives trading platformThe exchange group has investedâ€¦ https://t.co/LCfn3NzM5d,nan,Deutsche BÃ¶rse makes strategic investment into private derivatives trading platformThe exchange group has investedâ€¦ https://t.co/LCfn3NzM5d,neutral,0.06,0.93,0.02,neutral,0.06,0.93,0.02,True,English,"['private derivatives trading platform', 'Deutsche BÃ¶rse', 'strategic investment', 'exchange group', 'LCfn3NzM5d', 'private derivatives trading platform', 'Deutsche BÃ¶rse', 'strategic investment', 'exchange group', 'LCfn3NzM5d']",2022-10-28,2022-10-28,Unknown
12296,EuroNext,NewsApi.org,https://finance.yahoo.com/news/pharming-announces-european-medicines-agency-050000524.html,Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib,"Pharming Group N.V. (""Pharming"" or ""the Company"") (EURONEXT Amsterdam: PHARM / Nasdaq: PHAR) announces today that its Marketing Authorisation Application...","Marketing authorisation in the European Economic Area anticipated in H1 2023LEIDEN  Netherlands  Oct. 28  2022 /PRNewswire/ -- Pharming Group N.V. (""Pharming"" or ""the Company"") (EURONEXT Amsterdam: PHARM / Nasdaq: PHAR) announces today that its Marketing Authorisation Application (MAA) for leniolisib has been validated for scientific evaluation under an accelerated assessment by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). The application  submitted earlier in October 2022  is for the investigational drug  leniolisib  an oral  selective phosphoinositide 3-kinase delta (PI3KÎ´) inhibitor  as a treatment for activated phosphoinositide 3-kinase delta syndrome (APDS)  a rare primary immunodeficiency  in adolescents and adults 12 years or older.Pharming Group N.V. logoIn August 2022  Pharming announced the leniolisib MAA was granted accelerated assessment by EMA's CHMP. The accelerated assessment reduces the review timeframe from 210 days to 150 days. Upon request  EMA will grant an accelerated assessment of an MAA if they decide the product is of major interest for public health  and in particular  from the viewpoint of therapeutic innovation. Marketing authorisation for leniolisib in the European Economic Area is anticipated in H1 2023.The MAA is supported by positive data from a Phase II/III study of leniolisib  announced on February 2  2022  which met its co-primary endpoints of reduction in lymph node size and increase in percentage of naÃ¯ve B cells in patients with APDS. Furthermore  safety data from the study showed that leniolisib was well tolerated by participants. Also submitted as part of the MAA were data from a long-term  open-label extension clinical trial in patients with APDS treated with leniolisib.Anurag Relan  MD  MPH  Chief Medical Officer of Pharming  commented:""EMA's validation for review of our MAA under an accelerated assessment pathway highlights Pharming's ongoing commitment to advance leniolisib as a targeted treatment for adults and adolescents 12 years of age or older with APDS. We anticipate that leniolisib will fill an unmet need for patients with APDS  who currently rely on supportive therapies to treat their primary symptoms. This review constitutes a key milestone in Pharming's effort to give healthcare providers and their patients global access to leniolisib. We look forward to collaborating with EMA as needed throughout the regulatory process.""Story continuesAbout Activated Phosphoinositide 3-Kinase Î´ Syndrome (APDS)APDS is a rare primary immunodeficiency that affects approximately 1 to 2 people per million. APDS is caused by variants in either of two genes  PIK3CD or PIK3R1  that regulate maturation of white blood cells. Variants of these genes lead to hyperactivity of the PI3KÎ´ (phosphoinositide 3-kinase delta) pathway.1 2 Balanced signaling in the PI3KÎ´ pathway is essential for physiological immune function. When this pathway is hyperactive  immune cells fail to mature and function properly  leading to immunodeficiency and dysregulation.1 3 APDS is characterized by severe  recurrent sinopulmonary infections  lymphoproliferation  autoimmunity  and enteropathy.4 5 Because these symptoms can be associated with a variety of conditions  including other primary immunodeficiencies  people with APDS are frequently misdiagnosed and suffer a median 7-year diagnostic delay.6 As APDS is a progressive disease  this delay may lead to an accumulation of damage over time  including permanent lung damage and lymphoma.4-7 The only way to definitively diagnose this condition is through genetic testing.About LeniolisibLeniolisib is a small-molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class IA PI3K. PI3KÎ´ is expressed predominately in hematopoietic cells and is essential to normal immune system function through conversion of phosphatidylinositol-4-5-trisphosphate (PIP2) to phosphatidylinositol-3-4-5-trisphosphate (PIP3). Leniolisib inhibits the production of PIP3 and PIP3 serves as an important cellular messenger activating AKT (via PDK1) and regulates a multitude of cell functions such as proliferation  differentiation  cytokine production  cell survival  angiogenesis  and metabolism. Unlike PI3KÎ± and PI3KÎ²  which are ubiquitously expressed  PI3KáºŸ and PI3KÎ³ are expressed primarily in cells of hematopoietic origin. The central role of PI3KáºŸ in regulating numerous cellular functions of the adaptive immune system (B-cells and  to a lesser extent  T cells) as well as the innate immune system (neutrophils  mast cells  and macrophages) strongly indicates that PI3KáºŸ is a valid and potentially effective therapeutic target for immune diseases such as APDS. To date  leniolisib has been well tolerated during both the Phase 1 first-in-human trial in healthy subjects and the Phase II/III registration-enabling study in patients with APDS.About Pharming Group N.V.Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare  debilitating  and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines  including small molecules  biologics  and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden  Netherlands  and has employees around the globe who serve patients in over 30 markets in North America  Europe  the Middle East  Africa  and Asia-Pacific.For more information  visit www.pharming.com.Forward-Looking StatementsThis press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results  performance or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as ""aim""  ""ambition""  ''anticipate''  ''believe''  ''could''  ''estimate''  ''expect''  ''goals''  ''intend''  ''may''  ""milestones""  ''objectives''  ''outlook''  ''plan''  ''probably''  ''project''  ''risks''  ""schedule""  ''seek''  ''should''  ''target''  ''will'' and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates  Pharming's clinical and commercial prospects  and Pharming's expectations regarding its projected working capital requirements and cash resources  which statements are subject to a number of risks  uncertainties and assumptions  including  but not limited to the scope  progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical  scientific  regulatory and technical developments. In light of these risks and uncertainties  and other risks and uncertainties that are described in Pharming's 2021 Annual Report and the Annual Report on Form 20-F for the year ended December 31  2021 filed with the U.S. Securities and Exchange Commission  the events and circumstances discussed in such forward-looking statements may not occur  and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information  future events or other information.Inside InformationThis press release relates to the disclosure of information that qualifies  or may have qualified  as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.References1. Lucas CL  et al. Nat Immunol. 2014;15:88-97.2. Elkaim E  et al. J Allergy Clin Immunol. 2016;138(1):210-218.3. Nunes-Santos C  Uzel G  Rosenzweig SD. J Allergy Clin Immunol. 2019;143(5):1676-1687.4. Coulter TI  et al. J Allergy Clin Immunol. 2017;139(2):597-606.5. Maccari ME  et al. Front Immunol. 2018;9:543.6. Jamee M  et al. Clin Rev Allergy Immunol. 2019;May 21.7. Condliffe AM  Chandra A. Front Immunol. 2018;9:338.For further public information  contact:Pharming Group  Leiden  The NetherlandsHeather Robertson  Investor Relations & Corporate Communications ManagerT: +31 71 524 7400E: investor@pharming.comFTI Consulting  London  UKVictoria Foster Mitchell/Alex ShawithAmy ByrneT: +44 203 727 1000LifeSpring Life Sciences Communication  Amsterdam  The NetherlandsLeon MelensT: +31 6 53 81 64 27E: pharming@lifespring.nlUS PR:Ethan MetelenisE: Ethan.Metelenis@precisionvh.comT: +1 (917) 882 9038EU PR:Dan CaleyE: Dan.caley@aprilsix.comT: +44 (0) 787 546 8942Logo - https://mma.prnewswire.com/media/1454235/Pharming_Group_NV_Logo.jpgCisionView original content:https://www.prnewswire.co.uk/news-releases/pharming-announces-european-medicines-agency-ema-validates-its-marketing-authorisation-application-under-accelerated-assessment-for-leniolisib-301661947.html",neutral,0.0,1.0,0.0,mixed,0.57,0.28,0.15,True,English,"['European Medicines Agency', 'Marketing Authorisation Application', 'Accelerated Assessment', 'Pharming', 'EMA', 'leniolisib', 'long-term, open-label extension clinical trial', 'oral, selective phosphoinositide 3-kinase delta', 'Pharming Group N.V. logo', 'severe, recurrent sinopulmonary infections', 'phosphoinositide 3-kinase delta syndrome', 'median 7-year diagnostic delay', 'naÃ¯ve B cells', 'phosphoinositide 3-kinase delta) pathway', 'normal immune system function', 'Phase II/III registration-enabling study', 'Phosphoinositide 3-Kinase Î´ Syndrome', 'European Economic Area', 'European Medicines Agency', 'lymph node size', 'Chief Medical Officer', '110 kDa catalytic subunit', 'important cellular messenger', 'adaptive immune system', 'innate immune system', 'Phase II/III study', 'other primary immunodeficiencies', 'numerous cellular functions', 'effective therapeutic target', 'white blood cells', 'permanent lung damage', 'rare primary immunodeficiency', 'global biopharmaceutical company', 'class IA PI3K', 'Marketing Authorisation Application', 'accelerated assessment pathway', 'delta isoform', 'immune function', 'human trial', 'immune cells', 'immune diseases', 'rare, debil', 'primary endpoints', 'therapeutic innovation', 'global access', 'cell functions', 'hematopoietic cells', 'T cells', 'primary symptoms', 'EURONEXT Amsterdam', 'scientific evaluation', 'Medicinal Products', 'Human Use', 'investigational drug', 'major interest', 'public health', 'Anurag Relan', 'ongoing commitment', 'unmet need', 'supportive therapies', 'key milestone', 'healthcare providers', 'regulatory process', 'Balanced signaling', 'progressive disease', 'genetic testing', 'small-molecule inhibitor', 'cell survival', 'hematopoietic origin', 'central role', 'lesser extent', 'healthy subjects', 'PI3KÎ´ pathway', 'positive data', 'safety data', 'targeted treatment', '1 to 2 people', 'two genes', 'cytokine production', 'PI3KÎ´) inhibitor', 'review timeframe', 'The MAA', 'Phase 1', 'leniolisib MAA', 'PI3KÎ±', 'PI3KÎ²', 'PI3KÎ³', 'H1', 'LEIDEN', 'Netherlands', 'PRNewswire', 'Nasdaq', 'CHMP', 'October', 'APDS', 'adolescents', 'adults', 'August', '210 days', '150 days', 'request', 'viewpoint', 'February', 'reduction', 'percentage', 'patients', 'participants', 'MD', 'validation', 'years', 'effort', 'Story', 'million', 'variants', 'PIK3CD', 'PIK3R', 'maturation', 'hyperactivity', 'dysregulation', 'lymphoproliferation', 'autoimmunity', 'enteropathy', 'variety', 'conditions', 'lymphoma', 'conversion', 'PIP', 'AKT', 'PDK', 'multitude', 'differentiation', 'angiogenesis', 'metabolism', 'B-cells', 'neutrophils', 'macrophages', 'date', 'lives']",2022-10-28,2022-10-28,finance.yahoo.com
12297,EuroNext,NewsApi.org,https://finance.yahoo.com/news/amg-advanced-metallurgical-group-n-160000617.html,AMG Advanced Metallurgical Group N.V. Schedule for Third Quarter 2022 Earnings Release,"Amsterdam  28 October 2022 --- AMG Advanced Metallurgical Group N.V. (""AMG""  EURONEXT AMSTERDAM: ""AMG"") will release its third quarter 2022 financial results...","AMG Advanced Metallurgical Group N.V.Amsterdam  28 October 2022 --- AMG Advanced Metallurgical Group N.V. (""AMG""  EURONEXT AMSTERDAM: ""AMG"") will release its third quarter 2022 financial results on Wednesday  November 2  2022  at approximately 17:00 CET. AMG will host a conference call to discuss its financial results for the third quarter 2022 at 15:00 CET (15:00 GMT / 10:00AM EDT) on Thursday  November 3  2022.Please connect approximately 10 minutes prior to the beginning of the call to ensure participation. The call-in information is as follows:Europe 44 (0) 33 0551 0200Europe (toll free) 0808 109 0700North America 1 212 999 6659North America (toll free) 1 866 966 5335When prompted  tell the operator you are dialing in for â€œAMG earningsâ€ and you will be directed onto the call. The conference call will be available on the website www.amg-nv.com within twenty-four hours following completion of the call.About AMGAMG is a global critical materials company at the forefront of CO 2 reduction trends. AMG produces highly engineered specialty metals and mineral products and provides related vacuum furnace systems and services to the transportation  infrastructure  energy  and specialty metals & chemicals end markets.AMG Clean Energy Materials segment combines AMGâ€™s recycling and mining operations  producing materials for infrastructure and energy storage solutions while reducing the CO 2 footprint of both suppliers and customers. AMG Clean Energy Materials segment spans the vanadium  lithium  and tantalum value chains. AMG Critical Materials Technologies segment combines AMGâ€™s leading vacuum furnace technology line with high-purity materials serving global leaders in the aerospace sector. AMG Critical Minerals segment consists of AMGâ€™s mineral processing operations in antimony  graphite  and silicon metal.Story continuesWith approximately 3 300 employees  AMG operates globally with production facilities in Germany  the United Kingdom  France  the United States  China  Mexico  Brazil  India  Sri Lanka  and Mozambique  and has sales and customer service offices in Japan (www.amg-nv.com).For further information  please contact:AMG Advanced Metallurgical Group N.V. +1 610 975 4979Michele Fischermfischer@amg-nv.comDisclaimerCertain statements in this press release are not historical facts and are â€œforward lookingâ€. Forward looking statements include statements concerning AMGâ€™s plans  expectations  projections  objectives  targets  goals  strategies  future events  future revenues or performance  capital expenditures  financing needs  plans and intentions relating to acquisitions  AMGâ€™s competitive strengths and weaknesses  plans or goals relating to forecasted production  reserves  financial position and future operations and development  AMGâ€™s business strategy and the trends AMG anticipates in the industries and the political and legal environment in which it operates and other information that is not historical information. When used in this press release  the words â€œexpects â€ â€œbelieves â€ â€œanticipates â€ â€œplans â€ â€œmay â€ â€œwill â€ â€œshould â€ and similar expressions  and the negatives thereof  are intended to identify forward looking statements. By their very nature  forward looking statements involve inherent risks and uncertainties  both general and specific  and risks exist that the predictions  forecasts  projections and other forward looking statements will not be achieved. These forward looking statements speak only as of the date of this press release. AMG expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward looking statement contained herein to reflect any change in AMG's expectations with regard thereto or any change in events  conditions  or circumstances on which any forward looking statement is based.Attachment",neutral,0.0,1.0,0.0,mixed,0.11,0.09,0.8,True,English,"['AMG Advanced Metallurgical Group N.V. Schedule', 'Third Quarter 2022 Earnings Release', 'AMG Advanced Metallurgical Group N.V.', 'leading vacuum furnace technology line', 'AMG Critical Materials Technologies segment', 'AMG Clean Energy Materials segment', 'related vacuum furnace systems', 'AMG Critical Minerals segment', 'other forward looking statements', 'third quarter 2022 financial results', 'critical materials company', 'energy storage solutions', 'chemicals end markets', 'tantalum value chains', 'customer service offices', 'mineral processing operations', 'CO 2 reduction trends', 'high-purity materials', 'financial position', 'mineral products', 'CO 2 footprint', 'other information', 'mining operations', 'future operations', 'AMG earnings', '10:00AM EDT', 'North America', 'twenty-four hours', 'specialty metals', 'aerospace sector', 'silicon metal', 'United Kingdom', 'United States', 'Sri Lanka', 'Michele Fischer', 'press release', 'historical facts', 'future revenues', 'capital expenditures', 'financing needs', 'competitive strengths', 'business strategy', 'legal environment', 'similar expressions', 'EURONEXT AMSTERDAM', 'global leaders', 'production facilities', 'future events', 'historical information', 'inherent risks', 'conference call', 'Wednesday', 'November', '17:00 CET', '15:00 CET', 'Thursday', 'beginning', 'participation', 'Europe', 'operator', 'website', 'completion', 'forefront', 'services', 'transportation', 'infrastructure', 'recycling', 'suppliers', 'customers', 'vanadium', 'lithium', 'antimony', 'graphite', 'Story', '3,300 employees', 'Germany', 'France', 'China', 'Mexico', 'Brazil', 'India', 'Mozambique', 'sales', 'Japan', 'mfischer', 'Disclaimer', 'plans', 'expectations', 'projections', 'objectives', 'targets', 'goals', 'strategies', 'performance', 'intentions', 'acquisitions', 'weaknesses', 'reserves', 'development', 'industries', 'political', 'words', 'expects', 'believes', 'negatives', 'nature', 'uncertainties', 'predictions', 'forecasts', 'date', 'obligation', 'undertaking', 'revisions', 'change', 'regard', 'conditions', 'circumstances', 'Attachment']",2022-10-28,2022-10-28,finance.yahoo.com
12298,EuroNext,NewsApi.org,https://finance.yahoo.com/news/quantum-genomics-announces-lack-significant-060000256.html,Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study  FRESH and is Redirecting to New Developments,Firibastat efficacy non-significant versus placeboThe REFRESH study and the development of firibastat in cardiology have been stoppedCash of 11 million euros...,"Quantum GenomicsFiribastat efficacy non-significant versus placeboThe REFRESH study and the development of firibastat in cardiology have been stoppedCash of 11 million euros allotted to the development of new innovative treatments  after discontinuation of the REFRESH studyPARIS  Oct. 28  2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC)  a biopharmaceutical company specialising in the development of a new class of medications that directly target the brain to treat resistant hypertension and heart failure  announces that efficacy results for firibastat in its phase III study FRESH  are non-significant versus placebo. These results will be presented in detail at the AHA congress.""Firibastat has unfortunately failed to demonstrate significantly greater efficacy than placebo in the phase III study FRESH. This has caused the Company to prematurely discontinue the second phase III study  REFRESH  for ethical reasons concerning the patients. For the same reason  in view of these results  it has been decided to stop the development of firibastat in cardiovascular "" added Bruno Besse  Medical Director of Quantum Genomics.""Nevertheless  we are committed to the mobilisation of all our strengths in the development of new innovative treatments designed to save more lives in more patients. It is with this in mind that we have already identified BioTech/MedTech with whom negotiations are on-going. I wish to thank all those who are working alongside us and those who are supporting us towards therapeutic innovation which has always been our mission "" declared Jean-Philippe Milon  CEO of Quantum Genomics.""Stopping the development of firibastat in cardiology and discontinuing the REFRESH study in particular  will enable the Company to switch its financial horizon for the third quarter 2023. Henceforth we will be re-allotting our funds  amounting to 11 million euros before the discontinuation of the REFRESH study  to the development of new innovative molecules in unmet therapeutic domains "" adds Benoit Gueugnon  Quantum Genomics Chief Financial Officer.Story continuesAll questions can be sent to: contact@quantum-genomics.comAbout Quantum GenomicsQuantum Genomics is a biopharmaceutical company specialising in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. It relies on over twenty years of research conducted at Paris-Descartes University and on work directed by Dr Catherine Llorens-Cortes at the CollÃ¨ge de France (French National Institute of Health and Medical Research (INSERM)/ Scientific Centre for National Research (CNRS) laboratory). The goal of Quantum Genomics is to develop innovative treatments for difficult-to-treat or even resistant hypertension (hypertension is poorly or inadequately controlled in 30% of patients) and heart failure (one in two patients diagnosed with severe heart failure will die within five years).Based in Paris and New York  the company is listed on Euronext Growth in Paris (FR0011648971- ALQGC) and trades on the OTCQX Market in the United States (symbol: QNNTF).For more information on www.quantum-genomics.com  please visit our Twitter and LinkedIn sites.Contact informationQuantum Genomics contact@quantum-genomics.comEdifice Communication (EUROPE) Financial and media communicationsquantum-genomics@edifice-communication.comLifeSci (USA) Mike TattoryMedia communications+1 (646) 751-4362 - mtattory@lifescipublicrelations.com",neutral,0.01,0.97,0.02,mixed,0.29,0.14,0.57,True,English,"['Phase III Study', 'Quantum Genomics', 'Significant Efficacy', 'New Developments', 'Lack', 'Firibastat', 'FRESH', 'Quantum Genomics Chief Financial Officer', 'CollÃ¨ge de France', 'Mike Tattory Media communications', 'brain aminopeptidase A inhibition', 'second phase III study', 'media communications quantum', 'Dr Catherine Llorens-Cortes', 'unmet therapeutic domains', 'French National Institute', 'new innovative molecules', 'new innovative treatments', 'severe heart failure', 'financial horizon', 'innovative approach', 'new class', 'therapeutic innovation', 'New York', 'REFRESH study', 'National Research', '11 million euros', 'GLOBE NEWSWIRE', 'Euronext Growth', 'AHA congress', 'greater efficacy', 'ethical reasons', 'same reason', 'Bruno Besse', 'Medical Director', 'Jean-Philippe Milon', 'third quarter', 'Benoit Gueugnon', 'twenty years', 'Paris-Descartes University', 'Scientific Centre', 'five years', 'OTCQX Market', 'United States', 'LinkedIn sites', 'Edifice Communication', 'Medical Research', 'Contact information', 'biopharmaceutical company', 'efficacy results', 'two patients', 'Firibastat efficacy', 'cardiovascular medications', 'resistant hypertension', 'placebo', 'development', 'cardiology', 'Cash', 'discontinuation', 'ALQGC', 'detail', 'view', 'mobilisation', 'strengths', 'lives', 'mind', 'BioTech/MedTech', 'negotiations', 'mission', 'CEO', 'funds', 'Story', 'questions', 'quantum-genomics', 'BAPAI', 'world', 'work', 'Health', 'INSERM', 'CNRS', 'laboratory', 'goal', 'trades', 'symbol', 'QNNTF', 'Twitter', 'EUROPE', 'edifice-communication', 'LifeSci', 'USA', 'mtattory']",2022-10-28,2022-10-28,finance.yahoo.com
12299,EuroNext,NewsApi.org,https://finance.yahoo.com/news/hipay-group-press-release-hipay-161700804.html,HiPay Group: Press Release from HiPay Groupâ€™s Board of Directors,Paris  28 October 2022: The Board of Directors of HiPay Group SA (code ISIN FR0012821916 â€“ ALHYP)  a fintech specialising in omni-channel payments  met on...,HiPay GroupParis  28 October 2022: The Board of Directors of HiPay Group SA (code ISIN FR0012821916 â€“ ALHYP)  a fintech specialising in omni-channel payments  met on October 21st  2022 and on October 27th  2022  in order to review the Groupâ€™s governance.During these meetings  the Board decided to terminate the mandates of Mr. GrÃ©goire Bourdin as CEO of HiPay Group SA and PrÃ©sident of HiPay SAS  with immediate effect.The Board of Directors wishes to thank Mr. GrÃ©goire Bourdin for all the work accomplished throughout the recent years.The development of the Group now requires a closer collaboration between the Management and the Board.The Board of Directors has decided to appoint Mr. Benjamin Jayet as CEO of HiPay Group SA  being acknowledged that Mr. Jayet also remains Chairman of the Board.About HiPayHiPay is a global payment services provider. Using the power of payment data  we help our sellers grow by giving them a 360Â° overview of their business.More information at hipay.com. You can also find us on LinkedIn.HiPay Group is listed on Euronext Growth (ISIN: FR0012821916 â€“ ALHYP).ContactsPRAnnie Hurley (CMO)+33 (0)6 81 16 07 52ahurley@hipay.comInvestor RelationsJÃ©rÃ´me Daguet (CFO)+33 (0)7 86 53 93 93jdaguet@hipay.comThis release does not constitute a sale offer or the solicitation of an offer to purchase HiPay securities. If you would like more information about HiPay Group  please visit the Investors section on our website hipay.com. This release may contain provisional declarations. Although HiPay Group believes that these declarations are based on hypotheses that are reasonable on the releaseâ€™s publication date  they are by nature subject to risk and uncertainty that can lead to differences between the actual figures and those indicated or inferred in these declarations. HiPay Group operates in one of the most volatile sectors where new risk factors can emerge. HiPay Group does not have any obligation to update these provisional declarations based on new information  events or circumstances.Story continuesAttachment,neutral,0.0,1.0,0.0,mixed,0.48,0.02,0.5,True,English,"['HiPay Group', 'Press Release', 'Board', 'Directors', 'JÃ©rÃ´me Daguet', 'Mr. GrÃ©goire Bourdin', 'global payment services provider', 'Mr. Benjamin Jayet', 'new risk factors', 'HiPay Group SA', 'Mr. Jayet', 'payment data', 'new information', 'fintech specialising', 'omni-channel payments', 'PrÃ©sident', 'immediate effect', 'recent years', 'closer collaboration', 'Euronext Growth', 'Contacts PR', 'Annie Hurley', 'Investor Relations', 'Investors section', 'publication date', 'actual figures', 'volatile sectors', 'HiPay SAS', 'HiPay securities', 'More information', 'sale offer', 'provisional declarations', 'The Board', 'Paris', 'Directors', 'code', 'ALHYP', 'October', 'order', 'governance', 'meetings', 'mandates', 'CEO', 'work', 'development', 'Management', 'Chairman', 'power', 'sellers', '360Â° overview', 'business', 'LinkedIn', 'CMO', 'ahurley', 'CFO', 'jdaguet', 'release', 'solicitation', 'website', 'hypotheses', 'nature', 'uncertainty', 'differences', 'obligation', 'events', 'circumstances', 'Story', 'Attachment', '7']",2022-10-28,2022-10-28,finance.yahoo.com
12300,EuroNext,NewsApi.org,https://finance.yahoo.com/news/harvard-business-school-case-study-053000404.html,A Harvard Business School Case Study on Navya  an Autonomous Mobility Pioneer  to be Included in the MBA Curriculum - Yahoo Finance,VILLEURBANNE  France  October 28  2022--Regulatory News: NAVYA (FR0013018041- Navya)  an autonomous mobility systems leader  has been selected to exemplify...,"VILLEURBANNE  France  October 28  2022--(BUSINESS WIRE)--Regulatory News:NAVYA (FR0013018041- Navya)  an autonomous mobility systems leader  has been selected to exemplify autonomous mobility in a new Harvard Business School case study to be taught in the MBA program this fall.In light of its growing importance and potential leading role it will play in the coming years  autonomous mobility is considered as a topic relevant for future managers. Harvard Business School professors Julian De Freitas and Elie Ofek have selected Navya to exemplify and demonstrate this burgeoning industry. The company is one of the rare players on the market that offers turn-key solutions for the transportation of people and goods and has demonstrated not only its technological mastery  but also its global leadership as well as the reach of its use cases across the world.The case study will be included in the Harvard Business School curriculum in November 2022. It traces Navyaâ€™s evolution  and focuses on the strategic decisions the company faces in terms of positioning  business model  product portfolio  pricing and international strategy  and prompts students to grapple with the managerial challenges involved.Harvard Business School interviewed several members of Navya's management team and a number of its partners and customers  e.g. US based Beep  to put together its case study. It also invited Sophie DesormiÃ¨re  CEO of Navya  to attend its debut in person before a gathering of students.""Autonomous mobility is a rapidly evolving technology that has the potential to address today's major societal  environmental and mobility challenges  and meets them by applying the fundamentals of innovation and marketing on the one hand  and finance and business plans on the other. We look forward to introducing our students to the topic of autonomous mobility and the strategic decisions Navya faces.""Elie Ofek  Malcolm P. McNair Professor of Marketing  Harvard Business SchoolStory continues""Autonomous mobility is emerging as a topic that is of interest at leading business schools. Navya considers itself privileged to have been selected to exemplify this topic of the future in a Harvard Business School case. We are a technological company based in France but with an international presence  and we have become a benchmark for inclusive  autonomous transportation. We are looking forward to how the students will react to autonomous mobility in general and Navya in particular  and I will be happy to exchange points of view directly with them on autonomous transportation and our strategies to achieve it.""Sophie DesormiÃ¨re  CEO of NavyaAbout Harvard Business SchoolFounded in 1908 as part of Harvard University  Harvard Business School is located on a 40-acre campus in Boston. Its faculty of more than 200 offers full-time programs leading to the MBA and PHD degrees  as well as more than 70 open enrollment Executive Education programs and 55 custom programs  and Harvard Business School Online  the Schoolâ€™s digital learning platform. For more than a century  HBS faculty have drawn on their research  their experience in working with organizations worldwide  and their passion for teaching to educate leaders who make a difference in the world  shaping the practice of business and entrepreneurship around the globe.About NAVYANAVYA is a leading French company that specializes in the supply of autonomous mobility systems and related services. It was founded in 2014 and has a total of 280 employees in France (Paris and Lyon)  in the United States (Michigan) and in Singapore. NAVYA's aim is to become the benchmark provider of level 4 autonomous mobility systems for the transportation of people and goods. The company achieved a world first when it launched its AutonomÂ® Shuttle for passengers in 2015. Since that year and up until 31 December 2021  more than 200 vehicles were sold in 25 countries. In 2021 Navya launched its industry equivalent  the AutonomÂ® Tract  a tractor for the transportation of goods. The company is firmly and actively committed to CSR  and it was awarded the ISO 9001 certification in September 2021. The Valeo and Keolis groups count among Navya's historical shareholders.NAVYA is listed on the Euronext regulated market in Paris (ISIN code: FR0013018041- Navya).For further information  visit our website: http://www.navya.techView source version on businesswire.com: https://www.businesswire.com/news/home/20221027006098/en/ContactsNAVYAMarketing & CommunicationDepartmentmarketing@navya.techChief Financial OfficerPierre Guibertfinance@navya.techNewCapInvestor RelationsThomas GrojeanNicolas Fossieznavya@newcap.eu+33 (0)1 44 71 94 94NewCapMedia RelationsNicolas Merigeaunavya@newcap.eu+33 (0)1 44 71 94 98",neutral,0.0,0.99,0.0,positive,0.83,0.11,0.06,True,English,"['A Harvard Business School Case Study', 'Autonomous Mobility Pioneer', 'MBA Curriculum', 'Yahoo Finance', 'Navya', '70 open enrollment Executive Education programs', 'new Harvard Business School case study', 'Malcolm P. McNair Professor', 'Harvard Business School professors', 'Harvard Business School curriculum', 'autonomous mobility systems leader', 'level 4 autonomous mobility systems', 'leading business schools', 'Julian De Freitas', 'Sophie DesormiÃ¨re', 'digital learning platform', 'Chief Financial Officer', 'potential leading role', 'Euronext regulated market', 'leading French company', 'NewCap Media Relations', 'inclusive, autonomous transportation', 'Harvard University', 'BUSINESS WIRE', 'business model', 'business plans', 'full-time programs', '55 custom programs', 'mobility challenges', 'Investor Relations', 'Regulatory News', 'growing importance', 'coming years', 'Elie Ofek', 'burgeoning industry', 'rare players', 'turn-key solutions', 'technological mastery', 'global leadership', 'use cases', 'strategic decisions', 'product portfolio', 'international strategy', 'managerial challenges', 'several members', 'management team', 'one hand', 'international presence', '40-acre campus', 'PHD degrees', 'a century', 'related services', 'United States', 'AutonomÂ® Shuttle', 'industry equivalent', 'AutonomÂ® Tract', 'ISO 9001 certification', 'The Valeo', 'Keolis groups', 'historical shareholders', 'ISIN code', 'source version', 'Communication Department', 'Pierre Guibert', 'Thomas Grojean', 'Nicolas Fossiez', 'Nicolas Merigeau', 'MBA program', 'future managers', 'technological company', 'HBS faculty', 'benchmark provider', 'VILLEURBANNE', 'France', 'October', 'NAVYA', 'light', 'topic', 'people', 'goods', 'reach', 'world', 'November', 'evolution', 'terms', 'positioning', 'pricing', 'students', 'number', 'partners', 'customers', 'Beep', 'CEO', 'debut', 'person', 'gathering', 'technology', 'environmental', 'fundamentals', 'innovation', 'marketing', 'finance', 'Story', 'interest', 'general', 'points', 'view', 'strategies', 'Boston', 'research', 'experience', 'organizations', 'passion', 'difference', 'practice', 'globe', 'supply', 'total', '280 employees', 'Paris', 'Lyon', 'Michigan', 'Singapore', 'aim', 'passengers', '31 December', '200 vehicles', '25 countries', 'tractor', 'CSR', 'September', 'information', 'website', 'businesswire', 'Contacts', '2021']",2022-10-28,2022-10-28,finance.yahoo.com
12301,EuroNext,NewsApi.org,https://finance.yahoo.com/news/press-release-biocartis-group-nv-050000802.html,Press release Biocartis Group NV: Invitation to the Extraordinary Shareholdersâ€™ Meeting,PRESS RELEASE: REGULATED INFORMATION 28 October 2022  07:00 CEST Invitation to the Extraordinary Shareholdersâ€™ Meeting Mechelen  Belgium  28 October 2022...,"Biocartis NVPRESS RELEASE: REGULATED INFORMATION28 October 2022  07:00 CESTInvitation to the Extraordinary Shareholdersâ€™ MeetingMechelen  Belgium  28 October 2022 â€“ As the attendance quorum for certain items on the agenda of the extraordinary general shareholders' meeting (""EGM"") of 27 October 2022 was not reached  Biocartis Group NV (the ""Company"" or ""Biocartis"")  an innovative molecular diagnostics company (Euronext Brussels: BCART)  has the honor to invite its shareholders  holders of subscription rights  holders of convertible bonds  directors and statutory auditor to a second EGM which will be held on Monday 14 November 2022 at 2:00 p.m. CEST at the offices of the Company at Generaal de Wittelaan 11B  2800 Mechelen  Belgium. The legally required attendance quorum to validly deliberate and vote on items 2 to 6 of the agenda of the extraordinary general shareholders' meeting  which was held on 27 October 2022  was not reached. There will be no attendance quorum for this EGM.At the EGM  shareholders will be requested to approve various aspects of the comprehensive recapitalization transaction which was announced by the Company on 1 September 2022. The Company believes that such transaction is an important milestone for the Company to secure the financing necessary for its future growth which benefits all of its stakeholders and therefore encourages shareholders to grant the necessary consents to implement it.All proposed resolutions submitted to the EGM require an approval by a majority of 75% of the votes validly cast by the shareholders. In the event that the shareholders do not approve the proposed resolutions  the recapitalization transaction will not complete in full  the Company will not be recapitalized  various fees and expenses will need to be paid by the Company  certain terms of the proposed new convertible terms loans become more restrictive  and the Company will need to consider alternative arrangements  which may not be available on time or at all. The proposal to approve and ratify certain change of control clauses in the legal documentation regarding the recapitalisation transactions was already approved by the EGM held on 27 October 2022.Story continuesIt is currently envisaged that the Company will be legally allowed to organize its EGM at its offices at Generaal de Wittelaan 11B  2800 Mechelen  Belgium  and that the holders of securities of the Company will be allowed to physically attend the meeting as set out in the convening notice. However  the evolution of the COVID-19 pandemic is uncertain and the Belgian government may again impose measures which may have an impact on the organization of the EGM  such as imposing limitations on the number of people allowed to attend gatherings. The Company will monitor the situation and potential measures in light of the COVID-19 pandemic  and may provide further updates that are relevant or have an impact on the EGM on the Biocartis website.In order to be admitted to the EGM  the holders of securities issued by the Company must comply with Article 7:134 of the Belgian Code of Companies and Associations and the articles of association of the Company  and fulfill the formalities described in the convening notice. The convening notice and other documents relating to the EGM can be consulted on the website of the Company.--- END ---More information:Renate DegraveHead of Corporate Communications & Investor Relations Biocartise-mail rdegrave@biocartis.comtel +32 15 631 729mobile +32 471 53 60 64About BiocartisWith its revolutionary and proprietary Idyllaâ„¢ platform  Biocartis (Euronext Brussels: BCART) aspires to enable personalized medicine for patients around the world through universal access to molecular testing  by making molecular testing actionable  convenient  fast and suitable for any lab. The Idyllaâ„¢ platform is a fully automated sample-to-result  real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house access to accurate molecular information in a minimum amount of time for faster  informed treatment decisions. Idyllaâ„¢â€™s continuously expanding menu of molecular diagnostic tests address key unmet clinical needs  with a focus in oncology. This is the fastest growing segment of the molecular diagnostics market worldwide. Today  Biocartis offers tests supporting melanoma  colorectal  lung and liver cancer  as well as for COVID-19  Flu  RSV and sepsis. For more information  visit www.biocartis.com or follow Biocartis on Twitter @Biocartis_   Facebook or LinkedIn.Biocartis and Idyllaâ„¢ are registered trademarks in Europe  the United States and other countries. The Biocartis and Idyllaâ„¢ trademark and logo are used trademarks owned by Biocartis. Please refer to the product labeling for applicable intended uses for each individual Biocartis product.This press release is not for distribution  directly or indirectly  in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933  as amended.Forward-looking statementsCertain statements  beliefs and opinions in this press release are forward-looking  which reflect the Company's or  as appropriate  the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations  financial condition  liquidity  performance  prospects  growth  strategies and the industry in which the Company operates. By their nature  forward-looking statements involve a number of risks  uncertainties  assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks  uncertainties  assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including  but not limited to  changes in demand  competition and technology  can cause actual events  performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition  even if actual results or developments are consistent with the forward-looking statements contained in this press release  those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result  the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events  conditions  assumptions or circumstances on which these forward-looking statements are based  except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements  which speak only as of the date of this press release.",neutral,0.01,0.99,0.0,mixed,0.26,0.15,0.59,True,English,"['Biocartis Group NV', 'Extraordinary Shareholdersâ€™ Meeting', 'Press release', 'Invitation', 'faster, informed treatment decisions', 'key unmet clinical needs', 'new convertible terms loans', ""extraordinary general shareholders' meeting"", 'innovative molecular diagnostics company', 'molecular diagnostics market', 'Generaal de Wittelaan', 'Polymerase Chain Reaction', 'fastest growing segment', 'Extraordinary Shareholdersâ€™ Meeting', 'proprietary Idyllaâ„¢ platform', 'accurate molecular information', 'molecular diagnostic tests', 'Investor Relations Biocartis', 'comprehensive recapitalization transaction', 'The Idyllaâ„¢ platform', 'individual Biocartis product', 'convertible bonds', 'molecular testing', 'product labeling', 'PRESS RELEASE', 'REGULATED INFORMATION', 'attendance quorum', 'Euronext Brussels', 'subscription rights', 'statutory auditor', 'Monday 14 November', 'various aspects', 'important milestone', 'future growth', 'necessary consents', 'various fees', 'alternative arrangements', 'control clauses', 'legal documentation', 'recapitalisation transactions', 'convening notice', 'COVID-19 pandemic', 'Belgian government', 'Belgian Code', 'other documents', 'More information', 'Renate Degrave', 'Corporate Communications', 'personalized medicine', 'real-time PCR', 'based system', 'minimum amount', 'expanding menu', 'liver cancer', 'United States', 'other countries', 'Idyllaâ„¢ trademark', 'intended uses', 'The Biocartis', 'The Company', 'Biocartis NV', 'Biocartis Group', 'proposed resolutions', 'potential measures', 'universal access', 'second EGM', 'Biocartis website', 'October', 'Invitation', 'Mechelen', 'Belgium', 'items', 'agenda', 'BCART', 'honor', 'directors', 'CEST', 'offices', '1 September', 'financing', 'stakeholders', 'approval', 'majority', 'votes', 'event', 'expenses', 'proposal', 'change', 'Story', 'securities', 'evolution', 'impact', 'organization', 'limitations', 'number', 'people', 'gatherings', 'situation', 'light', 'updates', 'order', 'Article', 'Companies', 'Associations', 'formalities', 'Head', 'mail', 'patients', 'world', 'sample', 'result', 'house', 'focus', 'oncology', 'melanoma', 'colorectal', 'lung', 'Flu', 'RSV', 'sepsis', 'Twitter', 'Facebook', 'LinkedIn', 'trademarks', 'Europe', 'logo', 'applicable', 'distribution', 'jurisdiction', 'persons', 'restrictions', 'responsibili', '07', '28', '2:00']",2022-10-28,2022-10-28,finance.yahoo.com
12302,EuroNext,NewsApi.org,https://finance.yahoo.com/news/press-release-biocartis-group-nv-050100498.html,Press release Biocartis Group NV: Biocartis Announces Conversion of a Portion of the Convertible Term Loan into New Shares and Discloses Outstanding Voting Securities,PRESS RELEASE: REGULATED INFORMATION 28 October 2022  07:01 CEST Biocartis Announces Conversion of a Portion of the Convertible Term Loan into New Shares and...,"Biocartis NVPRESS RELEASE: REGULATED INFORMATION28 October 2022  07:01 CESTBiocartis Announces Conversion of a Portion of the Convertible Term Loan into New Shares and Discloses Outstanding Voting SecuritiesMechelen  Belgium  28 October 2022 â€“ Biocartis Group NV (the ""Company"" or ""Biocartis"")  an innovative molecular diagnostics company (Euronext Brussels: BCART)  today announces that following the first drawdown by the Company under the new senior secured convertible term loan (â€œConvertible Term Loanâ€) concluded with certain funds and accounts managed or advised by Highbridge Capital Management LLC (â€œHighbridgeâ€) and certain funds managed or advised by Whitebox Advisors LLC (â€œWhiteboxâ€  and together with Highbridge  the â€œLendersâ€) announced on 20 October 2022  a first portion of the receivables due by the Company to Highbridge under the Convertible Term Loan in an amount of EUR 60 509.79 (consisting of principal amount  interest and redemption amount) was contributed in kind by Highbridge against the issuance of 60 559 new shares of the Company at an issue price of ca. EUR 0.99918 per share.In view hereof  and in accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers of which shares are admitted to trading on a regulated market and laying down miscellaneous provisions  the outstanding share capital and outstanding voting securities of the Company can be summarized as follows:Total outstanding share capital: EUR 584 169.56;Total outstanding voting securities: 58 416 956;Total outstanding voting rights: 58 416 956;Shares that can still be issued upon exercise of subscription rights: 2 248 458 shares (each share entailing one voting right)  of which: 150 896 shares can be issued upon the exercise of 150 896 outstanding share options (each share option having the form of a subscription right) that are still outstanding under the '2013 Plan' for employees  consultants and management members of the Company  entitling the holders thereof to acquire one new share per option; 140 064 shares can be issued upon the exercise of 140 064 outstanding share options (each share option having the form of a subscription right) that are still outstanding under the '2015 Plan' for employees  consultants  management members and directors of the Company  entitling the holders thereof to acquire one new share per option; 470 836 shares can be issued upon the exercise of 470 836 outstanding share options (each share option having the form of a subscription right) that are still outstanding under the '2018 Plan' for (mainly) certain selected employees of the Company and its subsidiaries  as well as for consultants of the Company and its subsidiaries  independent directors of the Company and directors of the Company's subsidiaries  entitling the holders thereof to acquire one new share per option; 626 662 shares can be issued upon the exercise of 626 662 outstanding share options (each share option having the form of a subscription right) that are still outstanding under the '2020 Plan' for members of the personnel of the Company and/or its subsidiaries  entitling the holders thereof to acquire one new share per option; and 860 000 shares can be issued upon the exercise of 860 000 outstanding share options (each share option having the form of a subscription right) that are still outstanding under the '2020B Plan' for members of the executive management of the Company  entitling the holders thereof to acquire one new share per option.Story continuesIn addition  a number of shares are issuable pursuant to the terms of (i) the abovementioned Convertible Term Loan  (ii) certain outstanding 4.00% convertible bonds initially due 2024/2027  and (iii) certain outstanding 4.50% convertible bonds initially due 2024/2026.Going forward  the Company will issue a press release at the end of each month with an update on further conversions and outstanding voting securities.--- END ---More information:Renate DegraveHead of Corporate Communications & Investor Relations Biocartise-mail rdegrave@biocartis.comtel +32 15 631 729mobile +32 471 53 60 64About BiocartisWith its revolutionary and proprietary Idyllaâ„¢ platform  Biocartis (Euronext Brussels: BCART) aspires to enable personalized medicine for patients around the world through universal access to molecular testing  by making molecular testing actionable  convenient  fast and suitable for any lab. The Idyllaâ„¢ platform is a fully automated sample-to-result  real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house access to accurate molecular information in a minimum amount of time for faster  informed treatment decisions. Idyllaâ„¢â€™s continuously expanding menu of molecular diagnostic tests address key unmet clinical needs  with a focus in oncology. This is the fastest growing segment of the molecular diagnostics market worldwide. Today  Biocartis offers tests supporting melanoma  colorectal  lung and liver cancer  as well as for COVID-19  Flu  RSV and sepsis. For more information  visit www.biocartis.com or follow Biocartis on Twitter @Biocartis_   Facebook or LinkedIn.Biocartis and Idyllaâ„¢ are registered trademarks in Europe  the United States and other countries. The Biocartis and Idyllaâ„¢ trademark and logo are used trademarks owned by Biocartis. Please refer to the product labeling for applicable intended uses for each individual Biocartis product.This press release is not for distribution  directly or indirectly  in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933  as amended.Forward-looking statementsCertain statements  beliefs and opinions in this press release are forward-looking  which reflect the Company's or  as appropriate  the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations  financial condition  liquidity  performance  prospects  growth  strategies and the industry in which the Company operates. By their nature  forward-looking statements involve a number of risks  uncertainties  assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks  uncertainties  assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including  but not limited to  changes in demand  competition and technology  can cause actual events  performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition  even if actual results or developments are consistent with the forward-looking statements contained in this press release  those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result  the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events  conditions  assumptions or circumstances on which these forward-looking statements are based  except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements  which speak only as of the date of this press release.",neutral,0.01,0.99,0.0,positive,0.43,0.23,0.34,True,English,"['Convertible Term Loan', 'Outstanding Voting Securities', 'Biocartis Group NV', 'Press release', 'New Shares', 'Conversion', 'Portion', 'new senior secured convertible term loan', 'faster, informed treatment decisions', 'key unmet clinical needs', 'Total outstanding voting securities', 'Total outstanding voting rights', 'Total outstanding share capital', 'innovative molecular diagnostics company', 'Highbridge Capital Management LLC', 'outstanding 4.00% convertible bonds', 'outstanding 4.50% convertible bonds', 'Polymerase Chain Reaction', 'fastest growing segment', 'molecular diagnostics market', '150,896 outstanding share options', '140,064 outstanding share options', '470,836 outstanding share options', '626,662 outstanding share options', '860,000 outstanding share options', 'one new share', 'Whitebox Advisors LLC', 'one voting right', 'proprietary Idyllaâ„¢ platform', 'The Idyllaâ„¢ platform', 'molecular diagnostic tests', 'accurate molecular information', 'Biocartis Group NV', 'subscription rights', 'molecular testing', 'regulated market', 'New Shares', 'executive management', 'PRESS RELEASE', 'Euronext Brussels', 'first drawdown', 'issue price', 'Belgian Act', 'major shareholdings', 'miscellaneous provisions', 'Renate Degrave', 'Corporate Communications', 'Investor Relations', 'personalized medicine', 'real-time PCR', 'expanding menu', 'liver cancer', 'Biocartis NV', 'principal amount', 'redemption amount', 'More information', 'minimum amount', 'first portion', 'management members', 'universal access', 'independent directors', '2020B Plan', '2013 Plan', '2015 Plan', '2018 Plan', '2020 Plan', '2,248,458 shares', '150,896 shares', '140,064 shares', '470,836 shares', '626,662 shares', '860,000 shares', 'October', 'Conversion', 'Mechelen', 'Belgium', 'BCART', 'funds', 'accounts', 'Lenders', 'receivables', 'interest', 'kind', 'issuance', 'view', 'accordance', 'article', '2 May', 'disclosure', 'issuers', 'exercise', 'employees', 'consultants', 'holders', 'subsidiaries', 'personnel', 'Story', 'addition', 'number', 'terms', 'month', 'update', 'Head', 'mail', 'revolutionary', 'patients', 'world', 'lab', 'result', 'system', 'house', 'focus', 'oncology', 'melanoma', 'colorectal', 'lung', 'COVID', 'Flu', 'RSV', 'sepsis', '07', '28']",2022-10-28,2022-10-28,finance.yahoo.com
12303,EuroNext,NewsApi.org,https://finance.yahoo.com/news/information-total-number-voting-rights-170000164.html,Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA,Negma Group has converted 580 convertible bonds in Oxurion resulting in a EUR 1 450 000 capital increase. This is part of Negma Groupâ€™s EUR 30 million...,Oxurion NVNegma Group has converted 580 convertible bonds in Oxurion resulting in a EUR 1 450 000 capital increase. This is part of Negma Groupâ€™s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.Leuven  BELGIUM  Boston  MA  US â€“ October 28  2022 â€“ 07.00 PM CET â€“ In accordance with article 15 of the Belgian Act of May 2  2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions  Oxurion NV (Euronext Brussels: OXUR) (the â€œCompanyâ€ or â€œOxurionâ€)  announces the below information  following the issuance of (i) 909 090 new ordinary shares on October 12  2022  for a total amount of EUR 100 000  as the result of the conversion of 40 class A convertible bonds  (ii) 4 750 000 new ordinary shares on October 12  2022  for a total amount of EUR 332 500  as the result of the conversion of 133 class B convertible bonds  (iii) 5.857.142 new ordinary shares on October 19  2022  for a total amount of EUR 410 000  as the result of the conversion of 164 class B convertible bonds  (iv) 5 000 000 new ordinary shares on October 24  2022  for a total amount of EUR 300 000  as the result of the conversion of 120 class B convertible bonds  and (v) 6 150 000 new ordinary shares on October 26  2022  for a total amount of EUR 307 500  as the result of the conversion of 123 class B convertible bonds  all pursuant to the Capital Commitment entered into with Negma Group.Following completion of the capital increase through the conversion of the convertible bonds  the total number of shares issued by Oxurion amounts to 77 825 765 outstanding ordinary shares carrying voting rights (compared to 55 159 533 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.Therefore  Oxurion publishes the following updated information:Share capital (EUR) 72 356 161.32 Total number of securities with voting rights (all ordinary shares) 77 825 765 Total number of ordinary shares (= denominator) 77 825 765 Number of outstanding  granted rights to subscribe to securities carrying voting rights not yet issued: 719 500 subscription rights (â€œSRsâ€) issued on November 20  2017  entitling their holders to subscribe to a total number of 719 500 securities carrying voting rights (all ordinary shares);60 000 SRs issued on December 23  2020  entitling their holders to subscribe to a total number of 60 000 securities carrying voting rights (all ordinary shares);1 007 250 SRs issued on April 14  2021  entitling their holders to subscribe to a total number of 1 007 250 securities carrying voting rights (all ordinary shares);550 000 SRs issued on September 22  2021  entitling their holders to subscribe to a total number of 550 000 securities carrying voting rights (all ordinary shares);725 749 SRs issued on December 30  2021  entitling their holders to subscribe to a total number of 725 749 securities carrying voting rights (all ordinary shares);1 060 convertible bonds issued on September 5  2022  and 21 October 2022  entitling their holder (Negma Group) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions set forth in the issuance and subscription agreement entered into between the Company and Negma Group on August 26  2021  and the addendum thereto dated September 2  2022; and100 convertible bonds issued on December 20  2021  entitling their holders (Kreos Capital VI (UK) Limited  Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds as attached to the Agreement for the provision of a Loan Facility entered into between the Company  Kreos Capital VI (UK) Limited  Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.  on November 21  2021.ENDAbout OxurionOxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies  which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME)  the leading cause of vision loss in working-age people  as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders  including the successful development of THR-149  its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven  Belgium  with corporate operations in Boston  MA. More information is available at www.oxurion.com.Important information about forward-looking statementsCertain statements in this press release may be considered â€œforward-lookingâ€. Such forward-looking statements are based on current expectations  and  accordingly  entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement  whether as a result of new information  future events  or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Companyâ€™s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933  as amended  or in compliance with an exemption therefrom  and in accordance with any applicable U.S. state securities laws.For further information please contact:Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13 10tom.graney@oxurion.comMichaÃ«l DillenChief Business OfficerTel: +32 16 75 13 10michael.dillen@oxurion.com USConway CommunicationsBeth Kurthbkurth@conwaycommsir.comICR WestwickeChristopher BrinzeyTel: +1 617 835 9304chris.brinzey@westwicke.com1 Press release Oxurion  06/04/2021 and Press release Oxurion  02/09/2022Attachment,neutral,0.0,1.0,0.0,positive,0.72,0.23,0.05,True,English,"['Total Number', 'Voting Rights', 'Conversion Notice', 'Information', 'Denominator', 'NEGMA', 'potent plasma kallikrein inhibitor', 'EUR 30 million Capital Commitment1', '40 class A convertible bonds', '133 class B convertible bonds', '164 class B convertible bonds', '120 class B convertible bonds', '123 class B convertible bonds', 'eye drug candidate', 'Pontifax Medison Finance', 'next generation standard', 'diabetic macular edema', 'potential new standard', 'EUR 1,450,000 capital increase', 'Kreos Capital VI', 'potential market opportunities', 'care ophthalmic therapies', '909,090 new ordinary shares', '4,750,000 new ordinary shares', '5.857.142 new ordinary shares', '5,000,000 new ordinary shares', '6,150,000 new ordinary shares', '77,825,765 outstanding ordinary shares', '55,159,533 outstanding ordinary shares', '580 convertible bonds', '1,060 convertible bonds', '100 convertible bonds', 'Share capital', 'regulated market', 'Negma Group', 'differentiated back', 'Belgian Act', 'major participations', 'miscellaneous provisions', 'Euronext Brussels', 'total amount', 'L.P.', 'Loan Facility', 'retinal disorders', 'leading cause', 'working-age people', 'important role', 'successful development', 'suboptimal response', 'anti-VEGF therapy', 'corporate operations', 'voting rights', '719,500 subscription rights', 'total number', 'updated information', 'More information', 'Important information', 'subscription agreement', 'vision loss', 'novel therapeutic', 'other conditions', 'biopharmaceutical company', 'Oxurion NV', 'DME patients', 'Leuven', 'BELGIUM', 'Boston', 'October', '07.00 PM', 'accordance', 'article', 'May', 'disclosure', 'issuers', 'issuance', 'result', 'conversion', 'completion', 'denominator', 'calculation', 'percentages', 'shareholdings', 'securities', 'SRs', 'November', 'holders', 'December', 'April', 'September', 'terms', 'August', 'addendum', 'UK', 'Israel', 'Cayman', 'Limited', 'treatment', 'THR-149']",2022-10-28,2022-10-28,finance.yahoo.com
12304,EuroNext,NewsApi.org,https://finance.yahoo.com/news/netedi-changes-name-cegedim-e-083000026.html,NetEDI changes its name to Cegedim e-business,The publicly listed company Cegedim identified NetEDI Ltd as a prominent business in the supply chain sector. As the leading UK provider of PEPPOL for the...,Conducting an international rebrand to reflect Cegedim's European position  and expand the SY by Cegedim product offering into the UK marketLANCASHIRE  England  Oct. 28  2022 /PRNewswire/ -- The publicly listed company Cegedim identified NetEDI Ltd as a prominent business in the supply chain sector. As the leading UK provider of PEPPOL for the NHS Supply Chain  NetEDI established an international client base through its unified commerce solution Netix  leading to the acquisition in 2019. Creating synergy across all business units and expanding customer reach  NetEDI is rebranding as Cegedim e-business.The new brand identity captures Cegedim e-business' dedication to delivering excellent quality  performance  and service to support businesses in their digital transformation. As a European leader  Cegedim strengthens its position by conducting a rebrand in the United Kingdom and Germany. Expanding the SY by Cegedim product suite into new territories to support international clients.Aligning the brands helps to create a new product offering through the SY by Cegedim branding  enabling Cegedim e-business to launch SY Supply Chain in the United Kingdom. A suite of products  services  and solutions enables various sectors to optimise their entire procure-to-pay process.About Cegedim e-business UKCegedim e-business deliver unified commerce solutions for business to optimise their supply chain management. The SY Supply Chain offering enables various organisations to harness excellent quality products  solutions  and services to optimise their entire procure-to-pay process. The core product Netix processes over 1 billion documents annually.Cegedim e-business are the chosen PEPPOL Managed Service Provider for NHS Supply Chain.Find out more: http://www.sybycegedim.co.uk/enFollow Cegedim e-business UK on Twitter  LinkedIn  and YouTubeAbout Cegedim e-businessCegedim e-business is a European leader in B2B process automation and digitalisation. It handles over 900 million data flows annually and connects 120 000 companies worldwide. Cegedim e-business uses its unique range of e-procurement  e-invoicing  e-archiving  and e-signature services to help companies of every size and in every business  sector make a successful digital transition. Cegedim e-business is a member of the PEPPOL and EESPA European networks. It operates a multichannel electronic exchanges platform that handles any type of document  from contracts to payments  and helps streamline client-supplier relationships while significantly improving administrative efficiency  cash management  and traceability.Story continuesFind out more at: www.sybycegedim.com/enFollow Cegedim e-business on Twitter  LinkedIn and YouTubeAbout CegedimFounded in 1969  Cegedim is an innovative technology and services company in the field of digital data flow management for healthcare ecosystems and B2B  and a business software publisher for healthcare and insurance professionals. Cegedim employs more than 5 600 people in more than 10 countries and generated revenue of â‚¬525 million in 2021.Cegedim SA is listed in Paris (EURONEXT: CGM).To learn more  please visit: www.cegedim.frAnd follow Cegedim on Twitter @CegedimGroup  LinkedIn and Facebook.ContactAude BalleydierCegedimCommunication & Media Relations Manageraude.balleydier@cegedim.frChelsey MorrisonCegedim e-businessMarketing ManagerChelsey.morrison@cegedim.com+44 (0)177-297-7781CisionView original content:https://www.prnewswire.co.uk/news-releases/netedi-changes-its-name-to-cegedim-e-business-301661573.html,neutral,0.0,1.0,0.0,mixed,0.42,0.35,0.23,True,English,"['NetEDI', 'name', 'Cegedim', 'business', 'The SY Supply Chain offering', 'multichannel electronic exchanges platform', 'core product Netix processes', 'digital data flow management', 'business Marketing Manager Chelsey', 'PEPPOL Managed Service Provider', 'NHS Supply Chain', 'supply chain management', 'new product offering', '900 million data flows', 'Media Relations Manager', 'unified commerce solution', 'successful digital transition', 'leading UK provider', 'supply chain sector', 'new brand identity', 'international client base', 'Cegedim product offering', 'EESPA European networks', 'excellent quality products', 'business software publisher', 'B2B process automation', ""Cegedim e-business' dedication"", 'Cegedim product suite', 'digital transformation', 'cash management', 'new territories', 'Chelsey Morrison', 'international clients', 'pay process', 'UK market', 'European leader', 'customer reach', 'United Kingdom', 'various sectors', 'various organisations', '1 billion documents', 'unique range', 'client-supplier relationships', 'administrative efficiency', 'innovative technology', 'insurance professionals', 'original content', 'business UK', 'international rebrand', 'European position', 'prominent business', 'business units', 'signature services', 'healthcare ecosystems', 'Aude Balleydier', 'Cegedim branding', 'Cegedim SA', 'Cegedim Communication', 'NetEDI Ltd', 'services company', 'solutions', 'LANCASHIRE', 'England', 'PRNewswire', 'acquisition', 'synergy', 'performance', 'businesses', 'Germany', 'brands', 'entire', 'Twitter', 'LinkedIn', 'YouTube', 'digitalisation', '120,000 companies', 'procurement', 'invoicing', 'archiving', 'size', 'member', 'type', 'contracts', 'payments', 'traceability', 'Story', 'field', '5,600 people', '10 countries', 'revenue', 'Paris', 'CGM', 'CegedimGroup', 'Facebook', 'Contact', 'Cision', 'news-releases', 'name']",2022-10-28,2022-10-28,finance.yahoo.com
12305,EuroNext,NewsApi.org,https://www.businesswire.com/news/home/20221027005925/en/Wolters-Kluwer-Global-Growth-Markets-executives-to-present-a-path-to-equitable-and-improved-patient-care-at-the-Global-Digital-Health-Summit,Wolters Kluwer Global Growth Markets executives to present a path to equitable and improved patient care at the Global Digital Health Summit,NEW DELHI--(BUSINESS WIRE)-- #digitalhealth--Wolters Kluwer Global Growth Markets CEO Cathy Wolfe and VP Ruchi Tushir will focus on the necessity of digital healthcare for all.,NEW DELHI--(BUSINESS WIRE)--Wolters Kluwer (AEX: WKL)  a leading global provider of expert solutions  insights and services for professionals  announces that Cathy Wolfe and Ruchi Tushir will present on the dramatic impact of digital health tools for clinicians at Global Digital Health Summit. This yearâ€™s summit  themed â€œDigital Health for All â€ will examine how digitalization is transforming healthcare and feature dignitaries like Dr. Jitendra Singh  Hon'ble Union Minister of State  Prime Minister's Office  Government of India.Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians  patients  researchers  and the next generation of healthcare providers in effective decision-making and consistent outcomes across healthcare. The company focuses on clinical effectiveness  research and learning  clinical surveillance and compliance  as well as data solutions.Cathy Wolfe and Ruchi Tushir will focus on the ways in which digital solutions are improving the quality of and access to healthcare. They will each show that digitalization will help each patient get the right care at the right time thus leading to better outcomes. Cathy and Ruchi will provide recommendations on how India can improve the health of its population by incorporating evidence-based digital health tools into its standards for clinicians.â€œThe shortage of doctors in India means that a significant number of citizens lack access to quality healthcare. Study after study shows that the use of clinical decision support tools helps fill that gap and improves health outcomes across populations. In India and throughout the world  the value of these tools transcends advanced technology  it is about the evidence-based content that saves lives every day â€ says Cathy Wolfe  CEO and President of Wolters Kluwer Global Growth Markets.â€œThe importance of adopting and training clinicians on digital solutions cannot be overstated. In addition to superior diagnostic tools  digital solutions help clinicians be more effective and improve the patient experience throughout their care journey â€ says Ruchi Tushir  Vice President and General Manager of Wolters Kluwer Global Growth Markets India.â€œDigital Health is now the default operating system of healthcare. India can lead the way to establish a systematic approach to digitalization. This will ensure quality healthcare for all. I am thrilled to have Cathy Wolfe and Ruchi Tushir share their vast expertise at the Global Digital Health Summit as they each demonstrate how digital healthcare products improve and save lives â€ says Rajendra Pratap Gupta  author of the book Digital Health â€“ Truly Transformational and chair of the Global Digital Health Summit.Session Title: Return on Investment in Digital Health Keynote: Cathy Wolfe  President and CEO  Wolters Kluwer Global Growth Markets Date/Time: Friday  October 28  11:30 â€“ 1:00 pm IST Session Title: Adoption of Digital Health across the Continuum of Care Panelists include: Ruchi Tushir  Vice President and General Manager  Wolters Kluwer Global Growth Markets India Date/Time: 3:00 â€“ 4:00 pm ISTFor more information about Wolters Kluwer  please visit www.wolterskluwer.com.About Wolters KluwerWolters Kluwer (WKL) is a global leader in professional information  software solutions  and services for the healthcare; tax and accounting; governance  risk and compliance; and legal and regulatory sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.Wolters Kluwer reported 2021 annual revenues of â‚¬4.8 billion. The group serves customers in over 180 countries  maintains operations in over 40 countries  and employs approximately 19 800 people worldwide. The company is headquartered in Alphen aan den Rijn  the Netherlands.Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).For more information  visit www.wolterskluwer.com  follow us on LinkedIn  Twitter  Facebook  and YouTube.,neutral,0.07,0.93,0.0,mixed,0.65,0.1,0.25,True,English,"['Wolters Kluwer Global Growth Markets executives', 'Global Digital Health Summit', 'patient care', 'path', 'equitable', 'Wolters Kluwer Global Growth Markets India', 'Alphen aan den Rijn', 'Level 1 American Depositary Receipt', ""Hon'ble Union Minister"", 'clinical decision support tools', 'Global Digital Health Summit', 'evidence-based digital health tools', 'leading global provider', 'Wolters Kluwer shares', 'Dr. Jitendra Singh', 'superior diagnostic tools', 'default operating system', 'Rajendra Pratap Gupta', 'deep domain knowledge', 'Digital Health Keynote', 'trusted clinical technology', 'digital healthcare products', 'global leader', 'Prime Minister', 'digital solutions', 'clinical effectiveness', 'clinical surveillance', 'evidence-based solutions', 'evidence-based content', 'health outcomes', 'advanced technology', 'specialized technology', 'NEW DELHI', 'BUSINESS WIRE', 'expert solutions', 'dramatic impact', 'next generation', 'effective decision-making', 'data solutions', 'right care', 'significant number', 'care journey', 'General Manager', 'systematic approach', 'vast expertise', 'Session Title', 'Care Panelists', 'software solutions', 'regulatory sectors', 'critical decisions', '2021 annual revenues', 'Euronext Amsterdam', 'Euronext 100 indices', 'ADR) program', 'counter market', 'U.S.', 'Cathy Wolfe', 'Ruchi Tushir', 'consistent outcomes', 'healthcare providers', 'patient experience', 'Vice President', 'right time', 'professional information', 'quality healthcare', 'AEX', 'WKL', 'insights', 'services', 'professionals', 'clinicians', 'year', 'digitalization', 'dignitaries', 'State', 'Office', 'Government', 'patients', 'researchers', 'company', 'learning', 'compliance', 'ways', 'access', 'better', 'recommendations', 'population', 'standards', 'shortage', 'doctors', 'citizens', 'Study', 'use', 'gap', 'world', 'value', 'lives', 'CEO', 'importance', 'addition', 'author', 'book', 'chair', 'Return', 'Investment', 'Friday', 'October', 'Adoption', 'Continuum', 'wolterskluwer', 'tax', 'accounting', 'governance', 'risk', 'legal', 'customers', 'group', '180 countries', 'operations', '40 countries', '19,800 people', 'Netherlands', 'ADRs', 'WTKWY', 'LinkedIn', 'Twitter', 'YouTube', '11:30', '1:00', '4:00']",2022-10-28,2022-10-28,businesswire.com
12306,EuroNext,NewsApi.org,https://finance.yahoo.com/news/bghl-eur-nav-053000961.html,BGHL (EUR): NAV(s),BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for...,"BOUSSARD AND GAVAUDAN HOLDING LIMITED (EUR)BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 27 Oct 2022.Estimated NAVEuro Shares Sterling Shares Estimated NAV â‚¬ 28.1670 Â£ 24.7017 Estimated MTD return -0.30 % -0.18 % Estimated YTD return -3.54 % -2.38 % Estimated ITD return 181.67 % 147.02 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close â‚¬ 22.20 N/A Premium/discount to estimated NAV -21.18 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 2 000.00 Premium/discount to estimated NAV N/A -19.03 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 315 188 130 254 Held in treasury 1 400 N/A Shares Issued 12 316 588 130 254Estimated BG Fund NAVClass B Euro Shares (estimated) â‚¬ 245.8942 Class GBP A Shares (estimated) Â£ 131.7642The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.For further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comStory continuesThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.0,1.0,0.0,negative,0.0,0.16,0.84,True,English,"['BGHL', 'EUR', 'NAV', 'The Class B Euro Shares', 'Euro Shares Sterling Shares Number', 'BGHL Ordinary Shares Euro Shares', 'A Liquidity Enhancement Agreement', 'Class GBP A Shares', 'London Stock Exchange plc', 'Guernsey Financial Services Commission', 'N/A Sterling Shares Amsterdam', 'Dutch Financial Supervision Act', 'A N/A Average Price', 'US Investment Company Act', 'Euro Shares Amsterdam', 'Sterling Shares Shares', 'A N/A Range', 'GAVAUDAN HOLDING LIMITED', 'expert financial advice', 'Guernsey Policy Council', 'collective investment scheme', 'UK Listing Authority', 'other professional advice', 'BG Fund ICAV', 'closed-ended investment company', 'US Securities Act', 'Gavaudan Investment Management', 'investment manager fees', 'BG Fund NAV', '1,400 N/A Shares', 'The Shares', 'Dutch Authority', 'Euronext Amsterdam', 'US persons', 'Emmanuel Gavaudan', 'Financial Markets', 'The Directors', 'The Company', 'investment performance', 'original investment', 'investment decision', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'United States', 'following information', 'information purposes', 'necessary approval', 'main market', 'future results', 'listed securities', 'Market information', 'BOUSSARD', 'business', 'returns', 'AEX', 'LSE', 'Transactions', 'treasury', 'respect', 'role', 'LLP.', 'Email', 'Story', 'article', 'conjunction', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2022-10-28,2022-10-28,finance.yahoo.com
12307,EuroNext,NewsApi.org,https://www.prnewswire.co.uk/news-releases/pharming-announces-european-medicines-agency-ema-validates-its-marketing-authorisation-application-under-accelerated-assessment-for-leniolisib-301661947.html,Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib,"Marketing authorisation in the European Economic Area anticipated in H1 2023 LEIDEN  Netherlands  Oct. 28  2022 /PRNewswire/ -- Pharming Group N.V. (""Pharming"" or ""the Company"") (EURONEXT Amsterdam: PHARM / Nasdaq: PHAR) announces today that its Marketing Autâ€¦","Marketing authorisation in the European Economic Area anticipated in H1 2023LEIDEN  Netherlands  Oct. 28  2022 /PRNewswire/ -- Pharming Group N.V. (""Pharming"" or ""the Company"") (EURONEXT Amsterdam: PHARM / Nasdaq: PHAR) announces today that its Marketing Authorisation Application (MAA) for leniolisib has been validated for scientific evaluation under an accelerated assessment by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). The application  submitted earlier in October 2022  is for the investigational drug  leniolisib  an oral  selective phosphoinositide 3-kinase delta (PI3KÎ´) inhibitor  as a treatment for activated phosphoinositide 3-kinase delta syndrome (APDS)  a rare primary immunodeficiency  in adolescents and adults 12 years or older.In August 2022  Pharming announced the leniolisib MAA was granted accelerated assessment by EMA's CHMP. The accelerated assessment reduces the review timeframe from 210 days to 150 days. Upon request  EMA will grant an accelerated assessment of an MAA if they decide the product is of major interest for public health  and in particular  from the viewpoint of therapeutic innovation. Marketing authorisation for leniolisib in the European Economic Area is anticipated in H1 2023.The MAA is supported by positive data from a Phase II/III study of leniolisib  announced on February 2  2022  which met its co-primary endpoints of reduction in lymph node size and increase in percentage of naÃ¯ve B cells in patients with APDS. Furthermore  safety data from the study showed that leniolisib was well tolerated by participants. Also submitted as part of the MAA were data from a long-term  open-label extension clinical trial in patients with APDS treated with leniolisib.Anurag Relan  MD  MPH  Chief Medical Officer of Pharming  commented:""EMA's validation for review of our MAA under an accelerated assessment pathway highlights Pharming's ongoing commitment to advance leniolisib as a targeted treatment for adults and adolescents 12 years of age or older with APDS. We anticipate that leniolisib will fill an unmet need for patients with APDS  who currently rely on supportive therapies to treat their primary symptoms. This review constitutes a key milestone in Pharming's effort to give healthcare providers and their patients global access to leniolisib. We look forward to collaborating with EMA as needed throughout the regulatory process.""About Activated Phosphoinositide 3-Kinase Î´ Syndrome (APDS)APDS is a rare primary immunodeficiency that affects approximately 1 to 2 people per million. APDS is caused by variants in either of two genes  PIK3CD or PIK3R1  that regulate maturation of white blood cells. Variants of these genes lead to hyperactivity of the PI3KÎ´ (phosphoinositide 3-kinase delta) pathway.1 2 Balanced signaling in the PI3KÎ´ pathway is essential for physiological immune function. When this pathway is hyperactive  immune cells fail to mature and function properly  leading to immunodeficiency and dysregulation.1 3 APDS is characterized by severe  recurrent sinopulmonary infections  lymphoproliferation  autoimmunity  and enteropathy.4 5 Because these symptoms can be associated with a variety of conditions  including other primary immunodeficiencies  people with APDS are frequently misdiagnosed and suffer a median 7-year diagnostic delay.6 As APDS is a progressive disease  this delay may lead to an accumulation of damage over time  including permanent lung damage and lymphoma.4-7 The only way to definitively diagnose this condition is through genetic testing.About LeniolisibLeniolisib is a small-molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class IA PI3K. PI3KÎ´ is expressed predominately in hematopoietic cells and is essential to normal immune system function through conversion of phosphatidylinositol-4-5-trisphosphate (PIP2) to phosphatidylinositol-3-4-5-trisphosphate (PIP3). Leniolisib inhibits the production of PIP3 and PIP3 serves as an important cellular messenger activating AKT (via PDK1) and regulates a multitude of cell functions such as proliferation  differentiation  cytokine production  cell survival  angiogenesis  and metabolism. Unlike PI3KÎ± and PI3KÎ²  which are ubiquitously expressed  PI3KáºŸ and PI3KÎ³ are expressed primarily in cells of hematopoietic origin. The central role of PI3KáºŸ in regulating numerous cellular functions of the adaptive immune system (B-cells and  to a lesser extent  T cells) as well as the innate immune system (neutrophils  mast cells  and macrophages) strongly indicates that PI3KáºŸ is a valid and potentially effective therapeutic target for immune diseases such as APDS. To date  leniolisib has been well tolerated during both the Phase 1 first-in-human trial in healthy subjects and the Phase II/III registration-enabling study in patients with APDS.About Pharming Group N.V.Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare  debilitating  and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines  including small molecules  biologics  and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden  Netherlands  and has employees around the globe who serve patients in over 30 markets in North America  Europe  the Middle East  Africa  and Asia-Pacific.For more information  visit www.pharming.com.Forward-Looking StatementsThis press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results  performance or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as ""aim""  ""ambition""  ''anticipate''  ''believe''  ''could''  ''estimate''  ''expect''  ''goals''  ''intend''  ''may''  ""milestones""  ''objectives''  ''outlook''  ''plan''  ''probably''  ''project''  ''risks''  ""schedule""  ''seek''  ''should''  ''target''  ''will'' and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates  Pharming's clinical and commercial prospects  and Pharming's expectations regarding its projected working capital requirements and cash resources  which statements are subject to a number of risks  uncertainties and assumptions  including  but not limited to the scope  progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical  scientific  regulatory and technical developments. In light of these risks and uncertainties  and other risks and uncertainties that are described in Pharming's 2021 Annual Report and the Annual Report on Form 20-F for the year ended December 31  2021 filed with the U.S. Securities and Exchange Commission  the events and circumstances discussed in such forward-looking statements may not occur  and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information  future events or other information.Inside InformationThis press release relates to the disclosure of information that qualifies  or may have qualified  as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.References1. Lucas CL  et al. Nat Immunol. 2014;15:88-97.2. Elkaim E  et al. J Allergy Clin Immunol. 2016;138(1):210-218.3. Nunes-Santos C  Uzel G  Rosenzweig SD. J Allergy Clin Immunol. 2019;143(5):1676-1687.4. Coulter TI  et al. J Allergy Clin Immunol. 2017;139(2):597-606.5. Maccari ME  et al. Front Immunol. 2018;9:543.6. Jamee M  et al. Clin Rev Allergy Immunol. 2019;May 21.7. Condliffe AM  Chandra A. Front Immunol. 2018;9:338.For further public information  contact:Pharming Group  Leiden  The NetherlandsHeather Robertson  Investor Relations & Corporate Communications ManagerT: +31 71 524 7400E: investor@pharming.comFTI Consulting  London  UKVictoria Foster Mitchell/Alex ShawithAmy ByrneT: +44 203 727 1000LifeSpring Life Sciences Communication  Amsterdam  The NetherlandsLeon MelensT: +31 6 53 81 64 27E: pharming@lifespring.nlUS PR:Ethan MetelenisE: Ethan.Metelenis@precisionvh.comT: +1 (917) 882 9038EU PR:Dan CaleyE: Dan.caley@aprilsix.comT: +44 (0) 787 546 8942Logo - https://mma.prnewswire.com/media/1454235/Pharming_Group_NV_Logo.jpgSOURCE Pharming Group N.V.",neutral,0.0,1.0,0.0,mixed,0.62,0.23,0.15,True,English,"['European Medicines Agency', 'Marketing Authorisation Application', 'Accelerated Assessment', 'Pharming', 'EMA', 'leniolisib', 'long-term, open-label extension clinical trial', 'oral, selective phosphoinositide 3-kinase delta', 'severe, recurrent sinopulmonary infections', 'phosphoinositide 3-kinase delta syndrome', 'median 7-year diagnostic delay', 'naÃ¯ve B cells', 'phosphoinositide 3-kinase delta) pathway', 'Pharming Group N.V.', 'normal immune system function', 'Phase II/III registration-enabling study', 'Phosphoinositide 3-Kinase Î´ Syndrome', 'European Economic Area', 'European Medicines Agency', 'lymph node size', 'Chief Medical Officer', '110 kDa catalytic subunit', 'important cellular messenger', 'adaptive immune system', 'innate immune system', 'Phase II/III study', 'other primary immunodeficiencies', 'numerous cellular functions', 'effective therapeutic target', 'white blood cells', 'permanent lung damage', 'rare primary immunodeficiency', 'global biopharmaceutical company', 'class IA PI3K', 'Marketing Authorisation Application', 'accelerated assessment pathway', 'delta isoform', 'immune function', 'human trial', 'immune cells', 'immune diseases', 'primary endpoints', 'therapeutic innovation', 'global access', 'cell functions', 'hematopoietic cells', 'T cells', 'primary symptoms', 'EURONEXT Amsterdam', 'scientific evaluation', 'Medicinal Products', 'Human Use', 'investigational drug', 'major interest', 'public health', 'Anurag Relan', 'ongoing commitment', 'unmet need', 'supportive therapies', 'key milestone', 'healthcare providers', 'regulatory process', 'Balanced signaling', 'progressive disease', 'genetic testing', 'small-molecule inhibitor', 'cell survival', 'hematopoietic origin', 'central role', 'lesser extent', 'healthy subjects', 'life-threatening diseases', 'PI3KÎ´ pathway', 'positive data', 'safety data', 'targeted treatment', '1 to 2 people', 'two genes', 'cytokine production', 'PI3KÎ´) inhibitor', 'review timeframe', 'Phase 1', 'leniolisib MAA', 'PI3KÎ±', 'PI3KÎ²', 'PI3KÎ³', 'H1', 'LEIDEN', 'Netherlands', 'Nasdaq', 'CHMP', 'October', 'APDS', 'adolescents', 'adults', 'August', '210 days', '150 days', 'request', 'viewpoint', 'February', 'reduction', 'percentage', 'patients', 'participants', 'MD', 'validation', 'years', 'effort', 'million', 'variants', 'PIK3CD', 'PIK3R', 'maturation', 'hyperactivity', 'dysregulation', 'lymphoproliferation', 'autoimmunity', 'enteropathy', 'variety', 'conditions', 'lymphoma', 'conversion', 'PIP', 'AKT', 'PDK', 'multitude', 'differentiation', 'angiogenesis', 'metabolism', 'B-cells', 'neutrophils', 'macrophages', 'date', 'lives']",2022-10-28,2022-10-28,prnewswire.co.uk
12308,EuroNext,NewsApi.org,https://finance.yahoo.com/news/signify-reports-third-quarter-sales-050000983.html,Signify reports third quarter sales of EUR 1.9 billion  comparable sales growth of 4.3% and an operational profitability of 10.4%,Press Release October 28  2022 Signify reports third quarter sales of EUR 1.9 billion  comparable sales growth of 4.3% and an operational profitability of...,SignifyPress ReleaseOctober 28  2022Signify reports third quarter sales of EUR 1.9 billion  comparable sales growth of 4.3% and an operational profitability of 10.4%Third quarter 20221Signify's installed base of connected light points increased from 103 million in Q2 22 to 109 million in Q3 22Sales of EUR 1 912 million; nominal sales increase of 16.3% and CSG of 4.3%LED-based sales represented 83% of total sales (Q3 21: 83%)Adj. EBITA margin of 10.4% (Q3 21: 11.1%)Net income of EUR 112 million (Q3 21: EUR 94 million)Free cash flow of EUR 135 million (Q3 21: EUR 85 million)Net debt/EBITDA ratio of 1.5x (Q3 21: 1.8x)Eindhoven  the Netherlands â€“ Signify (Euronext: LIGHT)  the world leader in lighting  today announced the companyâ€™s third quarter 2022 results.â€œIn the third quarter  we delivered solid topline growth in an increasingly volatile environment. The strong performance of our professional business compensated lower consumer demand and the continued slowdown in China. We managed to improve profitability compared to the second quarter despite the impact of energy costs and currency movements. As expected  our free cash flow generation strengthened  driven by improved profitability and the stabilization of our working capital. Given the uncertain near-term outlook  the continued softness of the consumer segment and of the Chinese market  we now expect to achieve comparable sales growth between 2% and 3% for the full year 2022. Regarding the adjusted EBITA margin and free cash flow  we are targeting the lower end of both guidance ranges â€ said CEO Eric Rondolat.â€œAs we enter the final quarter of 2022  we have shifted gears to adapt the company to a structurally weaker external environment in the coming quarters  when current headwinds and volatility are likely to persist. We will therefore focus on measures to control costs and cash flow  in line with our track record of delivering margin expansion and strong free cash flow generation in difficult environments. While some areas will be more affected  connected energy efficient lighting solutions will continue to benefit from strong demand given the energy prices surge.â€Story continuesBrighter Lives  Better World 2025In the third quarter of the year  Signify continued to deliver on its Brighter Lives  Better World 2025 sustainability program commitments that contribute to doubling its positive impact on the environment and society.Double the pace of the Paris Agreement:Cumulative carbon reduction over the value chain is on track  mainly driven by energy-efficient and connected LED lightingDouble Circular revenues to 32%:Circular revenues were at 30% and on track. This positive trend is driven by serviceable and circular luminairesDouble Brighter lives revenues to 32%:Brighter lives revenues increased to 28%  mainly driven by the Safety & security and consumer well-being portfoliosDouble the percentage of women in leadership positions to 34%:The percentage of women in leadership positions was 27%  stable with Q2. Signify continued to create action plans to address gaps and accelerate its progress. In addition  Signify published its first-ever Diversity  Equity  and Inclusion report.OutlookGiven the uncertain near-term outlook and the continued softness both of the consumer segment and of the Chinese market  we now expect to achieve comparable sales growth between 2% and 3% for the full year 2022. We are targeting the lower end of the range for both the 11.0-11.4% Adjusted EBITA margin guidance and the 5-7% free cash flow guidance.Financial reviewThird quarter Nine months 2021 2022 change in millions of EUR  except percentages 2021 2022 change 4.3 % Comparable sales growth 5.3 % 8.1 % Effects of currency movements 6.6 % 4.0 % Consolidation and other changes 2.2 % 1 643 1 912 16.3 % Sales 4 852 5 536 14.1 % 634 713 12.6 % Adjusted gross margin 1 909 2 072 8.6 % 38.6% 37.3% Adj. gross margin (as % of sales) 39.3% 37.4% -415 -471 Adj. SG&A expenses -1 262 -1 392 -68 -75 Adj. R&D expenses -210 -219 -483 -546 -13.0 % Adj. indirect costs -1 473 -1 611 -9.4 % 29.4% 28.6% Adj. indirect costs (as % of sales) 30.4% 29.1% 182 199 9.1 % Adjusted EBITA 530 560 5.8 % 11.1% 10.4% Adjusted EBITA margin 10.9% 10.1% -34 -6 Adjusted items -130 118 149 193 29.7 % EBITA 399 678 69.9 % 118 161 36.3 % Income from operations (EBIT) 309 582 88.5 % -4 -17 Net financial income/expense -20 -12 -20 -32 Income tax expense -52 -123 94 112 18.4 % Net income 236 447 89.0 % 85 135 Free cash flow 357 81 0.72 0.86 Basic EPS (â‚¬) 1.84 3.52 37 069 34 273 Employees (FTE) 37 069 34 273Third quarterSales increased by 16.3% to EUR 1 912 million  with a comparable sales growth of 4.3%  as continued strength in the professional channel more than offset weaker consumer channel sales. Nominal sales included a positive currency effect of 8.1%  mainly from the appreciation of the USD  and a positive effect of 4.0% from the Q2 acquisitions of Fluence and Pierlite.The Adjusted gross margin decreased by 130 bps to 37.3%. While continued price increases more than offset the input cost increases and the surge in energy costs  the Adjusted gross margin was impacted by an adverse currency effect. Adjusted indirect costs as a percentage of sales decreased by 80 bps to 28.6%  driven by operating leverage and strengthened cost discipline.Adjusted EBITA was EUR 199 million  up 9.1% vs. Q3 2021. The Adjusted EBITA margin decreased by 70 bps to 10.4%  with price increases more than offsetting higher input costs. Yet  the Adjusted EBITA margin was negatively affected by a 220bps currency effect  being the combination both from the weakening of the EUR versus the USD and CNY  and from a temporary FX hedging headwind. Excluding this temporary adverse hedging effect  the Adjusted EBITA margin was stable vs Q3 21.Adjusted items were EUR -6 million. Restructuring costs decreased year on year to EUR -6 million  while acquisition-related charges of EUR -10 million were fully compensated by incidental items of EUR 10 million. The incidental items benefited from a release of tax indemnification liabilities. Net income increased by 18.4% from EUR 94 million to EUR 112 million.The number of employees (FTE) decreased from 37 069 at the end of Q3 21 to 34 273 at the end of Q3 22. The employee base was exceptionally high in Q3 21  due to the strong volume recovery and additional staff requirements in factories  following the peak of the COVID-19 pandemic. The number of FTEs is affected by fluctuations in volume and seasonality.1 This press release contains certain non-IFRS financial measures and ratios  such as comparable sales growth  EBITA  adjusted EBITA and free cash flow  and related ratios  which are not recognized measures of financial performance or liquidity under IFRS. For a reconciliation of these non-IFRS financial measures to the most directly comparable IFRS financial measures  see appendix B  Reconciliation of non-IFRS financial measures  of this press release.For the full and original version of the press release click hereFor the presentation click hereConference call and audio webcastEric Rondolat (CEO) and Javier van Engelen (CFO) will host a conference call for analysts and institutional investors at 9:00 a.m. CET to discuss the third quarter 2022 results. A live audio webcast of the conference call will be available via the Investor Relations website .Financial calendar 2023January 27  2023 Fourth quarter and full-year results 2022February 28  2023 Annual Report 2022For further information  please contact:Signify Investor RelationsThelke GerdesTel: +31 6 1801 7131E-mail: thelke.gerdes@signify.comSignify Corporate CommunicationsLeanne CarmodyTel: +31 6 3928 0201E-mail: leanne.carmody@signify.comAbigail LeveneTel: +31 6 2939 3895E-mail: abigail.levene@signify.comAbout SignifySignify (Euronext: LIGHT) is the world leader in lighting for professionals and consumers and lighting for the Internet of Things. Our Philips products  Interact connected lighting systems and data-enabled services  deliver business value and transform life in homes  buildings and public spaces. In 2021  we had sales of EUR 6.9 billion  approximately 37 000 employees and a presence in over 70 countries. We unlock the extraordinary potential of light for brighter lives and a better world. We achieved carbon neutrality in 2020  have been in the Dow Jones Sustainability World Index since our IPO for five consecutive years and were named Industry Leader in 2017   2018 and 2019 . News from Signify is located at the Newsroom   Twitter   LinkedIn and Instagram . Information for investors can be found on the Investor Relations page.Important InformationForward-Looking Statements and Risks & UncertaintiesThis document and the related oral presentation contain  and responses to questions following the presentation may contain  forward-looking statements that reflect the intentions  beliefs or current expectations and projections of Signify N.V. (the â€œCompanyâ€  and together with its subsidiaries  the â€œGroupâ€)  including statements regarding strategy  estimates of sales growth and future operational results.By their nature  these statements involve risks and uncertainties facing the Company and its Group companies  and a number of important factors could cause actual results or outcomes to differ materially from those expressed in any forward-looking statement as a result of risks and uncertainties. Such risks  uncertainties and other important factors include but are not limited to: adverse economic and political developments  in particular the impacts of the Russia-Ukraine conflict  the energy crisis in Europe  the impacts of COVID-19  supply chain constraints  component shortages  cost inflation  rapid technological change  competition in the general lighting market  development of lighting systems and services  successful implementation of business transformation programs  impact of acquisitions and other transactions  reputational and adverse effects on business due to activities in Environment  Health & Safety  compliance risks  ability to attract and retain talented personnel  adverse currency effects  pension liabilities  and exposure to international tax laws.Additional risks currently not known to the Group or that the Group has not considered material as of the date of this document could also prove to be important and may have a material adverse effect on the business  results of operations  financial condition and prospects of the Group or could cause the forward-looking events discussed in this document not to occur. The Group undertakes no duty to and will not necessarily update any of the forward-looking statements in light of new information or future events  except to the extent required by applicable law.Market and Industry InformationAll references to market share  market data  industry statistics and industry forecasts in this document consist of estimates compiled by industry professionals  competitors  organizations or analysts  of publicly available information or of the Groupâ€™s own assessment of its sales and markets. Rankings are based on sales unless otherwise stated.Non-IFRS Financial MeasuresCertain parts of this document contain non-IFRS financial measures and ratios  such as comparable sales growth  adjusted gross margin  EBITA  adjusted EBITA  and free cash flow  and other related ratios  which are not recognized measures of financial performance or liquidity under IFRS. The non-IFRS financial measures presented are measures used by management to monitor the underlying performance of the Groupâ€™s business and operations and  accordingly  they have not been audited nor reviewed. Not all companies calculate non-IFRS financial measures in the same manner or on a consistent basis and these measures and ratios may not be comparable to measures used by other companies under the same or similar names. A reconciliation of these non-IFRS financial measures to the most directly comparable IFRS financial measures is contained in this document. For further information on non-IFRS financial measures  see â€œChapter 18 Reconciliation of non-IFRS measuresâ€ in the Annual Report 2021.PresentationAll amounts are in millions of euros unless otherwise stated. Due to rounding  amounts may not add up to totals provided. All reported data are unaudited. Unless otherwise indicated  financial information has been prepared in accordance with the accounting policies as stated in the Annual Report 2021 and the Semi-Annual Report 2022.Market Abuse RegulationThis press release contains information within the meaning of Article 7(1) of the EU Market Abuse Regulation.,neutral,0.01,0.99,0.0,mixed,0.54,0.26,0.2,True,English,"['third quarter sales', 'comparable sales growth', 'operational profitability', 'Signify', 'Brighter Lives, Better World 2025 sustainability program commitments', 'circular luminaires Double Brighter lives', '5-7% free cash flow guidance', '11.0-11.4% Adjusted EBITA margin guidance', 'strong free cash flow generation', 'energy efficient lighting solutions', 'Third quarter Nine months', 'weaker consumer channel sales', 'Brighter lives revenues', 'Double Circular revenues', 'solid topline growth', 'CEO Eric Rondolat', 'Cumulative carbon reduction', 'SG&A expenses', 'R&D expenses', 'consumer well-being portfolios', 'connected LED lighting', 'weaker external environment', 'Net debt/EBITDA ratio', 'uncertain near-term outlook', 'comparable sales growth', 'third quarter 2022 results', 'connected light points', 'nominal sales increase', 'lower consumer demand', 'third quarter sales', 'positive currency effect', 'Income tax expense', 'Adj. EBITA margin', 'Adj. indirect costs', 'guidance ranges', 'world leader', 'strong demand', 'strong performance', 'professional channel', 'consumer segment', 'positive effect', 'energy costs', 'energy prices', 'margin expansion', 'gross margin', 'second quarter', 'final quarter', 'Net income', 'currency movements', 'lower end', 'LED-based sales', 'total sales', 'positive trend', 'Press Release', 'installed base', 'volatile environment', 'professional business', 'continued slowdown', 'working capital', 'continued softness', 'Chinese market', 'coming quarters', 'current headwinds', 'difficult environments', 'Paris Agreement', 'value chain', 'leadership positions', 'action plans', 'Inclusion report', 'Financial review', 'other changes', 'Basic EPS', 'price increases', 'positive impact', 'full year', 'operational profitability', 'track record', 'Q2 acquisitions', 'Q2.', 'October', 'Signify', 'Q3', 'CSG', '1.5x', 'Eindhoven', 'Netherlands', 'Euronext', 'company', 'China', 'stabilization', 'gears', 'volatility', 'measures', 'areas', 'Story', 'society', 'pace', 'energy-efficient', 'serviceable', 'Safety', 'security', 'percentage', 'women', 'gaps', 'progress', 'addition', 'Diversity', 'Equity', 'millions', 'Effects', 'Consolidation', 'items', 'operations', 'Employees', 'FTE', 'strength', 'appreciation', 'USD', 'Fluence', 'Pierlite', 'offs', '32', '130']",2022-10-28,2022-10-28,finance.yahoo.com
12309,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/28/2544032/0/en/DEINOVE-REQUESTS-RECEIVERSHIP-PROCEEDINGS.html,DEINOVE REQUESTS RECEIVERSHIP PROCEEDINGS,DEINOVE (Euronext Growth Paris: ALDEI)  a French biotech company  pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent  global challenge of antibiotic resistance  announces having filed today a declaration of cessation oâ€¦,"English FrenchDEINOVE (Euronext Growth Paris: ALDEI)  a French biotech company  pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent  global challenge of antibiotic resistance  announces having filed today a declaration of cessation of payments (""dÃ©claration de cessation des paiements"") and a request for receivership proceedings (â€œprocÃ©dure de redressement judiciaireâ€) of the Company with the Montpellier Commercial Court.The employee representative bodies were notified in advance.The purpose of these proceedings is to evaluate all solutions that could enable the Company to continue its business activity  maintain employment  and pay off its liabilities under the best possible conditions  and also to initiate a process to attract investors within the framework of a recovery plan by way of continuation or a sale plan.The Company will continue its current activities during the observation period.The Company will inform the financial markets of the decision of the Montpellier Commercial Court.Under these conditions  DEINOVE has asked Euronext to suspend the listing of its shares (ISIN: FR0010879056) on Euronext Growth from October 28 before the opening of trading  pending the publication of a press release and until further notice. Given the uncertainty regarding the outcome of the steps taken by the Company  the suspension of the listing of the Company's shares (ISIN: FR0010879056) is maintained until further notice.ABOUT DEINOVEDEINOVE is a French biotechnology company pioneering the exploration of a new domain of life  unexplored at 99.9%: the â€œmicrobial dark matterâ€. By revealing the metabolic potential of rare bacteria or still classified as uncultivable  it tackles a global health and economic challenge: antimicrobial resistance.The new therapies discovered and developed by DEINOVE target superbugs (microbes that have become resistant to one or more antimicrobials) that cause life-threatening infections which are now spreading at high speed.This breakthrough approach gave rise to one of the worldâ€™s first specialized micro-biotechnology platforms and a unique collection of nearly 10 000 rare strains and thousands of bacterial extracts. Today  DEINOVE is conducting several development programs  of which its first antibiotic candidate is currently evaluated in a Phase II clinical trial in severe Clostridioides difficile infection  one of the worldâ€™s first emergencies. The Company has also developed new bacterial micro-factories that address the other issue in the race against antimicrobial resistance: the industrial production of these rare and low concentrated compounds with often too complex chemical structures to be generated by chemical synthesis.Located at the heart of the Euromedecine park in Montpellier  DEINOVE has been listed on EURONEXT GROWTHÂ® (ALDEI â€“ code ISIN FR0010879056) since 2010. The Company has 45 employees and relies on a network of world-class academic  technological  industrial and institutional partners.CONTACTSInvestorsMario AlcarazChief Financial and Administrative Officer+33 (0)4 48 19 01 00ir@deinove.comMediaATCG Partners+33 (0)9 81 87 46 72communication@deinove.comAttachment",neutral,0.03,0.96,0.01,negative,0.0,0.17,0.83,True,English,"['DEINOVE REQUESTS RECEIVERSHIP PROCEEDINGS', 'procÃ©dure de redressement judiciaire', 'Phase II clinical trial', 'severe Clostridioides difficile infection', 'first specialized micro-biotechnology platforms', 'world-class academic, technological, industrial', 'employee representative bodies', 'microbial dark matter', 'several development programs', 'low concentrated compounds', 'first antibiotic candidate', 'complex chemical structures', 'Montpellier Commercial Court', 'urgent, global challenge', 'best possible conditions', 'new bacterial micro-factories', 'French biotech company', 'French biotechnology company', 'Euronext Growth Paris', 'first emergencies', 'industrial production', 'English French', 'antibiotic resistance', 'global health', 'economic challenge', 'chemical synthesis', 'bacterial biodiversity', 'new domain', 'new therapies', 'bacterial extracts', 'EURONEXT GROWTHÂ®', 'dÃ©claration', 'business activity', 'recovery plan', 'sale plan', 'current activities', 'observation period', 'financial markets', 'press release', 'metabolic potential', 'antimicrobial resistance', 'life-threatening infections', 'high speed', 'breakthrough approach', 'unique collection', 'other issue', 'Euromedecine park', 'institutional partners', 'Mario Alcaraz', 'Chief Financial', 'Administrative Officer', 'ATCG Partners', 'The Company', 'rare bacteria', '10,000 rare strains', 'receivership proceedings', 'DEINOVE', 'ALDEI', 'pioneer', 'exploration', 'exploitation', 'declaration', 'cessation', 'payments', 'paiements', 'request', 'advance', 'purpose', 'solutions', 'employment', 'liabilities', 'process', 'investors', 'framework', 'way', 'continuation', 'decision', 'listing', 'shares', 'October', 'opening', 'trading', 'publication', 'notice', 'uncertainty', 'outcome', 'steps', 'suspension', 'ISIN', 'superbugs', 'microbes', 'antimicrobials', 'rise', 'thousands', 'race', 'heart', 'code', '45 employees', 'network', 'CONTACTS', 'Media', 'communication', 'Attachment', '9']",2022-10-28,2022-10-28,globenewswire.com
12310,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/27/2543441/0/en/Cellectis-to-Report-Third-Quarter-2022-Financial-Results.html,Cellectis to Report Third Quarter 2022 Financial Results,NEW YORK  Oct. 27  2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS)  a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies  today announced that it will reporâ€¦,NEW YORK  Oct. 27  2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS)  a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies  today announced that it will report financial results for the third quarter ended September 30th  2022  on Thursday  November 3rd  2022  after the close of the US market.The announcement will be followed by a conference call and live audio webcast on Friday  November 4th  2022  at 8:00 AM EDT / 2:00 PM CET. The call will include the Companyâ€™s third quarter results and an update on business activities. Details for the call are as follows:Friday  November 4th at 8:00 a.m. Eastern Time: Domestic: 1-877-413-2411 International: 1-201-389-0882 Conference ID: 13732988 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1571941&tp_key=ebcf814947About CellectisCellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology  pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients  and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 22 years of expertise in gene editing  Cellectis is developing life-changing product candidates utilizing TALENÂ®  its gene editing technology  and PulseAgile  its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Cellectisâ€™ headquarters are in Paris  France  with locations in New York  New York and Raleigh  North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).For more information  visit www.cellectis.com. Follow Cellectis on social media: @cellectis  LinkedIn and YouTube.For further information  please contact:Media contacts:Pascalyne Wilson  Director  Communications  +33 (0)7 76 99 14 33  media@cellectis.comMargaret Gandolfo  Senior Manager  Communications  +1 (646) 628 0300Investor Relation contact:Arthur Stril  Chief Business Officer  +1 (347) 809 5980  investors@cellectis.comAshley R. Robinson  LifeSci Advisors  +1 617 430 7577Forward-looking StatementsThis press release contains â€œforward-lookingâ€ statements within the meaning of applicable securities laws  including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as â€œanticipate â€ â€œbelieve â€ â€œintendâ€  â€œexpect â€ â€œplan â€ â€œscheduled â€ â€œcouldâ€ and â€œwill â€ or the negative of these and similar expressions. These forward-looking statements  which are based on our managementâ€™s current expectations and assumptions and on information currently available to management. Forward-looking statements include statements about the timing of our presentation of data and submission of regulatory filings  the adequacy of our supply of clinical vials  the operational capabilities at our manufacturing facilities  and the sufficiency of cash to fund operation. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties  including with respect to the numerous risks associated with biopharmaceutical product candidate development. With respect to our cash runway  our operating plans  including product development plans  may change as a result of various factors  including factors currently unknown to us. Furthermore  many other important factors  including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31  2021 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time  as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results  performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law  we assume no obligation to update these forward-looking statements publicly  or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements  even if new information becomes available in the future.Attachment,neutral,0.01,0.99,0.0,mixed,0.17,0.18,0.65,True,English,"['Third Quarter 2022 Financial Results', 'Cellectis', 'Private Securities Litigation Reform Act', 'biopharmaceutical product candidate development', 'many other important factors', 'applicable securities laws', 'Securities Exchange Commission', 'life-changing product candidates', 'product development plans', 'hemopoietic stem cells', 'clinical-stage biopharmaceutical company', 'unmet medical needs', 'Investor Relation contact', 'Ashley R. Robinson', 'clinical-stage biotechnology company', 'pioneering electroporation system', 'Chief Business Officer', 'pioneering gene-editing platform', 'live audio webcast', 'gene editing technology', 'Nasdaq Global Market', 'third quarter results', 'other known', 'US market', 'business activities', 'immune system', 'operating plans', 'various factors', 'financial results', 'actual results', 'gene therapies', 'therapeutic gene', 'NEW YORK', 'GLOBE NEWSWIRE', 'Euronext Growth', 'life-saving cell', 'Conference ID', 'allogeneic approach', 'CAR-T immunotherapies', 'CAR T-cells', 'cancer patients', 'North Carolina', 'social media', 'Media contacts', 'Pascalyne Wilson', 'Margaret Gandolfo', 'Senior Manager', 'Arthur Stril', 'LifeSci Advisors', 'press release', 'similar expressions', 'current expectations', 'regulatory filings', 'clinical vials', 'operational capabilities', 'manufacturing facilities', 'numerous risks', 'Annual Report', 'Form 20-F', 'financial report', 'subsequent filings', 'unknown risks', 'Forward-looking Statements', 'forward-lookingâ€ statements', 'various diseases', 'cash runway', 'conference call', 'Eastern Time', 'management report', 'new information', 'Cellectisâ€™ headquarters', 'ALCLS', 'CLLS', 'September', 'Thursday', 'November', 'close', 'announcement', 'Friday', '8:00 AM', '2:00 PM', 'update', 'Details', 'Domestic', 'oncology', 'concept', 'shelf', '22 years', 'expertise', 'PulseAgile', 'power', 'order', 'Paris', 'France', 'locations', 'Raleigh', 'LinkedIn', 'YouTube', 'Director', 'Communications', 'investors', 'meaning', 'words', 'believe', 'assumptions', 'timing', 'presentation', 'data', 'submission', 'adequacy', 'supply', 'sufficiency', 'light', 'uncertainties', 'respect', 'performance', 'achievements', 'obligation', 'reasons', 'future', 'Attachment', 'Â®', '7']",2022-10-27,2022-10-28,globenewswire.com
12311,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/28/2544044/0/en/AMG-Advanced-Metallurgical-Group-N-V-Schedule-for-Third-Quarter-2022-Earnings-Release.html,AMG Advanced Metallurgical Group N.V. Schedule for Third Quarter 2022 Earnings Release,"Amsterdam  28 October 2022 --- AMG Advanced Metallurgical Group N.V. (""AMG""  EURONEXT AMSTERDAM: ""AMG"") will release its third quarter 2022 financial results on Wednesday  November 2  2022  at approximately 17:00 CET. AMG will host a conference call to discusâ€¦","Amsterdam  28 October 2022 --- AMG Advanced Metallurgical Group N.V. (""AMG""  EURONEXT AMSTERDAM: ""AMG"") will release its third quarter 2022 financial results on Wednesday  November 2  2022  at approximately 17:00 CET. AMG will host a conference call to discuss its financial results for the third quarter 2022 at 15:00 CET (15:00 GMT / 10:00AM EDT) on Thursday  November 3  2022.Please connect approximately 10 minutes prior to the beginning of the call to ensure participation. The call-in information is as follows:Europe 44 (0) 33 0551 0200Europe (toll free) 0808 109 0700North America 1 212 999 6659North America (toll free) 1 866 966 5335When prompted  tell the operator you are dialing in for â€œAMG earningsâ€ and you will be directed onto the call. The conference call will be available on the website www.amg-nv.com within twenty-four hours following completion of the call.About AMGAMG is a global critical materials company at the forefront of CO 2 reduction trends. AMG produces highly engineered specialty metals and mineral products and provides related vacuum furnace systems and services to the transportation  infrastructure  energy  and specialty metals & chemicals end markets.AMG Clean Energy Materials segment combines AMGâ€™s recycling and mining operations  producing materials for infrastructure and energy storage solutions while reducing the CO 2 footprint of both suppliers and customers. AMG Clean Energy Materials segment spans the vanadium  lithium  and tantalum value chains. AMG Critical Materials Technologies segment combines AMGâ€™s leading vacuum furnace technology line with high-purity materials serving global leaders in the aerospace sector. AMG Critical Minerals segment consists of AMGâ€™s mineral processing operations in antimony  graphite  and silicon metal.With approximately 3 300 employees  AMG operates globally with production facilities in Germany  the United Kingdom  France  the United States  China  Mexico  Brazil  India  Sri Lanka  and Mozambique  and has sales and customer service offices in Japan (www.amg-nv.com).For further information  please contact:AMG Advanced Metallurgical Group N.V. +1 610 975 4979Michele Fischermfischer@amg-nv.comDisclaimerCertain statements in this press release are not historical facts and are â€œforward lookingâ€. Forward looking statements include statements concerning AMGâ€™s plans  expectations  projections  objectives  targets  goals  strategies  future events  future revenues or performance  capital expenditures  financing needs  plans and intentions relating to acquisitions  AMGâ€™s competitive strengths and weaknesses  plans or goals relating to forecasted production  reserves  financial position and future operations and development  AMGâ€™s business strategy and the trends AMG anticipates in the industries and the political and legal environment in which it operates and other information that is not historical information. When used in this press release  the words â€œexpects â€ â€œbelieves â€ â€œanticipates â€ â€œplans â€ â€œmay â€ â€œwill â€ â€œshould â€ and similar expressions  and the negatives thereof  are intended to identify forward looking statements. By their very nature  forward looking statements involve inherent risks and uncertainties  both general and specific  and risks exist that the predictions  forecasts  projections and other forward looking statements will not be achieved. These forward looking statements speak only as of the date of this press release. AMG expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward looking statement contained herein to reflect any change in AMG's expectations with regard thereto or any change in events  conditions  or circumstances on which any forward looking statement is based.Attachment",neutral,0.0,1.0,0.0,negative,0.0,0.04,0.96,True,English,"['AMG Advanced Metallurgical Group N.V. Schedule', 'Third Quarter 2022 Earnings Release', 'AMG Advanced Metallurgical Group N.V.', 'leading vacuum furnace technology line', 'AMG Critical Materials Technologies segment', 'AMG Clean Energy Materials segment', 'related vacuum furnace systems', 'AMG Critical Minerals segment', 'third quarter 2022 financial results', 'other forward looking statements', 'critical materials company', 'energy storage solutions', 'chemicals end markets', 'tantalum value chains', 'customer service offices', 'mineral processing operations', 'CO 2 reduction trends', 'high-purity materials', 'financial position', 'mineral products', 'CO 2 footprint', 'other information', 'mining operations', 'future operations', 'AMG earnings', '10:00AM EDT', 'North America', 'twenty-four hours', 'specialty metals', 'aerospace sector', 'silicon metal', 'United Kingdom', 'United States', 'Sri Lanka', 'Michele Fischer', 'press release', 'historical facts', 'future revenues', 'capital expenditures', 'financing needs', 'competitive strengths', 'business strategy', 'legal environment', 'similar expressions', 'EURONEXT AMSTERDAM', 'global leaders', 'production facilities', 'future events', 'historical information', 'inherent risks', 'conference call', 'Wednesday', 'November', '17:00 CET', '15:00 CET', 'Thursday', 'beginning', 'participation', 'Europe', 'operator', 'website', 'completion', 'forefront', 'services', 'transportation', 'infrastructure', 'recycling', 'suppliers', 'customers', 'vanadium', 'lithium', 'antimony', 'graphite', '3,300 employees', 'Germany', 'France', 'China', 'Mexico', 'Brazil', 'India', 'Mozambique', 'sales', 'Japan', 'mfischer', 'Disclaimer', 'plans', 'expectations', 'projections', 'objectives', 'targets', 'goals', 'strategies', 'performance', 'intentions', 'acquisitions', 'weaknesses', 'reserves', 'development', 'industries', 'political', 'words', 'expects', 'believes', 'negatives', 'nature', 'uncertainties', 'predictions', 'forecasts', 'date', 'obligation', 'undertaking', 'revisions', 'change', 'regard', 'conditions', 'circumstances', 'Attachment']",2022-10-28,2022-10-28,globenewswire.com
12312,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/28/2543551/0/en/Bekaert-Update-on-the-Share-Buyback-Program-and-the-Liquidity-Agreement.html,Bekaert - Update on the Share Buyback Program and the Liquidity Agreement,Update on the Share Buyback Program and the Liquidity AgreementPeriod from 20Â October 2022 to 26Â October 2022  Share Buyback Program  In the context...,English Dutch FrenchUpdate on the Share Buyback Program and the Liquidity AgreementPeriod from 20 October 2022 to 26 October 2022Share Buyback ProgramIn the context of the share buyback program of Bekaert  announced on 25 February 2022   the third tranche of â‚¬ 30 million started on 29 July 2022 .Bekaert announces today that during the period from 20 October 2022 to 26 October 2022  Kepler Cheuvreux on behalf of Bekaert has bought 53 640 shares.The table below provides an overview of the transactions under the third tranche of the share buyback program during the period from 20 October 2022 to 26 October 2022:Repurchase of shares Date Market Number of Shares Average Price paid (â‚¬) Highest Price paid (â‚¬) Lowest Price paid (â‚¬) Total Amount (â‚¬) 20 October 2022 Euronext Brussels 4 226 27.53 27.60 27.42 116 342 MTF CBOE 3 120 27.50 27.60 27.36 85 800 MTF Turquoise â€” â€” â€” â€” â€” MTF Aquis â€” â€” â€” â€” â€” 21 October 2022 Euronext Brussels 7 697 27.59 27.84 27.34 212 360 MTF CBOE 6 874 27.58 27.82 27.34 189 585 MTF Turquoise â€” â€” â€” â€” â€” MTF Aquis â€” â€” â€” â€” â€” 24 October 2022 Euronext Brussels 7 581 28.13 28.38 27.82 213 254 MTF CBOE 7 281 28.12 28.38 27.80 204 742 MTF Turquoise â€” â€” â€” â€” â€” MTF Aquis â€” â€” â€” â€” â€” 25 October 2022 Euronext Brussels 8 226 28.20 28.48 27.98 231 973 MTF CBOE 7 038 28.21 28.44 28.00 198 542 MTF Turquoise 990 28.08 28.08 28.08 27 799 MTF Aquis â€” â€” â€” â€” â€” 26 October 2022 Euronext Brussels 607 28.28 28.28 28.00 17 166 MTF CBOE â€” â€” â€” â€” â€” MTF Turquoise â€” â€” â€” â€” â€” MTF Aquis â€” â€” â€” â€” â€” Total 53 640 27.92 28.48 27.34 1 497 563As announced on 25 February 2022 and 29 July 2022  the purpose of the program is to reduce the issued share capital of the company. All shares repurchased as part of the program will be cancelled.Liquidity agreementIn the context of the renewed liquidity agreement with Kepler Cheuvreux  Bekaert announces today that Kepler Cheuvreux on behalf of Bekaert has bought 7 400 shares during the period from 20 October 2022 to 26 October 2022 on Euronext Brussels. During the same period  Kepler Cheuvreux on behalf of Bekaert has sold 5 800 shares on Euronext Brussels.The tables below provide an overview of the transactions under the liquidity agreement during the period from20 October 2022 to 26 October 2022:Purchase of shares Date Number of Shares Average Price (â‚¬) Highest Price (â‚¬) Lowest Price (â‚¬) Total Amount (â‚¬) 20 October 2022 500 27.50 27.50 27.50 13 750 21 October 2022 3 000 27.68 27.88 27.30 83 040 24 October 2022 1 000 27.88 28.00 27.80 27 880 25 October 2022 1 600 28.15 28.30 28.00 45 040 26 October 2022 1 300 27.90 28.00 27.80 36 270 Total 7 400 â€” â€” â€” 205 980Sale of shares Date Number of Shares Average Price (â‚¬) Highest Price (â‚¬) Lowest Price (â‚¬) Total Amount (â‚¬) 20 October 2022 2 100 27.98 28.10 27.80 58 758 21 October 2022 0 0.00 0.00 0.00 0 24 October 2022 1 900 28.14 28.30 28.00 53 466 25 October 2022 1 000 28.38 28.50 28.30 28 380 26 October 2022 800 28.17 28.24 28.10 22 536 Total 5 800 â€” â€” â€” 163 140The balance held by Bekaert under the liquidity agreement at the end of the period is 85 271 shares.On 26 October 2022 after closing of the market  Bekaert holds 4 064 190 own shares  or 6.89% of the total number of the outstanding shares.Related press release: 2 September 2022: Bekaert renews existing liquidity contractThis information is also made available on the investor relations pages of our website.Attachment,neutral,0.02,0.97,0.0,positive,0.92,0.08,0.0,True,English,"['Share Buyback Program', 'Liquidity Agreement', 'Bekaert', 'Update', 'English Dutch French', 'investor relations pages', 'existing liquidity contract', 'Share Buyback Program', 'Shares Average Price', 'Date Market Number', 'Liquidity Agreement Period', 'share capital', 'Date Number', 'Highest Price', 'Lowest Price', 'total number', 'third tranche', 'Kepler Cheuvreux', 'Total Amount', 'Euronext Brussels', 'MTF CBOE', '800 MTF Turquoise', 'MTF Aquis', 'press release', 'outstanding shares', 'same period', '53 640 shares', '7 400 shares', '5 800 shares', '85 271 shares', 'Update', '20 October', '26 October', 'context', 'Bekaert', '25 February', '29 July', 'behalf', 'table', 'overview', 'transactions', 'Repurchase', '21 October', '24 October', '25 October', 'purpose', 'company', 'part', 'Sale', 'balance', 'end', 'closing', 'information', 'website', 'Attachment', '190']",2022-10-28,2022-10-28,globenewswire.com
12313,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/28/2543536/0/en/Quantum-Genomics-Announces-Lack-of-Significant-Efficacy-for-Firibastat-in-Their-Phase-III-Study-FRESH-and-is-Redirecting-to-New-Developments.html,Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study  FRESH and is Redirecting to New Developments,PARIS  Oct. 28  2022 (GLOBE NEWSWIRE) -- QuantumÂ Genomics (EuronextÂ Growth - FR0011648971 - ALQGC)  a biopharmaceutical company specialising in the development of a new class of medications that directly target the brain to treat resistant hypertension and heâ€¦,"Firibastat efficacy non-significant versus placeboThe REFRESH study and the development of firibastat in cardiology have been stoppedCash of 11 million euros allotted to the development of new innovative treatments  after discontinuation of the REFRESH studyPARIS  Oct. 28  2022 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC)  a biopharmaceutical company specialising in the development of a new class of medications that directly target the brain to treat resistant hypertension and heart failure  announces that efficacy results for firibastat in its phase III study FRESH  are non-significant versus placebo. These results will be presented in detail at the AHA congress.""Firibastat has unfortunately failed to demonstrate significantly greater efficacy than placebo in the phase III study FRESH. This has caused the Company to prematurely discontinue the second phase III study  REFRESH  for ethical reasons concerning the patients. For the same reason  in view of these results  it has been decided to stop the development of firibastat in cardiovascular "" added Bruno Besse  Medical Director of Quantum Genomics.""Nevertheless  we are committed to the mobilisation of all our strengths in the development of new innovative treatments designed to save more lives in more patients. It is with this in mind that we have already identified BioTech/MedTech with whom negotiations are on-going. I wish to thank all those who are working alongside us and those who are supporting us towards therapeutic innovation which has always been our mission "" declared Jean-Philippe Milon  CEO of Quantum Genomics.""Stopping the development of firibastat in cardiology and discontinuing the REFRESH study in particular  will enable the Company to switch its financial horizon for the third quarter 2023. Henceforth we will be re-allotting our funds  amounting to 11 million euros before the discontinuation of the REFRESH study  to the development of new innovative molecules in unmet therapeutic domains "" adds Benoit Gueugnon  Quantum Genomics Chief Financial Officer.All questions can be sent to: contact@quantum-genomics.comAbout Quantum GenomicsQuantum Genomics is a biopharmaceutical company specialising in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. It relies on over twenty years of research conducted at Paris-Descartes University and on work directed by Dr Catherine Llorens-Cortes at the CollÃ¨ge de France (French National Institute of Health and Medical Research (INSERM)/ Scientific Centre for National Research (CNRS) laboratory). The goal of Quantum Genomics is to develop innovative treatments for difficult-to-treat or even resistant hypertension (hypertension is poorly or inadequately controlled in 30% of patients) and heart failure (one in two patients diagnosed with severe heart failure will die within five years).Based in Paris and New York  the company is listed on Euronext Growth in Paris (FR0011648971- ALQGC) and trades on the OTCQX Market in the United States (symbol: QNNTF).For more information on www.quantum-genomics.com  please visit our Twitter and LinkedIn sites.Contact information",neutral,0.01,0.97,0.02,mixed,0.24,0.06,0.69,True,English,"['Phase III Study', 'Quantum Genomics', 'Significant Efficacy', 'New Developments', 'Lack', 'Firibastat', 'FRESH', 'Quantum Genomics Chief Financial Officer', 'brain aminopeptidase A inhibition', 'second phase III study', 'Dr Catherine Llorens-Cortes', 'CollÃ¨ge de', 'unmet therapeutic domains', 'French National Institute', 'new innovative molecules', 'new innovative treatments', 'severe heart failure', 'financial horizon', 'innovative approach', 'new class', 'therapeutic innovation', 'New York', 'REFRESH study', 'National Research', '11 million euros', 'GLOBE NEWSWIRE', 'Euronext Growth', 'AHA congress', 'greater efficacy', 'ethical reasons', 'same reason', 'Bruno Besse', 'Medical Director', 'Jean-Philippe Milon', 'third quarter', 'Benoit Gueugnon', 'twenty years', 'Paris-Descartes University', 'Scientific Centre', 'five years', 'OTCQX Market', 'United States', 'LinkedIn sites', 'Medical Research', 'Contact information', 'biopharmaceutical company', 'efficacy results', 'two patients', 'Firibastat efficacy', 'cardiovascular medications', 'resistant hypertension', 'placebo', 'development', 'cardiology', 'Cash', 'discontinuation', 'ALQGC', 'detail', 'view', 'mobilisation', 'strengths', 'lives', 'mind', 'BioTech/MedTech', 'negotiations', 'mission', 'CEO', 'funds', 'questions', 'quantum-genomics', 'BAPAI', 'world', 'work', 'France', 'Health', 'INSERM', 'CNRS', 'laboratory', 'goal', 'symbol', 'QNNTF', 'Twitter']",2022-10-28,2022-10-28,globenewswire.com
12314,EuroNext,NewsApi.org,https://finance.yahoo.com/news/aegon-takes-note-equity-issuance-073000089.html,Aegon takes note of equity issuance by a.s.r.,The Hague  October 28  2022 - Aegon has taken note of the issuance of approximately 10% additional shares that a.s.r. announced on October 28  2022  as part ...,Aegon N.V.The Hague  October 28  2022 - Aegon has taken note of the issuance of approximately 10% additional shares that a.s.r. announced on October 28  2022  as part of its funding in relation to the transaction to combine a.s.r. with Aegonâ€™s Dutch pension  life and non-life insurance  banking  and mortgage origination activities.As per the transaction announced yesterday  Aegon will receive a 29.99% strategic shareholding in a.s.r. and cash proceeds upon closing. Commensurate with the increase in the number of a.s.r. shares resulting from the equity issuance  the number of shares that Aegon is expected to receive on closing of the transaction increases by 10% from approximately 57.4 million to approximately 63.3 million.Based on the closing price of a.s.r.â€™s shares on October 26  2022 â€“ the day before announcement of the transaction â€“ this represents an increase in the value of the shareholding of EUR 0.3 billion to EUR 2.7 billion. As a consequence of the adjustment mechanism agreed between parties  the cash proceeds will be reduced by EUR 0.3 billion to EUR 2.2 billion.About AegonAegon is an integrated  diversified  international financial services group. The company offers investment  protection  and retirement solutions  with a strategic focus on three core markets (the United States  the United Kingdom  and the Netherlands)  three growth markets (Spain & Portugal  Brazil  and China)  and one global asset manager. Aegon's purpose of Helping people live their best lives runs through all its activities. As a leading global investor and employer  the company seeks to have a positive impact by addressing critical environmental and societal issues  with a focus on climate change and inclusion & diversity. Aegon is headquartered in The Hague  the Netherlands  and listed on Euronext Amsterdam and the New York Stock Exchange. More information can be found at aegon.com.Contacts Media relations Investor relations Carolien van der Giessen Jan Willem Weidema+31 (0)6 11 95 33 67 +31(0) 70 344 8028 carolien.vandergiessen@aegon.com janwillem.weidema@aegon.comForward-looking statementsThe statements contained in this document that are not historical facts are forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. The following are words that identify such forward-looking statements: aim  believe  estimate  target  intend  may  expect  anticipate  predict  project  counting on  plan  continue  want  forecast  goal  should  would  could  is confident  will  and similar expressions as they relate to Aegon. These statements may contain information about financial prospects  economic conditions and trends and involve risks and uncertainties. In addition  any statements that refer to sustainability  environmental and social targets  commitments  goals  efforts and expectations and other events or circumstances that are partially dependent on future events are forward-looking statements. These statements are not guarantees of future performance and involve risks  uncertainties and assumptions that are difficult to predict. Aegon undertakes no obligation  and expressly disclaims any duty  to publicly update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements  which merely reflect company expectations at the time of writing. Actual results may differ materially and adversely from expectations conveyed in forward-looking statements due to changes caused by various risks and uncertainties. Such risks and uncertainties include but are not limited to the following:Story continuesUnexpected delays  difficulties  and expenses in executing against our environmental  climate  diversity and inclusion or other â€œESGâ€ targets  goals and commitments  and changes in laws or regulations affecting us  such as changes in data privacy  environmental  safety and health laws;Changes in general economic and/or governmental conditions  particularly in the United States  the Netherlands and the United Kingdom;Civil unrest  (geo-) political tensions  military action or other instability in a country or geographic region;Changes in the performance of financial markets  including emerging markets  such as with regard to: The frequency and severity of defaults by issuers in Aegonâ€™s fixed income investment portfolios; The effects of corporate bankruptcies and/or accounting restatements on the financial markets and the resulting decline in the value of equity and debt securities Aegon holds; The effects of declining creditworthiness of certain public sector securities and the resulting decline in the value of government exposure that Aegon holds;Changes in the performance of Aegonâ€™s investment portfolio and decline in ratings of Aegonâ€™s counterparties;Lowering of one or more of Aegonâ€™s debt ratings issued by recognized rating organizations and the adverse impact such action may have on Aegonâ€™s ability to raise capital and on its liquidity and financial condition;Lowering of one or more of insurer financial strength ratings of Aegonâ€™s insurance subsidiaries and the adverse impact such action may have on the written premium  policy retention  profitability and liquidity of its insurance subsidiaries;The effect of the European Unionâ€™s Solvency II requirements and other regulations in other jurisdictions affecting the capital Aegon is required to maintain;Changes affecting interest rate levels and continuing low or rapidly changing interest rate levels;Changes affecting currency exchange rates  in particular the EUR/USD and EUR/GBP exchange rates;Changes in the availability of  and costs associated with  liquidity sources such as bank and capital markets funding  as well as conditions in the credit markets in general such as changes in borrower and counterparty creditworthiness;Increasing levels of competition in the United States  the Netherlands  the United Kingdom and emerging markets;Catastrophic events  either manmade or by nature  including by way of example acts of God  acts of terrorism  acts of war and pandemics  could result in material losses and significantly interrupt Aegonâ€™s business;The frequency and severity of insured loss events;Changes affecting longevity  mortality  morbidity  persistence and other factors that may impact the profitability of Aegonâ€™s insurance products;Aegonâ€™s projected results are highly sensitive to complex mathematical models of financial markets  mortality  longevity  and other dynamic systems subject to shocks and unpredictable volatility. Should assumptions to these models later prove incorrect  or should errors in those models escape the controls in place to detect them  future performance will vary from projected results;Reinsurers to whom Aegon has ceded significant underwriting risks may fail to meet their obligations;Changes in customer behavior and public opinion in general related to  among other things  the type of products Aegon sells  including legal  regulatory or commercial necessity to meet changing customer expectations;Customer responsiveness to both new products and distribution channels;As Aegonâ€™s operations support complex transactions and are highly dependent on the proper functioning of information technology  operational risks such as system disruptions or failures  security or data privacy breaches  cyberattacks  human error  failure to safeguard personally identifiable information  changes in operational practices or inadequate controls including with respect to third parties with which we do business may disrupt Aegonâ€™s business  damage its reputation and adversely affect its results of operations  financial condition and cash flows;The impact of acquisitions and divestitures  restructurings  product withdrawals and other unusual items  including Aegonâ€™s ability to integrate acquisitions and to obtain the anticipated results and synergies from acquisitions;Aegonâ€™s failure to achieve anticipated levels of earnings or operational efficiencies  as well as other management initiatives related to cost savings  Cash Capital at Holding  gross financial leverage and free cash flow;Changes in the policies of central banks and/or governments;Litigation or regulatory action that could require Aegon to pay significant damages or change the way Aegon does business;Competitive  legal  regulatory  or tax changes that affect profitability  the distribution cost of or demand for Aegonâ€™s products;Consequences of an actual or potential break-up of the European monetary union in whole or in part  or the exit of the United Kingdom from the European Union and potential consequences if other European Union countries leave the European Union;Changes in laws and regulations  particularly those affecting Aegonâ€™s operationsâ€™ ability to hire and retain key personnel  taxation of Aegon companies  the products Aegon sells  and the attractiveness of certain products to its consumers;Regulatory changes relating to the pensions  investment  and insurance industries in the jurisdictions in which Aegon operates;Standard setting initiatives of supranational standard setting bodies such as the Financial Stability Board and the International Association of Insurance Supervisors or changes to such standards that may have an impact on regional (such as EU)  national or US federal or state level financial regulation or the application thereof to Aegon  including the designation of Aegon by the Financial Stability Board as a Global Systemically Important Insurer (G-SII); andChanges in accounting regulations and policies or a change by Aegon in applying such regulations and policies  voluntarily or otherwise  which may affect Aegonâ€™s reported results  shareholdersâ€™ equity or regulatory capital adequacy levels.Further details of potential risks and uncertainties affecting Aegon are described in its filings with the Netherlands Authority for the Financial Markets and the US Securities and Exchange Commission  including the Annual Report. These forward-looking statements speak only as of the date of this document. Except as required by any applicable law or regulation  Aegon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Aegonâ€™s expectations with regard thereto or any change in events  conditions or circumstances on which any such statement is based.Attachment,neutral,0.01,0.98,0.0,mixed,0.08,0.11,0.81,True,English,"['equity issuance', 's.r', 'Aegon', 'note', 'US Private Securities Litigation Reform Act', 'integrated, diversified, international financial services group', 'New York Stock Exchange', 'Carolien van der Giessen', 'one global asset manager', 'Media relations Investor relations', 'fixed income investment portfolios', 'insurer financial strength ra', 'a.s.r. shares', 'leading global investor', 'public sector securities', 'Jan Willem Weidema', 'three core markets', 'three growth markets', 'mortgage origination activities', 'other â€œESGâ€ targets', 'Aegon N.V.', 'debt securities', 'financial markets', 'financial prospects', 'financial condition', 'social targets', 'emerging markets', 'other events', 'other instability', 'The Hague', '10% additional shares', 'Dutch pension', 'adjustment mechanism', 'retirement solutions', 'United States', 'United Kingdom', 'best lives', 'positive impact', 'societal issues', 'climate change', 'Euronext Amsterdam', 'historical facts', 'similar expressions', 'economic conditions', 'future events', 'undue reliance', 'Actual results', 'Unexpected delays', 'data privacy', 'general economic', 'governmental conditions', 'Civil unrest', 'geographic region', 'corporate bankruptcies', 'accounting restatements', 'government exposure', 'rating organizations', 'adverse impact', 'resulting decline', 'Forward-looking statements', 'life insurance', '29.99% strategic shareholding', 'cash proceeds', 'strategic focus', 'More information', 'various risks', 'Such risks', 'health laws', 'military action', 'debt ratings', 'closing price', 'critical environmental', 'future performance', 'equity issuance', 'company expectations', 'note', 'October', 'part', 'funding', 'transaction', 'banking', 'increase', 'number', 'announcement', 'value', 'consequence', 'protection', 'Netherlands', 'Spain', 'Portugal', 'Brazil', 'China', 'purpose', 'people', 'employer', 'inclusion', 'diversity', 'Contacts', 'vandergiessen', 'document', 'words', 'project', 'plan', 'goal', 'trends', 'uncertainties', 'sustainability', 'commitments', 'efforts', 'circumstances', 'guarantees', 'assumptions', 'obligation', 'duty', 'Readers', 'time', 'writing', 'changes', 'Story', 'difficulties', 'expenses', 'regulations', 'safety', 'country', 'regard', 'frequency', 'severity', 'defaults', 'issuers', 'effects', 'declining', 'creditworthiness', 'Lowering', 'capital', 'liquidity']",2022-10-28,2022-10-28,finance.yahoo.com
12315,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/28/2544042/0/en/Disclosure-of-notification-received-from-Active-Ownership-Corporation-S-%C3%A0-r-l.html,Disclosure of notification received from Active Ownership Corporation S.Ã  r.l.,Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands)  28 October 2022 â€“ 6PM CET        Disclosure of notification received from Active......,English DutchRegulated informationNazareth (Belgium)/Rotterdam (The Netherlands)  28 October 2022 â€“ 6PM CETDisclosure of notification received from Active Ownership Corporation S.Ã  r.l.Pursuant to the Belgian law of 2 May 2007 regarding the disclosure of major shareholdings in listed companies  Fagron received a notification from Active Ownership Corporation S.Ã  r.l.Notification Active Ownership Corporation S.Ã  r.l.On 27 October 2022  Fagron received a notification that the shareholding of Active Ownership Corporation S.Ã  r.l. crossed the disclosure threshold of 5% on 21 October 2022 as the result of the acquisition of voting securities or voting rights.The notification is made by a â€˜parent undertaking or a controlling personâ€™.On 21 October 2022  Active Ownership Corporation S.Ã  r.l. held a total of 4 160 000 voting rights.Based on the denominator of 72 992 654 (total number of voting rights)  Active Ownership Corporation S.Ã  r.l. held 5.70% of the total number of voting rights on 21 October 2022.Active Ownership Corporation S.Ã  r.l. is jointly controlled by two shareholders  Active Ownership Advisors GmbH and Active Ownership Investments Ltd. Active Ownership Advisors GmbH is controlled by Florian Schuhbauer. Active Ownership Investments Ltd. is controlled by Active Ownership LP  which is controlled by Active Ownership Management Ltd  which is controlled by Klaus RÃ¶hrig.On 1 October 2019  an agreement was concluded by Active Ownership Fund SICAV-FIS SCS regarding the appointment of Active Ownership Corporation S.Ã  r.l. as AIFM (alternative investment fund manager) for Active Ownership Fund SICAV-FIS SCS. Pursuant to this agreement and appointment Active Ownership Corporation S.Ã  r.l will exercise the voting rights with respect to shares held by Active Ownership Fund SICAV-FIS SCS.Active Ownership Corporation S.Ã  r.l. is an alternative investment fund manager  which can exercise the voting rights at its discretion in the absence of specific instructions.The notification of Active Ownership Corporation S.Ã  r.l. can be viewed via this link.Further informationKaren BergGlobal Investor Relations ManagerTel. +31 6 53 44 91 99karen.berg@fagron.comAbout FagronFagron is a leading global company active in pharmaceutical compounding  focusing on delivering personalized medicine to hospitals  pharmacies  clinics  and patients in 35 countries around the world.Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol â€˜FAGRâ€™. Fagronâ€™s operational activities are managed by the Dutch company Fagron BV  which is headquartered in Rotterdam.In the event of differences between the English translation and the Dutch original of this press release  the latter prevails.Please open the link below for the full press release:Disclosure of notification received from Active Ownership Corporation S.Ã  r.l.,neutral,0.0,1.0,0.0,neutral,0.01,0.98,0.0,True,English,"['Active Ownership Corporation S.Ã ', 'Disclosure', 'notification', 'Active Ownership Corporation S.Ã  r.l.', 'l. Notification Active Ownership Corporation S', 'Active Ownership Fund SICAV-FIS SCS', 'Active Ownership Advisors GmbH', 'Active Ownership Management Ltd', 'Active Ownership Investments Ltd.', 'alternative investment fund manager', 'Global Investor Relations Manager', 'Active Ownership LP', 'Klaus RÃ¶hrig', 'leading global company', 'full press release', 'Belgian company', 'Dutch company', 'English Dutch', 'Regulated information', 'The Netherlands', 'Belgian law', 'major shareholdings', 'listed companies', 'voting securities', 'voting rights', 'parent undertaking', 'controlling person', 'two shareholders', 'Florian Schuhbauer', 'specific instructions', 'Further information', 'pharmaceutical compounding', 'personalized medicine', 'Euronext Brussels', 'Euronext Amsterdam', 'ticker symbol', 'operational activities', 'English translation', 'Dutch original', 'total number', 'disclosure threshold', 'Fagron NV', 'Fagron BV', 'Karen Berg', 'Nazareth', 'Belgium', 'Rotterdam', '28 October', '6PM', '2 May', '27 October', '21 October', 'result', 'acquisition', 'denominator', 'agreement', 'appointment', 'AIFM', 'respect', 'shares', 'discretion', 'absence', 'link', 'Tel.', 'hospitals', 'pharmacies', 'clinics', 'patients', '35 countries', 'world', 'registered', 'office', 'event', 'differences', 'latter', '31']",2022-10-28,2022-10-28,globenewswire.com
12316,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/28/2544057/0/en/HiPay-Group-Press-Release-from-HiPay-Group-s-Board-of-Directors.html,HiPay Group: Press Release from HiPay Groupâ€™s Board of Directors,Paris  28 October 2022: The Board of Directors of HiPay Group SA (code ISIN FR0012821916 â€“ ALHYP)  a fintech specialising in omni-channel payments  met on October 21st  2022 and on October 27th  2022  in order to review the Groupâ€™s governance.,English FrenchParis  28 October 2022: The Board of Directors of HiPay Group SA (code ISIN FR0012821916 â€“ ALHYP)  a fintech specialising in omni-channel payments  met on October 21st  2022 and on October 27th  2022  in order to review the Groupâ€™s governance.During these meetings  the Board decided to terminate the mandates of Mr. GrÃ©goire Bourdin as CEO of HiPay Group SA and PrÃ©sident of HiPay SAS  with immediate effect.The Board of Directors wishes to thank Mr. GrÃ©goire Bourdin for all the work accomplished throughout the recent years.The development of the Group now requires a closer collaboration between the Management and the Board.The Board of Directors has decided to appoint Mr. Benjamin Jayet as CEO of HiPay Group SA  being acknowledged that Mr. Jayet also remains Chairman of the Board.About HiPayHiPay is a global payment services provider. Using the power of payment data  we help our sellers grow by giving them a 360Â° overview of their business.More information at hipay.com. You can also find us on LinkedIn.HiPay Group is listed on Euronext Growth (ISIN: FR0012821916 â€“ ALHYP).ContactsPRAnnie Hurley (CMO)+33 (0)6 81 16 07 52ahurley@hipay.comInvestor RelationsJÃ©rÃ´me Daguet (CFO)+33 (0)7 86 53 93 93jdaguet@hipay.comThis release does not constitute a sale offer or the solicitation of an offer to purchase HiPay securities. If you would like more information about HiPay Group  please visit the Investors section on our website hipay.com. This release may contain provisional declarations. Although HiPay Group believes that these declarations are based on hypotheses that are reasonable on the releaseâ€™s publication date  they are by nature subject to risk and uncertainty that can lead to differences between the actual figures and those indicated or inferred in these declarations. HiPay Group operates in one of the most volatile sectors where new risk factors can emerge. HiPay Group does not have any obligation to update these provisional declarations based on new information  events or circumstances.Attachment,neutral,0.0,1.0,0.0,mixed,0.44,0.06,0.5,True,English,"['HiPay Group', 'Press Release', 'Board', 'Directors', 'JÃ©rÃ´me Daguet', 'Mr. GrÃ©goire Bourdin', 'global payment services provider', 'Mr. Benjamin Jayet', 'new risk factors', 'HiPay Group SA', 'Mr. Jayet', 'payment data', 'new information', 'English French', 'fintech specialising', 'omni-channel payments', 'PrÃ©sident', 'immediate effect', 'recent years', 'closer collaboration', 'Euronext Growth', 'Contacts PR', 'Annie Hurley', 'Investor Relations', 'Investors section', 'publication date', 'actual figures', 'volatile sectors', 'HiPay SAS', 'HiPay securities', 'More information', 'sale offer', 'provisional declarations', 'The Board', 'Paris', 'Directors', 'code', 'ALHYP', 'October', 'order', 'governance', 'meetings', 'mandates', 'CEO', 'work', 'development', 'Management', 'Chairman', 'power', 'sellers', '360Â° overview', 'business', 'LinkedIn', 'CMO', 'ahurley', 'CFO', 'jdaguet', 'release', 'solicitation', 'website', 'hypotheses', 'nature', 'uncertainty', 'differences', 'obligation', 'events', 'circumstances', 'Attachment', '7']",2022-10-28,2022-10-28,globenewswire.com
12317,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/28/2543561/0/en/Eurospine-Congress-a-very-successful-meeting-with-spine-professionals-for-Spineway.html,Eurospine Congress a very successful meeting with spine professionals for Spineway,Press Release Â Â Â Â Â Â Â Â Ecully  28th of October  2022 â€“ 8:45 am    Remarkable participation at 2022 Eurospine congress in Milan  Spineway and Spine......,English FrenchPress Release Ecully  28th of October  2022 â€“ 8:45 amRemarkable participation at 2022 Eurospine congress in MilanSpineway and Spine Innovations  the Groupâ€™s latest acquisition  were present from 19 to 21 October 2022 in Milan at the Eurospine international congress to present the Groupâ€™s product lines to the entire spinal implant industry.At the largest scientific and commercial European congress dedicated to spinal surgery  which this year brought together almost 2 000 surgeons from around the world  Spineway was able to present its flagship instruments and implants (Mont-Blanc  Mont-Blanc MIS and Twin Peaks)  three new ranges of Group spinal implants : Kaphorn  Veos  Acifbox and the two models of cervical and lumbar ESP disc prosthesis from Spine Innovations.The Group was thus able to show its know-how thanks to its extensive range of products. Many international distributors from the five continents  as well as new potential distributors (Canada  Argentina  Spain  Austria)  expressed at this occasion their great interest in the Groupâ€™s products.Spineway also successfully hosted two specific events for distributors and surgeons :A sales meeting attended by s ome 30 international distributors from 12 different countries  to announce the integration of Spine Innovations and to present the new product lines from 12 different countries  to announce the integration of Spine Innovations and to present the new product lines  A scientific meeting organized by Spine Innovations in front of an audience of fifty international surgeons to present the work of two French and Swedish surgeons  key opinion leaders on prosthetic discs.These fruitful meetings confirm the relevance of product and territory synergies between the two companies.Based on this successful event  Spineway will continue its development in order to position itself as a European player of reference in the spine sector.Shareholders meeting2022 3rd quarter activity and Eurospine congressThursday the 3rd of October  2022  8:00 pm by visioconferenceRegistration hereSPINEWAY IS ELIGIBLE FOR PEA-SME (EQUITY SAVINGS PLANS FOR SMES)Find out all about Spineway at www.spineway.comThis press release has been prepared in both English and French. In case of discrepancies  the French version shall prevail.Spineway designs  manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.Spineway has an international network of over 50 independent distributors and 90% of its revenue comes from exports.Spineway  which is eligible for investment through FCPIs (French unit trusts specializing in innovation)  has received the OSEO Excellence award since 2011 and has won the Deloitte Fast 50 award (2011). RhÃ´ne Alpes INPI Patent Innovation award (2013) â€“ INPI Talent award (2015).ISIN: FR001400BVK2 - ALSPWContacts:SPINEWAYShareholder-services lineAvailable Tuesday through Thursday+33 (0)806 706 060Eligible PEA / PMEALSPWEURONEXT GROWTHAeliumFinance & CommunicationInvestor relationsSolÃ¨ne Kennisspineway@aelium.frAttachment,positive,0.97,0.03,0.0,mixed,0.51,0.33,0.17,True,English,"['Eurospine Congress', 'successful meeting', 'spine professionals', 'Spineway', 'RhÃ´ne Alpes INPI Patent Innovation award', 'lumbar ESP disc prosthesis', 'entire spinal implant industry', 'INPI Talent award', 'SolÃ¨ne Kennis', 'OSEO Excellence award', 'Deloitte Fast 50 award', 'three new ranges', 'key opinion leaders', '2022 3rd quarter activity', 'EQUITY SAVINGS PLANS', 'two specific events', 'new potential distributors', 'commercial European congress', 'French unit trusts', 'new product lines', 'Many international distributors', 'Eurospine international congress', 'fifty international surgeons', 'Group spinal implants', '2022 Eurospine congress', '30 international distributors', 'spinal surgery', 'spinal column', 'international network', 'European player', 'two models', 'two French', 'two companies', '50 independent distributors', 'Press Release', 'Remarkable participation', 'Spine Innovations', 'latest acquisition', 'largest scientific', 'flagship instruments', 'Twin Peaks', 'extensive range', 'five continents', 'great interest', 'sales meeting', '12 different countries', 'scientific meeting', 'prosthetic discs', 'fruitful meetings', 'territory synergies', 'successful event', 'spine sector', 'Shareholders meeting', 'French version', 'innovative implants', 'surgical instruments', 'severe disorders', 'Shareholder-services line', 'Eligible PEA', 'EURONEXT GROWTH', 'Investor relations', 'Swedish surgeons', 'The Group', 'English French', 'ALSPW Contacts', 'Spineway designs', '2,000 surgeons', 'Ecully', '28th', 'October', 'Milan', 'world', 'Mont-Blanc', 'Kaphorn', 'Veos', 'Acifbox', 'cervical', 'know-how', 'products', 'Canada', 'Argentina', 'Spain', 'Austria', 'occasion', 'integration', 'front', 'audience', 'relevance', 'development', 'reference', 'Thursday', 'visioconference', 'Registration', 'PEA-SME', 'SMES', 'case', 'discrepancies', 'revenue', 'exports', 'investment', 'FCPIs', 'ISIN', 'Tuesday', 'Aelium', 'Finance', 'Communication', 'Attachment', '8:45', '19']",2022-10-28,2022-10-28,globenewswire.com
12318,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/28/2543525/0/en/Press-release-Biocartis-Group-NV-Biocartis-Announces-Conversion-of-a-Portion-of-the-Convertible-Term-Loan-into-New-Shares-and-Discloses-Outstanding-Voting-Securities.html,Press release Biocartis Group NV: Biocartis Announces Conversion of a Portion of the Convertible Term Loan into New Shares and Discloses Outstanding Voting Securities,PRESS RELEASE: REGULATED INFORMATIONÂ     28 October 2022  07:01 CEST    Biocartis Announces Conversion of a Portion of the Convertible Term Loan into...,"English DutchPRESS RELEASE: REGULATED INFORMATION28 October 2022  07:01 CESTBiocartis Announces Conversion of a Portion of the Convertible Term Loan into New Shares and Discloses Outstanding Voting SecuritiesMechelen  Belgium  28 October 2022 â€“ Biocartis Group NV (the ""Company"" or ""Biocartis"")  an innovative molecular diagnostics company (Euronext Brussels: BCART)  today announces that following the first drawdown by the Company under the new senior secured convertible term loan (â€œConvertible Term Loanâ€) concluded with certain funds and accounts managed or advised by Highbridge Capital Management LLC (â€œHighbridgeâ€) and certain funds managed or advised by Whitebox Advisors LLC (â€œWhiteboxâ€  and together with Highbridge  the â€œLendersâ€) announced on 20 October 2022  a first portion of the receivables due by the Company to Highbridge under the Convertible Term Loan in an amount of EUR 60 509.79 (consisting of principal amount  interest and redemption amount) was contributed in kind by Highbridge against the issuance of 60 559 new shares of the Company at an issue price of ca. EUR 0.99918 per share.In view hereof  and in accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers of which shares are admitted to trading on a regulated market and laying down miscellaneous provisions  the outstanding share capital and outstanding voting securities of the Company can be summarized as follows:Total outstanding share capital: EUR 584 169.56;Total outstanding voting securities: 58 416 956;Total outstanding voting rights: 58 416 956;Shares that can still be issued upon exercise of subscription rights: 2 248 458 shares (each share entailing one voting right)  of which: 150 896 shares can be issued upon the exercise of 150 896 outstanding share options (each share option having the form of a subscription right) that are still outstanding under the '2013 Plan' for employees  consultants and management members of the Company  entitling the holders thereof to acquire one new share per option; 140 064 shares can be issued upon the exercise of 140 064 outstanding share options (each share option having the form of a subscription right) that are still outstanding under the '2015 Plan' for employees  consultants  management members and directors of the Company  entitling the holders thereof to acquire one new share per option; 470 836 shares can be issued upon the exercise of 470 836 outstanding share options (each share option having the form of a subscription right) that are still outstanding under the '2018 Plan' for (mainly) certain selected employees of the Company and its subsidiaries  as well as for consultants of the Company and its subsidiaries  independent directors of the Company and directors of the Company's subsidiaries  entitling the holders thereof to acquire one new share per option; 626 662 shares can be issued upon the exercise of 626 662 outstanding share options (each share option having the form of a subscription right) that are still outstanding under the '2020 Plan' for members of the personnel of the Company and/or its subsidiaries  entitling the holders thereof to acquire one new share per option; and 860 000 shares can be issued upon the exercise of 860 000 outstanding share options (each share option having the form of a subscription right) that are still outstanding under the '2020B Plan' for members of the executive management of the Company  entitling the holders thereof to acquire one new share per option.In addition  a number of shares are issuable pursuant to the terms of (i) the abovementioned Convertible Term Loan  (ii) certain outstanding 4.00% convertible bonds initially due 2024/2027  and (iii) certain outstanding 4.50% convertible bonds initially due 2024/2026.Going forward  the Company will issue a press release at the end of each month with an update on further conversions and outstanding voting securities.--- END ---More information:Renate DegraveHead of Corporate Communications & Investor Relations Biocartise-mail rdegrave@biocartis.comtel +32 15 631 729mobile +32 471 53 60 64About BiocartisWith its revolutionary and proprietary Idyllaâ„¢ platform  Biocartis (Euronext Brussels: BCART) aspires to enable personalized medicine for patients around the world through universal access to molecular testing  by making molecular testing actionable  convenient  fast and suitable for any lab. The Idyllaâ„¢ platform is a fully automated sample-to-result  real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house access to accurate molecular information in a minimum amount of time for faster  informed treatment decisions. Idyllaâ„¢â€™s continuously expanding menu of molecular diagnostic tests address key unmet clinical needs  with a focus in oncology. This is the fastest growing segment of the molecular diagnostics market worldwide. Today  Biocartis offers tests supporting melanoma  colorectal  lung and liver cancer  as well as for COVID-19  Flu  RSV and sepsis. For more information  visit www.biocartis.com or follow Biocartis on Twitter @Biocartis_   Facebook or LinkedIn.Biocartis and Idyllaâ„¢ are registered trademarks in Europe  the United States and other countries. The Biocartis and Idyllaâ„¢ trademark and logo are used trademarks owned by Biocartis. Please refer to the product labeling for applicable intended uses for each individual Biocartis product.This press release is not for distribution  directly or indirectly  in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933  as amended.Forward-looking statementsCertain statements  beliefs and opinions in this press release are forward-looking  which reflect the Company's or  as appropriate  the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations  financial condition  liquidity  performance  prospects  growth  strategies and the industry in which the Company operates. By their nature  forward-looking statements involve a number of risks  uncertainties  assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks  uncertainties  assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including  but not limited to  changes in demand  competition and technology  can cause actual events  performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition  even if actual results or developments are consistent with the forward-looking statements contained in this press release  those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result  the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events  conditions  assumptions or circumstances on which these forward-looking statements are based  except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements  which speak only as of the date of this press release.",neutral,0.01,0.99,0.0,neutral,0.02,0.97,0.01,True,English,"['Convertible Term Loan', 'Outstanding Voting Securities', 'Biocartis Group NV', 'Press release', 'New Shares', 'Conversion', 'Portion', 'new senior secured convertible term loan', 'faster, informed treatment decisions', 'key unmet clinical needs', 'Total outstanding voting securities', 'Total outstanding voting rights', 'Total outstanding share capital', 'innovative molecular diagnostics company', 'Highbridge Capital Management LLC', 'outstanding 4.00% convertible bonds', 'outstanding 4.50% convertible bonds', 'Polymerase Chain Reaction', 'fastest growing segment', 'molecular diagnostics market', '150,896 outstanding share options', '140,064 outstanding share options', '470,836 outstanding share options', '626,662 outstanding share options', '860,000 outstanding share options', 'one new share', 'Whitebox Advisors LLC', 'one voting right', 'proprietary Idyllaâ„¢ platform', 'The Idyllaâ„¢ platform', 'accurate molecular information', 'molecular diagnostic tests', 'Biocartis Group NV', 'Investor Relations Biocartis', 'subscription rights', 'molecular testing', 'regulated market', 'New Shares', 'executive management', 'English Dutch', 'PRESS RELEASE', 'REGULATED INFORMATION', 'Euronext Brussels', 'first drawdown', 'issue price', 'Belgian Act', 'major shareholdings', 'miscellaneous provisions', 'More information', 'Renate Degrave', 'Corporate Communications', 'personalized medicine', 'real-time PCR', 'expanding menu', 'liver cancer', 'principal amount', 'redemption amount', 'minimum amount', 'first portion', 'management members', 'universal access', 'independent directors', '2020B Plan', '2013 Plan', '2015 Plan', '2018 Plan', '2020 Plan', '2,248,458 shares', '150,896 shares', '140,064 shares', '470,836 shares', '626,662 shares', '860,000 shares', 'October', 'Conversion', 'Mechelen', 'Belgium', 'BCART', 'funds', 'accounts', 'Lenders', 'receivables', 'interest', 'kind', 'issuance', 'view', 'accordance', 'article', '2 May', 'disclosure', 'issuers', 'exercise', 'employees', 'consultants', 'holders', 'subsidiaries', 'personnel', 'addition', 'number', 'terms', 'month', 'update', 'Head', 'mail', 'revolutionary', 'patients', 'world', 'lab', 'result', 'system', 'house', 'focus', 'oncology', 'melanoma', 'colorectal', 'lung', 'COVID', 'Flu', 'RSV', 'sepsis', '07', '28']",2022-10-28,2022-10-28,globenewswire.com
12319,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/28/2543518/0/en/Press-release-Biocartis-Group-NV-Invitation-to-the-Extraordinary-Shareholders-Meeting.html,Press release Biocartis Group NV: Invitation to the Extraordinary Shareholdersâ€™ Meeting,PRESS RELEASE:Â REGULATED INFORMATION  28 October 2022  07:00 CEST  Invitation to the Extraordinary Shareholdersâ€™ Meeting  Mechelen  Belgium  28 October......,"English DutchPRESS RELEASE: REGULATED INFORMATION28 October 2022  07:00 CESTInvitation to the Extraordinary Shareholdersâ€™ MeetingMechelen  Belgium  28 October 2022 â€“ As the attendance quorum for certain items on the agenda of the extraordinary general shareholders' meeting (""EGM"") of 27 October 2022 was not reached  Biocartis Group NV (the ""Company"" or ""Biocartis"")  an innovative molecular diagnostics company (Euronext Brussels: BCART)  has the honor to invite its shareholders  holders of subscription rights  holders of convertible bonds  directors and statutory auditor to a second EGM which will be held on Monday 14 November 2022 at 2:00 p.m. CEST at the offices of the Company at Generaal de Wittelaan 11B  2800 Mechelen  Belgium. The legally required attendance quorum to validly deliberate and vote on items 2 to 6 of the agenda of the extraordinary general shareholders' meeting  which was held on 27 October 2022  was not reached. There will be no attendance quorum for this EGM.At the EGM  shareholders will be requested to approve various aspects of the comprehensive recapitalization transaction which was announced by the Company on 1 September 2022. The Company believes that such transaction is an important milestone for the Company to secure the financing necessary for its future growth which benefits all of its stakeholders and therefore encourages shareholders to grant the necessary consents to implement it.All proposed resolutions submitted to the EGM require an approval by a majority of 75% of the votes validly cast by the shareholders. In the event that the shareholders do not approve the proposed resolutions  the recapitalization transaction will not complete in full  the Company will not be recapitalized  various fees and expenses will need to be paid by the Company  certain terms of the proposed new convertible terms loans become more restrictive  and the Company will need to consider alternative arrangements  which may not be available on time or at all. The proposal to approve and ratify certain change of control clauses in the legal documentation regarding the recapitalisation transactions was already approved by the EGM held on 27 October 2022.It is currently envisaged that the Company will be legally allowed to organize its EGM at its offices at Generaal de Wittelaan 11B  2800 Mechelen  Belgium  and that the holders of securities of the Company will be allowed to physically attend the meeting as set out in the convening notice. However  the evolution of the COVID-19 pandemic is uncertain and the Belgian government may again impose measures which may have an impact on the organization of the EGM  such as imposing limitations on the number of people allowed to attend gatherings. The Company will monitor the situation and potential measures in light of the COVID-19 pandemic  and may provide further updates that are relevant or have an impact on the EGM on the Biocartis website.In order to be admitted to the EGM  the holders of securities issued by the Company must comply with Article 7:134 of the Belgian Code of Companies and Associations and the articles of association of the Company  and fulfill the formalities described in the convening notice. The convening notice and other documents relating to the EGM can be consulted on the website of the Company.--- END ---More information:Renate DegraveHead of Corporate Communications & Investor Relations Biocartise-mail rdegrave@biocartis.comtel +32 15 631 729mobile +32 471 53 60 64About BiocartisWith its revolutionary and proprietary Idyllaâ„¢ platform  Biocartis (Euronext Brussels: BCART) aspires to enable personalized medicine for patients around the world through universal access to molecular testing  by making molecular testing actionable  convenient  fast and suitable for any lab. The Idyllaâ„¢ platform is a fully automated sample-to-result  real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house access to accurate molecular information in a minimum amount of time for faster  informed treatment decisions. Idyllaâ„¢â€™s continuously expanding menu of molecular diagnostic tests address key unmet clinical needs  with a focus in oncology. This is the fastest growing segment of the molecular diagnostics market worldwide. Today  Biocartis offers tests supporting melanoma  colorectal  lung and liver cancer  as well as for COVID-19  Flu  RSV and sepsis. For more information  visit www.biocartis.com or follow Biocartis on Twitter @Biocartis_   Facebook or LinkedIn.Biocartis and Idyllaâ„¢ are registered trademarks in Europe  the United States and other countries. The Biocartis and Idyllaâ„¢ trademark and logo are used trademarks owned by Biocartis. Please refer to the product labeling for applicable intended uses for each individual Biocartis product.This press release is not for distribution  directly or indirectly  in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933  as amended.Forward-looking statementsCertain statements  beliefs and opinions in this press release are forward-looking  which reflect the Company's or  as appropriate  the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations  financial condition  liquidity  performance  prospects  growth  strategies and the industry in which the Company operates. By their nature  forward-looking statements involve a number of risks  uncertainties  assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks  uncertainties  assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including  but not limited to  changes in demand  competition and technology  can cause actual events  performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition  even if actual results or developments are consistent with the forward-looking statements contained in this press release  those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result  the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events  conditions  assumptions or circumstances on which these forward-looking statements are based  except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements  which speak only as of the date of this press release.",neutral,0.01,0.99,0.0,mixed,0.21,0.15,0.65,True,English,"['Biocartis Group NV', 'Extraordinary Shareholdersâ€™ Meeting', 'Press release', 'Invitation', 'faster, informed treatment decisions', 'key unmet clinical needs', 'new convertible terms loans', ""extraordinary general shareholders' meeting"", 'innovative molecular diagnostics company', 'molecular diagnostics market', 'Generaal de Wittelaan', 'Polymerase Chain Reaction', 'fastest growing segment', 'applicable intended uses', 'Extraordinary Shareholdersâ€™ Meeting', 'proprietary Idyllaâ„¢ platform', 'accurate molecular information', 'molecular diagnostic tests', 'comprehensive recapitalization transaction', 'The Idyllaâ„¢ platform', 'individual Biocartis product', 'convertible bonds', 'molecular testing', 'product labeling', 'English Dutch', 'PRESS RELEASE', 'REGULATED INFORMATION', 'attendance quorum', 'Euronext Brussels', 'subscription rights', 'statutory auditor', 'Monday 14 November', 'various aspects', 'important milestone', 'future growth', 'necessary consents', 'various fees', 'alternative arrangements', 'control clauses', 'legal documentation', 'recapitalisation transactions', 'convening notice', 'COVID-19 pandemic', 'Belgian government', 'Belgian Code', 'other documents', 'More information', 'Renate Degrave', 'Corporate Communications', 'Investor Relations', 'personalized medicine', 'real-time PCR', 'minimum amount', 'expanding menu', 'liver cancer', 'United States', 'other countries', 'Idyllaâ„¢ trademark', 'The Biocartis', 'The Company', 'proposed resolutions', 'potential measures', 'universal access', 'Biocartis Group', 'second EGM', 'Biocartis website', 'October', 'Invitation', 'Mechelen', 'Belgium', 'items', 'agenda', 'BCART', 'honor', 'directors', 'CEST', 'offices', '1 September', 'financing', 'stakeholders', 'approval', 'majority', 'votes', 'event', 'expenses', 'proposal', 'change', 'securities', 'evolution', 'impact', 'organization', 'limitations', 'number', 'people', 'gatherings', 'situation', 'light', 'updates', 'order', 'Article', 'Companies', 'Associations', 'formalities', 'Head', 'mail', 'patients', 'world', 'result', 'system', 'house', 'focus', 'oncology', 'melanoma', 'colorectal', 'lung', 'Flu', 'RSV', 'sepsis', 'Twitter', 'Facebook', 'LinkedIn', 'trademarks', 'Europe', 'logo', 'distribution', 'jurisdiction', 'persons', 'restrictions', 'responsibility', 'viola', '07', '28', '2:00']",2022-10-28,2022-10-28,globenewswire.com
12320,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/28/2544080/0/en/Information-on-the-Total-Number-of-Voting-Rights-Denominator-following-Conversion-Notice-from-NEGMA.html,Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA,Negma Group has converted 580 convertible bonds in Oxurion resulting in a EUR 1 450 000 capital increase. This is part of Negma Groupâ€™s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of theâ€¦,English DutchNegma Group has converted 580 convertible bonds in Oxurion resulting in a EUR 1 450 000 capital increase. This is part of Negma Groupâ€™s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.Leuven  BELGIUM  Boston  MA  US â€“ October 28  2022 â€“ 07.00 PM CET â€“ In accordance with article 15 of the Belgian Act of May 2  2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions  Oxurion NV (Euronext Brussels: OXUR) (the â€œCompanyâ€ or â€œOxurionâ€)  announces the below information  following the issuance of (i) 909 090 new ordinary shares on October 12  2022  for a total amount of EUR 100 000  as the result of the conversion of 40 class A convertible bonds  (ii) 4 750 000 new ordinary shares on October 12  2022  for a total amount of EUR 332 500  as the result of the conversion of 133 class B convertible bonds  (iii) 5.857.142 new ordinary shares on October 19  2022  for a total amount of EUR 410 000  as the result of the conversion of 164 class B convertible bonds  (iv) 5 000 000 new ordinary shares on October 24  2022  for a total amount of EUR 300 000  as the result of the conversion of 120 class B convertible bonds  and (v) 6 150 000 new ordinary shares on October 26  2022  for a total amount of EUR 307 500  as the result of the conversion of 123 class B convertible bonds  all pursuant to the Capital Commitment entered into with Negma Group.Following completion of the capital increase through the conversion of the convertible bonds  the total number of shares issued by Oxurion amounts to 77 825 765 outstanding ordinary shares carrying voting rights (compared to 55 159 533 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of shareholdings.Therefore  Oxurion publishes the following updated information:Share capital (EUR) 72 356 161.32 Total number of securities with voting rights (all ordinary shares) 77 825 765 Total number of ordinary shares (= denominator) 77 825 765 Number of outstanding  granted rights to subscribe to securities carrying voting rights not yet issued: 719 500 subscription rights (â€œSRsâ€) issued on November 20  2017  entitling their holders to subscribe to a total number of 719 500 securities carrying voting rights (all ordinary shares);60 000 SRs issued on December 23  2020  entitling their holders to subscribe to a total number of 60 000 securities carrying voting rights (all ordinary shares);1 007 250 SRs issued on April 14  2021  entitling their holders to subscribe to a total number of 1 007 250 securities carrying voting rights (all ordinary shares);550 000 SRs issued on September 22  2021  entitling their holders to subscribe to a total number of 550 000 securities carrying voting rights (all ordinary shares);725 749 SRs issued on December 30  2021  entitling their holders to subscribe to a total number of 725 749 securities carrying voting rights (all ordinary shares);1 060 convertible bonds issued on September 5  2022  and 21 October 2022  entitling their holder (Negma Group) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions set forth in the issuance and subscription agreement entered into between the Company and Negma Group on August 26  2021  and the addendum thereto dated September 2  2022; and100 convertible bonds issued on December 20  2021  entitling their holders (Kreos Capital VI (UK) Limited  Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.) to subscribe to a total number of securities carrying voting rights (all ordinary shares) in accordance with the terms and conditions of these convertible bonds as attached to the Agreement for the provision of a Loan Facility entered into between the Company  Kreos Capital VI (UK) Limited  Pontifax Medison Finance (Israel) L.P. and Pontifax Medison Finance (Cayman) L.P.  on November 21  2021.ENDAbout OxurionOxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies  which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME)  the leading cause of vision loss in working-age people  as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders  including the successful development of THR-149  its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven  Belgium  with corporate operations in Boston  MA. More information is available at www.oxurion.com.Important information about forward-looking statementsCertain statements in this press release may be considered â€œforward-lookingâ€. Such forward-looking statements are based on current expectations  and  accordingly  entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement  whether as a result of new information  future events  or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Companyâ€™s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933  as amended  or in compliance with an exemption therefrom  and in accordance with any applicable U.S. state securities laws.For further information please contact:Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13 10tom.graney@oxurion.comMichaÃ«l DillenChief Business OfficerTel: +32 16 75 13 10michael.dillen@oxurion.com USConway CommunicationsBeth Kurthbkurth@conwaycommsir.comICR WestwickeChristopher BrinzeyTel: +1 617 835 9304chris.brinzey@westwicke.com1 Press release Oxurion  06/04/2021 and Press release Oxurion  02/09/2022Attachment,neutral,0.0,1.0,0.0,positive,0.72,0.22,0.06,True,English,"['Total Number', 'Voting Rights', 'Conversion Notice', 'Information', 'Denominator', 'NEGMA', 'potent plasma kallikrein inhibitor', 'EUR 30 million Capital Commitment1', '40 class A convertible bonds', '133 class B convertible bonds', '164 class B convertible bonds', '120 class B convertible bonds', '123 class B convertible bonds', 'eye drug candidate', 'Pontifax Medison Finance', 'next generation standard', 'diabetic macular edema', 'potential new standard', 'EUR 1,450,000 capital increase', 'Kreos Capital VI', 'potential market opportunities', 'care ophthalmic therapies', '909,090 new ordinary shares', '4,750,000 new ordinary shares', '5.857.142 new ordinary shares', '5,000,000 new ordinary shares', '6,150,000 new ordinary shares', '77,825,765 outstanding ordinary shares', '55,159,533 outstanding ordinary shares', '580 convertible bonds', '1,060 convertible bonds', '100 convertible bonds', 'Share capital', 'regulated market', 'English Dutch', 'Negma Group', 'Belgian Act', 'major participations', 'miscellaneous provisions', 'Euronext Brussels', 'total amount', 'L.P.', 'Loan Facility', 'retinal disorders', 'leading cause', 'working-age people', 'important role', 'successful development', 'suboptimal response', 'anti-VEGF therapy', 'corporate operations', 'voting rights', '719,500 subscription rights', 'total number', 'updated information', 'More information', 'Important information', 'subscription agreement', 'vision loss', 'novel therapeutic', 'other conditions', 'biopharmaceutical company', 'Oxurion NV', 'DME patients', 'back', 'Leuven', 'BELGIUM', 'Boston', 'October', '07.00 PM', 'accordance', 'article', 'May', 'disclosure', 'issuers', 'issuance', 'result', 'conversion', 'completion', 'denominator', 'calculation', 'percentages', 'shareholdings', 'securities', 'SRs', 'November', 'holders', 'December', 'April', 'September', 'terms', 'August', 'addendum', 'UK', 'Israel', 'Cayman', 'Limited', 'treatment', 'THR-149']",2022-10-28,2022-10-28,globenewswire.com
12321,EuroNext,NewsApi.org,https://www.prnewswire.co.uk/news-releases/netedi-changes-its-name-to-cegedim-e-business-301661573.html,NetEDI changes its name to Cegedim e-business,Conducting an international rebrand to reflect Cegedim's European position  and expand the SY by Cegedim product offering into the UK market LANCASHIRE  England  Oct. 28  2022 /PRNewswire/ -- The publicly listed company Cegedim identified NetEDI Ltd as a promâ€¦,Conducting an international rebrand to reflect Cegedim's European position  and expand the SY by Cegedim product offering into the UK marketLANCASHIRE  England  Oct. 28  2022 /PRNewswire/ -- The publicly listed company Cegedim identified NetEDI Ltd as a prominent business in the supply chain sector. As the leading UK provider of PEPPOL for the NHS Supply Chain  NetEDI established an international client base through its unified commerce solution Netix  leading to the acquisition in 2019. Creating synergy across all business units and expanding customer reach  NetEDI is rebranding as Cegedim e-business.The new brand identity captures Cegedim e-business' dedication to delivering excellent quality  performance  and service to support businesses in their digital transformation. As a European leader  Cegedim strengthens its position by conducting a rebrand in the United Kingdom and Germany. Expanding the SY by Cegedim product suite into new territories to support international clients.Aligning the brands helps to create a new product offering through the SY by Cegedim branding  enabling Cegedim e-business to launch SY Supply Chain in the United Kingdom. A suite of products  services  and solutions enables various sectors to optimise their entire procure-to-pay process.About Cegedim e-business UKCegedim e-business deliver unified commerce solutions for business to optimise their supply chain management. The SY Supply Chain offering enables various organisations to harness excellent quality products  solutions  and services to optimise their entire procure-to-pay process. The core product Netix processes over 1 billion documents annually.Cegedim e-business are the chosen PEPPOL Managed Service Provider for NHS Supply Chain.Find out more: http://www.sybycegedim.co.uk/enFollow Cegedim e-business UK on Twitter  LinkedIn  and YouTubeAbout Cegedim e-businessCegedim e-business is a European leader in B2B process automation and digitalisation. It handles over 900 million data flows annually and connects 120 000 companies worldwide. Cegedim e-business uses its unique range of e-procurement  e-invoicing  e-archiving  and e-signature services to help companies of every size and in every business  sector make a successful digital transition. Cegedim e-business is a member of the PEPPOL and EESPA European networks. It operates a multichannel electronic exchanges platform that handles any type of document  from contracts to payments  and helps streamline client-supplier relationships while significantly improving administrative efficiency  cash management  and traceability.Find out more at: www.sybycegedim.com/enFollow Cegedim e-business on Twitter  LinkedIn and YouTubeAbout CegedimFounded in 1969  Cegedim is an innovative technology and services company in the field of digital data flow management for healthcare ecosystems and B2B  and a business software publisher for healthcare and insurance professionals. Cegedim employs more than 5 600 people in more than 10 countries and generated revenue of â‚¬525 million in 2021.Cegedim SA is listed in Paris (EURONEXT: CGM).To learn more  please visit: www.cegedim.frAnd follow Cegedim on Twitter @CegedimGroup  LinkedIn and Facebook.ContactAude BalleydierCegedimCommunication & Media Relations Manageraude.balleydier@cegedim.frChelsey MorrisonCegedim e-businessMarketing ManagerChelsey.morrison@cegedim.com+44 (0)177-297-7781SOURCE CEGEDIM E-BUSINESS LTD,neutral,0.0,1.0,0.0,positive,0.74,0.25,0.01,True,English,"['NetEDI', 'name', 'Cegedim', 'business', 'The SY Supply Chain offering', 'multichannel electronic exchanges platform', 'core product Netix processes', 'digital data flow management', 'business Marketing Manager Chelsey', 'PEPPOL Managed Service Provider', 'SOURCE CEGEDIM E-BUSINESS LTD', 'NHS Supply Chain', 'supply chain management', 'new product offering', '900 million data flows', 'Media Relations Manager', 'unified commerce solution', 'successful digital transition', 'leading UK provider', 'supply chain sector', 'new brand identity', 'Cegedim product offering', 'international client base', 'EESPA European networks', 'excellent quality products', 'business software publisher', ""Cegedim e-business' dedication"", 'B2B process automation', 'Cegedim product suite', 'digital transformation', 'cash management', 'new territories', 'Chelsey Morrison', 'international clients', 'pay process', 'NetEDI Ltd', 'UK market', 'European leader', 'customer reach', 'United Kingdom', 'various sectors', 'various organisations', '1 billion documents', 'unique range', 'client-supplier relationships', 'administrative efficiency', 'innovative technology', 'insurance professionals', 'business UK', 'international rebrand', 'European position', 'prominent business', 'business units', 'Cegedim branding', 'signature services', 'healthcare ecosystems', 'Cegedim SA', 'Aude Balleydier', 'Cegedim Communication', 'services company', 'solutions', 'LANCASHIRE', 'England', 'PRNewswire', 'acquisition', 'synergy', 'performance', 'businesses', 'Germany', 'brands', 'entire', 'Twitter', 'LinkedIn', 'YouTube', 'digitalisation', '120,000 companies', 'procurement', 'invoicing', 'archiving', 'size', 'member', 'type', 'contracts', 'payments', 'traceability', 'field', '5,600 people', '10 countries', 'revenue', 'Paris', 'EURONEXT', 'CGM', 'CegedimGroup', 'Facebook', 'Contact']",2022-10-28,2022-10-28,prnewswire.co.uk
12322,EuroNext,NewsApi.org,https://finance.yahoo.com/news/wendel-9-months-2022-trading-050000541.html,Wendel: 9 months 2022 Trading update - Good growth year-to-date across portfolio,press release - october 28  20229 months 2022 Trading update Good growth year-to-date across portfolio 9 months 2022 consolidated net sales: â‚¬6 507.8 million...,WENDELpress release - october 28  20229 months 2022 Trading updateGood growth year-to-date across portfolio9 months 2022 consolidated net sales: â‚¬6 507.8 million  up 17.9% overall and up 10.9% organically year-to-dateÂ·Strong growth across the portfolio in Q3 2022: +20.9% of reported growth on consolidated sales of which +12.1% is organicÂ·Double digit organic growth for ACAMS  CPI  Constantia Flexibles and Tarkett in Q3 and over 9 monthsÂ·Sustained organic growth for Bureau Veritas (+7.3%) and for Stahl (+7.8%) over 9 monthsÂ·Positive FX impacts across the portfolio (+5.0% consolidated over 9 months)Net asset value as of September 30  2022: â‚¬6 885 million or â‚¬155.2 per shareÂ·Restated for the â‚¬3 dividend per share paid in June 2022  NAV is down 4.5% since the end of June and down 15.9% YTD driven mostly by market declines  whilst the higher-than-expected performance of unlisted portfolio companies and FX contributed positivelyÂ·As a reminder  the valuations of Wendelâ€™s unlisted assets are updated on a quarterly basis using end of quarter stock market multiplesSignificant portfolio rotation and capital deployment over the first nine months of 2022Disposal of Cromology closed on January 21  2022  generating â‚¬896 million of proceeds to Wendelâ‚¬304 1 million equity invested to acquire ACAMS on March 10  2022Wendel Lab: â‚¬51 million additional commitments into funds year-to-date bringing the total to around â‚¬167 millionStrong financial structureLTV ratio of 6.0% as of September 30  2022Wendelâ€™s bond debt average maturity of 6.6 2 years with an average weighted cost of 1.7%Total liquidity of â‚¬1.7 billion as of September 30  2022  including â‚¬973 million of cash and â‚¬750 million available under the committed sustainability-linked credit facility (fully undrawn)Governance: Laurent Mignon to be appointed Group CEO from December 2  2022AndrÃ© FranÃ§ois-Poncet  Wendelâ€™s current Group CEO  is in his role until Laurent Mignon joins WendelStory continuesAndrÃ© FranÃ§ois-Poncet  Wendel Group CEO  commented:â€œOur portfolio companies have generally been doing well under deteriorating macroeconomic circumstances  largely due to pricing and cost containment initiatives and they are actively pursuing ESG initiatives. The ACAMS carve-out is proceeding according to plan. We sold our headquarters building at a very good price and we refinanced our nearest bond and credit lines at terms that we are unlikely to see again for a long time.Wendelâ€™s strong balance sheet will allow the Firm to continue to make acquisitions under our roadmap while remaining vigilant on prices. Short term  we continue to support our companiesâ€™ projects  including external growth and actively consider the numerous opportunities which are now emerging for the Wendel Lab.â€Nine months 2022 sales of Group companiesNine months 2022 consolidated sales(in millions of euros) 9 months 2021 9 months 2022 Growth Organic Growth Bureau Veritas 3 664.1 4 150.5 +13.3% +7.3% Constantia Flexibles 1 168.3 1 537.9 +31.6% +23.7% Stahl 624.4 696.4 +11.5% +7.8% Crisis Prevention Institute 63.9 83.5 +30.7% +17.7% ACAMS(1) n.a 39.6 n.a n.a Consolidated net sales 5 520.6 6 507.8 +17.9% +10.9%ACAMS accounts have been consolidated since March 11  2022. The sales include a PPA restatement for an impact of -â‚¬11.0M  excluding this restatement the sales are â‚¬50.6M.Nine months 2022 sales of equity accounted companies(in millions of euros) 9 months 2021 9 months 2022 Growth Organic Growth Tarkett 2 070.6 2 569.4 +24.1% +13.1%Q3 2022 sales of Group companiesQ3 2022 consolidated sales(in millions of euros) Q3 2021 Q3 2022 Growth Organic Growth Bureau Veritas 1 245.7 1 457.1 +17.0% +8.7% Constantia Flexibles 416.2 552.7 +32.8% +25.7% Stahl 204.6 225.5 +10.2% +5.3% Crisis Prevention Institute 27.4 35.3 +28.8% +13.0% ACAMS(1) n.a 19.8 n.a n.a Consolidated net sales 1 893.8 2 290.3 +20.9% +12.1%ACAMS accounts have been consolidated since March 11  2022. The sales include a PPA restatement for an impact of - â‚¬1.5M  excluding this restatement Q3 sales are â‚¬21.3M.Q3 2022 sales of equity accounted companies(in millions of euros) Q3 2021 Q3 2022 Growth Organic Growth Tarkett 809.4 1 005.4 +24.2% +12.0%Sales of Group companiesBureau Veritas â€“ Strong organic revenue growth in the third quarter of 2022; 2022 Full Year outlook confirmed(Full consolidation)Bureau Veritasâ€™ revenue in the third quarter of 2022 amounted to â‚¬1 457.1 million  a 17.0% increase compared with Q3 2021. Organic growth was 8.7%. This brought the 9-month organic revenue growth to 7.3%.The 8.7% organic revenue growth was notably led by a strong performance in Buildings & Infrastructure (+11.0% in Q3)  Industry (+10.6% in Q3)  Marine & Offshore (+9.7%)  as well as Agri-Food & Commodities (+9.6%) in Q3. The diversity of Bureau Veritas portfolio  its solid sales pipeline and its leadership in terms of Sustainability and ESG solutions  position Bureau Veritas well to grow in a sustained manner in the medium term. Around 55% of Bureau Veritas sales  in the first 9-month of the year  are related to Sustainability through the BV Green Line of services & solutions.By geography  activities in the Americas strongly outperformed the rest of Bureau Veritas (29% of revenue; up 15.0% organically)  led by a 9.5% increase in North America (Buildings & Infrastructure driven) and by a 25.3% increase in Latin America (led by Brazil notably). The activity in Asia Pacific (31% of revenue; up 4.6% organically) benefited from robust growth in Australia as well as strong growth in South-East Asian countries (notably Vietnam). Europe (31% of revenue) delivered homogeneous growth across the board; up 6.0% organically  with above-average performance in Italy and France  notably. Finally  in Africa and the Middle East (9% of revenue)  business increased by 16.2% on an organic basis  essentially driven by Buildings & Infrastructure and energy projects in the Middle East.The scope effect was a positive 1.3%  reflecting the four bolt-on acquisitions realized since the beginning of 2022  alongside those of the prior year.Currency fluctuations had a positive impact of 7.0%  mainly due to the strong appreciation of the USD and pegged currencies against the euro  which was partly offset by the depreciation of some emerging countriesâ€™ currencies.2022 outlook confirmed:Based on the year-to-date performance  the significant growth opportunities related to its sustainabilityrange of services and solutions  and excluding the full-year impact of the Covid-19 lockdowns in China Bureau Veritas still expects for 2022 to:Achieve mid-single-digit organic revenue growth;Improve the adjusted operating margin;Generate sustained strong cash flow  with a cash conversion above 90%.For more information: https://group.bureauveritas.comConstantia Flexiblesâ€”9 months total growth of +31.6%  with record organic growth of 23.7% mainly driven by price increases but also through volume growth and mix improvement(Full consolidation)Sales in the first nine months of 2022 totaled â‚¬1 537.9 million  up +23.7% on an organic basis with strong performance across both markets  Consumer and Pharma both posted above 20% organic growth. Sales are up +31.6% in total over the period  driven mostly by necessary price increases enabling to compensate for the inflationary input costs pressure. Since the start of the year  despite raw material shortages  Constantia has experienced an encouraging return to market share gains  thereby confirming the good momentum instilled by the new management teamâ€™s commercial initiatives. The market in India remains challenging and management is rolling out successfully the â€œRestoring Success programâ€ to return to profitability whilst reviewing various strategic options for this division.Year-to-date activity also benefited from the acquisition of Propak in June 2021 and FFP Packaging Solutions in August 2022 (impact of +4.0%). Foreign exchange had a +4.0% positive impact on sales.Constantia is carefully managing the inflationary cost environment as well as the availability of energy supply and raw materials. The Company is focusing its efforts on preserving the profitability working both on the passthrough of input costs as well as pursuing its cost control program. Constantia is also actively working on its supply base and energy supply sources in the context of a potential shortage of gas in Europe in the coming months.In August 2022  Constantia Flexibles has signed an agreement  to acquire 100% of FFP Packaging Solutions  a leading player for sustainable  flexible packaging in the film consumer market from Northampton  UK. This acquisition aligns well with Vision 2025 growth strategy of investing in competitive businesses with potential for future growth. FFP Packaging Solutions joining the Constantia Flexibles Group will expand its overall market position. Its significant experience and credibility allow for strong relationships across the UK food industry. The transaction closed in August.Stahlâ€”Sales up 11.5% with organic growth of 7.8% mostly driven by price increases to offset input cost inflation(Full consolidation)Stahl  the world leader in coating layers and surface treatments for flexible materials  posted total sales of â‚¬696.4 million in the first nine months of 2022  representing an increase of +11.5% over the period. Organic growth stood at +7.8% while FX contributed positively (+3.7%)  mostly through USD strengthening.Activity for the period is above expectations at group level  with a strong growth in Coatings and Leather over the past nine months. Growth was largely led by price/mix effects as volumes declined  notably due to (i) slowdown in certain end markets  (ii) China lockdowns and (iii) continued supply disruptions in automotive.Across all segments  price increases have been implemented since the beginning of the year to mitigate the strong impact of rising input costs. The company has taken and is ready to take additional measures to protect its margin where needed. Stahlâ€™s management continues to closely monitor the inflationary environment  as well as the supply chain and potential energy disruptions.The order book slightly decreased following the strong commercial activity in H1 2022 but remains at high levels compared to historical standards.Stahl announced on July 5  2022  the submission of a greenhouse gas (GHG) emissions reduction target  aligned with the most recent guidance provided by the Science-Based Targets initiative (SBTi).Stahlâ€™s SBTi submission includes a specific commitment regarding the companyâ€™s Scope 3 upstream emissions  which Stahl aims to reduce by at least 25% over the next 10 years  compared with the base year (2021). Stahlâ€™s Scope 3 emissions currently represent over 90% of its carbon footprint. This reduction would primarily be achieved by Stahl replacing its fossil-based raw materials with lower-carbon alternatives. The target is a major step towards the objective of limiting global warming temperature increase to 1.5 Â°C above pre-industrial levels by 2050  as agreed at the 2015 Paris Climate Accords.Stahlâ€™s extended commitment builds on the companyâ€™s existing targets to reduce its emission for Scopes 1 and 2  which were set shortly after the Paris Agreement in 2015. Stahl has since reduced its Scope 1 and 2 (direct) GHG emissions by more than 30%  thanks to operational efficiency gains and by decarbonizing its energy supply.In September 2022  Stahl has been awarded the highest EcoVadis Platinum rating  placing it within the top 1% of companies assessed by EcoVadis. The award underlines Stahlâ€™s commitment to collaborating with its partners to reduce its environmental impact and build a more responsible and transparent supply chain.Crisis Prevention Instituteâ€”9 months revenue growth of +16.1% as compared with 2021  +17.7% organically(Full consolidation since March 11  2022)Crisis Prevention Institute recorded revenue of $88.8 million in the first nine months of 2022  up +16.1% in total compared to the same period in 2021 and +17.7% organically. Foreign exchange impact was -1.6%. This performance reflects several factors:The return to â€œnormalâ€ business conditions has made it easier for customers  particularly for schools and hospitals  to prioritize and schedule training  allowing Certified Instructors to conduct internal training;The success of new program launches  including specialty topics such as Trauma  Autism  and Advanced Physical Skills  which now collectively represent more than 20% of Initial Certifications for the first nine months;The international expansion strategy outside of North America  notably in English-speaking countries  with a growth rate of nearly +23%;A continued mix shift toward digital solutions for both new CIs and renewals  which supplement required in-person training components of programs. Virtual Learner Materials continue to comprise a strong share of overall delivery  accounting for 44% of total Learner Materials sales.During the quarter  CPIâ€™s President Susan Driscoll and JÃ©rÃ´me Richard  Operating Partner at Wendel  were added to the CPI Board. Susan Driscoll has held multiple executive positions across training and education businesses over the course of her career  including serving as President of the professional and education and nurse learning divisions during her seven-year tenure at Wolters Kluwer Health. Susan has served as President of Crisis Prevention Institute since 2017.ACAMSâ€“Strong year-to-date performance for ACAMS  with reported revenue3 up +7.8% and +17.8% pro forma for conference timing. Carve-out process on track.(Full consolidation since March 11  2022)On March 10  2022  Wendel acquired ACAMS  a global leader in training and certifications for anti-financial crime prevention professionals. ACAMSâ€™s separation from its prior parent company is on schedule and expected to be fully completed early 2023.For the nine months ended September 30  2022  ACAMS reported revenue of $69.5 million4 up +7.8% vs. the same period in 2021. Organic growth for these first nine months was +8.0%  and the impact of foreign exchange was -0.3%. ACAMSâ€™s flagship Las Vegas conference  the largest organized by ACAMS  was held in October 2022  one month later than that of the prior year in September 2021  skewing the year-over-year comparison. Normalized for the timing of this event  pro forma growth over the first 9 months would have been +17.8%.The pro forma revenue growth was driven by post-COVID conference recovery and greater sales of Certifications  Memberships and Training  primarily a result of sales to larger enterprise customers. Revenue growth should ease and return to more normative levels for the remainder of 2022 and into 2023.Tarkettâ€“Q3 turnover growth driven by solid performance in Sports and sales price increases(Accounted for by the equity method since 07.07.2021)The company reported its Q3 2022 sales on October 25  2022. For more information: https://www.tarkett-group.com/en/investors/Net revenue for the Group was â‚¬1 005 million  up by +24.2% compared to the third quarter of 2021. Organic growth was +12.0% including the sales price increases in the CIS region implemented at the beginning of the year5. The total effect of the sales price increases implemented across all segments is +11.9% on average compared to the third quarter of 2021.By segment:As expected  the Sport segment continues to show very strong growth for the third consecutive quarter. Revenue was â‚¬343 million  up by +46.4% and including +30.5% organic growth compared to the third quarter of 2021. The market is extremely dynamic in North America for both artificial turf and athletic tracks  two segments where Tarkett benefits from its leadership.The North America segment reported a revenue of â‚¬251 million  up +29.5% compared to the third quarter of 2021  reflecting solid like-for-like growth of +11.5% and a positive currency effect due to the appreciation of the dollar against the euro (+18.0%)The EMEA segment achieved a turnover of â‚¬220 million  up +1.4% compared to the third quarter of 2021  including an unfavourable currency effect of -1.3% and +2.7% of organic growth.Revenue in the CIS  APAC and Latin America segment amounted to â‚¬191 million  up +16.5% compared to the third quarter of 2021  thanks to a positive currency effect mainly due to the appreciation of the ruble (+18.0%).End of October  Claude Ehlinger  Senior Advisor of Wendel SE  was appointed Board members of Tarkett Participation and Charles Goulet  Senior Director of Wendel SE  was appointed Censor to the Board of Tarkett SA.IHS Towersâ€”IHS Towers will report its Q3 2022 consolidated sales in November.Wendelâ€™s net asset value: â‚¬155.2 per share as of September 30  2022As per its NAV Methodology  Wendelâ€™s unlisted assets valuations are updated on a quarterly basis using end of quarter markets multiples. Investments in funds are valued at the last valuation received from the General Partner. Listed investments are valued on the basis of the average closing price of the 20 trading days prior to the valuation date.Net asset value was â‚¬6 885 million  or â‚¬155.2 per share  as of September 30  2022 (see Appendix 1 and 2 below for details)  a decrease of 17.5% from â‚¬188.1 per share as of December 31  2021  and down 15.9% restated from dividend (â‚¬3 per share) paid in June 2022. Compared to the last 20-day average share price as of September 30  the discount to the September 30  2022  NAV per share was of 50.9%.Restated for the â‚¬3 dividend per share paid in June 2022  NAV is down 4.5% since the end of June and down 15.9% YTD driven mostly by marketsâ€™ decline  whilst the higher-than-expected performance of unlisted portfolio companies and FX contributed positively.Wendel further improves its debt profile and structureLoan-to-value (LTV) ratio at 6.0% as of September 30  2022Total liquidity of â‚¬1.7 billion as of September 30  2022  including â‚¬973 million of cash and â‚¬750 million available under the committed sustainable-linked credit facility (fully undrawn)Syndicated Credit Facility extended to July 2027Average debt maturity extended to 6.6 years and average weighted cost lowered to 1.7% following the successful placement of a â‚¬300 million 12-year bond at 1 375% interest on January 13  2022  and exercise on April 19  2022  of the make-whole redemption of bonds maturing in October 2024Investment grade corporate ratings: Moodyâ€™s Baa2 with stable outlook/S&P BBB with stable outlook2022 other significant events:Laurent Mignon to be appointed Group CEO from December 2On September 2022  the Supervisory Board of Wendel  chaired by Nicolas ver Hulst  appointed Laurent Mignon Member of the Executive Board and Group CEO of Wendel with effect on January 1st  2023  at the latest. Starting from December 2  he will succeed AndrÃ© FranÃ§ois-Poncet  Wendelâ€™s current Group CEO  is in his role until Laurent Mignon joins Wendel  at which point in time Wendelâ€™s Executive Board will be comprised of Laurent Mignon  Group CEO  and David Darmon  Deputy Group CEO and Member of the Executive Board since 2019.Amendment to extend Wendelâ€™s undrawn â‚¬750 million syndicated credit facility to 2027Wendel signed on July 27  2022  an amendment to its undrawn â‚¬750 million syndicated credit facility maturing in October 2024 to extend it to July 2027  with two options to extend it further by one year (1 + 1)  pending banks approval for each additional extension. This syndicated credit facility integrates Environmental  Social and Governance (ESG) criteria. Measurable aspects of the non-financial performance of Wendel and the companies in its portfolio are taken into account in the calculation of the financing cost of this syndicated credit. They are in line with certain quantitative ESG targets the Group has set in its ESG 2023 roadmap.Wendel sold its headquarters buildingWendel sold its headquarters building on Taitbout street. Generali Vie acquired the property. The transaction amount results in a value creation of â‚¬1.5 per share in Wendelâ€™s NAV. This transaction was closed in the second half of 2022.Wendel acquires ACAMS  the worldâ€™s largest membership organization dedicated to fighting financial crimeAnnounced on January 24  2022  Wendel has completed the acquisition of the Association of Certified Anti-Money Laundering Specialists (â€œACAMSâ€ or the â€œCompanyâ€) from Adtalem Global Education (NYSE: ATGE) on March 10  2022. Wendel invested c.$338 million of equity for a c. 98% interest in the Company  alongside ACAMSâ€™s management and a minority investor.ACAMS is the global leader in training and certifications for anti-money laundering (â€œAMLâ€) and financial crime prevention professionals. ACAMS has a large  global membership base with more than 90 000 members in 175 jurisdictions  including over 50 000 professionals who have obtained their CAMS certification-an industry-recognized AML qualificationâ€”that promotes ongoing education through participation in conferences  webinars  and other training opportunities.The Company has approximately 275 employees primarily located in the U.S.  London and Hong Kong that serve its global customers.Sale of Cromology completedAfter obtaining the necessary authorizations  Wendel completed on January 21  2022  the sale of Cromology to DuluxGroup  a subsidiary of Nippon Paint Holdings Co.  Ltd. For Wendel  the transaction generated net proceeds of â‚¬896 million or â‚¬358 million above Cromologyâ€™s valuation in Wendelâ€™s net asset value published before the transaction announcement  i.e.  as of June 30  2021.This transaction is a milestone in Wendelâ€™s 2021-24 roadmap  and its target to accelerate the redeployment of its capital toward growth companies.AgendaDecember 1st  2022Investor Day 2022March 17th  20232022 Full Year Resultsâ€”Publication of NAV as of December 31  2022 (pre-market release)April 28th  2023Q1 2023 Trading updateâ€”Publication of NAV as of March 31  2023 (pre-market release)June 15th  2023Annual General MeetingJuly 28th  2023H1 2023 resultsâ€”Publication of NAV as of June 30  2023  and condensed Half-Year consolidated financial statements (pre-market release).October 27th  2023Q3 2023 Trading updateâ€”Publication of NAV as of September 30  2023 (pre-market release).December 7th  20232023 Investor Day.About WendelWendel is one of Europeâ€™s leading listed investment firms. The Group invests in Europe and North America in companies which are leaders in their field  such as Bureau Veritas  ACAMS  Constantia Flexibles  Crisis Prevention Institute  IHS Towers  Stahl and Tarkett. Wendel often plays an active role as a controlling or significant shareholder in its portfolio companies. Wendel seeks to implement long-term development strategies  which involve boosting growth and margins of companies so as to enhance their leading market positions.Wendel is listed on Eurolist by Euronext Paris.Standard & Poorâ€™s ratings: Long-term: BBB  stable outlookâ€”Short-term: A-2 since January 25  2019Moodyâ€™s ratings: Long-term: Baa2  stable outlookâ€”Short-term: P-2 since September 5  2018Wendel is the Founding Sponsor of Centre Pompidou-Metz. In recognition of its long-term patronage of the arts  Wendel received the distinction of â€œGrand MÃ©cÃ¨ne de la Cultureâ€ in 2012.For more information: wendelgroup.comFollow us on Twitter @WendelGroupPress contacts Analyst and investor contactsChristine Anglade-Pirzadeh: +33 (0)1 42 85 63 24 Olivier Allot : +33 (0)1 42 85 63 73c.anglade@wendelgroup.com o.allot@wendelgroup.comCaroline Decaux: +33 (0)1 42 85 91 27 Lucile Roch : +33 (0)1 42 85 63 72c.decaux@wendelgroup.com l.roch@wendelgroup.comAlexis de Maigret / Sara-Louise Boukara: +33 (0)6 17 76 79 71Vae Solis Communicationswendel@vae-solis.comTodd Fogarty: + 1 212 521 4854Kekst CNCtodd.fogarty@kekstcnc.comAppendix 1: NAV as of September 30  2022: â‚¬155.2 per share(in millions of euros) 09/30/2022 12/31/2021 Listed equity investments Number of shares Share price (1) 4 370 5 559 Bureau Veritas 160.8/160.8 m â‚¬24.0/â‚¬28.7 3 860 4 616 IHS Towers 63.0/63.0m $6.4/$13.5 412 748 Tarkett â‚¬12.5/â‚¬18.6 98 195 Investment in unlisted assets (2) 2 938 3 732 Other assets and liabilities of Wendel and holding companies(3) 17 97 Net cash position & financial assets (4) 973 650 Gross asset value 8 299 10 038 Wendel bond debt -1 414 -1 619 Net Asset Value 6 885 8 419 Of which net debt -441 -969 Number of shares 44 370 620 44 747 943 Net Asset Value per share â‚¬155.2 â‚¬188.1 Wendelâ€™s 20 days share price average â‚¬76.1 â‚¬102.3 Premium (discount) on NAV -50.9% -45.6%Last 20 trading days average as of September 30  2022  and December 31  2021. Investments in non-publicly traded companies (Cromology (as of December 31  2021)  Stahl  Constantia Flexibles  Crisis Prevention Institute  ACAMS (as of September 30  2022)  Wendel Lab). Aggregates retained for the calculation exclude the impact of IFRS 16. As per Wendel methodology  ACAMS valuation is weighted at 66.7% on acquisition multiple and 33.3% on listed peer-group multiples. Of which 1 116 456 treasury shares as of December 31  2021  and 997 494 treasury shares as of September 30  2022 Cash position and financial assets of Wendel & holdings. As of September 30  2022  this comprises â‚¬0.7 bn of cash and cash equivalents and â‚¬0.3 bn short term financial investment.Assets and liabilities denominated in currencies other than the euro have been converted at exchange rates prevailing on the date of the NAV calculation.If co-investment and managements LTIP conditions are realized  subsequent dilutive effects on Wendelâ€™s economic ownership are accounted for in NAV calculations. See page 374 of the 2021 Universal Registration Document.1 c. $338 million at 1.112 EURUSD2 As of September 30  20223 Revenue is shown excluding the purchase price allocation entry related to deferred revenue4 Revenue is shown excluding the purchase price allocation entry related to deferred revenue5 Selling price adjustments in the CIS countries are historically intended to offset currency movements and are therefore excluded from the â€œorganic growthâ€ indicator. Excluding these price increases  organic growth was +9.7%.Attachment,neutral,0.35,0.65,0.0,mixed,0.62,0.16,0.22,True,English,"['Trading update', 'Good growth', 'Wendel', '9 months', 'portfolio', 'Growth Organic Growth Bureau Veritas', 'Double digit organic growth', 'bond debt average maturity', 'quarter stock market multiples', '9-month organic revenue growth', 'Growth Organic Growth Tarkett', 'Strong organic revenue growth', '8.7% organic revenue growth', 'Bureau Veritasâ€™ revenue', 'average weighted cost', 'AndrÃ© FranÃ§ois-Poncet', 'deteriorating macroeconomic circumstances', 'Crisis Prevention Institute', 'Strong financial structure', 'strong balance sheet', 'million additional commitments', 'sustainability-linked credit facility', 'cost containment initiatives', '2022 Full Year outlook', 'Net asset value', 'Bureau Veritas portfolio', 'equity accounted companies', 'Positive FX impacts', 'Significant portfolio rotation', 'current Group CEO', 'Bureau Veritas sales', 'solid sales pipeline', 'unlisted portfolio companies', 'Wendel Group CEO', 'first nine months', 'Strong growth', 'first 9-month', 'Good growth', 'external growth', '304 1 million equity', 'market declines', 'nearest bond', 'strong performance', 'Group companies', 'third quarter', 'unlisted assets', 'ESG initiatives', 'credit lines', 'Full consolidation', 'companiesâ€™ projects', 'press release', 'Trading update', 'Constantia Flexibles', 'expected performance', 'quarterly basis', 'capital deployment', 'LTV ratio', 'Laurent Mignon', 'headquarters building', 'good price', 'long time', 'numerous opportunities', 'ESG solutions', 'sustained manner', 'net sales', 'consolidated sales', 'Total liquidity', 'The ACAMS', 'ACAMS accounts', 'PPA restatement', 'medium term', 'Wendel Lab', 'Q3 2022 sales', 'Q3 sales', '9 months', 'Q3.', 'october', 'CPI', 'Stahl', 'September', 'share', 'â‚¬3 dividend', 'June', 'NAV', 'higher', 'reminder', 'Disposal', 'Cromology', 'January', 'proceeds', 'March', 'funds', '6.6 2 years', 'cash', 'Governance', 'December', 'role', 'Story', 'pricing', 'plan', 'terms', 'Firm', 'acquisitions', 'roadmap', 'prices', 'millions', 'euros', '17.0% increase', 'Buildings', 'Infrastructure', 'Industry', 'Marine', 'Offshore', 'Agri-Food', 'Commodities', 'diversity', 'leadership']",2022-10-28,2022-10-28,finance.yahoo.com
12323,EuroNext,NewsApi.org,https://www.prnewswire.com/news-releases/pharming-announces-european-medicines-agency-ema-validates-its-marketing-authorisation-application-under-accelerated-assessment-for-leniolisib-301661947.html,Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib,"Marketing authorisation in the European Economic Area anticipated in H1 2023 LEIDEN  Netherlands  Oct. 28  2022 /PRNewswire/ -- Pharming Group N.V. (""Pharming"" or ""the Company"") (EURONEXT Amsterdam: PHARM / Nasdaq: PHAR) announces today that its Marketing Autâ€¦","Marketing authorisation in the European Economic Area anticipated in H1 2023LEIDEN  Netherlands  Oct. 28  2022 /PRNewswire/ -- Pharming Group N.V. (""Pharming"" or ""the Company"") (EURONEXT Amsterdam: PHARM /Nasdaq: PHAR) announces today that its Marketing Authorisation Application (MAA) for leniolisib has been validated for scientific evaluation under an accelerated assessment by the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). The application  submitted earlier in October 2022  is for the investigational drug  leniolisib  an oral  selective phosphoinositide 3-kinase delta (PI3KÎ´) inhibitor  as a treatment for activated phosphoinositide 3-kinase delta syndrome (APDS)  a rare primary immunodeficiency  in adolescents and adults 12 years or older.In August 2022  Pharming announced the leniolisib MAA was granted accelerated assessment by EMA's CHMP. The accelerated assessment reduces the review timeframe from 210 days to 150 days. Upon request  EMA will grant an accelerated assessment of an MAA if they decide the product is of major interest for public health  and in particular  from the viewpoint of therapeutic innovation. Marketing authorisation for leniolisib in the European Economic Area is anticipated in H1 2023.The MAA is supported by positive data from a Phase II/III study of leniolisib  announced on February 2  2022  which met its co-primary endpoints of reduction in lymph node size and increase in percentage of naÃ¯ve B cells in patients with APDS. Furthermore  safety data from the study showed that leniolisib was well tolerated by participants. Also submitted as part of the MAA were data from a long-term  open-label extension clinical trial in patients with APDS treated with leniolisib.Anurag Relan  MD  MPH  Chief Medical Officer of Pharming  commented:""EMA's validation for review of our MAA under an accelerated assessment pathway highlights Pharming's ongoing commitment to advance leniolisib as a targeted treatment for adults and adolescents 12 years of age or older with APDS. We anticipate that leniolisib will fill an unmet need for patients with APDS  who currently rely on supportive therapies to treat their primary symptoms. This review constitutes a key milestone in Pharming's effort to give healthcare providers and their patients global access to leniolisib. We look forward to collaborating with EMA as needed throughout the regulatory process.""About Activated Phosphoinositide 3-Kinase Î´ Syndrome (APDS)APDS is a rare primary immunodeficiency that affects approximately 1 to 2 people per million. APDS is caused by variants in either of two genes  PIK3CD or PIK3R1  that regulate maturation of white blood cells. Variants of these genes lead to hyperactivity of the PI3KÎ´ (phosphoinositide 3-kinase delta) pathway.1 2 Balanced signaling in the PI3KÎ´ pathway is essential for physiological immune function. When this pathway is hyperactive  immune cells fail to mature and function properly  leading to immunodeficiency and dysregulation.1 3 APDS is characterized by severe  recurrent sinopulmonary infections  lymphoproliferation  autoimmunity  and enteropathy.4 5 Because these symptoms can be associated with a variety of conditions  including other primary immunodeficiencies  people with APDS are frequently misdiagnosed and suffer a median 7-year diagnostic delay.6 As APDS is a progressive disease  this delay may lead to an accumulation of damage over time  including permanent lung damage and lymphoma.4-7 The only way to definitively diagnose this condition is through genetic testing.About LeniolisibLeniolisib is a small-molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class IA PI3K. PI3KÎ´ is expressed predominately in hematopoietic cells and is essential to normal immune system function through conversion of phosphatidylinositol-4-5-trisphosphate (PIP2) to phosphatidylinositol-3-4-5-trisphosphate (PIP3). Leniolisib inhibits the production of PIP3 and PIP3 serves as an important cellular messenger activating AKT (via PDK1) and regulates a multitude of cell functions such as proliferation  differentiation  cytokine production  cell survival  angiogenesis  and metabolism. Unlike PI3KÎ± and PI3KÎ²  which are ubiquitously expressed  PI3KáºŸ and PI3KÎ³ are expressed primarily in cells of hematopoietic origin. The central role of PI3KáºŸ in regulating numerous cellular functions of the adaptive immune system (B-cells and  to a lesser extent  T cells) as well as the innate immune system (neutrophils  mast cells  and macrophages) strongly indicates that PI3KáºŸ is a valid and potentially effective therapeutic target for immune diseases such as APDS. To date  leniolisib has been well tolerated during both the Phase 1 first-in-human trial in healthy subjects and the Phase II/III registration-enabling study in patients with APDS.About Pharming Group N.V.Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare  debilitating  and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines  including small molecules  biologics  and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden  Netherlands  and has employees around the globe who serve patients in over 30 markets in North America  Europe  the Middle East  Africa  and Asia-Pacific.For more information  visit www.pharming.com.Forward-Looking StatementsThis press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results  performance or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as ""aim""  ""ambition""  ''anticipate''  ''believe''  ''could''  ''estimate''  ''expect''  ''goals''  ''intend''  ''may''  ""milestones""  ''objectives''  ''outlook''  ''plan''  ''probably''  ''project''  ''risks''  ""schedule""  ''seek''  ''should''  ''target''  ''will'' and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates  Pharming's clinical and commercial prospects  and Pharming's expectations regarding its projected working capital requirements and cash resources  which statements are subject to a number of risks  uncertainties and assumptions  including  but not limited to the scope  progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical  scientific  regulatory and technical developments. In light of these risks and uncertainties  and other risks and uncertainties that are described in Pharming's 2021 Annual Report and the Annual Report on Form 20-F for the year ended December 31  2021 filed with the U.S. Securities and Exchange Commission  the events and circumstances discussed in such forward-looking statements may not occur  and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information  future events or other information.Inside InformationThis press release relates to the disclosure of information that qualifies  or may have qualified  as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.References1. Lucas CL  et al. Nat Immunol. 2014;15:88-97.2. Elkaim E  et al. J Allergy Clin Immunol. 2016;138(1):210-218.3. Nunes-Santos C  Uzel G  Rosenzweig SD. J Allergy Clin Immunol. 2019;143(5):1676-1687.4. Coulter TI  et al. J Allergy Clin Immunol. 2017;139(2):597-606.5. Maccari ME  et al. Front Immunol. 2018;9:543.6. Jamee M  et al. Clin Rev Allergy Immunol. 2019;May 21.7. Condliffe AM  Chandra A. Front Immunol. 2018;9:338.For further public information  contact:Pharming Group  Leiden  The NetherlandsHeather Robertson  Investor Relations & Corporate Communications ManagerT: +31 71 524 7400E: [email protected]FTI Consulting  London  UKVictoria Foster Mitchell/Alex ShawithAmy ByrneT: +44 203 727 1000LifeSpring Life Sciences Communication  Amsterdam  The NetherlandsLeon MelensT: +31 6 53 81 64 27E: [email protected]US PR:Ethan MetelenisE: [email protected]T: +1 (917) 882 9038EU PR:Dan CaleyE: [email protected]T: +44 (0) 787 546 8942Logo - https://mma.prnewswire.com/media/1454235/Pharming_Group_NV_Logo.jpgSOURCE Pharming Group N.V.",neutral,0.0,1.0,0.0,mixed,0.62,0.23,0.15,True,English,"['European Medicines Agency', 'Marketing Authorisation Application', 'Accelerated Assessment', 'Pharming', 'EMA', 'leniolisib', 'long-term, open-label extension clinical trial', 'oral, selective phosphoinositide 3-kinase delta', 'severe, recurrent sinopulmonary infections', 'phosphoinositide 3-kinase delta syndrome', 'median 7-year diagnostic delay', 'naÃ¯ve B cells', 'phosphoinositide 3-kinase delta) pathway', 'Pharming Group N.V.', 'normal immune system function', 'Phase II/III registration-enabling study', 'Phosphoinositide 3-Kinase Î´ Syndrome', 'European Economic Area', 'European Medicines Agency', 'lymph node size', 'Chief Medical Officer', '110 kDa catalytic subunit', 'important cellular messenger', 'adaptive immune system', 'innate immune system', 'Phase II/III study', 'other primary immunodeficiencies', 'numerous cellular functions', 'effective therapeutic target', 'white blood cells', 'permanent lung damage', 'rare primary immunodeficiency', 'global biopharmaceutical company', 'class IA PI3K', 'Marketing Authorisation Application', 'accelerated assessment pathway', 'delta isoform', 'immune function', 'human trial', 'immune cells', 'immune diseases', 'rare, debilitating', 'primary endpoints', 'therapeutic innovation', 'global access', 'cell functions', 'hematopoietic cells', 'T cells', 'primary symptoms', 'EURONEXT Amsterdam', 'scientific evaluation', 'Medicinal Products', 'Human Use', 'investigational drug', 'major interest', 'public health', 'Anurag Relan', 'ongoing commitment', 'unmet need', 'supportive therapies', 'key milestone', 'healthcare providers', 'regulatory process', 'Balanced signaling', 'progressive disease', 'genetic testing', 'small-molecule inhibitor', 'cell survival', 'hematopoietic origin', 'central role', 'lesser extent', 'healthy subjects', 'life-threatening diseases', 'PI3KÎ´ pathway', 'positive data', 'safety data', 'targeted treatment', '1 to 2 people', 'two genes', 'cytokine production', 'PI3KÎ´) inhibitor', 'review timeframe', 'EMA) Committee', 'Phase 1', 'leniolisib MAA', 'PI3KÎ±', 'PI3KÎ²', 'PI3KÎ³', 'H1', 'LEIDEN', 'Netherlands', 'PRNewswire', 'Nasdaq', 'CHMP', 'October', 'APDS', 'adolescents', 'adults', 'August', '210 days', '150 days', 'request', 'viewpoint', 'February', 'reduction', 'percentage', 'patients', 'participants', 'MD', 'validation', 'years', 'effort', 'million', 'variants', 'PIK3CD', 'PIK3R', 'maturation', 'hyperactivity', 'dysregulation', 'lymphoproliferation', 'autoimmunity', 'enteropathy', 'variety', 'conditions', 'lymphoma', 'conversion', 'PIP', 'AKT', 'PDK', 'multitude', 'differentiation', 'angiogenesis', 'metabolism', 'B-cells', 'neutrophils', 'macrophages', 'date', 'lives']",2022-10-28,2022-10-28,prnewswire.com
12324,EuroNext,NewsApi.org,https://finance.yahoo.com/news/sato-corporation-interim-report-1-060000138.html,SATO Corporation Interim Report 1 January to 30 September 2022: Positive occupancy rate growth continued,SATO Corporation  Interim Report 28 October 2022 at 9:00 am Summary for 1 January to 30 September 2022 (1 January to 30 September 2021) The economic...,SATO OyjSATO Corporation  Interim Report 28 October 2022 at 9:00 amSummary for 1 January to 30 September 2022 (1 January to 30 September 2021)The economic occupancy rate in Finland was 9 5 . 1 % (9 4 . 7 ).Net sales totalled EUR 2 19 . 8 million (22 3 . 2 ).Net rental income was EUR 15 2 . 4 million ( 157.3 ) .Profit before taxes was EUR 182 . 9 million ( 211.7 ) .The unrealised change in the fair value of investment properties included in the result was EUR 43 . 2 million ( 114 . 4 ) .Housing investments amounted to EUR 1 22 . 1 million ( 116 . 9 ) .Invested capital at the end of the review period was EUR 4  650 . 7 million ( 4 479.8 ) .Return on invested capital was 6 .3% ( 7 . 3 ) .Equity was EUR 2  507 . 4 million ( 2 310.7 )  or EUR 4 4 . 29 per share ( 40 . 8 2).Earnings per share were EUR 2. 58 ( 2 . 99 ).A total of 19 2 rental apartments ( 41 )  0 owner-occupied apartments ( 0 ) and 0 Flex Homes ( 0 ) were acquired or completed.A total of 1  387 rental apartments ( 1 294 )  0 owner-occupied apartments ( 71 ) and 52 FlexHomes ( 52 ) are under construction.SATO invested in new rental homes in the Skanssi district of Turku. This is the first time in five years that SATO is investing in new homes in the city.Despite the uncertainty in the market  SATO has succeeded in improving the occupancy rate.Summary for 1 July to 30 September 2022 (1 July to 30 September 2021)The economic occupancy rate in Finland was 95. 6 % (9 5 . 1 ).Net sales totalled EUR 7 2 . 6 million (7 4 . 9 ).Net rental income was EUR 5 4 . 0 million ( 57 .3) .Profit before taxes was EUR 38 . 4 million ( 40.5 ).The unrealised change in the fair value of investment properties included in the result was EUR 2. 9 million ( 2 . 4 ).Housing investments amounted to EUR 5 3 . 6 million ( 57 . 3 ) .Earnings per share were EUR 0.5 4 (0. 5 7).A total of 1 rental apartments (0)  0 owner-occupied apartments (0) and 0 Flex Homes (0) were acquired or completed.President and CEO Antti Aarnio:During the period under review (1 July to 30 September 2022)  SATOâ€™s occupancy rate improved and was 95.6% (95.1). Demand for rental homes picked up from the early months of the year  and the higher occupancy rate has mainly been attributable to growth in service consumption and the consequent improvement in service-sector employment rate as well as to upper secondary education resuming contact teaching. Economic uncertainty and higher consumer prices and interest rates are also in part reflected in the rising demand for rental homes.In the Helsinki Metropolitan Area in particular  the continued high level of new housing production has sustained intense competition for good tenants. Due to the competitive situation  it has not been possible to transfer increasing maintenance costs in full to apartment rents.With the choice available for those looking for a home growing  a successful customer experience plays an important role. SATO is investing strongly in its operations in 24/7 digital services and in presence close to customers.In August  SATO signed a contract under which we buy an apartment building from builders Lujatalo constructed in Skanssi  Turku. The eight-storey building at the address Sorakatu 9 will have 77 new rental homes. This is the first time in five years that SATO is investing in new homes in the city. Construction started in August and the homes will be move-in ready in late October 2023.SATO is developing 257 new rental homes in the Finnoo district of Espoo  close to the new metro station. Construction started in August 2022 and the homes will be completed in stages during autumn 2024. Peijinkuja project is grounded in long-running development efforts where  together with the City of Espoo  we drafted a new local detailed plan for the terraced house property owned by SATO in the old Hannus area of detached houses that is now on its way to become the new Finnoo district of Espoo.In September  we published our Sustainability Programme for 2023âˆ’2026. The programme is themed on sustainable housing  wellbeing in communities and sustainable profitability. We aim to be a forerunner in sustainable rental housing. SATOâ€™s new Sustainability Programme is based on an analysis  conducted with stakeholders  of the elements of sustainability that are perceived to be the most important. The Sustainability Programme and its targets will serve as guidance in both day-to-day decision-making and more long-term development efforts.I would like to thank SATO employees for their great work to develop customer satisfaction and the housing comfort of our residents.Story continuesOperating environmentOver the reporting period  SATOâ€™s operating environment was affected by the war in Ukraine  the constant rise in costs and  particularly in the Helsinki Metropolitan Area  the continued high level of rental housing supply.Russiaâ€™s attack on Ukraine that started in February is still continuing and has made the economic outlook increasingly uncertain and accelerated inflation. Exceptionally high inflation has forced central banks to respond to the situation by making rapid interest rate hikes. In September  the European Central Bank (ECB) raised the key interest rates by 75 basis points to 1.25%. The previous hike took place in July and was 50 basis points. The war in Ukraine and the resulting uncertainty is eroding consumer confidence. Consumer confidence has remained at a very low level already since the spring and is dampening private consumption.In particular the surge in energy and food prices coinciding with climbing interest rates will reverse economic growth towards the end of the year. According to the Bank of Finland forecast of 15 September 2022  Finlandâ€™s economy is projected to grow by 2.2% this year following a robust start to the current year but then decline to 0.3% next year. The outlook is highly uncertain  but the forecast anticipates that the upward trend in prices will subside in late 2023 and the economy will resume slow growth in 2024.The record-high rate of construction seen for a long period of time will slow due to the economic uncertainty. Sales volumes of both new and old homes have decreased. Statistics published by the Federation of Real Estate Agency in August show a decrease in sales volumes of new and old homes compared with the figures reported for the spring and early summer. The figure was down by 21% compared with July 2021. According to data released by Statistics Finland in August  there was a 35% year-on-year decrease in building permits granted and a 12% year-on-year decrease in building projects started in Q2 of 2022. The number of residential units to be completed  particularly in the Helsinki Metropolitan Area  will  however  remain at a high level during the rest of 2022 as well as throughout 2023  maintaining intense competition for tenants.Despite the economic uncertainty  there is demand for rental homes and the urbanisation trend continues. Dense urban housing with good access to public transport is becoming increasingly popular in Finland. The Helsinki Metropolitan Area (HMA)  Tampere and Turku continue to enjoy strong growth  while at the same time Statistics Finland forecasts a downturn in the nationwide population trend in 2031. The HMA is projected to grow by more than 200 000 new residents by 2040. Almost 80% of HMA residents already live in households with one to two members  and the proportion of small households continues to grow. The proportion of immigrants is projected to increase in the HMA from the current 17% to 25% by 2030. The ageing population is moving to growth centres providing access to services and expects more and more housing-related services.The demographic change and the price development of owner-occupied homes create a stable foundation for rental housing demand  especially in the HMA  Tampere and Turku. Outside growth centres  the real prices of homes are declining  which makes home ownership in a growth centre even more challenging for people coming from those areas.REVIEW PERIOD 1 JANUARY TO 30 SEPTEMBER 2022 (1 JANUARY TO 30 SEPTEMBER 2021)Net sales and profitIn Januaryâ€“September 2022  SATO Corporationâ€™s consolidated net sales totalled EUR 219.8 million (223.2).Operating profit was EUR 217.0 million (245.4). Operating profit without the change in the fair value of investment properties was EUR 173.8 million (130.9). The unrealised change in fair value through profit or loss was EUR 43.2 million (114 4).Net financing expenses totalled EUR -34.1 million (-33.7).Profit before taxes was EUR 182.9 million (211.7). Cash earnings (free cash flow after taxes excluding changes in fair value) in Januaryâ€“September amounted to EUR 116.3 million (74.7).Earnings per share were EUR 2.58 (2.99).Financial position and financingThe consolidated balance sheet total at the end of September was EUR 5 226.0 million (5 070.8). Equity totalled EUR 2 507.4 million (2 310.7). Equity per share was EUR 44.29 (40.82).The Groupâ€™s equity ratio at the end of September was 48.0% (45.6). EUR 0.0 million in new long-term financing was drawn and the solvency ratio at the end of September was 40.0% (42.6).The Groupâ€™s annualised return on equity was 8.0% (10.1). Return on invested capital was 6.3% (7.3).Interest-bearing liabilities at the end of September totalled EUR 2 143.3 million (2 169.1)  of which loans on market terms amounted to EUR 1 987.7 million (1 976.9). The average loan interest rate was 1.8% (1.7). Net financing costs totalled EUR -34.1 million (-33.7).The calculated impact of changes in the market value of interest hedging on equity was EUR 46.2 million (10.9).The proportion of loans without asset-based securities was 87.3% (86.2) of all loans. At the end of September  unencumbered assets accounted for 88.9% of total assets (87.5).Housing businessOur housing business includes rental activities  customer service  lifecycle management and maintenance. Effective rental activities and digital services provide home-seekers with quick access to a home  and the Group with a steadily increasing cash flow. High-quality maintenance operations ensure the comfort of residents and that the apartments stay in good condition and maintain their value. We serve our customers in daily housing issues through our customer-oriented service organisation.Rental income was EUR 219.8 million (223.2). On average  the economic occupancy rate of apartments in Finland was 95.1% (94.7) and the external tenant turnover 28.4% (31.6).At the end of the reporting period  the average monthly rent of SATO rental homes in Finland was EUR 17.80 per m2(17.46).Net rental income from apartments totalled EUR 152.4 million (157.3).Investment propertiesOn 30 September 2022  SATO owned a total of 24 947 homes (26 594). The reporting period saw the completion of 191 rental homes (41). The number of divested rental apartments and part-ownership apartments redeemed by residents totalled 2 018.Fair valueThe development of the value of rental apartments is a key factor for SATO. Its housing stock is concentrated in areas and apartment sizes which are expected to be the focus  in the long term  of increasing rental apartment demand. The allocation of building repairs is based on life-cycle plans and repair need specifications.At the end of September  the fair value of investment properties came to a total of EUR 5 035.3 million (4 975.4). The change in the value of investment properties  including the rental apartments acquired and divested during the reporting period  was EUR 2.6 million (221.9).At the end of September  the commuting zone of the Helsinki Metropolitan Area accounted for around 87%  Tampere and Turku together made up around 11% and St Petersburg around 2% of the value of apartments.Investments  divestments and property developmentInvestment activities are used to manage the housing portfolio and prepare the ground for growth. Since 2000  SATO has invested more than EUR 3 billion in non-subsidised rental apartments. SATO acquires and builds entire rental buildings and single rental apartments. Property development allows for new investments in rental apartments in Finland. The rental potential and value of rental apartments owned by SATO are developed through renovation activities.Investments in apartments totalled EUR 122.1 million (116.9). The Helsinki Metropolitan Area represented 79% of all investments during the period under review. New apartments accounted for 61% of the total. In addition  on 30 September 2022  there were binding purchase agreements to a total of EUR 150.2 million (120.0) million in Finland.During the reporting period  2 018 (14) rental apartments were divested in Finland. Their total value amounted to EUR 208.8 million (2.8).The book value of the plot reserve owned at the end of September totalled EUR 36.0 million (39.8). The value of new plots acquired by the end of September totalled EUR 9.1 million (15.3).Permitted building volume for around 1 700 homes is being developed for plots in the companyâ€™s housing portfolio. This allows SATO to utilise existing infrastructure  create a denser urban structure and thus bring more customers closer to services and public transport connections.In Finland  191 rental homes (41) and 0 owner-occupied homes (0) and 0 FlexHomes (0) were completed. On 30 September 2022  a total of 1 387 rental homes (1 294) and 0 owner-occupied homes (71) as well as 52 FlexHomes (52) were under construction.A total of EUR 56.1 million (67.6) was spent on repairing apartments and improving their quality.At the end of September  SATO had a total of 522 (531) apartments in St Petersburg. The economic occupancy rate of rental homes in St Petersburg averaged 94.0% (95.6). Investments in Russia commenced in 2007. The last investment decision was made in 2013 and the property was completed in 2016. SATO has made a decision in principle to exit the business in Russia. The company is actively seeking a solution.PersonnelAt the end of September  the Group had a total of 325 employees (289)  of whom 291 (265) had a permanent employment contract. The average number of personnel in Januaryâ€“September was 330 (268).REVIEW PERIOD 1 JULY TO 30 SEPTEMBER 2022 (1 JULY TO 30 SEPTEMBER 2021)Net sales and profitIn Julyâ€“September 2022  SATO Corporationâ€™s consolidated net sales totalled EUR 72.6 million (74.9).Operating profit was EUR 50.2 million (51.4). Operating profit without the change in the fair value of investment properties was EUR 47.3 million (49.0). The unrealised change in fair value through profit or loss was EUR 2.9 million (2.4).Net financing expenses totalled EUR -11.8 (million (-10.9).Profit before taxes was EUR 38.4 million (40.5). Cash earnings (free cash flow after taxes excluding changes in fair value) in Julyâ€“September amounted to EUR 31.7 million (36.2).Earnings per share were EUR 0.54 (0.57).Housing businessOur housing business includes rental activities  customer service  lifecycle management and maintenance. Effective rental activities and digital services provide home-seekers with quick access to a home  and the Group with a steadily increasing cash flow. High-quality maintenance operations ensure the comfort of residents and that the apartments stay in good condition and maintain their value. We serve our customers in daily housing issues through our customer-oriented service organisation.Rental income was EUR 72.6 million (74.9). On average  the economic occupancy rate of apartments in Finland was 95.6% (95.1) and the external tenant turnover 27.7% (30.6).At the end of the reporting period  the average monthly rent of SATO rental homes in Finland was EUR 17.80 per m2 (17.46).Net rental income from apartments totalled EUR 54.0 million (57.3).Investment propertiesOn 30 September 2022  SATO owned a total of 24 947 homes (26 594). The reporting period saw the completion of 0 rental homes (0). The number of divested rental apartments and part-ownership apartments redeemed by residents totalled 3.Fair valueThe development of the value of rental apartments is a key factor for SATO. Its housing stock is concentrated in areas and apartment sizes which are expected to be the focus  in the long term  of increasing rental apartment demand. The allocation of building repairs is based on life-cycle plans and repair need specifications.At the end of September  the fair value of investment properties came to a total of EUR 5 035.3 million (4 975.4). The change in the value of investment properties  including the rental apartments acquired and divested during the reporting period  was EUR 58.6 million (59.0).At the end of September  the commuting zone of the Helsinki Metropolitan Area accounted for around 87%  Tampere and Turku together made up around 11% and St Petersburg around 2%.Investments  divestments and property developmentInvestment activities are used to manage the housing portfolio and prepare the ground for growth. Since 2000  SATO has invested more than EUR 3 billion in non-subsidised rental apartments. SATO acquires and builds entire rental buildings and single rental apartments. Property development allows for new investments in rental apartments in Finland. The rental potential and value of rental apartments owned by SATO are developed through renovation activities.Investments in apartments totalled EUR 53.6 million (57.3). Helsinki Metropolitan Area represented 80% of all investments during the period under review. New apartments accounted for 63% of the total. In addition  on 30 September 2022  there were binding purchase agreements to a total of EUR 150.2 million (120.0).In August  SATO signed a contract under which SATO buys an apartment building from builders Lujatalo constructed in Skanssi  Turku. The eight-storey building at the address Sorakatu 9 will have 77 new rental homes. This is the first time in five years that SATO is investing in new homes in the city. Construction started in August and the homes will be move-in ready in late October 2023.SATO is developing 257 new rental homes in the Finnoo district of Espoo. Construction started in August 2022 and the homes will be completed in stages during autumn 2024.During the reporting period  3 (3) rental apartments were divested in Finland. Their total value amounted to EUR 0.5 million (0.8).The book value of the plot reserve owned at the end of September totalled EUR 36.0 million (39.8). The value of new plots acquired by the end of September totalled EUR 9.1 million (0.0).Permitted building volume for around 1 700 homes is being developed for plots in the companyâ€™s housing portfolio. This allows SATO to utilise existing infrastructure  create a denser urban structure and thus bring more customers closer to services and public transport connections.In Finland  0 rental homes (0) and 0 owner-occupied homes (0) and 0 FlexHomes (0) were completed. On 30 September 2022  a total of 1 387 rental homes (1 294) and 0 owner-occupied homes (71) as well as 52 FlexHomes (52) were under construction.A total of EUR 24.6 million (26.8) was spent on repairing apartments and improving their quality.At the end of September  SATO had a total of 522 (531) apartments in St Petersburg. The economic occupancy rate of rental homes in St Petersburg averaged 93.6% (96.4). Investments in Russia commenced in 2007. The last investment decision was made in 2013 and the property was completed in 2016. SATO has made a decision in principle to exit the business in Russia. The company is actively seeking a solution.PersonnelAt the end of September  the Group had a total of 325 employees (289)  of whom 291 (265) had a permanent employment contract. The average number of personnel in Julyâ€“September was 333 (285).Events after the review periodDue to increased construction  maintenance and financing costs  as well as the moderate rent development due to the competitive situation  SATO will not start new projects for the time being and postpones their start to the future.Short-term risks and uncertaintiesRisk management is used to ensure that risks impacting the companyâ€™s business are identified  managed and monitored. The main risks of SATOâ€™s business are risks related to the business environment and financial risks.The war in Ukraine is a short-term risk affecting the operating environment  the duration and impacts of which on the Finnish economy are difficult to estimate. The warâ€™s biggest impacts have been seen in the prices of energy  food and materials as well as in supply chains. The surge in prices has resulted in a rapid increase in the interest rate level. The increase in energy  food and consumer goods prices may slow economic growth  continue to considerably increase the interest rate level  and have a negative effect on the purchasing power of consumers as well as on their capacity to perform their obligations. Such a decline in the economy or economic activity may have an adverse effect on the financial performance or activities  finance costs or value of SATO-owned properties.The highest risks in apartment rental are to do with cyclical movements and changes in supply and demand. The market risk may push the supply of rental homes higher than their demand. This would result in idle rental housing stock and pressure for rents to level off or fall  especially as regards old housing stock.A decline in the housing market may have a negative effect on the market value of SATOâ€™s housing stock. In line with its refined strategy  SATO has been focusing in its investments on growth centres and on renovating and repairing existing housing stock and  consequently  ensuring the rentability and value development of the apartments.Changes in regulation by the authorities and in legislation and related uncertainty may have a significant impact on the reliability of the investment environment and  consequently  on SATOâ€™s business. SATO monitors and anticipates these changes and also calls attention to what it considers to be negative impacts of regulation.The management of financial risks is steered by the Groupâ€™s treasury policy. Our risk management principles have been defined in the treasury policy adopted by SATOâ€™s Board of Directors. Our most significant financial risks relate to liquidity  refinancing and interest rates. We manage our liquidity and refinancing risks by diversifying the financing sources and maturity of our loan portfolio  and by holding sufficient liquidity reserves in the form of committed credit facilities and other financing commitments. In 2019  the company issued an EUR 1.5 billion Euro Medium Term Notes (EMTN) Programme  under which SATO has issued bonds in the total amount of EUR 1 050.0 million.The means for managing liquidity risk at SATO include cash assets  a bank account limit  EUR 700 million in committed credit facilities and a EUR 400 million commercial paper programme. We increase the amount of reserves as the funding requirements grow. Our objective is to keep the liquidity requirements of the next 12 months covered by committed agreements.Floating rate loans represent an interest rate risk which we manage by balancing the share of fixed and floating rate loans either by fixed rate debt arrangements or interest rate derivatives. In accordance with our treasury policy  our aim is for fixed-rate loans  including interest rate derivatives  to account for more than 60% of our debt portfolio.SATO currently has 522 apartments in St Petersburg. Investments in Russia commenced in 2007. The last investment decision was made in 2013 and the property was completed in 2016. SATO has made a decision in principle to exit the business in Russia. Following the start of the war in Ukraine  the company has looked into opportunities to exit the business in Russia. According to the explorations  a speedy exit has not been possible  which is why SATO will continue to rent out the homes in St Petersburg for the time being until an exit method is found. The company is actively seeking a solution. There are risks related to the business environment in our St Petersburg operations  including currency risk. The consolidation of foreign currency-denominated assets in the consolidated financial statements also involves a translation risk  with related hedging options examined in accordance with our treasury policy. It is expected that the operating environment in Russia will be highly uncertain for a long period of time and could result in disruptions to SATO's business activities in Russia and with parties related to business in Russia. It may impact the ability of SATO to make payments to its suppliers  employees and authorities as well as receive payments from its customers  which could  therefore  have a material adverse effect on SATO's business in Russia and even result in SATO limiting or ceasing its operations in Russia and with parties related to Russia for a long period of time. Should the war in Ukraine be prolonged  carrying out business in Russia may have negative impacts on the companyâ€™s reputation and may hamper business in Finland or have adverse effects on the companyâ€™s ability to access finance in the market  which may have an adverse effect on the financial performance or activities  financial costs or value of SATO-owned properties.For a broader description of risks and risk management  see the Groupâ€™s website and Annual Report for 2021 at www.sato.fi/en.OutlookIn the operating environment  SATOâ€™s business activities are mainly affected by consumer confidence  development of purchasing power  rent and price development for apartments  competitive situation and interest rate level.Russiaâ€™s attack on Ukraine that started in February is still continuing and has made the economic outlook increasingly uncertain and accelerated inflation. Exceptionally high inflation has forced central banks to respond to the situation by making rapid interest rate hikes. In September  the European Central Bank (ECB) raised the key interest rates by 75 basis points to 1.25%. The previous hike took place in July and was 50 basis points. The war in Ukraine and the resulting uncertainty is eroding consumer confidence. Consumer confidence has remained at a very low level already since the spring and is dampening private consumption.In particular the surge in energy and food prices coinciding with climbing interest rates will reverse economic growth towards the end of the year. According to the Bank of Finland forecast of 15 September 2022  Finlandâ€™s economy is projected to grow by 2.2% this year following a robust start to the current year but then decline to 0.3% next year. The outlook is highly uncertain  but the forecast anticipates that the upward trend in prices will subside in late 2023 and the economy will resume slow growth in 2024.The surge in energy prices has a direct impact on the companyâ€™s profitability  as it is currently not possible to transfer costs in full directly to rents due to the intense competitive situation.The record-high rate of construction seen for a long period of time will slow due to the economic uncertainty. Sales volumes of both new and old homes have decreased. Statistics published by the Federation of Real Estate Agency in August show a decrease in sales volumes of new and old homes compared with the figures reported for the spring and early summer. The figure was down by 21% compared with July 2021. According to data released by Statistics Finland in August  there was a 35% year-on-year decrease in building permits granted and a 12% year-on-year decrease in building projects started in Q2 of 2022. The number of residential units to be completed  particularly in the Helsinki Metropolitan Area  will  however  remain at a high level during the rest of 2022 as well as throughout 2023  maintaining intense competition for tenants. The improved service-sector employment rate and the resumption of contact teaching in upper secondary education have resulted in demand for rental homes picking up  which is reflected in an improved occupancy rate. The economic uncertainty  pressure for interest rate hikes and increases in consumer prices have also been in part reflected in increased demand for rental homes.The continued high level of housing supply particularly in the Helsinki Metropolitan Area has maintained intense competition for good tenants and was reflected over the period under review in SATOâ€™s business as a slight decrease in average rents year on year. With greater choice available for those looking for a home  the role of a successful customer experience has become even more important. SATO is strongly invested in increasing its presence close to customers and in digital services.SATO Corporationâ€™s shareholders on 30 September 2022Largest shareholders and their holdingsno. of shares % Balder Finska Otas AB (Fastighets AB Balder) 31 971 535 56.3%Stichting Depositary APG Strategic Real Estate Pool 12 811 647 22.6%Elo Mutual Pension Insurance Company 7 233 081 12.7%State Pension Fund of Finland 2 796 200 4.9%Valkila Erkka 385 000 0.7%SATO Corporation 166 000 0.3%EntelÃ¤ Tuula 159 000 0.3%Heinonen Erkki 146 684 0.3%Tradeka-invest Ltd 126 500 0.2%Others (118 shareholders) 987 420 1.7%On 30 September 2022  SATO had 56 783 067 shares and 127 shareholders registered in the book-entry system. The share turnover rate was 1.55% for the period from 1 January to 30 September 2022.For media enquiries please contact:Antti Aarnio  President and CEO  phone: +358 201 34 4200Markku Honkasalo  CFO  phone: +358 201 34 4226www.sato.fi/enENCLOSURESInterim Report 1 January to 30 September 2022Interim Report presentation 1 January to 30 September 2022DISTRIBUTIONNASDAQ Helsinki Ltd  Euronext Dublin  main media  www.sato.fi/enSATO Corporation is an expert in sustainable rental housing and one of Finlandâ€™s largest rental housing providers. SATO owns around 25 000 rental homes in the Helsinki Metropolitan Area  Tampere and Turku.SATO aims to provide an excellent customer experience and a comprehensive range of urban rental housing alternatives with good access to public transport and services. We promote sustainable development and work in open interaction with our stakeholders. SATO invests profitably  sustainably and with a long-term view. We increase the value of our assets through investments  divestments and repairs.In 2021  SATO Groupâ€™s net sales totalled EUR 298.3 million  operating profit EUR 304.5 million and profit before taxes EUR 259.4 million. The value of SATOâ€™s investment properties is around EUR 5 billion. www.sato.fi/enAttachments,neutral,0.02,0.98,0.0,mixed,0.34,0.14,0.51,True,English,"['SATO Corporation Interim Report', 'Positive occupancy rate growth', 'January', '30 September', 'new local detailed plan', 'CEO Antti Aarnio', 'upper secondary education', 'higher consumer prices', 'Helsinki Metropolitan Area', '24/7 digital services', 'running development efforts', 'terraced house property', 'old Hannus area', 'long-term development efforts', 'new metro station', 'service-sector employment rate', 'continued high level', 'successful customer experience', 'new housing production', 'higher occupancy rate', 'Net rental income', 'rental housing supply', 'increasing maintenance costs', 'economic occupancy rate', 'new Finnoo district', 'new rental homes', 'The Sustainability Programme', 'new Sustainability Programme', 'sustainable rental housing', 'new homes', 'sustainable housing', '19 2 rental apartments', '1, 387 rental apartments', '1 rental apartments', 'Net sales', 'customer satisfaction', 'economic outlook', 'Housing investments', 'housing comfort', 'sustainable profitability', 'high inflation', '0 Flex Homes', 'Interim Report', 'unrealised change', 'fair value', 'investment properties', '0 owner-occupied apartments', 'first time', 'five years', 'early months', 'service consumption', 'consequent improvement', 'contact teaching', 'Economic uncertainty', 'interest rates', 'rising demand', 'intense competition', 'good tenants', 'competitive situation', 'apartment rents', 'home growing', 'important role', 'apartment building', 'builders Lujatalo', 'eight-storey building', 'Peijinkuja project', 'detached houses', 'great work', 'Operating environment', 'constant rise', 'Skanssi district', 'reporting period', 'late October', 'day decision-making', 'SATO Oyj', 'SATO Corporation', 'SATO employees', 'review period', 'Summary', '1 January', '30 September', 'Finland', 'taxes', 'result', 'capital', 'end', 'Return', 'Equity', 'share', 'Earnings', 'total', '52 FlexHomes', 'construction', 'Turku', 'city', 'market', '1 July', 'EUR', 'President', 'growth', 'full', 'choice', 'available', 'operations', 'presence', 'customers', 'August', 'contract', 'address', 'Sorakatu', 'Espoo', 'stages', 'autumn', 'way', 'wellbeing', 'communities', 'forerunner', 'analysis', 'stakeholders', 'elements', 'targets', 'guidance', 'residents', 'Story', 'war', 'Ukraine', 'Russia', 'attack', 'February', '9:00', '1,294']",2022-10-28,2022-10-28,finance.yahoo.com
12325,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/28/2543530/0/en/BGHL-GBP-NAV-s.html,BGHL (GBP): NAV(s),BOUSSARD & GAVAUDAN HOLDING LIMITED   Ordinary Shares  The Directors of Boussard & Gavaudan Holding...,"BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 27 Oct 2022.Estimated NAVEuro Shares Sterling Shares Estimated NAV â‚¬ 28.1670 Â£ 24.7017 Estimated MTD return -0.30 % -0.18 % Estimated YTD return -3.54 % -2.38 % Estimated ITD return 181.67 % 147.02 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close â‚¬ 22.20 N/A Premium/discount to estimated NAV -21.18 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 2 000.00 Premium/discount to estimated NAV N/A -19.03 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 315 188 130 254 Held in treasury 1 400 N/A Shares Issued 12 316 588 130 254Estimated BG Fund NAVClass B Euro Shares (estimated) â‚¬ 245.8942 Class GBP A Shares (estimated) Â£ 131.7642The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.For further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.0,1.0,0.0,negative,0.0,0.23,0.77,True,English,"['BGHL', 'GBP', 'NAV', 'GAVAUDAN HOLDING LIMITED Ordinary Shares', 'The Class B Euro Shares', 'BGHL Ordinary Shares Euro Shares', 'A Liquidity Enhancement Agreement', 'Class GBP A Shares', 'Euro Shares Sterling Shares', 'London Stock Exchange plc', 'Guernsey Financial Services Commission', 'Dutch Financial Supervision Act', 'N/A Sterling Shares Amsterdam', 'A N/A Average Price', 'US Investment Company Act', 'Euro Shares Amsterdam', 'Sterling Shares Shares', 'A N/A Range', 'expert financial advice', 'Guernsey Policy Council', 'collective investment scheme', 'other professional advice', 'BG Fund ICAV', 'Gavaudan Investment Management', 'closed-ended investment company', 'UK Listing Authority', 'US Securities Act', 'investment manager fees', 'BG Fund NAV', '1,400 N/A Shares', 'The Shares', 'Dutch Authority', 'Emmanuel Gavaudan', 'N/A GBX', 'Euronext Amsterdam', 'US persons', 'Financial Markets', 'The Directors', 'The Company', 'investment performance', 'original investment', 'investment decision', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'United States', 'following information', 'information purposes', 'necessary approval', 'main market', 'future results', 'listed securities', 'Market information', 'BOUSSARD', 'business', 'Oct', 'returns', 'AEX', 'LSE', 'Transactions', 'treasury', 'Number', 'respect', 'role', 'LLP.', 'Email', 'article', 'conjunction', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2022-10-28,2022-10-28,globenewswire.com
12326,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/28/2543529/0/en/BGHL-EUR-NAV-s.html,BGHL (EUR): NAV(s),BOUSSARD & GAVAUDAN HOLDING LIMITED   Ordinary Shares  The Directors of Boussard & Gavaudan Holding...,"BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 27 Oct 2022.Estimated NAVEuro Shares Sterling Shares Estimated NAV â‚¬ 28.1670 Â£ 24.7017 Estimated MTD return -0.30 % -0.18 % Estimated YTD return -3.54 % -2.38 % Estimated ITD return 181.67 % 147.02 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close â‚¬ 22.20 N/A Premium/discount to estimated NAV -21.18 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 2 000.00 Premium/discount to estimated NAV N/A -19.03 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 315 188 130 254 Held in treasury 1 400 N/A Shares Issued 12 316 588 130 254Estimated BG Fund NAVClass B Euro Shares (estimated) â‚¬ 245.8942 Class GBP A Shares (estimated) Â£ 131.7642The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.For further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.0,1.0,0.0,negative,0.0,0.23,0.77,True,English,"['BGHL', 'EUR', 'NAV', 'GAVAUDAN HOLDING LIMITED Ordinary Shares', 'The Class B Euro Shares', 'BGHL Ordinary Shares Euro Shares', 'A Liquidity Enhancement Agreement', 'Class GBP A Shares', 'Euro Shares Sterling Shares', 'London Stock Exchange plc', 'Guernsey Financial Services Commission', 'Dutch Financial Supervision Act', 'N/A Sterling Shares Amsterdam', 'A N/A Average Price', 'US Investment Company Act', 'Euro Shares Amsterdam', 'Sterling Shares Shares', 'A N/A Range', 'expert financial advice', 'Guernsey Policy Council', 'collective investment scheme', 'other professional advice', 'BG Fund ICAV', 'Gavaudan Investment Management', 'closed-ended investment company', 'UK Listing Authority', 'US Securities Act', 'investment manager fees', 'BG Fund NAV', '1,400 N/A Shares', 'The Shares', 'Dutch Authority', 'Emmanuel Gavaudan', 'N/A GBX', 'Euronext Amsterdam', 'US persons', 'Financial Markets', 'The Directors', 'The Company', 'investment performance', 'original investment', 'investment decision', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'United States', 'following information', 'information purposes', 'necessary approval', 'main market', 'future results', 'listed securities', 'Market information', 'BOUSSARD', 'business', 'Oct', 'returns', 'AEX', 'LSE', 'Transactions', 'treasury', 'Number', 'respect', 'role', 'LLP.', 'Email', 'article', 'conjunction', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2022-10-28,2022-10-28,globenewswire.com
12327,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/28/2543520/0/en/Signify-reports-third-quarter-sales-of-EUR-1-9-billion-comparable-sales-growth-of-4-3-and-an-operational-profitability-of-10-4.html,Signify reports third quarter sales of EUR 1.9 billion  comparable sales growth of 4.3% and an operational profitability of 10.4%,Press Release   October 28  2022  Signify reports third quarter sales of EUR 1.9 billion  comparable sales growth of 4.3% and an operational...,Press ReleaseOctober 28  2022Signify reports third quarter sales of EUR 1.9 billion  comparable sales growth of 4.3% and an operational profitability of 10.4%Third quarter 20221Signify's installed base of connected light points increased from 103 million in Q2 22 to 109 million in Q3 22Sales of EUR 1 912 million; nominal sales increase of 16.3% and CSG of 4.3%LED-based sales represented 83% of total sales (Q3 21: 83%)Adj. EBITA margin of 10.4% (Q3 21: 11.1%)Net income of EUR 112 million (Q3 21: EUR 94 million)Free cash flow of EUR 135 million (Q3 21: EUR 85 million)Net debt/EBITDA ratio of 1.5x (Q3 21: 1.8x)Eindhoven  the Netherlands â€“ Signify (Euronext: LIGHT)  the world leader in lighting  today announced the companyâ€™s third quarter 2022 results.â€œIn the third quarter  we delivered solid topline growth in an increasingly volatile environment. The strong performance of our professional business compensated lower consumer demand and the continued slowdown in China. We managed to improve profitability compared to the second quarter despite the impact of energy costs and currency movements. As expected  our free cash flow generation strengthened  driven by improved profitability and the stabilization of our working capital. Given the uncertain near-term outlook  the continued softness of the consumer segment and of the Chinese market  we now expect to achieve comparable sales growth between 2% and 3% for the full year 2022. Regarding the adjusted EBITA margin and free cash flow  we are targeting the lower end of both guidance ranges â€ said CEO Eric Rondolat.â€œAs we enter the final quarter of 2022  we have shifted gears to adapt the company to a structurally weaker external environment in the coming quarters  when current headwinds and volatility are likely to persist. We will therefore focus on measures to control costs and cash flow  in line with our track record of delivering margin expansion and strong free cash flow generation in difficult environments. While some areas will be more affected  connected energy efficient lighting solutions will continue to benefit from strong demand given the energy prices surge.â€Brighter Lives  Better World 2025In the third quarter of the year  Signify continued to deliver on its Brighter Lives  Better World 2025 sustainability program commitments that contribute to doubling its positive impact on the environment and society.Double the pace of the Paris Agreement:Cumulative carbon reduction over the value chain is on track  mainly driven by energy-efficient and connected LED lightingDouble Circular revenues to 32%:Circular revenues were at 30% and on track. This positive trend is driven by serviceable and circular luminairesDouble Brighter lives revenues to 32%:Brighter lives revenues increased to 28%  mainly driven by the Safety & security and consumer well-being portfoliosDouble the percentage of women in leadership positions to 34%:The percentage of women in leadership positions was 27%  stable with Q2. Signify continued to create action plans to address gaps and accelerate its progress. In addition  Signify published its first-ever Diversity  Equity  and Inclusion report.OutlookGiven the uncertain near-term outlook and the continued softness both of the consumer segment and of the Chinese market  we now expect to achieve comparable sales growth between 2% and 3% for the full year 2022. We are targeting the lower end of the range for both the 11.0-11.4% Adjusted EBITA margin guidance and the 5-7% free cash flow guidance.Financial reviewThird quarter Nine months 2021 2022 change in millions of EUR  except percentages 2021 2022 change 4.3 % Comparable sales growth 5.3 % 8.1 % Effects of currency movements 6.6 % 4.0 % Consolidation and other changes 2.2 % 1 643 1 912 16.3 % Sales 4 852 5 536 14.1 % 634 713 12.6 % Adjusted gross margin 1 909 2 072 8.6 % 38.6% 37.3% Adj. gross margin (as % of sales) 39.3% 37.4% -415 -471 Adj. SG&A expenses -1 262 -1 392 -68 -75 Adj. R&D expenses -210 -219 -483 -546 -13.0 % Adj. indirect costs -1 473 -1 611 -9.4 % 29.4% 28.6% Adj. indirect costs (as % of sales) 30.4% 29.1% 182 199 9.1 % Adjusted EBITA 530 560 5.8 % 11.1% 10.4% Adjusted EBITA margin 10.9% 10.1% -34 -6 Adjusted items -130 118 149 193 29.7 % EBITA 399 678 69.9 % 118 161 36.3 % Income from operations (EBIT) 309 582 88.5 % -4 -17 Net financial income/expense -20 -12 -20 -32 Income tax expense -52 -123 94 112 18.4 % Net income 236 447 89.0 % 85 135 Free cash flow 357 81 0.72 0.86 Basic EPS (â‚¬) 1.84 3.52 37 069 34 273 Employees (FTE) 37 069 34 273Third quarterSales increased by 16.3% to EUR 1 912 million  with a comparable sales growth of 4.3%  as continued strength in the professional channel more than offset weaker consumer channel sales. Nominal sales included a positive currency effect of 8.1%  mainly from the appreciation of the USD  and a positive effect of 4.0% from the Q2 acquisitions of Fluence and Pierlite.The Adjusted gross margin decreased by 130 bps to 37.3%. While continued price increases more than offset the input cost increases and the surge in energy costs  the Adjusted gross margin was impacted by an adverse currency effect. Adjusted indirect costs as a percentage of sales decreased by 80 bps to 28.6%  driven by operating leverage and strengthened cost discipline.Adjusted EBITA was EUR 199 million  up 9.1% vs. Q3 2021. The Adjusted EBITA margin decreased by 70 bps to 10.4%  with price increases more than offsetting higher input costs. Yet  the Adjusted EBITA margin was negatively affected by a 220bps currency effect  being the combination both from the weakening of the EUR versus the USD and CNY  and from a temporary FX hedging headwind. Excluding this temporary adverse hedging effect  the Adjusted EBITA margin was stable vs Q3 21.Adjusted items were EUR -6 million. Restructuring costs decreased year on year to EUR -6 million  while acquisition-related charges of EUR -10 million were fully compensated by incidental items of EUR 10 million. The incidental items benefited from a release of tax indemnification liabilities. Net income increased by 18.4% from EUR 94 million to EUR 112 million.The number of employees (FTE) decreased from 37 069 at the end of Q3 21 to 34 273 at the end of Q3 22. The employee base was exceptionally high in Q3 21  due to the strong volume recovery and additional staff requirements in factories  following the peak of the COVID-19 pandemic. The number of FTEs is affected by fluctuations in volume and seasonality.1 This press release contains certain non-IFRS financial measures and ratios  such as comparable sales growth  EBITA  adjusted EBITA and free cash flow  and related ratios  which are not recognized measures of financial performance or liquidity under IFRS. For a reconciliation of these non-IFRS financial measures to the most directly comparable IFRS financial measures  see appendix B  Reconciliation of non-IFRS financial measures  of this press release.For the full and original version of the press release click hereFor the presentation click hereConference call and audio webcastEric Rondolat (CEO) and Javier van Engelen (CFO) will host a conference call for analysts and institutional investors at 9:00 a.m. CET to discuss the third quarter 2022 results. A live audio webcast of the conference call will be available via the Investor Relations website .Financial calendar 2023January 27  2023 Fourth quarter and full-year results 2022February 28  2023 Annual Report 2022For further information  please contact:Signify Investor RelationsThelke GerdesTel: +31 6 1801 7131E-mail: thelke.gerdes@signify.comSignify Corporate CommunicationsLeanne CarmodyTel: +31 6 3928 0201E-mail: leanne.carmody@signify.comAbigail LeveneTel: +31 6 2939 3895E-mail: abigail.levene@signify.comAbout SignifySignify (Euronext: LIGHT) is the world leader in lighting for professionals and consumers and lighting for the Internet of Things. Our Philips products  Interact connected lighting systems and data-enabled services  deliver business value and transform life in homes  buildings and public spaces. In 2021  we had sales of EUR 6.9 billion  approximately 37 000 employees and a presence in over 70 countries. We unlock the extraordinary potential of light for brighter lives and a better world. We achieved carbon neutrality in 2020  have been in the Dow Jones Sustainability World Index since our IPO for five consecutive years and were named Industry Leader in 2017   2018 and 2019 . News from Signify is located at the Newsroom   Twitter   LinkedIn and Instagram . Information for investors can be found on the Investor Relations page.Important InformationForward-Looking Statements and Risks & UncertaintiesThis document and the related oral presentation contain  and responses to questions following the presentation may contain  forward-looking statements that reflect the intentions  beliefs or current expectations and projections of Signify N.V. (the â€œCompanyâ€  and together with its subsidiaries  the â€œGroupâ€)  including statements regarding strategy  estimates of sales growth and future operational results.By their nature  these statements involve risks and uncertainties facing the Company and its Group companies  and a number of important factors could cause actual results or outcomes to differ materially from those expressed in any forward-looking statement as a result of risks and uncertainties. Such risks  uncertainties and other important factors include but are not limited to: adverse economic and political developments  in particular the impacts of the Russia-Ukraine conflict  the energy crisis in Europe  the impacts of COVID-19  supply chain constraints  component shortages  cost inflation  rapid technological change  competition in the general lighting market  development of lighting systems and services  successful implementation of business transformation programs  impact of acquisitions and other transactions  reputational and adverse effects on business due to activities in Environment  Health & Safety  compliance risks  ability to attract and retain talented personnel  adverse currency effects  pension liabilities  and exposure to international tax laws.Additional risks currently not known to the Group or that the Group has not considered material as of the date of this document could also prove to be important and may have a material adverse effect on the business  results of operations  financial condition and prospects of the Group or could cause the forward-looking events discussed in this document not to occur. The Group undertakes no duty to and will not necessarily update any of the forward-looking statements in light of new information or future events  except to the extent required by applicable law.Market and Industry InformationAll references to market share  market data  industry statistics and industry forecasts in this document consist of estimates compiled by industry professionals  competitors  organizations or analysts  of publicly available information or of the Groupâ€™s own assessment of its sales and markets. Rankings are based on sales unless otherwise stated.Non-IFRS Financial MeasuresCertain parts of this document contain non-IFRS financial measures and ratios  such as comparable sales growth  adjusted gross margin  EBITA  adjusted EBITA  and free cash flow  and other related ratios  which are not recognized measures of financial performance or liquidity under IFRS. The non-IFRS financial measures presented are measures used by management to monitor the underlying performance of the Groupâ€™s business and operations and  accordingly  they have not been audited nor reviewed. Not all companies calculate non-IFRS financial measures in the same manner or on a consistent basis and these measures and ratios may not be comparable to measures used by other companies under the same or similar names. A reconciliation of these non-IFRS financial measures to the most directly comparable IFRS financial measures is contained in this document. For further information on non-IFRS financial measures  see â€œChapter 18 Reconciliation of non-IFRS measuresâ€ in the Annual Report 2021.PresentationAll amounts are in millions of euros unless otherwise stated. Due to rounding  amounts may not add up to totals provided. All reported data are unaudited. Unless otherwise indicated  financial information has been prepared in accordance with the accounting policies as stated in the Annual Report 2021 and the Semi-Annual Report 2022.Market Abuse RegulationThis press release contains information within the meaning of Article 7(1) of the EU Market Abuse Regulation.,neutral,0.01,0.99,0.0,mixed,0.7,0.18,0.12,True,English,"['third quarter sales', 'comparable sales growth', 'operational profitability', 'Signify', 'Brighter Lives, Better World 2025 sustainability program commitments', '5-7% free cash flow guidance', 'connected energy efficient lighting solutions', '11.0-11.4% Adjusted EBITA margin guidance', 'strong free cash flow generation', 'Third quarter Nine months', 'weaker consumer channel sales', 'Double Brighter lives', 'Brighter lives revenues', 'connected LED lighting', 'solid topline growth', 'CEO Eric Rondolat', 'Cumulative carbon reduction', 'SG&A expenses', 'R&D expenses', 'input cost increase', 'consumer well-being portfolios', 'connected light points', 'Net debt/EBITDA ratio', 'weaker external environment', 'uncertain near-term outlook', 'comparable sales growth', 'third quarter 2022 results', 'nominal sales increase', 'lower consumer demand', 'Double Circular revenues', 'third quarter sales', 'Net financial income', 'Income tax expense', 'positive currency effect', 'Adj. EBITA margin', 'Adj. indirect costs', 'guidance ranges', 'world leader', 'strong demand', 'strong performance', 'energy costs', 'energy prices', 'professional channel', 'consumer segment', 'positive effect', 'Net income', 'margin expansion', 'Financial review', 'gross margin', 'second quarter', 'final quarter', 'currency movements', 'lower end', 'circular luminaires', 'LED-based sales', 'total sales', 'positive trend', 'Press Release', 'installed base', 'volatile environment', 'professional business', 'continued slowdown', 'working capital', 'continued softness', 'Chinese market', 'coming quarters', 'current headwinds', 'difficult environments', 'Paris Agreement', 'value chain', 'leadership positions', 'action plans', 'Inclusion report', 'other changes', 'Basic EPS', 'price increases', 'positive impact', 'full year', 'operational profitability', 'track record', 'Q2 acquisitions', 'Q2.', 'October', 'Signify', 'Q3', 'EUR', 'CSG', 'Eindhoven', 'Netherlands', 'company', 'China', 'stabilization', 'gears', 'volatility', 'measures', 'areas', 'society', 'pace', 'energy-efficient', 'serviceable', 'Safety', 'security', 'percentage', 'women', 'gaps', 'progress', 'addition', 'Diversity', 'Equity', 'millions', 'Effects', 'Consolidation', 'items', 'operations', 'Employees', 'FTE', 'strength', 'appreciation', 'USD', 'Fluence', 'Pierlite', '130']",2022-10-28,2022-10-28,globenewswire.com
12328,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/28/2543570/0/en/Aegon-takes-note-of-equity-issuance-by-a-s-r.html,Aegon takes note of equity issuance by a.s.r.,The Hague  October 28  2022 -Â Aegon has taken note of the issuance of approximately 10% additional shares that a.s.r. announced on October 28  2022  as part of its funding in relation to the transaction to combine a.s.r. with Aegonâ€™s Dutch pension  life and nâ€¦,The Hague  October 28  2022 - Aegon has taken note of the issuance of approximately 10% additional shares that a.s.r. announced on October 28  2022  as part of its funding in relation to the transaction to combine a.s.r. with Aegonâ€™s Dutch pension  life and non-life insurance  banking  and mortgage origination activities.As per the transaction announced yesterday  Aegon will receive a 29.99% strategic shareholding in a.s.r. and cash proceeds upon closing. Commensurate with the increase in the number of a.s.r. shares resulting from the equity issuance  the number of shares that Aegon is expected to receive on closing of the transaction increases by 10% from approximately 57.4 million to approximately 63.3 million.Based on the closing price of a.s.r.â€™s shares on October 26  2022 â€“ the day before announcement of the transaction â€“ this represents an increase in the value of the shareholding of EUR 0.3 billion to EUR 2.7 billion. As a consequence of the adjustment mechanism agreed between parties  the cash proceeds will be reduced by EUR 0.3 billion to EUR 2.2 billion.About AegonAegon is an integrated  diversified  international financial services group. The company offers investment  protection  and retirement solutions  with a strategic focus on three core markets (the United States  the United Kingdom  and the Netherlands)  three growth markets (Spain & Portugal  Brazil  and China)  and one global asset manager. Aegon's purpose of Helping people live their best lives runs through all its activities. As a leading global investor and employer  the company seeks to have a positive impact by addressing critical environmental and societal issues  with a focus on climate change and inclusion & diversity. Aegon is headquartered in The Hague  the Netherlands  and listed on Euronext Amsterdam and the New York Stock Exchange. More information can be found at aegon.com.Contacts Media relations Investor relations Carolien van der Giessen Jan Willem Weidema+31 (0)6 11 95 33 67 +31(0) 70 344 8028 carolien.vandergiessen@aegon.com janwillem.weidema@aegon.comForward-looking statementsThe statements contained in this document that are not historical facts are forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995. The following are words that identify such forward-looking statements: aim  believe  estimate  target  intend  may  expect  anticipate  predict  project  counting on  plan  continue  want  forecast  goal  should  would  could  is confident  will  and similar expressions as they relate to Aegon. These statements may contain information about financial prospects  economic conditions and trends and involve risks and uncertainties. In addition  any statements that refer to sustainability  environmental and social targets  commitments  goals  efforts and expectations and other events or circumstances that are partially dependent on future events are forward-looking statements. These statements are not guarantees of future performance and involve risks  uncertainties and assumptions that are difficult to predict. Aegon undertakes no obligation  and expressly disclaims any duty  to publicly update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements  which merely reflect company expectations at the time of writing. Actual results may differ materially and adversely from expectations conveyed in forward-looking statements due to changes caused by various risks and uncertainties. Such risks and uncertainties include but are not limited to the following:Unexpected delays  difficulties  and expenses in executing against our environmental  climate  diversity and inclusion or other â€œESGâ€ targets  goals and commitments  and changes in laws or regulations affecting us  such as changes in data privacy  environmental  safety and health laws;Changes in general economic and/or governmental conditions  particularly in the United States  the Netherlands and the United Kingdom;Civil unrest  (geo-) political tensions  military action or other instability in a country or geographic region;Changes in the performance of financial markets  including emerging markets  such as with regard to: The frequency and severity of defaults by issuers in Aegonâ€™s fixed income investment portfolios; The effects of corporate bankruptcies and/or accounting restatements on the financial markets and the resulting decline in the value of equity and debt securities Aegon holds; The effects of declining creditworthiness of certain public sector securities and the resulting decline in the value of government exposure that Aegon holds;Changes in the performance of Aegonâ€™s investment portfolio and decline in ratings of Aegonâ€™s counterparties;Lowering of one or more of Aegonâ€™s debt ratings issued by recognized rating organizations and the adverse impact such action may have on Aegonâ€™s ability to raise capital and on its liquidity and financial condition;Lowering of one or more of insurer financial strength ratings of Aegonâ€™s insurance subsidiaries and the adverse impact such action may have on the written premium  policy retention  profitability and liquidity of its insurance subsidiaries;The effect of the European Unionâ€™s Solvency II requirements and other regulations in other jurisdictions affecting the capital Aegon is required to maintain;Changes affecting interest rate levels and continuing low or rapidly changing interest rate levels;Changes affecting currency exchange rates  in particular the EUR/USD and EUR/GBP exchange rates;Changes in the availability of  and costs associated with  liquidity sources such as bank and capital markets funding  as well as conditions in the credit markets in general such as changes in borrower and counterparty creditworthiness;Increasing levels of competition in the United States  the Netherlands  the United Kingdom and emerging markets;Catastrophic events  either manmade or by nature  including by way of example acts of God  acts of terrorism  acts of war and pandemics  could result in material losses and significantly interrupt Aegonâ€™s business;The frequency and severity of insured loss events;Changes affecting longevity  mortality  morbidity  persistence and other factors that may impact the profitability of Aegonâ€™s insurance products;Aegonâ€™s projected results are highly sensitive to complex mathematical models of financial markets  mortality  longevity  and other dynamic systems subject to shocks and unpredictable volatility. Should assumptions to these models later prove incorrect  or should errors in those models escape the controls in place to detect them  future performance will vary from projected results;Reinsurers to whom Aegon has ceded significant underwriting risks may fail to meet their obligations;Changes in customer behavior and public opinion in general related to  among other things  the type of products Aegon sells  including legal  regulatory or commercial necessity to meet changing customer expectations;Customer responsiveness to both new products and distribution channels;As Aegonâ€™s operations support complex transactions and are highly dependent on the proper functioning of information technology  operational risks such as system disruptions or failures  security or data privacy breaches  cyberattacks  human error  failure to safeguard personally identifiable information  changes in operational practices or inadequate controls including with respect to third parties with which we do business may disrupt Aegonâ€™s business  damage its reputation and adversely affect its results of operations  financial condition and cash flows;The impact of acquisitions and divestitures  restructurings  product withdrawals and other unusual items  including Aegonâ€™s ability to integrate acquisitions and to obtain the anticipated results and synergies from acquisitions;Aegonâ€™s failure to achieve anticipated levels of earnings or operational efficiencies  as well as other management initiatives related to cost savings  Cash Capital at Holding  gross financial leverage and free cash flow;Changes in the policies of central banks and/or governments;Litigation or regulatory action that could require Aegon to pay significant damages or change the way Aegon does business;Competitive  legal  regulatory  or tax changes that affect profitability  the distribution cost of or demand for Aegonâ€™s products;Consequences of an actual or potential break-up of the European monetary union in whole or in part  or the exit of the United Kingdom from the European Union and potential consequences if other European Union countries leave the European Union;Changes in laws and regulations  particularly those affecting Aegonâ€™s operationsâ€™ ability to hire and retain key personnel  taxation of Aegon companies  the products Aegon sells  and the attractiveness of certain products to its consumers;Regulatory changes relating to the pensions  investment  and insurance industries in the jurisdictions in which Aegon operates;Standard setting initiatives of supranational standard setting bodies such as the Financial Stability Board and the International Association of Insurance Supervisors or changes to such standards that may have an impact on regional (such as EU)  national or US federal or state level financial regulation or the application thereof to Aegon  including the designation of Aegon by the Financial Stability Board as a Global Systemically Important Insurer (G-SII); andChanges in accounting regulations and policies or a change by Aegon in applying such regulations and policies  voluntarily or otherwise  which may affect Aegonâ€™s reported results  shareholdersâ€™ equity or regulatory capital adequacy levels.Further details of potential risks and uncertainties affecting Aegon are described in its filings with the Netherlands Authority for the Financial Markets and the US Securities and Exchange Commission  including the Annual Report. These forward-looking statements speak only as of the date of this document. Except as required by any applicable law or regulation  Aegon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Aegonâ€™s expectations with regard thereto or any change in events  conditions or circumstances on which any such statement is based.Attachment,neutral,0.01,0.98,0.0,mixed,0.09,0.18,0.73,True,English,"['equity issuance', 's.r', 'Aegon', 'note', 'US Private Securities Litigation Reform Act', 'integrated, diversified, international financial services group', 'New York Stock Exchange', 'Carolien van der Giessen', 'one global asset manager', 'Media relations Investor relations', 'fixed income investment portfolios', 'insurer financial strength ratings', 'a.s.r. shares', 'leading global investor', 'public sector securities', 'Jan Willem Weidema', 'three core markets', 'three growth markets', 'mortgage origination activities', 'other â€œESGâ€ targets', 'debt securities', 'financial markets', 'financial prospects', 'financial condition', 'social targets', 'emerging markets', 'other events', 'other instability', 'debt ratings', 'The Hague', '10% additional shares', 'Dutch pension', 'adjustment mechanism', 'retirement solutions', 'United States', 'United Kingdom', 'best lives', 'positive impact', 'societal issues', 'climate change', 'Euronext Amsterdam', 'historical facts', 'similar expressions', 'future events', 'undue reliance', 'Actual results', 'Unexpected delays', 'data privacy', 'general economic', 'Civil unrest', 'geographic region', 'corporate bankruptcies', 'accounting restatements', 'government exposure', 'rating organizations', 'adverse impact', 'resulting decline', 'Forward-looking statements', '29.99% strategic shareholding', 'cash proceeds', 'strategic focus', 'More information', 'economic conditions', 'various risks', 'Such risks', 'health laws', 'military action', 'closing price', 'critical environmental', 'future performance', 'life insurance', 'equity issuance', 'company expectations', 'Aegon', 'note', 'October', 'part', 'funding', 'transaction', 'banking', 'increase', 'number', 'announcement', 'value', 'consequence', 'protection', 'Netherlands', 'Spain', 'Portugal', 'Brazil', 'China', 'purpose', 'people', 'employer', 'inclusion', 'diversity', 'Contacts', 'vandergiessen', 'document', 'words', 'project', 'plan', 'goal', 'trends', 'uncertainties', 'sustainability', 'commitments', 'efforts', 'circumstances', 'guarantees', 'assumptions', 'obligation', 'duty', 'Readers', 'time', 'writing', 'changes', 'difficulties', 'expenses', 'regulations', 'safety', 'country', 'regard', 'frequency', 'severity', 'defaults', 'issuers', 'effects', 'declining', 'creditworthiness', 'Lowering', 'capital', 'liquidity']",2022-10-28,2022-10-28,globenewswire.com
12329,EuroNext,NewsApi.org,https://finance.yahoo.com/news/chart-industries-reports-2022-third-100100671.html,Chart Industries Reports 2022 Third Quarter Results,ATLANTA  Oct. 28  2022 (GLOBE NEWSWIRE) -- Chart Industries  Inc. (NYSE: GTLS) today reported results for the third quarter ended September 30  2022. Further...,"Chart Industries  Inc.ATLANTA  Oct. 28  2022 (GLOBE NEWSWIRE) -- Chart Industries  Inc. (NYSE: GTLS) today reported results for the third quarter ended September 30  2022. Further details can be found in the supplemental presentation accompanying this release and published in the investor relations section of our website.Record backlog of $2 254.1 million (+104% versus prior year) is our eighth consecutive record backlog quarter  surpassing $2 billion for the first time in our historyRecord sales of $412.1 million (+25.5% versus prior year) including foreign exchange headwinds and project timing movementsRecord reported gross margin of $104.6 million (+39.7% versus prior year) reflected volume  pricing  productivity and cost control actions and resulted in reported gross margin as a percent of sales of 25.4%  the highest since the first quarter of 2021 (adjusted gross margin as a percent of sales of 27.3%)Record reported operating income of $41.7 million (+202.2% versus prior year) contributed to record reported non-diluted earnings per share (â€œEPS)â€ of $1.15 and record adjusted non-diluted EPS of $1.49Reported 10.1% operating income as a percent of sales (adjusted 12.6%) was our highest since the third quarter 2020 and including this quarter has only been achieved four times in ten yearsThird quarter 2022 orders of $729.4 million  including 71 orders each over $1 million  a 108% increase compared to the third quarter 2021Received Full Notice to Proceed (â€œFNTPâ€) on Venture Global Plaquemineâ€™s Phase 2 Big LNG project  resulting in a third quarter order of $91.8 millionInflation Reduction Act of 2022 (â€œIRAâ€) continues to accelerate commercial activity  thereby increasing our estimated total addressable market (â€œTAMâ€) for Specialty Products in the near-term to $9.65 billion (prior was $7.65 billion) and 2030 TAM to $49.25 billion (prior was $42.0 billion)2022 full-year sales guidance range of $1.65 billion to $1.70 billion (prior guidance of $1.725 billion to $1.80 billion); associated 2022 full-year adjusted non-diluted EPS guidance is in the range of $5.00 to $5.25 (prior guidance of $5.20 to 5.60) on 35.87 million shares outstanding (prior 35.86 million shares) and a tax rate of 17% (prior tax rate of 20%)2023 full-year sales outlook range of $2.10 billion to $2.20 billion; associated 2023 full-year adjusted non-diluted EPS outlook is in the range of $7.50 to $8.50 on 35.87 million shares outstanding and a tax rate of 19%Story continuesThird quarter 2022 was all-time record backlog  sales  reported gross margin  reported operating income  reported non-diluted EPS and adjusted non-diluted EPS  amongst numerous other historical records within the business.Our third quarter 2022 orders of $729.4 million (second highest in our history with our top three quarters all occurring in 2022) contributed to our eighth consecutive quarter of record backlog ($2 254.1 million); backlog is 104% higher than one year ago and sequentially 15% higher than the second quarter 2022  which was our highest order quarter in our history. Both Heat Transfer Systems (â€œHTSâ€) and Specialty Products have record backlogs as of the third quarter 2022. Additionally  all three of quarters in 2022 to date have had book-to-bill ratios above 1.8  which is a contributor to our outlook for 2023 sales to grow between 23% and 30% year-over-year over.We posted record sales of $412.1 million (an increase of 25.5% versus prior year) in the quarter  which were negatively impacted by foreign exchange (â€œFXâ€) headwinds primarily in our Cryo Tank Solutions (â€œCTSâ€) segment and as is typical between quarters  project timing movements related to liquefaction projects in Specialty Products. We estimate that foreign exchange headwinds had a $17 million negative impact on sales  with the U.S. dollar appreciating versus the Euro and the Indian Rupee. Note that we do not addback or adjust for foreign exchange impacts in our adjusted EPS. In addition to our total record sales  we set sales records in the quarter for mobile equipment  brazed aluminum heat exchangers  systems  space exploration  L.A. Turbineâ€™s aftermarket and VRV.Third quarter 2022 reported gross margin of $104.6 million was the highest in our history and 39.7% higher than the third quarter 2021  reflecting our increasing positive margin mix  pricing actions taken  productivity and cost control. Reported gross margin as a percent of sales of 25.4% was the highest since the second quarter of 2021  and when adjusted for one-time items including restructuring and start and capacity expansion costs was 27.3%; three of our four segments reported gross margin as a percent of sales increased by more than 170 basis points sequentially compared to the second quarter 2022 with HTS increasing 720 basis points. This contributed to record reported operating income of $41.7 million  an increase of 202.2% compared to the third quarter 2021 and when adjusted for one-time items such as deal-related costs and restructuring  record adjusted operating income of $51.9 million. The third quarter 2022 was only the fourth time in the past decade that we had reported operating income as a percent of sales of 10.1% (adjusted 12.6%). HTS also had record operating income and operating income as a percent of sales in the quarter.Third quarter 2022 reported non-diluted EPS of $1.15 is a historical record and reflects the ongoing efforts of our global flexible manufacturing footprint to optimize â€œwhere we make whatâ€; when adjusted for one-time items primarily related to deal costs  year-one integrations and organic startup & capacity expenses  our adjusted non-diluted EPS is $1.49  also a record. As noted above  we did not addback the negative impact to sales or EPS from FX rate changes and we anticipate that these will continue to be variable in the coming quarters. We estimate the third quarter 2022 impact from the foreign exchange rate changes to be approximately net negative $0.06 to EPS (net of translation and transaction).Macro tailwinds are bolstering demand for multiple solutions in our portfolio; including energy security & access (LNG) and government actions such as the IRA (accelerating activity in Specialty Products).Macro TailwindsEnergy security  resiliency  access and independence continues to be a priority for countries around the world  with meaningful focus on Europe. This has been further heightened as winter nears  as well as the supply-demand linkage of available LNG. It is anticipated that gas demand increases each year globally between now and 2035  and in turn  more LNG supply capacity is anticipated to move to Final Investment Decision (â€œFIDâ€) and construction this decade. Additionally  United States rig count is at pre-pandemic levels  and we are seeing an increase in air cooler equipment sales.As we stated at the end of the second quarter 2022  and we reiterate now  the increase in immediacy for energy security has not come at the expense of the clean energy transition â€“ rather there is a heightened focus on all energy. Additionally  the third quarter 2022 brought further tailwinds to many of the end markets we serve with our Nexus of Cleanâ„¢ - clean power  clean water  clean food and clean industrials. One such tailwind was the passing of the IRA in August 2022  which approved $300 billion in spending for energy and climate change  with multiple areas of the IRA directly supporting investments being made by our customers in hydrogen  carbon capture  water  and industrial manufacturing. And hydrogen is not only limited to commercialization as the result of the IRA â€“ global funding commitments to 2030 now total $240 billion  up approximately 50% from a year ago  and cover the European Union and 22 other countries.In addition to the IRA  CO2 shortage continues to drive global interest in carbon capture solutions from small-scale (Chartâ€™s Earthly Labs small-scale CiCi solution) to large industrial scale (Chartâ€™s SES cryogenic carbon capture solution) and this 30% shortage is expected to continue with further permanent reductions in availability  thereby making CO2 recovery more important to the resolution of this challenge  as well as being a key part of the carbon emission reduction public and private sector targets.In summary  in the $729.4 million of orders booked in the third quarter 2022 there were 71 orders greater than $1 million each  bringing the year-to-date number to 197. Year-to-date through September 30  2022  individual orders each greater than $1 million grew 29.6% compared to the same period in 2021 and is at 87% of the full year 2021.In addition to our commercial pipeline for potential orders in the next 24 months being over $9.5 billion in active  various stage discussions  we have continued to see broad-based demand in October 2022 to start the fourth quarter. Month-to-date as of October 26  2022  we have received 17 orders each greater than $1 million dollars; of these larger orders  the range was wide â€“ from two multi-million dollar space exploration orders to regas to a refurbishment of a cold box  to multiple air cooler orders  to LNG fueling stations to a large bulk tank order for an industrial gas customer and a $3 million water treatment order.LNG  LNG  LNG.As winter approaches  in particular in the European Union  energy security and access are creating new and more imminent LNG opportunities  resulting in the continued increase in the four categories of LNG that we serve:Big LNG: In the third quarter 2022  we received FNTP on the remaining 12 cold box systems for Venture Global Plaquemines Phase 2 LNG export project. The third quarter order totaled $91.8 million  bringing our year-to-date Big LNG related orders to $620.7 million. Additionally  we have seen incremental increases to our potential future Big LNG orders since February 2022  driven by more international interest in modular mid-scale terminals  interest in our heavy hydrocarbon (â€œHHCâ€) removal and nitrogen-rejection unit (â€œNRUâ€) capabilities and more projects intending to move to FID. Currently our â€œnot yet bookedâ€ commercial opportunities for Big LNG total $5.68 billion  inclusive of retrofit; this is an increase to our pipeline since the end of the second quarter 2022 of $330 million  even after booking another $91.8 million related to the Venture Global Plaquemines 2 project in the third quarter 2022. Small-scale and floating LNG: We received commitments from three customers for small-scale and floating liquefaction projects in the third quarter  totaling $175 million. Even considering these orders  our commercial pipeline continues to grow for this category of LNG (318 potential projects globally)  with floating LNG opportunities at their all-time high. LNG infrastructure: We sell various equipment into the LNG infrastructure end-market and continue to see demand for fueling stations (12 ordered in the third quarter 2022)  regas systems  and other related tanks and trailers. ISO containers had record demand in the third quarter 2022  with 226 units sold. We had two regas orders in the quarter and growth in our vehicle fueling stations business compared to the third quarter 2021. And while year-to-date 2022 demand for HLNG over-the-road vehicle tanks has been meaningfully weaker than the same period in 2021  we saw a nearly 200% increase sequentially from the second quarter 2022 in these orders. LNG retrofits  refurbishments  repairs: We continue to see orders related to modifications and extensions of regas stations  with orders in the third quarter 2022 from Italgas. Additionally  we are receiving inbound requests for retrofits and refurbishments as well as expansions of brownfield facilities. This trend is expected to continue  in particular as timing of construction of new builds does not address the immediate need for additional gas supply  and numerous customers are looking for long-term lifecycle services more so than previously.IRA accelerating activity in Specialty Products.The IRA in the United States is accelerating activity in our business in key areas that benefit within the IRA  including carbon capture  hydrogen  fuel refueling  water and industrial facilities. We believe that the IRA will accelerate certain investments and purchases from our customers in carbon capture and storage (â€œCCUSâ€)  hydrogen and water in particular. In the third quarter 2022  Specialty Products orders were $202.9 million  our second consecutive quarter with Specialty Products orders above $200 million  and bringing year-to-date to $569.1 million  over 88% of the full year 2021 Specialty Products orders. With seven consecutive quarters having Specialty Products orders greater than $100 million each  the business is proving to be a consistent and increasing contributor to our overall growth.Hydrogen orders of $102.4 million in the third quarter 2022 included a large hydrogen liquefaction order from a North American customer bringing our year-to-date 2022 hydrogen related orders above our full year 2021 of $282.1 million. Additionally  the same customer has signed a letter of intent (not booked as an order or in backlog) with Chart for process and equipment for the additional three phases of the project  each 250 Megawatts  with the same content as the first phase. Also  in the quarter we received a $6.2 million order for hydrogen systems and equipment from a European shipyard  who  with Chart  is working closely with a large European cruise line on a hydrogen powered vessel  a $5.8 million order for two of the first transportable fuel stations for hydrogen fuel cell trucks and liquid hydrogen tank orders for a major industrial gas customerâ€™s liquefaction plant in Europe. Importantly  this is another example of the global adoption of liquid hydrogen (historically Europe was predominantly focused on gaseous hydrogen). While not yet booked  we also received a letter of intent (â€œLOIâ€) from one of our industrial gas customers for a hydrogen liquefaction plant  which we expect could move to order in 2023.We saw meaningfully more inbound interest in our CCUS offering since the IRA was approved than we had prior  including a pipeline of 363 customers and potential customers (+142% since December 31  2021). In our Earthly Labsâ€™ small-scale CCUS business  we successfully installed a CiCi unit at a large winery  shipping our first Earthly Labsâ€™ units to New Zealand  Australia and the United Kingdom early this quarter. Additionally  new inbound opportunities in our small-scale Earthly Labs carbon capture business totaled $9.22 million in the 75 days following the IRA announcement  compared to new opportunities in the 60 days prior to the IRA of $5.56 million. In the third quarter 2022  we booked orders for our SES cryogenic carbon capture solutions (â€œSES CCCâ€) with a customer in Saudi Arabia  as well as with a European energy infrastructure company. We signed 4 Memorandums of Understanding (â€œMOUsâ€) related to CCUS in the third quarter 2022  including one with C.A.T. Group and one with Koch for partnering on CCUS project work. We received an order for a feasibility study with Fluxys  with whom we are excited to collaborate on the application of our SES CCC technology to their emissions sources to support their net zero emissions target.We received $16.7 million in orders for water treatment systems in the third quarter 2022  the second highest in our history  and multiple orders for full treatment solutions  each over $2 million  such as an order from Smith Construction for Madera County  California manganese treatment for drinking water  another from Garney Construction for Brighton  Colorado nitrate treatment for drinking water  and a $4.67 million order in India.We have also been seeing an increase in clean air (methane emission elimination) activity  which also will benefit from the IRA  with $5.6M in orders through Q3 and new commitments equaling that total in the first 3 weeks Q4. And not to be left out  we received record ISO container orders (226) in the quarter  as well as the largest order of the year-to-date in food & beverage for QTâ€™s new convenience Stores. As the result of this continued and consistent order activity as well as the IRA adding more certainty to this decade opportunities  we are increasing our estimated total addressable market in the near-term from $7.7 billion to $9.65 billion for Specialty Products  and to $49.25 billion through 2030 from $42.0 billion.Third quarter 2022: Eight MOUs and partnerships executed  eight new certifications received  79 additional new customer orders  17 new first-of-a-kind (â€œFOAKâ€) orders and expanded organic capacity drive further differentiation of the Chart business.We continue to expand our business globally through partnerships  leading regional certifications in our specialty markets  and utilizing our global manufacturing footprint to serve new customers and new applications with our cryogenic expertise.In the third quarter 2022 we executed eight MOUs of which two included master supply agreements. Four were related to carbon capture and CO2 equipment  and two for hydrogen  and one each for liquefaction and LNG  further demonstrating the breadth of our solution offering and penetration across the Nexus of Cleanâ„¢. One of the master supply agreements was for LNG equipment with Yanchange and Shell Petroleum  while another was with a major beverage company for carbon capture and storage technology and equipment.Our 79 new customers this quarter (bringing year-to-date through third quarter 2022 to 248) were across a broad reach of geographies. 43% of the third quarter 2022 new customers were North American  37% Asia Pacific and approximately 20% were in Europe and the Middle East.FOAK orders of 17 in the third quarter 2022 were also comprised of geographic and application breadth. We kicked off the first feasibility study with Bioveritas for carbon capture with bio-based food ingredients  booked an order with Firefly for a space exploration application  and welcomed new customer PT Arohera in Asia Pacific for food and beverage equipment for their end user  a global food manufacturer.Certifications globally and regionally in cryogenic equipment are a key differentiator  especially in newer end markets that have localized requirements. In the third quarter 2022  we received numerous new certifications (11  not including normal course of business renewals)  including approvals for specific product lines for use in Australia  Canada  and Korea (specifics can be found on slide 21 of the supplemental presentation).Our organic capacity expansions remain on track  and in some cases are ahead of schedule where we were able to accelerate toward completion as demand continues to increase. September 2022 marked the exciting arrival of our brazing furnace at our Tulsa  Oklahoma flexible manufacturing facility. We will begin post brazing in the fourth quarter 2022 at this site  offering additional capacity and shorter lead-times for certain brazed aluminum heat exchangers. Our Goch  Germany trailer facility expansion remains on track for second half 2023 production and is an example of our incorporation of ESG into our manufacturing  with the design including heat pumps with low energy consumption and extra insulation for less energy usage.Margin improvement resulting from our actions taken to respond to cost changes with pricing and surcharges and ongoing improving productivity; despite ongoing macroeconomic inflationary and supply chain challenges.In the third quarter 2022  input costs were similar to the second quarter 2022 (i.e. indexes are stabilizing)  yet with the backdrop of continued geopolitical and inflationary uncertainty. Gas and energy prices are a key driver in component availability and costs  in particular in the EU  and while recent prices have been declining  they are still over five times the 2019 standard price. In the EU  the shortage of supply and the rising energy prices could impact raw material producers  and therefore we have and continue to proactively fortify our supply chain channels both globally and locally to reduce the associated risks. Examples of this include future volume commitments on material and components that are more readily available now  and ensuring that we can access material locally in all geographies in which we manufacture in. Despite the ongoing and well-discussed supply chain challenges  12 of our manufacturing facilities had 100% on-time delivery in the third quarter 2022.Third quarter 2022 reported gross margin as a percent of sales of 25.4% was 27.3% when adjusting for organic startup and capacity  year-one integration and other one-time expenses  our highest gross margin as a percent of sales quarter since the second quarter 2021 and in line with our sequential quarterly anticipated margin improvement  which we expect to continue in the fourth quarter 2022. Reported gross margin as a percent of sales increased more than 200 basis points sequentially in the third quarter 2022 when compared to the second quarter 2022 in three of our four segments  with HTS at 21.6% (an increase of 720 bps sequentially) and RSL at 38.4% (an increase of 410 bps sequentially). CTS reported gross margin as a percent of sales of 18.0% reflected our first quarter of sequential margin improvement in a year  in part driven by the pull in of lower margin backlog to the second quarter 2022. Specialty Products  which typically has volume and mix movements between quarters  had lower than anticipated sales driven by the timing shifts of two projectsâ€™ revenue recognition due to timing of inbound components  which are anticipated to be recognized in the fourth quarter 2022. This project mix shift negatively impacted reported gross margin as a percent of sales for Specialty Products  which was 31.6% for the third quarter 2022. Also impacting the segment was the continued low volume in higher margined HLNG vehicle tanks and one large customer freight revenue which had no associated margin  neither of which are considered adjustments to our adjusted gross profit or adjusted operating profit. We did finalize our year-one integrations for AdEdge and L.A. Turbine  and when adjusting for integration  startup/capacity and restructuring costs in Specialty Products  adjusted gross margin as a percent of sales was 35.6%  similar to the second quarter 2022 adjusted gross margin as a percent of sales of 35.8%.Our reported operating income as a percent of sales in the third quarter 2022 of 10.1% was an increase of 590 basis points compared to the third quarter 2021. It is also worth noting that in the third quarter 2021  we did not include any short-term incentive compensation expense as we were not hitting the threshold. In each quarter of 2022  including the third quarter  we have been booking our short-term incentive costs through SG&A. Therefore  the increase in reported operating income as a percent of sales in the third quarter 2022 compared to the third quarter 2021 is operationally even more significant (an increase of 710 basis points). When adjusted for one-time and unusual items  adjusted operating income as a percent of sales in the third quarter 2022 was 12.6%.â€œThe third quarter of 2022 not only reinforced our customersâ€™ continued broad-based demand for LNG and solutions across our Nexus of Cleanâ„¢ serving power  water  food and industrials  our outlook for 2023 and the coming decade was further bolstered by the passing of the IRA at a macro level and our record backlog  sales  gross profit  operating profit and EPS â€ stated Jill Evanko  Chartâ€™s CEO and President. â€œWe continue to execute our margin expansion activities ranging from pricing to organic productivity  which was reflected in the sequential margin improvement and our anticipated sequential margin expansion in the fourth quarter 2022 and into 2023.â€Free cash flow generation.In the third quarter 2022  we generated $37 million cash from operations  had $18 million of capital expenditures related activity  and $17 million of unusual addback items (including $2 million for escrow payments for Earthly Labs)  resulting in adjusted free cash flow (â€œFCFâ€) of $36 million. This brings year-to-date adjusted FCF to $68 million. Considering the expected timing of larger project milestone payments (over $100 million expected) in the fourth quarter 2022  our full year FCF outlook is approximately $175 million. We accelerated certain capital projects expenditures related to capacity expansions into the third quarter 2022 as we continue to see lead-time and increased demand for deliveries across the next 24 months. Specifically  we pulled ahead capital to accelerate our ability to produce in our expanded roof-covered facility in New Iberia  Louisiana (cold box shop) and certain activities in our Tulsa  Oklahoma flexible manufacturing facility. As of the end of the third quarter 2022  our net leverage ratio is 2.92  and during the quarter we repaid $80M million in borrowings outstanding under our revolving credit facility during the third quarter 2022.2022 Guidance.Our outlook for 2022 for sales is in the range of $1.65 billion to $1.70 billion  with associated adjusted non-diluted EPS in the range of $5.00 to $5.25 on approximately 35.87 million weighted shares outstanding with an assumed tax rate of 17%. The change to our prior sales guidance of $1.725 billion to $1.80 billion is driven by currency headwinds and timing of specific project revenue recognition  which is typical in our business.2023 first outlook with increased confidence driven by record backlog  multiple global tailwinds and customersâ€™ forecasts.Our outlook for 2023 for sales is in a range of $2.10 billion to $2.20 billion  which includes only Big LNG projects that are in backlog as of September 30  2022. Associated adjusted non-diluted EPS is anticipated to be in the range of $7.50 to $8.50 on 35.87 million weighted shares outstanding. This assumes a tax rate of 19%. Note that this outlook does not include any new or additional mid-size or large projects that could come into the order book between now and the end of the first half 2023 which we would anticipate having sales associated with them in the year. If one or more mid or large-size project comes into the order book between now and the end of the first quarter 2023  we would anticipate recognizing between $50 to $75 million dollars more of revenue into the full year.FORWARD-LOOKING STATEMENTSCertain statements made in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning the Companyâ€™s business plans  including statements regarding completed acquisitions  divestitures  and investments  cost synergies and efficiency savings  objectives  future orders  revenues  margins  segment sales mix  earnings or performance  liquidity and cash flow  inventory levels  capital expenditures  supply chain challenges  inflationary pressures including material cost and pricing increases  business trends  clean energy market opportunities including addressable markets and projected industry-wide investments  and governmental initiatives  including executive orders and other information that is not historical in nature. Forward-looking statements may be identified by terminology such as ""may "" ""will "" ""should "" ""could "" ""expects "" ""anticipates "" ""believes "" ""projects "" ""forecasts "" â€œoutlook â€ â€œguidance â€ ""continue "" â€œtarget â€ or the negative of such terms or comparable terminology.Forward-looking statements contained in this press release or in other statements made by the Company are made based on management's expectations and beliefs concerning future events impacting the Company and are subject to uncertainties and factors relating to the Company's operations and business environment  all of which are difficult to predict and many of which are beyond the Company's control  that could cause the Company's actual results to differ materially from those matters expressed or implied by forward-looking statements. Factors that could cause the Companyâ€™s actual results to differ materially from those described in the forward-looking statements include: the Companyâ€™s ability to successfully integrate recent acquisitions and achieve the anticipated revenue  earnings  accretion and other benefits from these acquisitions; slower than anticipated growth and market acceptance of new clean energy product offerings; inability to achieve expected pricing increases or continued supply chain challenges including volatility in raw materials and supply; risks relating to the outbreak and continued uncertainty associated with the coronavirus (COVID-19) and the conflict between Russia and Ukraine  including potential energy shortages in Europe and elsewhere  and the other factors discussed in Item 1A (Risk Factors) in the Companyâ€™s most recent Annual Report on Form 10-K filed with the SEC  which should be reviewed carefully. The Company undertakes no obligation to update or revise any forward-looking statement.USE OF NON-GAAP FINANCIAL INFORMATIONThis press release contains non-GAAP financial information  including adjusted gross profit as a percent of sales  adjusted earnings per non-diluted share  net income attributable to Chart Industries  Inc. adjusted  free cash flow and adjusted free cash flow and adjusted operating income  EBITDA and adjusted EBITDA. For additional information regarding the Company's use of non-GAAP financial information  as well as reconciliations of non-GAAP financial measures to the most directly comparable financial measures calculated and presented in accordance with accounting principles generally accepted in the United States (""GAAP"")  please see the reconciliation pages at the end of this news release and the slides titled ""Third Quarter 2022 Earnings Per Share "" â€œSegment Sales and Operating Margin Information â€ â€œSegment Sales and Gross Margin Information â€ â€œThird Quarter 2022 Free Cash Flowâ€  â€œSegment Informationâ€  and â€œThird Quarter 2022 Adjusted EBITDAâ€ included in the supplemental slides accompanying this release.The Company believes these non-GAAP measures are of interest to investors and facilitate useful period-to-period comparisons of the Companyâ€™s financial results  and this information is used by the Company in evaluating internal performance. With respect to the Companyâ€™s 2022 and 2023 full year earnings outlook  the Company is not able to provide a reconciliation of the adjusted earnings per non-diluted share or adjusted free cash flow because certain items may have not yet occurred or are out of the Companyâ€™s control and/or cannot be reasonably predicted.CONFERENCE CALLAs previously announced  the Company will discuss its third quarter 2022 financial results on a conference call on Friday  October 28  2022 at 8:30 a.m. ET. A live webcast and replay will be available on the Company's investor relations website  ir.chartindustries.com. Participants wishing to join the live Q&A session may request a conference call dial-in number by registering in advance using the following registration link: https://register.vevent.com/register/BI61fabcd99a7b47da8825fae9fe33d636About Chart Industries  Inc.Chart Industries  Inc. is a leading independent global manufacturer of highly engineered equipment servicing multiple applications in the Energy and Industrial Gas markets. Our unique product portfolio is used in every phase of the liquid gas supply chain  including upfront engineering  service and repair. Being at the forefront of the clean energy transition  Chart is a leading provider of technology  equipment and services related to liquefied natural gas  hydrogen  biogas and carbon capture and storage amongst other applications. We are committed to excellence in environmental  social and corporate governance (ESG) issues both for our company as well as our customers. With over 25 global manufacturing locations from the United States to China  Australia  India  Europe and South America  we maintain accountability and transparency to our team members  suppliers  customers and communities. To learn more  visit www.Chartindustries.com.For more information  click here:http://ir.chartindustries.com/Investor Relations Contact:Wade Suki  CFADirector of Investor Relations945-225-6803wade.suki@chartindustries.comCHART INDUSTRIES  INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)(Dollars and shares in millions  except per share amounts)Three Months Ended Nine Months Ended September 30 2022 September 30 2021 June 30 2022 September 30 2022 September 30 2021 Sales $ 412.1 $ 328.3 $ 404.8 $ 1 171.0 $ 938.8 Cost of sales 307.5 253.4 310.0 887.9 696.8 Gross profit 104.6 74.9 94.8 283.1 242.0 Selling  general  and administrative expenses 52.3 51.0 53.5 159.3 145.4 Amortization expense 10.6 10.1 11.7 32.4 28.5 Operating expenses 62.9 61.1 65.2 191.7 173.9 Operating income(1) (2) (3) (4) 41.7 13.8 29.6 91.4 68.1 Interest expense  net 5.7 3.2 4.4 13.3 7.4 Unrealized (gain) loss on investments in equity securities (1.3 ) (10.4 ) 9.6 10.9 (1.2 ) Financing costs amortization 0.7 1.2 0.7 2.1 3.5 Realized gain on equity method investment â€” â€” (0.3 ) (0.3 ) â€” Foreign currency (gain) loss (2.5 ) (0.8 ) (1.7 ) (2.6 ) 0.1 Other (income) expense (0.7 ) (0.6 ) (0.2 ) (1.5 ) â€” Income before income taxes and equity in earnings (loss) of unconsolidated affiliates  net 39.8 21.2 17.1 69.5 58.3 Income tax (benefit) expense (1.6 ) 5.5 3.5 4.0 9.9 Income before equity in earnings (loss) of unconsolidated affiliates  net 41.4 15.7 13.6 65.5 48.4 Equity in earnings (loss) of unconsolidated affiliates  net 0.2 (0.1 ) (0.2 ) (0.3 ) 0.1 Net income(5) 41.6 15.6 13.4 65.2 48.5 Less: Income attributable to noncontrolling interests  net of taxes 0.4 0.7 0.4 0.8 1.5 Net income attributable to Chart Industries  Inc. $ 41.2 $ 14.9 $ 13.0 $ 64.4 $ 47.0 Net income attributable to Chart Industries  Inc. per common share: Basic $ 1.15 $ 0.42 $ 0.36 $ 1.80 $ 1.32 Diluted $ 0.98 $ 0.36 $ 0.31 $ 1.56 $ 1.15 Weighted-average number of common shares outstanding: Basic 35.87 35.62 35.86 35.85 35.59 Diluted(6) (7) 41.86 41.44 41.56 41.40 40.96_______________(1) Includes depreciation expense of:$9.6  $10.3 and $10.0 for the three months ended September 30  2022  September 30  2021 and June 30  2022  respectively  and$30.0 and $31.3 for the nine months ended September 30  2022 and September 30  2021  respectively.(2) Includes restructuring (credits)/costs of:$(1.4)  $1.9  and $0.2 for the three months ended September 30  2022  September 30  2021 and June 30  2022  respectively  and$(1.1) and $2.9 for the nine months ended September 30  2022 and September 30  2021  respectively.(3) Includes acquisition-related contingent consideration (credits)/charges in our Specialty Products segment of:$(1.7)  $0.3  and $(0.2) for the three months ended September 30  2022  September 30  2021 and June 30  2022  respectively  and$(2.7) and $2.3 for the nine months ended September 30  2022 and September 30  2021  respectively.(4) Includes deal-related and integration costs of:$6.7 and $5.1 for the three months ended September 30  2022 and June 30  2022  respectively  and$16.0 for the nine months ended September 30  2022.(5) Includes income taxes and interest expense related to previous divestitures of:$1.2 for the three months ended September 30  2021 and$2.5 for the nine months ended September 30  2021.(6) Includes an additional 5.71 and 5.29 shares related to the convertible notes due 2024 and associated warrants in our diluted earnings per share calculation for the three and nine months ended September 30  2022  respectively. The associated hedge  which helps offset this dilution  cannot be taken into account under U.S. generally accepted accounting principles (â€œGAAPâ€). If the hedge could have been considered  it would have reduced the additional shares by 3.01 and 2.82 for the three and nine months ended September 30  2022  respectively.(7) Includes an additional 5.44 shares related to the convertible notes due 2024 and associated warrants in our diluted earnings per share calculation for the three months ended June 30  2022. The associated hedge  which helps offset this dilution  cannot be taken into account under U.S. GAAP. If the hedge could have been considered  it would have reduced the additional shares by 2.89 for the three months ended June 30  2022.CHART INDUSTRIES  INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)(Dollars in millions)Three Months Ended Nine Months Ended September 30 2022 September 30 2021 June 30 2022 September 30 2022 September 30 2021 Net Cash Provided By (Used In) Operating Activities $ 37.8 $ (13.3 ) $ 34.7 $ 50.3 $ (41.6 ) Investing Activities Acquisition of businesses  net of cash acquired (0.5 ) (114.1 ) (24.5 ) (25.8 ) (169.1 ) Investments (1.0 ) (50.3 ) â€” (4.9 ) (103.2 ) Capital expenditures (18.4 ) (9.8 ) (17.2 ) (48.2 ) (36.5 ) Cash received from settlement of cross-currency swap agreements 5.8 â€” 3.6 9.4 â€” Government grants and other (0.5 ) 0.1 (0.1 ) (0.8 ) 0.4 Net Cash Used In Investing Activities (14.6 ) (174.1 ) (38.2 ) (70.3 ) (308.4 ) Financing Activities Borrowings on revolving credit facility 70.0 220.0 179.3 503.3 644.1 Repayments on revolving credit facility (150.0 ) (129.1 ) (125.3 ) (511.2 ) (321.6 ) Proceeds from exercise of stock options 0.5 0.4 0.4 1.9 7.0 Common stock repurchases from share-based compensation plans (0.1 ) â€” (0.1 ) (3.4 ) (3.2 ) Net Cash (Used in) Provided By Financing Activities (79.6 ) 91.3 54.3 (9.4 ) 326.3 Effect of exchange rate changes on cash (3.8 ) 0.4 (1.0 ) (3.5 ) 0.7 Net (decrease) increase in cash  cash equivalents  restricted cash  and restricted cash equivalents (60.2 ) (95.7 ) 49.8 (32.9 ) (23.0 ) Cash  cash equivalents  restricted cash  and restricted cash equivalents at beginning of period(1) 149.7 198.8 99.9 122.4 126.1 CASH  CASH EQUIVALENTS  RESTRICTED CASH  AND RESTRICTED CASH EQUIVALENTS AT END OF PERIOD(1) $ 89.5 $ 103.1 $ 149.7 $ 89.5 $ 103.1(1) Includes restricted cash and restricted cash equivalents of $0.2 as of March 31  2022  September 30  2021 and December 31  2021 and $1.0 as of June 30  2021 and December 31  2020.CHART INDUSTRIES  INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)(Dollars in millions)September 30 2022 December 31 2021 ASSETS Cash and cash equivalents $ 89.5 $ 122.2 Accounts receivable  net 276.9 236.3 Inventories  net 357.5 321.5 Other current assets 205.6 173.5 Property  plant  and equipment  net 407.1 416.0 Goodwill 977.3 994.6 Identifiable intangible assets  net 535.5 556.1 Equity method investments 91.7 99.6 Investments in equity securities 66.9 77.8 Other assets 61.2 46.2 TOTAL ASSETS $ 3 069.2 $ 3 043.8 LIABILITIES AND EQUITY Current liabilities $ 754.9 $ 693.9 Long-term debt 580.8 600.8 Other long-term liabilities 107.6 123.9 Equity 1 625.9 1 625.2 TOTAL LIABILITIES AND EQUITY $ 3 069.2 $ 3 043.8CHART INDUSTRIES  INC. AND SUBSIDIARIESOPERATING SEGMENTS (UNAUDITED)(Dollars in millions)Three Months Ended Nine Months Ended September 30 2022 September 30 2021 June 30 2022 September 30 2022 September 30 2021 Sales Cryo Tank Solutions $ 126.9 $ 112.2 $ 132.9 $ 377.9 $ 313.9 Heat Transfer Systems 132.1 56.4 102.9 314.3 190.8 Specialty Products 108.1 116.9 115.3 330.9 301.0 Repair  Service & Leasing 49.7 46.3 55.4 154.4 142.3 Intersegment eliminations (4.7 ) (3.5 ) (1.7 ) (6.5 ) (9.2 ) Consolidated $ 412.1 $ 328.3 $ 404.8 $ 1 171.0 $ 938.8 Gross Profit Cryo Tank Solutions $ 22.8 $ 22.6 $ 21.6 $ 69.8 $ 71.0 Heat Transfer Systems 28.5 2.2 14.8 53.4 29.2 Specialty Products 34.2 40.7 39.4 106.2 105.6 Repair  Service & Leasing 19.1 9.4 19.0 53.7 36.2 Consolidated $ 104.6 $ 74.9 $ 94.8 $ 283.1 $ 242.0 Gross Profit Margin Cryo Tank Solutions 18.0 % 20.1 % 16.3 % 18.5 % 22.6 % Heat Transfer Systems 21.6 % 3.9 % 14.4 % 17.0 % 15.3 % Specialty Products 31.6 % 34.8 % 34.2 % 32.1 % 35.1 % Repair  Service & Leasing 38.4 % 20.3 % 34.3 % 34.8 % 25.4 % Consolidated 25.4 % 22.8 % 23.4 % 24.2 % 25.8 % Operating Income (Loss) Cryo Tank Solutions $ 12.2 $ 13.0 $ 9.9 $ 36.2 $ 42.0 Heat Transfer Systems 18.3 (10.0 ) 5.7 23.8 (6.7 ) Specialty Products 16.7 26.4 20.8 53.7 67.7 Repair  Service & Leasing 12.0 2.2 12.0 32.3 16.1 Corporate (17.5 ) (17.8 ) (18.8 ) (54.6 ) (51.0 ) Consolidated(1) (2) (3) (4) $ 41.7 $ 13.8 $ 29.6 $ 91.4 $ 68.1 Operating Margin (Loss) Cryo Tank Solutions 9.6 % 11.6 % 7.4 % 9.6 % 13.4 % Heat Transfer Systems 13.9 % (17.7) % 5.5 % 7.6 % (3.5) % Specialty Products 15.4 % 22.6 % 18.0 % 16.2 % 22.5 % Repair  Service & Leasing 24.1 % 4.8 % 21.7 % 20.9 % 11.3 % Consolidated 10.1 % 4.2 % 7.3 % 7.8 % 7.3 %_______________(1) Restructuring (credits)/costs for the three months ended:September 30  2022 were $(1.4) ($(1.3) - Repair  Service & Leasing  offsetting restructuring related costs in the segment in 2022  and $(0.1) - Specialty Products).September 30  2021 were $1.9 ($0.5 - Heat Transfer Systems and $1.4 - Repair  Service & Leasing).June 30  2022 were $0.2 ($0.1 - Cryo Tank Solutions and $0.1 - Specialty Products).(2) Restructuring (credits)/costs for the nine months ended:September 30  2022 were $(1.1) ($(1.3) - Repair  Service & Leasing  offsetting restructuring related costs in the segment in 2022  $0.1 - Cryo Tank Solutions and $0.1 - Heat Transfer Systems).September 30  2021 were $2.9 ($0.3 - Cryo Tank Solutions  $1.2 - Heat Transfer Systems and $1.4 - Repair  Service & Leasing).(3) Includes acquisition-related contingent consideration (credits)/charges in our Specialty Products Segment of:$(1.7)  $0.3  and $(0.2) for the three months ended September 30  2022  September 30  2021 and June 30  2022  respectively  and$(2.7) and $2.3 for the nine months ended September 30  2022 and September 30  2021  respectively.(4) Includes deal-related and integration costs of:$6.7 and $5.1 for the three months ended September 30  2022 and June 30  2022  respectively  and$16.0 for the nine months ended September 30  2022.CHART INDUSTRIES  INC. AND SUBSIDIARIESORDERS AND BACKLOG (UNAUDITED)(Dollars in millions)Three Months Ended September 30 2022 September 30 2021 June 30 2022 Orders Cryo Tank Solutions $ 120.2 $ 133.3 $ 106.1 Heat Transfer Systems 357.7 41.1 470.1 Specialty Products 202.9 131.3 265.7 Repair  Service & Leasing 61.7 52.9 47.4 Intersegment eliminations (13.1 ) (8.4 ) (1.5 ) Consolidated $ 729.4 $ 350.2 $ 887.8As of September 30 2022 September 30 2021 June 30 2022 Backlog Cryo Tank Solutions $ 355.2 $ 345.3 $ 331.9 Heat Transfer Systems 1 225.4 335.1 1 003.8 Specialty Products 666.1 381.2 570.4 Repair  Service & Leasing 41.6 54.4 48.5 Intersegment eliminations (34.2 ) (13.8 ) (1.3 ) Consolidated $ 2 254.1 $ 1 102.2 $ 1 953.3_______________CHART INDUSTRIES  INC. AND SUBSIDIARIESRECONCILIATION OF BASIC EARNINGS PER COMMON SHARE ATTRIBUTABLE TO CHART INDUSTRIES  INC. TO NORMALIZED NON-DILUTED EARNINGS PER COMMON SHARE ATTRIBUTABLE TO CHART INDUSTRIES INC. AND ADJUSTED NON-DILUTED EARNINGS PER COMMON SHARE ATTRIBUTABLE TO CHART INDUSTRIES  INC. (UNAUDITED)(Dollars in millions  except per share amounts)Three Months Ended Nine Months Ended September 30 2022 June 30 2022 September 30 2022 September 30 2021 Basic earnings per common share attributable to Chart Industries  Inc. (U.S. GAAP) $ 1.15 $ 0.36 $ 1.80 $ 1.32 Investment equities mark-to-market  net(1) (0.04 ) 0.27 0.38 (0.06 ) Tax effects 0.02 (0.05 ) (0.06 ) 0.01 Normalized non-diluted earnings per common share attributable to Chart Industries  Inc. (non-GAAP) $ 1.13 $ 0.58 $ 2.12 $ 1.27 Restructuring related costs(2) 0.09 0.13 0.37 0.53 Deal-related and integration costs(3) 0.19 0.14 0.45 0.30 Start-up costs (organic)(4) 0.09 0.09 0.23 0.17 Tax effects (0.01 ) (0.06 ) (0.13 ) (0.18 ) Adjusted non-diluted earnings per common share attributable to Chart Industries  Inc. (non-GAAP) $ 1.49 $ 0.88 $ 3.04 $ 2.09_______________(1) Investment equities mark-to-market  net includes:Unrealized gain of $1.3 and unrealized loss of $9.6 on the mark-to-market adjustments of our investments in equity securities related to McPhy (Euronext Paris: MCPHY â€“ ISIN; FR0011742329) and Stabilis Energy  Inc. (NasdaqCM: SLNG) for the three months ended September 30  2022 and June 30  2022  respectively  and an unrealized loss of $10.9 and unrealized gain of $1.2 for the nine months ended September 30  2022 and 2021  respectively. The nine months ended September 30  2021 includes mark-to-market adjustment upon remeasurement of our initial HTEC investment due to an observable price change in an orderly transaction for similar instruments of the same issuer.Foreign currency gain of $2.6 and foreign currency loss of $0.1 for the nine months ended September 30  2022 and 2021  respectively.Equity in earnings of unconsolidated affiliates  net of $0.2 and equity in loss of unconsolidated affiliates  net of $0.2 for the three months ended September 30  2022 and June 30  2022  respectively  and equity in loss of unconsolidated affiliates  net of $0.3 and equity in earnings of unconsolidated affiliates  net of $0.1 for the nine months ended September 30  2022 and 2021  respectively.(2) Restructuring related costs of $3.3 and $4.5 for the three months ended September 30  2022 and June 30  2022  respectively  and $13.1 for the nine months ended September 30  2022 were comprised of relocation and facility start-up costs and departmental restructuring  including headcount reductions.(3) Deal-related and integration costs of $6.7 and $5.1 during the three months ended September 30  2022 and June 30  2022  respectively  were mainly comprised of pre-closing  due diligence and integration costs related to our acquisitions of L.A. Turbine  AdEdge Holdings  LLC  Earthly Labs Inc.  AdEdge India  CSC Cryogenic Service Center AB and Fronti Fabrications and legal costs related to a specific pre-closing liability from a previous divestiture.(4) Start-up costs (organic) during the during the three months ended:September 30  2022 of $3.1 were comprised of product line start-up costs for our Tulsa  Oklahoma brazed aluminum heat exchangers  trailer expansion costs for Goch  Germany and startup and training costs for our Tulsa  Oklahoma vaporizer line.June 30  2022 of $3.4 were comprised of Richburg  South Carolina repair facility start-up costs  Tulsa  Oklahoma product line start-up costs and incremental costs related to our flex manufacturing facility in Tulsa  Oklahoma._______________Normalized non-diluted earnings per common share attributable to Chart Industries  Inc. and adjusted non-diluted earnings per common share attributable to Chart Industries  Inc. are not measures of financial performance under U.S. GAAP and should not be considered as an alternative to earnings per share in accordance with U.S. GAAP. Management believes that normalized non-diluted earnings per common share attributable to Chart Industries  Inc. and adjusted non-diluted earnings per common share attributable to Chart Industries  Inc. facilitate useful period-to-period comparisons of our financial results and this information is used by us in evaluating internal performance. Our calculation of these non-GAAP measures may not be comparable to the calculations of similarly titled measures reported by other companies.CHART INDUSTRIES  INC. AND SUBSIDIARIESRECONCILIATION OF NET INCOME ATTRIBUTABLE TO CHART INDUSTRIES  INC. TO NET INCOME  ADJUSTED (UNAUDITED)(Dollars in millions)Three Months Ended Nine Months Ended September 30 2022 September 30 2021 September 30 2022 September 30 2021 Net income attributable to Chart Industries  Inc.  (U.S. GAAP) $ 41.2 $ 14.9 $ 64.4 $ 47.0 Income attributable to noncontrolling interests  net of taxes 0.4 0.7 0.8 1.5 Net income (U.S. GAAP) 41.6 15.6 65.2 48.5 Employee share-based compensation expense 2.3 2.3 7.9 8.1 Financing costs amortization 0.7 1.2 2.1 3.5 Unrealized foreign currency transaction loss (gain) 0.1 (2.9 ) (4.2 ) (5.8 ) Unrealized (gain) loss on investments in equity securities (1.3 ) (10.4 ) 10.9 (1.2 ) Equity in (earnings) loss of unconsolidated affiliates (0.3 ) 0.1 0.3 (0.1 ) Realized gain on equity method investment â€” â€” (0.3 ) â€” Other non-cash operating activities 2.3 0.9 3.4 2.6 Net income  adjusted (non-GAAP) $ 45.4 $ 6.8 $ 85.3 $ 55.6_______________Net income  adjusted is not a measure of financial performance under U.S. GAAP and should not be considered as an alternative to net income in accordance with U.S. GAAP. Management believes that net income  adjusted  facilitates useful period-to-period comparisons of our financial results and this information is used by us in evaluating internal performance. Our calculation of this non-GAAP measure may not be comparable to the calculations of similarly titled measures reported by other companies.RECONCILIATION OF NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES TO FREE CASH FLOW AND ADJUSTED FREE CASH FLOW (UNAUDITED)(Dollars in millions)Three Months Ended Nine Months Ended September 30 2022 September 30 2021 September 30 2022 September 30 2021 Net cash provided by (used in) operating activities (U.S. GAAP) $ 37.8 $ (13.3 ) $ 50.3 $ (41.6 ) Capital expenditures (18.4 ) (9.8 ) (48.2 ) (36.5 ) Free cash flow (non-GAAP) 19.4 (23.1 ) 2.1 (78.1 ) Non-recurring costs 12.8 15.0 42.7 33.0 Divestiture related tax payments â€” â€” â€” 21.0 Add back inventory for strategic build 2.4 36.0 21.4 79.0 Acquisition escrow release $ 1.5 $ â€” $ 1.5 $ â€” Adjusted free cash flow (non-GAAP) $ 36.1 $ 27.9 $ 67.7 $ 54.9_______________Free cash flow and adjusted free cash flow are not measures of financial performance under U.S. GAAP and should not be considered as an alternative to net cash provided by (used in) operating activities in accordance with U.S. GAAP. Management believes that free cash flow and adjusted free cash flow facilitate useful period-to-period comparisons of our financial results and this information is used by us in evaluating internal performance. Our calculation of these non-GAAP measures may not be comparable to the calculations of similarly titled measures reported by other companies.CHART INDUSTRIES  INC. AND SUBSIDIARIESRECONCILIATIONS OF GROSS PROFIT TO ADJUSTED GROSS PROFIT AND OPERATING INCOME (LOSS) TO ADJUSTED OPERATING INCOME (LOSS) (UNAUDITED)(Dollars in millions)Three Months Ended September 30  2022 Cryo TankSolutions Heat TransferSystems SpecialtyProducts Repair Service &Leasing IntersegmentEliminations Corporate Consolidated Sales $ 126.9 $ 132.1 $ 108.1 $ 49.7 $ (4.7 ) $ â€” $ 412.1 Gross profit as reported (U.S. GAAP) 22.8 28.5 34.2 19.1 â€” â€” 104.6 Restructuring related  deal-related  integration and other one time costs 1.6 2.8 4.3 (0.7 ) â€” â€” 8.0 Adjusted gross profit (non-GAAP) $ 24.4 $ 31.3 $ 38.5 $ 18.4 $ â€” $ â€” $ 112.6 Adjusted gross profit margin (non-GAAP) 19.2 % 23.7 % 35.6 % 37.0 % â€” % â€” % 27.3 % Operating income (loss) as reported (U.S. GAAP) $ 12.2 $ 18.3 $ 16.7 $ 12.0 $ â€” $ (17.5 ) 41.7 Restructuring related  deal-related  integration and other one time costs 1.6 3.0 4.6 (0.6 ) â€” 1.6 10.2 Adjusted operating income (loss) (non-GAAP) $ 13.8 $ 21.3 $ 21.3 $ 11.4 $ â€” $ (15.9 ) $ 51.9 Adjusted operating margin (non-GAAP) 10.9 % 16.1 % 19.7 % 22.9 % â€” % â€” % 12.6 %Three Months Ended September 30  2021 Cryo TankSolutions Heat TransferSystems SpecialtyProducts Repair Service &Leasing IntersegmentEliminations Corporate Consolidated Sales $ 112.2 $ 56.4 $ 116.9 $ 46.3 $ (3.5 ) $ â€” $ 328.3 Gross profit as reported (U.S. GAAP) 22.6 2.2 40.7 9.4 â€” â€” 74.9 Restructuring  transaction-related and other one-time costs 3.1 2.3 2.7 3.9 â€” â€” 12.0 Adjusted gross profit (non-GAAP) $ 25.7 $ 4.5 $ 43.4 $ 13.3 $ â€” $ â€” $ 86.9 Adjusted gross profit margin (non-GAAP) 22.9 % 8.0 % 37.1 % 28.7 % â€” % â€” % 26.5 % Operating income (loss) as reported (U.S. GAAP) $ 13.0 $ (10.0 ) $ 26.4 $ 2.2 $ â€” $ (17.8 ) 13.8 Restructuring  transaction-related and other one-time costs 3.3 2.5 3.0 4.0 â€” 1.9 14.7 Adjusted operating income (loss) (non-GAAP) $ 16.3 $ (7.5 ) $ 29.4 $ 6.2 $ â€” $ (15.9 ) $ 28.5 Adjusted operating margin (non-GAAP) 14.5 % (13.3) % 25.1 % 13.4 % â€” % â€” % 8.7 %CHART INDUSTRIES  INC. AND SUBSIDIARIESRECONCILIATIONS OF GROSS PROFIT TO ADJUSTED GROSS PROFIT AND OPERATING INCOME (LOSS) TO ADJUSTED OPERATING INCOME (LOSS) (UNAUDITED) (CONTINUED)(Dollars in millions)Three Months Ended June 30  2022 Cryo TankSolutions Heat TransferSystems SpecialtyProducts Repair Service &Leasing IntersegmentEliminations Corporate Consolidated Sales $ 132.9 $ 102.9 $ 115.3 $ 55.4 $ (1.7 ) $ â€” $ 404.8 Gross profit as reported (U.S. GAAP) 21.6 14.8 39.4 $ 19.0 â€” â€” 94.8 Restructuring related  deal-related  integration and other one time costs 3.4 1.6 1.9 0.7 â€” â€” 7.6 Adjusted gross profit (non-GAAP) $ 25.0 $ 16.4 $ 41.3 $ 19.7 $ â€” $ â€” $ 102.4 Adjusted gross profit margin (non-GAAP) 18.8 % 15.9 % 35.8 % 35.6 % â€” % â€” % 25.3 % Operating income (loss) as reported (U.S. GAAP) $ 9.9 $ 5.7 $ 20.8 $ 12.0 $ â€” $ (18.8 ) 29.6 Restructuring related  deal-related  integration and other one time costs 3.4 1.9 2.8 0.7 â€” 1.6 10.4 Adjusted operating income (loss) (non-GAAP) $ 13.3 $ 7.6 $ 23.6 $ 12.7 $ â€” $ (17.2 ) $ 40.0 Adjusted operating margin (non-GAAP) 10.0 % 7.4 % 20.5 % 22.9 % â€” % â€” % 9.9 %Nine Months Ended September 30  2022 Cryo TankSolutions Heat TransferSystems SpecialtyProducts Repair Service &Leasing IntersegmentEliminations Corporate Consolidated Sales $ 377.9 $ 314.3 $ 330.9 $ 154.4 $ (6.5 ) $ â€” $ 1 171.0 Gross profit as reported (U.S. GAAP) 69.8 53.4 106.2 $ 53.7 â€” â€” 283.1 Restructuring related  deal-related  integration and other one time costs 8.3 6.9 7.6 1.5 â€” â€” 24.3 Adjusted gross profit (non-GAAP) $ 78.1 $ 60.3 $ 113.8 $ 55.2 $ â€” $ â€” $ 307.4 Adjusted gross profit margin (non-GAAP) 20.7 % 19.2 % 34.4 % 35.8 % â€” % â€” % 26.3 % Operating income (loss) as reported (U.S. GAAP) $ 36.2 $ 23.8 $ 53.7 $ 32.3 $ â€” $ (54.6 ) 91.4 Restructuring related  deal-related  integration and other one time costs 8.4 7.4 9.3 1.6 â€” 4.4 31.1 Adjusted operating income (loss) (non-GAAP) $ 44.6 $ 31.2 $ 63.0 $ 33.9 $ â€” $ (50.2 ) $ 122.5 Adjusted operating margin (non-GAAP) 11.8 % 9.9 % 19.0 % 22.0 % â€” % â€” % 10.5 %CHART INDUSTRIES  INC. AND SUBSIDIARIESRECONCILIATIONS OF GROSS PROFIT TO ADJUSTED GROSS PROFIT AND OPERATING INCOME (LOSS) TO ADJUSTED OPERATING INCOME (LOSS) (UNAUDITED) (CONTINUED)(Dollars in millions)Nine Months Ended September 30  2021 Cryo TankSolutions Heat TransferSystems SpecialtyProducts Repair Service &Leasing IntersegmentEliminations Corporate Consolidated Sales $ 313.9 $ 190.8 $ 301.0 $ 142.3 $ (9.2 ) $ â€” $ 938.8 Gross profit as reported (U.S. GAAP) 71.0 29.2 105.6 $ 36.2 â€” â€” 242.0 Restructuring related  deal-related  integration and other one time costs 5.2 9.4 5.2 4.8 â€” â€” 24.6 Adjusted gross profit (non-GAAP) $ 76.2 $ 38.6 $ 110.8 $ 41.0 $ â€” $ â€” $ 266.6 Adjusted gross profit margin (non-GAAP) 24.3 % 20.2 % 36.8 % 28.8 % â€” % â€” % 28.4 % Operating income (loss) as reported (U.S. GAAP) $ 42.0 $ (6.7 ) $ 67.7 $ 16.1 $ â€” $ (51.0 ) 68.1 Restructuring related  deal-related  integration and other one time costs 5.7 9.8 8.0 4.9 â€” 4.5 32.9 Adjusted operating income (loss) (non-GAAP) $ 47.7 $ 3.1 $ 75.7 $ 21.0 $ â€” $ (46.5 ) $ 101.0 Adjusted operating margin (non-GAAP) 15.2 % 1.6 % 25.1 % 14.8 % â€” % â€” % 10.8 %_______________Adjusted gross profit and adjusted operating income (loss) are not measures of financial performance under U.S. GAAP and should not be considered as an alternative to gross profit and operating income (loss) in accordance with U.S. GAAP. Management believes that adjusted gross profit and adjusted operating income (loss) facilitate useful period-to-period comparisons of our financial results and this information is used by us in evaluating internal performance. Our calculation of these non-GAAP measures may not be comparable to the calculations of similarly titled measures reported by other companies.",neutral,0.0,1.0,0.0,mixed,0.14,0.17,0.69,True,English,"['Chart Industries Reports', '2022 Third Quarter Results', '2023 full-year adjusted non-diluted EPS outlook', '2022 full-year adjusted non-diluted EPS guidance', 'Phase 2 Big LNG project', 'numerous other historical records', 'eighth consecutive record backlog quarter', 'increasing positive margin mix', '2023 full-year sales outlook range', '2022 full-year sales guidance range', 'eighth consecutive quarter', 'project timing movements', 'investor relations section', 'Venture Global Plaquemine', 'Inflation Reduction Act', 'total addressable market', 'Cryo Tank Solutions', 'U.S. dollar', 'aluminum heat exchangers', 'L.A. Turbine', '$17 million negative impact', 'foreign exchange impacts', 'capacity expansion costs', 'highest order quarter', 'Heat Transfer Systems', 'foreign exchange headwinds', 'top three quarters', 'cost control actions', 'third quarter order', 'time record backlog', 'prior 35.86 million shares', 'prior tax rate', 'Third quarter 2022 orders', 'total record sales', 'prior guidance', '35.87 million shares', 'sales records', 'first time', 'deal-related costs', 'gross margin', 'first quarter', 'second quarter', 'prior year', 'Chart Industries', 'GLOBE NEWSWIRE', 'Further details', 'supplemental presentation', 'operating income', 'ten years', 'Full Notice', 'commercial activity', 'Specialty Products', 'record backlogs', 'bill ratios', 'liquefaction projects', 'Indian Rupee', 'mobile equipment', 'space exploration', 'pricing actions', 'one-time items', 'four segments', '71 orders', '2023 sales', 'ATLANTA', 'NYSE', 'GTLS', 'results', 'release', 'website', 'history', 'volume', 'productivity', 'percent', '108% increase', 'FNTP', 'IRA', 'TAM', 'near-term', 'business', 'HTS', 'date', 'book', 'contributor', 'FX', 'Euro', 'addition', 'aftermarket', 'VRV', 'restructuring', 'start', '170 basis', '720 basis']",2022-10-28,2022-10-28,finance.yahoo.com
12330,EuroNext,NewsApi.org,https://www.prnewswire.co.uk/news-releases/pharming-group-reports-earnings-for-the-first-nine-months-of-2022-301660492.html,Pharming Group reports earnings for the first nine months of 2022,Leniolisib remains on track for marketing authorization in the US and European Economic Area in H1 2023 Revenues increased by 3% to US$151.0 million  compared to the first nine months of 2021 Operating profit increased by 86% to US$28.4 million Strong balanceâ€¦,"Leniolisib remains on track for marketing authorization in the US and European Economic Area in H1 2023Revenues increased by 3% to US$151.0 million   compared to the first nine months of 2021Operating profit increased by 86% to US$28.4 millionStrong balance sheet and stable sales from RUCONESTÂ® underpinning continued investment in launch preparations for leniolisib and Pharming's long-term growthLEIDEN  Netherlands  Oct. 27  2022 /PRNewswire/ -- Pharming Group N.V. (""Pharming"" or ""the Company"") (Euronext Amsterdam: PHARM) (NASDAQ: PHAR) presents its preliminary  unaudited financial report for the first nine months ended September 30  2022.Chief Executive Officer  Sijmen de Vries  commented:""In the first nine months of 2022 Pharming continued to perform well despite challenging industry conditions. Our commercialized asset RUCONESTÂ® saw increased sales of 3% or US$151.0 million  compared to the same period last year  highlighting the continued need for a safe and effective acute hereditary angioedema therapy.From a strategic perspective  we continued to make significant progress delivering on a number of important regulatory milestones for leniolisib  a rare immunodeficiency disease. Of note  our New Drug Application for leniolisib was accepted by the US FDA for Priority Review with a PDUFA goal date of March 29  2023. Furthermore  we submitted a Marketing Authorisation Application for the product to the European Medicines Agency following the grant of accelerated assessment. We remain on track for the anticipated marketing authorization of leniolisib as a treatment of APDS in key markets next year.Looking ahead  the anticipated launch and commercialization of leniolisib will be supported by our strong balance sheet and the steady sales of RUCONESTÂ®. We will continue focusing on our strategic objectives and the internal review of our pipeline as we look to bring the unserved rare disease patient the solutions they need. We look forward to presenting more detailed plans at our full year financial results.""Strategic highlightsDuring the first nine months of 2022  we continued to execute on our strategic objectives of building a sustainable business by focusing on RUCONESTÂ® sales  the approval  launch and commercialization of leniolisib  and the ongoing development and management of our pipeline as we prioritize our efforts on rare diseases.As announced during the half year financial results in August 2022  we initiated an internal review of our pipeline with a greater and renewed focus towards rare diseases. As a result  we will advance the development of our pipeline through a combination of internal development projects - including the development of additional indications for leniolisib  as well as OTL-105 as a gene therapy for HAE - and the potential acquisition of new  late-stage assets through in-licensing and M&A opportunities.We believe these potential acquisitions and in-licensing will be financed through a combination of positive cash flow from the RUCONESTÂ® business  anticipated future leniolisib business  as well as available cash from our strong balance sheet. If required  Pharming will access additional funding from the capital markets.Pipeline developmentleniolisibFor leniolisib  Pharming has a three-step approach planned for the coming years.The first step is the anticipated marketing authorization and commercial launch of leniolisib for the treatment of activated PI3K delta syndrome (APDS) in adults and adolescents aged 12 and older in the US during the first half of 2023. This will be followed by key markets in the European Economic Area (EEA) and the UK in the second half of 2023 and early 2024  respectively  dependent upon regulatory approval. The Company will evaluate additional countries and regions and will commercialize the product either directly or through strategic distribution partnerships.The second step includes the marketing authorization and commercial launch of leniolisib as a treatment of APDS in children as young as one year of age.The third step is the continued life cycle management of the leniolisib compound into further indications which will be disclosed when decisions have been taken.US marketWe remain on track for the anticipated commercial approval of leniolisib in the first quarter of 2023  subject to approval from the US Food and Drug Administration (FDA)  followed by the commercial launch of leniolisib in the second quarter of 2023.In the third quarter of 2022  we delivered on a number of important regulatory milestones including the filing and acceptance of a New Drug Application (NDA) for Priority Review by the FDA.As a result of receiving Priority Review  Pharming's NDA for leniolisib was assigned a Prescription Drug User Fee Act (PDUFA) goal date of March 29  2023.In anticipation of a positive outcome from the FDA  we continued to grow our US field force and leverage our marketing capabilities for the commercialization of leniolisib.Finally  the ICD-10-CM code for APDS took effect on October 1  2022. The assignment of the ICD-10-CM code enables physicians and payors in the US to add a diagnosis of APDS to patients' health records  which will help connect these individuals with researchers studying the prevalence and course of the disease. In addition  by allocating a specific diagnosis  the new ICD-10-CM code may help confirm medical necessity in individual patients  thus improving their access to relevant care options through US health insurance plans.European Economic Area (EEA) and UK marketIn the EEA  we announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) had granted an accelerated assessment for the Marketing Authorisation Application (MAA) for leniolisib in adults and adolescents aged 12 and older. Upon further request  EMA will grant an accelerated assessment of an MAA if they decide the product is of major interest for public health  and in particular  from the viewpoint of therapeutic innovation. The accelerated assessment reduces the review timeframe from 210 days to 150 days.Further positive milestones were reached in October 2022 when we announced that we had submitted a Marketing Authorisation Application for leniolisib to the EMA. We expect to receive EMA validation of the MAA at the end of October 2022  with anticipated marketing authorization in H1 2023.Moving on to the UK market  in April 2022  the Medicines and Healthcare products Regulatory Agency (MHRA) granted Promising Innovative Medicine (PIM) designation to leniolisib for the treatment of APDS. A PIM designation is an early indication that leniolisib is a candidate for the MHRA's Early Access to Medicines Scheme. This scheme provides an opportunity for treatment options to be used in clinical practice in parallel with the later stages of the regulatory process.Finally  on September 30  2022  the UK government took the decision to extend the European Commission Decision Reliance Procedure (ECDRP) by 12 months  until December 31  2023. The ECDRP allows a company to submit a product that has received approval from EMA to the UK's MHRA. The MHRA can grant a license relying on the EMA's decision  thereby ensuring a less time consuming in-country review.The extension of the ECDRP has several benefits including aligned EU and UK dossiers  consistent labeling across the EU and UK  and the potential for an earlier Marketing Authorisation Approval. As such  Pharming has decided that the ECDRP procedure will be used for the application of leniolisib to the MHRA. Under ECDRP  if the submission of an application is made within five days of an EMA CHMP positive opinion  the MHRA will aim to determine a decision within a 67-day timeline. The anticipated MHRA decision should be known in H2 2023.Pediatric clinical developmentAs previously announced  we intend to expand access to leniolisib for the treatment of pediatric APDS. As a result  Pharming has developed a clinical plan to include children as young as one year of age. During the first half of the year  positive decisions were received from EMA and MHRA on the Pediatric Investigation Plan (PIP) for leniolisib as a treatment for APDS in children. The leniolisib PIP includes two planned  global clinical trials in pediatric patients with APDS aged 4 to 11 with a second study in patients aged 1 to 6. These two studies will support regulatory filings worldwide. Pharming expects to initiate recruitment for this pediatric program for leniolisib in the fourth quarter of 2022.OTL-105Pharming's strategic collaboration with Orchard Therapeutics to research  develop  manufacture and commercialize OTL-105  a newly disclosed investigational ex vivo autologous hematopoietic stem cell (HSC) gene therapy for the treatment of hereditary angioedema (HAE) is ongoing. The program has made good progress developing the lentiviral vector to enhance C1-inhibitor expression and is now testing in preclinical HAE disease models. We anticipate providing further updates as we move towards preparing an Investigational New Drug (IND) filing.Acute Kidney Injury (AKI)As announced at our half year 2022 financial results  following an internal review of our pipeline  we have taken the strategic decision to discontinue further development of rhC1INH therapy for Acute Kidney Injury. We are considering strategic options to gain value from the work done to date and have de-prioritized further development and investment in the large-scale production of rhC1INH through the use of our transgenic cattle herd. The herd is being maintained to allow all possible outcomes to be explored.The ongoing Phase IIb clinical trial is continuing as we evaluate these strategic options.We will update the market at our full year 2022 financial results on further progress in this area.PompeWe continue the preclinical investigation of a next-generation alpha-glucosidase therapy for the treatment of Pompe disease and will update the market on the results as appropriate.Financial SummaryAmounts in US$m except per share data YTD 2022 YTD 2021 % Change Income StatementRevenues 151.0 146.1 3 % Gross profit 139.7 130.6 7 % Operating profit 28.4 15.3 86 % Profit for the year 28.3 13.9 104 % Balance SheetCash & marketable securities 189.9 184.8 3 % Share InformationBasic earnings per share (US$) 0.043 0.022 95 % Diluted earnings per share (US$) 0.040 0.018 122 %Financial highlightsYTD Q3 2022Revenues for the first nine months of 2022 were US$151.0 million  a 3% increase compared to the first nine months of 2021 (US$146.1 million).Gross profit for the first nine months of 2022 increased 7% to US$139.7 million. This increase was driven by growth in revenues  production efficiencies and a favorable tailwind in currency translation effects.Operating costs for the first nine months of 2022 increased by US$9.8 million to US$126.9 million versus the same period last year. The increase results from a combination of increased R&D expenditure  launch preparation and manufacturing costs for leniolisib  and an increase in travel related expenses post-COVID-19. This increase was partly offset by significant one-off costs in Q3 2021 relating to the in-licensing of OTL-105 from Orchard Therapeutics.Operating profit for the first nine months of 2022 was US$28.4 million  increasing 86% versus the same period last year. This was mainly driven by the increase in other income of US$13.8 million as a result of a reduced minority stake in BioConnection communicated in our H1 2022 press release.Net profit for the first nine months of 2022 was US$28.3 million  a 104% increase compared to the same period last year (US$13.9 million). This was driven by the increase in other income of US$13.8 million.Cash and cash equivalents  together with restricted cash  decreased from US$193.0 million at the end of 2021  to US$189.9 million at the end of the third quarter 2022.OutlookFor the financial year of 2022:Single digit growth in Group revenues from RUCONESTÂ® sales. Quarterly fluctuations are expected.Subject to a positive outcome from the FDA review  we anticipate marketing authorization in the US for leniolisib at the end of Q1 2023  with an anticipated launch and commercialization in Q2 2023.Subject to a positive outcome from the EMA review  we anticipate a positive opinion from the CHMP for leniolisib  followed by the issuance of an MAA by the European Commission towards the end of H1 2023. Initial commercial launches in EU markets are planned for H2 2023.Following an anticipated positive CHMP opinion  we intend to submit an ECDRP filing for leniolisib with the MHRA in the UK in H2 2023.Pharming will continue to allocate resources towards the anticipated launch and commercialization of leniolisib with the view of accelerating future growth. Investments in launch preparations and focused clinical development for leniolisib will continue to impact profit for the remainder of 2022 and throughout 2023. However  no additional financing to support the current business is expected with the continued cash flow from RUCONESTÂ® funding these investments.Investment and continued focus on potential acquisitions and in-licensing of new  late- stage development opportunities and assets in rare diseases. Financing  if required  would come via a combination of our strong balance sheet and access to capital markets.No further specific financial guidance for 2022 is provided.Additional informationPresentationThe conference call presentation will be available on the Pharming.com website from 10:30 CET on October 27  2022.Conference CallThe conference call will begin at 13:30 CET on October 27  2022. A transcript of the call will be available on the Pharming.com website the following day at 14:30 CET.Please note  the Company will only take questions from dial-in attendees.Dial-in numbers for conference callNetherlands (Local) +31 85 888 7233United Kingdom +44 800 640 6441United Kingdom (Local) +44 20 3936 2999United States +1 855 979 6654United States (Local) +1 646 664 1960All other locations +44 20 3936 2999Access code: 497472Webcast link: https://webcast.openbriefing.com/pharming-q32022/Financial calendar 2022Credit Suisse 31st Annual Healthcare Conference: November 8 - 10Stifel Healthcare Conference 2022: November 15 - 16Jefferies London Healthcare Conference: November 15 - 17For further public information  contact:Pharming Group  Leiden  The NetherlandsHeather Robertson  Investor Relations & Corporate Communications ManagerT: +31 7 1 524 7400investor@pharming.comFTI Consulting  London  UKVictoria Foster Mitchell/Alex ShawT: +44 203 727 1000FTI Consulting  USAJim PolsonT: +1 (312) 553-6730LifeSpring Life Sciences Communication  Amsterdam  The NetherlandsLeon MelensT: +31 6 53 81 64 27E: pharming@lifespring.nlAbout Pharming Group N.V.Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare  debilitating  and life-threatening diseases. Pharming is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines  including small molecules  biologics  and gene therapies that are in early to late-stage development. Pharming is headquartered in Leiden  Netherlands  and has employees around the globe who serve patients in over 30 markets in North America  Europe  the Middle East  Africa  and Asia-Pacific. For more information  visit www.pharming.com and find us on LinkedIn .Auditor's involvementThe Condensed Consolidated Interim Financial Statements have not been audited by the Company's statutory auditor.Risk profileThe risks outlined in the 2021 Annual Report continued to apply in the first nine months of 2022and are expected to apply for the rest of the financial year. We continue to closely monitor the key risks and opportunities  and will respond appropriately to any emerging risk.Related party transactionsThere are no material changes in the nature  scope  and (relative) scale in this reporting periodcompared to last year.Forward-looking StatementsThis press release may contain forward-looking statements. Forward-looking statements are statements of future expectations that are based on management's current expectations and assumptions and involve known and unknown risks and uncertainties that could cause actual results  performance  or events to differ materially from those expressed or implied in these statements. These forward-looking statements are identified by their use of terms and phrases such as ""aim""  ""ambition""  ''anticipate''  ''believe''  ''could''  ''estimate''  ''expect''  ''goals''  ''intend''  ''may''  ""milestones""  ''objectives''  ''outlook''  ''plan''  ''probably''  ''project''  ''risks''  ""schedule""  ''seek''  ''should''  ''target''  ''will'' and similar terms and phrases. Examples of forward-looking statements may include statements with respect to timing and progress of Pharming's preclinical studies and clinical trials of its product candidates  Pharming's clinical and commercial prospects  and Pharming's expectations regarding its projected working capital requirements and cash resources  which statements are subject to a number of risks  uncertainties and assumptions  including  but not limited to the scope  progress and expansion of Pharming's clinical trials and ramifications for the cost thereof; and clinical  scientific  regulatory and technical developments. In light of these risks and uncertainties  and other risks and uncertainties that are described in Pharming's 2021 Annual Report and the Annual Report on Form 20-F for the year ended December 31  2021  filed with the U.S. Securities and Exchange Commission  the events and circumstances discussed in such forward-looking statements may not occur  and Pharming's actual results could differ materially and adversely from those anticipated or implied thereby. All forward-looking statements contained in this press release are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Readers should not place undue reliance on forward-looking statements. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release. Pharming does not undertake any obligation to publicly update or revise any forward-looking statement as a result of new information  future events or other information.Inside InformationThis press release relates to the disclosure of information that qualifies  or may have qualified  as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.Pharming Group N.V.Condensed Consolidated Interim Financial Statements in US Dollars (unaudited)For the period ended 30 September 2022Condensed consolidated statement of profit and lossCondensed consolidated statement of comprehensive incomeCondensed consolidated balance sheetCondensed consolidated statement of cash flowCONDENSED CONSOLIDATED STATEMENT OF PROFIT AND LOSSFor the 9-month period ended 30 September 2022Amounts in US$ '000 YTD 2022 YTD 2021 Revenues 151.001 146.101 Costs of sales (11.288) (15.500) Gross profit 139.712 130.601 Other income 15.602 1.808 Research and development (41.639) (37.580) OTL-105 in-licensing 0 (13.105) General and administrative (28.446) (22.510) Marketing and sales (56.819) (43.880) Other Operating Costs (126.904) (117.075) Operating profit 28.410 15.334 Fair value gain (loss) on revaluation derivatives 0 59 Other finance income 9.297 9.907 Other finance expenses (3.978) (4.466) Finance cost net 5.319 5.500 Share of net profits in associates using the equity method (660) 511 Profit before tax 33.069 21.345 Income tax credit (expense) (4.765) (7.412) Profit for the year 28.304 13.933 Basic earnings per share (US$) 0.043 0.022 Fully-diluted earnings per share (US$) 0.040 0.018CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOMEFor the 9-month period ended 30 September 2022Amounts in US$ '000 YTD 2022 YTD 2021 Profit for the year 28.304 13.933 Currency translation differences (26.313) (10.506) Fair value remeasurement investments (573) (1.475) Items that may be subsequently reclassified to profit or loss (26.886) (11.981) Other comprehensive income (loss)  net of tax (26.886) (11.981) Total comprehensive income (loss) for the year 1.418 1.952CONDENSED CONSOLIDATED BALANCE SHEETAs at 30 September 2022Amounts in US$ '000 30 September 2022 31 December 2021 Non-current assetsIntangible assets 70.123 83.834 Property  plant and equipment 10.812 13.222 Right-of-use assets 16.970 19.943 Long-term prepayments 210 194 Deferred tax assets 21.187 21.216 Investments accounted for using the equity method 2.845 7.201 Investment in equity instruments designated as at FVTOCI 545 1.449 Investment in debt instruments designated as at FVTPL 7.386 0 Restricted cash 197 812 Total non-current assets 130.275 147.871 Current assetsInventories 33.506 27.310 Trade and other receivables 28.828 29.983 Restricted cash 1.011 227 Cash and cash equivalents 188.703 191.924 Total current assets 252.048 249.444 Total assets 382.323 397.315EquityShare capital 7.482 7.429 Share premium 459.450 455.254 Legal reserves (24.145) 3.400 Accumulated deficit (242.533) (273.167) Shareholders' equity 200.254 192.916 Non-current liabilitiesConvertible bonds 120.005 139.007 Lease liabilities 15.227 18.456 Other financial liabilities 143 165 Total non-current liabilities 135.375 157.628Current liabilitiesConvertible bonds 1.627 1.879 Derivative financial liabilities 0 0 Trade and other payables 42.744 42.473 Lease liabilities 2.323 2.419 Total current liabilities 46.694 46.771 Total equity and liabilities 382.323 397.315CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS in US DollarFor the 9-month period ended 30 September 2022Amounts in $'000 YTD 2022 YTD 2021Profit before tax 33.069 21.345Non-cash adjustments:Depreciation  amortization  impairment 6.216 6.867Equity settled share based payments 4.522 5.706Fair value gain (loss) on revaluation of derivatives 0 (59)Gain on disposal of investment in associate (12.382) 0Other finance income (9.296) (9.907)Other finance expense 3.978 4.466Share of net profits in associates using the equity method 660 (511)Other 0 272Operating cash flows before changes in working capital 26.767 28.179Changes in working capital:Inventories (6.196) (3.941)Trade and other receivables 1.155 3.092Payables and other current liabilities 272 (5.514)Restricted Cash 169 42Total changes in working capital (4.600) (6.321)Interest received 31 51Income taxes paid (4.975) 0Net cash flows generated from (used in) operating activities 17.223 21.909Capital expenditure for property  plant and equipment (1.071) (7.451)Investment intangible assets (591) (1.544)Investment in equity instruments designated as at FVTOCI 0 (4.589)Investment in associate 7.384 0Acquisition of license 0 (1.593)Net cash flows used in investing activities 5.722 (15.177)Repayment on loans and borrowings 0 0Payment on contingent consideration 0 (25.000)Payment of lease liabilities (2.385) (2.476)Proceeds of issued convertible bonds 0 0Interests on loans and leases (3.999) (4.493)Proceeds of equity and warrants 1.124 4.237Net cash flows generated from (used in) financing activities (5.260) (27.732)Increase (decrease) of cash 17.685 (21.000)Exchange rate effects (20.906) (835)Cash and cash equivalents at 1 January 191.924 205.159Total cash and cash equivalents at 30 September 188.703 183.324Logo - https://mma.prnewswire.com/media/1778344/Pharming_Group_NV_Logo.jpgSOURCE Pharming Group N.V.",neutral,0.0,1.0,0.0,mixed,0.5,0.26,0.24,True,English,"['first nine months', 'Pharming Group', 'earnings', 'effective acute hereditary angioedema therapy', 'Prescription Drug User Fee Act', 'preliminary, unaudited financial report', 'full year financial results', 'unserved rare disease patient', 'half year financial results', 'Pharming Group N.V.', 'continued life cycle management', 'rare immunodeficiency disease', 'New Drug Application', 'European Economic Area', 'Strong balance sheet', 'Chief Executive Officer', 'Sijmen de Vries', 'challenging industry conditions', 'PDUFA goal date', 'European Medicines Agency', 'new, late-stage assets', 'M&A opportunities', 'PI3K delta syndrome', 'PDUFA) goal date', 'important regulatory milestones', 'first nine months', 'strategic distribution partnerships', 'Marketing Authorisation Application', 'positive cash flow', 'US field force', 'internal development projects', 'future leniolisib business', 'gene therapy', 'one year', 'Drug Administration', 'first half', 'rare diseases', 'continued investment', 'continued need', 'second half', 'first step', 'first quarter', 'available cash', 'positive outcome', 'internal review', 'sustainable business', 'strategic perspective', 'strategic objectives', 'Strategic highlights', 'marketing authorization', 'regulatory approval', 'marketing capabilities', 'Operating profit', 'long-term growth', 'Euronext Amsterdam', 'commercialized asset', 'same period', 'significant progress', 'Priority Review', 'accelerated assessment', 'key markets', 'detailed plans', 'renewed focus', 'potential acquisition', 'additional funding', 'capital markets', 'three-step approach', 'coming years', 'additional countries', 'second step', 'third step', 'second quarter', 'third quarter', 'US market', 'US Food', 'ongoing development', 'stable sales', 'steady sales', 'RUCONESTÂ® business', 'additional indications', 'commercial launch', 'commercial approval', 'ICD-10-CM code', 'leniolisib compound', 'RUCONESTÂ® sales', 'US FDA', 'Pipeline development', 'track', 'H1', 'Revenues', 'preparations', 'LEIDEN', 'Netherlands', 'PRNewswire', 'Company', 'NASDAQ', 'safe', 'number', 'note', 'March', 'product', 'grant', 'treatment', 'APDS', 'commercialization', 'solutions', 'efforts', 'August', 'greater', 'combination', 'HAE', 'licensing', 'activated', 'adults', 'adolescents', 'EEA', 'UK', 'early', 'regions', 'children', 'decisions', 'filing', 'acceptance', 'NDA', 'anticipation', 'October', 'assignment', '2022']",2022-10-27,2022-10-28,prnewswire.co.uk
12331,EuroNext,NewsApi.org,https://www.businesswire.com/news/home/20221026006095/en/Anheuser-Busch-InBev-Reports-Third-Quarter-2022-Results,Anheuser-Busch InBev Reports Third Quarter 2022 Results,BRUSSELS--(BUSINESS WIRE)--Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): Regulated and inside information1 â€œWe delivered broad-based volume growth of 3.7% this quarter resulting in an accelerated increase in revenue of 12.1%. We continue â€¦,BRUSSELS--(BUSINESS WIRE)--Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD):Regulated and inside information1â€œWe delivered broad-based volume growth of 3.7% this quarter resulting in an accelerated increase in revenue of 12.1%. We continue to see strong consumer demand for our portfolio and a resilient beer category as we navigate the dynamic operating environment. As a result of our performance and continued momentum  we are raising the bottom-end of our FY22 EBITDA outlook.â€ â€“ Michel Doukeris  CEO  AB InBevTotal Revenue+ 12.1%Revenue increased by 12.1% in 3Q22 with revenue per hl growth of 8.0% and by 11.5% in 9M22 with revenue per hl growth of 7.8%.12.7% increase in combined revenues of our global brands  Budweiser  Stella Artois and Corona  outside of their respective home markets in 3Q22  and 9.6% in 9M22.Approximately 57% of our revenue now through B2B digital platforms with the monthly active user base of BEES reaching 3.1 million users as of 30 September 2022.Over 385 million USD of revenue and approximately 17 million ecommerce orders generated by our direct-to-consumer ecosystem in 3Q22.Total Volume+3.7%In 3Q22  total volumes grew by 3.7%   with own beer volumes up by 3.4% and non-beer volumes up by 5.2% . In 9M22  total volumes grew by 3.3% with own beer volumes up by 2.8% and non-beer volumes up by 6.5%.Normalized EBITDA+ 6.5%In 3Q22 normalized EBITDA of 5 313 million USD represents an increase of 6.5% with normalized EBITDA margin contraction of 183 bps to 35.2% . In 9M22  normalized EBITDA increased by 7.0% to 14 896 million USD and normalized EBITDA margin contracted by 143 bps to 34.5%. Normalized EBITDA figures of 9M22 and 9M21 include an impact of 201 million USD and 226 million USD from tax credits in Brazil that were recorded in 2Q22 and 2Q21 respectively. For more details  please see page 10.Underlying Profit1 682 million USDUnderlying profit (normalized profit attributable to equity holders of AB InBev excluding mark-to-market gains and losses linked to the hedging of our share-based payment programs and the impact of hyperinflation) was 1 682 million USD in 3Q22 compared to 1 699 million USD in 3Q21 and was 4 354 million USD in 9M22 compared to 4 290 million USD in 9M21.Underlying EPS0.84 USDUnderlying EPS was 0.84 USD in 3Q22  a decrease from 0.85 USD in 3Q21 and was 2.16 USD in 9M22  an increase from 2.14 USD in 9M21.1The enclosed information constitutes inside information as defined in Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse  and regulated information as defined in the Belgian Royal Decree of 14 November 2007 regarding the duties of issuers of financial instruments which have been admitted for trading on a regulated market. For important disclaimers and notes on the basis of preparation  please refer to page 14.Management commentsBest quarterly volume performance this year driven by accelerated digital transformation and continued consumer demand for our brand portfolioOur volume momentum accelerated this quarter as we delivered 3.7% growth  even in the context of the ongoing dynamic operating environment. Top-line grew by 12.1% with 8.0% revenue per hl growth  driven by revenue management initiatives and continued premiumization across most of our markets. EBITDA increased by 6.5% as our top-line growth was partially offset by anticipated transactional FX and commodity cost headwinds and increased sales and marketing investments in our brands.Following the recognition of our brand building and creative marketing capabilities at the Cannes Lions International Festival of Creativity  we were honored to be named the Worldâ€™s Most Effective Marketer in the Global Effie Effectiveness Index for the first time in our company history.As we continue on our deleveraging path  our bond portfolio maintains a very manageable weighted average pre-tax coupon rate of approximately 4% with 94% of the portfolio fixed rate. The weighted average maturity remains more than 16 years with no near- or medium-term refinancing requirements.Consistent execution of our strategyWe continue to execute on and invest in three key strategic pillars to deliver consistent growth and long-term value creation.See Image 1.1. Lead and grow the category:This quarter we delivered a broad-based total volume increase of 3.7% with growth in more than 60% of our markets.2. Digitize and monetize our ecosystem:BEES is now live in 19 markets and has reached 3.1 million monthly active users as of 30 September 2022  a 7% increase versus 2Q22. BEES Marketplace is now live in 14 markets with 44% of BEES customers now also Marketplace buyers.3. Optimize our business:In 9M22  our EBITDA grew by 7.0% and  as a result of deleveraging  our net interest expense decreased by approximately 200 million USD versus 9M21.1. Lead and grow the category:We are executing on five proven and scalable levers to drive category expansion:Inclusive Category : In 3Q22  consumer participation with our portfolio increased in most of our focus markets  according to our estimates  driven by brand  pack and liquid innovations focused on expanding inclusivity and accessibility. For example  in Mexico  our pack size initiatives across both upsizing and downsizing grew strong double-digits this quarter  contributing over 1 million hlâ€™s in volume and improving profitability in both the core and above core segments of our portfolio.In 3Q22  consumer participation with our portfolio increased in most of our focus markets  according to our estimates  driven by brand  pack and liquid innovations focused on expanding inclusivity and accessibility. For example  in Mexico  our pack size initiatives across both upsizing and downsizing grew strong double-digits this quarter  contributing over 1 million hlâ€™s in volume and improving profitability in both the core and above core segments of our portfolio. Core Superiority: In 3Q22  our mainstream portfolio continued to outperform the industry across the majority of our focus markets  according to our estimates  and delivered low-teens revenue growth  led by particularly strong performances in Mexico  Brazil and South Africa.In 3Q22  our mainstream portfolio continued to outperform the industry across the majority of our focus markets  according to our estimates  and delivered low-teens revenue growth  led by particularly strong performances in Mexico  Brazil and South Africa. Occasions Development: Our global non-alcohol beer portfolio delivered double-digit revenue growth this quarter led by Budweiser Zero and Stella Artois LibertÃ© in the US.Our global non-alcohol beer portfolio delivered double-digit revenue growth this quarter led by Budweiser Zero and Stella Artois LibertÃ© in the US. Premiumization: Our above core portfolio grew revenue by low-teens this quarter  led by continued double-digit growth of Michelob ULTRA in the US and Mexico and further expansion of Spaten in Brazil. Our global brands grew revenue by 12.7% outside of their home markets this quarter  led by Corona with 23.5% growth. Budweiser grew by 8.9% despite the impact of COVID-19 restrictions in China  the brandâ€™s largest market. Stella Artois grew by 7.0% with continued growth in focus markets such as the US and Brazil.Our above core portfolio grew revenue by low-teens this quarter  led by continued double-digit growth of Michelob ULTRA in the US and Mexico and further expansion of Spaten in Brazil. Our global brands grew revenue by 12.7% outside of their home markets this quarter  led by Corona with 23.5% growth. Budweiser grew by 8.9% despite the impact of COVID-19 restrictions in China  the brandâ€™s largest market. Stella Artois grew by 7.0% with continued growth in focus markets such as the US and Brazil. Beyond Beer: Our global Beyond Beer business grew revenue by over 10% this quarter  contributing more than 400 million USD of revenue. In the US  within the spirits-based ready-to-drink segment  our portfolio continued to grow strong double-digits  ahead of the industry  led by Cutwater and NÃœTRL vodka seltzer. In South Africa  Brutal Fruit and Flying Fish delivered continued double-digit volume growth.2. Digitize and monetize our ecosystemDigitizing our relationships with our more than 6 million customers globally: As of 30 September 2022  BEES is live in 19 markets with approximately 57% of our revenues now through B2B digital platforms. In 3Q22  BEES reached 3.1 million monthly active users and captured approximately 7.7 billion USD in gross merchandise value (GMV)  growth of over 40% versus 3Q21. BEES Marketplace is now live in 14 markets and generated September annualized revenues from sales of third party products of approximately 850 million USD. As of September 2022  44% of BEES customers were also Marketplace buyers.As of 30 September 2022  BEES is live in 19 markets with approximately 57% of our revenues now through B2B digital platforms. In 3Q22  BEES reached 3.1 million monthly active users and captured approximately 7.7 billion USD in gross merchandise value (GMV)  growth of over 40% versus 3Q21. BEES Marketplace is now live in 14 markets and generated September annualized revenues from sales of third party products of approximately 850 million USD. As of September 2022  44% of BEES customers were also Marketplace buyers. Leading the way in DTC solutions: Our digital direct-to-consumer (DTC) products  Ze Delivery  TaDa and PerfectDraft are now available in 17 markets and generated over 100 million USD in revenue and 17 million orders in the quarter. Our network of physical retail products  such as Modelorama in Mexico and Pit Stop in Brazil  continued to deliver revenue growth across our footprint of approximately 13 000 stores. Combined  our omni-channel DTC ecosystem of digital and physical DTC products generated revenue of over 1 billion USD in 9M22  mid-teens growth versus 9M21.3. Optimize our businessIn 9M22  we continued to focus on disciplined resource allocation and delivered 7.0% EBITDA growth. Our bond portfolio maintains a very manageable weighted average pre-tax coupon rate of approximately 4% with 94% of the portfolio fixed rate. Our net interest expense for 9M22 decreased by approximately 200 million USD versus 9M21  principally as a result of our gross debt reduction efforts.Advancing our ESG prioritiesAs we continue to advance our sustainability agenda  we were proud to recently be included on Fortuneâ€™s Change the World List in recognition of our global initiatives in water stewardship. We are also making progress towards our ambition to achieve net zero by 2040  reaching carbon neutrality at five facilities in Brazil and one in Argentina in 9M22.Creating a future with more cheersThrough the implementation of our category expansion levers  we continue to lead and grow the beer category resulting in broad-based volume growth of 3.7% this quarter. We are digitizing and monetizing our ecosystem with 57% of our revenue now through digital channels and we continue to optimize our business through efficient resource allocation and dynamically balancing our capital allocation priorities to drive long-term value creation. We remain focused on the consistent execution of our strategy and ESG priorities to generate value for our stakeholders and deliver on our purpose to create a future with more cheers.2022 OutlookOverall Performance: We expect our FY22 EBITDA to grow between 6-8% and our revenue to grow ahead of EBITDA from a healthy combination of volume and price. Our medium-term outlook  which aims to deliver EBITDA growth of 4-8%  remains unchanged.Net Finance Costs: Net pension interest expenses and accretion expenses are expected to be in the range of 170 to 200 million USD per quarter  depending on currency and interest rate fluctuations. We expect the average gross debt coupon in FY22 to be approximately 4.0%. Net finance costs will continue to be impacted by any gains and losses related to the hedging of our share-based payment programs.Effective Tax Rates (ETR): We expect the normalized ETR in FY22 to be in the range of 28% to 30% excluding any gains and losses relating to the hedging of our share-based payment programs. The ETR outlook does not consider the impact of potential future changes in legislation.Net Capital Expenditure: We expect net capital expenditure of between 4.5 and 5.0 billion USD in FY22.Figure 1. Consolidated performance (million USD) 3Q21 3Q22 Organic growth Total Volumes (thousand hls) 151 629 157 284 3.7% AB InBev own beer 131 354 137 796 3.4% Non-beer volumes 19 308 18 332 5.2% Third party products 968 1 156 19.4% Revenue 14 274 15 091 12.1% Gross profit 8 236 8 232 6.2% Gross margin 57.7% 54.5% -300 bps Normalized EBITDA 5 214 5 313 6.5% Normalized EBITDA margin 36.5% 35.2% -183 bps Normalized EBIT 4 020 4 055 4.4% Normalized EBIT margin 28.2% 26.9% -195 bps Profit attributable to equity holders of AB InBev 250 1 433 Normalized profit attributable to equity holders of AB InBev 1 002 1 629 Underlying profit attributable to equity holders of AB InBev 1 699 1 682 Earnings per share (USD) 0.12 0.71 Normalized earnings per share (USD) 0.50 0.81 Underlying earnings per share (USD) 0.85 0.84 . . 9M21 9M22 Organic growth Total Volumes (thousand hls) 432 027 446 358 3.3% AB InBev own beer 378 989 389 488 2.8% Non-beer volumes 50 551 53 820 6.5% Third party products 2 487 3 050 22.6% Revenue 40 106 43 118 11.5% Gross profit 23 105 23 475 5.9% Gross margin 57.6% 54.4% -286 bps Normalized EBITDA 14 327 14 896 7.0% Normalized EBITDA margin 35.7% 34.5% -143 bps Normalized EBIT 10 788 11 160 5.9% Normalized EBIT margin 26.9% 25.9% -134 bps Profit attributable to equity holders of AB InBev 2 708 3 126 Normalized profit attributable to equity holders of AB InBev 3 926 4 489 Underlying profit attributable to equity holders of AB InBev 4 290 4 354 Earnings per share (USD) 1.35 1.55 Normalized earnings per share (USD) 1.96 2.23 Underlying earnings per share (USD) 2.14 2.16Figure 2. Volumes (thousand hls) 3Q21 Scope Organic 3Q22 Organic growth growth Total Volume Own beer volume North America 28 137 1 -362 27 775 -1.3% -1.7% Middle Americas 35 591 19 1 705 37 314 4.8% 6.0% South America 39 399 106 1 140 40 644 2.9% 0.4% EMEA 22 124 24 1 576 23 724 7.1% 7.3% Asia Pacific 26 020 1 1 589 27 610 6.1% 6.1% Global Export and Holding Companies 360 -150 8 217 3.7% -0.1% AB InBev Worldwide 151 629 - 5 655 157 284 3.7% 3.4% . 9M21 Scope Organic 9M22 Organic growth growth Total Volume Own beer volume North America 81 389 1 -2 166 79 223 -2.7% -2.6% Middle Americas 103 570 41 5 727 109 338 5.5% 6.6% South America 111 327 257 5 875 117 459 5.3% 2.5% EMEA 62 665 53 3 968 66 686 6.3% 6.3% Asia Pacific 72 101 2 891 72 995 1.2% 1.3% Global Export and Holding Companies 975 -354 36 657 5.8% 4.2% AB InBev Worldwide 432 027 - 14 331 446 358 3.3% 2.8%Key Market PerformancesUnited States: Continued top-line growth driven by our above core portfolioOperating performance: 3Q22: Revenue grew by 1.9% with revenue per hl increasing by 3.8%. Sales-to-wholesalers (STWs) were down by 1.8% and sales-to-retailers (STRs) declined by 1.7%  estimated to be below the industry  with September volumes benefitting from shipment phasing ahead of our October price increase. EBITDA declined by 2.0%.9M22: Top line grew by 2.2% with revenue per hl growth of 5.1%. Our STWs were down by 2.7% and STRâ€™s declined by 3.1%. EBITDA decreased by 0.9%.Commercial highlights: The beer industry remains resilient even in the context of an ongoing inflationary environment. We continue to progress on our commercial strategy to rebalance our portfolio with our above core beer and Beyond Beer brands now generating approximately 40% of our revenue. Our above core beer portfolio outperformed the industry this quarter  led by Michelob ULTRA which grew by double-digits and complemented by growth in Stella Artois  Kona Big Wave and Estrella Jalisco. In Beyond Beer  our spirits-based ready-to-drink portfolio continued to outperform the industry  led by Cutwater  the #1 spirits-based cocktail in the country  and NÃœTRL vodka seltzer which both grew strong double-digits.Mexico: Double-digit top- and bottom-line growth with accelerated market share gainOperating performance: 3Q22: Revenue grew by mid-twenties with revenue per hl growth of mid-teens  driven by revenue management initiatives and premiumization. Our volumes grew by more than 10% as we continued to outperform the industry. EBITDA grew by low-twenties.9M22: Top-line grew by high-teens with high-single digit volume and revenue per hl growth of more than 10%. EBITDA increased by mid-teens.Commercial highlights: We delivered volume growth across all segments of our portfolio this quarter  with our above core portfolio delivering growth in the high-twenties  led by Modelo  Pacifico and Michelob Ultra. We continued to develop our distribution footprint  expanding into over 800 additional Oxxo stores this quarter with the rollout now approximately 80% complete. BEES continues to expand  with approximately 86% of our revenues now digital and 60% of our BEES customers now also BEES Marketplace buyers.Colombia: Double-digit top-line growth with record high per capita consumptionOperating performance: 3Q22: Revenue grew by high-teens with high-single digit volume and low-teens revenue per hl growth  driven by revenue management initiatives and premiumization. EBITDA grew by high-single digits.9M22: Revenue grew by low-twenties with volume increasing by high-single digits and revenue per hl growth of low-teens. EBITDA grew by low-teens.Commercial highlights: Led by the consistent implementation of our category expansion levers  we delivered volume growth across all segments of our portfolio this quarter. Our premium and super premium portfolio continued to lead the way  delivering high-teens volume growth and reaching an all-time high volume and share of our total revenue. More than 30% of our BEES customers are now also BEES Marketplace buyers.Brazil: Double-digit top- and bottom-line growth with margin expansionOperating performance: 3Q22: Revenue grew by 20.1%  with volume growth of 2.4% and revenue per hl growth of 17.3%. Our beer volumes were flat  as we cycled a strong performance in 3Q21. Non-beer volumes grew by 9.2%. EBITDA grew by 23.7% with margin expansion of 75bps.9M22: Total volume grew by 5.9% with beer volumes up by 3.4% and non-beer volumes up by 13.9%. Revenue increased by 21.1%  with revenue per hl growth of 14.3%. EBITDA grew by 18.1%.Commercial highlights: Our premium and super premium brands continued to outperform this quarter  delivering high-single digit volume growth. Our core beer portfolio increased volumes by mid-single digits  and we continued to invest behind the development of our core plus brands. Non-beer volume growth was led by the performance of our premium and wellness brands. Over 70% of our BEES customers are now also BEES Marketplace buyers. Our digital DTC platform  ZÃ© Delivery  fulfilled over 15 million orders in 3Q22  and has reached 4.3 million monthly active users.Europe: Double-digit top-line growth offset by elevated cost pressuresOperating performance: 3Q22: Revenue grew by double-digits  with mid-single digit volume and high-single digit revenue per hl growth  driven by ongoing demand for our premium brands  revenue management initiatives and on-premise recovery. EBITDA declined by mid-single digits  impacted by commodity cost headwinds and increased sales and marketing investments to support our premium strategy and FIFA World Cup TM activations.9M22: Revenue grew by low-teens with high-single digit revenue per hl and low-single digit volume growth. EBITDA increased by mid-single digits.Commercial highlights: We continue to premiumize our portfolio in Europe  with our global and super premium brands both delivering double-digit revenue growth this quarter. Led by the consistent execution of our strategy  in 9M22 we expanded or maintained market share in the majority of our key markets  according to our estimates. Our DTC product  PerfectDraft  expanded its shopper base by more than 20% versus 3Q21.South Africa: Double-digit top- and bottom-line growth and additional investment in capacity to support growthOperating performance: 3Q22: Revenue grew by mid-twenties  with mid-single digit revenue per hl growth  primarily driven by revenue management initiatives. Our volumes grew by high-teens  driven by the execution of our category expansion levers and supported by a favorable comparable from a 25 day ban on alcohol sales in 3Q21. EBITDA grew by over 30%. Versus 3Q19  volumes grew by low-teens  ahead of the industry according to our estimates.9M22: Revenue grew by more than 20% with mid-single digit revenue per hl growth and mid-teens increase in volume. EBITDA grew by high-twenties.Commercial highlights: We delivered growth across all segments of our portfolio this quarter  despite production capacity constraints limiting our ability to fully service consumer demand. We have invested in additional capacity which is expected to come on-line in 4Q22. Our performance was led by over 30% revenue growth in our leading core brand  Carling Black Label. Our premium  super premium and Beyond Beer portfolios all delivered a double-digit increase in volumes. Over 50% of BEES customers are now also BEES Marketplace users.China: Underlying consumer demand remains consistent  though industry impacted by continued COVID-19 restrictionsOperating performance: 3Q22 : COVID-19 restrictions continued to disproportionately impact our key regions and sales channels. Our volumes grew by 3.6%. Revenue per hl declined by 1.9%  driven by negative channel and geographic mix  resulting in total revenue growth of 1.7%. EBITDA declined by 2.3%. 9M22: Volumes declined by 2.2% and revenue per hl grew by 0.7%  leading to total revenue decline of 1.6%. EBITDA declined by 5.1%Commercial highlights: We continue to invest behind our commercial strategy  focused on premiumization  channel and geographic expansion and digital transformation. In our expansion cities  excluding those impacted by restrictions  Budweiser and our super premium portfolio grew volumes by double-digits. Our BEES platform has expanded to more than 90 cities with over 10% of our revenue through digital channels in September.Highlights from our other marketsCanada: Our total volume outperformed the industry. Total revenue grew by high-single digits this quarter with volume growth of mid-single digits.Our total volume outperformed the industry. Total revenue grew by high-single digits this quarter with volume growth of mid-single digits. Peru: Fueled by the consistent execution of our commercial strategy and ongoing portfolio transformation  we delivered record high volumes for the quarter. Revenue grew by low-teens with high-single digit revenue per hl and low-single digit volume growth. Over 50% of BEES customers are now also BEES Marketplace buyers.Fueled by the consistent execution of our commercial strategy and ongoing portfolio transformation  we delivered record high volumes for the quarter. Revenue grew by low-teens with high-single digit revenue per hl and low-single digit volume growth. Over 50% of BEES customers are now also BEES Marketplace buyers. Ecuador: We delivered low-twenties revenue growth with a volume increase of low-teens this quarter  driven by continued expansion of the beer category and a favorable comparable from COVID-19 recovery. Over 60% of BEES customers are now also BEES Marketplace buyers.We delivered low-twenties revenue growth with a volume increase of low-teens this quarter  driven by continued expansion of the beer category and a favorable comparable from COVID-19 recovery. Over 60% of BEES customers are now also BEES Marketplace buyers. Argentina: Volumes grew by high-single digits this quarter  led by our core beer portfolio and global brands. Revenue per hl grew by double-digits  driven primarily by revenue management initiatives in a highly inflationary environment.Volumes grew by high-single digits this quarter  led by our core beer portfolio and global brands. Revenue per hl grew by double-digits  driven primarily by revenue management initiatives in a highly inflationary environment. Africa excluding South Africa : In Nigeria  our top-line grew by high-single digits this quarter  driven by revenue management initiatives  though volumes declined due to a soft industry and ongoing supply chain constraints. In our other key markets  we delivered double-digit revenue growth in 3Q22  driven by Tanzania  Zambia and Botswana. We are investing in additional capacity in Zambia to support growth.: In Nigeria  our top-line grew by high-single digits this quarter  driven by revenue management initiatives  though volumes declined due to a soft industry and ongoing supply chain constraints. In our other key markets  we delivered double-digit revenue growth in 3Q22  driven by Tanzania  Zambia and Botswana. We are investing in additional capacity in Zambia to support growth. South Korea: Volumes grew by mid-teens this quarter  driven by our leading core brand â€˜All New Cassâ€™  continued market share gains and further improvement in the operating environment. Revenue per hl increased by mid-single digits resulting in double-digit revenue growth.Consolidated Income Statement Figure 3. Consolidated income statement (million USD) 3Q21 3Q22 Organic growth Revenue 14 274 15 091 12.1% Cost of sales -6 039 -6 860 -20.0% Gross profit 8 236 8 232 6.2% SG&A -4 379 -4 347 -8.0% Other operating income/(expenses) 163 170 8.1% Normalized profit from operations (normalized EBIT) 4 020 4 055 4.4% Non-underlying items above EBIT -73 -165 Net finance income/(cost) -1 900 -1 392 Non-underlying net finance income/(cost) -747 -65 Share of results of associates 73 81 Income tax expense -679 -688 Profit 695 1 825 Profit attributable to non-controlling interest 444 392 Profit attributable to equity holders of AB InBev 250 1 433 Normalized EBITDA 5 214 5 313 6.5% Normalized profit attributable to equity holders of AB InBev 1 002 1 629 . 9M21 9M22 Organic growth Revenue 40 106 43 118 11.5% Cost of sales -17 001 -19 644 -19.0% Gross profit 23 105 23 475 5.9% SG&A -12 950 -12 963 -6.1% Other operating income/(expenses) 633 648 9.9% Normalized profit from operations (normalized EBIT) 10 788 11 160 5.9% Non-underlying items above EBIT -290 -270 Net finance income/(cost) -3 948 -3 674 Non-underlying net finance income/(cost) -1 046 -51 Share of results of associates 174 210 Non-underlying share of results of associates - -1 143 Income tax expense -1 910 -1 933 Profit 3 768 4 299 Profit attributable to non-controlling interest 1 061 1 174 Profit attributable to equity holders of AB InBev 2 708 3 126 Normalized EBITDA 14 327 14 896 7.0% Normalized profit attributable to equity holders of AB InBev 3 926 4 489Consolidated other operating income/(expenses) in 9M22 increased by 9.9% primarily driven by higher government grants. In 9M22  Ambev recognized 201 million USD income in other operating income related to tax credits (9M21: 226 million USD). The net impact is presented as a scope change and does not affect the presented organic growth rates.Non-underlying items above EBIT & Non-underlying share of results of associates Figure 4. Non-underlying items above EBIT & Non-underlying share of results of associates (million USD) 3Q21 3Q22 9M21 9M22 COVID-19 costs -30 -2 -84 -16 Restructuring -38 -13 -135 -63 Business and asset disposal (incl. impairment losses) - -149 14 -143 AB InBev Efes related costs - -1 - -48 Acquisition costs / Business combinations -5 - -12 - SAB Zenzele Kabili costs - - -73 - Non-underlying items in EBIT -73 -165 -290 -270 Non-underlying share of results of associates - - - -1 143EBIT excludes negative non-underlying items of 165 million USD in 3Q22 and 270 million USD in 9M22. Business and asset disposals in 3Q22 comprise mainly impairment of intangible assets and other non-core assets sold in the period.Non-underlying share of results of associates includes the non-cash impairment of 1 143 million USD the company recorded on its investment in AB InBev Efes in 1Q22.Net finance income/(cost) Figure 5. Net finance income/(cost) (million USD) 3Q21 3Q22 9M21 9M22 Net interest expense -880 -826 -2 709 -2 509 Net interest on net defined benefit liabilities -18 -18 -55 -55 Accretion expense -161 -215 -427 -551 Mark-to-market -683 -79 -335 83 Net interest income on Brazilian tax credits 14 34 102 146 Other financial results -171 -287 -524 -788 Net finance income/(cost) -1 900 -1 392 -3 948 -3 674Net finance costs in 9M22 were positively impacted by the mark-to-market gain on the hedging of our share-based payment programs. The number of shares covered by the hedging of our share-based payment programs  and the opening and closing share prices  are shown in figure 6 below.Figure 6. Share-based payment hedge 3Q21 3Q22 9M21 9M22 Share price at the start of the period (Euro) 60.81 51.36 57.01 53.17 Share price at the end of the period (Euro) 49.15 46.75 49.15 46.75 Number of equity derivative instruments at the end of the period (millions) 55.0 55.0 55.0 55.0Non-underlying net finance income/(cost)Figure 7. Non-underlying net finance income/(cost) (million USD) 3Q21 3Q22 9M21 9M22 Mark-to-market -567 -65 -284 69 Early termination fee of Bonds and Other -180 - -762 -120 Non-underlying net finance income/(cost) -747 -65 -1 046 -51Non-underlying net finance cost in 9M22 includes mark-to-market gains on derivative instruments entered into to hedge the shares issued in relation to the Grupo Modelo and SAB combinations.The number of shares covered by the hedging of the deferred share instrument and the restricted shares are shown in figure 8  together with the opening and closing share prices.Figure 8. Non-underlying equity derivative instruments 3Q21 3Q22 9M21 9M22 Share price at the start of the period (Euro) 60.81 51.36 57.01 53.17 Share price at the end of the period (Euro) 49.15 46.75 49.15 46.75 Number of equity derivative instruments at the end of the period (millions) 45.5 45.5 45.5 45.5Income tax expense Figure 9. Income tax expense (million USD) 3Q21 3Q22 9M21 9M22 Income tax expense 679 688 1 910 1 933 Effective tax rate 52.2% 28.3% 34.7% 27.0% Normalized effective tax rate 35.1% 27.1% 29.5% 27.2% Normalized effective tax rate before MTM 26.5% 26.3% 28.1% 27.5%The decrease in normalized ETR excluding mark-to-market gains and losses linked to the hedging of our share-based payment programs in 3Q22 compared to 3Q21 and the decrease in 9M22 compared to 9M21 is driven by country mix.Figure 10. Normalized Profit attributable to equity holders of AB InBev (million USD) 3Q21 3Q22 9M21 9M22 Profit attributable to equity holders of AB InBev 250 1 433 2 708 3 126 Net impact of non-underlying items on profit 752 195 1 218 1 363 Normalized profit attributable to equity holders of AB InBev 1 002 1 629 3 926 4 489 Underlying profit attributable to equity holders of AB InBev 1 699 1 682 4 290 4 354Basic  normalized and underlying EPS Figure 11. Earnings per share (USD) 3Q21 3Q22 9M21 9M22 Basic earnings per share 0.12 0.71 1.35 1.55 Net impact of non-underlying items on profit 0.38 0.09 0.61 0.68 Normalized earnings per share 0.50 0.81 1.96 2.23 Underlying earnings per share 0.85 0.84 2.14 2.16 Weighted average number of ordinary and restricted shares (million) 2 006 2 012 2 006 2 012Figure 12. Key components - Normalized Earnings per share in USD 3Q21 3Q22 9M21 9M22 Normalized EBIT before hyperinflation 2.01 2.02 5.40 5.58 Hyperinflation impacts in normalized EBIT - -0.01 -0.02 -0.03 Normalized EBIT 2.01 2.02 5.38 5.55 Mark-to-market (share-based payment programs) -0.34 -0.04 -0.17 0.04 Net finance cost -0.61 -0.65 -1.80 -1.87 Income tax expense -0.37 -0.36 -1.01 -1.01 Associates & non-controlling interest -0.19 -0.15 -0.45 -0.48 Normalized EPS 0.50 0.81 1.96 2.23 Mark-to-market (share-based payment programs) 0.34 0.04 0.17 -0.04 Hyperinflation impacts in EPS 0.01 -0.01 0.01 -0.03 Underlying EPS 0.85 0.84 2.14 2.16 Weighted average number of ordinary and restricted shares (million) 2 006 2 012 2 006 2 012Reconciliation between profit attributable to equity holders and normalized EBITDAFigure 13. Reconciliation of normalized EBITDA to profit attributable to equity holders of AB InBev (million USD) 3Q21 3Q22 9M21 9M22 Profit attributable to equity holders of AB InBev 250 1 433 2 708 3 126 Non-controlling interests 444 392 1 061 1 174 Profit 695 1 825 3 768 4 299 Income tax expense 679 688 1 910 1 933 Share of result of associates -73 -81 -174 -210 Non-underlying share of results of associates - - - 1 143 Net finance (income)/cost 1 900 1 392 3 948 3 674 Non-underlying net finance (income)/cost 747 65 1 046 51 Non-underlying items above EBIT 73 165 290 270 Normalized EBIT 4 020 4 055 10 788 11 160 Depreciation  amortization and impairment 1 194 1 259 3 539 3 736 Normalized EBITDA 5 214 5 313 14 327 14 896Normalized EBITDA and normalized EBIT are measures utilized by AB InBev to demonstrate the companyâ€™s underlying performance.Normalized EBITDA is calculated excluding the following effects from profit attributable to equity holders of AB InBev: (i) non-controlling interest; (ii) income tax expense; (iii) share of results of associates; (iv) non-underlying share of results of associates; (v) net finance cost; (vi) non-underlying net finance cost; (vii) non-underlying items above EBIT; and (viii) depreciation  amortization and impairment.Normalized EBITDA and normalized EBIT are not accounting measures under IFRS accounting and should not be considered as an alternative to profit attributable to equity holders as a measure of operational performance  or an alternative to cash flow as a measure of liquidity. Normalized EBITDA and normalized EBIT do not have a standard calculation method and AB InBevâ€™s definition of normalized EBITDA and normalized EBIT may not be comparable to that of other companies.NotesTo facilitate the understanding of AB InBevâ€™s underlying performance  the analyses of growth  including all comments in this press release  unless otherwise indicated  are based on organic growth and normalized numbers. In other words  financials are analyzed eliminating the impact of changes in currencies on translation of foreign operations  and scope changes. Scope changes represent the impact of acquisitions and divestitures  the start or termination of activities or the transfer of activities between segments  curtailment gains and losses and year over year changes in accounting estimates and other assumptions that management does not consider as part of the underlying performance of the business. All references per hectoliter (per hl) exclude US non-beer activities. Whenever presented in this document  all performance measures (EBITDA  EBIT  profit  tax rate  EPS) are presented on a â€œnormalizedâ€ basis  which means they are presented before non-underlying items. Non-underlying items are either income or expenses which do not occur regularly as part of the normal activities of the Company. They are presented separately because they are important for the understanding of the underlying sustainable performance of the Company due to their size or nature. Normalized measures are additional measures used by management and should not replace the measures determined in accordance with IFRS as an indicator of the Companyâ€™s performance. We are reporting the results from Argentina applying hyperinflation accounting  starting from the 3Q18 results release in which we accounted for the hyperinflation impact for the first nine months of 2018. The IFRS rules (IAS 29) require us to restate the year-to-date results for the change in the general purchasing power of the local currency  using official indices before converting the local amounts at the closing rate of the period. These impacts are excluded from organic calculations and are identified separately in the annexes within the column labeled â€œHyperinflation restatementâ€ for the quarter and within the column â€œCurrency translationâ€ year to date. In 9M22  we reported a positive impact on the profit attributable to equity holders of AB InBev of 52 million USD. The impact in 9M22 normalized EPS was 0.03 USD. Values in the figures and annexes may not add up  due to rounding. 3Q22 and 9M22 EPS is based upon a weighted average of 2 012 million shares compared to a weighted average of 2 006 million shares for 3Q21 and 9M21.Legal disclaimerThis release contains â€œforward-looking statementsâ€. These statements are based on the current expectations and views of future events and developments of the management of AB InBev and are naturally subject to uncertainty and changes in circumstances. The forward-looking statements contained in this release include statements other than historical facts and include statements typically containing words such as â€œwillâ€  â€œmayâ€  â€œshouldâ€  â€œbelieveâ€  â€œintendsâ€  â€œexpectsâ€  â€œanticipatesâ€  â€œtargetsâ€  â€œestimatesâ€  â€œlikelyâ€  â€œforeseesâ€ and words of similar import. All statements other than statements of historical facts are forward-looking statements. You should not place undue reliance on these forward-looking statements  which reflect the current views of the management of AB InBev  are subject to numerous risks and uncertainties about AB InBev and are dependent on many factors  some of which are outside of AB InBevâ€™s control. There are important factors  risks and uncertainties that could cause actual outcomes and results to be materially different  including  but not limited to  the effects of the COVID-19 pandemic and uncertainties about its impact and duration and the risks and uncertainties relating to AB InBev described under Item 3.D of AB InBevâ€™s Annual Report on Form 20-F filed with the SEC on 18 March 2022. Many of these risks and uncertainties are  and will be  exacerbated by the COVID-19 pandemic and the ongoing conflict in Russia and Ukraine and any worsening of the global business and economic environment. Other unknown or unpredictable factors could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements should be read in conjunction with the other cautionary statements that are included elsewhere  including AB InBevâ€™s most recent Form 20-F and other reports furnished on Form 6-K  and any other documents that AB InBev has made public. Any forward-looking statements made in this communication are qualified in their entirety by these cautionary statements and there can be no assurance that the actual results or developments anticipated by AB InBev will be realized or  even if substantially realized  that they will have the expected consequences to  or effects on  AB InBev or its business or operations. Except as required by law  AB InBev undertakes no obligation to publicly update or revise any forward-looking statements  whether as a result of new information  future events or otherwise. The third quarter 2022 (3Q22) and nine month (9M22) financial data set out in Figure 1 (except for the volume information)  Figures 3 to 5  7  9  10 and 13 of this press release have been extracted from the groupâ€™s unaudited condensed consolidated interim financial statements as of and for the nine months ended 30 September 2022  which have been reviewed by our statutory auditors PwC RÃ©viseurs dâ€™Entreprises SRL / PwC Bedrijfsrevisoren BV in accordance with the standards of the Public Company Accounting Oversight Board (United States). Financial data included in Figures 6  8 11 and 12 have been extracted from the underlying accounting records as of and for the nine months ended 30 September 2022 (except for the volume information). References in this document to materials on our websites  such as www.bees.com  are included as an aid to their location and are not incorporated by reference into this document.Conference call and webcastInvestor Conference call and webcast on Thursday  27 October 2022:3.00pm Brussels / 2.00pm London / 9.00am New YorkRegistration details:Webcast (listen-only mode):AB InBev 3Q & 9M22 Results WebcastTo join by phone  please use one of the following two phone numbers:Toll-Free: 877-407-8029Toll: 201-689-8029About Anheuser-Busch InBevAnheuser-Busch InBev is a publicly traded company (Euronext: ABI) based in Leuven  Belgium  with secondary listings on the Mexico (MEXBOL: ANB) and South Africa (JSE: ANH) stock exchanges and with American Depositary Receipts on the New York Stock Exchange (NYSE: BUD). As a company  we dream big to create a future with more cheers. We are always looking to serve up new ways to meet lifeâ€™s moments  move our industry forward and make a meaningful impact in the world. We are committed to building great brands that stand the test of time and to brewing the best beers using the finest ingredients. Our diverse portfolio of well over 500 beer brands includes global brands BudweiserÂ®  CoronaÂ® and Stella ArtoisÂ®; multi-country brands Beckâ€™sÂ®  HoegaardenÂ®  LeffeÂ® and Michelob ULTRAÂ®; and local champions such as AguilaÂ®  AntarcticaÂ®  Bud LightÂ®  BrahmaÂ®  CassÂ®  CastleÂ®  Castle LiteÂ®  CristalÂ®  HarbinÂ®  JupilerÂ®  Modelo EspecialÂ®  QuilmesÂ®  VictoriaÂ®  SedrinÂ®  and SkolÂ®. Our brewing heritage dates back more than 600 years  spanning continents and generations. From our European roots at the Den Hoorn brewery in Leuven  Belgium. To the pioneering spirit of the Anheuser & Co brewery in St. Louis  US. To the creation of the Castle Brewery in South Africa during the Johannesburg gold rush. To Bohemia  the first brewery in Brazil. Geographically diversified with a balanced exposure to developed and developing markets  we leverage the collective strengths of approximately 169 000 colleagues based in nearly 50 countries worldwide. For 2021  AB InBevâ€™s reported revenue was 54.3 billion USD (excluding JVs and associates).Annex 1AB InBev Worldwide 3Q21 Scope Currency Translation Hyperinflation restatement Organic Growth 3Q22 Organic Growth Total volumes (thousand hls) 151 629 - - - 5 655 157 284 3.7% of which AB InBev own beer 131 354 1 885 - - 4 557 137 796 3.4% Revenue 14 274 -118 -966 193 1 708 15 091 12.1% Cost of sales -6 039 3 462 -81 -1 205 -6 860 -20.0% Gross profit 8 236 -115 -504 112 503 8 232 6.2% SG&A -4 379 111 311 -49 -341 -4 347 -8.0% Other operating income/(expenses) 163 -1 -12 6 14 170 8.1% Normalized EBIT 4 020 -5 -206 69 176 4 055 4.4% Normalized EBITDA 5 214 -12 -302 76 337 5 313 6.5% Normalized EBITDA margin 36.5% 35.2% -183 bps North America 3Q21 Scope Currency Translation Hyperinflation restatement Organic Growth 3Q22 Organic Growth Total volumes (thousand hls) 28 137 1 - - -362 27 775 -1.3% Revenue 4 342 - -23 - 122 4 442 2.8% Cost of sales -1 625 -2 8 - -180 -1 800 -11.1% Gross profit 2 717 -2 -15 - -58 2 642 -2.1% SG&A -1 189 -22 8 - 61 -1 142 5.1% Other operating income/(expenses) 16 3 - - -13 6 -70.3% Normalized EBIT 1 544 -22 -6 - -11 1 506 -0.7% Normalized EBITDA 1 743 -21 -7 - -29 1 686 -1.6% Normalized EBITDA margin 40.1% 37.9% -174 bps Middle Americas 3Q21 Scope Currency Translation Hyperinflation restatement Organic Growth 3Q22 Organic Growth Total volumes (thousand hls) 35 591 19 - - 1 705 37 314 4.8% Revenue 3 163 -13 -66 - 490 3 574 15.5% Cost of sales -1 117 6 27 - -311 -1 395 -28.0% Gross profit 2 047 -7 -39 - 179 2 180 8.8% SG&A -759 4 15 - -139 -880 -18.4% Other operating income/(expenses) 5 - - - -2 3 - Normalized EBIT 1 292 -3 -24 - 38 1 303 2.9% Normalized EBITDA 1 572 -3 -29 - 91 1 631 5.8% Normalized EBITDA margin 49.7% 45.6% -421 bps South America 3Q21 Scope Currency Translation Hyperinflation restatement Organic Growth 3Q22 Organic Growth Total volumes (thousand hls) 39 399 106 - - 1 140 40 644 2.9% Revenue 2 459 33 -459 193 661 2 887 27.0% Cost of sales -1 291 -11 219 -81 -359 -1 522 -27.9% Gross profit 1 168 22 -240 112 302 1 364 26.0% SG&A -705 -40 132 -49 -192 -854 -26.2% Other operating income/(expenses) 48 -4 -3 6 17 64 32.1% Normalized EBIT 511 -22 -112 69 128 574 26.4% Normalized EBITDA 716 -22 -148 76 172 795 25.0% Normalized EBITDA margin 29.1% 27.5% -41 bpsEMEA 3Q21 Scope Currency Translation Hyperinflation restatement Organic Growth 3Q22 Organic Growth Total volumes (thousand hls) 22 124 24 - - 1 576 23 724 7.1% Revenue 2 136 -63 -272 - 310 2 110 14.9% Cost of sales - 984 -3 141 - -219 -1 065 -22.1% Gross profit 1 152 -66 -132 - 91 1 045 8.4% SG&A -704 67 90 - -79 -627 -12.3% Other operating income/(expenses) 58 1 -7 - -2 50 -4.1% Normalized EBIT 506 1 -49 - 10 468 1.9% Normalized EBITDA 754 -7 -83 - 79 744 10.6% Normalized EBITDA margin 35.3% 35.3% -135 bps Asia Pacific 3Q21 Scope Currency Translation Hyperinflation restatement Organic Growth 3Q22 Organic Growth Total volumes (thousand hls) 26 020 1 - - 1 589 27 610 6.1% Revenue 1 901 -27 -131 - 132 1 876 7.1% Cost of sales -825 -1 59 - -121 -889 -14.7% Gross profit 1 076 -28 -72 - 11 987 1.1% SG&A -603 26 39 - -11 -549 -1.9% Other operating income/(expenses) 28 - -2 - 10 36 35.0% Normalized EBIT 500 -2 -35 - 10 474 1.9% Normalized EBITDA 673 -2 -45 - 11 638 1.7% Normalized EBITDA margin 35.4% 34.0% -180 bps Global Export and Holding Companies 3Q21 Scope Currency Translation Hyperinflation restatement Organic Growth 3Q22 Organic Growth Total volumes (thousand hls) 360 -150 - - 8 217 3.7% Revenue 272 -47 -16 - -7 202 -3.2% Cost of sales -196 14 8 - -14 -189 -7.9% Gross profit 76 -33 -8 - -22 14 -50.2% SG&A -418 76 27 - 19 -296 5.3% Other operating income/(expenses) 7 - - - 5 12 64.3% Normalized EBIT -334 43 19 - 2 -270 0.7% Normalized EBITDA -245 43 10 - 12 -181 5.3%Annex 2AB InBev Worldwide 9M21 Scope Currency Translation Organic Growth 9M22 Organic Growth Total volumes (thousand hls) 432 027 - - 14 331 446 358 3.3% of which AB InBev own beer 378 989 - 7 - 10 506 389 488 2.8% Revenue 40 106 -346 -1 215 4 573 43 118 11.5% Cost of sales -17 001 6 573 -3 222 -19 644 -19.0% Gross profit 23 105 -340 -641 1 351 23 475 5.9% SG&A -12 950 324 433 -771 -12 963 -6.1% Other operating income/(expenses) 633 -19 -8 42 648 9.9% Normalized EBIT 10 788 -35 -216 622 11 160 5.9% Normalized EBITDA 14 327 -56 -361 986 14 896 7.0% Normalized EBITDA margin 35.7% 34.5% -143 bps North America 9M21 Scope Currency Translation Organic Growth 9M22 Organic Growth Total volumes (thousand hls) 81 389 1 - -2 166 79 223 -2.7% Revenue 12 382 - -40 293 12 634 2.4% Cost of sales -4 705 -8 15 -450 -5 149 -9.6% Gross profit 7 677 -8 -26 -158 7 486 -2.1% SG&A -3 539 -24 15 126 -3 421 3.6% Other operating income/(expenses) 31 9 - -6 34 -15.6% Normalized EBIT 4 169 -23 -11 -38 4 098 -0.9% Normalized EBITDA 4 756 -21 -13 -62 4 660 -1.3% Normalized EBITDA margin 38.4% 36.9% -137 bps Middle Americas 9M21 Scope Currency Translation Organic Growth 9M22 Organic Growth Total volumes (thousand hls) 103 570 41 - 5 727 109 338 5.5% Revenue 9 057 -40 -173 1 424 10 267 15.8% Cost of sales -3 171 15 67 -930 -4 020 -29.5% Gross profit 5 885 -25 -106 493 6 248 8.4% SG&A -2 336 18 40 -234 -2 511 -10.1% Other operating income/(expenses) 9 - 1 -19 -9 - Normalized EBIT 3 558 -6 -65 240 3 728 6.8% Normalized EBITDA 4 397 -6 -76 377 4 691 8.6% Normalized EBITDA margin 48.5% 45.7% -303 bps South America 9M21 Scope Currency Translation Organic Growth 9M22 Organic Growth Total volumes (thousand hls) 111 327 257 - 5 875 117 459 5.3% Revenue 6 605 85 -259 1 789 8 220 27.1% Cost of sales -3 382 -23 123 -1 034 -4 315 -30.6% Gross profit 3 223 62 -135 755 3 905 23.3% SG&A -1 960 -100 72 -476 -2 463 -23.4% Other operating income/(expenses) 336 -29 3 67 376 55.8% Normalized EBIT 1 599 -67 -60 345 1 818 26.2% Normalized EBITDA 2 163 -67 -89 454 2 461 24.1% Normalized EBITDA margin 32.7% 29.9% -64 bps,neutral,0.0,1.0,0.0,positive,0.9,0.1,0.0,True,English,"['Third Quarter 2022 Results', 'Anheuser-Busch InBev', 'manageable weighted average pre-tax coupon rate', 'monthly active user base', 'Cannes Lions International Festival', 'three key strategic pillars', 'Global Effie Effectiveness Index', 'ongoing dynamic operating environment', 'Best quarterly volume performance', '3.1 million monthly active users', 'normalized EBITDA margin contraction', 'broad-based total volume increase', 'share-based payment programs', 'Belgian Royal Decree', 'commodity cost headwinds', 'medium-term refinancing requirements', 'long-term value creation', 'net interest expense', 'B2B digital platforms', 'creative marketing capabilities', '17 million ecommerce orders', 'broad-based volume growth', 'FY22 EBITDA outlook', 'strong consumer demand', 'respective home markets', 'resilient beer category', 'revenue management initiatives', '3Q22 normalized EBITDA', 'fixed rate', 'average maturity', '3.1 million users', 'volume momentum', 'global brands', 'Management comments', 'digital transformation', 'marketing investments', 'total volumes', 'normalized profit', 'beer volumes', 'consumer participation', '385 million USD', '200 million USD', 'Anheuser-Busch InBev', 'Michel Doukeris', 'AB InBev', 'combined revenues', 'Stella Artois', 'tax credits', 'equity holders', 'market gains', 'Underlying EPS', 'EU) No', 'European Parliament', 'market abuse', 'financial instruments', 'regulated market', 'important disclaimers', 'transactional FX', 'brand building', 'first time', 'company history', 'Consistent execution', 'Marketplace buyers', 'five proven', 'scalable levers', 'EBITDA figures', 'consumer ecosystem', 'Total Revenue', 'category expansion', 'BUSINESS WIRE', 'continued momentum', 'deleveraging path', 'consistent growth', 'BEES Marketplace', 'BEES customers', 'brand portfolio', 'bond portfolio', 'inside information', 'top-line growth', '313 million', '896 million', '12.7% increase', '3.7% growth', '19 markets', '14 markets', '8.0% revenue', 'BRUSSELS', 'BMV', 'ANB', 'JSE', 'BUD', 'information1', 'result', 'bottom-end', 'CEO', '9M22', 'Corona', '30 September', '9M21', 'impact', 'Brazil', '2Q22', '2Q21', 'details', 'page', 'losses', 'hedging', 'hyperinflation', '3Q21', 'decrease', 'Regulation', 'Council', '16 April', '14 November', 'duties', 'issuers', 'trading', 'notes', 'basis', 'preparation', 'context', 'premiumization', 'sales', 'recognition', 'Creativity', 'World', 'Marketer', '16 years', 'strategy', 'Image', '183', '143', '1 699', '4 290', '0.']",2022-10-27,2022-10-28,businesswire.com
12332,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/27/2543115/0/en/Coface-reports-a-new-record-result-of-84-0m-in-Q3-2022-Annualised-return-on-tangible-equity-at-16-4.html,Coface reports a new record result of â‚¬84.0m in Q3-2022. Annualised return on tangible equity at 16.4%,Coface reports a new record result of â‚¬84.0m in Q3-2022. Annualised return on tangible equity at 16.4%  Paris  27 October 2022 â€“ 17.35  Turnover of...,"English FrenchCoface reports a new record result of â‚¬84.0m in Q3-2022. Annualised return on tangible equity at 16.4%Paris  27 October 2022 â€“ 17.35Turnover of first nine months : â‚¬ 1 363 m  up 1 5.2 % at constant FX and perimeter and up 17.7 % on a reported basis Trade Credit Insurance premiums growing by 16.6% driven by high client activity in still inflationary environment Client retention at record highs (93.5%); pricing down (-3.0%) in line with H1-22 Business information momentum continues (revenues up +15.6% at constant FX)9M-2022 n et loss ratio at 36.9%  up by 11.5 ppts ; n et combined ratio at 63.8 %   up by 7.7 ppts Gross loss ratio up by 5.0 ppts at 30.2%  as normalization of risk environment continues Net cost ratio down by (3.8) ppts at 26.9% reflecting continued operating leverage and higher reinsurance commissions Q3-2022 net combined ratio at 59.6% on continued low loss ratioNet income (group share) at â‚¬ 228.4 m  including â‚¬ 84.0 m for Q 3 -2022 ; annualised RoATE 1 at 16 . 4 % Successful early refinancing of its grandfathered T2 debt  de-risking 2024 deadline Moodyâ€™s confirmed its credit rating for Coface and raised its outlook to ""Positive""Unless otherwise indicated  change comparisons refer to the results as at 30 September 2021.Xavier Durand  Cofaceâ€™s Chief Executive Officer  commented:â€œThe third quarter brought no improvement in terms of the major risks facing the global economy: monetary tightening remains aggressive as inflation remains high  the conflict in Ukraine is continuing and the European energy crisis remains acute. The situation in the United Kingdom served as a reminder that governments have little financial leeway and that fiscal and monetary policies need to be aligned. As expected  global growth forecasts have been downgraded.Bankruptcies are continuing to rise  especially in developed countries. Coface maintains its prudent reserving policy on Russia. This environment did not prevent Coface from achieving record net income of â‚¬84m in the third quarter  with the YTD figure now totalling â‚¬228m  higher than in fiscal year 2021. This corresponds to annualised return on tangible equity of 16.4%.Investments in adjacent businesses are continuing. Information services (+15.6%) and factoring (+13.0%) recorded continued growth in turnover. Coface is also continuing to focus on service quality  reflected in the record high retention rate and an improvement in the net promoter score (NPS) to 38%.We welcome Moodyâ€™s decision to assign our credit rating a positive outlook. This acknowledges the work done by all of Coface's teams over the past few years and our strengths at the beginning of a more complex stage in the economic cycle.""Key figures at 30 September 2022The Board of Directors of COFACE SA examined the consolidated financial statements at 30 September 2022 (non-audited figures) at its meeting of 27 October 2022. The Audit Committee at its meeting on 26 October 2022 also previously reviewed them.Income statements items in â‚¬m 9M-21 9M-22 % %ex. FX* Gross earned premiums 969.5 1 152.1 +18.8% +16.6% Services revenue 188.9 211.0 +11.7% +7.9% REVENUE 1 158.4 1 363.1 +17.7% +15.2% UNDERWRITING INCOME/LOSS AFTER REINSURANCE 235.2 295.7 +25.7% +29.8% Investment income  net of management expenses 30.9 39.1 +26.5% +26.8% CURRENT OPERATING INCOME 266.1 334.8 +25.8% +29.4% Other operating income / expenses (0.8) (5.0) +499.8% +484.7% OPERATING INCOME 265.3 329.8 +24.3% +28.0% NET INCOME 190.9 228.4 +19.6% +24.7% Key ratios 9M-21 9M-22 % %ex. FX* Loss ratio net of reinsurance 25.4% 36.9% +11.5 ppts Cost ratio net of reinsurance 30.7% 26.9% (3.8) ppts COMBINED RATIO NET OF REINSURANCE 56.1% 63.8% +7.7 ppts Balance sheet items in â‚¬m 2021 9M-22 % %ex. FX* Total Equity (group share) 2 141.0 1 955.2 (8.7)%* Also excludes scope impact1. TurnoverCoface recorded a consolidated turnover of â‚¬1 363.1m over the first nine months of 2022  up +15.2% at constant FX and perimeter compared to 9M-21. On a reported basis (at current FX and perimeter)  turnover was up +17.7%.Revenues from insurance activities (including bonding and Single Risk) increased by +16.6% at constant FX and perimeter (and by +18.8% at current FX) compared to 9M-21. Growth benefited from an increase in client activity and continued high retention.The retention rate reached a record level of 93.5%  up +1.4% compared to 9M-21. New business totalled â‚¬82m  down â‚¬20m compared to 9M-21 in an increasingly competitive market.The growth in Cofaceâ€™s client activity had a positive impact of +11.1% over 9M-22. This record increase for the first nine months reflects the scale of the recent economic recovery and inflation. The price effect continued to reverse  coming in at -3.0% in 9M-22  in line with the -3.0% fall in H1-22. This is largely due to previous very low loss experience.Revenues from other activities were up +7.9% compared to 9M-21  still with contrasting trends in the different businesses. Turnover from factoring rose +13.0%  mainly due to the increase in volumes refinanced in Poland. Revenues from information services continued to grow  rising +15.6% (vs. +13.4% in 9M-21). Fee and commission income (collection fees) was impacted by the decline in claims to be recovered and dropped -37.9% while commissions were up by +6.7%.Total revenue - in â‚¬m(by country of invoicing) 9M-21 9M-22 Variation %ex. FX2 Northern Europe 250.4 277.3 +10.7% +9.6% Western Europe 233.6 271.0 +16.0% +14.8% Central & Eastern Europe 115.3 135.6 +17.6% +16.8% Mediterranean & Africa 313.8 362.0 +15.4% +17.2% North America 99.3 125.1 +26.0% +12.4% Latin America 55.3 78.2 +41.3% +29.8% Asia Pacific 90.7 114.0 +25.7% +16.6% Total Group 1 158.4 1 363.1 +17.7% +15.2%In Northern Europe  turnover increased by +9.6% at constant FX (+10.7% at current FX). Trade credit insurance benefited from the increase in client activity and a high retention rate. Factoring turnover increased by +7.0%.In Western Europe  turnover was up by +14.8% at constant FX (+16.0% at current FX) thanks to a high retention rate and client activity.In Central and Eastern Europe  turnover was up by +16.8% and by +17.6% at constant FX  due to high retention  and growth in trade credit insurance driven by client activity. Factoring turnover continued to increase significantly  rising by +36.9%.In Mediterranean and Africa  a region driven by Italy and Spain  turnover grew by +17.2% and by +15.4% at current FX. This was due to high levels of new business and high retention. Revenues from services increased by +27.7%.In North America  turnover increased +12.4% at constant FX and +26.0% as reported  driven by high client activity and positive FX effect  which were partially offset by premium refunds.In Latin America  turnover was up +29.8% at constant FX and +41.3% at current FX  driven by strong retention as well as growth in client activity driven by the rise in commodity prices.In Asia-Pacific  turnover increased +16.6% at constant FX and +25.7% at current FX. This growth was driven by high retention and increased client activity as well as a positive currency effect.2. ResultCombined ratioThe combined ratio  net of reinsurance  stood at 63.8% for 9M-22 (a rise of 7.7 points compared to 9M-21).(i) Loss ratioThe gross loss ratio stood at 30.2%  up 5.0 ppts compared to the previous year. This reflects an increased claims frequency since H1-21  with the number of claims close to pre-Covid levels and the return of relatively large claims  which nevertheless remain below average. Coface increased its provisions relating to the residual exposure in Russia.The Groupâ€™s reserving policy remains unchanged. Strict management of past claims enabled Coface to record 53.1 ppts of recoveries. The loss ratio for the 2022 underwriting year is still high at 80.9%  signalling that Coface anticipates an increase in the number of bankruptcies in the coming quarters  and an increase in reserves on Russia.The loss ratio net of reinsurance came out at 36.9%  up by 11.5 ppts compared to 9M-21.(ii) Cost ratioCoface is following its strict policy of cost management. In the third quarter 2022  costs rose by +16.0% at constant FX and perimeter  and +20.1% at current FX. This increase is in line with the growth in turnover  even though Coface continued to invest. The cost ratio before reinsurance was 32.2%  an improvement of 0.8 ppt over one year.The cost ratio  net of reinsurance was 26.9% for the first nine months  an improvement of 3.8 ppts year-on-year  reflecting lower gross cost ratio and higher reinsurance commissions.Financial resultNet financial income for 9M-22 was â‚¬39.1m  up by â‚¬8.2m compared to 9M-21. This figure includes â‚¬10.7m in realised capital gains and positive hedging results as well as a currency effect of â‚¬3.2m. This performance was achieved against a particularly turbulent market backdrop  primarily due to the effectiveness of hedging policies.The portfolioâ€™s current yield (i.e. excluding capital gains  depreciation and FX impact) is â‚¬29.5m (compared to â‚¬25.2m in 9M-21). The accounting yield3  excluding capital gains and depreciation  stood at 1.0% in 9M-22  up compared to the previous year (0.9%)  mainly due to higher reinvestment rates.Operating income and net incomeOperating income for 9M-22 was â‚¬329.8m  up +24.3%  mainly due to increased growth and a still low loss ratio.The effective tax rate was 26%  compared to 24% for 9M-21.In total  net income (group share) was â‚¬228.4m  up +19.6% compared to 9M-21  of which â‚¬84.0m in Q3-22.3. Shareholdersâ€™ equity & solvencyAt 30 September 2022  Group shareholdersâ€™ equity stood at â‚¬1 955.2m  down â‚¬185.8m  or -8.7% (compared to â‚¬2 141.0m at 31 December 2021).This change is mainly due to the positive net income of â‚¬228.4m  the payment of the dividend (-â‚¬224.8m) and the fall in unrealised capital gains (-â‚¬240.5m).The annualised return on average tangible equity (RoATE) was 16.4% at 30 September 2022  mainly due to the improvement in underwriting income.4. OutlookThe risks threatening global growth were confirmed in the third quarter. The leading central banks continued to tighten monetary policy in a bid to curb inflation  which remains high. There was no improvement in the conflict in Ukraine and the energy crisis in Europe remains acute. European countries are taking substantial financial measures to limit the consequences of the crisis but there are considerable disparities in the extent of their intervention and the lack of coordination is undermining their effectiveness. The Chinese economy continues to be periodically affected by local lockdowns and is facing the consequences of the bursting of the property market bubble.As expected  growth forecasts for the global economy continue to be downgraded. Coface has lowered its financial outlook for 49 economic sectors  following significant downgrades to its country risk assessments in the second quarter.It is continuing to monitor the worsening economic environment. With its strong underwriting discipline and its reserving policy  which remains unchanged  Coface is well positioned to successfully navigate this more complex stage in the economic cycle. The raising of its credit rating outlook by Moodyâ€™s attests to the robustness of Coface's business model and its careful risk management.Coface is continuing to invest in expanding its service activities such as information services (growth of +15.6%) and factoring (+13.0%). Its record retention rate (93.5%) and the steady rise in its net promoter score (NPS) to 38% reflect client recognition of its constant focus on service quality.Conference call for financial analystsCofaceâ€™s results for 9M-2022 will be discussed with financial analysts during the conference call on Thursday 27 October at 18.00 (Paris time). Dial one of the following numbers:The presentation will be available (in English only) at the following address:http://www.coface.com/Investors/financial-results-and-reportsAppendixQuarterly resultsIncome statement items in â‚¬m - Quarterly figures Q1-21 Q2-21 Q3-21 Q4-21 Q1-22 Q2-22 Q3-22 % %ex. FX* Gross earned premiums 312.1 326.7 330.7 343.2 361.3 392.7 398.1 +20.4% +17.6% Services revenue 65.9 63.4 59.6 66.3 69.5 71.4 70.1 +17.6% +10.2% REVENUE 377.9 390.1 390.4 409.5 430.8 464.1 468.2 +19.9% +16.4% UNDERWRITING INCOME(LOSS) AFTER REINSURANCE 74.3 81.5 79.4 38.7 84.9 98.1 112.7 +41.9% +51.7% Investment income  net of management expenses 5.7 10.1 15.0 11.3 12.3 12.0 14.7 (2.3)% (13.5)% CURRENT OPERATING INCOME 80.0 91.6 94.5 49.9 97.2 110.1 127.4 +34.9% +42.0% Other operating income / expenses (0.4) 0.8 (1.3) (2.3) (1.2) (3.2) (0.7) (49.0)% (58.6)% OPERATING INCOME 79.6 92.4 93.2 47.6 96.1 106.9 126.8 +36.0% +43.4% NET INCOME 56.4 66.9 67.7 32.9 66.2 78.2 84.0 +24.1% +33.9% Income tax rate 24.6% 23.0% 23.3% 20.6% 27.2% 23.0% 27.0% + 3.7 pptsCumulated resultsIncome statement items in â‚¬mCumulated figures Q1-21 H1-21 9M-21 FY-21 Q1-22 H1-22 9M-22 % % ex. FX* Gross earned premiums 312.1 638.7 969.5 1 312.6 361.3 754.0 1 152.1 +18.8% +16.6% Services revenue 65.9 129.3 188.9 255.2 69.5 140.9 211.0 +11.7% +7.9% REVENUE 377.9 768.0 1 158.4 1 567.9 430.8 894.9 1 363.1 +17.7% +15.2% UNDERWRITING INCOME(LOSS)AFTER REINSURANCE 74.3 155.8 235.2 273.9 84.9 183.0 295.7 +25.7% +29.8% Investment income net of management expenses 5.7 15.9 30.9 42.2 12.3 24.4 39.1 +26.5% +26.8% CURRENT OPERATING INCOME 80.0 171.6 266.1 316.0 97.2 207.3 334.8 +25.8% +29.4% Other operating income / expenses (0.4) 0.4 (0.8) (3.2) (1.2) (4.3) (5.0) +499.8% +484.7% OPERATING INCOME 79.6 172.1 265.3 312.9 96.1 203.0 329.8 +24.3% +28.0% NET INCOME 56.4 123.2 190.9 223.8 66.2 144.4 228.4 +19.6% +24.7% Income tax rate 24.6% 23.8% 23.6% 23.2% 27.2% 25.1% 25.8% + 2.2 ppts* Also excludes scope impactCONTACTSANALYSTS / INVESTORSThomas JACQUET: +33 1 49 02 12 58 â€“ thomas.jacquet@coface.comBenoÃ®t CHASTEL: +33 1 49 02 22 28 â€“ benoit.chastel@coface.comMEDIA RELATIONSSaphia GAOUAOUI: +33 1 49 02 14 91 â€“ saphia.gaouaoui@coface.comCorentin HENRY: +33 1 49 02 23 94 â€“ corentin.henry@coface.comFINANCIAL CALENDAR 2022/2023(subject to change)FY-2022 results: 16 February 2023 (after market close)Annual General Shareholdersâ€™ Meeting 2022: 16 May 2023FINANCIAL INFORMATIONThis press release  as well as COFACE SAâ€™s integral regulatory information  can be found on the Groupâ€™s website:http://www.coface.com/InvestorsFor regulated information on Alternative Performance Measures (APM)  please refer to our Interim Financial Report for H1-2022 and our 2021 Universal Registration Document (see part 3.7 â€œKey financial performance indicatorsâ€).Regulated documents posted by COFACE SA have been secured and authenticated with the blockchain technology by Wiztrust. You can check the authenticity on the website www.wiztrust.com.COFACE: FOR TRADEWith more than 75 years of experience and the most extensive international network  Coface is one of the leader in trade credit insurance and adjacent specialty services  including Factoring  Single Risk insurance  Bonding and Information services. Cofaceâ€™s experts work to the beat of the global economy  helping ~50 000 clients build successful  growing  and dynamic businesses across the world. Coface helps companies in their credit decisions. The Group's services and solutions strengthen their ability to sell by protecting them against the risks of non-payment in their domestic and export markets. In 2021  Coface employed ~4 538 people and registered a turnover of â‚¬1.57 billion.www.coface.comCOFACE SA is quoted in Compartment A of Euronext ParisCode ISIN: FR0010667147 / MnÃ©monique : COFADISCLAIMER - Certain declarations featured in this press release may contain forecasts that notably relate to future events  trends  projects or targets. By nature  these forecasts include identified or unidentified risks and uncertainties  and may be affected by many factors likely to give rise to a significant discrepancy between the real results and those stated in these declarations. Please refer to chapter 5 â€œMain risk factors and their management within the Groupâ€ of the Coface Group's 2021 Universal Registration Document filed with AMF on 6 April 2022 under the number D.22-0244 in order to obtain a description of certain major factors  risks and uncertainties likely to influence the Coface Group's businesses. The Coface Group disclaims any intention or obligation to publish an update of these forecasts  or provide new information on future events or any other circumstance.1 Return on average tangible equity2 Also excludes scope impact3 Book yield calculated on the average of the investment portfolio excluding non-consolidated subsidiaries.Attachment",neutral,0.01,0.99,0.0,mixed,0.22,0.24,0.54,True,English,"['new record result', 'Annualised return', 'tangible equity', 'Coface', 'Q3-20', 'previous very low loss experience', 'n et combined ratio', 'H1-22 Business information momentum', 'record high retention rate', 'low loss ratio', 'net combined ratio', 'COMBINED RATIO NET', 'first nine months', 'Successful early refinancing', 'grandfathered T2 debt', 'Chief Executive Officer', 'European energy crisis', 'prudent reserving policy', 'Balance sheet items', 'net promoter score', 'Net cost ratio', 'Cost ratio net', 'little financial leeway', 'The Audit Committee', 'recent economic recovery', 'new record result', 'continued operating leverage', 'record net income', 'Income statements items', 'high client activity', 'Gross loss ratio', 'higher reinsurance commissions', 'global growth forecasts', 'Other operating income', 'Credit Insurance premiums', 'New business', '9M-2022 n', 'Information services', 'financial statements', 'Client retention', 'record highs', 'record level', 'global economy', 'economic cycle', 'The Board', 'insurance activities', 'other activities', 'credit rating', 'continued growth', 'Investment income', 'English French', 'Annualised return', 'tangible equity', 'constant FX', 'group share', 'change comparisons', 'Xavier Durand', 'third quarter', 'major risks', 'monetary tightening', 'United Kingdom', 'monetary policies', 'developed countries', 'YTD figure', 'adjacent businesses', 'service quality', 'positive outlook', 'complex stage', 'Key ratios', 'Total Equity', 'current FX', 'Single Risk', 'competitive market', 'record increase', 'price effect', 'contrasting trends', 'different businesses', 'inflationary environment', 'risk environment', 'basis Trade', 'fiscal year', 'Key figures', 'Services revenue', 'management expenses', 'positive impact', 'consolidated turnover', 'COFACE SA', 'Q3-20', '27 October', 'perimeter', 'pricing', 'line', 'revenues', '11.5 ppts', '7.7 ppts', '5.0 ppts', 'normalization', 'RoATE', 'Moody', 'results', '30 September', 'improvement', 'terms', 'conflict', 'Ukraine', 'situation', 'reminder', 'governments', 'Bankruptcies', 'Russia', 'Investments', 'factoring', 'NPS', 'decision', 'work', 'teams', 'past', 'years', 'strengths', 'beginning', 'Directors', 'meeting', '26 October', 'scope', 'bonding', 'scale', '9M-22', 'volumes', 'Poland', '30.', '59', 'â‚¬']",2022-10-27,2022-10-28,globenewswire.com
12333,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2022/10/27/2542384/0/en/Arcadis-Trading-Update-Q3-2022.html,Arcadis Trading Update Q3 2022,Continued strong client demand and improved performanceÂ Â Â Â Â Â Â Â     Strong client demand for energy transition solutions  new mobility and industrial......,"Continued strong client demand and improved performanceStrong client demand for energy transition solutions  new mobility and industrial manufacturingNet revenue at â‚¬740 million; organic growth of 10.9% 1 )Organic backlog growth year-on-year of 5.0% 1)Operating EBITA margin improved to 10.3% (Q3â€˜21: 9.5%)Net Working Capital improved to 13.8% (Q3â€˜21: 14.0%) and DSO to 72 days (Q3â€˜21: 74 days)Accelerating strategy through the acquisitions of IBI Group  DPS Group and Giftge Consult  and the divestments of a number of non-core operationsAmsterdam  27 October 2022 â€“ Arcadis (EURONEXT: ARCAD)  the leading global Design & Consultancy organization for natural and built assets  sees a continued growing client demand across its Global Business Areas (GBAs)  resulting in an organic net revenue growth of 10.9%  and an organic backlog growth of 5.0%. Operating EBITA margin increased to 10.3% (last year: 9.5%)  driven by improved performance across the GBAs.Peter Oosterveer  CEO Arcadis  comments:â€œDuring the last quarter  we have continued to see growing client demand across our three Global Business Areas. Our Resilience business continues to benefit from increased client demand for sustainability advisory  energy transition and climate adaptation solutions. In our Places business we have enjoyed large wins in North America and Germany  and increased demand from manufacturing and governmental clients. For our Mobility business  significant rail wins in the Netherlands and a growing demand for smart mobility solutions from highways and public transport clients created strong results.We have also made significant progress in optimizing our portfolio and focusing our efforts on geographies where we see the most attractive opportunities. This has resulted in the divestments of operations in Singapore  Malaysia  our Design and Engineering business in Hong Kong  Switzerland and our environmental restoration business in France. These follow the divestments made earlier on in the year; of our operations in Thailand  Czech Republic and Slovakia.As we look ahead to 2023  our focus is on fully embedding both IBI and DPS into our four Global Business Areas  and the shaping of our fourth GBA â€œIntelligenceâ€. Through these acquisitions  we not only significantly grow our presence in North America and Europe  but we will also be in the position to provide complementary client services and solutions in high growth markets  including life sciences  semiconductors  and industrial manufacturing.Although the evolving geo-political situation and inflationary headwinds remain firmly on our radar  our record backlog and continued focus on the optimization of our portfolio  combined with the exciting new growth opportunities IBI  DPS and Giftge Consulting offer  position us well to meet our strategic targets. I can only be very proud of all the teams across Arcadis that have kept the right focus on our clients in these busy and exciting times for our company.â€KEY FIGURESAs the acquisition of the IBI Group has been formally closed on 27th of September 2022  the Arcadis consolidated financial statements include IBI consolidated data for balance sheet items (those items having an impact on NWC% and DSO calculated for Arcadis as a whole). Arcadis backlog includes IBI backlog as well. As the three days of P&L of IBI Group between September 27th and September 30th have been considered as non-significant  P&L data and corresponding KPIâ€™s (e.g. EBITDA  order intake  FCF) for the third quarter represent Arcadis standalone data.in â‚¬ millions Third quarter Year-to-date Period ended 30 September 2022 2022 2021 change 2022 2021 change Gross revenues 1 003 828 21% 2 851 2 489 15% Net revenues 740 636 16% 2 158 1 912 13% Organic growth1) 10.9% 4.8% 8.2% 3.9% Operating EBITDA2) 101 83 21% 284 252 12% Operating EBITDA margin 13.6% 13.1% 13.2% 13.2% EBITA 27 57 -52% 158 171 -8% EBITA margin 3.7% 9.0% 7.3% 9.0% Operating EBITA2) 76 60 26% 208 177 18% Operating EBITA margin 10.3% 9.5% 9.7% 9.2% Free Cash Flow3) 38 75 -50% 27 105 -74% Net Working Capital %4) 13.8% 14.0% Days Sales Outstanding4) 72 74 Net Debt4) 880 298 195% Backlog net revenues4) 2 813 2 126 32% Backlog organic growth (y-o-y)1) 5.0%1) Underlying growth excluding the impact of currency movements  acquisitions or footprint reductions  such as the Middle East  winddowns or divestments2) This excludes the net result on divestment of consolidated companies  and acquisitions  restructuring  and integration-related costs. The Operating EBITDA is used when calculating the strategic target: average net debt / (Operating) EBITDA  guided for 1.5-2.5x3) Free Cash flow: Cash Flow from Operations corrected for Capex and Lease liabilities4) Including IBI Group  transaction closing per 27th of September 2022INCOME STATEMENTNet revenues totaled â‚¬740 million and increased organically by 10.9%. Growth was driven by all three GBAs  with Resilience and Mobility being exceptionally strong in North America and the UK. The currency impact was 9%. The operating EBITA margin improved to 10.3% (Q3â€˜21: 9.5%)  driven by all three GBAs  and a significant year-on-year improvement driven by Places from improved operational efficiencies  despite lower working days in the UK and Australia due to Queen Elizabethâ€™s funeral.Non-operating costs were â‚¬49 million and include transaction costs related to the three recently announced acquisitions  and a net loss on divestments of operations in Singapore  Malaysia  Hong Kong (Design & Engineering business)  Switzerland and France (Environmental Restoration business). These net losses had no impact on Free Cash Flow.ORDER INTAKE &BACKLOGAt the end of September 2022 backlog reached a record high level of â‚¬2 813 million (Q3â€˜21: â‚¬2 126 million)  of which â‚¬530 million was added through the acquisition of the IBI Group. Strong order intake  with almost no cancellations in the quarter resulted in a solid organic backlog growth of 5.0% year-over-year  with a positive contribution of all three GBAs.BALANCE SHEET & CASH FLOWNet working capital as a percentage of annualized gross revenues was 13.8% (Q3â€˜21: 14.0%)  globally in line with last year performance. Days Sales Outstanding (DSO) decreased to 72 days (Q3â€˜21: 74 days). Net debt increased to â‚¬880 million (Q3â€˜21: â‚¬298 million)  including the â‚¬600 million bridge loan for IBI acquisition and IBI net debt of â‚¬54 million.Free cash flow generation during the quarter was â‚¬38 million and below last yearâ€™s (Q3â€˜21: â‚¬75 million)  driven by sharp revenue growth elevating working capital levels  and some transaction costs relating to the recent acquisitions. Free cash flow generation year-to-date was â‚¬27 million (Q3â€˜21: â‚¬105 million)  which was impacted by a normalization of working capital levels compared to 2021.STRATEGIC PROGRESSFocus & Scale is one of the three key pillars of our â€œMaximizing Impactâ€ business strategy for 2021-2023. Arcadis has focused on driving operational efficiencies through the implementation of the GBA model  focus on key clients  and greater use of the Global Excellence Centers (GECs)  as well as investing in high growth markets  for instance through the acquisitions of IBI  DPS and Giftge Consult.At the same time  â€œFocus & Scaleâ€ triggered a portfolio assessment  reviewing operations on their scalability  growth potential  financial performance  and scope of services. This has resulted in the following divestment of non-core operations  from a geographic or business point of view: Singapore  Malaysia  Hong Kong (Design & Engineering business)  Switzerland and France (Environmental Restoration business)  representing ~900 people and â‚¬47 million of annual net revenues. This was in addition to the divestments of Czech Republic  Slovakia and Thailand that occurred in the first half of 2022  representing ~190 people and â‚¬11 million of annual net revenues.The recent acquisitions of IBI  DPS and Giftge  together with the divestments  have rebalanced the geographic and business portfolio  and repositioned Arcadis towards high growth and resilient markets such as placemaking and urban planning in North America  and industrial manufacturing engineering in the US and Europe. The creation of the fourth GBA â€œIntelligence""  will enhance Arcadisâ€™ position as a digital leader  and ability to serve its clients in a more efficient way across all phases of the asset lifecycle. The backlog for Intelligence at the end of the third quarter was â‚¬112 million  representing 4% of the total Arcadis backlog.PERFORMANCE BY GLOBAL BUSINESS AREARESILIENCE(43% of net revenues) in â‚¬ millions Third quarter Year-to-date Period ended 30 September 2022 2022 2021 change 2022 2021 change Net revenues 320 259 24% 909 771 18% Organic growth1) 13.7% 9.7% Backlog net revenues 943 Backlog organic growth (y-o-y)1) 5.4%Resilience showed continued solid revenue and backlog growth for the third quarter  driven by continued strong client demand in energy transition  climate adaptation and mitigation  including a new commission as lead designer of a flood defense for Battery Park  New York City  complementing resiliency work for southeast and lower Manhattan. Revenue growth was supported by the successful onboarding of new hires  especially in the US.The Resilience business closed the quarter at a backlog of â‚¬943 million  representing 34% of total Arcadis backlog.PLACES(32% of net revenues) in â‚¬ millions Third quarter Year-to-date Period ended 30 September 2022 2022 2021 change 2022 2021 change Net revenues 234 209 12% 697 656 6% Organic growth1) 3.6% 2.8% Backlog net revenues 1 216 Backlog organic growth (y-o-y)1) 2.1%Revenue and backlog growth in the third quarter were driven by a strong Continental Europe and US  with good demand for sustainable and intelligent buildings  including the development of datacenters and automotive giga-factories for electric vehicle battery production. Revenue and backlog growth was somewhat hampered by weakening market circumstances in China.The absolute backlog of Places increased by 29% year-on-year to â‚¬1 216 million. The position includes the backlog of IBI Group  which was marked by strong order intake in the third quarter and excludes the divested countries in Southeast Asia. These strategic decisions led to a significant repositioning of the Places backlog  now representing 43% of total Arcadis backlog  with an increased focus on North America and Europe.MOBILITY(25% of net revenues) in â‚¬ millions Third quarter Year-to-date Period ended 30 September 2022 2022 2021 change 2022 2021 change Net revenues 186 168 11% 552 485 14% Organic growth1) 15.4% 12.5% Backlog net revenues 542 Backlog organic growth (y-o-y)1) 9.0%Stellar revenue growth for Mobility in the third quarter was driven by the UK  Australia and the US. A strong backlog development came from large highway and rail wins; such as for ProRail in the Netherlands  and a growing demand for smart mobility solutions from highways and public transport clients. At the end of Q3  mobility backlog amounted to â‚¬542 million  representing 19% of total Arcadis backlog.IBIâ€™s experience in developing digital tools including Travel-IQ will further help to pursue new opportunities and strengthen our Mobility business both in North America and across the world.Financial calendar:16 February 2023 â€“ Q4 & FY 2022 Results4 May 2023 â€“ Q1 2023 Trading Update27 July 2023 â€“ Q2 & HY 2023 Results26 October 2023 â€“ Q3 2023 Trading UpdateFor further information please contact:Arcadis Investor RelationsChristine DischMobile: +31 (0)6 1537 6020E-mail: christine.disch@arcadis.comArcadis Corporate CommunicationsTanno MassarMobile: +31 (0)6 1158 9121E-mail: tanno.massar@arcadis.comAnalyst meetingArcadis will hold an analyst webcast to discuss the Q3results for 2022. The analyst meeting will be held at 10.00 hours CET today. The webcast can be accessed via the investor relations section on the companyâ€™s website at: https://channel.royalcast.com/landingpage/arcadisinvestors/20221027_1/About ArcadisArcadis is a leading global Design & Consultancy organization for natural and built assets. Applying our deep market sector insights and collective design  consultancy  engineering  project and management services we work in partnership with our clients to deliver exceptional and sustainable outcomes throughout the lifecycle of their natural and built assets. We are 33 000 people  active in over 70 countries that generate â‚¬3.8 billion in revenues. We support UN-Habitat with knowledge and expertise to improve the quality of life in rapidly growing cities around the world. www.arcadis.com.Regulated informationThis press release contains information that qualifies or may qualify as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.Forward looking statementsStatements included in this press release that are not historical facts (including any statements concerning investment objectives  other plans and objectives of management for future operations or economic performance  or assumptions or forecasts related thereto) are forward-looking statements. These statements are only predictions and are not guarantees. Actual events or the results of our operations could differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements are typically identified by the use of terms such as â€œmayâ€  â€œwillâ€  â€œshouldâ€  â€œexpectâ€  â€œcouldâ€  â€œintendâ€  â€œplanâ€  â€œanticipateâ€  â€œestimateâ€  â€œbelieveâ€  â€œcontinueâ€  â€œpredictâ€  â€œpotentialâ€ or the negative of such terms and other comparable terminology. The forward-looking statements are based upon our current expectations  plans  estimates  assumptions and beliefs that involve numerous risks and uncertainties. Assumptions relating to the foregoing involve judgments with respect to  among other things  future economic  competitive and market conditions and future business decisions  all of which are difficult or impossible to predict accurately and many of which are beyond our control. Although we believe that the expectations reflected in such forward-looking statements are based on reasonable assumptions  our actual results and performance could differ materially from those set forth in the forward-looking statements.Attachments",neutral,0.0,1.0,0.0,mixed,0.68,0.2,0.12,True,English,"['Arcadis Trading Update', 'four Global Business Areas', 'three Global Business Areas', 'exciting new growth opportunities', 'organic net revenue growth', 'evolving geo-political situation', 'complementary client services', 'environmental restoration business', 'Net Working Capital', 'leading global Design', 'climate adaptation solutions', 'high growth markets', 'Giftge Consulting offer', 'Free Cash Flow', 'average net debt', 'significant rail wins', 'balance sheet items', 'strong client demand', 'growing client demand', 'public transport clients', 'Organic backlog growth', 'Operating EBITA margin', 'P&L data', 'The Operating EBITDA', 'energy transition solutions', 'smart mobility solutions', 'Backlog net revenues', 'IBI consolidated data', 'organic growth', 'growing demand', 'new mobility', 'attractive opportunities', 'exciting times', 'Places business', 'Mobility business', 'Engineering business', 'strong results', 'standalone data', 'EBITDA margin', 'net result', 'large wins', 'significant progress', 'record backlog', 'consolidated companies', 'IBI backlog', 'Resilience business', 'Gross revenues', 'Accelerating strategy', 'Consultancy organization', 'built assets', 'Peter Oosterveer', 'last quarter', 'sustainability advisory', 'North America', 'Hong Kong', 'Czech Republic', 'life sciences', 'inflationary headwinds', 'strategic targets', 'financial statements', 'three days', 'corresponding KPI', 'order intake', 'third quarter', 'date Period', 'currency movements', 'Middle East', 'integration-related costs', '1.5-2.5x', 'Lease liabilities', 'INCOME STATEMENT', 'three GBAs', 'IBI Group', 'Arcadis backlog', 'industrial manufacturing', 'DPS Group', 'right focus', 'currency impact', 'CEO Arcadis', 'core operations', '72 days', 'performance', 'year', 'DSO', 'acquisitions', 'divestments', 'number', 'Amsterdam', 'EURONEXT', 'natural', 'continued', 'comments', 'Germany', 'Netherlands', 'highways', 'portfolio', 'efforts', 'geographies', 'Singapore', 'Malaysia', 'Switzerland', 'France', 'Thailand', 'Slovakia', 'shaping', 'Intelligence', 'presence', 'Europe', 'position', 'semiconductors', 'radar', 'optimization', 'teams', 'busy', 'company', 'FIGURES', '27th', 'September', 'FCF', '2021 change', 'footprint', 'reductions', 'winddowns', 'restructuring', 'Capex', 'transaction', 'UK', '10.', '5.0', '74', 'â‚¬']",2022-10-27,2022-10-28,globenewswire.com
12334,EuroNext,Bing API,https://au.sports.yahoo.com/deinove-requests-receivership-proceedings-155100432.html,DEINOVE REQUESTS RECEIVERSHIP PROCEEDINGS,DEINOVE (Euronext Growth Paris: ALDEI)  a French biotech company  pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent  global challenge of antibiotic resistance ,"DeinoveDEINOVE (Euronext Growth Paris: ALDEI)  a French biotech company  pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent  global challenge of antibiotic resistance  announces having filed today a declaration of cessation of payments (""dÃ©claration de cessation des paiements"") and a request for receivership proceedings (â€œprocÃ©dure de redressement judiciaireâ€) of the Company with the Montpellier Commercial Court.The employee representative bodies were notified in advance.The purpose of these proceedings is to evaluate all solutions that could enable the Company to continue its business activity  maintain employment  and pay off its liabilities under the best possible conditions  and also to initiate a process to attract investors within the framework of a recovery plan by way of continuation or a sale plan.The Company will continue its current activities during the observation period.The Company will inform the financial markets of the decision of the Montpellier Commercial Court.Under these conditions  DEINOVE has asked Euronext to suspend the listing of its shares (ISIN: FR0010879056) on Euronext Growth from October 28 before the opening of trading  pending the publication of a press release and until further notice. Given the uncertainty regarding the outcome of the steps taken by the Company  the suspension of the listing of the Company's shares (ISIN: FR0010879056) is maintained until further notice.ABOUT DEINOVEDEINOVE is a French biotechnology company pioneering the exploration of a new domain of life  unexplored at 99.9%: the â€œmicrobial dark matterâ€. By revealing the metabolic potential of rare bacteria or still classified as uncultivable  it tackles a global health and economic challenge: antimicrobial resistance.The new therapies discovered and developed by DEINOVE target superbugs (microbes that have become resistant to one or more antimicrobials) that cause life-threatening infections which are now spreading at high speed.Story continuesThis breakthrough approach gave rise to one of the worldâ€™s first specialized micro-biotechnology platforms and a unique collection of nearly 10 000 rare strains and thousands of bacterial extracts. Today  DEINOVE is conducting several development programs  of which its first antibiotic candidate is currently evaluated in a Phase II clinical trial in severe Clostridioides difficile infection  one of the worldâ€™s first emergencies. The Company has also developed new bacterial micro-factories that address the other issue in the race against antimicrobial resistance: the industrial production of these rare and low concentrated compounds with often too complex chemical structures to be generated by chemical synthesis.Located at the heart of the Euromedecine park in Montpellier  DEINOVE has been listed on EURONEXT GROWTHÂ® (ALDEI â€“ code ISIN FR0010879056) since 2010. The Company has 45 employees and relies on a network of world-class academic  technological  industrial and institutional partners.CONTACTSInvestorsMario AlcarazChief Financial and Administrative Officer+33 (0)4 48 19 01 00ir@deinove.comMediaATCG Partners+33 (0)9 81 87 46 72communication@deinove.comAttachment",neutral,0.03,0.96,0.01,mixed,0.14,0.16,0.69,True,English,"['DEINOVE REQUESTS RECEIVERSHIP PROCEEDINGS', 'procÃ©dure de redressement judiciaire', 'Phase II clinical trial', 'severe Clostridioides difficile infection', 'first specialized micro-biotechnology platforms', 'world-class academic, technological, industrial', 'employee representative bodies', 'microbial dark matter', 'several development programs', 'low concentrated compounds', 'first antibiotic candidate', 'complex chemical structures', 'Montpellier Commercial Court', 'urgent, global challenge', 'best possible conditions', 'French biotech company', 'French biotechnology company', 'new bacterial micro-factories', 'Euronext Growth Paris', 'first emergencies', 'industrial production', 'antibiotic resistance', 'global health', 'economic challenge', 'chemical synthesis', 'bacterial biodiversity', 'new domain', 'new therapies', 'bacterial extracts', 'EURONEXT GROWTHÂ®', 'dÃ©claration', 'business activity', 'recovery plan', 'sale plan', 'current activities', 'observation period', 'financial markets', 'press release', 'metabolic potential', 'antimicrobial resistance', 'life-threatening infections', 'high speed', 'breakthrough approach', 'unique collection', 'other issue', 'Euromedecine park', 'institutional partners', 'Mario Alcaraz', 'Chief Financial', 'Administrative Officer', 'ATCG Partners', 'The Company', 'rare bacteria', '10,000 rare strains', 'receivership proceedings', 'Deinove', 'ALDEI', 'pioneer', 'exploration', 'exploitation', 'declaration', 'cessation', 'payments', 'paiements', 'request', 'advance', 'purpose', 'solutions', 'employment', 'liabilities', 'process', 'investors', 'framework', 'way', 'continuation', 'decision', 'listing', 'shares', 'October', 'opening', 'trading', 'publication', 'notice', 'uncertainty', 'outcome', 'steps', 'suspension', 'ISIN', 'superbugs', 'microbes', 'antimicrobials', 'Story', 'rise', 'thousands', 'race', 'heart', 'code', '45 employees', 'network', 'CONTACTS', 'Media', 'communication', 'Attachment', '9']",2022-10-28,2022-10-28,au.sports.yahoo.com
12335,EuroNext,Bing API,https://www.thetradenews.com/leaders-in-trading-2022-meet-the-nominees-for-outstanding-post-trade-services-provider/,Leaders in Trading 2022: Meet the nominees forâ€¦. Outstanding Post-Trade Services Provider,Learn more about the five firms shortlisted for our Editorsâ€™ Choice Award for Outstanding Post-Trade Services Provider this year: including DTCC  Deutsche BÃ¶rse  Euronext  LCH and OSTTRA.,The TRADE is happy to introduce the shortlist for our Editorsâ€™ Choice  Outstanding Post-Trade Services Provider. The shortlisted post-trade services providers have all experienced great years and achieved outstanding performance. Learn more about our shortlisted candidates below  including DTCC  Deutsche BÃ¶rse  Euronext  LCH and OSTTRA.DTCCEarlier this year  the Depository Trust & Clearing Corporationâ€™s (DTCC) went live with its distributed ledger technology (DLT) based settlement platform in a parallel production environment  processing up to 160 000 transactions per day. Named Project Ion  the platform has been in the works since May 2020  with a view to support a netted T+0 settlement cycle  as well as T+2  T+1 and extended cycles.Going live in parallel to existing settlement infrastructure  the project is processing an average of over 100 000 bilateral equity transactions per day  and almost 160 000 transactions on peak days. The Depository Trust Companyâ€™s (DTC) classic settlement systems remaining the authoritative record. Project ION has been developed in collaboration with the likes of BNY Mellon  Citi and JP Morgan.Elsewhere  DTCC Institutional Trade Processing (ITP) provides an open  post-trade infrastructure that aims to remove redundancies and manual processing across asset classes in an effort to create a place where users can manage the entire trade lifecycle  from post-execution to settlement  on one platform.Deutsche BÃ¶rseDeutsche BÃ¶rse Groupâ€™s clearing houses  Eurex Clearing AG and European Commodity Clearing AG  act as central counterparties  i.e. as buyer to each seller and as seller to each buyer  to minimise credit default risk. The clearing houses offer efficient clearing of a wide range of transaction types  both on-exchange and over-the-counter (OTC).Deutsche BÃ¶rse recently acquired the North American Nodal Exchange by the EEX Group  adding a third clearing house  Nodal Clear  to its roster.Towards the end of last year  Deutsche BÃ¶rse rolled out a major technology overhaul with the launch of digital post-trade platform. The fully digital post-trade platform provides same-day-issuance and paperless  automated straight-through processing for the entire value chain of issuance  custody  settlement  and asset servicing for digital securities.Working with distributed ledger technology (DLT) specialist  Digital Asset  as a partner on the project  the German exchange groupâ€™s new initiative uses a cloud-backed and DLT-ready platform to enable the digitisation of financial products with continuing access to both existing central and distributed infrastructures and markets.EuronextEuronext serves as the largest pan-European exchange and market infrastructure  connecting seven markets across the continent. The last year has proved fruitful for the exchange with surging trading volumes alongside a series of successful acquisitions.In August  Euronext reported a particularly â€˜solidâ€™ Q2 driven by the sustained dynamism of non-volume activities and of trading operations. The exchange reported a 14% increase in revenue and income in Q2 of this year  compared to the same period last year  which reached â‚¬374.7 million â€“ driven by the growth of non-volume related business and trading activities.Non-volume related revenue accounted for 59% of Euronextâ€™s Q2 total revenue this year  while trading revenue grew to â‚¬129.2 million  a 15.6% increase compared to the same period last year â€“ a result linked to robust performance across all asset classes in a volatile market environment. Growth was also driven by the recent Borsa Italiana acquisition  which also bumped up the exchangeâ€™s strong Q1 results.Elsewhere  Euronext reported that net income  share of the parent company shareholders was up 37.2% to â‚¬118.9 million  an increase by â‚¬32.2 million compared to the same period last year.LCHGlobal clearing house LCH  which is part of the post-trade division of London Stock Exchange Group (LSEG)  has had an impressive year with several revenue increases across its business. LCH continues to partner with market participants globally to offer clearing services and provide risk management capabilities across a range of asset classes  including OTC and listed interest rates  fixed income  FX  CDS  equities and commodities.The clearing house has helped reduce systemic risk and strengthen stability in financial markets alongside allowing participants to benefit from capital and operational efficiencies. In 2021  LSEG post-trade experienced improved revenue figures  with total income rising to Â£483 million  which was an increase by 8.5% compared to 2022. This comprised of Â£191m for OTC derivatives; Â£122m for securities and repo; Â£49m for non-cash collateral and Â£121m for net trade income (NTI). Elsewhere  LCH has seen growth across its services and record clearing activity in H1 2022.OSTTRAOSTTRA was formed in 2021 through the combination of four businesses that have been involved in the post-trade for over 20 years  namely MarkitServ  Traiana  TriOptima and Reset. The combination of these businesses allows OSTTRA to play a role in supporting global financial markets  connecting thousands of counterparties via its multi-asset networks that support the post-trade lifecycle from trade capture  through portfolio optimisation  to clearing and settlement services.OSTTRA boasts over 9 000 connections on its network  including major banks  investment managers and clearing houses. The firm processes over 80 million trades monthly  including matching  confirming and booking transactions  managing credit limits and reconciling portfolios. Every second  OSTTRA performs over 10 trillion calculations  optimising counterparty risk  margin and capital efficiency.As a company  OSTTRA looks to keep pace with market reforms. Through ongoing dialogue with regulators and market participants  OSTTRA responds to new regulatory mandates with standardised solutions and workflows that minimise costs and compliance risks for its customers.Elsewhere  to manage market volatility  OSTTRA continually works with its client base to automate and streamline new steps in post trade workflows to improve efficiency and reduce operational risk during peak market volumes.,positive,0.97,0.03,0.0,positive,0.81,0.18,0.0,True,English,"['Outstanding Post-Trade Services Provider', 'Leaders', 'Trading', 'nominees', 'recent Borsa Italiana acquisition', 'paperless, automated straight-through processing', 'European Commodity Clearing AG', 'London Stock Exchange Group', 'North American Nodal Exchange', 'Deutsche BÃ¶rse Group', 'The Depository Trust Company', 'Outstanding Post-Trade Services Provider', 'DTCC Institutional Trade Processing', 'Global clearing house LCH', 'parent company shareholders', 'Eurex Clearing AG', 'entire trade lifecycle', 'major technology overhaul', 'entire value chain', 'strong Q1 results', 'listed interest rates', 'distributed ledger technology', 'credit default risk', 'risk management capabilities', 'third clearing house', 'German exchange group', 'up to 160,000 transactions', '100,000 bilateral equity transactions', 'Non-volume related revenue', 'volatile market environment', 'several revenue increases', 'open, post-trade infrastructure', 'largest pan-European exchange', 'surging trading volumes', 'T+0 settlement cycle', 'classic settlement systems', 'post-trade services providers', 'parallel production environment', 'volume related business', 'net trade income', 'existing settlement infrastructure', 'digital post-trade platform', 'Q2 total revenue', 'The TRADE', 'manual processing', 'EEX Group', 'clearing services', 'outstanding performance', 'Nodal Clear', 'market infrastructure', 'distributed infrastructures', 'systemic risk', 'post-trade division', 'trading revenue', 'Clearing Corporation', 'clearing houses', 'efficient clearing', 'clearing activity', 'Digital Asset', 'existing central', 'volume activities', 'net income', 'total income', 'revenue figures', 'settlement platform', 'trading operations', 'trading activities', 'one platform', 'DLT-ready platform', 'LSEG post-trade', 'Editorsâ€™ Choice', 'shortlisted candidates', 'DLT) based', 'extended cycles', 'peak days', 'authoritative record', 'BNY Mellon', 'JP Morgan', 'asset classes', 'central counterparties', 'transaction types', 'asset servicing', 'digital securities', 'DLT) specialist', 'new initiative', 'financial products', 'continuing access', 'successful acquisitions', 'solidâ€™ Q2', 'sustained dynamism', 'same period', 'robust performance', 'fixed income', 'operational efficiencies', 'cash collateral', 'market participants', 'last year', 'impressive year', 'seven markets', 'financial markets', 'great years', 'Project Ion', 'wide range', 'OTC derivatives', 'four businesses', '20 years', 'Euronext', 'OSTTRA', 'works', 'May', 'view', 'average', 'collaboration', 'likes', 'Citi', 'ITP', 'redundancies', 'effort', 'place', 'users', 'post-execution', 'buyer', 'seller', 'roster', 'launch', 'same-day-issuance', 'custody', 'partner', 'cloud-backed', 'digitisation', 'continent', 'series', 'August', '14% increase', 'growth', '15.6% increase', 'FX', 'CDS', 'equities', 'commodities', 'stability', 'capital', 'repo', 'H1', 'combination', 'MarkitServ', 'Traiana', 'TriOptima', 'Reset', '+1']",2022-10-28,2022-10-28,thetradenews.com
12336,EuroNext,Bing API,https://www.thetradenews.com/euronext-taps-fca-for-new-head-of-market-structure/,Euronext taps FCA for new head of market structure,Euronext has selected a former Financial Conduct Authority individual to head up its market structure. Samantha Page joins Euronext after seven and a half years at the UK Watchdog in its wholesale banking division. Prior to joining the FCA in 2015 ...,Euronext has selected a former Financial Conduct Authority individual to head up its market structure.Samantha Page joins Euronext after seven and a half years at the UK Watchdog in its wholesale banking division.Prior to joining the FCA in 2015  Page spent three years as a director in sales and marketing for futures and over the counter clearing at Bank of America Merrill Lynch and just under two years at Royal Bank of Scotland as a director in central counterparty clearing.Previously she also spent two years at CME Group as an associate director in strategic sales  as well as four years in business development and four years in sales at NYSE â€“ Liffe and virt-x respectively.â€œWe are delighted to announce that Samantha Page has joined our Euronext teams as head of market structure  a key function within the Group in order to further unroll Euronextâ€™s strategic ambition to build the leading European market infrastructure â€ Simon Gallagher  head of cash and derivatives at Euronext  told The TRADE.â€œSamanthaâ€™s role will be instrumental. We chose Sam because she brings extensive experience in the regulatory and legislative arena  along with her background in the FMI space. As head of market structure for the Euronext Group  she will be participating in our existing engagement with regulators and with policy makers  working with our members on key joint initiatives  and representing Euronext and our members at key industry events.â€,neutral,0.0,0.99,0.0,positive,0.54,0.45,0.0,True,English,"['new head', 'market structure', 'Euronext', 'FCA', 'former Financial Conduct Authority individual', 'leading European market infrastructure', 'wholesale banking division', 'America Merrill Lynch', 'key joint initiatives', 'key industry events', 'central counterparty clearing', 'a half years', 'key function', 'market structure', 'counter clearing', 'three years', 'two years', 'four years', 'UK Watchdog', 'business development', 'strategic ambition', 'Simon Gallagher', 'The TRADE', 'extensive experience', 'legislative arena', 'FMI space', 'existing engagement', 'policy makers', 'CME Group', 'Royal Bank', 'Samantha Page', 'associate director', 'strategic sales', 'Euronext teams', 'Euronext Group', 'seven', 'FCA', 'marketing', 'futures', 'Scotland', 'NYSE', 'Liffe', 'virt', 'head', 'order', 'cash', 'derivatives', 'role', 'regulatory', 'background', 'regulators', 'members']",2022-10-28,2022-10-28,thetradenews.com
12337,EuroNext,Bing API,https://www.oedigital.com/news/500533-dolphin-drilling-starts-trading-on-euronext-growth,Dolphin Drilling Starts Trading on Euronext Growth,Offshore drilling company Dolphin Drilling on Thursday announced public trading on Euronext Growth  after a recent private placement and share issue with total gross proceeds of $45 million. â€œDolphin Drilling has attractive assets  a strong team and a ...,"Offshore drilling company Dolphin Drilling on Thursday announced public trading on Euronext Growth  after a recent private placement and share issue with total gross proceeds of $45 million.â€œDolphin Drilling has attractive assets  a strong team and a solid platform to leverage on the favorable market development with improved rates. The most recent contract for Blackford Dolphin underlines the potential of the company and its assets  and we believe Dolphin Drilling will capitalize on the continued expected tight rig market for the rest of the fleet â€ says Martin Nes  Chairman of Dolphin Drilling.Dolphin Drilling owns three harsh environment moored semisubmersibles which have been rebuilt with 4th and 5th generation rigs.Growth opportunities""The company is well-positioned to secure additional contracts at attractive levels  benefitting from current market improvements and an attractive positioning in the niche moored semisubmersible market. In addition  the opportunity to acquire and/or manage two latest generation harsh environment semisubmersibles as well as to manage and operate non-owned rigs provide attractive additional growth opportunities "" Dolphin Drilling said.The company completed a private placement on September 5  2022  raising gross proceeds of $45 million. On October 4  2022  the company announced the award of the 12-month contract for the moored semi- submersible Blackford Dolphin by General Hydrocarbons Limited in Nigeria. The total value of the contract is approximately USD 96 million.The proceeds from the private placement will primarily be used to finance the special periodic survey and mobilization of Blackford Dolphin  as well as the reactivation of Borgland Dolphin drilling rig  general corporate purposes and working capital.""The first day of trading represents an important milestone for the company and returning the company to the public markets further strengthens our commitment to our strategy. Our three harsh environment semisubmersibles are fit for purpose and capable of delivering cost efficient services for customers â€ says BjÃ¸rnar Iversen  CEO of Dolphin Drilling.On 28 October 2022  the shares of Dolphin Drilling start trading on Euronext Growth under the ticker code DDRIL.",neutral,0.02,0.98,0.0,mixed,0.72,0.03,0.25,True,English,"['Dolphin Drilling', 'Euronext Growth', 'Trading', 'two latest generation harsh environment', 'three harsh environment semisubmersibles', 'semi- submersible Blackford Dolphin', 'Borgland Dolphin drilling rig', 'attractive additional growth opportunities', 'tight rig market', '5th generation rigs', 'favorable market development', 'current market improvements', 'moored semisubmersible market', 'General Hydrocarbons Limited', 'special periodic survey', 'general corporate purposes', 'cost efficient services', 'BjÃ¸rnar Iversen', 'recent private placement', 'total gross proceeds', 'Offshore drilling company', 'additional contracts', 'Euronext Growth', 'attractive levels', 'attractive positioning', 'non-owned rigs', 'total value', 'recent contract', 'share issue', 'attractive assets', 'strong team', 'solid platform', 'improved rates', 'Martin Nes', 'working capital', 'first day', 'important milestone', 'public markets', 'ticker code', '12-month contract', 'public trading', 'Thursday', 'potential', 'rest', 'fleet', 'Chairman', '4th', 'opportunity', 'September', 'October', 'award', 'Nigeria', 'mobilization', 'reactivation', 'commitment', 'strategy', 'customers', 'CEO', 'shares', 'DDRIL']",2022-10-28,2022-10-28,oedigital.com
12338,EuroNext,Bing API,https://www.avanza.se/placera/pressmeddelanden/2022/10/28/dolphin-drilling-as-first-day-of-trading-for-dolphin-drilling-as-on-euronext-growth.html,First day of trading for Dolphin Drilling AS on Euronext Growth,Dolphin Drilling has attractive assets  a strong team and a solid platform to leverage on the favorable market development with improved rates. The most recent contract for Blackford Dolphin underlines the potential of the company and its assets ,Oslo  28 October 2022 Dolphin Drilling AS (Dolphin Drilling  OSE: DDRIL) today announces public trading on Euronext Growth  following the successful previously announced private placement and share issue with total gross proceeds of USD 45 million. The companyâ€™s Blackford Dolphin will commence a 12-month USD 96 million contract in the fourth quarter 2022  and Dolphin Drilling reiterates its strong outlook.â€œDolphin Drilling has attractive assets  a strong team and a solid platform to leverage on the favorable market development with improved rates. The most recent contract for Blackford Dolphin underlines the potential of the company and its assets  and we believe Dolphin Drilling will capitalize on the continued expected tight rig market for the rest of the fleet â€ says Martin Nes  Chairman of Dolphin Drilling.Dolphin Drilling today owns three harsh environment moored semisubmersibles which have been rebuilt with 4th and 5th generation rigs. The company is well-positioned to secure additional contracts at attractive levels  benefitting from current market improvements and an attractive positioning in the niche moored semisubmersible market. In addition  the opportunity to acquire and/or manage two latest generation harsh environment semisubmersibles as well as to manage and operate non-owned rigs provide attractive additional growth opportunities.The company successfully completed a private placement 5 September 2022 which attracted strong interest from high-quality institutional investors. It raised gross proceeds of USD 45 million. On 4 October 2022  the company announced the award of the 12-month contract for the moored semisubmersible Blackford Dolphin by General Hydrocarbons Limited in Nigeria. The total value of the contract is approximately USD 96 million. The proceeds from the private placement will primarily be used to finance the special periodic survey and mobilization of Blackford Dolphin  as well as the reactivation of Borgland Dolphin  general corporate purposes and working capital.â€œThe first day of trading represents an important milestone for the company and returning the company to the public markets further strengthens our commitment to our strategy. Our three harsh environment semisubmersibles are fit for purpose and capable of delivering cost efficient services for customers â€ says BjÃ¸rnar Iversen  CEO of Dolphin Drilling.On 28 October 2022  the shares of Dolphin Drilling commence trading on Euronext Growth under the ticker code DDRIL. A separate announcement was published earlier today concerning an information document published in relation to the listing on Dolphin Drillingâ€™s website https://www.dolphindrilling.com/investor-relations.Dolphin Drilling retained DNB Markets  a part of DNB Bank ASA  Arctic Securities AS and Pareto Securities AS as managers in connection with the private placement. DNB Markets has acted as Euronext Growth Advisor in connection with the admission. Advokatfirmaet SchjÃ¸dt AS is acting as legal counsel to Dolphin Drilling.For further information  please contact:Stephen Cox email: stephen.cox@dolphindrilling.com  tel: +44 7800 612 130Ingolf Gillesdal email: ingolf.gillesdal@dolphindrilling.com  tel: +47 920 45 320Dolphin Drilling | www.dolphindrilling.comDolphin Drilling is a leading harsh environment drilling contractor for the offshore oil and gas industry. Dolphin Drilling owns a fleet of three high-technical standard 4th and 5th generation enhanced Aker H3 units  Borgland Dolphin  Blackford Dolphin  and Bideford Dolphin  operated by an experienced team with strong operational track record. The company has approximately 260 offshore and onshore employees  and onshore locations in Norway  Scotland  Brazil  Nigeria  and Mexico.,neutral,0.09,0.9,0.01,mixed,0.45,0.13,0.42,True,English,"['Dolphin Drilling AS', 'First day', 'Euronext Growth', 'trading', 'two latest generation harsh environment', 'leading harsh environment drilling contractor', 'Advokatfirmaet SchjÃ¸dt AS', 'three harsh environment semisubmersibles', 'strong operational track record', 'three high-technical standard 4th', '12-month USD 96 million contract', 'attractive additional growth opportunities', 'Arctic Securities AS', 'Pareto Securities AS', 'favorable market development', 'tight rig market', 'current market improvements', 'moored semisubmersible market', 'high-quality institutional investors', 'General Hydrocarbons Limited', 'special periodic survey', 'general corporate purposes', 'cost efficient services', 'BjÃ¸rnar Iversen', 'Aker H3 units', '5th generation rigs', 'DNB Bank ASA', 'Euronext Growth Advisor', 'Dolphin Drilling AS', 'semisubmersible Blackford Dolphin', 'total gross proceeds', '12-month contract', 'additional contracts', 'strong outlook', 'strong team', 'attractive levels', 'attractive positioning', 'non-owned rigs', 'strong interest', 'total value', 'DNB Markets', 'recent contract', 'Borgland Dolphin', 'Bideford Dolphin', 'private placement', 'share issue', 'fourth quarter', 'attractive assets', 'solid platform', 'improved rates', 'Martin Nes', 'working capital', 'first day', 'important milestone', 'public markets', 'ticker code', 'separate announcement', 'legal counsel', 'Stephen Cox', 'gas industry', 'experienced team', 'onshore employees', 'onshore locations', 'information document', 'Ingolf Gillesdal', 'offshore oil', 'public trading', '260 offshore', 'Oslo', 'DDRIL', 'company', 'potential', 'fleet', 'Chairman', 'opportunity', '4 October', 'award', 'Nigeria', 'mobilization', 'reactivation', 'commitment', 'strategy', 'customers', 'CEO', '28 October', 'shares', 'relation', 'listing', 'website', 'part', 'managers', 'connection', 'email', 'dolphindrilling', 'Norway', 'Scotland', 'Brazil', 'Mexico']",2022-10-28,2022-10-28,avanza.se
12339,EuroNext,Twitter API,Twitter,Dolphin Drilling Lists On Euronext Growth https://t.co/IiEc0Zw7kt https://t.co/ypBRtyLD3j,nan,Dolphin Drilling Lists On Euronext Growth https://t.co/IiEc0Zw7kt https://t.co/ypBRtyLD3j,neutral,0.02,0.97,0.01,neutral,0.02,0.97,0.01,True,English,"['Dolphin Drilling Lists', 'Euronext Growth', 'Dolphin Drilling Lists', 'Euronext Growth']",2022-10-28,2022-10-28,Unknown
12340,EuroNext,Twitter API,Twitter,DEINOVE (Euronext Growth Paris: ALDEI)  a French biotech company  pioneer in the exploration and exploitation of baâ€¦ https://t.co/ODI1QNXLFN,nan,DEINOVE (Euronext Growth Paris: ALDEI)  a French biotech company  pioneer in the exploration and exploitation of baâ€¦ https://t.co/ODI1QNXLFN,neutral,0.07,0.92,0.01,neutral,0.07,0.92,0.01,True,English,"['Euronext Growth Paris', 'French biotech company', 'DEINOVE', 'ALDEI', 'pioneer', 'exploration', 'exploitation', 'ODI1QNXLFN', 'Euronext Growth Paris', 'French biotech company', 'DEINOVE', 'ALDEI', 'pioneer', 'exploration', 'exploitation', 'ODI1QNXLFN']",2022-10-28,2022-10-28,Unknown
12341,EuroNext,Twitter API,Twitter,DEINOVE (Euronext Growth Paris: ALDEI)  a French biotech company  pioneer in the exploration and exploitation of baâ€¦ https://t.co/zpAzJ6aqIe,nan,DEINOVE (Euronext Growth Paris: ALDEI)  a French biotech company  pioneer in the exploration and exploitation of baâ€¦ https://t.co/zpAzJ6aqIe,neutral,0.1,0.89,0.02,neutral,0.1,0.89,0.02,True,English,"['Euronext Growth Paris', 'French biotech company', 'DEINOVE', 'ALDEI', 'pioneer', 'exploration', 'exploitation', 'Euronext Growth Paris', 'French biotech company', 'DEINOVE', 'ALDEI', 'pioneer', 'exploration', 'exploitation']",2022-10-28,2022-10-28,Unknown
12342,EuroNext,Twitter API,Twitter,DEINOVE REQUESTS RECEIVERSHIP PROCEEDINGS - https://t.co/0JYvbWwhEL (Euronext Growth Paris: ALDEI)  a French biotecâ€¦ https://t.co/nHIhN5GxA7,nan,DEINOVE REQUESTS RECEIVERSHIP PROCEEDINGS - https://t.co/0JYvbWwhEL (Euronext Growth Paris: ALDEI)  a French biotecâ€¦ https://t.co/nHIhN5GxA7,neutral,0.07,0.9,0.03,neutral,0.07,0.9,0.03,True,English,"['DEINOVE REQUESTS RECEIVERSHIP PROCEEDINGS', 'Euronext Growth Paris', 'French biotec', 'ALDEI', 'DEINOVE REQUESTS RECEIVERSHIP PROCEEDINGS', 'Euronext Growth Paris', 'French biotec', 'ALDEI']",2022-10-28,2022-10-28,Unknown
12343,EuroNext,Twitter API,Twitter,Euronext taps FCA for new head of market structurehttps://t.co/gxZXDLWIBv,nan,Euronext taps FCA for new head of market structurehttps://t.co/gxZXDLWIBv,neutral,0.01,0.99,0.0,neutral,0.01,0.99,0.0,True,English,"['new head', 'market structure', 'Euronext', 'FCA', 'new head', 'market structure', 'Euronext', 'FCA']",2022-10-28,2022-10-28,Unknown
12344,EuroNext,Twitter API,Twitter,Global equities have bullish positioning in Euronext 100  #DAX  &amp; Australian ASX 200. While being underweight $EEMâ€¦ https://t.co/mWbVCLQLGL,nan,Global equities have bullish positioning in Euronext 100  #DAX  &amp; Australian ASX 200. While being underweight $EEMâ€¦ https://t.co/mWbVCLQLGL,negative,0.0,0.1,0.89,negative,0.0,0.1,0.89,True,English,"['Global equities', 'bullish positioning', 'Australian ASX', 'Euronext', 'amp', 'Global equities', 'bullish positioning', 'Australian ASX', 'Euronext', 'amp']",2022-10-28,2022-10-28,Unknown
12345,EuroNext,Twitter API,Twitter,@QuantumGenomics - Firibastat misses endpoints in Phase III $ALQGC #ALQGC #euronext @euronextRead now  is greater than  https://t.co/fjDRbS4uiy,nan,@QuantumGenomics - Firibastat misses endpoints in Phase III $ALQGC #ALQGC #euronext @euronextRead now  is greater than  https://t.co/fjDRbS4uiy,neutral,0.02,0.96,0.02,neutral,0.02,0.96,0.02,True,English,"['Phase III', 'QuantumGenomics', 'Firibastat', 'endpoints', '$ALQGC', 'Phase III', 'QuantumGenomics', 'Firibastat', 'endpoints', '$ALQGC']",2022-10-28,2022-10-28,Unknown
12346,EuroNext,Twitter API,Twitter,Euronext taps FCA for new head of market structure https://t.co/CURXfMaKTi,nan,Euronext taps FCA for new head of market structure https://t.co/CURXfMaKTi,neutral,0.01,0.99,0.0,neutral,0.01,0.99,0.0,True,English,"['new head', 'market structure', 'Euronext', 'FCA', 'CURXfMaKTi', 'new head', 'market structure', 'Euronext', 'FCA', 'CURXfMaKTi']",2022-10-28,2022-10-28,Unknown
12347,EuroNext,Twitter API,Twitter,Dolphin Drilling Starts Trading on EuronextÂ Growth https://t.co/6W0dyuL87I,nan,Dolphin Drilling Starts Trading on EuronextÂ Growth https://t.co/6W0dyuL87I,neutral,0.01,0.99,0.0,neutral,0.01,0.99,0.0,True,English,"['Dolphin Drilling', 'Euronext\xa0Growth', 'Trading', 'Dolphin Drilling', 'Euronext\xa0Growth', 'Trading']",2022-10-28,2022-10-28,Unknown
12348,EuroNext,Twitter API,Twitter,#Cac40 CAC 40 6 219 40 | Euronext Live cours de bourse https://t.co/Iqh8wn15YL https://t.co/08tdmsvZzF,nan,#Cac40 CAC 40 6 219 40 | Euronext Live cours de bourse https://t.co/Iqh8wn15YL https://t.co/08tdmsvZzF,neutral,0.02,0.98,0.0,neutral,0.02,0.98,0.0,True,English,"['Euronext Live cours', 'Cac40', 'bourse', 'Euronext Live cours', 'Cac40', 'bourse']",2022-10-28,2022-10-28,Unknown
